

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 18, 2004, 08:16:16 ; Search time 0.001 Seconds

(without alignments)

589.248 Million cell updates/sec

Title: US-10-006-191-79

Perfect score: 27

Sequence: 1 agagtggacaaaagtacatgttg 27

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 886 seqs, 10912 residues

Total number of hits satisfying chosen parameters: 1772

Minimum DB seq length: 8

Maximum DB seq length: 50

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 886 summaries

Database : rng19.seq *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	20	74.1	20	1	ADB5654
C 2	20	74.1	20	1	ADB5671
C 3	20	74.1	20	1	ADB5655
C 4	20	74.1	20	1	ADB5670
C 5	16	59.3	20	1	ADB5653
C 6	14.4	53.3	20	1	ABK40462
C 7	14.4	53.3	20	1	ADJ37525
C 8	14.4	53.3	20	1	ADG56449
C 9	14	51.9	20	1	ADB5669
C 10	12.2	45.2	17	1	AAV36534
C 11	12.2	45.2	17	1	ABV99418
C 12	12.2	45.2	17	1	ADL49182
C 13	12.2	45.2	17	1	ADL49182
C 14	12.2	45.2	17	1	ADL50023
C 15	11.4	42.2	13	1	ABC78606
C 16	11.4	42.2	13	1	ABC78607
C 17	11.4	42.2	13	1	ABC78609
C 18	11.4	42.2	13	1	ABC30594
C 19	11.4	42.2	13	1	ABC78608
C 20	11.4	42.2	13	1	ABC24651
C 21	11.4	42.2	13	1	ABC24650
C 22	11.4	42.2	13	1	ABC30595
C 23	11.4	42.2	15	1	AAJ30977
C 24	11.4	42.2	15	1	ABK19330
C 25	11	40.7	15	1	ABK70527
C 26	10.8	40.0	15	1	AAJ15778
C 27	10.8	40.0	15	1	AAJ73958
C 28	10.4	38.5	12	1	ABH81622
C 29	10.4	38.5	12	1	ABH81622
C 30	10.4	38.5	12	1	ABH74839
C 31	10.4	38.5	12	1	ABH71745
C 32	10.4	38.5	12	1	ABH49941
C 33	10.4	38.5	12	1	ABH52271

C 34	10.4	38.5	12	1	ABH71735	Oligonucleotide pr
C 35	10.4	38.5	12	1	ABH49627	Oligonucleotide pr
C 36	10.4	38.5	12	1	ABH33967	Oligonucleotide pr
C 37	10.4	38.5	12	1	ABH42142	Oligonucleotide pr
C 38	10.4	38.5	12	1	ABH107774	Oligonucleotide pr
C 39	10.4	38.5	13	1	ABC72025	Oligonucleotide pr
C 40	10.4	38.5	13	1	ABC56759	Oligonucleotide pr
C 41	10.4	38.5	13	1	ABH48560	Oligonucleotide pr
C 42	10.4	38.5	13	1	ABH34854	Oligonucleotide pr
C 43	10.4	38.5	13	1	ABH34989	Oligonucleotide pr
C 44	10.4	38.5	13	1	ABH48561	Oligonucleotide pr
C 45	10.4	38.5	13	1	ABH34988	Oligonucleotide pr
C 46	10.4	38.5	13	1	ABC56760	Oligonucleotide pr
C 47	10.4	38.5	13	1	ABC72021	Oligonucleotide pr
C 48	10.4	38.5	13	1	ABC58336	Oligonucleotide pr
C 49	10.4	38.5	13	1	ABC79759	Oligonucleotide pr
C 50	10.4	38.5	13	1	ABH08279	Oligonucleotide pr
C 51	10.4	38.5	13	1	ABH34855	Oligonucleotide pr
C 52	10.4	38.5	13	1	ABH48563	Oligonucleotide pr
C 53	10.4	38.5	13	1	ABH08276	Oligonucleotide pr
C 54	10.4	38.5	13	1	ABC56758	Oligonucleotide pr
C 55	10.4	38.5	13	1	ABH48552	Oligonucleotide pr
C 56	10.4	38.5	13	1	ABC58337	Oligonucleotide pr
C 57	10.4	38.5	13	1	ABC79758	Oligonucleotide pr
C 58	10.4	38.5	13	1	ABC56761	Oligonucleotide pr
C 59	10.4	38.5	13	1	ABH08277	Oligonucleotide pr
C 60	10.4	38.5	13	1	ABC72020	Oligonucleotide pr
C 61	10.4	38.5	13	1	ABC72024	Oligonucleotide pr
C 62	10.4	38.5	13	1	ABH08278	Oligonucleotide pr
C 63	10	37.0	10	1	ABK23686	Transcript tag DNA
C 64	10	37.0	10	1	ABH08935	Oligonucleotide pr
C 65	10	37.0	10	1	ABC90746	Oligonucleotide pr
C 66	10	37.0	10	1	ABH08934	Oligonucleotide pr
C 67	10	37.0	10	1	ABC90727	Oligonucleotide pr
C 68	9.8	36.3	13	1	ABC70173	Oligonucleotide pr
C 69	9.8	36.3	13	1	ABC24649	Oligonucleotide pr
C 70	9.8	36.3	13	1	ABC83940	Oligonucleotide pr
C 71	9.8	36.3	13	1	ABC89770	Oligonucleotide pr
C 72	9.8	36.3	13	1	ABF69703	Oligonucleotide pr
C 73	9.8	36.3	13	1	ABF73956	Oligonucleotide pr
C 74	9.8	36.3	13	1	ABH35801	Oligonucleotide pr
C 75	9.8	36.3	13	1	ABC23838	Oligonucleotide pr
C 76	9.8	36.3	13	1	ABC24988	Oligonucleotide pr
C 77	9.8	36.3	13	1	ABC30596	Oligonucleotide pr
C 78	9.8	36.3	13	1	ABC83931	Oligonucleotide pr
C 79	9.8	36.3	13	1	ABC84116	Oligonucleotide pr
C 80	9.8	36.3	13	1	ABC89375	Oligonucleotide pr
C 81	9.8	36.3	13	1	ABF41324	Oligonucleotide pr
C 82	9.8	36.3	13	1	ABH22579	Oligonucleotide pr
C 83	9.8	36.3	13	1	ABH44353	Oligonucleotide pr
C 84	9.8	36.3	13	1	ABC23839	Oligonucleotide pr
C 85	9.8	36.3	13	1	ABC78604	Oligonucleotide pr
C 86	9.8	36.3	13	1	ABC56765	Oligonucleotide pr
C 87	9.8	36.3	13	1	ABC12793	Oligonucleotide pr
C 88	9.8	36.3	13	1	ABC89771	Oligonucleotide pr
C 89	9.8	36.3	13	1	ABF68250	Oligonucleotide pr
C 90	9.8	36.3	13	1	ABF70020	Oligonucleotide pr
C 91	9.8	36.3	13	1	ABF53803	Oligonucleotide pr
C 92	9.8	36.3	13	1	ABH52974	Oligonucleotide pr
C 93	9.8	36.3	13	1	ABC70172	Oligonucleotide pr
C 94	9.8	36.3	13	1	ABC50758	Oligonucleotide pr
C 95	9.8	36.3	13	1	ABC36264	Oligonucleotide pr
C 96	9.8	36.3	13	1	ABC89773	Oligonucleotide pr
C 97	9.8	36.3	13	1	ABH35800	Oligonucleotide pr
C 98	9.8	36.3	13	1	ABH50898	Oligonucleotide pr
C 99	9.8	36.3	13	1	ABC83933	Oligonucleotide pr
C 100	9.8	36.3	13	1	ABC83943	Oligonucleotide pr
C 101	9.8	36.3	13	1	ABF41325	Oligonucleotide pr
C 102	9.8	36.3	13	1	ABC24989	Oligonucleotide pr
C 103	9.8	36.3	13	1	ABC58322	Oligonucleotide pr
C 104	9.8	36.3	13	1	ABF70021	Oligonucleotide pr
C 105	9.8	36.3	13	1	ABF73957	Oligonucleotide pr
C 106	9.8	36.3	13	1	ABH10604	Oligonucleotide pr

C 253 9.4 34.8 13 1 ABC60017 Oligonucleotide SE C 326 9.4 34.8 13 1 ABC82015 Oligonucleotide SE
C 254 9.4 34.8 13 1 ABP12588 Oligonucleotide SE C 327 9.4 34.8 13 1 ABF08266 Oligonucleotide SE
C 255 9.4 34.8 13 1 ABP13161 Oligonucleotide SE C 328 9.4 34.8 13 1 ABC60088 Oligonucleotide SE
C 256 9.4 34.8 13 1 ABC90277 Oligonucleotide SE C 329 9.4 34.8 13 1 ABF24340 Oligonucleotide SE
C 257 9.4 34.8 13 1 ABF22036 Oligonucleotide SE C 330 9.4 34.8 13 1 ABH04241 Oligonucleotide SE
C 258 9.4 34.8 13 1 ABF22040 Oligonucleotide SE C 331 9.4 34.8 13 1 ABF05020 Oligonucleotide SE
C 259 9.4 34.8 13 1 ABF32562 Oligonucleotide SE C 332 9.4 34.8 13 1 ABC82014 Oligonucleotide SE
C 260 9.4 34.8 13 1 ABH23614 Oligonucleotide SE C 333 9.4 34.8 13 1 ABC34247 Oligonucleotide SE
C 261 9.4 34.8 13 1 ABF98926 Oligonucleotide SE C 334 9.4 34.8 13 1 ABC87019 Oligonucleotide SE
C 262 9.4 34.8 13 1 ABF53024 Oligonucleotide SE C 335 9.4 34.8 13 1 ABF12094 Oligonucleotide SE
C 263 9.4 34.8 13 1 ABH04240 Oligonucleotide SE C 336 9.4 34.8 13 1 ABF33254 Oligonucleotide SE
C 264 9.4 34.8 13 1 ABF88892 Oligonucleotide SE C 337 9.4 34.8 13 1 ABF75257 Oligonucleotide SE
C 265 9.4 34.8 13 1 ABC47954 Oligonucleotide SE C 338 9.4 34.8 13 1 ABH08732 Oligonucleotide SE
C 266 9.4 34.8 13 1 ABC26270 Oligonucleotide SE C 339 9.4 34.8 13 1 ABH34747 Oligonucleotide SE
C 267 9.4 34.8 13 1 ABF22037 Oligonucleotide SE C 340 9.4 34.8 13 1 ABF57081 Oligonucleotide SE
C 268 9.4 34.8 13 1 ABF35563 Oligonucleotide SE C 341 9.4 34.8 13 1 ABF12589 Oligonucleotide SE
C 269 9.4 34.8 13 1 ABF70173 Oligonucleotide SE C 342 9.4 34.8 13 1 ABP13695 Oligonucleotide SE
C 270 9.4 34.8 13 1 ABH08735 Oligonucleotide SE C 343 9.4 34.8 13 1 ABC16210 Oligonucleotide SE
C 271 9.4 34.8 13 1 ABH35883 Oligonucleotide SE C 344 9.4 34.8 13 1 ABH17680 Oligonucleotide SE
C 272 9.4 34.8 13 1 ABF60968 Oligonucleotide SE C 345 9.4 34.8 13 1 ABH19289 Oligonucleotide SE
C 273 9.4 34.8 13 1 ABF90882 Oligonucleotide SE C 346 9.4 34.8 13 1 ABF96441 Oligonucleotide SE
C 274 9.4 34.8 13 1 ABF90882 Oligonucleotide SE C 347 9.4 34.8 13 1 ABH03655 Oligonucleotide SE
C 275 9.4 34.8 13 1 ABC17571 Oligonucleotide SE C 348 9.4 34.8 13 1 ABH31181 Oligonucleotide SE
C 276 9.4 34.8 13 1 ABC18565 Oligonucleotide SE C 349 9.4 34.8 13 1 ABH52424 Oligonucleotide SE
C 277 9.4 34.8 13 1 ABC47955 Oligonucleotide SE C 350 9.4 34.8 13 1 ABC92352 Oligonucleotide SE
C 278 9.4 34.8 13 1 ABC49583 Oligonucleotide SE C 351 9.4 34.8 13 1 ABC17570 Oligonucleotide SE
C 279 9.4 34.8 13 1 ABC17148 Oligonucleotide SE C 352 9.4 34.8 13 1 ABF55052 Oligonucleotide SE
C 280 9.4 34.8 13 1 ABF32563 Oligonucleotide SE C 353 9.4 34.8 13 1 ABC55257 Oligonucleotide SE
C 281 9.4 34.8 13 1 ABF77176 Oligonucleotide SE C 354 9.4 34.8 13 1 ABF08267 Oligonucleotide SE
C 282 9.4 34.8 13 1 ABH30878 Oligonucleotide SE C 355 9.4 34.8 13 1 ABF32561 Oligonucleotide SE
C 283 9.4 34.8 13 1 ABH30879 Oligonucleotide SE C 356 9.4 34.8 13 1 ABF72397 Oligonucleotide SE
C 284 9.4 34.8 13 1 ABF82059 Oligonucleotide SE C 357 9.4 34.8 13 1 ABF98925 Oligonucleotide SE
C 285 9.4 34.8 13 1 ABH42367 Oligonucleotide SE C 358 9.4 34.8 13 1 ABF75256 Oligonucleotide SE
C 286 9.4 34.8 13 1 ABC29311 Oligonucleotide SE C 359 9.4 34.8 13 1 ABF60279 Oligonucleotide SE
C 287 9.4 34.8 13 1 ABC55033 Oligonucleotide SE C 360 9.4 34.8 13 1 ABF89730 Oligonucleotide SE
C 288 9.4 34.8 13 1 ABC57078 Oligonucleotide SE C 361 9.4 34.8 13 1 ABH16643 Oligonucleotide SE
C 289 9.4 34.8 13 1 ABF71761 Oligonucleotide SE C 362 9.4 34.8 13 1 ABC19844 Oligonucleotide SE
C 290 9.4 34.8 13 1 ABF70172 Oligonucleotide SE C 363 9.4 34.8 13 1 ABC19845 Oligonucleotide SE
C 291 9.4 34.8 13 1 ABF53025 Oligonucleotide SE C 364 9.4 34.8 13 1 ABC31732 Oligonucleotide SE
C 292 9.4 34.8 13 1 ABF55461 Oligonucleotide SE C 365 9.4 34.8 13 1 ABF06916 Oligonucleotide SE
C 293 9.4 34.8 13 1 ABF65415 Oligonucleotide SE C 366 9.4 34.8 13 1 ABC82013 Oligonucleotide SE
C 294 9.4 34.8 13 1 ABH15644 Oligonucleotide SE C 367 9.4 34.8 13 1 ABF13350 Oligonucleotide SE
C 295 9.4 34.8 13 1 ABH46083 Oligonucleotide SE C 368 9.4 34.8 13 1 ABC90276 Oligonucleotide SE
C 296 9.4 34.8 13 1 ABC60089 Oligonucleotide SE C 369 9.4 34.8 13 1 ABF35562 Oligonucleotide SE
C 297 9.4 34.8 13 1 ABC71749 Oligonucleotide SE C 370 9.4 34.8 13 1 ABF99477 Oligonucleotide SE
C 298 9.4 34.8 13 1 ABF23828 Oligonucleotide SE C 371 9.4 34.8 13 1 ABF82250 Oligonucleotide SE
C 299 9.4 34.8 13 1 ABF24341 Oligonucleotide SE C 372 9.4 34.8 13 1 ABF60278 Oligonucleotide SE
C 300 9.4 34.8 13 1 ABF32560 Oligonucleotide SE C 373 9.4 34.8 13 1 ABF89735 Oligonucleotide SE
C 301 9.4 34.8 13 1 ABF32561 Oligonucleotide SE C 374 9.4 34.8 13 1 ABF90884 Oligonucleotide SE
C 302 9.4 34.8 13 1 ABF32562 Oligonucleotide SE C 375 9.4 34.8 13 1 ABH51583 Oligonucleotide SE
C 303 9.4 34.8 13 1 ABF32563 Oligonucleotide SE C 376 9.4 34.8 13 1 ABC23309 Oligonucleotide SE
C 304 9.4 34.8 13 1 ABF32564 Oligonucleotide SE C 377 9.4 34.8 13 1 ABC74080 Oligonucleotide SE
C 305 9.4 34.8 13 1 ABH19350 Oligonucleotide SE C 378 9.4 34.8 13 1 ABF72396 Oligonucleotide SE
C 306 9.4 34.8 13 1 ABF95142 Oligonucleotide SE C 379 9.4 34.8 13 1 ABF98924 Oligonucleotide SE
C 307 9.4 34.8 13 1 ABF72688 Oligonucleotide SE C 380 9.4 34.8 13 1 ABH03814 Oligonucleotide SE
C 308 9.4 34.8 13 1 ABF98927 Oligonucleotide SE C 381 9.4 34.8 13 1 ABF82058 Oligonucleotide SE
C 309 9.4 34.8 13 1 ABH03815 Oligonucleotide SE C 382 9.4 34.8 13 1 ABF89731 Oligonucleotide SE
C 310 9.4 34.8 13 1 ABH35882 Oligonucleotide SE C 383 9.4 34.8 13 1 ABC27365 Oligonucleotide SE
C 311 9.4 34.8 13 1 ABF60969 Oligonucleotide SE C 384 9.4 34.8 13 1 ABF08271 Oligonucleotide SE
C 312 9.4 34.8 13 1 ABC49582 Oligonucleotide SE C 385 9.4 34.8 13 1 ABF14499 Oligonucleotide SE
C 313 9.4 34.8 13 1 ABC31733 Oligonucleotide SE C 386 9.4 34.8 13 1 ABC16211 Oligonucleotide SE
C 314 9.4 34.8 13 1 ABF22041 Oligonucleotide SE C 387 9.4 34.8 13 1 ABF95143 Oligonucleotide SE
C 315 9.4 34.8 13 1 ABF96440 Oligonucleotide SE C 388 9.4 34.8 13 1 ABH23615 Oligonucleotide SE
C 316 9.4 34.8 13 1 ABF77177 Oligonucleotide SE C 389 9.4 34.8 13 1 ABF99476 Oligonucleotide SE
C 317 9.4 34.8 13 1 ABF55460 Oligonucleotide SE C 390 9.4 34.8 13 1 ABH35160 Oligonucleotide SE
C 318 9.4 34.8 13 1 ABF82251 Oligonucleotide SE C 391 9.4 34.8 13 1 ABF90885 Oligonucleotide SE
C 319 9.4 34.8 13 1 ABF65414 Oligonucleotide SE C 392 9.4 34.8 13 1 ABH16642 Oligonucleotide SE
C 320 9.4 34.8 13 1 ABC18564 Oligonucleotide SE C 393 9.4 34.8 13 1 ABH46082 Oligonucleotide SE
C 321 9.4 34.8 13 1 ABC23308 Oligonucleotide SE C 394 9.4 34.8 13 1 ABH59441 Oligonucleotide SE
C 322 9.4 34.8 13 1 ABC05974 Oligonucleotide SE C 395 9.4 34.8 13 1 ABH61414 Oligonucleotide SE
C 323 9.4 34.8 13 1 ABC05975 Oligonucleotide SE C 396 9.4 34.8 13 1 ABC26271 Oligonucleotide SE
C 324 9.4 34.8 13 1 ABF06917 Oligonucleotide SE C 397 9.4 34.8 13 1 ABC29310 Oligonucleotide SE
C 325 9.4 34.8 13 1 ABC82012 Oligonucleotide SE C 398 9.4 34.8 13 1 ABF05021 Oligonucleotide SE

545	8.8	32.6	12	1	ABI07835	Oligonucleotide pr	c 618	8.4	31.1	11	1	AAH55107	Genomic DNA methyl
546	8.8	32.6	12	1	ABI33492	Oligonucleotide pr	c 619	8.4	31.1	11	1	AAH55108	Genomic DNA methyl
547	8.8	32.6	12	1	ABH08943	Oligonucleotide pr	c 620	8.4	31.1	11	1	ABQ86506	Human skin stress/
548	8.8	32.6	12	1	ABH086758	Oligonucleotide pr	c 621	8.4	31.1	11	1	ABQ87043	Human skin stress/
549	8.8	32.6	12	1	ABI37226	Oligonucleotide pr	c 622	8.4	31.1	11	1	ABQ87534	Human skin stress/
550	8.8	32.6	12	1	ABH90339	Oligonucleotide pr	c 623	8.4	31.1	11	1	ABQ87282	Human skin stress/
551	8.8	32.6	12	1	ABI50778	Oligonucleotide pr	c 624	8.4	31.1	11	1	ABV4034	Human skin EST 182
552	8.8	32.6	12	1	ABI53415	Oligonucleotide pr	c 625	8.4	31.1	11	1	ABV4034	Human skin EST 182
553	8.8	32.6	12	1	ABH91581	Oligonucleotide pr	c 626	8.4	31.1	11	1	ABV69946	Human skin EST 773
554	8.8	32.6	12	1	ABH70836	Oligonucleotide pr	c 627	8.4	31.1	11	1	ABV7422	Human skin EST 520
555	8.8	32.6	12	1	ABH00546	Oligonucleotide pr	c 628	8.4	31.1	11	1	ABV69109	Human skin EST 689
556	8.8	32.6	12	1	ABH79073	Oligonucleotide pr	c 629	8.4	31.1	11	1	ABV66433	Human skin EST 421
557	8.8	32.6	12	1	ABH29888	Oligonucleotide pr	c 630	8.4	31.1	11	1	ABV71455	Human skin EST 924
558	8.8	32.6	12	1	ABI33246	Oligonucleotide pr	c 631	8.4	31.1	11	1	ABV62525	Human skin EST 311
559	8.8	32.6	12	1	ABI37243	Oligonucleotide pr	c 632	8.4	31.1	11	1	ABV64573	Human skin EST 235
560	8.8	32.6	12	1	ABI49693	Oligonucleotide pr	c 633	8.4	31.1	11	1	ABV66821	Human skin EST 460
561	8.8	32.6	12	1	ABI74720	Oligonucleotide pr	c 634	8.4	31.1	11	1	ABV65066	Human skin EST 295
562	8.8	32.6	12	1	ABI62368	Oligonucleotide pr	c 635	8.4	31.1	11	1	ABV71994	Human skin EST 978
563	8.8	32.6	12	1	ABI76317	Oligonucleotide pr	c 636	8.4	31.1	11	1	ABV68903	Human skin EST 688
564	8.8	32.6	12	1	ABI65421	Oligonucleotide pr	c 637	8.4	31.1	11	1	ABV65861	Human skin EST 364
565	8.8	32.6	12	1	ABH73752	Oligonucleotide pr	c 638	8.4	31.1	11	1	ABV67158	Human skin EST 450
566	8.8	32.6	12	1	ABI36991	Oligonucleotide pr	c 639	8.4	31.1	11	1	ABV66189	Human skin EST 397
567	8.8	32.6	12	1	ABI60121	Oligonucleotide pr	c 640	8.4	31.1	11	1	ACL92008	Short human Tumour
568	8.8	32.6	12	1	ABI02621	Oligonucleotide pr	c 641	8.4	31.1	11	1	ACA61503	Modified promoter
569	8.8	32.6	12	1	ABH81997	Oligonucleotide pr	c 642	8.4	31.1	11	1	ABX71933	DNA tag used to id
570	8.8	32.6	12	1	ABI08371	Oligonucleotide pr	c 643	8.4	31.1	11	1	ADQ29874	Human VRL exon 1a
571	8.8	32.6	12	1	ABI08674	Oligonucleotide pr	c 644	8.4	31.1	11	1	ADQ29886	Murine VRL exon 1a
572	8.8	32.6	12	1	ABH87275	Oligonucleotide pr	c 645	8.4	31.1	11	1	ADQ35599	Human hair-bearing
573	8.8	32.6	12	1	ABI47891	Oligonucleotide pr	c 646	8.4	31.1	11	1	ADQ35819	Human hair-bearing
574	8.8	32.6	12	1	ABI62180	Oligonucleotide pr	c 647	8.4	31.1	11	1	ADQ36261	Human hair-bearing
575	8.8	32.6	12	1	ABI63029	Oligonucleotide pr	c 648	8.4	31.1	11	1	ADQ36457	Human hair-bearing
576	8.8	32.6	12	1	ABX15954	Antisense oligonuc	c 649	8.4	31.1	11	1	ADQ35802	Human hair-bearing
577	8.8	32.6	12	1	ABX16005	Antisense oligonuc	c 650	8.4	31.1	11	1	ADQ34842	Human hair-bearing
578	8.4	31.1	10	1	AAQ38703	2'-O-methyl oligon	c 651	8.4	31.1	11	1	ADQ32414	Human facial skin-
579	8.4	31.1	10	1	AAI96111	Calibration oligon	c 652	8.4	31.1	11	1	ADQ32947	Human facial skin-
580	8.4	31.1	10	1	AAZ82626	Metastatic breast	c 653	8.4	31.1	11	1	ADQ33099	Human facial skin-
581	8.4	31.1	10	1	AAZ86089	Metastatic breast	c 654	8.4	31.1	11	1	ADQ33003	Human facial skin-
582	8.4	31.1	10	1	AAZ81055	Metastatic breast	c 655	8.4	31.1	11	1	ADQ32752	Human facial skin-
583	8.4	31.1	10	1	AAZ88682	Ras RNA binding 2'	c 656	8.4	31.1	12	1	AAC93147	Newcastle disease
584	8.4	31.1	10	1	AAH63248	Human colon epithe	c 657	8.4	31.1	12	1	ABH94949	Oligonucleotide pr
585	8.4	31.1	10	1	AAH63310	Human colon epithe	c 658	8.4	31.1	12	1	ABH20692	Oligonucleotide pr
586	8.4	31.1	10	1	AAH63362	Human melanocyte s	c 659	8.4	31.1	12	1	ABH70818	Oligonucleotide pr
587	8.4	31.1	10	1	AAH63364	Human melanocyte s	c 660	8.4	31.1	12	1	ABH21917	Oligonucleotide pr
588	8.4	31.1	10	1	AAAF74044	Human SLC6A4 allel	c 661	8.4	31.1	12	1	ABH74210	Oligonucleotide pr
589	8.4	31.1	10	1	AAAF40439	Yeast NORF gene SA	c 662	8.4	31.1	12	1	ABH32127	Oligonucleotide pr
590	8.4	31.1	10	1	AAAF41011	Yeast NORF gene SA	c 663	8.4	31.1	12	1	ABH34257	Oligonucleotide pr
591	8.4	31.1	10	1	AAAF42006	Yeast NORF gene SA	c 664	8.4	31.1	12	1	ABH84898	Oligonucleotide pr
592	8.4	31.1	10	1	AAAF43317	Yeast NORF gene SA	c 665	8.4	31.1	12	1	ABH10287	Oligonucleotide pr
593	8.4	31.1	10	1	AAAF40798	Yeast NORF gene SA	c 666	8.4	31.1	12	1	ABH15800	Oligonucleotide pr
594	8.4	31.1	10	1	AAAF38269	Yeast NORF gene SA	c 667	8.4	31.1	12	1	ABH43356	Oligonucleotide pr
595	8.4	31.1	10	1	AAAF35345	Yeast NORF gene SA	c 668	8.4	31.1	12	1	ABH151324	Oligonucleotide pr
596	8.4	31.1	10	1	AAAF33860	Yeast NORF gene SA	c 669	8.4	31.1	12	1	ABH173035	Oligonucleotide pr
597	8.4	31.1	10	1	AAAF38462	Yeast NORF gene SA	c 670	8.4	31.1	12	1	ABH160884	Oligonucleotide pr
598	8.4	31.1	10	1	AAAF38459	Yeast NORF gene SA	c 671	8.4	31.1	12	1	ABH161879	Oligonucleotide pr
599	8.4	31.1	10	1	AAAF36865	Yeast NORF gene SA	c 672	8.4	31.1	12	1	ABH160290	Oligonucleotide pr
600	8.4	31.1	10	1	AAAF38454	Yeast NORF gene SA	c 673	8.4	31.1	12	1	ABH69527	Oligonucleotide pr
601	8.4	31.1	10	1	AAAF37124	Yeast NORF gene SA	c 674	8.4	31.1	12	1	ABH19758	Oligonucleotide pr
602	8.4	31.1	10	1	AAAF39808	Yeast NORF gene SA	c 675	8.4	31.1	12	1	ABH23870	Oligonucleotide pr
603	8.4	31.1	10	1	AAAF43316	Yeast NORF gene SA	c 676	8.4	31.1	12	1	ABH29761	Oligonucleotide pr
604	8.4	31.1	10	1	ABV84769	Chronic hepatitis	c 677	8.4	31.1	12	1	ABH30985	Oligonucleotide pr
605	8.4	31.1	10	1	ABV84230	Human chronic hepa	c 678	8.4	31.1	12	1	ABH82366	Oligonucleotide pr
606	8.4	31.1	10	1	ABK70750	Primer-extension o	c 679	8.4	31.1	12	1	ABH83243	Oligonucleotide pr
607	8.4	31.1	10	1	ABN81270	Oligonucleotide pr	c 680	8.4	31.1	12	1	ABH39437	Oligonucleotide pr
608	8.4	31.1	10	1	ACC41666	Zinc finger protei	c 681	8.4	31.1	12	1	ABH14005	Oligonucleotide pr
609	8.4	31.1	10	1	ADE73174	Oligon #11 used to	c 682	8.4	31.1	12	1	ABH45592	Oligonucleotide pr
610	8.4	31.1	10	1	AAAL56066	Human BAGE 5 intro	c 683	8.4	31.1	12	1	ABH45838	Oligonucleotide pr
611	8.4	31.1	10	1	AAAL56049	Human BAGE 2 intro	c 684	8.4	31.1	12	1	ABH55931	Oligonucleotide pr
612	8.4	31.1	10	1	ADL96132	CD15+ myeloid cell	c 685	8.4	31.1	12	1	ABH56634	Oligonucleotide pr
613	8.4	31.1	10	1	ADH14478	Human retinoblasto	c 686	8.4	31.1	12	1	ABH70972	Oligonucleotide pr
614	8.4	31.1	10	1	ADK13337	Human glioma endot	c 687	8.4	31.1	12	1	ABH73521	Oligonucleotide pr
615	8.4	31.1	10	1	ADK12886	Human glioma endot	c 688	8.4	31.1	12	1	ABH75085	Oligonucleotide pr
616	8.4	31.1	10	1	ADK13362	Human glioma endot	c 689	8.4	31.1	12	1	ABH78626	Oligonucleotide pr
617	8.4	31.1	11	1	AAV82624	Target binding sit	c 690	8.4	31.1	12	1	ABH86239	Oligonucleotide pr

691	8.4	31.1	12	1	ABI03629	Oligonucleotide pr
692	8.4	31.1	12	1	ABH79574	Oligonucleotide pr
693	8.4	31.1	12	1	ABI07513	Oligonucleotide pr
694	8.4	31.1	12	1	ABI07790	Oligonucleotide pr
695	8.4	31.1	12	1	ABI48543	Oligonucleotide pr
696	8.4	31.1	12	1	ABI53698	Oligonucleotide pr
697	8.4	31.1	12	1	ABI70210	Oligonucleotide pr
698	8.4	31.1	12	1	ABI60008	Oligonucleotide pr
699	8.4	31.1	12	1	ABI74866	Oligonucleotide pr
700	8.4	31.1	12	1	ABH76227	Oligonucleotide pr
701	8.4	31.1	12	1	ABH70324	Oligonucleotide pr
702	8.4	31.1	12	1	ABH82215	Oligonucleotide pr
703	8.4	31.1	12	1	ABH86310	Oligonucleotide pr
704	8.4	31.1	12	1	ABI12868	Oligonucleotide pr
705	8.4	31.1	12	1	ABI41815	Oligonucleotide pr
706	8.4	31.1	12	1	ABI49149	Oligonucleotide pr
707	8.4	31.1	12	1	ABI69154	Oligonucleotide pr
708	8.4	31.1	12	1	ABI74582	Oligonucleotide pr
709	8.4	31.1	12	1	ABH69592	Oligonucleotide pr
710	8.4	31.1	12	1	ABH74068	Oligonucleotide pr
711	8.4	31.1	12	1	ABH74532	Oligonucleotide pr
712	8.4	31.1	12	1	ABH99676	Oligonucleotide pr
713	8.4	31.1	12	1	ABH75004	Oligonucleotide pr
714	8.4	31.1	12	1	ABI25982	Oligonucleotide pr
715	8.4	31.1	12	1	ABI26700	Oligonucleotide pr
716	8.4	31.1	12	1	ABI44041	Oligonucleotide pr
717	8.4	31.1	12	1	ABI54160	Oligonucleotide pr
718	8.4	31.1	12	1	ABI55384	Oligonucleotide pr
719	8.4	31.1	12	1	ABI70168	Oligonucleotide pr
720	8.4	31.1	12	1	ABI59356	Oligonucleotide pr
721	8.4	31.1	12	1	ABI73271	Oligonucleotide pr
722	8.4	31.1	12	1	ABI22008	Oligonucleotide pr
723	8.4	31.1	12	1	ABI07647	Oligonucleotide pr
724	8.4	31.1	12	1	ABH6376	Oligonucleotide pr
725	8.4	31.1	12	1	ABH44319	Oligonucleotide pr
726	8.4	31.1	12	1	ABH74583	Oligonucleotide pr
727	8.4	31.1	12	1	ABI55245	Oligonucleotide pr
728	8.4	31.1	12	1	ABI63409	Oligonucleotide pr
729	8.4	31.1	12	1	ABI80489	Oligonucleotide pr
730	8.4	31.1	12	1	ABI25674	Oligonucleotide pr
731	8.4	31.1	12	1	ABH7809	Oligonucleotide pr
732	8.4	31.1	12	1	ABH78190	Oligonucleotide pr
733	8.4	31.1	12	1	ABH30496	Oligonucleotide pr
734	8.4	31.1	12	1	ABI07772	Oligonucleotide pr
735	8.4	31.1	12	1	ABI62233	Oligonucleotide pr
736	8.4	31.1	12	1	ABI50633	Oligonucleotide pr
737	8.4	31.1	12	1	ABI69035	Oligonucleotide pr
738	8.4	31.1	12	1	ABI80435	Oligonucleotide pr
739	8.4	31.1	12	1	ABH94461	Oligonucleotide pr
740	8.4	31.1	12	1	ABI19759	Oligonucleotide pr
741	8.4	31.1	12	1	ABI02122	Oligonucleotide pr
742	8.4	31.1	12	1	ABI03729	Oligonucleotide pr
743	8.4	31.1	12	1	ABI31308	Oligonucleotide pr
744	8.4	31.1	12	1	ABH44477	Oligonucleotide pr
745	8.4	31.1	12	1	ABI44147	Oligonucleotide pr
746	8.4	31.1	12	1	ABI45966	Oligonucleotide pr
747	8.4	31.1	12	1	ABI70868	Oligonucleotide pr
748	8.4	31.1	12	1	ABI57581	Oligonucleotide pr
749	8.4	31.1	12	1	ABI74058	Oligonucleotide pr
750	8.4	31.1	12	1	ABI76381	Oligonucleotide pr
751	8.4	31.1	12	1	ABI63441	Oligonucleotide pr
752	8.4	31.1	12	1	ABI80040	Oligonucleotide pr
753	8.4	31.1	12	1	ABI80160	Oligonucleotide pr
754	8.4	31.1	12	1	ABH6088	Oligonucleotide pr
755	8.4	31.1	12	1	ABH73743	Oligonucleotide pr
756	8.4	31.1	12	1	ABI00070	Oligonucleotide pr
757	8.4	31.1	12	1	ABH83889	Oligonucleotide pr
758	8.4	31.1	12	1	ABI39196	Oligonucleotide pr
759	8.4	31.1	12	1	ABI40471	Oligonucleotide pr
760	8.4	31.1	12	1	ABH92093	Oligonucleotide pr
761	8.4	31.1	12	1	ABI48451	Oligonucleotide pr
762	8.4	31.1	12	1	ABI68097	Oligonucleotide pr
763	8.4	31.1	12	1	ABI68747	Oligonucleotide pr
764	8.4	31.1	12	1	ABI56919	Oligonucleotide pr
765	8.4	31.1	12	1	ABI62778	Oligonucleotide pr
766	8.4	31.1	12	1	ABI77268	Oligonucleotide pr
767	8.4	31.1	12	1	ABI65580	Oligonucleotide pr
768	8.4	31.1	12	1	ABI66101	Oligonucleotide pr
769	8.4	31.1	12	1	ABI80039	Oligonucleotide pr
770	8.4	31.1	12	1	ABH71218	Oligonucleotide pr
771	8.4	31.1	12	1	ABI26809	Oligonucleotide pr
772	8.4	31.1	12	1	ABI02095	Oligonucleotide pr
773	8.4	31.1	12	1	ABI02251	Oligonucleotide pr
774	8.4	31.1	12	1	ABI03272	Oligonucleotide pr
775	8.4	31.1	12	1	ABH78244	Oligonucleotide pr
776	8.4	31.1	12	1	ABI30491	Oligonucleotide pr
777	8.4	31.1	12	1	ABH80892	Oligonucleotide pr
778	8.4	31.1	12	1	ABI08067	Oligonucleotide pr
779	8.4	31.1	12	1	ABH84767	Oligonucleotide pr
780	8.4	31.1	12	1	ABI37811	Oligonucleotide pr
781	8.4	31.1	12	1	ABI14259	Oligonucleotide pr
782	8.4	31.1	12	1	ABH90009	Oligonucleotide pr
783	8.4	31.1	12	1	ABI49736	Oligonucleotide pr
784	8.4	31.1	12	1	ABI74883	Oligonucleotide pr
785	8.4	31.1	12	1	ABI18050	Oligonucleotide pr
786	8.4	31.1	12	1	ABH93224	Oligonucleotide pr
787	8.4	31.1	12	1	ABH68672	Oligonucleotide pr
788	8.4	31.1	12	1	ABH74218	Oligonucleotide pr
789	8.4	31.1	12	1	ABH99975	Oligonucleotide pr
790	8.4	31.1	12	1	ABH75361	Oligonucleotide pr
791	8.4	31.1	12	1	ABI27718	Oligonucleotide pr
792	8.4	31.1	12	1	ABI07423	Oligonucleotide pr
793	8.4	31.1	12	1	ABI07539	Oligonucleotide pr
794	8.4	31.1	12	1	ABH86141	Oligonucleotide pr
795	8.4	31.1	12	1	ABI17314	Oligonucleotide pr
796	8.4	31.1	12	1	ABI43376	Oligonucleotide pr
797	8.4	31.1	12	1	ABI48057	Oligonucleotide pr
798	8.4	31.1	12	1	ABI54181	Oligonucleotide pr
799	8.4	31.1	12	1	ABI54184	Oligonucleotide pr
800	8.4	31.1	12	1	ABI68709	Oligonucleotide pr
801	8.4	31.1	12	1	ABI68786	Oligonucleotide pr
802	8.4	31.1	12	1	ABI56803	Oligonucleotide pr
803	8.4	31.1	12	1	ABI73769	Oligonucleotide pr
804	8.4	31.1	12	1	ABI78563	Oligonucleotide pr
805	8.4	31.1	12	1	ABI67192	Oligonucleotide pr
806	8.4	31.1	12	1	ABH67895	Oligonucleotide pr
807	8.4	31.1	12	1	ABH77338	Oligonucleotide pr
808	8.4	31.1	12	1	ABI34133	Oligonucleotide pr
809	8.4	31.1	12	1	ABI36475	Oligonucleotide pr
810	8.4	31.1	12	1	ABI43240	Oligonucleotide pr
811	8.4	31.1	12	1	ABI44537	Oligonucleotide pr
812	8.4	31.1	12	1	ABI45007	Oligonucleotide pr
813	8.4	31.1	12	1	ABI50001	Oligonucleotide pr
814	8.4	31.1	12	1	ABI56185	Oligonucleotide pr
815	8.4	31.1	12	1	ABI76427	Oligonucleotide pr
816	8.4	31.1	12	1	ABI78268	Oligonucleotide pr
817	8.4	31.1	12	1	ABI79156	Oligonucleotide pr
818	8.4	31.1	12	1	ABI79510	Oligonucleotide pr
819	8.4	31.1	12	1	ABI65753	Oligonucleotide pr
820	8.4	31.1	12	1	ABH73741	Oligonucleotide pr
821	8.4	31.1	12	1	ABI02843	Oligonucleotide pr
822	8.4	31.1	12	1	ABH78716	Oligonucleotide pr
823	8.4	31.1	12	1	ABH78834	Oligonucleotide pr
824	8.4	31.1	12	1	ABH82209	Oligonucleotide pr
825	8.4	31.1	12	1	ABH82461	Oligonucleotide pr
826	8.4	31.1	12	1	ABI08426	Oligonucleotide pr
827	8.4	31.1	12	1	ABH84318	Oligonucleotide pr
828	8.4	31.1	12	1	ABI46251	Oligonucleotide pr
829	8.4	31.1	12	1	ABI70904	Oligonucleotide pr
830	8.4	31.1	12	1	ABI62344	Oligonucleotide pr
831	8.4	31.1	12	1	ABI65740	Oligonucleotide pr
832	8.4	31.1	12	1	ABH67811	Oligonucleotide pr
833	8.4	31.1	12	1	ABI19419	Oligonucleotide pr
834	8.4	31.1	12	1	ABH74722	Oligonucleotide pr
835	8.4	31.1	12	1	ABH99973	Oligonucleotide pr
836	8.4	31.1	12	1	ABI26971	Oligonucleotide pr

```
C 837 8.4 31.1 12 1 ABH77510 Oligonucleotide pr
C 838 8.4 31.1 12 1 ABH03900 Oligonucleotide pr
C 839 8.4 31.1 12 1 ABH83255 Oligonucleotide pr
C 840 8.4 31.1 12 1 ABH33514 Oligonucleotide pr
C 841 8.4 31.1 12 1 ABH42680 Oligonucleotide pr
C 842 8.4 31.1 12 1 ABH44148 Oligonucleotide pr
C 843 8.4 31.1 12 1 ABH55912 Oligonucleotide pr
C 844 8.4 31.1 12 1 ABH56477 Oligonucleotide pr
C 845 8.4 31.1 12 1 ABH71747 Oligonucleotide pr
C 846 8.4 31.1 12 1 ABH72421 Oligonucleotide pr
C 847 8.4 31.1 12 1 ABH75967 Oligonucleotide pr
C 848 8.4 31.1 12 1 ABH75967 Oligonucleotide pr
C 849 8.4 31.1 12 1 ABH75967 Oligonucleotide pr
C 850 8.4 31.1 12 1 ABH62899 Oligonucleotide pr
C 851 8.4 31.1 12 1 ABH68673 Oligonucleotide pr
C 852 8.4 31.1 12 1 ABH77024 Oligonucleotide pr
C 853 8.4 31.1 12 1 ABH04988 Oligonucleotide pr
C 854 8.4 31.1 12 1 ABH05944 Oligonucleotide pr
C 855 8.4 31.1 12 1 ABH07069 Oligonucleotide pr
C 856 8.4 31.1 12 1 ABH82172 Oligonucleotide pr
C 857 8.4 31.1 12 1 ABH84446 Oligonucleotide pr
C 858 8.4 31.1 12 1 ABH87939 Oligonucleotide pr
C 859 8.4 31.1 12 1 ABH89692 Oligonucleotide pr
C 860 8.4 31.1 12 1 ABH44215 Oligonucleotide pr
C 861 8.4 31.1 12 1 ABH67950 Oligonucleotide pr
C 862 8.4 31.1 12 1 ABH70580 Oligonucleotide pr
C 863 8.4 31.1 12 1 ABH75910 Oligonucleotide pr
C 864 8.4 31.1 12 1 ABH67100 Oligonucleotide pr
C 865 8.4 31.1 12 1 ABH92370 Oligonucleotide pr
C 866 8.4 31.1 12 1 ABH68307 Oligonucleotide pr
C 867 8.4 31.1 12 1 ABH18919 Oligonucleotide pr
C 868 8.4 31.1 12 1 ABH97542 Oligonucleotide pr
C 869 8.4 31.1 12 1 ABH74170 Oligonucleotide pr
C 870 8.4 31.1 12 1 ABH74595 Oligonucleotide pr
C 871 8.4 31.1 12 1 ABH33553 Oligonucleotide pr
C 872 8.4 31.1 12 1 ABH09981 Oligonucleotide pr
C 873 8.4 31.1 12 1 ABH84528 Oligonucleotide pr
C 874 8.4 31.1 12 1 ABH36547 Oligonucleotide pr
C 875 8.4 31.1 12 1 ABH14509 Oligonucleotide pr
C 876 8.4 31.1 12 1 ABH40947 Oligonucleotide pr
C 877 8.4 31.1 12 1 ABH16868 Oligonucleotide pr
C 878 8.4 31.1 12 1 ABH51360 Oligonucleotide pr
C 879 8.4 31.1 12 1 ABH51468 Oligonucleotide pr
C 880 8.4 31.1 12 1 ABH76055 Oligonucleotide pr
C 881 8.4 31.1 12 1 ABH64981 Oligonucleotide pr
C 882 8.4 31.1 12 1 ABH66823 Oligonucleotide pr
C 883 8.4 31.1 12 1 ABH80759 Oligonucleotide pr
C 884 8.4 31.1 12 1 ABH234313 HIV-1 reverse tran
C 885 8.4 31.1 12 1 ADF78584 Chromosomal abnorm
C 886 8.4 31.1 12 1 ADF78619 Chromosomal abnorm
```

ALIGNMENTS

```
RESULT 1
ADB25654/c
ID ADB25654 standard; DNA; 20 BP.
XX
AC ADB25654;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human connective tissue growth factor antisense oligo DNA (seqid 47).
XX
KW antisense; human; ss; connective tissue growth factor; CTGF;
KW chromosome 6q23.1; ctgofact; fibroblast inducible secreted protein;
KW fisp-12; NOV2;
KW insulin-like growth factor binding protein-related protein 2; IGFBP-rp2;
KW IGFBP-8; Hcs24; ecogenin; acute lymphoblastic leukaemia; gene therapy;
KW hyperproliferative disorder; cancer; pulmonary fibrosis; renal fibrosis;
KW scleroderma; atherosclerosis; cytostatic; dermatological;
KW antiarteriosclerotic.

Query Match 74.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1,2;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2213 GAGTGTGACCAAAAGTTACA 2232
Db 20 GAGTGTGACCAAAAGTTACA 1

RESULT 2
ADB25671/c
ID ADB25671 standard; DNA; 20 BP.
XX
AC ADB25671;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human connective tissue growth factor antisense oligo DNA (seqid 64).
XX
KW antisense; human; ss; connective tissue growth factor; CTGF;
```

KW chromosome 6q23.1; ctgfact; fibroblast inducible secreted protein;
 KW fisp-12; NOV2;
 KW insulin-like growth factor binding protein-related protein 2; IGFBP-rp2;
 KW IGFBP-8; Hcs24; ecogenin; acute lymphoblastic leukaemia; gene therapy;
 KW hyperproliferative disorder; cancer; pulmonary fibrosis; renal fibrosis;
 KW scleroderma; atherosclerosis; cytostatic; dermatological;
 KW antiarteriosclerotic.
 OS Homo sapiens.
 XX
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "OTHER= phosphorothioate backbone, where 1-5 and
 FT 16-20 are 2' methoxyethyl nucleotides. All cytidines are
 FT 5-methylcytidines"
 XX
 XX
 PN WO2003053340-A2.
 XX
 XX
 PD 03-JUL-2003.
 XX
 XX
 PF 09-DEC-2002; 2002WO-US038618.
 XX
 XX
 PR 10-DEC-2001; 2001US-00006191.
 XX
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 XX
 PI Gaarde WA, Watt AT;
 XX
 DR WPI; 2003-559091/52.
 XX
 XX
 PT New antisense oligonucleotides for modulating connective tissue growth
 PT factor expression, particularly useful for treating cancers (e.g. breast
 PT or prostate cancer), pulmonary or renal fibrosis, scleroderma or
 PT atherosclerosis.
 XX
 PS Claim 3; Page 85; 139pp; English.
 XX
 CC This invention relates to novel methods for modulating the expression of
 CC connective tissue growth factor (CTGF) by antisense oligonucleotides.
 CC CTGF has been mapped to human chromosome region 6q23.1, and is also known
 CC as ctgfact, fibroblast inducible secreted protein, fisp-12, NOV2,
 CC insulin-like growth factor binding protein-related protein 2, IGFBP-rp2,
 CC IGFBP-8, Hcs24 and ecogenin. It is known to stimulate DNA synthesis and
 CC promote chemotaxis of fibroblasts, however, it is also upregulated in
 CC acute lymphoblastic leukaemia and in tumour or endothelial cells
 CC associated with the vasculature. Accordingly, antisense oligonucleotides
 CC that inhibit the expression of CTGF in cells or tissues can be used in
 CC gene therapy to treat various conditions including hyperproliferative
 CC disorders (particularly cancer, e.g. breast, prostate or renal cancer),
 CC pulmonary fibrosis, renal fibrosis, scleroderma and atherosclerosis. As
 CC such, the present invention describes these antisense oligos as having
 CC cytostatic, dermatological and antiarteriosclerotic activities. This
 CC oligonucleotide sequence is a chimeric phosphorothioate antisense oligo
 CC with 2' MOE wings and a deoxy gap, which is used to inhibit expression of
 CC human CTGF of the invention.
 XX
 SQ Sequence 20 BP; 6 A; 4 C; 3 G; 7 T; 0 U; 0 Other;
 Query Match 74.1%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.2;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2219 GACCAAAAGTTACATGTTG 2238
 DB 20 GACCAAAAGTTACATGTTG 1
 RESULT 3
 ADB25655/c
 ID ADB25655 standard; DNA; 20 BP.
 XX

AC ADB25655;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Human connective tissue growth factor antisense oligo DNA (SeqID 48).
 XX
 KW antisense; human; ss; connective tissue growth factor; CTGF;
 KW chromosome 6q23.1; ctgfact; fibroblast inducible secreted protein;
 KW fisp-12; NOV2;
 KW insulin-like growth factor binding protein-related protein 2; IGFBP-rp2;
 KW IGFBP-8; Hcs24; ecogenin; acute lymphoblastic leukaemia; gene therapy;
 KW hyperproliferative disorder; cancer; pulmonary fibrosis; renal fibrosis;
 KW scleroderma; atherosclerosis; cytostatic; dermatological;
 KW antiarteriosclerotic.
 OS Homo sapiens.
 XX
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "OTHER= phosphorothioate backbone, where 1-5 and
 FT 16-20 are 2' methoxyethyl nucleotides. All cytidines are
 FT 5-methylcytidines"
 XX
 XX
 PN WO2003053340-A2.
 XX
 XX
 PD 03-JUL-2003.
 XX
 XX
 PF 09-DEC-2002; 2002WO-US038618.
 XX
 XX
 PR 10-DEC-2001; 2001US-00006191.
 XX
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 XX
 PI Gaarde WA, Watt AT;
 XX
 DR WPI; 2003-559091/52.
 XX
 XX
 PT New antisense oligonucleotides for modulating connective tissue growth
 PT factor expression, particularly useful for treating cancers (e.g. breast
 PT or prostate cancer), pulmonary or renal fibrosis, scleroderma or
 PT atherosclerosis.
 XX
 PS Claim 3; Page 85; 139pp; English.
 XX
 CC This invention relates to novel methods for modulating the expression of
 CC connective tissue growth factor (CTGF) by antisense oligonucleotides.
 CC CTGF has been mapped to human chromosome region 6q23.1, and is also known
 CC as ctgfact, fibroblast inducible secreted protein, fisp-12, NOV2,
 CC insulin-like growth factor binding protein-related protein 2, IGFBP-rp2,
 CC IGFBP-8, Hcs24 and ecogenin. It is known to stimulate DNA synthesis and
 CC promote chemotaxis of fibroblasts, however, it is also upregulated in
 CC acute lymphoblastic leukaemia and in tumour or endothelial cells
 CC associated with the vasculature. Accordingly, antisense oligonucleotides
 CC that inhibit the expression of CTGF in cells or tissues can be used in
 CC gene therapy to treat various conditions including hyperproliferative
 CC disorders (particularly cancer, e.g. breast, prostate or renal cancer),
 CC pulmonary fibrosis, renal fibrosis, scleroderma and atherosclerosis. As
 CC such, the present invention describes these antisense oligos as having
 CC cytostatic, dermatological and antiarteriosclerotic activities. This
 CC oligonucleotide sequence is a chimeric phosphorothioate antisense oligo
 CC with 2' MOE wings and a deoxy gap, which is used to inhibit expression of
 CC human CTGF of the invention.
 XX
 SQ Sequence 20 BP; 7 A; 3 C; 3 G; 7 T; 0 U; 0 Other;
 Query Match 74.1%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.2;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2218 TGACCAAAAGTTACATGTTT 2237
 |||||

CC such, the present invention describes these antisense oligos as having
 CC cytotostatic, dermatological and antiarteriosclerotic activities. This
 CC oligonucleotide sequence is a chimeric phosphorothioate antisense oligo
 CC with 2' MOE wings and a deoxy gap, which is used to inhibit expression of
 CC human CRGF of the invention.

XX Sequence 20 BP; 4 A; 7 C; 2 G; 7 T; 0 U; 0 Other;
 SQ Query Match 59.3%; Score 16; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 11;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2212 AGAGTGTGACCAAAAG 2227
 Db 16 AGAGTGTGACCAAAAG 1

RESULT 6
 ABK40462/c
 ID ABK40462 standard; DNA; 20 BP.

XX AC ABK40462;

XX DT 15-JUL-2002 (first entry)

XX DE Forward PCR primer for gene amplification analysis of human PRO4980.

XX Human; PRO; benign tumour; malignant tumour; lymphoid malignancy;
 KW leukaemia; neuronal disorder; stromal disorder; blastocoele disorder;
 KW inflammatory disorder; immune disorder; angiogenic disorder; cytostatic;
 KW neuroprotective; PCR; primer; ss.

XX OS Homo sapiens.

XX PN WO200153486-A1.

XX PD 26-JUL-2001.

XX PF 11-FEB-2000; 2000WO-US003565.

XX PR 08-MAR-1999; 99WO-US005028.

XX PR 11-MAR-1999; 99US-0123972P.

XX PR 11-MAY-1999; 99US-0133459P.

XX PR 02-JUN-1999; 99WO-US012252.

XX PR 22-JUN-1999; 99US-0140650P.

XX PR 22-JUN-1999; 99US-0140853P.

XX PR 20-JUL-1999; 99US-0144758P.

XX PR 26-JUL-1999; 99US-0145698P.

XX PR 28-JUL-1999; 99US-0146222P.

XX PR 17-AUG-1999; 99US-0149395P.

XX PR 31-AUG-1999; 99US-0151689P.

XX PR 01-SEP-1999; 99WO-US020111.

XX PR 15-SEP-1999; 99WO-US021090.

XX PR 30-NOV-1999; 99WO-US028313.

XX PR 01-DEC-1999; 99WO-US028301.

XX PR 01-DEC-1999; 99WO-US028634.

XX PR 05-JAN-2000; 2000WO-US000219.

XX PA (GETH) GENENTECH INC.

XX PI Ashkenazi AJ, Goddard A, Godowski PJ, Gurney AL, Hillan KJ;
 PI Marsters SA, Pan J, Pitti RM, Roy NA, Smith V, Stone DM;
 PI Watanabe CK, Wood WI;

XX WPI; 2002-205567/26.

CC polypeptides (AAU86128-AAU86162) and the polynucleotide sequences
 CC encoding them. The PRO polypeptides, agonists, antagonists or anti-PRO
 CC antibodies are useful for treating benign or malignant tumours (e.g.
 CC renal, kidney, bladder, breast, etc), leukaemias and lymphoid
 CC malignancies, other disorders such as neuronal, glial, astrocytal,
 CC hypothalamic, glandular, macrophagal, stromal and blastocoele disorders,
 CC inflammatory, immune and angiogenic disorders. The polynucleotide
 CC sequences are also useful in gene therapy. The present invention
 CC represents a PCR primer used in the methods of the present invention

XX SQ Sequence 20 BP; 4 A; 6 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 53.3%; Score 14.4; DB 1; Length 20;
 Best Local Similarity 93.8%; Pred. No. 28;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2212 AGAGTGTGACCAAAAG 2227
 Db 20 AGAGTGTGACCAAAAG 5

RESULT 7

ADJ37525/c

ID ADJ37525 standard; DNA; 20 BP.

XX AC ADJ37525;

XX DT 22-APR-2004 (first entry)

XX DE Tumour therapy associated PRO4980 primer seq id 244.

XX Cytostatic; gene therapy; PRO; PRO197; PRO207; PRO232; PRO243;
 KW PRO256; PRO269; PRO274; PRO304; PRO339; PRO558; PRO779; PRO1185;
 KW PRO1245; PRO1759; PRO5775; PRO7133; PRO7168; PRO5725; PRO202; PRO206;
 KW PRO264; PRO313; PRO342; PRO542; PRO773; PRO861; PRO1216; PRO1686;
 KW PRO1800; PRO3562; PRO3850; PRO539; PRO4316; PRO4980; cancer; tumour;
 KW neoplastic cell growth; neoplastic cell proliferation; carcinoma;
 KW lymphoma; blastoma; sarcoma; leukaemia; primer; ss.

XX OS Homo sapiens.

XX PN US2003211096-A1.

XX PD 13-NOV-2003.

XX PF 02-AUG-2002; 2002US-00211858.

XX PR 31-AUG-1999; 99US-0151689P.

XX PR 11-FEB-2000; 2000WO-US003565.

XX PR 09-AUG-2001; 2001US-00927796.

XX PA (GETH) GENENTECH INC.

XX PI Ashkenazi AJ, Goddard A, Godowski PJ, Gurney AL, Hillan KJ;
 PI Marsters SA, Pan J, Pitti RM, Roy NA, Smith V, Stone DM;
 PI Watanabe CK, Wood WI;

XX WPI; 2003-901564/82.

XX New isolated PRO polypeptides, useful as targets for the diagnosis,
 PT prevention and treatment of cancers, e.g. lymphoma, blastoma, sarcoma or
 PT leukemia, and as predictors of the prognosis of tumor treatment.

XX Example 26; SEQ ID NO 244; 307pp; English.

XX The invention describes an isolated PRO polypeptide. The PRO polypeptide:
 CC has at least 80% amino acid sequence identity to: (1) any one of 35 fully
 CC defined sequences of 104-954 amino acids (designated P1-P35) given in the
 CC specification, with or without its associated signal peptide; (2) an
 CC extracellular domain of any one of the polypeptides of P1-P35, with or
 CC without its associated signal peptide; or (3) an amino acid sequence
 CC encoded by the full-length coding sequence of the DNA deposited under
 CC ATCC accession number 209284, 209358, 209376, 209250, 209508, 209379,

CC acute lymphoblastic leukaemia and in tumour or endothelial cells
 CC associated with the vasculature. Accordingly, antisense oligonucleotides
 CC that inhibit the expression of CTGF in cells or tissues can be used in
 CC gene therapy to treat various conditions including hyperproliferative
 CC disorders (particularly cancer, e.g. breast, prostate or renal cancer),
 CC pulmonary fibrosis, renal fibrosis, scleroderma and atherosclerosis. As
 CC such, the present invention describes these antisense oligos as having
 CC cytostatic, dermatological and antiarteriosclerotic activities. This
 CC oligonucleotide sequence is a chimeric phosphorothioate antisense oligo
 CC with 2' MOE wings and a deoxy gap, which is used to inhibit expression of
 CC human CTGF of the invention.

XX
 SQ Sequence 20 BP; 6 A; 6 C; 2 G; 6 T; 0 U; 0 Other;
 Query Match 51.9%; Score 14; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 34;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2212 AGAGTGTGACCAAA 2225

DB 14 AGAGTGTGACCAAA 1

RESULT 10
 AAV96534/c
 ID AAV96534 standard; RNA; 17 BP.

XX AC AAV96534;
 XX 01-MAR-1999 (first entry)

XX Potato citrate synthase target sequence position 812.
 DE Solandine; glucosyltransferase; potato; citrate synthase; target;
 KW hammerhead ribozyme; hairpin ribozyme; alkaloid biosynthesis;
 KW flower formation; cleavage; solanaceous plant; ss.

XX Solanum tuberosum.
 OS WO9832843-A2.
 FN 30-JUL-1998.

XX 14-JAN-1998; 98WO-US000738.
 XX 28-JAN-1997; 97US-0036545P.
 XX 28-JAN-1997; 97US-0036599P.
 XX 24-NOV-1997; 97US-00979416.

XX (RIBO-) RIBOZYME PHARM INC.
 PA Zwick MG, Mcswiggen JA;
 PI WPI; 1998-427939/36.

XX New enzymatic nucleic acid(s) - useful for, e.g. reducing alkaloid
 XX biosynthesis or regulating flowering.
 XX Claim 53; Page 54; 79pp; English.

XX The present invention describes enzymatic nucleic acid molecules with RNA
 CC -cleaving activity (e.g. ribozymes) which are capable of modulating the
 CC expression of plant genes: (i) involved in biosynthesis of alkaloids; or
 CC (ii) involved in flower formation. AAV95982 to AAV96334, and AAV96335 to
 CC AAV96354 represent potato solandine glucosyltransferase hammerhead and
 CC hairpin ribozymes, respectively. AAV95629 to AAV95981, and AAV96355 to
 CC AAV96734 represent potato solandine glucosyltransferase target
 CC sequences. AAV96733 to AAV97170, and AAV97171 to AAV97195 represent
 CC potato citrate synthase hammerhead and hairpin ribozymes, respectively.
 CC AAV96735 to AAV96772, and AAV97196 to AAV97220 represent potato citrate
 CC synthase target sequences. Ribozymes of the present invention can be used
 CC to inhibit the synthesis of toxic alkaloids in solanaceous plants,
 CC particularly potato but also tomato, pepper, aubergine and ditura or to

CC inhibit flowering in potato, lettuce, spinach, cabbage, brussel sprouts,
 CC arugula, kale, collards, chard, beet, turnip, sweet potato and turf
 CC grass. Also the ribozymes can be used for RNA manipulation in the same
 CC way that restriction endonucleases are for DNA, as well as to examine
 CC genetic drift and mutations in plants and to detect specific RNA. The
 CC ribozymes can be targeted to specific genes or to consensus sequences
 CC within a family of related genes, and being catalytic need to be present
 CC at only very low concentrations

XX Sequence 17 BP; 5 A; 4 C; 2 G; 0 T; 6 U; 0 Other;
 SQ

Query Match 45.2%; Score 12.2; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 72;
 Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2216 TGTGACCAAAAGTTTACA 2232

DB 17 TGTGACCAAAAGTTTACA 1

RESULT 11
 ABV89418

ID ABV89418 standard; DNA; 17 BP.

XX AC ABV89418;
 XX 23-DEC-2002 (first entry)

XX Human POSHL1 scanning oligonucleotide SEQ ID NO 131.
 DE Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
 KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
 KW gene therapy; transgenic; ss.

XX Homo sapiens.
 OS EP1239051-A2.
 FN 11-SEP-2002.

XX 28-JAN-2002; 2002EP-00001165.
 XX 30-JAN-2001; 2001WO-US000663.
 XX 30-JAN-2001; 2001WO-US000664.
 XX 30-JAN-2001; 2001WO-US000665.
 XX 30-JAN-2001; 2001WO-US000666.
 XX 30-JAN-2001; 2001WO-US000667.
 XX 30-JAN-2001; 2001WO-US000668.
 XX 30-JAN-2001; 2001WO-US000669.
 XX 30-JAN-2001; 2001WO-US000670.
 XX 23-MAY-2001; 2001US-00864761.
 XX 10-OCT-2001; 2001US-0328205P.

XX (AECOM-) AECOMICA INC.

XX Shannon M;
 XX WPI; 2002-684061/74.

XX Novel human SH3 domain (POSH)-like signaling protein 1 polypeptide, POSHL
 PT -1, useful for treating disorders associated with decreased expression or
 PT activity of human POSHL1.
 PS Example 2; SEQ ID NO 131; 60pp + Sequence Listing; English.

XX The invention relates to an isolated SH3 domain (POSH)-like signalling
 CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
 CC acids (SI, AB883999), a sequence having 65% sequence identity to (SI),
 CC (SI) having 95% deviations, especially conservative substitutions or a
 CC fragment of the sequences comprising at least 8 contiguous amino acids.
 CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
 CC adaptor protein that interacts with Rho family small GTPases as well as
 CC downstream components of the signal transduction pathway. (I) is useful

CC for identifying a specific binding partner. (I) and nucleic acids (II)
CC encoding (I) are useful for diagnosing, monitoring disease and treating
CC caused by altered expression of human PSHL1 including diagnosing and
CC treating cancer, they useful in the development of vaccines and (II) is
CC useful in gene therapy. (II) is useful for constructing microarrays which
CC are useful for measuring and for surveying gene expression and creating
CC transgenic non-human animals capable of producing the proteins. The
CC present sequence is that of a scanning oligonucleotide useful in examples
CC of the invention. Note: The present sequence did not form part of the
CC printed specification, but is based on sequence information supplied to
CC Berwent by the European Patent Office

XX SQ Sequence 17 BP; 6 A; 3 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 45.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 72;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2219 TGACCAAAAGTTACATG 2234
1 TCAGCAGAGTTACATG 17

RESULT 12
ADI48826
ID ADI48826 standard; DNA; 17 BP.
AC ADI48826;
XX
DT 15-APR-2004 (first entry)
XX
DE Human tumour suppression/reversion-related DNA sequence SeqID1329.
XX
KW tumour suppression; tumour reversion; apoptosis; virus resistance;
KW cytostatic; virucide; neuroprotective; neurotropic; neuroleptic; probe;
KW primer; PCR; gene chip; antisense; viral disease; tumour;
KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS Homo sapiens.

XX WO2003025177-A2.
XX 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004523.
XX
PR 17-SEP-2001; 2001FR-00011980.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313354/30.

XX New isolated nucleic acid, useful for treating viral diseases associated
XX with tumours and cell degeneration, also related polypeptides, antibodies
XX and transfected cells.
XX
PS Disclosure; SEQ ID NO 1329; 30pp; French.

XX The invention relates to novel isolated nucleic acid sequences involved
XX in the phenomena of tumour suppression, tumour reversion, apoptosis
XX and/or resistance to viruses. The invention may be useful for the
XX development of compounds with a cytostatic, virucide, neuroprotective,
XX neurotropic or neuroleptic activity. The DNA sequences may be useful as
XX probes and primers for detecting, identifying, quantifying and/or
XX amplifying nucleic acid, for example as one component of a gene chip, in
XX vitro antisense reagents and for production of recombinant
XX polypeptides. The invention may therefore be useful for preparation of
XX pharmaceuticals for prevention and/or treatment of viral diseases that
XX are characterised by development and/or treatment of viral diseases that
XX specifically cancer but also Alzheimer's disease and schizophrenia. The
XX present sequence is that of a nucleic acid sequence of the invention.

CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/publishedseq_sequences

XX SQ Sequence 17 BP; 7 A; 3 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 45.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 72;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2219 GACCAAAAGTTACATG 2235
1 GATCAAAAATTACCTGT 17

RESULT 13
ADL49182/c
ID ADL49182 standard; RNA; 17 BP.
AC ADL49182;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human PKR substrate sequence #296.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
XX protein kinase PKR; cerebrovascular accident;
XX central nervous system injury; CNS injury; spinal cord injury; cancer;
XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX restenosis; asthma; Crohn's disease; diabetes; obesity;
XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
XX substrate; ds.

XX Unidentified.
XX WO200281628-A2.
XX 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.

XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 2715; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX
SQ Sequence 17 BP; 6 A; 2 C; 2 G; 0 T; 7 U; 0 Other;
Query Match 45.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 72;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 2217 GTGACCAAAAGTTACAT 2233
DB 17 GTGACCAATATTACAT 1
RESULT 14
ADL50023/c
ID ADL50023 standard; RNA; 17 BP.
XX
AC ADL50023;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human PKR substrate sequence #1137.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PK3; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PK3;
KW substrate; ds.
XX
OS Unidentified.
XX
FN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
PI Blatt L, Chowira B, Haerberli P, Meswigen J, Fosnaugh K;
XX
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 3556; 317pp; English.
PS
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PK3. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 4 C; 5 G; 0 T; 5 U; 0 Other;
Query Match 45.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 72;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 2216 TGTGACCAAAAGTTACA 2232
DB 17 TGTGACCGCAAGTCACA 1
RESULT 15
ABC78606
ID ABC78606 standard; DNA; 13 BP.
XX
AC ABC78606;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 78623 for detecting SNP TSC00200009.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
FN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 78623; 29pp + Sequence Listing; German.
PS
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABH00010-ABH92073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
Query Match 42.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 76;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2226 AGTTACATGTTTG 2238
DB 1 AGTTATATGTTTG 13

peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
central nervous system; gastrointestinal; respiratory; immune; metabolic.
Homo sapiens.
WO200177384-A2.
18-OCT-2001.
06-APR-2001; 2001WO-IB000713.
07-APR-2000; 2000DE-01019173.
(EPIG-) EPIGENOMICS AG.
Olek A, Piepenbrock C, Berlin K;
WPI; 2001-657177/75.
Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.
Claim 1; SEQ ID NO 78626; 29pp + Sequence Listing; German.
This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation. ABC00010
-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 4 C; 1 G; 2 T; 0 U; 0 Other;
Query Match 42.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 76;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2226 AGTTACATGTTTG 2238
Db 13 AGTTACATGTTTG 1
RESULT 18
ABC30594
ID ABC30594 standard; DNA; 13 BP.
XX
AC ABC30594;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 30611 for detecting SNP TSC0009381.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 78626; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 4 C; 1 G; 2 T; 0 U; 0 Other;
Query Match 42.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 76;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2226 AGTTACATGTTTG 2238
Db 13 AGTTACATGTTTG 1
RESULT 18
ABC30594
ID ABC30594 standard; DNA; 13 BP.
XX
AC ABC30594;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 30611 for detecting SNP TSC0009381.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX

peptide nucleic acid; cytosine methylation; human; diagnosis; PNA; cancer; CNS;
peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
central nervous system; gastrointestinal; respiratory; immune; metabolic.
Homo sapiens.
WO200177384-A2.
18-OCT-2001.
06-APR-2001; 2001WO-IB000713.
07-APR-2000; 2000DE-01019173.
(EPIG-) EPIGENOMICS AG.
Olek A, Piepenbrock C, Berlin K;
WPI; 2001-657177/75.
Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.
Claim 1; SEQ ID NO 78624; 29pp + Sequence Listing; German.
This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation. ABC00010
-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 7 A; 3 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 42.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 76;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2226 AGTTACATGTTTG 2238
Db 13 AGTTACATGTTTG 1
RESULT 17
ABC78609/c
ID ABC78609 standard; DNA; 13 BP.
XX
AC ABC78609;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 78626 for detecting SNP TSC0020009.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

PA (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 30611; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 5 A; 0 C; 2 G; 6 T; 0 U; 0 Other;
 Query Match 42.2%; Score 11.4; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 76;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2224 AAGTTACATGTT 2236
 DB 1 AAGTTACATGTT 13
 RESULT 19
 ABC78608
 ID ABC78608 standard; DNA; 13 BP.
 XX
 XX ABC78608;
 AC
 XX 21-FEB-2002 (first entry)
 DT
 XX Oligonucleotide SEQ ID NO 78625 for detecting SNP TSC0020009.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 78625; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 2 A; 1 C; 4 G; 6 T; 0 U; 0 Other;
 Query Match 42.2%; Score 11.4; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 76;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2226 AGTTACATGTTG 2238
 DB 1 AGTTACATGTTG 13
 RESULT 20
 ABC24651
 ID ABC24651 standard; DNA; 13 BP.
 XX
 XX ABC24651;
 AC
 XX 20-FEB-2002 (first entry)
 DT
 XX Oligonucleotide SEQ ID NO 24668 for detecting SNP TSC0005912.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 24668; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 5 A; 4 C; 1 G; 3 T; 0 U; 0 Other;

AC	ABC30595;
DT	20-FEB-2002 (first entry)
DE	Oligonucleotide SEQ ID NO 30612 for detecting SNP TSC0009381.
KW	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW	central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS	Homo sapiens.
PN	WO200177384-A2.
PD	18-OCT-2001.
PF	06-APR-2001; 2001WO-IB000713.
PR	07-APR-2000; 2000DE-01019173.
PA	(EPIG-) EPIGENOMICS AG.
PI	Olek A, Piepenbrock C, Berlin K;
XX	WPI; 2001-657177/75.
PT	Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.
PS	Claim 1; SEQ ID NO 30612; 29pp + Sequence Listing; German.
CC	This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences
SQ	Sequence 13 BP; 6 A; 2 C; 0 G; 5 T; 0 U; 0 Other;
	Query Match 42.2%; Score 11.4; DB 1; Length 13;
	Best Local Similarity 92.3%; Pred.No.76;
	Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY	2224 AAAGTTACATGTT 2236
Db	13 AAAGTTATAGTT 1
RESULT 23	
AAAX30977/c	ID ID AAX30977 standard; DNA; 15 BP.
XX AC	AAX30977;
XX AC	AAX30977;
DT DT	21-MAY-1999 (first entry)
DE DE	Tag sequence of a transcript increased in colorectal cancer.
XX KW	Tag sequence; colorectal cancer; pancreatic cancer; colon cancer;
XX KW	diagnosis; prognosis; treatment.-ss..
XX OS	Homo sapiens.
XX PN	WO9853319-A2.

XX PD 26-NOV-1998.
 XX FF 20-MAY-1998; 98WO-US010277.
 XX PR 21-MAY-1997; 97US-0047352P.
 XX PA (UYJO) UNIV JOHNS HOPKINS.
 XX PI Vogelstein B, Kinzler KW;
 XX DR WPI; 1999-070161/06.
 XX PT Use of isolated gene transcripts - useful for developing products for the
 PT diagnosis, prognosis and treatment of cancers, particularly colon and
 PT pancreatic cancer.
 XX PS Claim 2; Page 23; 120pp; English.
 XX CC AAX30947-31815 represent tag sequences of transcripts that are
 CC differentially expressed in colorectal cancer, in pancreatic cancer, or
 CC in both. The tag sequences can be used to identify genes by matching the
 CC tag to a gen data base member, or by using the tag sequences as probes to
 CC isolate unidentified genes from cDNA libraries. The tag sequences can
 CC also be used in a method for diagnosing colon or pancreatic cancer in a
 CC sample suspected of being neoplastic. The method comprises comparing the
 CC level of at least one transcript in a first sample of a tissue to a
 CC second sample, where the first sample is a colonic tissue suspected of
 CC being neoplastic and the second sample is a normal human colonic tissue.
 CC The transcript is identified by a tag selected from AAX30947-31815. The
 CC methods of the invention can be used in the diagnosis, prognosis and
 CC treatment of cancer
 XX SQ Sequence 15 BP; 3 A; 3 C; 2 G; 7 T; 0 U; 0 Other;
 Query Match 42.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 93;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2222 CAAAAGTTACATG 2234
 Db 13 CAAAATTACATG 1
 RESULT 24
 ABK31930/c
 ID ABK31930 standard; DNA; 15 BP.
 AC ABK31930;
 XX DT 23-APR-2002 (first entry)
 XX DE Human colon cancer SAGE tag #31.
 XX KW Human; colon cancer; colorectal cancer; pancreatic cancer; SAGE tag;
 KW serial analysis of gene expression; diagnostic; prognostic; probe;
 KW cancer marker; ss.
 XX OS Homo sapiens.
 XX US6333152-B1.
 XX PD 25-DEC-2001.
 XX PF 20-MAY-1998; 98US-00081646.
 XX PR 20-MAY-1998; 98US-00081646.
 XX PA (UYJO) UNIV JOHNS HOPKINS.
 XX PI Vogelstein B, Kinzler KW, Zhang L, Zhou W;
 XX DR WPI; 2002-153821/20.

XX PT New human nucleic acid containing specific SAGE tags, useful as
 PT diagnostic markers for cancer, also derived probes.
 XX PS Disclosure; Col 15; 161pp; English.
 XX CC The invention relates to an isolated, purified human nucleic acid (I)
 CC that has the same sequence as a mRNA found in humans and is a SAGE
 CC (serial analysis of gene expression) tag comprising a single stranded
 CC probe containing at least 10 consecutive nucleotides. SAGE tags, are
 CC diagnostic and prognostic markers of cancer, especially of the colon and
 CC pancreas. ABK31900-ABK32770 represent human colon and pancreatic cancer
 CC SAGE tags of the invention
 XX SQ Sequence 15 BP; 3 A; 3 C; 2 G; 7 T; 0 U; 0 Other;
 Query Match 42.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 93;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2222 CAAAAGTTACATG 2234
 Db 13 CAAAATTACATG 1
 RESULT 25
 ABK70527
 ID ABK70527 standard; DNA; 15 BP.
 AC ABK70527;
 XX DT 15-JUL-2002 (first entry)
 XX DE Human G protein-coupled receptor 7 allele-specific probe #11.
 XX KW Human; G protein-coupled receptor 7; GPR7; haplotyping; SNP;
 KW psychological disorder; neurological disorder; probe; ss;
 XX OS single nucleotide polymorphism.
 XX OS Homo sapiens.
 XX WO200222644-A1.
 XX PD 21-MAR-2002.
 XX PF 17-SEP-2001; 2001WO-US029207.
 XX PR 15-SEP-2000; 2000US-0232900P.
 XX PA (GENA-) GENAISSANCE PHARM INC.
 XX PI Koshiy B, Sanchis A, Tirrell C;
 XX DR WPI; 2002-383121/41.
 XX PT Novel genetic variants of G protein-coupled receptor 7 gene useful for
 PT therapeutic purposes and for expressing GPR7 protein useful in
 PT identifying drugs to treat psychological and neurological disorders.
 XX PS Claim 16; Page 13; 69pp; English.
 XX CC The invention relates to an isolated polynucleotide (I) comprising a
 CC nucleotide sequence which is a polymorphic variant of a reference
 CC sequence for G-protein coupled receptor 7 (GPR7) gene or its fragment, or
 CC a polymorphic variant of a reference sequence for a GPR7 cDNA or its
 CC fragment. The encoded polypeptide (II) is useful for screening for drugs
 CC targeting the polypeptide. (I) is useful for identifying an association
 CC between a trait such as a clinical response to a drug targeting GPR7 and
 CC a haplotype or haplotype pair of GPR7 gene. Such methods have
 CC applicability in developing diagnostic tests and therapeutic treatments
 CC psychological and neurological disorders. (I) is useful for studying the
 CC expression and function of GPR7 and expressing GPR7 protein for use in
 CC screening for candidate drugs to treat diseases related to GPR7 activity.

CC The polymorphism and haplotype data are useful for validating whether
 CC GPR7 is a suitable target for drugs to treat psychological and
 CC neurological disorders, screening for such drugs and reducing bias in
 CC clinical trials of such drugs. (I) is useful for therapeutic purposes.
 CC Establishing the GPR7 haplotype or haplotype pair of an individual is
 CC useful for improving the efficiency and reliability of several steps in
 CC the discovery and development of drugs for treating diseases associated
 CC with GPR7 activity psychological and neurological disorders. The
 CC haplotyping method is useful to validate GPR7 as a candidate target for
 CC treating a specific condition or disease predicted to be associated with
 CC GPR7 activity. The method is also useful in screening for compounds
 CC targeting GPR7 to treat a specific condition or disease predicted to be
 CC associated with GPR7 activity, e.g. detecting which of the GPR7
 CC haplotypes or haplotype pairs present in individual members of a
 CC population with the specific disease of interest enables one to screen
 CC for compounds that display the highest desired agonist or antagonist
 CC activity for each of the most frequent GPR7 isoforms present in the
 CC disease population. A polymorphic variant of GPR7 is useful in studying
 CC the effect of the variation on the biological activity of GPR7, on the
 CC binding affinity of candidate drugs targeting GPR7 for the treatment of
 CC psychological and neurological disorders and in assays to measure the
 CC binding affinities of one or more candidate drugs targeting the GPR7
 CC protein. (I) is useful for studying expression of the GPR7 isoforms in
 CC vivo, for in vivo screening and testing of drugs against GPR7 protein and
 CC for testing the efficacy of therapeutic agents and compounds for
 CC psychological and neurological disorders in a biological system. Antibody
 CC to (II) is useful for diagnostic and prognostic formats and therapeutic
 CC methods, for immunoprecipitating (II) from solution, for detecting GPR7
 CC protein isoforms in biological samples, frozen tissue sections, cells
 CC which have been fixed or unfixed and prepared on slides, for use in
 CC immunocytochemical, immunohistochemical and immunofluorescence
 CC techniques. ABK70517-ABK70558 represent human GPR7 allele-specific probes
 CC and primers used in haplotyping of human GPR7 as described in the
 CC invention.

XX
 SQ Sequence 15 BP; 5 A; 2 C; 2 G; 5 T; 0 U; 1 Other;

Query Match 40.7%; Score 11; DB 1; Length 15;
 Best Local Similarity 84.6%; Pred. No. 1.2e+02;
 Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 2222 CAAAGTTACATG 2234

DB 3 CTAAGTTACATG 15

RESULT 26

AAD15778/c

XX AAD15778 standard; DNA; 15 BP.

XX AAD15778;

XX 15-NOV-2001 (first entry)

DE Human interleukin 15 (IL-15) gene polymorphism detecting ASO primer #26.

XX Human; interleukin 15; IL-15; gene therapy; chromosome 4q31; infection;
 XX drug screening; anthropological lineage; paternity testing; HIV; primer;
 XX Human Immunodeficiency Virus; forensic application; T-cell leukaemia;
 XX ASO; allele-specific oligonucleotide; ss.

XX Homo sapiens.

XX WO200158914-A2.

XX 16-AUG-2001.

XX 08-FEB-2001; 2001WO-US004130.

XX 08-FEB-2000; 2000US-0181059P.

XX (GENA-) GENAISSANCE PHARM INC.

XX

PI

Anastasio AE, Chew A, Denton RR, Nandabalan K, Stephens JC;

DR WPI; 2001-522460/57.

XX Novel polymorphisms comprising one of 11, PS1-PS11, single nucleotide
 PT polymorphisms in human interleukin-15 gene, and useful for treating
 PT disorders affected by expression of function of interleukin-15 isogene.

PS Claim 16; Page 17; 78pp; English.

XX The present sequence is allele-specific oligonucleotide (ASO) primer
 CC useful for detecting human interleukin-15 (IL-15) gene polymorphism
 CC located on chromosome 4q31. the polymorphic variants of IL-15 genes are
 CC useful for studying the expression and function of IL-15 and expressing
 CC IL-15 protein for use in useful for screening for candidate drugs to
 CC treat diseases related to IL-15 activity. Genotyping or haplotyping an
 CC individual at the novel IL-15 polymorphic sites are useful for studying
 CC population diversity, anthropological lineage, the significance of
 CC diversity and lineage of the phenotypic level, paternity testing,
 CC forensic applications and for identifying associations between IL-15
 CC genetic variation and a trait such as level of drug response or
 CC susceptibility to disease. Identifying an association between a genotype
 CC or haplotype and a trait, is useful for developing diagnostic tests and
 CC therapeutic treatments for infections, human immunodeficiency virus and
 CC T-cell leukaemia. The identification of an association between a clinical
 CC response and a genotype or haplotype (or haplotype pair) for the IL-15
 CC gene may be the basis for designing a diagnostic method to determine
 CC those individuals who will or will not respond to the treatment, or
 CC alternatively, will respond at a lower level and thus may require more
 CC treatment, i.e. a greater dose of a drug. The genotyping or haplotyping
 CC methods are also useful for developing drugs targeting IL-15. The
 CC genotyping and haplotyping methods are also useful in designing clinical
 CC trials. IL-15 DNA is useful for therapeutic purposes for treating
 CC disorders affected by expression of function of novel IL-15 isogene and
 CC also in gene therapy. Expression of an IL-15 isogene may be turned off by
 CC transforming a targetted organ, tissue or cell population of an
 CC expression vector that expresses high levels of untranslatable mRNA for
 CC the isogene

SQ Sequence 15 BP; 4 A; 3 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 40.0%; Score 10.8; DB 1; Length 15;

Best Local Similarity 85.7%; Pred. No. 1.3e+02;

Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2221 CCAGAGTTACATG 2234

DB 14 CATAAGTTACATG 1

RESULT 27

AAF73958

ID AAF73958 standard; DNA; 15 BP.

XX AAF73958;

XX 30-APR-2001 (first entry)

XX Human SLC6A4 allele-specific oligonucleotide primer #78.

XX Solute carrier family 6 neurotransmitter transporter; section 4; SLC6A4;
 XX genotyping; allele specific oligonucleotide; ss.

XX Homo sapiens.

XX WO200109161-A1.

XX 08-FEB-2001.

XX 31-JUL-2000; 2000WO-US020638.

XX 29-JUL-1999; 99US-0146290P.

XX

PA (GENA-) GENAISSANCE PHARM INC.

xx Denton RR, Duda A, Nandabalan K, Sanchis A, Stephens JC;

XX
DR
WPI: 2001-123317/13.

XX PT New isolated polynucleotide comprising a polymorphic variant for the
PT solute carrier family 6 neurotransmitter transporter, serotonin member 4
PT gene for identifying drugs for treating disorders related to expression
PT of the protein.

XX
PS
Claim 12: Page 21: 152pp; English.

The present invention relates to a polymorphic variant of a reference sequence for the solute carrier family 6 neurotransmitter transporter, serotonin member 4 (SLC6A4) gene or a fragment of it or a sequence complementary to the first sequence. The invention is used in producing a recombinant organism that can be used to express SLC6A4 for protein structure analysis and binding studies. A composition comprising a genotyping oligonucleotide is used to detect a polymorphism in the SLC6A4 gene.

Sequence 15 BP: 7 A: 2 C: 2 G: 4 T: 0 U: 0 Other: XX SQ

Query Match 40.0%: Score 10.8: DB 1: Length 15:

Query Match	40.0%;	Score 10.8;	DB 1;	Length 15;
Best Local Similarity	85.7%;	Pred. No. 1.3e+02;		

BEST LOCAL SIMILARITY	83.7%	FREQ. NO. 1.5e+02,
Matches	12;	Conservative
	0;	Mismatches
	2;	Indels
	0;	Gaps
	0;	Gaps

2220 ACCAAAGTTACAT 2233

Db 1 ATCAAAGTTAGAT 14

RESULT 28

ABH81622/C

ABH81622/C
ID ABH81622 standard; DNA; 12 BP.

XX ABH81622:

XX
DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 281615 for detecting SNP TSC0009939.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX
OS Homo sapiens.

XX
PN
WC000177384-A2XX
18-OCT-2001

XX	20	21	22	23	24	25	26	27	28	29	30	31
XX	20	21	22	23	24	25	26	27	28	29	30	31

XX

XX

XX

XX
7

Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.

PS Claim 1; SEQ ID NO 281615; 29pp + Sequence Listing; German.
xx

XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pre-treated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and


```

XX PF 06-APR-2001; 2001WO-IB000713.
XX XX 07-APR-2000; 2000DE-01019173.
XX XX (EPIG-) EPIGENOMICS AG.
XX PA Olek A, Piepenbrock C, Berlin K;
XX PI WPI; 2001-657177/75.
XX DR
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 349914; 29pp + Sequence Listing; German.
XX XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 38.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 1.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2225 AAGTTACATGTT 2236
Db 1 AAGTTATATGTT 12

RESULT 33
ABI52271
ID ABI52271 standard; DNA; 12 BP.
XX AC ABI52271;
XX XX
XX DT 22-FEB-2002 (first entry)
XX DE
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX XX
XX PD 18-OCT-2001.
XX PF
XX PR 06-APR-2001; 2001WO-IB000713.
XX PR Oligonucleotide primer SEQ ID NO 352244 for detecting SNP TSC0047757.
XX XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX XX
XX PD 18-OCT-2001.
XX PF
XX PR 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX XX
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX PI WPI; 2001-657177/75.
XX DR
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine

```

```

PT methylation status.
XX Claim 1; SEQ ID NO 352244; 29pp + Sequence Listing; German.
XX XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 5 A; 0 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 38.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 1.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2224 AAGTTACATGTT 2235
Db 1 AAGTTATATGTT 12

RESULT 34
ABH71735/C
ID ABH71735 standard; DNA; 12 BP.
XX AC ABH71735;
XX XX
XX DT 22-FEB-2002 (first entry)
XX DE
XX KW Oligonucleotide primer SEQ ID NO 271712 for detecting SNP TSC0002597.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX XX
XX PD 18-OCT-2001.
XX PF
XX PR 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX XX
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX PI WPI; 2001-657177/75.
XX DR
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 271712; 29pp + Sequence Listing; German.
XX XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences

```

CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
 Query Match 38.5%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 1.2e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2222 CAAAAGTTACAT 2233
 Db 12 CAAAAGTTACAT 1

RESULT 35

ABI49627/c
 ID ABI49627 standard; DNA; 12 BP.
 XX AC
 XX AC ABI49627;
 XX DT 22-FEB-2002 (first entry)
 XX DE
 XX DE Oligonucleotide primer SEQ ID NO 349600 for detecting SNP TSC0046229.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX PS Claim 1; SEQ ID NO 349600; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 38.5%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 1.2e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2222 CAAAAGTTACAT 2233
 Db 12 CAAAAGTTACAT 1

XX SQ Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
 Query Match 38.5%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 1.2e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2222 CAAAAGTTACAT 2233
 Db 12 CAAAAGTTACAT 1

RESULT 36

ABI33967
 ID ABI33967 standard; DNA; 12 BP.
 XX AC
 XX AC ABI33967;
 XX DT 22-FEB-2002 (first entry)
 XX DE
 XX DE Oligonucleotide primer SEQ ID NO 333940 for detecting SNP TSC0037852.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX PS Claim 1; SEQ ID NO 333940; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 1 A; 1 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 38.5%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 1.2e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2227 GTTACATGTTTG 2238
 Db 1 GTTACATGTTTG 12

RESULT 37

ABI42142
 ID ABI42142 standard; DNA; 12 BP.

XX AC
 XX AC ABI42142;
 XX DT 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 342115 for detecting SNP TSC0007737.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 XX 18-OCT-2001.
 PD
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 FF
 XX
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX
 XX (EPIG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 XX methylation status.
 PT
 XX
 XX Claim 1; SEQ ID NO 342115; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 XX and cytosine methylation status in chemically pretreated genomic DNA. The
 XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 XX range of diseases including immune system, gastrointestinal, respiratory,
 XX central nervous system, cardiovascular and metabolic disorders. The
 XX oligomers are also used for detecting cell type differentiation. ABC00010
 XX -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 XX represent the oligomers described in the invention. NOTE: The sequence
 XX data for this patent did not form part of the printed specification, but
 XX was obtained in electronic format from WIPO at
 XX ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 12 BP; 7 A; 0 C; 2 G; 3 T; 0 U; 0 Other;
 Query Match 38.5%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 1.2e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 2223 AAAAGTTACATG 2234
 Db 1 AAAAGTTAAATG 12
 RESULT 38
 ABI0774/C
 ID ABI0774 standard; DNA; 12 BP.
 AC
 XX ABI0774;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX
 XX Oligonucleotide primer SEQ ID NO 307747 for detecting SNP TSC0022661.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 KW
 KW Homo sapiens.
 OS
 XX
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic

PA (EPIG-) EPIGENOMICS AG.
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 XX methylation status.
 PT
 XX
 XX Claim 1; SEQ ID NO 307747; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 XX and cytosine methylation status in chemically pretreated genomic DNA. The
 XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 XX range of diseases including immune system, gastrointestinal, respiratory,
 XX central nervous system, cardiovascular and metabolic disorders. The
 XX oligomers are also used for detecting cell type differentiation. ABC00010
 XX -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 XX represent the oligomers described in the invention. NOTE: The sequence
 XX data for this patent did not form part of the printed specification, but
 XX was obtained in electronic format from WIPO at
 XX ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
 Query Match 38.5%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 1.2e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 2226 AGTTACATGTTT 2237
 Db 12 AGTTATGTTT 1
 RESULT 39
 ABC72025/C
 ID ABC72025 standard; DNA; 13 BP.
 AC
 XX ABC72025;
 XX
 XX 21-FEB-2002 (first entry)
 DT
 XX
 XX Oligonucleotide SEQ ID NO 72042 for detecting SNP TSC0018618.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 KW
 KW Homo sapiens.
 OS
 XX
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX
 XX (EPIG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 XX methylation status.
 PT
 XX
 XX Claim 1; SEQ ID NO 72042; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic

```
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 5 C; 1 G; 1 T; 0 U; 0 Other;

Query Match 38.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2227 GTTACATGTTTG 2238
DB 12 GTTACGTTTG 1

RESULT 40
ABCS6759/c
ID ABC56759 standard; DNA; 13 BP.
XX
AC ABC56759;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 56776 for detecting SNP TSC0015380.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
Claim 1; SEQ ID NO 56776; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 1 Other;

Query Match 38.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2227 GTTACATGTTTG 2238
DB 12 GTTACGTTTG 1

RESULT 41
ABH48560/c
ID ABH48560 standard; DNA; 13 BP.
XX
AC ABH48560;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 248537 for detecting SNP TSC0060746.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
Claim 1; SEQ ID NO 248537; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 38.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2221 CCAAAAGTTTACA 2232
DB 13 CCAAAATTACA 2

RESULT 42
ABH34854
ID ABH34854 standard; DNA; 13 BP.
```

```
Query Match 38.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 2226 AGTTACATGTTT 2237
DB 13 AGTTATAGTTT 2
```

```
RESULT 41
ABH48560/c
ID ABH48560 standard; DNA; 13 BP.
XX
AC ABH48560;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 248537 for detecting SNP TSC0060746.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
Claim 1; SEQ ID NO 248537; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 3 G; 8 T; 0 U; 0 Other;
```

```
Query Match 38.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 2221 CCAAAAGTTTACA 2232
DB 13 CCAAAATTACA 2
```

```
RESULT 42
ABH34854
ID ABH34854 standard; DNA; 13 BP.
```

XX AC ABH34854;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide SEQ ID NO 234831 for detecting SNP TSC0057326.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177/75.
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX PS Claim 1; SEQ ID NO 234831; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABT00010-ABT2073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 13 BP; 4 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABT00010-ABT2073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 13 BP; 4 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
 Query Match 38.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 1.3e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 2226 AGTTACATGTTT 2237
 Db 1 AGTTAAATGTTT 12
 RESULT 43
 ABF34989
 ID ABF34989 standard; DNA; 13 BP.
 XX AC ABF34989;
 XX DT 21-FEB-2002 (first entry)
 XX DE Oligonucleotide SEQ ID NO 134986 for detecting SNP TSC0033649.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.

PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177/75.
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX PS Claim 1; SEQ ID NO 134986; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABT00010-ABT2073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 13 BP; 7 A; 2 C; 0 G; 4 T; 0 U; 0 Other;
 Query Match 38.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 1.3e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 2222 CAAAAGTTTACAT 2233
 Db 1 CAAAATTTCAT 12
 RESULT 44
 ABH48561
 ID ABH48561 standard; DNA; 13 BP.
 XX AC ABH48561;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide SEQ ID NO 248538 for detecting SNP TSC0060746.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 248538; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 8 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
XX
Query Match 38.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 2221 CCAAAAGTTACAT 2232
Db 1 CCAAAATTACAT 12
XX
RESULT 45
ABF34988/c
ID ABF34988 standard; DNA; 13 BP.
AC ABF34988;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 134985 for detecting SNP TSC0033649.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 134985; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
XX
Query Match 38.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 2222 CAAAAGTTACAT 2233
Db 13 CAAAATTACAT 2
XX
RESULT 46
ABC56760
ID ABC56760 standard; DNA; 13 BP.
XX
AC ABC56760;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 56777 for detecting SNP TSC0015380.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 56777; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 1 C; 3 G; 6 T; 0 U; 1 Other;
XX
Query Match 38.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;


```
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPiG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX XX WPI; 2001-657177/75.
XX DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PT
XX PS Claim 1; SEQ ID NO 79776; 29pp + Sequence Listing; German.
XX XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX XX
XX SQ Sequence 13 BP; 7 A; 4 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 38.5%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 1.3e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2220 ACCAAAAGTTTAC 2231
XX Db 2 ACCAAAAGTTTAC 13
XX
XX RESULT 50
XX ABH08279
XX ID ABH08279 standard; DNA; 13 BP.
XX AC ABH08279;
XX XX
XX 22-FEB-2002 (first entry)
XX DT
XX DE Oligonucleotide SEQ ID NO 208256 for detecting SNP TSC0050908.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX
XX WO200177384-A2.
XX PN
XX 18-OCT-2001.
XX PD
XX 06-APR-2001; 2001WO-IB000713.
XX PF
XX 07-APR-2000; 2000DE-01019173.
XX PR
XX (EPiG-) EPIGENOMICS AG.
XX PA
XX Olek A, Piepenbrock C, Berlin K;
XX PI
XX WPI; 2001-657177/75.
XX DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PT
```

```
PS Claim 1; SEQ ID NO 208256; 29pp + Sequence Listing; German.
XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX XX
XX SQ Sequence 13 BP; 6 A; 3 C; 0 G; 3 T; 0 U; 1 Other;
XX
XX Query Match 38.5%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 1.3e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2222 CAAAAGTTTACAT 2233
XX Db 2 CAAAAGTTTACAT 13
XX
XX RESULT 51
XX ABH34855/c
XX ID ABH34855 standard; DNA; 13 BP.
XX AC ABH34855;
XX XX
XX 22-FEB-2002 (first entry)
XX DT
XX DE Oligonucleotide SEQ ID NO 234832 for detecting SNP TSC0057326.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX
XX WO200177384-A2.
XX PN
XX 18-OCT-2001.
XX PD
XX 06-APR-2001; 2001WO-IB000713.
XX PF
XX 07-APR-2000; 2000DE-01019173.
XX PR
XX (EPiG-) EPIGENOMICS AG.
XX PA
XX Olek A, Piepenbrock C, Berlin K;
XX PI
XX WPI; 2001-657177/75.
XX DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PT
XX PS Claim 1; SEQ ID NO 234832; 29pp + Sequence Listing; German.
XX XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
```

Thu Nov 18 12:41:57 2004

```

CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 7 A; 2 C; 0 G; 4 T; 0 U; 0 Other;

Query Match      38.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2226 AGTTACATGTTT 2237
DB 13 AGTTAAATGTTT 2

RESULT 52
ABH48563
ID ABH48563 standard; DNA; 13 BP.
XX
AC ABH48563;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 248540 for detecting SNP TSC0060746.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001 (first entry)
XX
XX Oligonucleotide SEQ ID NO 248540 for detecting SNP TSC0060746.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 248540; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 7 A; 2 C; 0 G; 4 T; 0 U; 0 Other;

Query Match      38.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2221 CCAAAGTTTACA 2232
DB 1 CCAAAGTTTACA 12

RESULT 54
ABC56758
ID ABC56758 standard; DNA; 13 BP.
XX
AC ABC56758;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 56775 for detecting SNP TSC0015380.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 248540; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 7 A; 2 C; 0 G; 4 T; 0 U; 0 Other;

Query Match      38.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2221 CCAAAGTTTACA 2232
DB 1 CCAAAGTTTACA 12

```

```

RESULT 53
ABH08276/c
ID ABH08276 standard; DNA; 13 BP.
XX
AC ABH08276;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 208253 for detecting SNP TSC0050308.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 208253; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 1 Other;

Query Match      38.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2222 CAAAAGTTTACAT 2233
DB 12 CAAAAGTTTACAT 1

RESULT 54
ABC56758
ID ABC56758 standard; DNA; 13 BP.
XX
AC ABC56758;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 56775 for detecting SNP TSC0015380.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 208253; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 1 Other;

Query Match      38.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2222 CAAAAGTTTACAT 2233
DB 12 CAAAAGTTTACAT 1

```



```
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABG9989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 1 Other;
XX
XX Query Match 38.5%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 1.3e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2226 AGTTACATGTTT 2237
XX DB 1 AGTTATGTTT 12
XX
XX RESULT 55
XX ABH48562/c
XX ID ABH48562 standard; DNA; 13 BP.
XX AC ABH48562;
XX XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 248539 for detecting SNP TSC0060746.
XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABG9989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 1 Other;
```

```
PI Olek A, Piepenbrock C, Berlin K;
DR WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX
XX Claim 1; SEQ ID NO 248539; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABG9989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 13 BP; 2 A; 0 C; 4 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 38.5%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 1.3e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2221 CCAAAAGTTACA 2232
XX DB 13 CCAAAACTTACA 2
XX
XX RESULT 56
XX ABC68337/c
XX ID ABC68337 standard; DNA; 13 BP.
XX AC ABC68337;
XX XX
XX DT 21-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 68354 for detecting SNP TSC0017828.
XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX
XX Claim 1; SEQ ID NO 68354; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
```

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI0010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 13 BP; 6 A; 4 C; 1 G; 2 T; 0 U; 0 Other;

Query Match 38.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 1.3e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2226 AGTTACATGTTT 2237
 Db 12 AGTTACGTTT 1
 ||||| |||||

RESULT 57
 ABC79758/c
 ID ABC79758 standard; DNA; 13 BP.
 XX AC ABC79758;
 XX AC ABC79758;
 XX DT 21-FEB-2002 (first entry)
 XX DE Oligonucleotide SEQ ID NO 79775 for detecting SNP TSC0020261.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.
 PR 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 79775; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI0010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 13 BP; 2 A; 0 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 38.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 1.3e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Best Local Similarity 91.7%; Pred. No. 1.3e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 2220 ACCAAAGTTTAC 2231
 Db 12 ACCAAAGTTTAC 1
 ||||| |||||

RESULT 58
 ABC56761/c
 ID ABC56761 standard; DNA; 13 BP.
 XX AC ABC56761;
 XX AC ABC56761;
 XX DT 21-FEB-2002 (first entry)
 XX DE Oligonucleotide SEQ ID NO 56778 for detecting SNP TSC0015380.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.
 PR 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 56778; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI0010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 13 BP; 6 A; 3 C; 1 G; 2 T; 0 U; 1 Other;

Query Match 38.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 1.3e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2226 AGTTACATGTTT 2237
 Db 13 AGTTACGTTT 2
 ||||| |||||

RESULT 59
 ABH08277
 ID ABH08277 standard; DNA; 13 BP.
 XX AC ABH08277;
 XX AC ABH08277;

XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 208254 for detecting SNP TSC0050908.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX PI WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 208254; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 6 A; 2 C; 0 G; 4 T; 0 U; 1 Other;
Query Match 38.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2222 CAAAGCTTACAT 2233
Db ||||| |||||
2 CAAAGTTTACAT 13
RESULT 60
ABC72020
ID ABC72020 standard; DNA; 13 BP.
XX AC ABC72020;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 72037 for detecting SNP TSC0018618.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX PI WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 208254; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 6 A; 2 C; 0 G; 4 T; 0 U; 1 Other;
Query Match 38.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2222 CAAAGCTTACAT 2233
Db ||||| |||||
2 CAAAGTTTACAT 13
RESULT 61
ABC72024
ID ABC72024 standard; DNA; 13 BP.
XX AC ABC72024;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 72041 for detecting SNP TSC0018618.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX PI WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is

PD 18-OCT-2001.
XX XX
PF 06-APR-2001; 2001WO-IB000713.
XX XX
PR 07-APR-2000; 2000DE-01019173.
XX XX
PA (EPIG-) EPIGENOMICS AG.
XX XX
PI Olek A, Piepenbrock C, Berlin K;
XX XX
DR WPI; 2001-657177/75.
XX XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 72037; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 2 A; 0 C; 4 G; 7 T; 0 U; 0 Other;
Query Match 38.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2227 GTTACATGTTTG 2238
Db ||||| |||||
2 GTTATATGTTTG 13
RESULT 61
ABC72024
ID ABC72024 standard; DNA; 13 BP.
XX AC ABC72024;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 72041 for detecting SNP TSC0018618.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX PI WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

PS Claim 1; SEQ ID NO 72041; 29pp + Sequence Listing; German.

XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 1 A; 1 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 38.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2227 GTTACATGTTTG 2238

DB 2 GTTACGTTGTTG 13

RESULT 62

ABH08278/c
ID ABH08278 standard; DNA; 13 BP.

XX AC ABH08278;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide SEQ ID NO 208255 for detecting SNP TSC0050908.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX PS Claim 1; SEQ ID NO 208255; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 1 Other;

Query Match 38.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2222 CAAAAGTTACAT 2233

DB 12 CAAAACITACAT 1

RESULT 63

ABK23686/c
ID ABK23686 standard; DNA; 10 BP.

XX AC ABK23686;

XX DT 09-APR-2002 (first entry)

XX DE Transcript tag DNA sequence #275 induced or suppressed by N-myc.

XX KW Myc-dependent downstream gene; neoplastic; cancer; growth; invasion;
XX KW spread; myc target; myc tag; SAGE; serial analysis of gene expression;
XX KW myc oncogene; N-myc; human neuroblastoma; cytostatic; ds.

XX OS Homo sapiens.

XX PN WO200185941-A2.

XX PD 15-NOV-2001.

XX PF 11-MAY-2001; 2001WO-NL000361.

XX PR 11-MAY-2000; 2000EP-00201698.

XX PR 29-JUN-2000; 2000EP-00202284.

XX PA (UYAM-) UNIV AMSTERDAM ACAD ZIEKENHUIS BIJ VAN.

XX PI Versteeg R, Caron HN;

XX DR WPI; 2002-066603/09.

XX A new nucleic acid library of myc-dependent downstream genes capable of
PT supporting a neoplastic characteristic of cancer is useful to find new
PT therapies and diagnoses for cancer.

XX PS Disclosure; Page 56; 69pp; English.

XX The present invention relates to a nucleic acid library comprising myc-
CC dependent downstream genes or their functional fragments essentially
CC capable of supporting a neoplastic character of cancer such as growth,
CC invasion or spread. These myc target or tag sequences are identified by
CC SAGE (serial analysis of gene expression). The library is useful to find
CC new diagnoses and treatments for cancer. The invention is also useful to
CC enhance production of recombinant proteins in a production system with
CC high expression of endogenous or transfected myc oncogenes. ABK23412-
CC ABK23828 represent transcript tag DNA sequences that are activated or
CC repressed by N-myc in human neuroblastoma

XX SQ Sequence 10 BP; 2 A; 1 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 37.0%; Score 10; DB 1; Length 10;

Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2221 CCAAAAAGTTA 2230

DB 10 CCAAAAAGTTA 1

RESULT 64

ABH08935/c
ID ABH08935 standard; DNA; 13 BP.

AC ABH08935;

XX 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 208912 for detecting SNP TSC0007531.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX WO200177384-A2.

PN 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 208912; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 6 A; 3 C; 1 G; 2 T; 0 U; 1 Other;

Query Match 37.0%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 1.6e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 2226 AGTTACATGTTT 2237

DB 12 AGTTACGCTGTT 1

RESULT 65

ABC90726/c

ID ABC90726 standard; DNA; 13 BP.

AC ABC90726;

XX 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 90743 for detecting SNP TSC0022741.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

PN WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 90743; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 1 Other;

Query Match 37.0%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 1.6e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 2219 GACCAAAAGTTA 2230

DB 13 RACCAAAAATTA 2

RESULT 66

ABH08934

ID ABH08934 standard; DNA; 13 BP.

XX AC ABH08934;

XX 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 208911 for detecting SNP TSC0007531.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 208911; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 2 A; 1 C; 3 G; 6 T; 0 U; 1 Other;
 Query Match 37.0%; Score 10; DB 1; Length 13;
 Best Local Similarity 83.3%; Pred. No. 1.6e+02;
 Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 Qy 2226 AGTTACATGTTT 2237
 Db 2 AGTTACGTGTTT 13
 RESULT 67
 ABC90727
 ID ABC90727 standard; DNA; 13 BP.
 XX
 AC ABC90727;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 90744 for detecting SNP TSC0022741.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 FN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR Oligonucleotide SEQ ID NO 90744 for detecting SNP TSC0022741.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 FN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 90744; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 1 Other;
 Query Match 37.0%; Score 10; DB 1; Length 13;
 Best Local Similarity 83.3%; Pred. No. 1.6e+02;
 Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 Qy 2219 GACCAAAAGTTA 2230
 Db 1 RACCAAAAGTTA 12
 RESULT 68
 ABC70173/c
 ID ABC70173 standard; DNA; 13 BP.
 XX
 AC ABC70173;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 70190 for detecting SNP TSC0018249.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 FN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 70190; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 6 A; 1 C; 0 G; 6 T; 0 U; 0 Other;

```

Query Match      36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2223 AAAAGTTACATGT 2235
Db 13 AAAAGTTATATT 1

RESULT 69
ABC24649
ID ABC24649 standard; DNA; 13 BP.
AC ABC24649;
XX
XX 20-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 24666 for detecting SNP TSC0005912.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 24666; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 6 A; 4 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Query Match      36.3%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2221 CCAAAAGTTACAT 2233
Db 1 CCAACATTACAT 13

RESULT 70
ABC83940
ID ABC83940 standard; DNA; 13 BP.

```

```

XX
XX ABC83940;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 83957 for detecting SNP TSC0021124.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 83957; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 2 A; 2 C; 4 G; 5 T; 0 U; 0 Other;
XX
XX Query Match      36.3%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2226 AGTTACATGTTTG 2238
Db 1 AGTTACGCTTTG 13

RESULT 71
ABC89770
ID ABC89770 standard; DNA; 13 BP.
XX
XX ABC89770;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 89787 for detecting SNP TSC0022507.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.

```

PN WO200177384-A2.
 PD 18-OCT-2001.
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 89787; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 13 BP; 4 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
 XX
 CC Query Match 36.3%; Score 9.8; DB 1; Length 13;
 CC Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 CC Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2225 AAGTTACATGTTT 2237
 DB 1 AAGTTAGATTTT 13
 RESULT 72
 ABF69709/C
 ID ABF69709 standard; DNA; 13 BP.
 AC ABF69709;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 169706 for detecting SNP TSC0007737.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 PN 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 89787; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 13 BP; 4 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
 XX
 CC Query Match 36.3%; Score 9.8; DB 1; Length 13;
 CC Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 CC Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2225 AAGTTACATGTTT 2237
 DB 1 AAGTTAGATTTT 13
 RESULT 73
 ABF73956
 ID ABF73956 standard; DNA; 13 BP.
 AC ABF73956;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 173953 for detecting SNP TSC0043299.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 PN 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 173953; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 13 BP; 7 A; 2 C; 0 G; 4 T; 0 U; 0 Other;
 XX
 CC Query Match 36.3%; Score 9.8; DB 1; Length 13;
 CC Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 CC Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2224 AAGTTACATGTTT 2236
 DB 13 AAGTTATATGTT 1

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 169706; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 13 BP; 7 A; 2 C; 0 G; 4 T; 0 U; 0 Other;
 XX
 CC Query Match 36.3%; Score 9.8; DB 1; Length 13;
 CC Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 CC Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2224 AAGTTACATGTTT 2236
 DB 13 AAGTTATATGTT 1
 RESULT 73
 ABF73956
 ID ABF73956 standard; DNA; 13 BP.
 AC ABF73956;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 173953 for detecting SNP TSC0043299.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 PN 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 173953; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 13 BP; 7 A; 2 C; 0 G; 4 T; 0 U; 0 Other;
 XX
 CC Query Match 36.3%; Score 9.8; DB 1; Length 13;
 CC Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 CC Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2224 AAGTTACATGTTT 2236
 DB 13 AAGTTATATGTT 1

CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 XX
 SQ Sequence 13 BP; 5 A; 0 C; 1 G; 7 T; 0 U; 0 Other;
 Query Match 36.3%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2224 AAGTTACATGTT 2236
 DB 1 AATTTATATGTT 13

RESULT 74
 ABH35801
 ID ABH35801 standard; DNA; 13 BP.
 XX
 AC ABH35801;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 235778 for detecting SNP TSC0009202.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WC200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 235778; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 XX
 SQ Sequence 13 BP; 7 A; 3 C; 1 G; 2 T; 0 U; 0 Other;
 Query Match 36.3%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2220 ACCAAAGTTACA 2232
 DB 1 AACAAAGTTACA 13

RESULT 75
 ABC23838/c
 ID ABC23838 standard; DNA; 13 BP.
 XX
 AC ABC23838;
 XX
 DT 20-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 23855 for detecting SNP TSC0005417.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WC200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 23855; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 XX
 SQ Sequence 13 BP; 3 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
 Query Match 36.3%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2220 ACCAAAGTTACA 2232
 DB 13 ACTAAAGTTACA 1

RESULT 76
 ABC24988
 ID ABC24988 standard; DNA; 13 BP.
 XX
 AC ABC24988;
 XX
 DT 20-FEB-2002 (first entry)
 XX
 XX

DE Oligonucleotide SEQ ID NO 25005 for detecting SNP TSC0006056.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 25005; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 6 A; 0 C; 2 G; 5 T; 0 U; 0 Other;

XX Query Match 36.3%; Score 9.8; DB 1; Length 13;
 XX Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 2224 AAGATTACATGTT 2236

Db 1 AAGATATATGTT 13

RESULT 77

ABC30596

ID ABC30596 standard; DNA; 13 BP.

AC ABC30596;

XX 20-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 30613 for detecting SNP TSC0009381.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 30613; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 4 A; 0 C; 3 G; 6 T; 0 U; 0 Other;

XX Query Match 36.3%; Score 9.8; DB 1; Length 13;
 XX Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 2224 AAGATTACATGTT 2236

Db 1 AAGATTATGTT 13

RESULT 78

ABC83931/c

ID ABC83931 standard; DNA; 13 BP.

AC ABC83931;

XX 21-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 83948 for detecting SNP TSC0021124.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

```

PS Claim 1; SEQ ID NO 83948; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI0010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 3 C; 1 G; 3 T; 0 U; 0 Other;
    Query Match      36.3%; Score 9.8; DB 1; Length 13;
    Best Local Similarity 84.6%; Pred. No. 1.8e+02;
    Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2226 AGTTACATGTTG 2238
Db 13 AGTTACGTTG 1
    ||||| |||||
    ||||| |||||

RESULT 79
ABC84116
ID ABC84116 standard; DNA; 13 BP.
XX
AC ABC84116;
XX
XX 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 84133 for detecting SNP TSC0021160.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 84133; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI0010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 7 A; 3 C; 0 G; 3 T; 0 U; 0 Other;
    Query Match      36.3%; Score 9.8; DB 1; Length 13;
    Best Local Similarity 84.6%; Pred. No. 1.8e+02;
    Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2220 ACCAAAGTTACA 2232
Db 1 ACCTAAATTTACA 13
    ||||| |||||
    ||||| |||||

RESULT 80
ABC9375
ID ABC9375 standard; DNA; 13 BP.
XX
AC ABC9375;
XX
XX 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 89392 for detecting SNP TSC0022411.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 89392; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI0010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 7 A; 3 C; 0 G; 3 T; 0 U; 0 Other;
    Query Match      36.3%; Score 9.8; DB 1; Length 13;
    Best Local Similarity 84.6%; Pred. No. 1.8e+02;
    Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2220 ACCAAAGTTACA 2232
Db 1 ACCTAAATTTACA 13
    ||||| |||||
    ||||| |||||

```

```

RESULT 81
ID ABF41324 standard; DNA; 13 BP.
XX AC ABF41324;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 141321 for detecting SNP TSC0035419.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 22556; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 3 A; 5 C; 0 G; 5 T; 0 U; 0 Other;
XX Query Match 36.3%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.8%; Pred. No. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2213 GAGTGTGACCAAA 2225
DB 13 GAGTGTGAGTAAA 1
|||||
RESULT 83
ID ABH44353 standard; DNA; 13 BP.
XX AC ABH44353;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 244330 for detecting SNP TSC0059632.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 141321; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 5 A; 0 C; 2 G; 6 T; 0 U; 0 Other;
XX Query Match 36.3%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.8%; Pred. No. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2223 AAAAGTTACATGT 2235
DB 1 AAAAGTTATTTGT 13
|||||
RESULT 82
ID ABH22579/c standard; DNA; 13 BP.
XX AC ABH22579;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 22556 for detecting SNP TSC0054151.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

```

PI Olek A, Piepenbrock C, Berlin K;
 DR WPI; 2001-657177/75.
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 244330; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligonucleotides are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 8 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
 Query Match 36.3%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 1.8e+02; Indels 0; Gaps 0;
 Matches 11; Conservative 0; Mismatches 2;
 QY 2220 ACCAAAGTTTACA 2232
 Db 1 ACCAAAGTTTACA 13
 RESULT 84
 ABC23839
 ID ABC23839 standard; DNA; 13 BP.
 AC ABC23839;
 XX
 DT 20-FEB-2002 (first entry)
 DE
 DE Oligonucleotide SEQ ID NO 23856 for detecting SNP TSC0005417.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 PN WO200177384-A2.
 PD 18-OCT-2001.
 PF 06-APR-2001; 2001WO-IB000713.
 PR 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 23856; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 8 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
 Query Match 36.3%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 1.8e+02; Indels 0; Gaps 0;
 Matches 11; Conservative 0; Mismatches 2;
 QY 2220 ACCAAAGTTTACA 2232
 Db 1 ACTAAGAAATTACA 13
 RESULT 85
 ABC78604
 ID ABC78604 standard; DNA; 13 BP.
 AC ABC78604;
 XX
 DT 21-FEB-2002 (first entry)
 DE
 DE Oligonucleotide SEQ ID NO 78621 for detecting SNP TSC0020009.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 PN WO200177384-A2.
 PD 18-OCT-2001.
 PF 06-APR-2001; 2001WO-IB000713.
 PR 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 78621; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 2 A; 0 C; 4 G; 7 T; 0 U; 0 Other;
 Query Match 36.3%; Score 9.8; DB 1; Length 13;

Best Local Similarity 84.6%; Pred. No. 1.8e+02; Mismatches 2; Indels 0; Gaps 0;
Matches 11; Conservative 0

QY 2226 AGTTACATGTTG 2238
||||| |||||
Db 1 AGTTATGTTG 13

RESULT 86
ABC56765/c
ID ABC56765 standard; DNA; 13 BP.
AC ABC56765;
XX
XX 21-FEB-2002 (first entry)
XX
XX
XX Oligonucleotide SEQ ID NO 56782 for detecting SNP TSC0015381.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
PN
PD 18-OCT-2001.
XX
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 56782; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 5 A; 4 C; 1 G; 3 T; 0 U; 0 Other;
SQ

Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2225 AAGTTACATGTTT 2237
||||| |||||
Db 13 AAGTTACGGGTTT 1

RESULT 87
ABC12793
ID ABC12793 standard; DNA; 13 BP.
XX
XX ABC12793;
AC

XX
DT 20-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 12800 for detecting SNP TSC0002995.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX WO200177384-A2.
PN
PD 18-OCT-2001.
XX
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 12800; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 8 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
SQ

Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2221 CCAAAAGTTACAT 2233
||||| |||||
Db 1 CCAAAAGTTAAAT 13

RESULT 88
ABC89771/c
ID ABC89771 standard; DNA; 13 BP.
XX
XX ABC89771;
AC
XX
XX 21-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 89788 for detecting SNP TSC0022507.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX WO200177384-A2.
PN
XX

CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 6 A; 0 C; 1 G; 6 T; 0 U; 0 Other;
 Query Match 36.3%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2225 AAGTTACATGTTT 2237

Db 13 AAATTACATTTT 1

RESULT 91

ABF53803
 ID ABF53803 standard; DNA; 13 BP.

AC ABF53803;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 153800 for detecting SNP TSC0038891.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

PN WO200177384-A2.

XX 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 153800; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH0010-ABH99989 and ABT00010-ABT2073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 7 A; 3 C; 1 G; 2 T; 0 U; 0 Other;

Query Match 36.3%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2220 ACCAAAAGTTTACA 2232

|| ||| |||||

Db 1 ACAAAAGCTTACA 13

RESULT 92

ABH52974/C
 ID ABH52974 standard; DNA; 13 BP.

XX ABH52974;

DT 22-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 252951 for detecting SNP TSC0061698.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

PN WO200177384-A2.

XX 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 252951; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH0010-ABH99989 and ABT00010-ABT2073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 7 A; 0 C; 1 G; 5 T; 0 U; 0 Other;

Query Match 36.3%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2225 AAGTTACATGTTT 2237

Db 13 AAATTACATTTT 1

RESULT 93

ABC70172
 ID ABC70172 standard; DNA; 13 BP.

XX ABC70172;

DT 21-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 70189 for detecting SNP TSC0018249.


```
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 70189; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 6 A; 0 C; 1 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 36.3%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 1.8e+02;
XX Mismatches 0; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 2223 AAAAGTACATGTT 2235
XX
XX Db 1 AAAAGTATATTT 13
XX
XX RESULT 94
XX ABC50758
XX ID ABC50758 standard; DNA; 13 BP.
XX
XX AC ABC50758;
XX
XX DT 21-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 50775 for detecting SNP TSC0014233.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
```

```
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 50775; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 36.3%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 1.8e+02;
XX Mismatches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 2225 AAGTTACATGTTT 2237
XX
XX Db 1 AAGTTATATGTGT 13
XX
XX RESULT 95
XX ABC36264
XX ID ABC36264 standard; DNA; 13 BP.
XX
XX AC ABC36264;
XX
XX DT 20-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 36281 for detecting SNP TSC0011393.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 36281; 29pp + Sequence Listing; German.
XX
```

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 3 A; 1 C; 2 G; 7 T; 0 U; 0 Other;
 Query Match 36.3%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2225 AAGTTACATGTTT 2237
 Db 1 AATTACGTTT 13
 RESULT 96
 ABC89773/c
 ID ABC89773 standard; DNA; 13 BP.
 AC ABC89773;
 XX
 XX 21-FEB-2002 (first entry)
 DT
 DE Oligonucleotide SEQ ID NO 89790 for detecting SNP TSC0022507.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT
 XX Claim 1; SEQ ID NO 89790; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC

SQ Sequence 13 BP; 8 A; 1 C; 0 G; 4 T; 0 U; 0 Other;
 Query Match 36.3%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2225 AAGTTACATGTTT 2237
 Db 13 AAGTTATATTTT 1
 RESULT 97
 ABH35800/c
 ID ABH35800 standard; DNA; 13 BP.
 XX
 AC ABH35800;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 DE Oligonucleotide SEQ ID NO 235777 for detecting SNP TSC0009202.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT
 XX Claim 1; SEQ ID NO 235777; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 2 A; 1 C; 3 G; 7 T; 0 U; 0 Other;
 Query Match 36.3%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2220 ACCAAAGTTTACA 2232
 Db 13 AACAAAGTTTACA 1
 RESULT 98
 ABH50898

```

ID ABH50898 standard; DNA; 13 BP.
XX AC ABH50898;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 250875 for detecting SNP TSC0061240.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX FR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX DT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX PS Claim 1; SEQ ID NO 250875; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 6 A; 0 C; 2 G; 5 T; 0 U; 0 Other;
Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2224 AAAGTTACATGTT 2236
DB 1 AAAGTTAGATATT 13
RESULT 99
ABC83933/C
ID ABC83933 standard; DNA; 13 BP.
XX AC ABC83933;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 83950 for detecting SNP TSC0021124.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX FR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX OS Homo sapiens.
```

```

XX WO200177384-A2.
XX PN 18-OCT-2001.
XX PD 06-APR-2001; 2001WO-IB000713.
XX PF 07-APR-2000; 2000DE-01019173.
XX FR (EPIG-) EPIGENOMICS AG.
XX PA Olek A, Piepenbrock C, Berlin K;
XX PI WPI; 2001-657177/75.
XX DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 83950; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 6 A; 3 C; 1 G; 3 T; 0 U; 0 Other;
Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2226 AGTTACATGTTG 2238
DB 13 AGTTATATGTCG 1
RESULT 100
ABC83943/C
ID ABC83943 standard; DNA; 13 BP.
XX AC ABC83943;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 83960 for detecting SNP TSC0021124.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX FR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
```


QY 2224 AAAGTTACATGTT 2236
 DB 13 AAAGATAATGTT 1
 RESULT 103
 ABC58322
 ID ABC58322 standard; DNA; 13 BP.
 XX
 AC ABC58322;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 58339 for detecting SNP TSC0015654.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 PN WO200177384-A2.
 XX
 DT 18-OCT-2001.
 XX
 DE Oligonucleotide SEQ ID NO 58339; 29pp + Sequence Listing; German.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS Claim 1; SEQ ID NO 58339; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 4 A; 1 C; 6 G; 2 T; 0 U; 0 Other;
 Query Match 36.3%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2215 GTGTGACCAAAAG 2227
 DB 1 GTGTGACCAAGG 13
 RESULT 104
 ABF70021
 ID ABF70021 standard; DNA; 13 BP.
 XX
 AC ABF70021;
 XX
 DT 22-FEB-2002 (first entry)

XX
 DE Oligonucleotide SEQ ID NO 170018 for detecting SNP TSC0042449.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 PN WO200177384-A2.
 XX
 DT 18-OCT-2001.
 XX
 DE Oligonucleotide SEQ ID NO 170018; 29pp + Sequence Listing; German.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS Claim 1; SEQ ID NO 170018; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 6 A; 1 C; 0 G; 6 T; 0 U; 0 Other;
 Query Match 36.3%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2225 AAGTTACATGTT 2237
 DB 1 AAATTACATATT 13
 RESULT 105
 ABF73957/c
 ID ABF73957 standard; DNA; 13 BP.
 XX
 AC ABF73957;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 173954 for detecting SNP TSC0043299.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 PN WO200177384-A2.
 XX
 DT 18-OCT-2001.

```

PF 06-APR-2001; 2001WO-IB000713.
XX
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 173954; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 7 A; 1 C; 0 G; 5 T; 0 U; 0 Other;
SQ
XX
XX Query Match 36.3%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 2224 AAGTTTACATGTT 2236
DB 13 AATTATATATGTT 1
XX
XX RESULT 106
XX ABH10604
XX ID ABH10604 standard; DNA; 13 BP.
XX
XX AC ABH10604;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 210581 for detecting SNP TSC0051414.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 210581; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 7 A; 1 C; 0 G; 5 T; 0 U; 0 Other;
SQ
XX
XX Query Match 36.3%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 2225 AAGTTTACATGTT 2237
DB 1 AATTTACATGTT 13
XX
XX RESULT 107
XX ABH35793
XX ID ABH35793 standard; DNA; 13 BP.
XX
XX AC ABH35793;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 235770 for detecting SNP TSC0009202.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 235770; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 7 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
SQ

```

```

CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 9 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
  Query Match 36.3%; Score 9.8; DB 1; Length 13;
  Best Local Similarity 84.6%; Pred. No. 1.8e+02;
  Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2220 ACCAAAGTTTACA 2232
Db 1 AAAAAAATTACA 13

RESULT 108
ABC50760
ID ABC50760 standard; DNA; 13 BP.
XX AC ABC50760;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 50777 for detecting SNP TSC0014233.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
FN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 50777; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 4 C; 0 G; 4 T; 0 U; 0 Other;
  Query Match 36.3%; Score 9.8; DB 1; Length 13;
  Best Local Similarity 84.6%; Pred. No. 1.8e+02;
  Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2225 AAGTTACATGTTT 2237
Db 1 AAGTTAGATGTGT 13

RESULT 110
ABC83941/C
ID ABC83941 standard; DNA; 13 BP.
XX AC ABC83941;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 83958 for detecting SNP TSC0021124.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX

```

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PP 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 83958; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and AB10010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 4 C; 2 G; 2 T; 0 U; 0 Other;
Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2226 AGTTACATGTTG 2238
Db 13 AGTTACGCTTG 1
RESULT 111
ABC11551/c
ID ABC11551 standard; DNA; 13 BP.
XX
XX ABC11551;
AC
XX
XX 20-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 11550 for detecting SNP TSC0002804.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PP
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIG-) EPIGENOMICS AG.
PA

XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 11550; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and AB10010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 2 C; 0 G; 6 T; 0 U; 0 Other;
Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2223 AAAAGTTACATGT 2235
Db 13 AAATGTTAAATGT 1
RESULT 112
ABF93510/c
ID ABF93510 standard; DNA; 13 BP.
XX
XX ABF93510;
AC
XX
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 193507 for detecting SNP TSC0047603.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PP
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIG-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 193507; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC000010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 2 A; 0 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 36.3%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2220 ACCAAAGTTTACA 2232

Db 13 ACCAAACTTAA 1

RESULT 113

ABC98511

ID ABC98511 standard; DNA; 13 BP.

XX AC ABC98511;

XX DT 21-FEB-2002 (first entry)

XX DE Oligonucleotide SEQ ID NO 98528 for detecting SNP TSC0024492.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is

XX PT designed to detect single-nucleotide polymorphisms and cytosine

XX PT methylation status.

XX PS Claim 1; SEQ ID NO 98528; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic

XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

XX CC and cytosine methylation status in chemically pretreated genomic DNA. The

XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

XX CC range of diseases including immune system, gastrointestinal, respiratory,

XX CC central nervous system, cardiovascular and metabolic disorders. The

XX CC oligomers are also used for detecting cell type differentiation. ABC00010

XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

XX CC represent the oligomers described in the invention. NOTE: The sequence

XX CC data for this patent did not form part of the printed specification, but

XX CC was obtained in electronic format from WIPO at

XX CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 7 A; 5 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 36.3%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2220 ACCAAAGTTTACA 2232

Db 1 ACCAAACTTACA 13

RESULT 114

ABC83930

ID ABC83930 standard; DNA; 13 BP.

XX AC ABC83930;

XX DT 21-FEB-2002 (first entry)

XX DE Oligonucleotide SEQ ID NO 83947 for detecting SNP TSC0021124.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is

XX PT designed to detect single-nucleotide polymorphisms and cytosine

XX PT methylation status.

XX PS Claim 1; SEQ ID NO 83947; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic

XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

XX CC and cytosine methylation status in chemically pretreated genomic DNA. The

XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

XX CC range of diseases including immune system, gastrointestinal, respiratory,

XX CC central nervous system, cardiovascular and metabolic disorders. The

XX CC oligomers are also used for detecting cell type differentiation. ABC00010

XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

XX CC represent the oligomers described in the invention. NOTE: The sequence

XX CC data for this patent did not form part of the printed specification, but

XX CC was obtained in electronic format from WIPO at

XX CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 3 A; 1 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 36.3%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2226 AGTTACATGTTG 2238

Db 1 AGTTACATGTTG 13

RESULT 115

ABC83942

ID ABC83942 standard; DNA; 13 BP.

XX AC ABC83942;

XX DT 21-FEB-2002 (first entry)

XX DE Oligonucleotide SEQ ID NO 83947 for detecting SNP TSC0021124.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is

XX PT designed to detect single-nucleotide polymorphisms and cytosine

XX PT methylation status.

XX PS Claim 1; SEQ ID NO 83947; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic

XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

XX CC and cytosine methylation status in chemically pretreated genomic DNA. The

XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

XX CC range of diseases including immune system, gastrointestinal, respiratory,

XX CC central nervous system, cardiovascular and metabolic disorders. The

XX CC oligomers are also used for detecting cell type differentiation. ABC00010

XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

XX CC represent the oligomers described in the invention. NOTE: The sequence

XX CC data for this patent did not form part of the printed specification, but

XX CC was obtained in electronic format from WIPO at

XX CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 7 A; 5 C; 0 G; 1 T; 0 U; 0 Other;

AC ABC83942;
 XX
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 83959 for detecting SNP TSC0021124.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 PN
 XX
 PD 18-OCT-2001.
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPiG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT
 XX Claim 1; SEQ ID NO 83959; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ASI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 13 BP; 2 A; 2 C; 4 G; 5 T; 0 U; 0 Other;
 SQ
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ASI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 13 BP; 2 A; 2 C; 4 G; 5 T; 0 U; 0 Other;
 SQ
 CC Query Match 36.3%; Score 9.8; DB 1; Length 13;
 CC Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 CC Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2226 AGTTACATGTTG 2238
 DB 1 AGTTACATGTTG 13
 RESULT 116
 ABC36989/c
 ID ABC36989 standard; DNA; 13 BP.
 AC
 XX ABC36989;
 XX
 XX 20-FEB-2002 (first entry)
 DT
 DE Oligonucleotide SEQ ID NO 37006 for detecting SNP TSC0011565.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 PN

XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPiG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT
 XX Claim 1; SEQ ID NO 37006; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ASI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 13 BP; 6 A; 2 C; 0 G; 5 T; 0 U; 0 Other;
 SQ
 CC Query Match 36.3%; Score 9.8; DB 1; Length 13;
 CC Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 CC Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2224 AAAGTTACATGTT 2236
 DB 13 AAAGTTACATGTT 1
 RESULT 117
 ABH10605/c
 ID ABH10605 standard; DNA; 13 BP.
 AC
 XX ABH10605;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 DE Oligonucleotide SEQ ID NO 210582 for detecting SNP TSC0051414.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 PN
 XX
 PD 18-OCT-2001.
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPiG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 210582; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 7 A; 2 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 36.3%; Score 9.8; DB 1; Length 13;

Best Local Similarity 84.6%; Pred. No. 1.8e+02;

Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2225 AAGTTACATGTTT 2237

Db 13 AATTACATGTTT 1

RESULT 118

ABH52975

ID ABH52975 standard; DNA; 13 BP.

XX AC ABH52975;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide SEQ ID NO 252952 for detecting SNP TSC0061698.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX PX WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.

XX Claim 1; SEQ ID NO 252952; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010

CC

CC

CC

CC

XX

XX

SQ

Sequence 13 BP; 5 A; 1 C; 0 G; 7 T; 0 U; 0 Other;

Query Match 36.3%; Score 9.8; DB 1; Length 13;

Best Local Similarity 84.6%; Pred. No. 1.8e+02;

Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2225 AAGTTACATGTTT 2237

Db 1 AATTACATGTTT 13

RESULT 119

ABC50759/c

ID ABC50759 standard; DNA; 13 BP.

XX AC ABC50759;

XX DT 21-FEB-2002 (first entry)

XX DE Oligonucleotide SEQ ID NO 50776 for detecting SNP TSC0014233.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX PX WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.

XX Claim 1; SEQ ID NO 50776; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

CC represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 6 A; 3 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 36.3%; Score 9.8; DB 1; Length 13;

Best Local Similarity 84.6%; Pred. No. 1.8e+02;

Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2225 AAGTTACATGTTT 2237

```

Db      13 AAGTTATATGTGT 1
      ||||| |||||
RESULT 120
ABC36265/c
ID ABC36265 standard; DNA; 13 BP.
XX
XX AC ABC36265;
XX
XX DT 20-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 36282 for detecting SNP TSC0011393.
XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX FF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX DR WPI; 2001-657177/75.
XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX PS Claim 1; SEQ ID NO 36282; 29pp + Sequence Listing; German.
XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX PS Sequence 13 BP; 7 A; 2 C; 1 G; 3 T; 0 U; 0 Other;
XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX PS Sequence 13 BP; 7 A; 2 C; 1 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 36.3%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 2225 AAGTTACATGTTT 2237
XX ||||| |||||
XX 13 AATTTACGTGTTT 1
XX
XX RESULT 121
ABF68251/c
ID ABF68251 standard; DNA; 13 BP.
XX
XX AC ABF68251;
XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 168248 for detecting SNP TSC0042083.

```

```

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX FF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX DR WPI; 2001-657177/75.
XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX PS Claim 1; SEQ ID NO 168248; 29pp + Sequence Listing; German.
XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX PS Sequence 13 BP; 5 A; 1 C; 0 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 36.3%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 2223 AAAAGTTACATGT 2235
XX ||||| |||||
XX 13 AAAATTAAATGT 1
XX
XX RESULT 122
ABF69708
ID ABF69708 standard; DNA; 13 BP.
XX
XX AC ABF69708;
XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 169705 for detecting SNP TSC0007737.
XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX

```

```
PR 07-APR-2000; 2000DE-01019173.
XX (EPiG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 169705; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2224 AAGTTACATGTT 2236
DB 1 AATGTTATATGTT 13
RESULT 123
ABF76603/C
ID ABF76603 standard; DNA; 13 BP.
XX AC ABF76603;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 176600 for detecting SNP TSC0043818.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPiG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 176600; 29pp + Sequence Listing; German.
```

```
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 7 A; 2 C; 0 G; 4 T; 0 U; 0 Other;
Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2226 AGTTACATGTTG 2238
DB 13 AGTTAAATTTTG 1
RESULT 124
ABH63860
ID ABH63860 standard; DNA; 13 BP.
XX AC ABH63860;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 263837 for detecting SNP TSC0063954.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPiG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 263837; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
```

```

XX SQ Sequence 13 BP; 2 A; 0 C; 3 G; 8 T; 0 U; 0 Other;
Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2226 AGTTACATGTTG 2238
Db 1 AGTTTATGTTG 13

RESULT 125
ABC36988
ID ABC36988 standard; DNA; 13 BP.
XX AC ABC36988;
XX DT 20-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 37005 for detecting SNP TSC0011565.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX DE Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 37005; 29bp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABT00010-ABT82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 5 A; 0 C; 2 G; 6 T; 0 U; 0 Other;
Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2224 AAAGTTACATGTT 2236
Db 1 AAAGTTAGATTT 13

RESULT 126
ABC36988
ID ABC36988 standard; DNA; 13 BP.
XX AC ABC36988;
XX DT 20-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 37005 for detecting SNP TSC0011565.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX DE Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 37005; 29bp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABT00010-ABT82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 5 A; 0 C; 2 G; 6 T; 0 U; 0 Other;
Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2224 AAAGTTACATGTT 2236
Db 1 AAAGTTAGATTT 13

RESULT 126
ABC36988
ID ABC36988 standard; DNA; 13 BP.
XX AC ABC36988;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 114293 for detecting SNP TSC0028617.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX DE Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 12799; 29bp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABT00010-ABT82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 3 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2221 CCAAAAGTTTACAT 2233
Db 13 CCAAAAGTTTAAAT 13

RESULT 127
ABF14296
ID ABF14296 standard; DNA; 13 BP.
XX AC ABF14296;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 114293 for detecting SNP TSC0028617.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX DE Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 12799; 29bp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABT00010-ABT82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences

```

```

OS Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPiG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 114293; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 5 A; 0 C; 2 G; 6 T; 0 U; 0 Other;
SQ
Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e-02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2226 AGTTACATGCTTG 2238
DB 1 AGTTAAATATTTG 13
||||| |||||
1 AGTTAAATATTTG 13

RESULT 128
ABC89772
ID ABC89772 standard; DNA; 13 BP.
XX
AC ABC89772;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 89789 for detecting SNP TSC0022507.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX (EPiG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 114293; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 5 A; 0 C; 2 G; 6 T; 0 U; 0 Other;
SQ
Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e-02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 89789; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 0 C; 1 G; 8 T; 0 U; 0 Other;
SQ
Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2225 AAGTTACATGCTTT 2237
DB 1 AAGTTATATTTT 13
||||| |||||
1 AAGTTATATTTT 13

RESULT 129
ABF76602
ID ABF76602 standard; DNA; 13 BP.
XX
AC ABF76602;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 176599 for detecting SNP TSC0043818.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX (EPiG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 176599; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 0 C; 1 G; 8 T; 0 U; 0 Other;
SQ
Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 4 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
 Query Match 36.3%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2226 AGTTACATGTTG 2238
 DB 1 AGTTAAATTTTG 13
 RESULT 130
 ABH35792/c
 ID ABH35792 standard; DNA; 13 BP.
 XX
 AC ABH35792;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 235769 for detecting SNP TSC0009202.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 235769; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 2 A; 0 C; 2 G; 9 T; 0 U; 0 Other;
 Query Match 36.3%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2226 AGTTACATGTTG 2238
 DB 1 AGTTAAATTTTG 13
 RESULT 132
 ABC56764
 ID ABC56764 standard; DNA; 13 BP.
 XX
 AC ABC56764;
 XX

Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2220 ACCAAAAGTTTACA 2232
 DB 13 AACAAAATTACA 1
 RESULT 131
 ABH63861/c
 ID ABH63861 standard; DNA; 13 BP.
 XX
 AC ABH63861;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 263838 for detecting SNP TSC0063954.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 263838; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 8 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
 Query Match 36.3%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.8%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2226 AGTTACATGTTG 2238
 DB 13 AGTTTATGTTG 1
 RESULT 132
 ABC56764
 ID ABC56764 standard; DNA; 13 BP.
 XX
 AC ABC56764;
 XX


```

DT 21-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 56781 for detecting SNP TSC0015381.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 56781; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 3 A; 1 C; 4 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 36.3%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 2225 AAGTTACGCGTTT 2237
DB 1 AAGTTACGCGTTT 13
XX
XX RESULT 133
XX ABF93511
XX ID ABF93511 standard; DNA; 13 BP.
XX
XX AC ABF93511;
XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 193508 for detecting SNP TSC0047603.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX

```

```

XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX PS Claim 1; SEQ ID NO 193508; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 8 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 36.3%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 2220 ACCAAAGATTACA 2232
DB 1 ACCAAAGATTAAA 13
XX
XX RESULT 134
XX ABF53802/C
XX ID ABF53802 standard; DNA; 13 BP.
XX
XX AC ABF53802;
XX
XX DT 21-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 153799 for detecting SNP TSC0038881.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

```

```
PT methylation status.
XX
PS Claim 1; SEQ ID NO 153799; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 1 C; 3 G; 7 T; 0 U; 0 Other;
Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2220 ACCAAAGTTTACA 2232
DB 13 ACAAAAGTTTACA 1
RESULT 135
ABH50899/c
ID ABH50899 standard; DNA; 13 BP.
XX
AC ABH50899;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 250876 for detecting SNP TSC0061240.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 250876 for detecting SNP TSC0061240.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 250876; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 1 C; 3 G; 7 T; 0 U; 0 Other;
Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2220 ACCAAAGTTTACA 2232
DB 13 ACAAAAGTTTACA 1
RESULT 136
ABC48259/c
ID ABC48259 standard; DNA; 13 BP.
XX
AC ABC48259;
XX
XX 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 48276 for detecting SNP TSC0013776.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 48276; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 3 C; 0 G; 4 T; 0 U; 0 Other;
Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2224 AAAGTTACATGTT 2236
DB 13 AGAGTTATATGTT 1
```


PA (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX MPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 84134; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 13 BP; 7 A; 1 C; 0 G; 5 T; 0 U; 0 Other;
 XX Query Match 36.3%; Score 9.8; DB 1; Length 13;
 XX Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2224 AAAGTTACATGTT 2236
 DB 13 AAAGTTATATTT 1
 RESULT 140
 ABC12791
 ID ABC12791 standard; DNA; 13 BP.
 XX AC ABC12791;
 XX 20-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 12798 for detecting SNP TSC0002995.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 PF 06-APR-2001; 2001WO-IB000713.
 PR 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX MPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 12798; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 13 BP; 7 A; 2 C; 0 G; 4 T; 0 U; 0 Other;
 XX Query Match 36.3%; Score 9.8; DB 1; Length 13;
 XX Best Local Similarity 84.6%; Pred. No. 1.8e+02;
 XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2221 CCAAACTTACAT 2233
 DB 1 CCAAAATTAAAT 13
 RESULT 141
 ABC93374/C
 ID ABC93374 standard; DNA; 13 BP.
 XX AC ABC93374;
 XX 21-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 89391 for detecting SNP TSC0022411.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 PF 06-APR-2001; 2001WO-IB000713.
 PR 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX MPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 89391; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 13 BP; 3 A; 0 C; 3 G; 7 T; 0 U; 0 Other;

```

Query Match      36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2220 ACCAAAAGTTACA 2232
Db 13 ACCTAAATTTGTT 1

RESULT 142
ABF67701/c
ID ABF67701 standard; DNA; 13 BP.
XX
AC ABF67701;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 167698 for detecting SNP TSC0041968.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 167698; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 7 A; 2 C; 0 G; 4 T; 0 U; 0 Other;
XX
This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 7 A; 2 C; 0 G; 4 T; 0 U; 0 Other;

Query Match      36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2224 AAAGTTACATGTT 2236
Db 13 AAAGTTATTTGTT 1

RESULT 143
ABF14297/c
ID ABF14297 standard; DNA; 13 BP.
XX
ABF14297;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 114294 for detecting SNP TSC0028617.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 114294; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 2 C; 0 G; 5 T; 0 U; 0 Other;
XX
Query Match      36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2226 AGTTACATGTTG 2238
Db 13 AGTTAAATTTGTT 1

RESULT 144
ABH22578
ID ABH22578 standard; DNA; 13 BP.
XX
AC ABH22578;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 222555 for detecting SNP TSC0054151.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine-methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX

```


CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 1 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2220 ACCAAGTGTACA 2232
Db 13 ACCAAGTGTATA 1

RESULT 147
ABC48258
ID ABC48258 standard; DNA; 13 BP.
XX
AC ABC48258;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 48275 for detecting SNP TSC0013776.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 48275; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 0 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2220 ACCAAGTGTACA 2232
Db 13 ACCAAGTGTATA 1

RESULT 149
ABC98510/c
ID ABC98510 standard; DNA; 13 BP.
XX
AC ABC98510;
XX
DT 21-FEB-2002 (first entry)
XX
XX

Qy 2224 AAGTTACATGTT 2236
Db 1 AGAGTTATATGTT 13

RESULT 148
ABC73508/c
ID ABC73508 standard; DNA; 13 BP.
XX
AC ABC73508;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 73525 for detecting SNP TSC0018934.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 73525; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 0 C; 3 G; 9 T; 0 U; 0 Other;

Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2220 ACCAAGTGTACA 2232
Db 13 ACCAAGTGTATA 1

RESULT 149
ABC98510/c
ID ABC98510 standard; DNA; 13 BP.
XX
AC ABC98510;
XX
DT 21-FEB-2002 (first entry)
XX
XX

```
DE Oligonucleotide SEQ ID NO 98527 for detecting SNP TSC0024492.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 98527; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABR00010-ABR82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 1 A; 0 C; 5 G; 7 T; 0 U; 0 Other;
XX Query Match 36.3%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2220 ACCAAAGTTTACA 2232
DB ||||| |||||
13 ACCAAACCTACA 1
RESULT 150
ABC24648/C
ID ABC24648 standard; DNA; 13 BP.
XX AC ABC24648;
XX 20-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 24665 for detecting SNP TSC0005912.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 98527; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABR00010-ABR82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 1 A; 0 C; 5 G; 7 T; 0 U; 0 Other;
XX Query Match 36.3%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2220 ACCAAAGTTTACA 2232
DB ||||| |||||
13 ACCAAACCTACA 1
RESULT 151
ABC78605/C
ID ABC78605 standard; DNA; 13 BP.
XX AC ABC78605;
XX 21-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 78622 for detecting SNP TSC0020009.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 24665; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABR00010-ABR82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 3 A; 0 C; 4 G; 6 T; 0 U; 0 Other;
XX Query Match 36.3%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2221 CCAAACTTACAT 2233
DB ||||| |||||
13 CCAAACTTACAT 1
```


PS Claim 1; SEQ ID NO 78622; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI0010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 7 A; 4 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2226 AGTTACATGTTG 2238
Db 13 AGTTATGTTTG 1

RESULT 152
ABH10602
ID ABH10602 standard; DNA; 13 BP.
XX
AC ABH10602;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 210579 for detecting SNP TSC0051414.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS
XX WO200177384-A2.
FN
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 210579; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI0010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 5 A; 0 C; 1 G; 7 T; 0 U; 0 Other;

Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2225 AAGTTACATGTTT 2237
Db 1 AATTAAATGTTT 13

RESULT 153
ABH44355
ID ABH44355 standard; DNA; 13 BP.
XX
AC ABH44355;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 244332 for detecting SNP TSC0059632.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS
XX WO200177384-A2.
FN
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 244332; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI0010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 6 A; 3 C; 1 G; 3 T; 0 U; 0 Other;

Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2220 ACCAAAAGTTTACA 2232
Db 1 ACCAACGTTATA 13

```
RESULT 154
ABC58323/C
ID ABC58323 standard; DNA; 13 BP.
XX
AC ABC58323;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 58340 for detecting SNP TSC0015654.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 58340; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 6 C; 1 G; 4 T; 0 U; 0 Other;
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 6 C; 1 G; 4 T; 0 U; 0 Other;
XX
Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. NO. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 2215 GTGTGACCAAG 2227
DB 13 GTGTGACCAAG 1
RESULT 155
ABC83932
ID ABC83932 standard; DNA; 13 BP.
XX
AC ABC83932;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 83949 for detecting SNP TSC0021124.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
```

```
XX Homo sapiens.
OS
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 83949; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABT00010-ABT82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 3 A; 1 C; 3 G; 6 T; 0 U; 0 Other;
XX
Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. NO. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 2226 AGTTACATGTTG 2238
DB 1 AGTTACATGTTG 13
RESULT 156
ABC11550
ID ABC11550 standard; DNA; 13 BP.
XX
XX ABC11550;
XX
XX 20-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 11549 for detecting SNP TSC0002804.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
```

PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 11549; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 6 A; 0 C; 2 G; 5 T; 0 U; 0 Other;
XX
Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 2223 AAAAGTTACATGT 2235
DB 1 AAATGTTAAATGT 13
XX
RESULT 157
ABC12790/C
ID ABC12790 standard; DNA; 13 BP.
XX
AC ABC12790;
XX
XX 20-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 12797 for detecting SNP TSC0002995.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 12797; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
XX
Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 2221 CCAAAAGTTACAT 2233
DB 13 CCAAAATTTAAAT 1
XX
RESULT 158
ABF67700
ID ABF67700 standard; DNA; 13 BP.
XX
AC ABF67700;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 167697 for detecting SNP TSC0041968.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 167697; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
XX
Query Match 36.3%; Score 9.8; DB 1; Length 13;

Query Match

Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2224 AAAGTTACATGTT 2236
Db 1 AAAGTTATTTGTT 13

RESULT 159
ABH44352/c
ID ABH44352 standard; DNA; 13 BP.
XX AC
XX AC ABH44352;
XX DT 22-FEB-2002 (first entry)
XX DE
XX DE Oligonucleotide SEQ ID NO 244329 for detecting SNP TSC0059632.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX
XX FN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX XX
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX XX
XX PS Claim 1; SEQ ID NO 244329; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 3 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
Query Match 36.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2220 ACCAAAAGTTTACA 2232
Db 13 ACCAAAATTATA 1

RESULT 160
ADL09225/c
ID ADL09225 standard; DNA; 14 BP.
XX XX
XX AC ADL09225;

XX DT 20-MAY-2004 (first entry)
XX DE SP6 promoter DNA fragment #4.
XX KW amplification; primer; promoter; RNA polymerase; ds.
XX OS Enterobacteria phage SP6.
XX XX
XX PN WO2004016757-A2.
XX PD 26-FEB-2004.
XX PF 15-AUG-2003; 2003WO-US025564.
XX PR 16-AUG-2002; 2002US-0404075P.
XX XX (REGC) UNIV CALIFORNIA.
XX PA Karin M, Park JM;
XX PI
XX XX WPI; 2004-203788/19.
XX DR
XX PT Producing a nucleic acid sequence comprises amplifying double stranded
XX PT DNA sequence in the presence of first and second primers to produce a
XX PT first nucleic acid molecule having the double stranded DNA sequence in a
XX PT head to head orientation.
XX XX
XX PS Disclosure; SEQ ID NO 41; 55pp; English.
XX CC This invention describes a novel method for producing a nucleic acid
XX CC sequence comprising amplifying the double stranded DNA sequence of
XX CC interest in the presence of the first primer and the second primer to
XX CC produce a first nucleic acid molecule comprising the double stranded DNA
XX CC sequence of interest flanked by at least a portion of the first promoter
XX CC in a head to head orientation. The method involves providing RNA
XX CC polymerase that specifically binds to the first promoter and contacting
XX CC the first nucleic acid molecule with the RNA polymerase to produce double
XX CC stranded RNA that is complementary to the double stranded DNA sequence of
XX CC interest. This method further comprises providing a third primer
XX CC complementary to at least a portion of the first promoter and amplifying
XX CC the first nucleic acid molecule produced in the presence of the third
XX CC primer to produce a second nucleic acid molecule comprising the double
XX CC stranded DNA sequence of interest flanked by the first promoter in a head
XX CC to head orientation. The method further comprises providing RNA
XX CC polymerase that specifically binds to the first promoter and contacting
XX CC the second nucleic acid molecule with the RNA polymerase to produce
XX CC double stranded RNA that is complementary to the double stranded DNA
XX CC sequence of interest. The second strand of the double-stranded DNA
XX CC sequence of interest comprises at least a portion of a second promoter.
XX CC The second promoter is different from the first promoter. The first
XX CC promoter comprises T7, T3 or SP6 promoter. The first strand of the double
XX CC stranded DNA comprises a nucleotide sequence linked to the 3' end of the
XX CC first promoter, and the first primer further comprises a second sequence
XX CC complementary to the nucleotide sequence, where the second sequence is
XX CC linked to the 3' end of the first sequence of the first primer. The first
XX CC primer comprises a sequence complementary to T7, T3 or SP6 promoter. The
XX CC first sequence comprises a second primer complementary to at least a
XX CC portion of a promoter. The methods and kits are useful for producing
XX CC nucleic acid sequences as powerful alternative tools for functional
XX CC genomics.
XX SQ Sequence 14 BP; 4 A; 2 C; 3 G; 5 T; 0 U; 0 Other;
Query Match 36.3%; Score 9.8; DB 1; Length 14;
Best Local Similarity 84.6%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2214 AGTGTGACCAAAA 2226
Db 14 AGTGTGACCTAAA 2

RESULT 161
 ADL09227/c
 ID ADL09227 standard; DNA; 14 BP.
 XX
 AC ADL09227;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE SP6 promoter DNA fragment #6.
 XX
 KW amplification; primer; promoter; RNA polymerase; ds.
 XX
 OS Enterobacteria phage SP6.
 XX
 PN WO2004016757-A2.
 XX
 PD 26-FEB-2004.
 XX
 PF 15-AUG-2003; 2003WO-US025564.
 XX
 PR 16-AUG-2002; 2002US-0404075P.
 XX
 PA (REGC) UNIV CALIFORNIA.
 XX
 PI Karin M, Park JM;
 XX
 DR WPI; 2004-203788/19.
 XX
 PT Producing a nucleic acid sequence comprises amplifying double stranded
 PT DNA sequence in the presence of first and second primers to produce a
 PT first nucleic acid molecule having the double stranded DNA sequence in a
 PT head to head orientation.
 XX
 PS Disclosure; SEQ ID NO 43; 55pp; English.
 XX
 CC This invention describes a novel method for producing a nucleic acid
 CC sequence comprising amplifying the double stranded DNA sequence of
 CC interest in the presence of the first primer and the second primer to
 CC produce a first nucleic acid molecule comprising the double stranded DNA
 CC sequence of interest flanked by at least a portion of the first promoter
 CC in a head to head orientation. The method involves providing RNA
 CC polymerase that specifically binds to the first promoter and contacting
 CC the first nucleic acid molecule with the RNA polymerase to produce double
 CC stranded RNA that is complementary to the double stranded DNA sequence of
 CC interest. This method further comprises providing a third primer
 CC complementary to at least a portion of the first promoter and amplifying
 CC the first nucleic acid molecule produced in the presence of the third
 CC primer to produce a second nucleic acid molecule comprising the double
 CC stranded DNA sequence of interest flanked by the first promoter in a head
 CC to head orientation. The method further comprises providing RNA
 CC polymerase that specifically binds to the first promoter and contacting
 CC the second nucleic acid molecule with the RNA polymerase to produce
 CC double stranded RNA that is complementary to the double stranded DNA
 CC sequence of interest. The second strand of the double-stranded DNA
 CC sequence of interest comprises at least a portion of a second promoter.
 CC The second promoter is different from the first promoter. The first
 CC promoter comprises T7, T3 or SP6 promoter. The first strand of the double
 CC stranded DNA comprises a nucleotide sequence linked to the 3' end of the
 CC first promoter, and the first primer further comprises a second sequence
 CC complementary to the nucleotide sequence, where the second sequence is
 CC linked to the 3' end of the first sequence of the first primer. The first
 CC primer comprises a sequence complementary to T7, T3 or SP6 promoter. The
 CC first sequence comprises a second primer complementary to at least a
 CC portion of a promoter. The methods and kits are useful for producing
 CC nucleic acid sequences as powerful alternative tools for functional
 CC genomics.
 XX
 SQ Sequence 14 BP; 4 A; 2 C; 3 G; 5 T; 0 U; 0 Other;
 Query Match 36.3%; Score 9.8; DB 1; Length 14;
 Best Local Similarity 84.6%; Pred. No. 2e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2214 AGTGTGACCAAAA 2226
 DB 13 AGTGTGACCTAAA 1
 RESULT 162
 AAH55111/c
 ID AAH55111 standard; DNA; 11 BP.
 XX
 AC AAH55111;
 XX
 DT 03-SEP-2001 (first entry)
 XX
 DE Genomic DNA methylation parallel detection associated DNA fragment #13.
 XX
 KW DNA methylation; parallel detection; 5-umethylated cytosine; CpG; CpNpg;
 KW amplification; transcription regulation; genetic imprinting;
 XX
 OS Unidentified.
 XX
 PN WO200142493-A2.
 XX
 PD 14-JUN-2001.
 XX
 PF 06-DEC-2000; 2000WO-DE004381.
 XX
 PR 06-DEC-1999; 99DE-01059691.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C;
 XX
 DR WPI; 2001-381705/40.
 XX
 PT Parallel detection of the methylation pattern of many genomic DNA
 PT regions, useful for detecting aberrant methylation, includes multiple
 PT amplification of chemically modified DNA.
 XX
 PS Claim 18; Page 19; 63pp; German.
 XX
 CC This invention describes a novel method for the parallel detection of the
 CC methylation status of genomic DNA (1) which involves a (i) sample being
 CC treated chemically to convert 5-umethylated cytosine to uracil,
 CC thymidine or some other base having hybridization behavior different from
 CC that of C, then amplifying simultaneously at least 10 different fragments
 CC (of fewer than 2 kb) using synthetic oligonucleotide (ON) primers. These
 CC primers are based on regulatory, transcribed and/or translated segments
 CC present in the sample after chemical treatment. The sequence context of
 CC all, or some, of the CpG and CpNpg motifs in the amplified products is
 CC then determined. The method is used to detect aberrant methylation
 CC patterns in the genome, these are implicated in regulation of
 CC transcription, genetic imprinting and tumorigenesis. Many target regions
 CC in the genome can be analyzed simultaneously and it is not essential to
 CC know the sequence context of all targeted regions. Primers may be
 CC designed for preferential amplification of particular segments of
 CC interest (e.g. promoters and exons)
 XX
 SQ Sequence 11 BP; 3 A; 0 C; 1 G; 7 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 11;
 Best Local Similarity 90.9%; Pred. No. 1.7e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 2223 AAAAGTTACAT 2233
 DB 11 AAAAATTACAT 1
 RESULT 163
 AAH55112
 ID AAH55112 standard; DNA; 11 BP.
 XX

```

AC AAH55112;
XX
XX DT 03-SEP-2001 (first entry)
XX
XX DE Genomic DNA methylation parallel detection associated DNA fragment #14.
XX
XX KW DNA methylation; parallel detection; 5-unmethylated cytosine; CpG; CpNpG;
XX KW amplification; transcription regulation; genetic imprinting;
XX KW tumorigenesis; primer; ss.
XX
XX OS Unidentified.
XX
XX PN WO200142493-A2.
XX
XX PD 14-JUN-2001.
XX
XX PF 06-DEC-2000; 2000WO-DE004381.
XX
XX PR 06-DEC-1999; 99DE-01059691.
XX
XX PA (EPiG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C;
XX
XX DR WPI; 2001-381705/40.
XX
XX PT Parallel detection of the methylation pattern of many genomic DNA
XX PT regions, useful for detecting aberrant methylation, includes multiple
XX PT amplification of chemically modified DNA.
XX
XX PS Claim 18; Page 19; 63pp; German.
XX
XX CC This invention describes a novel method for the parallel detection of the
XX CC methylation status of genomic DNA (I) which involves a (I) sample being
XX CC treated chemically to convert 5-unmethylated cytosine to uracil,
XX CC thymidine or some other base having hybridization behavior different from
XX CC that of C, then amplifying simultaneously at least 10 different fragments
XX CC (of fewer than 2 kb) using synthetic oligonucleotide (ON) primers. These
XX CC primers are based on regulatory, transcribed and/or translated segments
XX CC present in the sample after chemical treatment. The sequence context of
XX CC all, or some, of the CpG and CpNpG motifs in the amplified products is
XX CC then determined. The method is used to detect aberrant methylation
XX CC patterns in the genome, these are implicated in regulation of
XX CC transcription, genetic imprinting and tumorigenesis. Many target regions
XX CC in the genome can be analyzed simultaneously and it is not essential to
XX CC know the sequence context of all targeted regions. Primers may be
XX CC designed for preferential amplification of particular segments of
XX CC interest (e.g. promoters and exons)
XX
XX SQ Sequence 11 BP; 7 A; 1 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 34.8%; Score 9.4; DB 1; Length 11;
XX Best Local Similarity 90.9%; Pred. No. 1.7e+02;
XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2223 AAAAGTTACAT 2233
XX Db 1 AAAAATTACAT 11
XX
XX RESULT 164
XX ABV67983/C
XX ID ABV67983 standard; cDNA; 11 BP.
XX
XX AC ABV67983;
XX
XX DT 21-OCT-2002 (first entry)
XX
XX DE Human skin EST 5769.
XX
XX KW Human; skin; dermatological; vulnary; antipsoriatic; antiseborrhaic;
XX KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
XX KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX

```

```

XX Homo sapiens.
XX OS
XX PN WO200253774-A2.
XX
XX PD 11-JUL-2002.
XX
XX PF 20-DEC-2001; 2001WO-EP015179.
XX
XX PR 03-JAN-2001; 2001DE-01000127.
XX
XX PA (HENK ) HENKEL KGAA.
XX
XX PI Petersohn D, Conradt M, Hofmann K;
XX
XX DR WPI; 2002-590638/63.
XX
XX PT In vitro identification of skin-expressed genes, useful for determining
XX PT homeostasis and identifying cosmetic or pharmaceutical agents against
XX PT e.g. skin cancer.
XX
XX PS Disclosure; Page 185; 1345pp; German.
XX
XX CC The invention relates to in vitro identification (M1) of genes expressed
XX CC in the skin of humans or animals by subjecting a mixture of genetically
XX CC encoded factors from skin, to serial analysis of gene expression (SAGE)
XX CC so as to identify skin-expressed genes and quantify their expression.
XX CC (M1) is useful for identifying genes involved in skin homeostasis; to
XX CC determine skin homeostasis and to test agent (A) that maintains or
XX CC promotes skin homeostasis or that can be used for treating skin
XX CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
XX CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
XX CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
XX CC skin. The present sequence is that of a human expressed sequence tag
XX CC (EST) of the invention
XX
XX SQ Sequence 11 BP; 2 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 34.8%; Score 9.4; DB 1; Length 11;
XX Best Local Similarity 90.9%; Pred. No. 1.7e+02;
XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2222 CAAAAGTTACA 2232
XX Db 11 CAAAAGTTACA 1
XX
XX RESULT 165
XX ABV69864/C
XX ID ABV69864 standard; cDNA; 11 BP.
XX
XX AC ABV69864;
XX
XX DT 21-OCT-2002 (first entry)
XX
XX DE Human skin EST 7650.
XX
XX KW Human; skin; dermatological; vulnary; antipsoriatic; antiseborrhaic;
XX KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
XX KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX
XX OS Homo sapiens.
XX
XX PN WO200253774-A2.
XX
XX PD 11-JUL-2002.
XX
XX PF 20-DEC-2001; 2001WO-EP015179.
XX
XX PR 03-JAN-2001; 2001DE-01000127.
XX
XX PA (HENK ) HENKEL KGAA.
XX

```

PI Petersohn D, Conradt M, Hofmann K;
XX WPI; 2002-590638/63.
XX In vitro identification of skin-expressed genes, useful for determining
PT homeostasis and identifying cosmetic or pharmaceutical agents against
PT e.g. skin cancer.
XX Claim 24; Page 242; 1345pp; German.
XX The invention relates to in vitro identification (M1) of genes expressed
CC in the skin of humans or animals by subjecting a mixture of genetically
CC encoded factors from skin, to serial analysis of gene expression (SAGE)
CC so as to identify skin-expressed genes and quantify their expression.
CC (M1) is useful for identifying genes involved in skin homeostasis; to
CC determine skin homeostasis and to test agent (A) that maintains or
CC promotes skin homeostasis or that can be used for treating skin
CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
CC skin. The present sequence is that of a human expressed sequence tag
CC (EST) of the invention
XX Sequence 11 BP; 2 A; 1 C; 2 G; 6 T; 0 U; 0 Other;
SQ Query Match 34.8%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 1.7e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2223 AAAAGTTACAT 2233
DB 11 AAAAGTCACAT 1
RESULT 166
ABV70995/C
ID ABV70995 standard; cDNA; 11 BP.
XX AC ABV70995;
XX 21-OCT-2002 (first entry)
XX Human skin EST 8781.
XX Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhaeic;
KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX Homo sapiens.
XX WO200253774-A2.
XX 11-JUL-2002.
XX 20-DEC-2001; 2001WO-EP015179.
XX 03-JAN-2001; 2001DE-01000127.
XX (HENK) HENKEL KGAA.
XX Petersohn D, Conradt M, Hofmann K;
XX WPI; 2002-590638/63.
XX In vitro identification of skin-expressed genes, useful for determining
PT homeostasis and identifying cosmetic or pharmaceutical agents against
PT e.g. skin cancer.
XX Claim 24; Page 281; 1345pp; German.
XX The invention relates to in vitro identification (M1) of genes expressed
CC in the skin of humans or animals by subjecting a mixture of genetically
CC encoded factors from skin, to serial analysis of gene expression (SAGE)

CC so as to identify skin-expressed genes and quantify their expression.
CC (M1) is useful for identifying genes involved in skin homeostasis; to
CC determine skin homeostasis and to test agent (A) that maintains or
CC promotes skin homeostasis or that can be used for treating skin
CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
CC skin. The present sequence is that of a human expressed sequence tag
CC (EST) of the invention
XX Sequence 11 BP; 1 A; 1 C; 2 G; 7 T; 0 U; 0 Other;
SQ Query Match 34.8%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 1.7e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2220 ACCAAAGTTA 2230
DB 11 ACCAAAGTAA 1
RESULT 167
ABV62443/C
ID ABV62443 standard; cDNA; 11 BP.
XX AC ABV62443;
XX 21-OCT-2002 (first entry)
XX Human skin EST 229.
XX Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhaeic;
KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX Homo sapiens.
XX WO200253774-A2.
XX 11-JUL-2002.
XX 20-DEC-2001; 2001WO-EP015179.
XX 03-JAN-2001; 2001DE-01000127.
XX (HENK) HENKEL KGAA.
XX Petersohn D, Conradt M, Hofmann K;
XX WPI; 2002-590638/63.
XX In vitro identification of skin-expressed genes, useful for determining
PT homeostasis and identifying cosmetic or pharmaceutical agents against
PT e.g. skin cancer.
XX Disclosure; Page 32; 1345pp; German.
XX The invention relates to in vitro identification (M1) of genes expressed
CC in the skin of humans or animals by subjecting a mixture of genetically
CC encoded factors from skin, to serial analysis of gene expression (SAGE)
CC so as to identify skin-expressed genes and quantify their expression.
CC (M1) is useful for identifying genes involved in skin homeostasis; to
CC determine skin homeostasis and to test agent (A) that maintains or
CC promotes skin homeostasis or that can be used for treating skin
CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
CC skin. The present sequence is that of a human expressed sequence tag
CC (EST) of the invention
XX Sequence 11 BP; 2 A; 1 C; 2 G; 6 T; 0 U; 0 Other;
SQ Query Match 34.8%; Score 9.4; DB 1; Length 11;

Best Local Similarity 90.9%; Pred. No. 1.7e+02; Mismatches 0; Indels 1; Gaps 0;
Matches 10; Conservative 0

QY 2223 AAAAGTTACAT 2233
DB 11 AAAAGTCACAT 1

RESULT 168
ABV63574/c
ID ABV63574 standard; cDNA; 11 BP.
XX AC ABV63574;
XX 21-OCT-2002 (first entry)
DT Human skin EST 1360.
DE Human; skin; dermatological; vulnary; antipsoriatic; antiseborrheic;
XX immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
KW
XX Homo sapiens.
OS
XX WO200253774-A2.
PN 11-JUL-2002.
XX 20-DEC-2001; 2001WO-EP015179.
XX 03-JAN-2001; 2001DE-01000127.
XX (HENK) HENKEL KGAA.
XX Petersohn D, Conradt M, Hofmann K;
PI WPI; 2002-590638/63.
XX In vitro identification of skin-expressed genes, useful for determining
PT homeostasis and identifying cosmetic or pharmaceutical agents against
PT e.g. skin cancer.
XX Disclosure; Page 62; 1345pp; German.
PS
XX The invention relates to in vitro identification (M1) of genes expressed
CC in the skin of humans or animals by subjecting a mixture of genetically
CC encoded factors from skin, to serial analysis of gene expression (SAGE)
CC so as to identify skin-expressed genes and quantify their expression.
CC (M1) is useful for identifying genes involved in skin homeostasis; to
CC determine skin homeostasis and to test agent (A) that maintains or
CC promotes skin homeostasis or that can be used for treating skin
CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
CC skin. The present sequence is that of a human expressed sequence tag
CC (EST) of the invention
XX
SQ Sequence 11 BP; 1 A; 1 C; 2 G; 7 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 1.7e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2220 ACCAAAAGTTA 2230
DB 11 ACCAAAAGTTA 1

RESULT 169
ABH76664/c
ID ABH76664 standard; DNA; 12 BP.
XX ABH76664;
AC

XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 276657 for detecting SNP TSC0004255.
DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
KW
XX Homo sapiens.
OS
XX WO200177384-A2.
PN 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A., Piepenbrock C, Berlin K;
PI WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 276657; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABJ00010-ABJ99989
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 4 A; 2 C; 0 G; 6 T; 0 U; 0 Other;
SQ
Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2224 AAAGTTACATG 2234
DB 12 AAAGTTATATG 2

RESULT 170
ABI31743
ID ABI31743 standard; DNA; 12 BP.
XX AC ABI31743;
XX 22-FEB-2002 (first entry)
DT Oligonucleotide primer SEQ ID NO 331716 for detecting SNP TSC0036427.
DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
KW
XX Homo sapiens.
OS
XX WO200177384-A2.
PN

CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 12;
 Best Local Similarity 90.9%; Pred. No. 2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTG 2238
 ||| |||||
 1 TTATATGTTG 11

Db
 RESULT 173
 ABH1066/C
 ID ABH1066 standard; DNA; 12 BP.
 XX AC
 XX ABH1066;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 381039 for detecting SNP TSC0064140.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 381039; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 12;
 Best Local Similarity 90.9%; Pred. No. 2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2222 CAAAGTTTACA 2222
 ||||| |||||

Db
 RESULT 175
 ABH71906/C
 ID ABH71906 standard; DNA; 12 BP.
 XX AC
 XX ABH71906;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 271883 for detecting SNP TSC0002643.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 271883; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

Db 11 CAAATTTCACA 1
 RESULT 174
 ABH67812/C
 ID ABH67812 standard; DNA; 12 BP.
 XX AC
 XX ABH67812;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 267789 for detecting SNP TSC0000529.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 267789; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 6 A; 1 C; 1 G; 4 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 12;
 Best Local Similarity 90.9%; Pred. No. 2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2227 GTTACATGTTT 2237
 ||||| |||||
 12 GTTACATATT 2

Db
 RESULT 175
 ABH71906/C
 ID ABH71906 standard; DNA; 12 BP.
 XX AC
 XX ABH71906;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 271883 for detecting SNP TSC0002643.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 267789; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
PI WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 271883; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2223 AAAAGTTACAT 2233
Db 11 AAAACTATACAT 1
RESULT 176
ABI27613/C
ID ABI27613 standard; DNA; 12 BP.
XX ABI27613;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 327586 for detecting SNP TSC0033749.
DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 327586; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2222 CAAAAGTTTACA 2232
Db 11 CAAAATTTACA 1
RESULT 177
ABI78288
ID ABI78288 standard; DNA; 12 BP.
XX ABI78288;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 378261 for detecting SNP TSC0062696.
DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
PI WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 378261; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB102073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 12;
 Best Local Similarity 90.9%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
 Matches 10; Conservative 0; Mismatches 0; Mismatches 0; Gaps 0;

Qy 2228 TTACATGTTTG 2238
 Db 1 TTACATGTTTG 11

RESULT 178
 ABI19684
 ID ABI19684 standard; DNA; 12 BP.
 AC ABI19684;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 319657 for detecting SNP TSC0029347.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 319657; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB102073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 12;
 Best Local Similarity 90.9%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
 Matches 10; Conservative 0; Mismatches 0; Mismatches 0; Gaps 0;

Qy 2228 TTACATGTTTG 2238
 Db 1 TTACATGTTTG 11

RESULT 178
 ABI19684
 ID ABI19684 standard; DNA; 12 BP.
 AC ABI19684;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 319657 for detecting SNP TSC0029347.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 319657; 29pp + Sequence Listing; German.

SQ Sequence 12 BP; 2 A; 1 C; 3 G; 6 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 12;
 Best Local Similarity 90.9%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
 Matches 10; Conservative 0; Mismatches 0; Mismatches 0; Gaps 0;

Qy 2227 GTTACATGTTT 2237
 Db 1 GTTACATGTTT 11

RESULT 179
 ABI29884/c
 ID ABI29884 standard; DNA; 12 BP.
 AC ABI29884;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 329857 for detecting SNP TSC0035199.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 329857; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB102073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 2 A; 1 C; 3 G; 6 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 12;
 Best Local Similarity 90.9%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
 Matches 10; Conservative 0; Mismatches 0; Mismatches 0; Gaps 0;

Qy 2222 CAAAAGTTACA 2232
 Db 1 CAAAAGTTACA 11

RESULT 180
 ABI35542/c

```

ID XX ABI35542 standard; DNA; 12 BP.
AC XX
XX XX
XX XX
DT DT 22-FEB-2002 (first entry)
XX XX
XX XX Oligonucleotide primer SEQ ID NO 335515 for detecting SNP TSC0038870.
XX XX
XX XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX
XX XX WO200177384-A2.
XX XX
XX XX 18-OCT-2001.
XX XX
XX XX 06-APR-2001; 2001WO-IB000713.
XX XX
XX XX 07-APR-2000; 2000DE-01019173.
XX XX
XX XX (EPIG-) EPIGENOMICS AG.
XX XX
XX XX Olek A, Piepenbrock C, Berlin K;
XX XX
XX XX WPI; 2001-657177/75.
XX XX
XX XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX XX designed to detect single-nucleotide polymorphisms and cytosine
XX XX methylation status.
XX XX
XX XX Claim 1; SEQ ID NO 335515; 29pp + Sequence Listing; German.
XX XX
XX XX This invention describes novel oligonucleotide primers or peptide nucleic
XX XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX XX range of diseases including immune system, gastrointestinal, respiratory,
XX XX central nervous system, cardiovascular and metabolic disorders. The
XX XX oligomers are also used for detecting cell type differentiation. ABC00010
XX XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX XX represent the oligomers described in the invention. NOTE: The sequence
XX XX data for this patent did not form part of the printed specification, but
XX XX was obtained in electronic format from WIPO at
XX XX ftp.wipo.int/pub/published_pct_sequences
XX XX
XX XX Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
XX XX
XX XX Query Match 34.8%; Score 9.4; DB 1; Length 12;
XX XX Best Local Similarity 90.9%; Pred. NO. 2e+02;
XX XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX XX
XX XX QY 2226 AGTACATGTT 2236
XX XX
XX XX 11 AGTATATGTT 1
XX XX
XX XX RESULT 181
XX XX ABI15399
XX XX ID ABI15399 standard; DNA; 12 BP.
XX XX
XX XX AC ABI15399;
XX XX
XX XX DT 22-FEB-2002 (first entry)
XX XX
XX XX Oligonucleotide primer SEQ ID NO 315372 for detecting SNP TSC0026873.
XX XX
XX XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX XX
XX XX OS Homo sapiens.

```

```

XX XX WO200177384-A2.
XX XX
XX XX 18-OCT-2001.
XX XX
XX XX 06-APR-2001; 2001WO-IB000713.
XX XX
XX XX 07-APR-2000; 2000DE-01019173.
XX XX
XX XX (EPIG-) EPIGENOMICS AG.
XX XX
XX XX Olek A, Piepenbrock C, Berlin K;
XX XX
XX XX WPI; 2001-657177/75.
XX XX
XX XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX XX designed to detect single-nucleotide polymorphisms and cytosine
XX XX methylation status.
XX XX
XX XX Claim 1; SEQ ID NO 315372; 29pp + Sequence Listing; German.
XX XX
XX XX This invention describes novel oligonucleotide primers or peptide nucleic
XX XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX XX range of diseases including immune system, gastrointestinal, respiratory,
XX XX central nervous system, cardiovascular and metabolic disorders. The
XX XX oligomers are also used for detecting cell type differentiation. ABC00010
XX XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX XX represent the oligomers described in the invention. NOTE: The sequence
XX XX data for this patent did not form part of the printed specification, but
XX XX was obtained in electronic format from WIPO at
XX XX ftp.wipo.int/pub/published_pct_sequences
XX XX
XX XX Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
XX XX
XX XX Query Match 34.8%; Score 9.4; DB 1; Length 12;
XX XX Best Local Similarity 90.9%; Pred. NO. 2e+02;
XX XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX XX
XX XX QY 2220 ACCAAAAGTTA 2230
XX XX
XX XX Db 2 ACCAAAATTTA 12
XX XX
XX XX RESULT 182
XX XX ABI77265
XX XX ID ABI77265 standard; DNA; 12 BP.
XX XX
XX XX AC ABI77265;
XX XX
XX XX DT 22-FEB-2002 (first entry)
XX XX
XX XX Oligonucleotide primer SEQ ID NO 377238 for detecting SNP TSC0010490.
XX XX
XX XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX XX
XX XX OS Homo sapiens.
XX XX
XX XX PN WO200177384-A2.
XX XX
XX XX PD 18-OCT-2001.
XX XX
XX XX 06-APR-2001; 2001WO-IB000713.
XX XX
XX XX 07-APR-2000; 2000DE-01019173.
XX XX
XX XX (EPIG-) EPIGENOMICS AG.
XX XX
XX XX Olek A, Piepenbrock C, Berlin K;
XX XX

```

DR WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 377238; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2228 TTATATGTTG 2238
DB 1 TTATATGTTG 11
RESULT 183
ABI30122/c
ID ABI30122 standard; DNA; 12 BP.
AC ABI30122;
XX
XX 22-FEB-2002 (first entry)
DT
DE Oligonucleotide primer SEQ ID NO 330095 for detecting SNP TSC0035335.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
PN
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 330095; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2228 TTATATGTTG 2238
DB 1 TTATATGTTG 11
RESULT 183
ABI30122/c
ID ABI30122 standard; DNA; 12 BP.
AC ABI30122;
XX
XX 22-FEB-2002 (first entry)
DT
DE Oligonucleotide primer SEQ ID NO 330095 for detecting SNP TSC0035335.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
PN
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 330095; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 3 A; 0 C; 1 G; 8 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2223 AAAAGTTTACAT 2233
DB 11 AAAAATTACAT 1
RESULT 184
ABI78505
ID ABI78505 standard; DNA; 12 BP.
AC ABI78505;
XX
XX 22-FEB-2002 (first entry)
DT
DE Oligonucleotide primer SEQ ID NO 378478 for detecting SNP TSC0062797.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
PN
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 378478; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
QY 2228 TTACATGTTTG 2238
Db 1 TTAATGTTTG 11

RESULT 185
ABI44044
ID ABI44044 standard; DNA; 12 BP.
XX
AC ABI44044;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 344017 for detecting SNP TSC0043334.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPITG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 344017; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 7 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 7 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
XX
Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2220 ACCAAAAGTTA 2230
Db 2 ACCAAAAGTTA 12

RESULT 186
ABI78763
ID ABI78763 standard; DNA; 12 BP.
XX
AC ABI78763;
XX
DT 22-FEB-2002 (first entry)
XX
```

```
XX
DE Oligonucleotide primer SEQ ID NO 378736 for detecting SNP TSC0062912.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 378736; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
XX
Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2220 ACCAAAAGTTA 2230
Db 1 ACCAAAAGTTA 11

RESULT 187
ABH94302
ID ABH94302 standard; DNA; 12 BP.
XX
AC ABH94302;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 294295 for detecting SNP TSC0015041.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
```

PF 06-APR-2001; 2001WO-IB000713.
 XX
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT
 XX
 PS Claim 1; SEQ ID NO 294295; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 7 A; 1 C; 0 G; 4 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 12;
 Best Local Similarity 90.9%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTACAT 2233
 DB 1 AAAATTACAT 11
 RESULT 188
 ABH85219/c
 ID ABH85219 standard; DNA; 12 BP.
 XX
 XX ABH85219;
 AC
 XX 22-FEB-2002 (first entry)
 DT
 XX Oligonucleotide primer SEQ ID NO 285212 for detecting SNP TSC0012196.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 KW
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 FN
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT
 XX
 PS Claim 1; SEQ ID NO 294295; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 7 A; 1 C; 0 G; 4 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 12;
 Best Local Similarity 90.9%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTACAT 2233
 DB 1 AAAATTACAT 11
 RESULT 188
 ABH85219/c
 ID ABH85219 standard; DNA; 12 BP.
 XX
 XX ABH85219;
 AC
 XX 22-FEB-2002 (first entry)
 DT
 XX Oligonucleotide primer SEQ ID NO 285212 for detecting SNP TSC0012196.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 KW
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 FN
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT

XX Claim 1; SEQ ID NO 285212; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 6 A; 3 C; 0 G; 3 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 12;
 Best Local Similarity 90.9%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2228 TTACATGTTTG 2238
 DB 11 TTACATGTTTG 1
 RESULT 189
 ABH90151
 ID ABH90151 standard; DNA; 12 BP.
 XX
 XX ABH90151;
 AC
 XX 22-FEB-2002 (first entry)
 DT
 XX Oligonucleotide primer SEQ ID NO 290144 for detecting SNP TSC0014233.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 KW
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 FN
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT
 XX
 PS Claim 1; SEQ ID NO 290144; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC

CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

SQ Sequence 12 BP; 4 A; 0 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2225 AGTTACATGT 2235

Db 2 AAGTTATATGT 12

RESULT 190

AB122109
ID AB122109 standard; DNA; 12 BP.

XX AC AB122109;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 322082 for detecting SNP TSC0030647.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX PI WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 322082; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2222 CAAAGTTTACA 2232

Db 2 CAAAGTTTACA 12

RESULT 191

ABH83316
ID ABH83316 standard; DNA; 12 BP.

XX AC ABH83316;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 283309 for detecting SNP TSC0011256.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX PI WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 283309; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2222 CAAAGTTTACA 2232

Db 1 CAAAGTTTACA 11

RESULT 192

ABH84060
ID ABH84060 standard; DNA; 12 BP.

XX AC ABH84060;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 284053 for detecting SNP TSC0011638.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 284053; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
SQ Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 2223 AAAAGTTACAT 2233
DB 1 AAAAATTACAT 11
RESULT 193
ABI40875/C
ID ABI40875 standard; DNA; 12 BP.
AC ABI40875;
XX 22-FEB-2002 (first entry)
DT Oligonucleotide primer SEQ ID NO 340848 for detecting SNP TSC0041713.
DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS WO200177384-A2.
XX 18-OCT-2001.
PD 06-APR-2001; 2001WO-IB000713.
PF 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 340848; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 7 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
SQ Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 2228 TTACATGTTTG 2238
DB 11 TTACATGTTTG 1
RESULT 194
ABI42569/C
ID ABI42569 standard; DNA; 12 BP.
AC ABI42569;
XX 22-FEB-2002 (first entry)
DT Oligonucleotide primer SEQ ID NO 342542 for detecting SNP TSC0042592.
DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS WO200177384-A2.
XX 18-OCT-2001.
PD 06-APR-2001; 2001WO-IB000713.
PF 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 342542; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 XX Sequence 12 BP; 3 A; 0 C; 1 G; 8 T; 0 U; 0 Other;
 SQ

Query Match 34.8%; Score 9.4; DB 1; Length 12;
 Best Local Similarity 90.9%; Pred. No. 2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACAT 2233
 DB 12 AAAATTACAT 2

RESULT 195
 ABI37195/c
 ID ABI37195 standard; DNA; 12 BP.
 XX
 AC ABI37195;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 337168 for detecting SNP TSC0039711.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PS 07-APR-2000; 2000DE-01019173.
 XX
 PR (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 337168; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 XX Sequence 12 BP; 4 A; 0 C; 1 G; 7 T; 0 U; 0 Other;
 SQ

Query Match 34.8%; Score 9.4; DB 1; Length 12;
 Best Local Similarity 90.9%; Pred. No. 2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACAT 2233
 DB 11 AAAATTACAT 1

RESULT 196
 ABI54798
 ID ABI54798 standard; DNA; 12 BP.
 XX
 AC ABI54798;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 354771 for detecting SNP TSC0049282.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PS 07-APR-2000; 2000DE-01019173.
 XX
 PR (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 354771; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 XX Sequence 12 BP; 6 A; 1 C; 0 G; 5 T; 0 U; 0 Other;
 SQ

Query Match 34.8%; Score 9.4; DB 1; Length 12;
 Best Local Similarity 90.9%; Pred. No. 2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACAT 2233
 DB 1 AAAATTACAT 11

RESULT 197
 ABH93701/c
 ID ABH93701 standard; DNA; 12 BP.
 XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PS Claim 1; SEQ ID NO 340756; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 4 A; 0 C; 1 G; 7 T; 0 U; 0 Other;
SQ
Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2223 AAAAGTTACAT 2233
Db 11 AAAATTACAT 1
RESULT 200
ABI78290/C
ID ABI78290 standard; DNA; 12 BP.
XX
AC ABI78290;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 378263 for detecting SNP TSC0062696.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PS Claim 1; SEQ ID NO 378263; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 4 A; 0 C; 1 G; 7 T; 0 U; 0 Other;
SQ

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 6 A; 3 C; 0 G; 3 T; 0 U; 0 Other;
SQ
Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2228 TTACATGTTTG 2238
Db 12 TTAGATGTTTG 2
RESULT 201
ABI78637
ID ABI78637 standard; DNA; 12 BP.
XX
AC ABI78637;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 378610 for detecting SNP TSC0062866.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PS Claim 1; SEQ ID NO 378610; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 2 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
SQ
Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2228 TTACATGTTTG 2238

```

Db      ||| ||| ||| ||| |||
        2 TTAGATGTTG 12

RESULT 202
ABH93832/c
ID      ABH93832 standard; DNA; 12 BP.
XX
XX      ABH93832;
XX
XX      22-FEB-2002 (first entry)
XX
XX      Oligonucleotide primer SEQ ID NO 293825 for detecting SNP TSC0015810.
XX
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX      Homo sapiens.
XX
XX      WO200177384-A2.
XX
XX      18-OCT-2001.
XX
XX      06-APR-2001; 2001WO-IB000713.
XX
XX      07-APR-2000; 2000DE-01019173.
XX
XX      (EPIG-) EPIGENOMICS AG.
XX
XX      Olek A, Piepenbrock C, Berlin K;
XX
XX      WPI; 2001-657177/75.
XX
XX      Set of oligonucleotides, useful for diagnosis and cell typing, is
XX      designed to detect single-nucleotide polymorphisms and cytosine
XX      methylation status.
XX
XX      Claim 1; SEQ ID NO 293825; 29pp + Sequence Listing; German.
XX
XX      This invention describes novel oligonucleotide primers or peptide nucleic
XX      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX      and cytosine methylation status in chemically pretreated genomic DNA. The
XX      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX      range of diseases including immune system, gastrointestinal, respiratory,
XX      central nervous system, cardiovascular and metabolic disorders. The
XX      oligomers are also used for detecting cell type differentiation. ABC00010
XX      -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX      represent the oligomers described in the invention. NOTE: The sequence
XX      data for this patent did not form part of the printed specification, but
XX      was obtained in electronic format from WIPO at
XX      ftp.wipo.int/pub/published_pct_sequences
XX
XX      Sequence 12 BP; 2 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
XX
XX      Query Match      34.8%; Score 9.4; DB 1; Length 12;
XX      Best Local Similarity 90.9%; Pred. No. 2e+02;
XX      Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX      QY      2222 CAAAGTTTACA 2232
XX      ||||| ||| ||| |||
XX      11 CAAAACTTACA 1
XX
XX      RESULT 203
XX      ABH83231
XX      ID      ABH83231 standard; DNA; 12 BP.
XX
XX      AC      ABH83231;
XX
XX      22-FEB-2002 (first entry)
XX
XX      Oligonucleotide primer SEQ ID NO 283224 for detecting SNP TSC0011213.

```

```

XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX      Homo sapiens.
XX
XX      WO200177384-A2.
XX
XX      18-OCT-2001.
XX
XX      06-APR-2001; 2001WO-IB000713.
XX
XX      07-APR-2000; 2000DE-01019173.
XX
XX      (EPIG-) EPIGENOMICS AG.
XX
XX      Olek A, Piepenbrock C, Berlin K;
XX
XX      WPI; 2001-657177/75.
XX
XX      Set of oligonucleotides, useful for diagnosis and cell typing, is
XX      designed to detect single-nucleotide polymorphisms and cytosine
XX      methylation status.
XX
XX      Claim 1; SEQ ID NO 283224; 29pp + Sequence Listing; German.
XX
XX      This invention describes novel oligonucleotide primers or peptide nucleic
XX      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX      and cytosine methylation status in chemically pretreated genomic DNA. The
XX      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX      range of diseases including immune system, gastrointestinal, respiratory,
XX      central nervous system, cardiovascular and metabolic disorders. The
XX      oligomers are also used for detecting cell type differentiation. ABC00010
XX      -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX      represent the oligomers described in the invention. NOTE: The sequence
XX      data for this patent did not form part of the printed specification, but
XX      was obtained in electronic format from WIPO at
XX      ftp.wipo.int/pub/published_pct_sequences
XX
XX      Sequence 12 BP; 8 A; 1 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX      Query Match      34.8%; Score 9.4; DB 1; Length 12;
XX      Best Local Similarity 90.9%; Pred. No. 2e+02;
XX      Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX      QY      2223 AAAAGTTTACAT 2233
XX      ||||| ||| ||| |||
XX      2 AAAAATTACAT 12
XX
XX      RESULT 204
XX      ABI09796/c
XX      ID      ABI09796 standard; DNA; 12 BP.
XX
XX      AC      ABI09796;
XX
XX      22-FEB-2002 (first entry)
XX
XX      Oligonucleotide primer SEQ ID NO 309769 for detecting SNP TSC0023664.
XX
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX      Homo sapiens.
XX
XX      WO200177384-A2.
XX
XX      18-OCT-2001.
XX
XX      06-APR-2001; 2001WO-IB000713.

```

PR 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
PA Olek A, Piepenbrock C, Berlin K;
PI WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 309769; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
XX Query Match 34.8%; Score 9.4; DB 1; Length 12;
XX Best Local Similarity 90.9%; Pred. No. 2e+02;
XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2222 CAAAAGTTTACA 2232
DB 12 CAAAATTACA 2
RESULT 205
ABI12365/C
ID ABI12365 standard; DNA; 12 BP.
XX AC ABI12365;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 312338 for detecting SNP TSC0025007.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 312338; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 4 A; 0 C; 1 G; 7 T; 0 U; 0 Other;
XX Query Match 34.8%; Score 9.4; DB 1; Length 12;
XX Best Local Similarity 90.9%; Pred. No. 2e+02;
XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2223 AAAAGTTTACAT 2233
DB 12 AAAAATTACAT 2
RESULT 206
ABH88948
ID ABH88948 standard; DNA; 12 BP.
XX AC ABH88948;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 288941 for detecting SNP TSC0013739.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 288941; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

OS Homo sapiens.
XX
FN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 345377; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -AB09989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI0010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2228 TTACATGTTTG 2238
DB 12 TTAATGTTTG 2
RESULT 210
ABI56339/c
ID ABI56339 standard; DNA; 12 BP.
XX
AC ABI56339;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 356312 for detecting SNP TSC0010448.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 356312; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -AB09989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI0010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2220 ACCAAAGTTTA 2230
DB 12 ACCAAAGTTTA 2
RESULT 211
ABH68410/c
ID ABH68410 standard; DNA; 12 BP.
XX
AC ABH68410;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 268387 for detecting SNP TSC0001097.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 268387; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -AB09989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI0010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;

CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 7 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
SQ Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2227 GTTACATGTTT 2237
Db 11 GTTAGATGTTT 1

RESULT 212
ABI68300/c
ID ABI68300 standard; DNA; 12 BP.
XX AC ABI68300;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 368273 for detecting SNP TSC0056896.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 368273; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 5 A; 1 C; 0 G; 6 T; 0 U; 0 Other;
SQ Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;

Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACAT 2233
Db 12 AAAAGTTATAT 2

RESULT 213
ABI21237/c
ID ABI21237 standard; DNA; 12 BP.
XX AC ABI21237;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 321210 for detecting SNP TSC0030110.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 321210; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
SQ Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2220 ACCAAAGTTTA 2230
Db 11 ACCAAATTTA 1

RESULT 214
ABI30123/c
ID ABI30123 standard; DNA; 12 BP.
XX AC ABI30123;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 321210 for detecting SNP TSC0030110.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 321210; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
SQ Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

DT 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 330096 for detecting SNP TSC0035335.
DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
CS WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 330096; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 3 A; 1 C; 1 G; 7 T; 0 U; 0 Other;
CC
CC Query Match 34.8%; Score 9.4; DB 1; Length 12;
CC Best Local Similarity 90.9%; Pred. No. 2e+02;
CC Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 223 AAAAGTTTACAT 2233
XX 11 AAAAATTACAT 1
XX
RESULT 215
ABH86927
ID ABH86927 standard; DNA; 12 BP.
XX
XX ABH86927;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 286920 for detecting SNP TSC0012877.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX

```

```

XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 286920; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 2 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 34.8%; Score 9.4; DB 1; Length 12;
XX Best Local Similarity 90.9%; Pred. No. 2e+02;
XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 222 GTTACATGTTT 2237
XX 1 GTTAGATGTTT 11
XX
RESULT 216
ABH87335/C
ID ABH87335 standard; DNA; 12 BP.
XX
XX ABH87335;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 287328 for detecting SNP TSC0013044.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX

```

```
PT methylation status.
XX Claim 1; SEQ ID NO 287328; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2220 ACCAAAGTTA 2230
DB 11 ACCAAATTTA 1
RESULT 217
ABI0400/C
ID ABI0400 standard; DNA; 12 BP.
AC
AC ABI0400;
XX
XX 22-FEB-2002 (first entry)
DE Oligonucleotide primer SEQ ID NO 340373 for detecting SNP TSC0041493.
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 340373; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2220 ACCAAAGTTA 2230
DB 11 ACCAAATTTA 1
RESULT 218
ABI58632
ID ABI58632 standard; DNA; 12 BP.
XX
AC ABI58632;
XX
XX 22-FEB-2002 (first entry)
DE Oligonucleotide primer SEQ ID NO 358605 for detecting SNP TSC0006593.
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 358605; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2222 CAAAAGTTTACA 2232
DB 1 CAAAATTTTACA 11
```

```
RESULT 219
ABH72035/c
ID ABH72035 standard; DNA; 12 BP.
XX
AC ABH72035;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 272014 for detecting SNP TSC0002685.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPiG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 272014; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Query Match 34.8%; Score 9.4; DB 1; Length 12;
XX Best Local Similarity 90.9%; Pred. No. 2e+02;
XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 2223 AAAAGTTACAT 2233
XX ||||| |||||
XX 12 AAAACTTACAT 2
XX
RESULT 220
ABI29882/c
ID ABI29882 standard; DNA; 12 BP.
XX
XX ABI29882;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 329855 for detecting SNP TSC0035199.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
```

```
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPiG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 329855; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Query Match 34.8%; Score 9.4; DB 1; Length 12;
XX Best Local Similarity 90.9%; Pred. No. 2e+02;
XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 2222 CAAAAGTTTACA 2232
XX ||||| |||||
XX 11 CAAAAATTACA 1
XX
RESULT 221
ABI14679
ID ABI14679 standard; DNA; 12 BP.
XX
XX ABI14679;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 314652 for detecting SNP TSC0026478.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
```


CC NCl domain conformational isomer, which has an amino acid sequence
 CC identical to the wild type alpha3 type IV collagen NCl domain, is
 CC stabilised by disulphide bonds, and has a molecular weight in a non-
 CC reducing sodium dodecyl sulphate gel of 22, 23, 25, 27, or 28 kD, and in
 CC a reducing sodium dodecyl sulphate gel of 29 kDa; and (2) an isolated
 CC type IV collagen alpha3 NCl domain. The human gene for GPBP is located on
 CC chromosome 5q13. The method is useful for treating autoimmune conditions,
 CC such as Goodpasture Syndrome, multiple sclerosis, systemic and cutaneous
 CC lupus erythematosus, pemphigus, pemphigoid and lichen planus. The present
 CC sequence represents an intron/exon boundary of the GPBP gene
 XX
 SQ Sequence 12 BP; 3 A; 2 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 12;
 Best Local Similarity 90.9%; Pred. No. 2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 2216 TGTGACCAAAA 2226
 Db 11 TGTGACTAAAA 1

RESULT 224
 ADF69380/C
 ID ADF69380 standard; DNA; 12 BP.
 XX
 AC ADF69380;

DT 12-FEB-2004 (first entry)

XX Human Goodpasture antigen binding protein related oligonucleotide #1.

KW Human; Goodpasture antigen binding protein; GPBP; ss;
 KW autoimmune disorder; apoptosis; cancer; tumour; cytostatic;
 KW immunosuppressive.

XX Homo sapiens.

PN US2003054488-A1.

XX 20-MAR-2003.

PF 11-OCT-2002; 2002US-00270837.

XX 24-FEB-2000; 2000US-00512563.

XX (SAUS/) SAUS J.

PA Saus J;

XX WPI; 2003-585167/55.

XX New nucleic acid, useful for preparing a composition for treating tumor
 PT or autoimmune disorder or for preventing cell apoptosis.

XX Disclosure; SEQ ID NO 55; 105pp; English.

XX The invention relates to Goodpasture antigen binding proteins (GPBP), the
 CC nucleic acids encoding them and GPBP variants. The invention also relates
 CC to an antibody that selectively binds to a protein of the invention,
 CC detecting the presence of the protein, detecting in a sample a sequence
 CC that is similar to the isolated nucleic acid, detecting an autoimmune
 CC condition in a patient, detecting cells undergoing apoptosis or cancer
 CC transformation in a tissue or body fluid sample, treating a patient with
 CC a tumour or an autoimmune disorder and preventing cell apoptosis. The
 CC nucleic acid is useful for preparing a composition for treating tumour or
 CC autoimmune disorders, or for preventing cell apoptosis. This sequence
 CC represents a GPBP-related oligonucleotide of the invention.

XX Sequence 12 BP; 3 A; 2 C; 2 G; 5 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 12;
 Best Local Similarity 90.9%; Pred. No. 2e+02;

Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Oy 2216 TGTGACCAAAA 2226
 Db 11 TGTGACTAAAA 1

RESULT 225
 ADK15494
 ID ADK15494 standard; DNA; 12 BP.

XX AC ADK15494;

DT 06-MAY-2004 (first entry)

XX GUS2 primer, seq id 29.

XX Pesticide; virucide; gene therapy; promoter; transcribable DNA; chimeric;
 KW Badnavirus; plant; Taro bacilliform virus; TaBV; PCR; primer; ss.

XX Unidentified.

PN WO2004007729-A1.

XX 22-JAN-2004.

PF 17-JUL-2003; 2003WO-AU000919.

XX 17-JUL-2002; 2002US-0396912P.

XX (UYQU-) UNIV QUEENSLAND TECHNOLOGY.

XX Dale JL, Harding RM, Becker DK, Hafner GJ, Yang I;
 PI WPI; 2004-122959/12.

XX New isolated DNA molecule comprising a promoter that is located upstream
 PT of a transcribable DNA sequence that hybridizes to a nucleic acid probe,
 PT useful for treating or preventing Badnaviral infection in plants.

XX Example 12; SEQ ID NO 29; 105pp; English.

XX The invention relates to an isolated DNA molecule comprising a promoter
 CC or its biologically active fragment, where the promoter is located
 CC upstream of a transcribable DNA sequence that hybridizes to a nucleic
 CC acid probe derived from the polynucleotide sequence of 6523 bp fully
 CC defined in the specification under at least low stringency conditions.
 CC Also disclosed is a chimeric DNA construct comprising the isolated
 CC promoter, its fragment or variant that is operably linked to a foreign or
 CC endogenous DNA sequence to be transcribed. The DNA molecule, polypeptide,
 CC agents and methods are useful for treating or preventing Badnaviral
 CC infection of a plant. The chimeric DNA construct is useful for the
 CC production of a transformed plant cell, plant or plant part. The current
 CC sequence represents a primer used in an example from the invention in the
 CC analysis of transgenic plants.

XX Sequence 12 BP; 1 A; 2 C; 2 G; 7 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 12;
 Best Local Similarity 90.9%; Pred. No. 2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 2228 TTACATGTTTG 2238
 Db 1 TTACTGTTTG 11

RESULT 226
 AAV11048
 ID AAV11048 standard; RNA; 13 BP.

XX AC AAV11048;

DT 25-MAR-2003 (revised)
 DT 14-JUL-1998 (first entry)
 DE Human ribozyme target sequence from HLA-DQB 03DQB #1.
 DE
 XX Ribozyme; target; human lymphocyte antigen; HLA-DQB; MHC allele;
 KW major histocompatibility complex; cleavage; suppression; transplant;
 KW incompatibility; autoimmune disease; juvenile diabetes;
 KW rheumatoid arthritis; ss.
 XX
 OS Homo sapiens.
 XX
 PN W09704087-A1.
 XX
 PD 06-FEB-1997.
 XX
 PF 18-JUL-1996; 96WO-EP0031173.
 XX
 PR 18-JUL-1995; 95EP-00111256.
 XX
 PA (KRUPP/) KRUPP G;
 PA (MARG/) MARGT M.
 PA (WEST/) WESTPHAL E.
 PA (MUEL/) MUELLER-RUCHHOLTZ W.
 XX
 PI Krupp G, Marget M, Westphal E, Mueller-Ruchholtz W;
 XX
 DR WPI; 1997-132628/12.
 XX
 XX Ribozyme that cleaves specific MHC allele(s) - used to inhibit graft
 PT versus host reactions, to overcome blood incompatibility and to treat
 PT autoimmune disease.
 XX
 PS Claim 5; Fig 1; 76pp; German.
 XX
 CC AAV10915-V1113 are target sequences for a novel ribozyme which cleaves
 CC specific alleles from the major histocompatibility complex (MHC). This
 CC ribozyme contains a catalytic region and a hybridisation region which is
 CC complementary to all mRNA transcribed from vertebrate genes of a specific
 CC family of closely related MHC alleles or to mRNA from a single MHC
 CC allele, and is able to cleave such mRNA. The mRNA has a target region
 CC which in case is essentially conserved in all genes of the family but
 CC differs from genes of all other MHC alleles to such a degree that no
 CC cleavage of mRNA transcribed from these other alleles occurs. This allows
 CC the selective reduction or inhibition of expression of all genes of a
 CC family or of a single gene. This ribozyme can be used for permanent or
 CC transient suppression of expression of MHC alleles, in vivo or in vitro.
 CC Specific applications are to prevent guest vs. host or host vs. guest
 CC reactions, to prevent blood incompatibilities (partic. of the ABO, thesus
 CC and Kell systems) and to treat autoimmune diseases such as juvenile
 CC diabetes and rheumatoid arthritis. The use of this ribozyme avoids the
 CC need for immunosuppressants in transplant patients. It provides very
 CC specific reduction of particular HLA molecules that cause incompatibility
 CC between donor and recipient. (Updated on 25-MAR-2003 to correct PA
 CC field.) (Updated on 25-MAR-2003 to correct PI field.)
 XX
 SQ Sequence 13 BP; 2 A; 2 C; 7 G; 0 T; 2 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 72.7%; Pred. No. 2.2e+02;
 Matches 8; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
 QY 2213 GAGTGTGACCA 2223
 Db 2 GGGUGUGACCA 12
 RESULT 227
 AAV42299/C
 ID AAV42299 standard; cDNA; 13 BP.
 XX
 AC AAV42299;
 XX

DT 23-SEP-1998 (first entry)
 XX
 DE Clone F4.1.3 kappa light chain transcript segemnt J-kappa.
 XX
 KW Human; immunoglobulin; Ig; transgenic; non-human mammal;
 KW inactivated endogenous Ig locus; B-cell development;
 KW human heavy chain Ig locus; micro constant region; J-H; D-H; V-H gene;
 KW kappa light chain Ig locus; kappa constant region; J-kappa gene; V-kappa;
 KW production; antibody; ss.
 XX
 OS Homo sapiens.
 XX
 PN W09824893-A2.
 XX
 PD 11-JUN-1998.
 XX
 PF 03-DEC-1997; 97WO-US023091.
 XX
 PR 03-DEC-1996; 96US-00759620.
 XX
 PA (ABGE-) ABGENIX INC.
 XX
 PI Jakobovits A, Kucherlapati R, Klapholz S, Mendez M, Green L;
 XX
 DR WPI; 1998-333314/29.
 XX
 XX New transgenic non-human mammals - having an inactivated immunoglobulin
 PT locus and a near complete human immunoglobulin locus, used for production
 PT of human antibodies.
 XX
 PS Example 8; Page 39; 128pp; English.
 XX
 CC AAV42284-99 represent human kappa light chain immunoglobulin (Ig)
 CC transcripts expressed in Xenomouse II strains. The Xenomice were produced
 CC using the method of the invention. The specification describes a
 CC transgenic non-human mammal which has genome modifications that comprise
 CC an inactivated endogenous Ig locus, so that the mammal does not display
 CC normal B-cell development. The modified genome also has an inserted human
 CC heavy chain Ig locus in germline configuration, the human heavy chain Ig
 CC locus comprising a human micro constant region and regulatory and switch
 CC sequences, human J-H genes, human D-H genes, and human V-H genes and an
 CC inserted human kappa light chain Ig locus in germline configuration, the
 CC human kappa light chain Ig locus comprising a human kappa constant
 CC region, J-kappa genes, and V-kappa genes, where the number of V-H and V-
 CC kappa genes inserted are selected to restore normal B-cell development in
 CC the mammal. The transgenic animals have a near complete human Ig locus,
 CC including both a human heavy chain locus and a human kappa light chain
 CC locus. They can be used for the production of human antibodies when
 CC exposed to particular antigens e.g. when exposed to human IL-8, EGFR or
 CC TNF- alpha the mice will produce antibodies to IL-8, EGFR or TNF- alpha
 CC respectively
 XX
 SQ Sequence 13 BP; 2 A; 4 C; 3 G; 4 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2218 TGACCAAAAGT 2228
 Db 12 TGGCAAAAGT 2
 RESULT 228
 ABC92353/c
 ID ABC92353 standard; DNA; 13 BP.
 XX
 AC ABC92353;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 92370 for detecting SNP TSC0023086.
 XX

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIC-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 92370; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX SQ Sequence 13 BP; 6 A; 3 C; 0 G; 3 T; 0 U; 1 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2227 GTTACATGTTT 2237
 Db 13 GTTAGATGTTT 3
 RESULT 229
 ABC74081/C
 ID ABC74081 standard; DNA; 13 BP.
 XX
 XX AC ABC74081;
 XX 21-FEB-2002 (first entry)
 XX Oligonucleotide SEQ ID NO 74038 for detecting SNP TSC0019057.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 74099; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX SQ Sequence 13 BP; 7 A; 2 C; 0 G; 4 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2228 TTACATGTTT 2238
 Db 12 TTATATGTTT 2
 RESULT 230
 ABC27364
 ID ABC27364 standard; DNA; 13 BP.
 XX
 XX AC ABC27364;
 XX 20-FEB-2002 (first entry)
 XX Oligonucleotide SEQ ID NO 27381 for detecting SNP TSC0007524.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIC-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 27381; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 2228 TTACATGTTG 2238
Db 1 TTAAATGTTG 11
RESULT 231
ABC34246
ID ABC34246 standard; DNA; 13 BP.
XX
AC ABC34246;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 34263 for detecting SNP TSC0010942.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
FN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 34263; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

SQ Sequence 13 BP; 6 A; 0 C; 2 G; 5 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 2223 AAAAGTTACAT 2233
Db 3 AAAAGTTACAT 13
RESULT 232
ABF13694
ID ABF13694 standard; DNA; 13 BP.
XX
AC ABF13694;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 113691 for detecting SNP TSC0028454.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
FN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 113691; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 2 G; 9 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 2228 TTACATGTTG 2238
Db 1 TTATATGTTG 11
RESULT 233
ABF14498/c

DR WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 152981; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 13 BP; 5 A; 0 C; 1 G; 7 T; 0 U; 0 Other;
 XX Query Match 34.8%; Score 9.4; DB 1; Length 13;
 XX Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTACAT 2233
 DB 12 AAAAATTACAT 2
 RESULT 236
 ABF52985
 ID ABF52985 standard; DNA; 13 BP.
 AC ABF52985;
 XX 21-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 152982 for detecting SNP TSC0038667.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 XX (EPIC-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 152982; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 13 BP; 5 A; 0 C; 1 G; 7 T; 0 U; 0 Other;
 XX Query Match 34.8%; Score 9.4; DB 1; Length 13;
 XX Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTACAT 2233
 DB 12 AAAAATTACAT 2

CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 13 BP; 7 A; 1 C; 0 G; 5 T; 0 U; 0 Other;
 XX Query Match 34.8%; Score 9.4; DB 1; Length 13;
 XX Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTACAT 2233
 DB 2 AAAAATTACAT 12
 RESULT 237
 ABH42366/c
 ID ABH42366 standard; DNA; 13 BP.
 XX ABH42366;
 AC ABH42366;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 242343 for detecting SNP TSC0059100.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 XX (EPIC-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 242343; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 13 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 1 Other;
 XX Query Match 34.8%; Score 9.4; DB 1; Length 13;
 XX Best Local Similarity 76.9%; Pred. No. 2.2e+02;
 XX Matches 10; Conservative 1; Mismatches 2; Indels 0; Gaps 0;


```
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 1 C; 0 G; 7 T; 0 U; 0 Other;

Query Match      34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2223 AAAAGTTACAT 2233
Db 13 AAAAGTTATAT 3

RESULT 243
ABH03654/c
ID ABH03654 standard; DNA; 13 BP.
XX
AC ABH03654;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 203631 for detecting SNP TSC0049990.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 203631; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 0 C; 1 G; 5 T; 0 U; 1 Other;

Query Match      34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 76.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 2225 AAGTTACATGTTT 2237
Db 13 RAATTACATATT 1

RESULT 244
ABH34746
ID ABH34746 standard; DNA; 13 BP.
XX
AC ABH34746;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 234723 for detecting SNP TSC0057295.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 234723; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 4 G; 7 T; 0 U; 0 Other;

Query Match      34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2228 TTACATGTTTG 2238
Db 3 TTACATGTTTG 13

RESULT 245
ABH35161/c
ID ABH35161 standard; DNA; 13 BP.
XX
AC ABH35161;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 235138 for detecting SNP TSC0057422.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
```


CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 7 A; 1 C; 0 G; 5 T; 0 U; 0 Other;
 SQ

Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACAT 2233
 Db 3 AAAATTACAT 13

RESULT 248
 ABH52425/C
 ID ABH52425 standard; DNA; 13 BP.
 XX
 AC ABH52425;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX
 DE Oligonucleotide SEQ ID NO 252402 for detecting SNP TSC0061571.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 OS WPI; 2001-657177/75.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 OS WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 252402; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 4 A; 1 C; 0 G; 8 T; 0 U; 0 Other;
 SQ

Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACAT 2233
 Db 11 AAAATTATAT 1

RESULT 249
 ABH59440/C
 ID ABH59440 standard; DNA; 13 BP.
 XX
 AC ABH59440;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX
 DE Oligonucleotide SEQ ID NO 259417 for detecting SNP TSC0063001.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 OS WPI; 2001-657177/75.
 XX
 PN Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 259417; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 4 A; 0 C; 1 G; 8 T; 0 U; 0 Other;
 SQ

Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACAT 2233
 Db 12 AAAAATTACAT 2

RESULT 250
 ABH61415/C
 ID ABH61415 standard; DNA; 13 BP.
 XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 57097; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
XX
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2222 CAAAAGTTTACA 2232
DB 12 CAAAAGTTTACA 2
RESULT 253
ABC60017/C
ID ABC60017 standard; DNA; 13 BP.
XX
AC ABC60017;
XX
AC ABC60017;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 60034 for detecting SNP TSC0016041.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 60034; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
XX

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 3 A; 3 C; 1 G; 6 T; 0 U; 0 Other;
XX
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2223 AAAAGTTTACAT 2233
DB 12 AAAAGTTTACGT 2
RESULT 254
ABF12588
ID ABF12588 standard; DNA; 13 BP.
XX
AC ABF12588;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 112585 for detecting SNP TSC0028146.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 112585; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 6 A; 0 C; 2 G; 4 T; 0 U; 1 Other;
XX
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 76.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 2224 AAAAGTTTACATCTT 2236

```

Db      1 AAAAGTAATATGTY 13
      ||||| | ||||:
RESULT 255
ABF13161
ID ABF13161 standard; DNA; 13 BP.
XX
AC ABF13161;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 113158 for detecting SNP TSC0028332.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 113158; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 4 C; 0 G; 3 T; 0 U; 0 Other;
XX
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 2221 CCAAAAGTTTAC 2231
      ||||| | ||||
Db      3 CCAAAATTTAC 13
      ||||| | ||||
RESULT 256
ABC90277/c
ID ABC90277 standard; DNA; 13 BP.
XX
AC ABC90277;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 90294 for detecting SNP TSC0022619.

```

```

XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 90294; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 1 C; 0 G; 8 T; 0 U; 0 Other;
XX
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 2223 AAAAGTTTACAT 2233
      ||||| | ||||
Db      13 AAAAGTTTATAT 3
      ||||| | ||||
RESULT 257
ABF22036
ID ABF22036 standard; DNA; 13 BP.
XX
AC ABF22036;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 122033 for detecting SNP TSC0030510.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.

```



```

XX SQ Sequence 13 BP; 3 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2223 AAAAGTTACAT 2233
Db 11 AAAAATTACAT 1

RESULT 260
ABH23614/C
ID ABH23614 standard; DNA; 13 BP.
XX AC ABH23614;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 223591 for detecting SNP TSC0054424.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX FA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX PI WPI; 2001-657177/75.
XX DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 223591; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 1 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2222 CAAAAGTTACA 2232
Db 11 CAAAAATTACA 1

RESULT 261
ABH23614/C
ID ABH23614 standard; DNA; 13 BP.
XX AC ABH23614;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 153021 for detecting SNP TSC0038680.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

```

OS Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB0000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 153021; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 13 BP; 3 A; 0 C; 4 G; 6 T; 0 U; 0 Other;
 XX Query Match 34.8%; Score 9.4; DB 1; Length 13;
 XX Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2227 GTTACATGTTT 2237
 DB 1 GTTACATGTTT 11
 RESULT 263
 ABH04240
 ID ABH04240 standard; DNA; 13 BP.
 XX ABH04240;
 AC
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 204217 for detecting SNP TSC0050100.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB0000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 153021; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 13 BP; 3 A; 0 C; 4 G; 6 T; 0 U; 0 Other;
 XX Query Match 34.8%; Score 9.4; DB 1; Length 13;
 XX Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2227 GTTACATGTTT 2237
 DB 1 GTTACATGTTT 11
 RESULT 263
 ABH04240
 ID ABH04240 standard; DNA; 13 BP.
 XX ABH04240;
 AC
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 204217 for detecting SNP TSC0050100.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB0000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 204217; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 13 BP; 3 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
 XX Query Match 34.8%; Score 9.4; DB 1; Length 13;
 XX Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2228 TTACATGTTT 2238
 DB 1 TTACATGTTT 11
 RESULT 264
 ABF88892/c
 ID ABF88892 standard; DNA; 13 BP.
 XX ABF88892;
 AC
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 188889 for detecting SNP TSC0046500.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB0000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 188889; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 1 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 76.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 2217 GTGACCAAAAGTT 2229
 Db 13 RTCACCAAAATT 1
 RESULT 265
 ABC47954
 ID ABC47954 standard; DNA; 13 BP.
 AC ABC47954;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 47971 for detecting SNP TSC0013728.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 DN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 WPI; 2001-657177/75.
 XX
 Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 47971; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 1 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 2222 CAAAAGTTACA 2232
 Db 13 CAAAATTACA 3
 RESULT 267
 ABF22037/c
 ID ABF22037 standard; DNA; 13 BP.
 AC ABF22037;
 XX
 XX

- Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2227 GTTACATGTTT 2237
 Db 1 GTTAAATGTTT 11
 RESULT 266
 ABC26270/c
 ID ABC26270 standard; DNA; 13 BP.
 XX
 AC ABC26270;
 XX
 DT 20-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 26287 for detecting SNP TSC0006896.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 DN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 WPI; 2001-657177/75.
 XX
 Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 26287; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 3 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2222 CAAAAGTTACA 2232
 Db 13 CAAAATTACA 3
 RESULT 267
 ABF22037/c
 ID ABF22037 standard; DNA; 13 BP.
 AC ABF22037;
 XX
 XX

DT 21-FEB-2002 (first entry)
DE Oligonucleotide SEQ ID NO 122034 for detecting SNP TSC0030510.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 122034; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 1 Other;
CC
CC Query Match 34.8%; Score 9.4; DB 1; Length 13;
CC Best Local Similarity 90.9%; Pred. No. 2.2e+02;
CC Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2227 GTTACATGTTT 2237
DB 12 GTTATATGTTT 2

RESULT 268
ABF35563/c
ID ABF35563 standard; DNA; 13 BP.
AC ABF35563;
XX
XX 21-FEB-2002 (first entry)
DE Oligonucleotide SEQ ID NO 135560 for detecting SNP TSC0033840.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 122034; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 1 Other;
CC
CC Query Match 34.8%; Score 9.4; DB 1; Length 13;
CC Best Local Similarity 90.9%; Pred. No. 2.2e+02;
CC Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2227 GTTACATGTTT 2237
DB 12 GTTATATGTTT 2

RESULT 268
ABF35563/c
ID ABF35563 standard; DNA; 13 BP.
AC ABF35563;
XX
XX 21-FEB-2002 (first entry)
DE Oligonucleotide SEQ ID NO 135560 for detecting SNP TSC0033840.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 135560; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 1 Other;
CC
CC Query Match 34.8%; Score 9.4; DB 1; Length 13;
CC Best Local Similarity 90.9%; Pred. No. 2.2e+02;
CC Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2228 TTACATGTTT 2238
DB 12 TTATATGTTT 2

RESULT 269
ABF70173/c
ID ABF70173 standard; DNA; 13 BP.
XX
XX AC ABF70173;
XX
XX 22-FEB-2002 (first entry)
DE Oligonucleotide SEQ ID NO 170170 for detecting SNP TSC0009903.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PT methylation status.
XX
PS Claim 1; SEQ ID NO 170170; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 7 A; 3 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2228 TTACATGTTTG 2238
DB 13 TTATATGTTTG 3
RESULT 270
ABH08735
ID ABH08735 standard; DNA; 13 BP.
XX
AC ABH08735;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 208712 for detecting SNP TSC0000598.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 208712; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 7 A; 3 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2228 TTACATGTTTG 2238
DB 13 TTATATGTTTG 3
RESULT 271
ABH35883
ID ABH35883 standard; DNA; 13 BP.
XX
AC ABH35883;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 235860 for detecting SNP TSC0057581.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 235860; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 7 A; 1 C; 0 G; 5 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2223 AAAAGTTTACAT 2233
DB 2 AAAAATTACAT 12

```

RESULT 272
ABF60968/C
ID ABF60968 standard; DNA; 13 BP.
XX AC ABF60968;
XX AC
XX DT 22-FEB-2002 (first entry)
XX DE
XX DE Oligonucleotide SEQ ID NO 160965 for detecting SNP TSC0005250.
XX XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX DT
XX DE
XX DE Oligonucleotide SEQ ID NO 160965 for detecting SNP TSC0005250.
XX XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 160965; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 2 A; 0 C; 3 G; 7 T; 0 U; 1 Other;
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 2 A; 0 C; 3 G; 7 T; 0 U; 1 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 76.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 2219 GACCAAAAGTTAC 2231
DB 13 RACCAAAATATAC 1
RESULT 273
ABF90882/C
ID ABF90882 standard; DNA; 13 BP.
XX AC ABF90882;
XX AC
XX DT 22-FEB-2002 (first entry)
XX DE
XX DE Oligonucleotide SEQ ID NO 190879 for detecting SNP TSC0007930.
XX XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 160965; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 2 A; 0 C; 3 G; 7 T; 0 U; 1 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 76.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 2219 GACCAAAAGTTAC 2231
DB 13 RACCAAAATATAC 1

```

```

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX DT
XX DE
XX DE Oligonucleotide SEQ ID NO 190880 for detecting SNP TSC0007930.
XX XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 190879; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 3 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2222 CAAAAGTTTACA 2232
DB 12 CAAAATTTACA 2
RESULT 274
ABF90883
ID ABF90883 standard; DNA; 13 BP.
XX AC ABF90883;
XX AC
XX DT 22-FEB-2002 (first entry)
XX DE
XX DE Oligonucleotide SEQ ID NO 190880 for detecting SNP TSC0007930.
XX XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 190879; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 3 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2222 CAAAAGTTTACA 2232
DB 12 CAAAATTTACA 2
RESULT 274
ABF90883
ID ABF90883 standard; DNA; 13 BP.
XX AC ABF90883;
XX AC
XX DT 22-FEB-2002 (first entry)
XX DE
XX DE Oligonucleotide SEQ ID NO 190880 for detecting SNP TSC0007930.
XX XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 190879; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 3 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2222 CAAAAGTTTACA 2232
DB 12 CAAAATTTACA 2

```

PA (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 190880; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 8 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 2222 CAAAAGTTTACA 2232
 DB 2 CAAAAGTTTACA 12
 RESULT 275
 ABC17571/C
 ID ABC17571 standard; DNA; 13 BP.
 AC ABC17571;
 DT 20-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 17578 for detecting SNP TSC0003772.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 DT
 XX
 DE
 XX
 KW
 KW
 KW
 XX
 OS
 XX
 XX
 PN
 XX
 PD
 XX
 PF
 XX
 PR
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 17578; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 8 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 2222 CAAAAGTTTACA 2232
 DB 2 CAAAAGTTTACA 12
 RESULT 275
 ABC17571/C
 ID ABC17571 standard; DNA; 13 BP.
 AC ABC17571;
 DT 20-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 17578 for detecting SNP TSC0003772.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 DT
 XX
 DE
 XX
 KW
 KW
 KW
 XX
 OS
 XX
 XX
 PN
 XX
 PD
 XX
 PF
 XX
 PR
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 17578; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 8 A; 2 C; 0 G; 3 T; 0 U; 0 Other;

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 2 A; 6 C; 1 G; 3 T; 0 U; 1 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 2212 AGAGTGTGACC 2222
 DB 13 AGAGTGTGAGC 3
 RESULT 276
 ABC18565/C
 ID ABC18565 standard; DNA; 13 BP.
 AC ABC18565;
 DT 20-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 18572 for detecting SNP TSC0003919.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 DT
 XX
 DE
 XX
 KW
 KW
 KW
 XX
 OS
 XX
 XX
 PN
 XX
 PD
 XX
 PF
 XX
 PR
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 18572; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 6 A; 2 C; 1 G; 3 T; 0 U; 1 Other;

DE Oligonucleotide SEQ ID NO 182056 for detecting SNP TSC0045007.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 182056; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 6 A; 4 C; 1 G; 2 T; 0 U; 0 Other;
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 6 A; 4 C; 1 G; 2 T; 0 U; 0 Other;
 XX
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2219 GACCAAAAGTT 2229
 DB 3 GACCAAAAGTT 13
 |||||
 RESULT 285
 ABH42367
 ID ABH42367 standard; DNA; 13 BP.
 AC
 AC ABH42367;
 XX
 XX 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 242344 for detecting SNP TSC0059100.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 242344; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 1 Other;
 XX
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 76.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 2220 ACCAAAGTTTACA 2232
 DB 1 RCCAAAAATTAAA 13
 |||||
 RESULT 286
 ABC29311
 ID ABC29311 standard; DNA; 13 BP.
 AC
 AC ABC29311;
 XX
 XX 20-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 29328 for detecting SNP TSC0008653.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX
 DE 06-APR-2001; 2001WO-IB000713.
 XX
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX

PS Claim 1; SEQ ID NO 29328; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 7 A; 3 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2222 CAAAAGTTTACA 2232
DB 1 CAAAATTACA 11
RESULT 287
ABC55033
ID ABC55033 standard; DNA; 13 BP.
XX
AC ABC55033;
XX
XX 21-FEB-2002 (first entry)
DT
XX
DE Oligonucleotide SEQ ID NO 55050 for detecting SNP TSC0015064.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 55050; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 2 C; 0 G; 4 T; 0 U; 1 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2222 CAAAAGTTTACA 2232
DB 3 CAAAATTACA 13
RESULT 288
ABC57078/C
ID ABC57078 standard; DNA; 13 BP.
XX
AC ABC57078;
XX
XX 21-FEB-2002 (first entry)
DT
XX
DE Oligonucleotide SEQ ID NO 57095 for detecting SNP TSC0015441.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 57095; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2222 CAAAAGTTTACA 2232
DB 12 CAAAATTACA 2

```

RESULT 289
ID ABH17681 standard; DNA; 13 BP.
XX AC ABH17681;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 217658 for detecting SNP TSC0052951.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 217658; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 6 A; 2 C; 0 G; 5 T; 0 U; 0 Other;
XX Query Match 34.8%; Score 9.4; DB 1; Length 13;
XX Best Local Similarity 90.9%; Pred. No. 2.2e+02;
XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX QY 2220 ACCAAGTTA 2230
XX Db 2 ACCAAGTTA 12
XX RESULT 290
ABF70172
ID ABF70172 standard; DNA; 13 BP.
XX AC ABF70172;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 170169 for detecting SNP TSC0009903.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

```

```

XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 170169; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 3 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
XX Query Match 34.8%; Score 9.4; DB 1; Length 13;
XX Best Local Similarity 90.9%; Pred. No. 2.2e+02;
XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX QY 2228 TTACATGTTG 2238
XX Db 1 TTATATGTTG 11
XX RESULT 291
ABF53025/c
ID ABF53025 standard; DNA; 13 BP.
XX AC ABF53025;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 153022 for detecting SNP TSC0038680.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.

```

PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 153022; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 6 A; 4 C; 0 G; 3 T; 0 U; 0 Other;
SQ
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2227 GTTACATGTTT 2237
DB 13 GTTACATGTTT 3
RESULT 292
ABF55461/C
ID ABF55461 standard; DNA; 13 BP.
XX
AC ABF55461;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 155458 for detecting SNP TSC0039254.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 155458; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 8 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
SQ
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2228 TTATATGTTT 2238
DB 13 TTATATGTTT 3
RESULT 293
ABF65415
ID ABF65415 standard; DNA; 13 BP.
XX
AC ABF65415;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 165412 for detecting SNP TSC0041486.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 165412; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 7 A; 3 C; 0 G; 3 T; 0 U; 0 Other;
SQ
Query Match 34.8%; Score 9.4; DB 1; Length 13;

Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2220 ACCAAAGTTA 2230
Dd ||||| |||||
2 ACCAAATTTA 12

RESULT 294
ABH16644/C
ID ABH16644 standard; DNA; 13 BP.
XX AC ABH16644;
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 216621 for detecting SNP TSC0052664.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 216621; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 5 A; 0 C; 1 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 34.8%; Score 9.4; DB 1; Length 13;
XX Best Local Similarity 90.9%; Pred. No. 2.2e+02;
XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACAT 2233
Dd ||||| |||||
11 AAAATTACAT 1

RESULT 295
ABH46083/C
ID ABH46083 standard; DNA; 13 BP.
XX AC ABH46083;
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 60106 for detecting SNP TSC0016063.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.

XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 246060 for detecting SNP TSC0060121.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 246060; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 5 A; 1 C; 0 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 34.8%; Score 9.4; DB 1; Length 13;
XX Best Local Similarity 90.9%; Pred. No. 2.2e+02;
XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACAT 2233
Dd ||||| |||||
12 AAAAGTTATAT 2

RESULT 296
ABC60089
ID ABC60089 standard; DNA; 13 BP.
XX AC ABC60089;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 60106 for detecting SNP TSC0016063.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.

PD 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 60106; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 13 BP; 8 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
 XX Query Match 34.8%; Score 9.4; DB 1; Length 13;
 XX Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2220 ACCAAAGTTA 2230
 Db 3 ACCAAAGTTA 13
 RESULT 297
 ABC17149
 ID ABC17149 standard; DNA; 13 BP.
 AC ABC17149;
 XX 20-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 17156 for detecting SNP TSC0003709.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 17156; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 13 BP; 6 A; 4 C; 0 G; 2 T; 0 U; 1 Other;
 XX Query Match 34.8%; Score 9.4; DB 1; Length 13;
 XX Best Local Similarity 76.9%; Pred. No. 2.2e+02;
 XX Matches 10; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 2219 GACCAAAAGTTAC 2231
 Db 1 RACCAAAATTAC 13
 RESULT 298
 ABF23828
 ID ABF23828 standard; DNA; 13 BP.
 AC ABF23828;
 XX 21-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 123825 for detecting SNP TSC0030956.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 123825; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 2 A; 0 C; 2 G; 9 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTTG 2238
 ||| |||||
 Db 3 TTATATGTTTG 13

RESULT 299
 ABF23829/C
 ID ABF23829 standard; DNA; 13 BP.
 XX AC ABF23829;
 XX DT 21-FEB-2002 (first entry)
 XX DE Oligonucleotide SEQ ID NO 123826 for detecting SNP TSC0030956.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX FN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 123826; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABH00010-ABH82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 9 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTTG 2238
 ||| |||||
 Db 3 TTATATGTTTG 13

RESULT 300
 ABF24341/C
 ID ABF24341 standard; DNA; 13 BP.
 XX AC ABF24341;
 XX DT 21-FEB-2002 (first entry)
 XX DE Oligonucleotide SEQ ID NO 124338 for detecting SNP TSC0031086.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX FN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 124338; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABH00010-ABH82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 8 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTTG 2238
 ||| |||||
 Db 12 TTATATGTTTG 2

RESULT 301
 ABF32560/C
 ID ABF32560 standard; DNA; 13 BP.
 XX AC ABF32560;
 XX DT 21-FEB-2002 (first entry)
 XX DE Oligonucleotide SEQ ID NO 132557 for detecting SNP TSC0033063.

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 132557; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 0 C; 1 G; 8 T; 0 U; 0 Other;
XX
XX Query Match 34.8%; Score 9.4; DB 1; Length 13;
XX Best Local Similarity 90.9%; Pred. No. 2.2e+02;
XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 2223 AAAAGTTACAT 2233
DB 11 AAAATTACAT 1
XX
XX RESULT 302
XX ABF36213/c
XX ID ABF36213 standard; DNA; 13 BP.
XX
XX AC ABF36213;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 136210 for detecting SNP TSC0034016.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX

XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 136210; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 6 A; 4 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 34.8%; Score 9.4; DB 1; Length 13;
XX Best Local Similarity 90.9%; Pred. No. 2.2e+02;
XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 2226 AGTTACATGTT 2236
DB 13 AGTTAGATGTT 3
XX
XX RESULT 303
XX ABF39058
XX ID ABF39058 standard; DNA; 13 BP.
XX
XX AC ABF39058;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 139055 for detecting SNP TSC0034834.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 139055; 29pp + Sequence Listing; German.
XX
XX

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 2 A; 0 C; 3 G; 8 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTATATGTTG 2238
 ||| |||||
 DB 2 TTATATGTTG 12

RESULT 304
 ABF39059/C
 ID ABF39059 standard; DNA; 13 BP.
 AC ABF39059;
 XX
 DT 21-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 139056 for detecting SNP TSC0034834.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 139056; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 8 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTATATGTTG 2238
 ||| |||||
 DB 12 TTATATGTTG 2

RESULT 305
 ABH19350/C
 ID ABH19350 standard; DNA; 13 BP.
 AC ABH19350;
 XX
 DT 22-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 219327 for detecting SNP TSC0053332.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 219327; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 3 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAATTACAT 2233
 |||||
 DB 13 AAAAATTACAT 3

RESULT 306
 ABF55142/C

ID ABF95142 standard; DNA; 13 BP.
 XX AC ABF95142;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 195139 for detecting SNP TSC0048013.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPITG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 195139; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 PS Sequence 13 BP; 2 A; 0 C; 3 G; 8 T; 0 U; 0 Other;
 XX
 CC Query Match 34.8%; Score 9.4; DB 1; Length 13;
 CC Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 CC Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX
 QY 2222 CAAAAGTTACA 2222
 DB 13 CAAAAGTTACA 3
 XX
 RESULT 307
 ABF72688
 ID ABF72688 standard; DNA; 13 BP.
 XX AC ABF72688;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 172685 for detecting SNP TSC0043037.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.

XX WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPITG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 172685; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 PS Sequence 13 BP; 7 A; 0 C; 1 G; 5 T; 0 U; 0 Other;
 XX
 CC Query Match 34.8%; Score 9.4; DB 1; Length 13;
 CC Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 CC Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX
 QY 2223 AAAAGTTATAT 2233
 DB 1 AAAAGTTATAT 11
 XX
 RESULT 308
 ABF98927/C
 ID ABF98927 standard; DNA; 13 BP.
 XX AC ABF98927;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 198924 for detecting SNP TSC0048966.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPITG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX

DR WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 198924; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG9989, ABF0010-ABF9989, ABH0010-ABH9989 and AB10010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 7 A; 1 C; 0 G; 4 T; 0 U; 1 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 76.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 2225 AAGTACATGTTT 2237

DB 13 AATTATATGTTT 1

RESULT 309

ABH03815
 ID ABH03815 standard; DNA; 13 BP.

AC ABH03815;

XX 22-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 203792 for detecting SNP TSC0050027.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 203792; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG9989, ABF0010-ABF9989, ABH0010-ABH9989 and AB10010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 8 A; 1 C; 0 G; 3 T; 0 U; 1 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACAT 2233

DB 2 AAAAATTACAT 12

RESULT 310

ABH35882/C
 ID ABH35882 standard; DNA; 13 BP.

XX ABH35882;

XX 22-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 235859 for detecting SNP TSC0057581.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 235859; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG9989, ABF0010-ABF9989, ABH0010-ABH9989 and AB10010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 5 A; 0 C; 1 G; 7 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

QY      2223 AAAAGTTACAT 2233
DB      12 AAAATTACAT 2
      ||||| |||||
RESULT 311
ABF60969
ID      ABF60969 standard; DNA; 13 BP.
XX
AC      ABF60969;
XX
DT      22-FEB-2002 (first entry)
DE
DE      Oligonucleotide SEQ ID NO 160966 for detecting SNP TSC0005250.
XX
KW      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
PN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX
PF      06-APR-2001; 2001WO-IB000713.
PR      07-APR-2000; 2000DE-01019173.
PA      (EPIG-) EPIGENOMICS AG.
PI      Olek A, Piepenbrock C, Berlin K;
XX
XX      WPI; 2001-657177/75.
XX
XX      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX
PS      Claim 1; SEQ ID NO 160966; 29pp + Sequence Listing; German.
XX
XX      This invention describes novel oligonucleotide primers or peptide nucleic
XX      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX      and cytosine methylation status in chemically pretreated genomic DNA. The
XX      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX      range of diseases including immune system, gastrointestinal, respiratory,
XX      central nervous system, cardiovascular and metabolic disorders. The
XX      oligomers are also used for detecting cell type differentiation. ABC00010
XX      -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX      represent the oligomers described in the invention. NOTE: The sequence
XX      data for this patent did not form part of the printed specification, but
XX      was obtained in electronic format from WIPO at
XX      ftp.wipo.int/pub/published_pct_sequences
XX
XX      Sequence 13 BP; 7 A; 3 C; 0 G; 2 T; 0 U; 1 Other;
XX
XX      Query Match      34.8%; Score 9.4; DB 1; Length 13;
XX      Best Local Similarity 76.9%; Pred. No. 2.2e+02;
XX      Matches 10; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
XX
QY      2219 GACCAAAAGTTAC 2231
DB      1 RACCAAAATATAC 13
      : ||||| |||||
RESULT 312
ABC49582
ID      ABC49582 standard; DNA; 13 BP.
XX
AC      ABC49582;
XX
XX      ABC49582;
XX
DT      21-FEB-2002 (first entry)

```

```

XX      Oligonucleotide SEQ ID NO 49599 for detecting SNP TSC0014013.
XX
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
PN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX
PF      06-APR-2001; 2001WO-IB000713.
PR      07-APR-2000; 2000DE-01019173.
PA      (EPIG-) EPIGENOMICS AG.
PI      Olek A, Piepenbrock C, Berlin K;
XX
XX      WPI; 2001-657177/75.
XX
XX      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX
PS      Claim 1; SEQ ID NO 49599; 29pp + Sequence Listing; German.
XX
XX      This invention describes novel oligonucleotide primers or peptide nucleic
XX      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX      and cytosine methylation status in chemically pretreated genomic DNA. The
XX      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX      range of diseases including immune system, gastrointestinal, respiratory,
XX      central nervous system, cardiovascular and metabolic disorders. The
XX      oligomers are also used for detecting cell type differentiation. ABC00010
XX      -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX      represent the oligomers described in the invention. NOTE: The sequence
XX      data for this patent did not form part of the printed specification, but
XX      was obtained in electronic format from WIPO at
XX      ftp.wipo.int/pub/published_pct_sequences
XX
XX      Sequence 13 BP; 5 A; 0 C; 1 G; 6 T; 0 U; 1 Other;
XX
XX      Query Match      34.8%; Score 9.4; DB 1; Length 13;
XX      Best Local Similarity 76.9%; Pred. No. 2.2e+02;
XX      Matches 10; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
XX
QY      2224 AAAGTTACATGT 2236
DB      1 AAATTATATGTY 13
      ||||| |||||
RESULT 313
ABC31733
ID      ABC31733 standard; DNA; 13 BP.
XX
XX      ABC31733;
XX
XX      ABC31733;
XX
DT      20-FEB-2002 (first entry)
XX
DE      Oligonucleotide SEQ ID NO 31750 for detecting SNP TSC0009892.
XX
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
PN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX

```

PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 31750; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP),
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 5 A; 4 C; 0 G; 4 T; 0 U; 0 Other;
 XX
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX
 Qy 2221 CCAAAAGCTTAC 2231
 Db 3 CCAAAAGCTTAC 13
 XX
 RESULT 314
 ABF22041/C
 ID ABF22041 standard; DNA; 13 BP.
 XX
 AC ABF22041;
 XX
 XX 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 122038 for detecting SNP TSC0030510.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 XX
 XX 18-OCT-2001.
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 XX
 XX 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIG-) EPIGENOMICS AG.
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 XX methylation status.

XX
 PS Claim 1; SEQ ID NO 122038; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 7 A; 3 C; 1 G; 1 T; 0 U; 1 Other;
 XX
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX
 Qy 2227 GTTACATGTTT 2237
 Db 12 GTTACGTTT 2
 XX
 RESULT 315
 ABF96440
 ID ABF96440 standard; DNA; 13 BP.
 XX
 XX ABF96440;
 AC
 XX 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 196437 for detecting SNP TSC0048351.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 XX
 XX 18-OCT-2001.
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 XX
 XX 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIG-) EPIGENOMICS AG.
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 XX methylation status.
 XX
 PS Claim 1; SEQ ID NO 196437; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

Sequence 13 BP; 5 A; 0 C; 1 G; 6 T; 0 U; 1 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 76.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 1; Mismatches 2; Indels

Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 76.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 1; Mismatches 2; Indels

QY 2224 AAAGTTACATGTT 2236

1 AAAGTTATATTY 13

2000

RESULT 316
XBB77177

ABF77177
ID ABF771

XX
AC ABF77177;

XX
DT 22-FEB-20

DE
XX
22 FEB-2002 (1118C enclty)

DE Oligonucleotide seq ID NO 17/174 for detecting SNP TSC0043935.
XX
XX
XX

SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.

XX
PN
WO200177384-A

22-XX-18-OCT-2001

FD 18-000T-2001. XX

PF 06-APR-2001; 20
XX

PR 07-APR-2000;
XXPA (EPIG-) EPIGENOMICS AG.
XX

PI Olek A, Piepenbrock C, Berl

XX
DR
WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for

PT designed to detect a
PT methylation status.

XX
XX
pg
claim 1, SPO ID NO 177174, 2089
technology status.

PS
XX
Claim 1; SEQ ID NO 17/174; 29pp + sequence listing; German.

CC This invention describes
CC acid (PNA) oligomers

CC and cytosine methylation status in chemically pretreated ge
CC oligonucleotides are used for diagnosis and/or prognosis of
CC

range of diseases including immune system, metabolic disorders, respiratory, central nervous system, cardiovascular and metabolic disorders. ABOC001010-oligomers are also used for detecting cell type differentiation. ABOC001010-ABF9989, ABOC0010-ABF9989, ABOC0010-ABH9959 and ABOC0010-ABH2298 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

Sequence 13 BP: 6 A: 3 C: 0 G: 4 T: 0 U: 0 Other: XX

Sequence	10	20	30	40	50	60	70	80	90	100	110	120	130	140	150	160	170	180	190	200	210	220	230	240	250	260	270	280	290	300	310	320	330	340	350	360	370	380	390	400	410	420	430	440	450	460	470	480	490	500	510	520	530	540	550	560	570	580	590	600	610	620	630	640	650	660	670	680	690	700	710	720	730	740	750	760	770	780	790	800	810	820	830	840	850	860	870	880	890	900	910	920	930	940	950	960	970	980	990	1000
Sequence	10	20	30	40	50	60	70	80	90	100	110	120	130	140	150	160	170	180	190	200	210	220	230	240	250	260	270	280	290	300	310	320	330	340	350	360	370	380	390	400	410	420	430	440	450	460	470	480	490	500	510	520	530	540	550	560	570	580	590	600	610	620	630	640	650	660	670	680	690	700	710	720	730	740	750	760	770	780	790	800	810	820	830	840	850	860	870	880	890	900	910	920	930	940	950	960	970	980	990	1000

Query Match	34.8%;	Score 9.4;	DB 1;
Best Local Similarity	90.9%;	Pred. No. 2.2e+02;	

```
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

Qy 2223 AAAAGTTACAT 2233

Db 2 AAAACTTACAT 12

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 FN WO200177384-A2.
 XX
 XX 18-OCT-2001.
 PD
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX
 XX (EPIG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 FT
 XX Claim 1; SEQ ID NO 182248; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 XX Sequence 13 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 1 Other;
 SQ
 CC Query Match 34.8%; Score 9.4; DB 1; Length 13;
 CC Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 CC Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 CC
 QY 2228 TTACATGTTG 2238
 DB |||||
 12 TTATATGTTG 2
 RESULT 319
 ABF65414/c
 ID ABF65414 standard; DNA; 13 BP.
 XX
 AC ABF65414;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX
 XX Oligonucleotide SEQ ID NO 165411 for detecting SNP TSC0041486.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 FN
 XX 18-OCT-2001.
 PD
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX
 XX (EPIG-) EPIGENOMICS AG.
 PA

XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 FT
 XX Claim 1; SEQ ID NO 165411; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 XX Sequence 13 BP; 3 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
 SQ
 CC Query Match 34.8%; Score 9.4; DB 1; Length 13;
 CC Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 CC Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 CC
 QY 2220 ACCAAAGTTA 2230
 DB |||||
 12 ACCAAATTTA 2
 RESULT 320
 ABC18564
 ID ABC18564 standard; DNA; 13 BP.
 XX
 AC ABC18564;
 XX
 XX 20-FEB-2002 (first entry)
 DT
 XX
 XX Oligonucleotide SEQ ID NO 18571 for detecting SNP TSC0003919.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 FN
 XX 18-OCT-2001.
 PD
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX
 XX (EPIG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 FT
 XX Claim 1; SEQ ID NO 18571; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 XX SQ Sequence 13 BP; 3 A; 1 C; 2 G; 6 T; 0 U; 1 Other;
 XX
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 76.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 XX
 QY 2225 AAGTTACAGTTT 2237
 Db 1 AAGTTACAGTTT 13
 XX
 RESULT 321
 ABC23308
 ID ABC23308 standard; DNA; 13 BP.
 XX AC ABC23308;
 XX
 DT 20-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 23325 for detecting SNP TSC0004828.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 XX methylation status.
 XX Claim 1; SEQ ID NO 23325; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 XX and cytosine methylation status in chemically pretreated genomic DNA. The
 XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 XX range of diseases including immune system, gastrointestinal, respiratory,
 XX central nervous system, cardiovascular and metabolic disorders. The
 XX oligomers are also used for detecting cell type differentiation. ABC00010
 XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 XX represent the oligomers described in the invention. NOTE: The sequence
 XX data for this patent did not form part of the printed specification, but
 XX was obtained in electronic format from WIPO at
 XX ftp.wipo.int/pub/published_pct_sequences
 XX
 XX SQ Sequence 13 BP; 2 A; 0 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2228 TTATCATGTTTG 2238
 Db 3 TTATCATGTTTG 13
 XX
 RESULT 322
 ABC05974/c
 ID ABC05974 standard; DNA; 13 BP.
 XX AC ABC05974;
 XX 20-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 5965 for detecting SNP TSC0001904.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 XX methylation status.
 XX Claim 1; SEQ ID NO 5965; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 XX and cytosine methylation status in chemically pretreated genomic DNA. The
 XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 XX range of diseases including immune system, gastrointestinal, respiratory,
 XX central nervous system, cardiovascular and metabolic disorders. The
 XX oligomers are also used for detecting cell type differentiation. ABC00010
 XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 XX represent the oligomers described in the invention. NOTE: The sequence
 XX data for this patent did not form part of the printed specification, but
 XX was obtained in electronic format from WIPO at
 XX ftp.wipo.int/pub/published_pct_sequences
 XX
 XX SQ Sequence 13 BP; 3 A; 0 C; 2 G; 8 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2222 CAAAGATTAC 2232
 Db 13 CAAAGATTAC 3
 XX
 RESULT 323
 ABC05975
 ID ABC05975 standard; DNA; 13 BP.
 XX

```

AC ABC05975;
XX
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 5966 for detecting SNP TSC0001904.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 5966; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 8 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 34.8%; Score 9.4; DB 1; Length 13;
XX Best Local Similarity 90.9%; Pred. No. 2.2e+02;
XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 2222 CAAAAGTTTACA 2232
DB 1 CAAAATTACA 11
XX
RESULT 324
ABF06917/C
ID ABF06917 standard; DNA; 13 BP.
XX
AC ABF06917;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 106914 for detecting SNP TSC0026765.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX WO200177384-A2.
XX

```

```

XX 19-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 106914; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 1 Other;
XX
XX Query Match 34.8%; Score 9.4; DB 1; Length 13;
XX Best Local Similarity 90.9%; Pred. No. 2.2e+02;
XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 2228 TTACATGTTTG 2238
DB 13 TTAATGTTTG 3
XX
RESULT 325
ABC82012
ID ABC82012 standard; DNA; 13 BP.
XX
XX ABC82012;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 82029 for detecting SNP TSC0020739.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX

```


Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.

Claim 1: SEQ ID NO 82039; 29pb + Sequence Listing; German.

This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010-ABC9999, ABF0010-ABF9999, ABG0010-ABG9999 and ABT0010-ABT9999 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at [ftp.wipo.int/pub/publications](http://wipo.int/pub/publications)

Sequence 13 BP: 3 A; 0 C; 4 G; 6 T; 0 U; 0 Other; XX SO

Query Match	34.8%	Score 9.4;	DB 1;	Length 13;
Best Local Similarity	90.9%	Pred. No. 2.2e+02;		
Matches	10;	Conservative	0;	Mismatches 1;
				Indels 0;
				Gaps 0;

Qy	2226	AGTTACATGTT	2236
Dh	2	AGTTAGATGTT	12

RESULT 326

ABC82015/c
ID ABC82015 standard; DNA; 13 BP.

AA ABC82015:

21-FEB-2002 (first entry)

XX DE Oligonucleotide SEQ ID NO 82032 for detecting SNP TSC0020739.

SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
central nervous system; gastrointestinal; respiratory; immune; metabolic;
XX

XX
OS Homo sapiens.

XX PN WO200177384-A2.

XX
PD 18-OCT-2001.XX
PF 06-APR-2001: 2001WO-IB0000713.XX
PR 07-APR-2000: 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX
PI
Olek A. Piepenbrock C. Berlin K:XX
DR WPI: 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX
PS
Claim 1: SEQ ID NO 82032: 29pp + Sequence Listing: German:

xx This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
cc and cytosine methylation status in chemically pretreated genomic DNA. The
cc oligonucleotides are used for diagnosis and/or prognosis of cancer and a
cc range of diseases including immune system, gastrointestinal, respiratory,
cc central nervous system, cardiovascular and metabolic disorders. The
cc oligomers are also used for detecting cell type differentiation. ABC00010

CC ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT92073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftw.wipo.int/pub/published_pct_sequences
CC

Sequence 13 BP: 7 A; 3 C; 0 G; 3 T; 0 U; 0 Other; XX SO

Query Match	34.8%	Score 9.4;	DB 1;	Length 13;
Best Local Similarity	90.9%	Pred. No. 2.2e+02;		
Matches 10: Conservative	0;	Mismatches 1;	Indels 0;	Gaps 0;

Qy 2226 AGTTACATGTT 2236
pb 12 AGTTATATGTT 2

RESULT 327

RESOL 327
ABF08266
ID ABF08266 standard: DNA: 13 BP:

XX ABF08266;

XX
DT 21-FEB-2002 (first entry)

XX DE Oligonucleotide SEQ ID NO 108263 for detecting SNP TSC0027110.

SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX
Homo sapiens

XX
PN
WO200177384-A2.

XX PD 18-OCT-2001.

XX
PF 06-APR-2001: 2001WO-IB0000713.XX
07-APR-2000: 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX
PT
Olek A. Piepenbrock C. Berlin K:XX
DR WPI: 2001-657177/75.

XX	Set of oligonucleotides, useful for diagnosis and cell typing, is
PT	designed to detect single-nucleotide polymorphisms and cytosine
PT	methylation status.
PT	

XX
PS Claim 1: SEQ ID NO 108263: 29pp + Sequence Listing: German.

This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010-ABC99999, ABF00010-ABF99999, ABH00010-ABH99999 and ABT00010-ABT99999 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at

Sequence 13 BP: 2 A: 0 C: 2 G: 9 T: 0 U: 0 Other: 0

Query Match	34.8%;	Score 9.4;	DB 1;	Length 13;
Best Local Similarity	90.9%;	Pred. No. 2.2e+02;		
Matches 10: Conservative	0;	Mismatches 1:	Indels	

Ov 2227 GTTACATGTTT 2237

```

Db      2 GTTATATGTTT 12
||||| |||||
RESULT 328
ABC60088/c
ID ABC60088 standard; DNA; 13 BP.
XX
AC ABC60088;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 60105 for detecting SNP TSC0016063.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
DE Oligonucleotide SEQ ID NO 60105 for detecting SNP TSC0016063.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 60105; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 3 G; 8 T; 0 U; 0 Other;
XX
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2220 ACCAAAGTTA 2230
||||| |||||
Db 11 ACCAAAGTTA 1
RESULT 329
ABF24340
ID ABF24340 standard; DNA; 13 BP.
XX
AC ABF24340;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 124337 for detecting SNP TSC0031086.
XX

```

```

XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
DE Oligonucleotide SEQ ID NO 204218 for detecting SNP TSC0050100.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PS Claim 1; SEQ ID NO 124337; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 3 G; 8 T; 0 U; 0 Other;
XX
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2228 TTACATGTTT 2238
||||| |||||
Db 2 TTACATGTTT 12
RESULT 330
ABH04241/c
ID ABH04241 standard; DNA; 13 BP.
XX
AC ABH04241;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 204218 for detecting SNP TSC0050100.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX

```

PR 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 204218; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF05020, ABF05020-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 7 A; 3 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2228 TTACATGTTTG 2238
DB 13 TTAGATGTTTG 3
RESULT 331
ABF05020
ID ABF05020 standard; DNA; 13 BP.
XX AC ABF05020;
XX 21-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 105017 for detecting SNP TSC0026297.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 105017; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF05020, ABF05020-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 7 A; 3 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2228 TTACATGTTTG 2238
DB 13 TTAGATGTTTG 3
RESULT 332
ABC82014
ID ABC82014 standard; DNA; 13 BP.
XX AC ABC82014;
XX 21-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 82031 for detecting SNP TSC0020739.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 82031; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF05020, ABF05020-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 3 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2228 TTACATGTTTG 2238
DB 2 TTAAATGTTTG 12
RESULT 333
ABC82014
ID ABC82014 standard; DNA; 13 BP.
XX AC ABC82014;
XX 21-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 82031 for detecting SNP TSC0020739.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 82031; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF05020, ABF05020-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 9 A; 2 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2227 GTTACATGTTT 2237
 Db 13 GTTATGTTT 3

RESULT 338
 ABH08734/C
 ID ABH08734 standard; DNA; 13 BP.

XX AC ABH08734;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide SEQ ID NO 208711 for detecting SNP TSC0000598.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX PS Claim 1; SEQ ID NO 208711; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

SQ Sequence 13 BP; 3 A; 0 C; 1 G; 9 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;

Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTACAT 2233
 Db 12 AAAAATTACAT 2

RESULT 339
 ABH34747/C
 ID ABH34747 standard; DNA; 13 BP.

XX AC ABH34747;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide SEQ ID NO 234724 for detecting SNP TSC0057295.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX PS Claim 1; SEQ ID NO 234724; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

SQ Sequence 13 BP; 7 A; 4 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTTG 2238
 Db 11 TTATGTTTG 1

RESULT 340
 ABC57081
 ID ABC57081 standard; DNA; 13 BP.

XX AC ABC57081;

XX

```

DT 21-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 57098 for detecting SNP TSC0015441.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 57098; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 7 A; 2 C; 0 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 34.8%; Score 9.4; DB 1; Length 13;
XX Best Local Similarity 90.9%; Pred. No. 2.2e+02;
XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2222 CAAAAGTTTACA 2232
XX ||||| |||||
XX 2 CAAAATTACA 12
XX
XX RESULT 341
XX ABF12589/C
XX ID ABF12589 standard; DNA; 13 BP.
XX
XX AC ABF12589;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 112586 for detecting SNP TSC0028145.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX

```

```

XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 112586; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 2 C; 0 G; 6 T; 0 U; 1 Other;
XX
XX Query Match 34.8%; Score 9.4; DB 1; Length 13;
XX Best Local Similarity 76.9%; Pred. No. 2.2e+02;
XX Matches 10; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 2224 AAAGTTACATGTT 2236
XX ||||| |||||
XX 13 AAAGTAATATGTY 1
XX
XX RESULT 342
XX ABF13695/C
XX ID ABF13695 standard; DNA; 13 BP.
XX
XX AC ABF13695;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 113692 for detecting SNP TSC0028454.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX

```

PT methylation status.

PS Claim 1; SEQ ID NO 113692; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 9 A; 2 C; 0 G; 2 T; 0 U; 0 Other;

XX Query Match 34.8%; Score 9.4; DB 1; Length 13;

XX Best Local Similarity 90.9%; Pred. No. 2.2e+02;

XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2228 TTATATGTTTG 2238

Db 13 TTATATGTTTG 3

RESULT 343

ABC16210

ID ABC16210 standard; DNA; 13 BP.

AC ABC16210;

XX 20-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 16217 for detecting SNP TSC0003547.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS; peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss; central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.

XX Claim 1; SEQ ID NO 16217; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 9 A; 2 C; 0 G; 2 T; 0 U; 0 Other;

XX Query Match 34.8%; Score 9.4; DB 1; Length 13;

XX Best Local Similarity 90.9%; Pred. No. 2.2e+02;

XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2228 TTATATGTTTG 2238

Db 13 TTATATGTTTG 3

RESULT 344

ABH17680/C

ID ABH17680 standard; DNA; 13 BP.

AC ABH17680;

XX 22-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 217657 for detecting SNP TSC0052951.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS; peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss; central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.

XX Claim 1; SEQ ID NO 217657; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 5 A; 0 C; 2 G; 6 T; 0 U; 0 Other;

XX Query Match 34.8%; Score 9.4; DB 1; Length 13;

XX Best Local Similarity 90.9%; Pred. No. 2.2e+02;

XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2220 ACCAAAGTTA 2230

Db 12 ACCAAAGTTA 2


```
RESULT 345
ABH19289 ID ABH19289 standard; DNA; 13 BP.
XX AC ABH19289;
XX 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 219266 for detecting SNP TSC0053321.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 219266; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 5 A; 1 C; 0 G; 6 T; 0 U; 1 Other;
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 5 A; 1 C; 0 G; 6 T; 0 U; 1 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 76.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 2224 AAAGTTACATGTT 2236
DB 1 AAATTTATATTT 13
RESULT 346
ABF96441/c ID ABF96441 standard; DNA; 13 BP.
XX AC ABF96441;
XX 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 196438 for detecting SNP TSC0048351.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
```

```
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 196438; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 6 A; 1 C; 0 G; 5 T; 0 U; 1 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 76.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 2224 AAAGTTACATGTT 2236
DB 13 AAAGTTATATTT 1
RESULT 347
ABH03655 ID ABH03655 standard; DNA; 13 BP.
XX AC ABH03655;
XX 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 203632 for detecting SNP TSC0049990.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX
```

PA (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 203632; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 13 BP; 5 A; 1 C; 0 G; 6 T; 0 U; 1 Other;
 SQ
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 76.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 2225 AAGTTACATGTTT 2237
 DB 1 RAATTACATATT 13
 RESULT 348
 ABH31181
 ID ABH31181 standard; DNA; 13 BP.
 AC ABH31181;
 XX
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 231158 for detecting SNP TSC0056372.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 FN
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 231158; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 13 BP; 8 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTACAT 2233
 DB 2 AAAACTTACAT 12
 RESULT 349
 ABH52424
 ID ABH52424 standard; DNA; 13 BP.
 AC ABH52424;
 XX
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 252401 for detecting SNP TSC0061571.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 FN
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 252401; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 13 BP; 8 A; 0 C; 1 G; 4 T; 0 U; 0 Other;
 SQ

```

Query Match      34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACAT 2233
DB 3 AAAAGTTATAT 13

RESULT 350
ABC92352
ID ABC92352 standard; DNA; 13 BP.
XX AC
XX DT
XX 21-FEB-2002 (first entry)
XX DE
XX Oligonucleotide SEQ ID NO 92369 for detecting SNP TSC0023086.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS
XX Homo sapiens.
XX PN
XX WO200177384-A2.
XX PD
XX 18-OCT-2001.
XX PF
XX 06-APR-2001; 2001WO-IB000713.
XX PR
XX 07-APR-2000; 2000DE-01019173.
XX PA (EPG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX PS Claim 1; SEQ ID NO 92369; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 1 Other;
XX Query Match      34.8%; Score 9.4; DB 1; Length 13;
XX Best Local Similarity 90.9%; Pred. No. 2.2e+02;
XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2227 GTTACATGTTT 2237
DB 1 GTTACATGTTT 11

RESULT 351
ABC17570
ID ABC17570 standard; DNA; 13 BP.
XX AC
XX DT
XX 21-FEB-2002 (first entry)
XX DE
XX Oligonucleotide SEQ ID NO 55049 for detecting SNP TSC0015064.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS
XX Homo sapiens.
XX PN
XX WO200177384-A2.
XX PD
XX 18-OCT-2001.
XX PF
XX 06-APR-2001; 2001WO-IB000713.
XX PR
XX 07-APR-2000; 2000DE-01019173.
XX PA (EPG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX PS Claim 1; SEQ ID NO 17577; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 1 Other;
XX Query Match      34.8%; Score 9.4; DB 1; Length 13;
XX Best Local Similarity 90.9%; Pred. No. 2.2e+02;
XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2212 AGAGTGTGACC 2222
DB 1 AGAGTGTGAGC 11

RESULT 352
ABC5032/c
ID ABC5032 standard; DNA; 13 BP.
XX AC
XX DT
XX 21-FEB-2002 (first entry)
XX DE
XX Oligonucleotide SEQ ID NO 55049 for detecting SNP TSC0015064.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS
XX Homo sapiens.

```

PN WO200177384-A2.
 XX 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 55049; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 13 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 1 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 2222 CAAAAGTTTACA 2232
 Db 11 CAAAATTACA 1
 RESULT 353
 ABC5257/c
 ID ABC5257 standard; DNA; 13 BP.
 XX ABC5257;
 XX 21-FEB-2002 (first entry)
 XX Oligonucleotide SEQ ID NO 55274 for detecting SNP TSC0015107.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 108264; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 13 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 1 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 2222 CAAAAGTTTACA 2232
 Db 11 CAAAATTACA 1
 RESULT 354
 ABF08267/c
 ID ABF08267 standard; DNA; 13 BP.
 XX ABF08267;
 XX 21-FEB-2002 (first entry)
 XX Oligonucleotide SEQ ID NO 108264 for detecting SNP TSC0027110.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 108264; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 13 BP; 6 A; 1 C; 0 G; 6 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 2223 AAAAGTTTACAT 2233
 Db 11 AAAAGTTTATAT 1

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 55274; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 13 BP; 6 A; 1 C; 0 G; 6 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 2223 AAAAGTTTACAT 2233
 Db 11 AAAAGTTTATAT 1
 RESULT 354
 ABF08267/c
 ID ABF08267 standard; DNA; 13 BP.
 XX ABF08267;
 XX 21-FEB-2002 (first entry)
 XX Oligonucleotide SEQ ID NO 108264 for detecting SNP TSC0027110.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 108264; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 9 A; 2 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2227 GTTATGTTT 2237
Db 12 GTTATGTTT 2

RESULT 355
ABF32561
ID ABF32561 standard; DNA; 13 BP.

XX AC ABF32561;

XX DT 21-FEB-2002 (first entry)

XX DE Oligonucleotide SEQ ID NO 132558 for detecting SNP TSC0033063.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

XX PS Claim 1; SEQ ID NO 132558; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 8 A; 1 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2223 AAAAGTTACAT 2233
Db 3 AAAATTTACAT 13

RESULT 356
ABF72397

ID ABF72397 standard; DNA; 13 BP.

XX AC ABF72397;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide SEQ ID NO 172394 for detecting SNP TSC0042980.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

XX PS Claim 1; SEQ ID NO 172394; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 4 A; 5 C; 1 G; 3 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2221 CCAAAAGTTAC 2231

Db 2 CCAACGTTAC 12

RESULT 357

ABF98925/C

ID ABF98925 standard; DNA; 13 BP.

XX AC ABF98925;

XX DT 22-FEB-2002 (first entry)

XX XX

PS Claim 1; SEQ ID NO 160276; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The CC and cytosine methylation status in chemically pretreated genomic DNA. The CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a CC range of diseases including immune system, gastrointestinal, respiratory, CC central nervous system, cardiovascular and metabolic disorders. The CC oligomers are also used for detecting cell type differentiation. ABC00010 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 CC represent the oligomers described in the invention. NOTE: The sequence CC data for this patent did not form part of the printed specification, but CC was obtained in electronic format from WIPO at

XX ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 5 A; 1 C; 0 G; 7 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACAT 2233
|||||
11 AAAAGTTATAT 1

Db

RESULT 360

ABF89730

ID ABF89730 standard; DNA; 13 BP.

AC ABF89730;

XX 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 189727 for detecting SNP TSC0045680.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

OS

XX WO200177384-A2.

PN

XX 18-OCT-2001.

PD

XX 06-APR-2001; 2001WO-IB000713.

PF

XX 07-APR-2000; 2000DE-01019173.

PR

XX (EPIG-) EPIGENOMICS AG.

PA

XX Olek A, Piepenbrock C, Berlin K;

PI

XX WPI; 2001-657177/75.

DR

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 189727; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The CC and cytosine methylation status in chemically pretreated genomic DNA. The CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a CC range of diseases including immune system, gastrointestinal, respiratory, CC central nervous system, cardiovascular and metabolic disorders. The CC oligomers are also used for detecting cell type differentiation. ABC00010 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 CC represent the oligomers described in the invention. NOTE: The sequence CC data for this patent did not form part of the printed specification, but CC was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_pct_sequences

XX

SQ Sequence 13 BP; 2 A; 0 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTATATGTTTG 2238
|||||
3 TTATATGTTTG 13

Db

RESULT 361

ABH16643

ID ABH16643 standard; DNA; 13 BP.

XX ABH16643;

AC

XX 22-FEB-2002 (first entry)

DT

XX Oligonucleotide SEQ ID NO 216620 for detecting SNP TSC0052664.

DE

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

OS

XX WO200177384-A2.

PN

XX 18-OCT-2001.

PD

XX 06-APR-2001; 2001WO-IB000713.

PF

XX 07-APR-2000; 2000DE-01019173.

PR

XX (EPIG-) EPIGENOMICS AG.

PA

XX Olek A, Piepenbrock C, Berlin K;

PI

XX WPI; 2001-657177/75.

DR

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 216620; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The CC and cytosine methylation status in chemically pretreated genomic DNA. The CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a CC range of diseases including immune system, gastrointestinal, respiratory, CC central nervous system, cardiovascular and metabolic disorders. The CC oligomers are also used for detecting cell type differentiation. ABC00010 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 CC represent the oligomers described in the invention. NOTE: The sequence CC data for this patent did not form part of the printed specification, but CC was obtained in electronic format from WIPO at

XX ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 7 A; 2 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACAT 2233
|||||
3 AAAAGTTACAT 13

Db

```

RESULT 362
ABC19844/c
ID ABC19844 standard; DNA; 13 BP.
XX
AC ABC19844;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 19861 for detecting SNP TSC0004100.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 19861; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 1 Other;
XX
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2222 CAAAAGTTTACA 2232
DB 12 CAAAATTACA 2

RESULT 363
ABC19845
ID ABC19845 standard; DNA; 13 BP.
XX
AC ABC19845;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 19862 for detecting SNP TSC0004100.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 19862; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 1 Other;
XX
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2222 CAAAAGTTTACA 2232
DB 12 CAAAATTACA 2

RESULT 364
ABC31732/c
ID ABC31732 standard; DNA; 13 BP.
XX
AC ABC31732;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 31749 for detecting SNP TSC0009892.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 19862; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 1 Other;
XX
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2222 CAAAAGTTTACA 2232
DB 2 CAAAATTACA 12

RESULT 365
ABC31732/c
ID ABC31732 standard; DNA; 13 BP.
XX
AC ABC31732;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 31749 for detecting SNP TSC0009892.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 19862; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 1 Other;
XX
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2222 CAAAAGTTTACA 2232
DB 2 CAAAATTACA 12

```


CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX
 SQ Sequence 13 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 1 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2228 TTACATGTTG 2238
 ||| |||||
 Db 2 TTATATGTTG 12
 ||| |||||

RESULT 372
 ABF60278
 ID ABF60278 standard; DNA; 13 BP.
 XX
 AC ABF60278;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 160275 for detecting SNP TSC0040359.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 OS WPI; 2001-657177/75.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 OS WPI; 2001-657177/75.
 XX
 PN Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 160275; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX
 SQ Sequence 13 BP; 7 A; 0 C; 1 G; 5 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2223 AAAAGTTATAT 2233
 ||| |||||

Db 3 AAAAGTTATAT 13
 ||| |||||

RESULT 373
 ABF89735/C
 ID ABF89735 standard; DNA; 13 BP.
 XX
 AC ABF89735;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 189732 for detecting SNP TSC0046680.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 OS WPI; 2001-657177/75.
 XX
 PN Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 189732; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX
 SQ Sequence 13 BP; 7 A; 4 C; 1 G; 1 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2228 TTACATGTTG 2238
 ||| |||||
 Db 11 TTACGTTGTTG 1
 ||| |||||

RESULT 374
 ABF90884/C
 ID ABF90884 standard; DNA; 13 BP.
 XX
 AC ABF90884;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 190881 for detecting SNP TSC0007930.
 XX
 OS WPI; 2001-657177/75.

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 190881; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. AEC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 13 BP; 2 A; 0 C; 2 G; 9 T; 0 U; 0 Other;
 SQ Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 2222 CAAAAGTTACA 2232
 Db 12 CAAAATTACA 2
 RESULT 375
 ABH51983/C
 ID ABH51983 standard; DNA; 13 BP.
 XX AC ABH51983;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide SEQ ID NO 251960 for detecting SNP TSC0061476.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 251960; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. AEC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 13 BP; 8 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
 SQ Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 2228 TTACATGTTG 2238
 Db 11 TTAATGTTG 1
 RESULT 376
 ABC23309/C
 ID ABC23309 standard; DNA; 13 BP.
 XX AC ABC23309;
 XX 20-FEB-2002 (first entry)
 XX Oligonucleotide SEQ ID NO 23326 for detecting SNP TSC0004828.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 23326; 29pp + Sequence Listing; German.

DR WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 182055; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 13 BP; 2 A; 1 C; 4 G; 6 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2219 GACCAAAAGTT 2229
 DB 11 GACCAAAAGTT 1
 RESULT 382
 ABF89731/C
 ID ABF89731 standard; DNA; 13 BP.
 XX AC ABF89731;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide SEQ ID NO 189728 for detecting SNP TSC0046680.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 189728; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 13 BP; 8 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2228 TTACATGTTTG 2238
 DB 11 TTATATGTTTG 1
 RESULT 383
 ABC27365/C
 ID ABC27365 standard; DNA; 13 BP.
 XX AC ABC27365;
 XX 20-FEB-2002 (first entry)
 XX Oligonucleotide SEQ ID NO 27382 for detecting SNP TSC0007524.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 27382; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 13 BP; 7 A; 2 C; 0 G; 4 T; 0 U; 0 Other;
 Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;


```

QY      2228 TTACATGTTT 2238
Db      13 TTAATGTTG 3
      ||| |||||
RESULT 384
ABF08271/c
XX      ABF08271 standard; DNA; 13 BP.
XX      AC
XX      ABF08271;
XX      21-FEB-2002 (first entry)
XX      Oligonucleotide SEQ ID NO 108269 for detecting SNP TSC0027110.
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX      OS
XX      Homo sapiens.
XX      WO200177384-A2.
XX      18-OCT-2001.
XX      06-APR-2001; 2001WO-IB000713.
XX      07-APR-2000; 2000DE-01019173.
XX      (EPIG-) EPIGENOMICS AG.
XX      Olek A, Piepenbrock C, Berlin K;
XX      WPI; 2001-657177/75.
XX      Set of oligonucleotides, useful for diagnosis and cell typing, is
XX      designed to detect single-nucleotide polymorphisms and cytosine
XX      methylation status.
XX      Claim 1; SEQ ID NO 108268; 29pp + Sequence Listing; German.
XX      This invention describes novel oligonucleotide primers or peptide nucleic
XX      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX      and cytosine methylation status in chemically pretreated genomic DNA. The
XX      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX      range of diseases including immune system, gastrointestinal, respiratory,
XX      central nervous system, cardiovascular and metabolic disorders. The
XX      oligomers are also used for detecting cell type differentiation. ABC00010
XX      -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX      represent the oligomers described in the invention. NOTE: The sequence
XX      data for this patent did not form part of the printed specification, but
XX      was obtained in electronic format from WIPO at
XX      ftp.wipo.int/pub/published_pct_sequences
XX      Sequence 13 BP; 8 A; 3 C; 1 G; 1 T; 0 U; 0 Other;
XX      This invention describes novel oligonucleotide primers or peptide nucleic
XX      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX      and cytosine methylation status in chemically pretreated genomic DNA. The
XX      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX      range of diseases including immune system, gastrointestinal, respiratory,
XX      central nervous system, cardiovascular and metabolic disorders. The
XX      oligomers are also used for detecting cell type differentiation. ABC00010
XX      -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX      represent the oligomers described in the invention. NOTE: The sequence
XX      data for this patent did not form part of the printed specification, but
XX      was obtained in electronic format from WIPO at
XX      ftp.wipo.int/pub/published_pct_sequences
XX      Sequence 13 BP; 8 A; 3 C; 1 G; 1 T; 0 U; 0 Other;
XX      Query Match      34.8%; Score 9.4; DB 1; Length 13;
XX      Best Local Similarity 90.9%; Pred. No. 2.2e+02;
XX      Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY      2227 GTTACATGTTT 2237
Db      12 GTTACGTTT 2
      ||| |||||
RESULT 385
ABF14499
XX      ABF14499 standard; DNA; 13 BP.
XX      AC
XX      ABF14499;
XX      21-FEB-2002 (first entry)

```

```

XX      Oligonucleotide SEQ ID NO 114496 for detecting SNP TSC0028664.
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX      OS
XX      Homo sapiens.
XX      WO200177384-A2.
XX      18-OCT-2001.
XX      06-APR-2001; 2001WO-IB000713.
XX      07-APR-2000; 2000DE-01019173.
XX      (EPIG-) EPIGENOMICS AG.
XX      Olek A, Piepenbrock C, Berlin K;
XX      WPI; 2001-657177/75.
XX      Set of oligonucleotides, useful for diagnosis and cell typing, is
XX      designed to detect single-nucleotide polymorphisms and cytosine
XX      methylation status.
XX      Claim 1; SEQ ID NO 114496; 29pp + Sequence Listing; German.
XX      This invention describes novel oligonucleotide primers or peptide nucleic
XX      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX      and cytosine methylation status in chemically pretreated genomic DNA. The
XX      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX      range of diseases including immune system, gastrointestinal, respiratory,
XX      central nervous system, cardiovascular and metabolic disorders. The
XX      oligomers are also used for detecting cell type differentiation. ABC00010
XX      -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX      represent the oligomers described in the invention. NOTE: The sequence
XX      data for this patent did not form part of the printed specification, but
XX      was obtained in electronic format from WIPO at
XX      ftp.wipo.int/pub/published_pct_sequences
XX      Sequence 13 BP; 7 A; 2 C; 0 G; 4 T; 0 U; 0 Other;
XX      Query Match      34.8%; Score 9.4; DB 1; Length 13;
XX      Best Local Similarity 90.9%; Pred. No. 2.2e+02;
XX      Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY      2220 ACCAAAGTTA 2230
Db      2 ACCAAAGTTA 12
      ||||| |||
RESULT 386
ABC16211/c
XX      ABC16211 standard; DNA; 13 BP.
XX      AC
XX      ABC16211;
XX      20-FEB-2002 (first entry)
XX      DE
XX      Oligonucleotide SEQ ID NO 16218 for detecting SNP TSC0003547.
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX      OS
XX      Homo sapiens.
XX      WO200177384-A2.
XX      18-OCT-2001.

```

```

PF 06-APR-2001; 2001WO-IB000713.
XX
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 16218; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 9 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 34.8%; Score 9.4; DB 1; Length 13;
XX Best Local Similarity 90.9%; Pred. No. 2.2e+02;
XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2228 TTACATGTTTG 2238
XX 12 TTATATGTTTG 2
XX
XX RESULT 387
XX ABF95143
XX ID ABF95143 standard; DNA; 13 BP.
XX
XX AC ABF95143;
XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 195140 for detecting SNP TSC0048013.
XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 223592; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 8 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 34.8%; Score 9.4; DB 1; Length 13;
XX Best Local Similarity 90.9%; Pred. No. 2.2e+02;
XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2222 CAAAAGTTTACA 2232
XX 1 CAAAATTTACA 11
XX
XX Db
XX
XX RESULT 388
XX ABH23615
XX ID ABH23615 standard; DNA; 13 BP.
XX
XX AC ABH23615;
XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 223592 for detecting SNP TSC0054424.
XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 223592; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 8 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 34.8%; Score 9.4; DB 1; Length 13;
XX Best Local Similarity 90.9%; Pred. No. 2.2e+02;
XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2222 CAAAAGTTTACA 2232
XX 1 CAAAATTTACA 11
XX
XX Db
XX
XX RESULT 388
XX ABH23615
XX ID ABH23615 standard; DNA; 13 BP.
XX
XX AC ABH23615;
XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 223592 for detecting SNP TSC0054424.
XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 223592; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 8 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 34.8%; Score 9.4; DB 1; Length 13;
XX Best Local Similarity 90.9%; Pred. No. 2.2e+02;
XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2222 CAAAAGTTTACA 2232
XX 1 CAAAATTTACA 11
XX
XX Db
XX
XX RESULT 388
XX ABH23615
XX ID ABH23615 standard; DNA; 13 BP.
XX
XX AC ABH23615;
XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 223592 for detecting SNP TSC0054424.
XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

```

```
CC was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
SQ Sequence 13 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 1 Other;

Query Match      34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2222 CAAAAGTTTACA 2232
Db 3 CAAAAGTTTACA 13

RESULT 389
ABF99476
XX ID ABF99476 standard; DNA; 13 BP.
XX AC ABF99476;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 199473 for detecting SNP TSC0049079.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 199473; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX Sequence 13 BP; 4 A; 0 C; 2 G; 7 T; 0 U; 0 Other;

Query Match      34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2227 GTTACATGTTT 2237
Db 1 GTTAAATGTTT 11

RESULT 391
ABF90885
XX ID ABF90885 standard; DNA; 13 BP.
XX AC ABF90885;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 190882 for detecting SNP TSC0007930.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
```

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 190882; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 13 BP; 9 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
 SQ Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 2222 CAAAAGTTTACA 2232
 DB ||||| |||||
 2 CAAAATTACA 12
 RESULT 392
 ABH16642/C
 ID ABH16642 standard; DNA; 13 BP.
 XX ABH16642;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 216619 for detecting SNP TSC0052664.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 216619; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 13 BP; 4 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
 SQ Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 2223 AAAAGTTTACAT 2233
 DB ||||| |||||
 11 AAAATTACAT 1
 RESULT 393
 ABH46082
 ID ABH46082 standard; DNA; 13 BP.
 XX ABH46082;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 246059 for detecting SNP TSC0060121.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 246059; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 7 A; 0 C; 1 G; 5 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACAT 2233
 Db 2 AAAAGTTATAT 12
 |||||

RESULT 394

ABH59441
 ID ABH59441 standard; DNA; 13 BP.

XX AC ABH59441;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 259418 for detecting SNP TSC0063001.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.

XX WO200177384-A2.

PN 18-OCT-2001.

PD 06-APR-2001; 2001WO-IB000713.

PF 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 259418; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 8 A; 1 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACAT 2233
 Db 2 AAAAATTACAT 12
 |||||

RESULT 395

ABH61414
 ID ABH61414 standard; DNA; 13 BP.

XX AC ABH61414;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 261391 for detecting SNP TSC0063448.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

PN 18-OCT-2001.

PD 06-APR-2001; 2001WO-IB000713.

PF 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 261391; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 5 A; 0 C; 2 G; 5 T; 0 U; 1 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 76.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 2224 AAAGTTACATGTT 2236
 Db 1 AATGTTAATGTY 13
 |||||

RESULT 396

ABC26271
 ID ABC26271 standard; DNA; 13 BP.

XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 105018; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 7 A; 3 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2228 TTACATGTTTG 2238

Db 12 TTAATGTTTG 2

RESULT 399

ABCS5256
 ID ABCS5256 standard; DNA; 13 BP.

AC ABCS5256;

XX 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 55273 for detecting SNP TSC0015107.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 55273; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 6 A; 0 C; 1 G; 6 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2223 AAAAGTTTACAT 2233

Db 3 AAAAGTTTATAT 13

RESULT 400

ABF08270

ID ABF08270 standard; DNA; 13 BP.

AC ABF08270;

XX 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 108267 for detecting SNP TSC0027110.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 108267; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 1 A; 1 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 34.8%; Score 9.4; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 2.2e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2227 GTTACATGTTT 2237

```

Db      ||||| |||||
        2 GTTAGTGTTT 12

RESULT 401
ABC60016
ID ABC60016 standard; DNA; 13 BP.
XX
AC ABC60016;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 60033 for detecting SNP TSC0016041.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
FN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.
XX
Claim 1; SEQ ID NO 60033; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation.
ABC00010
-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences
XX
Sequence 13 BP; 6 A; 1 C; 3 G; 3 T; 0 U; 0 Other;
XX
This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation.
ABC00010
-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the invention. NOTE: The sequence
data was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences
XX
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACAT 2233
Db 2 AAAAGTTACGT 12

RESULT 402
ABF12095
ID ABF12095 standard; DNA; 13 BP.
XX
AC ABF12095;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 112092 for detecting SNP TSC0027982.
XX
SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
central nervous system; gastrointestinal; respiratory; immune; metabolic.
Homo sapiens.
WO200177384-A2.
18-OCT-2001.
06-APR-2001; 2001WO-IB000713.

```

```

XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
FN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.
XX
Claim 1; SEQ ID NO 112092; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation.
ABC00010
-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences
XX
Sequence 13 BP; 5 A; 4 C; 0 G; 4 T; 0 U; 0 Other;
XX
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2221 CCAAAAGTTAC 2231
Db 2 CCAAAAGTTAC 12

RESULT 403
ABF33255/c
ID ABF33255 standard; DNA; 13 BP.
XX
AC ABF33255;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 133252 for detecting SNP TSC0033247.
XX
SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
central nervous system; gastrointestinal; respiratory; immune; metabolic.
Homo sapiens.
WO200177384-A2.
18-OCT-2001.
06-APR-2001; 2001WO-IB000713.

```


PR 07-APR-2000; 2000DE-01019173.
XX (EPiG-) EPIGENOMICS AG.
PA Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
DR Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 13252; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 7 A; 3 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2228 TTACATGTTG 2238
Db 12 TTACATGTTG 2
RESULT 404
ABF36212
ID ABF36212 standard; DNA; 13 BP.
XX
XX AC ABF36212;
XX
XX 21-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 136209 for detecting SNP TSC0034016.
DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX (EPiG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 136209; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 4 G; 6 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2226 AGTTACATGTT 2236
Db 1 AGTTACATGTT 11
RESULT 405
ABH31180/c
ID ABH31180 standard; DNA; 13 BP.
XX
XX AC ABH31180;
XX
XX 22-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 231157 for detecting SNP TSC0056372.
DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX (EPiG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 231157; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

```
XX SQ Sequence 13 BP; 3 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AARAGTTACAT 2233
DB 12 AAAACTTACAT 2
|||||
|||||

RESULT 406
ABF88893
ID ABF88893 standard; DNA; 13 BP.
XX AC ABF88893;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 188890 for detecting SNP TSC0046500.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 188890; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 13 BP; 6 A; 3 C; 0 G; 3 T; 0 U; 1 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 76.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 2217 GTGACCAAAAGTT 2229
DB 1 RTCACCAAAATT 13
|||||
|||||

RESULT 407
ABH51982
XX ABH51982 standard; DNA; 13 BP.
XX AC ABH51982;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 251959 for detecting SNP TSC0061476.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 251959; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 13 BP; 3 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTTG 2238
DB 3 TTAATGTTTG 13
|||||
|||||

RESULT 408
ACA62425
ID ACA62425 standard; DNA; 13 BP.
XX AC ACA62425;
XX DT 13-AUG-2003 (first entry)
XX DE Hepatitis B virus epsilon element priming reaction product.
XX KW HBV; hepatitis B virus core particle; ss; viral replication;
XX KW reverse transcript; antiviral agent; RNase H; epsilon element.
XX OS Hepatitis B virus.
```

XX	US6518014-B1.	XX	10-APR-2000 (first entry)	XX	10-APR-2000 (first entry)
XX	11-FEB-2003.	XX	Human dendritic cell SAGE tag, SEQ ID NO:571.	XX	Human dendritic cell SAGE tag, SEQ ID NO:571.
XX	11-JUL-1997; 97US-00890735.	XX	SAGE tag; serial analysis of gene expression; antigen-presenting cell;	XX	SAGE tag; serial analysis of gene expression; antigen-presenting cell;
XX	11-JUL-1996; 96US-0021561P.	XX	APC; monocyte-derived dendritic cell; differential gene expression;	XX	APC; monocyte-derived dendritic cell; differential gene expression;
XX	(BRIM) BRISTOL-MYERS SQUIBB CO.	XX	immunostimulatory cofactor; costimulatory factor; CTL;	XX	immunostimulatory cofactor; costimulatory factor; CTL;
XX		XX	cytotoxic T-lymphocyte; tumour antigen; immunotherapy; anticancer; ss.	XX	cytotoxic T-lymphocyte; tumour antigen; immunotherapy; anticancer; ss.
XX		XX	Homo sapiens.	XX	Homo sapiens.
XX	Seifer M, Hamatake R, Strandring DN;	XX	WO9965924-A2.	XX	WO9965924-A2.
XX	WPI; 2003-465600/44.	XX	23-DEC-1999.	XX	23-DEC-1999.
XX	Non-infectious, recombinant hepatitis virus core particle composition,	XX	18-JUN-1999; 99WO-US013800.	XX	18-JUN-1999; 99WO-US013800.
XX	comprises isolated hepatitis virus core particles, and template nucleic acid	XX	19-JUN-1998; 98US-0089833P.	XX	19-JUN-1998; 98US-0089833P.
XX	and hepatitis virus polymerase, both encapsidated in core particles.	XX	19-JUN-1998; 98US-0089844P.	XX	19-JUN-1998; 98US-0089844P.
XX	Disclosure; Col 16; 25pp; English.	XX	19-JUN-1998; 98US-0089853P.	XX	19-JUN-1998; 98US-0089853P.
XX	The invention relates to a non-infectious, recombinant hepatitis virus core	XX	19-JUN-1998; 98US-0089878P.	XX	19-JUN-1998; 98US-0089878P.
XX	particle composition, comprising isolated hepatitis virus core particles	XX	19-JUN-1998; 98US-0089911P.	XX	19-JUN-1998; 98US-0089911P.
XX	(HC), a template nucleic acid (TN) encapsidated in HC and hepatitis virus	XX	19-JUN-1998; 98US-0089922P.	XX	19-JUN-1998; 98US-0089922P.
XX	polymerase (HP) encapsidated in HC. Addition of deoxynucleoside	XX	19-JUN-1998; 98US-0089933P.	XX	19-JUN-1998; 98US-0089933P.
XX	triphosphates to the hepatitis virus core particle, HP incorporates	XX	19-JUN-1998; 98US-0089944P.	XX	19-JUN-1998; 98US-0089944P.
XX	deoxynucleotides into reverse transcripts (RTs) of TN beginning within	XX	19-JUN-1998; 98US-0089997P.	XX	19-JUN-1998; 98US-0089997P.
XX	first ten deoxynucleotides of RT. Also included is the preparation (M) of	XX	19-JUN-1998; 98US-0089999P.	XX	19-JUN-1998; 98US-0089999P.
XX	the hepatitis virus core particle, which involves transfecting/infecting a	XX	19-JUN-1998; 98US-0090000P.	XX	19-JUN-1998; 98US-0090000P.
XX	cell with one or more nucleic acid vectors that (i) encode hepatitis virus	XX	19-JUN-1998; 98US-0090035P.	XX	19-JUN-1998; 98US-0090035P.
XX	polymerase and express hepatitis virus polymerase in the transfecting or	XX	19-JUN-1998; 98US-0090036P.	XX	19-JUN-1998; 98US-0090036P.
XX	infected cell and (ii) encode hepatitis virus core protein and express	XX	19-JUN-1998; 98US-0090039P.	XX	19-JUN-1998; 98US-0090039P.
XX	hepatitis virus protein in the transfecting or infected cell, and (iii)	XX	19-JUN-1998; 98US-0090040P.	XX	19-JUN-1998; 98US-0090040P.
XX	contain a template nucleic acid, isolating core particles formed from the	XX	19-JUN-1998; 98US-0090041P.	XX	19-JUN-1998; 98US-0090041P.
XX	expressed hepatitis virus core protein, hepatitis virus polymerase and the	XX	19-JUN-1998; 98US-0090042P.	XX	19-JUN-1998; 98US-0090042P.
XX	template nucleic acid, which is derived from one of the nucleic acid	XX	19-JUN-1998; 98US-0090043P.	XX	19-JUN-1998; 98US-0090043P.
XX	vectors. The hepatitis virus core particle is useful for identifying	XX	19-JUN-1998; 98US-0090044P.	XX	19-JUN-1998; 98US-0090044P.
XX	characterising the potency of antiviral agents in interrupting or	XX	19-JUN-1998; 98US-0090045P.	XX	19-JUN-1998; 98US-0090045P.
XX	inhibiting hepatitis virus replication, by adding one or more	XX	19-JUN-1998; 98US-0090047P.	XX	19-JUN-1998; 98US-0090047P.
XX	deoxynucleoside triphosphates and a bioactive agent to the hepatitis virus	XX	19-JUN-1998; 98US-0090048P.	XX	19-JUN-1998; 98US-0090048P.
XX	core particle and either detecting formation of nucleic acids or	XX	19-JUN-1998; 98US-0090072P.	XX	19-JUN-1998; 98US-0090072P.
XX	detecting sizes of nucleic acids found in the hepatitis virus core particle,	XX	19-JUN-1998; 98US-0090076P.	XX	19-JUN-1998; 98US-0090076P.
XX	or measuring an RNase H activity exhibited by the hepatitis virus core	XX	19-JUN-1998; 98US-0090077P.	XX	19-JUN-1998; 98US-0090077P.
XX	particle. The method further involves measuring the priming reaction. The	XX	19-JUN-1998; 98US-0090078P.	XX	19-JUN-1998; 98US-0090078P.
XX	hepatitis virus core particle is useful for discovering or further	XX	19-JUN-1998; 98US-0090079P.	XX	19-JUN-1998; 98US-0090079P.
XX	characterising antiviral agents. The hepatitis virus core particle is useful	XX	08-DEC-1998; 98US-0111715P.	XX	08-DEC-1998; 98US-0111715P.
XX	for assaying for inhibitors of hepatitis virus replication, including	XX	(GENZ) GENZYME CORP.	XX	(GENZ) GENZYME CORP.
XX	inhibitors of one or more of the priming reaction, the translocation	XX	(ROBE/) ROBERTS B L.	XX	(ROBE/) ROBERTS B L.
XX	reaction, the (-) strand reaction, the elongation reaction, the (+)	XX	(SHAN/) SHANKARA S.	XX	(SHAN/) SHANKARA S.
XX	strand elongation reaction and RNase H reaction. The human hepatitis B	XX	Roberts BL, Shankara S;	XX	Roberts BL, Shankara S;
XX	virus (HBV, a hepatitis virus) strain ayw, was analysed and used to produce	XX	WPI; 2000-106077/09.	XX	WPI; 2000-106077/09.
XX	the recombinant hepatitis virus core particles of the invention. The HBV	XX	Isolated polynucleotides differentially expressed in antigen-presenting	XX	Isolated polynucleotides differentially expressed in antigen-presenting
XX	epsilon element is thought to form a stem-loop bulge and form the	XX	cells, useful in gene vaccines against cancer.	XX	cells, useful in gene vaccines against cancer.
XX	template for earliest priming step of reverse transcription. The present	XX	Claim 1; Page 81; 130pp; English.	XX	Claim 1; Page 81; 130pp; English.
XX	sequence is the priming product from the epsilon element	XX	Sequences AA27573-279709 represent SAGE (serial analysis of gene	XX	Sequences AA27573-279709 represent SAGE (serial analysis of gene
XX	Sequence 13 BP; 6 A; 1 C; 3 G; 3 T; 0 U; 0 Other;	XX	expression) tags used to identify mRNA transcripts encoding	XX	expression) tags used to identify mRNA transcripts encoding
XX	Query Match 34.8%; Score 9.4; DB 1; Length 13;	XX	immunostimulatory cofactor proteins which are preferentially or	XX	immunostimulatory cofactor proteins which are preferentially or
XX	Best Local Similarity 90.9%; Pred. No. 2.2e+02;	XX	differentially expressed in monocyte-derived dendritic cells compared	XX	differentially expressed in monocyte-derived dendritic cells compared
XX	Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	XX	with monocytes. Some of the transcripts correspond to known genes or ESTs	XX	with monocytes. Some of the transcripts correspond to known genes or ESTs
XX	QY 2223 AAAAGTTACAT 2233	XX	(expressed sequence tags) which were previously unknown to be	XX	(expressed sequence tags) which were previously unknown to be
XX	Db 3 AAAAGTTGCAT 13	XX	preferentially or differentially expressed in dendritic cells, while	XX	preferentially or differentially expressed in dendritic cells, while
XX	RESULT 409	XX	other transcripts correspond to novel genes. Antigen-presenting cell	XX	other transcripts correspond to novel genes. Antigen-presenting cell
XX	AAZ78143/C	XX	(APC)-associated costimulatory factors play an important role in the	XX	(APC)-associated costimulatory factors play an important role in the
XX	ID AAZ78143 standard; DNA; 10 BP.	XX	activation of the cytotoxic immune response, particularly against tumour	XX	activation of the cytotoxic immune response, particularly against tumour
XX	XX	XX	cells. Tumour antigen presentation via the MHC (major histocompatibility	XX	cells. Tumour antigen presentation via the MHC (major histocompatibility
XX	AAZ78143;	XX	complex) and subsequent recognition by T-cell receptors is alone	XX	complex) and subsequent recognition by T-cell receptors is alone

CC insufficient to activate a robust cytotoxic immune response that can lyse
 CC the tumour cells, immunostimulatory cofactors also being required for
 CC efficient activation of cytotoxic T-lymphocytes (CTLs). Nucleic acid
 CC sequences identified using the SAGE tags have several potential uses.
 CC They may be used in vaccines to induce an immune response, particularly
 CC against a tumour antigen; to modulate the genotype of an APC; to screen
 CC for agents that modulate expression of differentially expressed genes in
 CC an APC; and as hybridisation probes/amplification primers for the
 CC diagnosis, prognosis and monitoring of diseases related to abnormal
 CC expression of these genes. Detection of the dendritic cell differentially
 CC expressed genes, or of their encoded proteins, can be used to identify
 CC cells as belonging to the monocyte lineage. Cells containing these genes
 CC can be used in active immunotherapy (or to stimulate production of a
 CC population of antigen-specific effector cells) and vectors containing
 CC them are used in gene therapy. Co-administration of tumour antigens and
 CC APC-associated costimulatory factors ensures adequate antigen
 CC presentation to endogenous APCs and upregulates the APCs for the
 CC presentation of co-stimulatory signals, migration to T cell-rich sites,
 CC secretion of T cell growth factors and secretion of chemokines for
 CC recruitment of immune effector cells
 CC
 SQ Sequence 10 BP; 3 A; 3 C; 2 G; 2 T; 0 U; 0 Other;

Query Match 33.3%; Score 9; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2214 AGTGTGACC 2222

Db 9 AGTGTGACC 1

RESULT 410

AAZ83777/C
 ID AAZ83777 standard; DNA; 10 BP.

XX AC AAZ83777;

DT 07-APR-2000 (first entry)

DE Metastatic breast tumour cell upregulated transcript tag #3011.

XX Human; metastatic breast tumour tissue; breast cancer; tag; primer;
 KW non-metastatic breast tumour tissue; gene therapy; anticancer;
 KW antimetastatic; vaccine; diagnosis; ss.

OS Homo sapiens.

PN WO9965928-A2.

XX 23-DEC-1999.

PF 18-JUN-1999; 99WO-US013647.

XX 19-JUN-1998; 98US-0089853P.

PR 19-JUN-1998; 98US-0089997P.

PR 19-JUN-1998; 98US-0090039P.

PR 19-JUN-1998; 98US-0090040P.

PR 19-JUN-1998; 98US-0090041P.

XX (GENZ) GENZYME CORP.

PA (ROBE) ROBERTS B L.

PA (SHAN) SHANKARA S.

XX Roberts BL, Shankara S;

PI WPI; 2000-106079/09.

DR Isolated polynucleotides differentially expressed between metastatic and
 XX non-metastatic breast cancer cells, useful for diagnosis, prevention and
 PT treatment of cancer.
 XX
 PS Claim 1; Page 139; 219pp; English.

XX AAZ80767 to AAZ83941 represent tags corresponding to distinct transcripts
 CC that are preferentially transcribed in the metastatic breast tumour
 CC tissue (i.e. are upregulated in metastatic breast tumour cells). AAZ83942
 CC to AAZ86677 represent tags corresponding to distinct transcripts that are
 CC preferentially transcribed in the primary or non-metastatic breast tumour
 CC tissue (i.e. are downregulated in metastatic breast tumour cells). These
 CC transcripts can be used for diagnosis, prognosis, monitoring and
 CC treatment of breast cancer, particularly where metastatic. Diagnosis is
 CC by standard immunoassays or hybridisation/amplification reactions.
 CC Compounds that modulate expression of the transcripts are potentially
 CC useful for treatment of (metastatic) breast cancer, while promoters from
 CC the transcripts are used to direct expression, in selected cell types, of
 CC e.g. therapeutic genes (also ribozymes or antisense sequences),
 CC particularly an antigen-encoding sequence for use in gene or cell-based
 CC vaccines. Polypeptides encoded by the transcripts are also useful in
 CC vaccines; for diagnosing breast cancer and for raising specific
 CC antibodies (Ab). Ab are used to detect the polypeptides or as therapeutic
 CC agents. Host cells that produce the polypeptides can be used to expand
 CC and isolate populations of educated, antigen-specific immune effector
 CC cells, e.g. cytotoxic T lymphocytes, and these used for adoptive
 CC immunotherapy
 CC
 SQ Sequence 10 BP; 2 A; 2 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 33.3%; Score 9; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2221 CCAAAAGTT 2229

Db 9 CCAAAAGTT 1

RESULT 411

AAF36621
 ID AAF36621 standard; DNA; 10 BP.

XX AC AAF36621;

XX 23-MAR-2001 (first entry)

DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:3360.

XX Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
 KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
 KW serial analysis of gene expression; antifungal; tag; identification;
 KW linker; PCR primer; ds.

XX Saccharomyces cerevisiae.

XX WO200077214-A2.

XX 21-DEC-2000.

PF 14-JUN-2000; 2000WO-US016223.

XX 16-JUN-1999; 99US-00335032.

XX (UYJO) UNIV JOHNS HOPKINS.

XX Velculescu V, Vogelstein B, Kinzler K;

XX WPI; 2001-061874/07.

XX Yeast gene coding sequences comprising NORF genes with serial analysis of
 PT gene expression (SAGE) tags, useful for studying, monitoring and
 PT affecting phases of the cell cycle.

XX Example; Page 120; 419pp; English.

XX The present invention describes an isolated DNA molecule comprising a
 CC coding sequence of a yeast gene selected from a group of 745 NORF (not

CC previously assigned open reading frame, or nonannotated ORF) genes
 CC comprising a SAGE (serial analysis of gene expression) tag. Also
 CC described are: (1) a method (M1) of using NORF genes to affect the cell
 CC cycle comprising administering a NORF gene whose expression varies by at
 CC least 10% between any two phases of the cell cycle selected from log
 CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
 CC antifungal drugs comprising: (a) contacting a test substance with a yeast
 CC cell; and (b) monitoring expression of a NORF gene whose expression
 CC varies as in M1, where a test substance which modifies the expression of
 CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
 CC identifying human genes which are involved in cell cycle progression
 CC comprising contacting human DNA with a probe which comprises at least 10
 CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
 CC and (4) a method (M4) for identifying a candidate drug as a member of a
 CC class of drugs having a characteristic effect on gene expression in a
 CC yeast cell comprising contacting a yeast cell with a candidate drug and
 CC monitoring expression in the yeast cell of at least 1 NORF gene whose
 CC expression is affected by the class of drugs. The NORF genes may be used
 CC to study, monitor and affect phases of the cell cycle, the differentially
 CC expressed genes may be used as markers of phases of the cell cycle. The
 CC methods may be used to identify candidate drugs which affect the cell
 CC cycle and for identification of antifungal drugs. AAF33268 to AAF44064
 CC represent SAGE tags used in the exemplification of the present invention.
 CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
 CC method, in the exemplification of the present invention
 XX
 SQ Sequence 10 BP; 4 A; 2 C; 3 G; 1 T; 0 U; 0 Other;

Query Match 33.3%; Score 9; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2217 GTGACCAA 2225
 DB 2 GTGACCAA 10
 |||||

RESULT 412
 AAF36059
 ID AAF36059 standard; DNA; 10 BP.

AC AAF36059;
 XX
 XX 23-MAR-2001 (first entry)

XX Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:2798.

XX Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
 KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
 KW serial analysis of gene expression; antifungal; tag; identification;
 KW linker; PCR primer; ds.

XX Saccharomyces cerevisiae.

XX WO200077214-A2.

XX 21-DEC-2000.

XX 14-JUN-2000; 2000WO-US016223.

XX 16-JUN-1999; 99US-00335032.

XX (UYJO) UNIV JOHNS HOPKINS.

XX Velulescu V, Vogelstein B, Kinzler K;

XX WPI; 2001-061874/07.

XX Yeast gene coding sequences comprising NORF genes with serial analysis of
 PT gene expression (SAGE) tags, useful for studying, monitoring and
 PT affecting phases of the cell cycle.

XX Example; Page 99; 419pp; English.

XX The present invention describes an isolated DNA molecule comprising a
 CC coding sequence of a yeast gene selected from a group of 745 NORF (not
 CC previously assigned open reading frame; or nonannotated ORF) genes
 CC comprising a SAGE (serial analysis of gene expression) tag. Also
 CC described are: (1) a method (M1) of using NORF genes to affect the cell
 CC cycle comprising administering a NORF gene whose expression varies by at
 CC least 10% between any two phases of the cell cycle selected from log
 CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
 CC antifungal drugs comprising: (a) contacting a test substance with a yeast
 CC cell; and (b) monitoring expression of a NORF gene whose expression
 CC varies as in M1, where a test substance which modifies the expression of
 CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
 CC identifying human genes which are involved in cell cycle progression
 CC comprising contacting human DNA with a probe which comprises at least 10
 CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
 CC and (4) a method (M4) for identifying a candidate drug as a member of a
 CC class of drugs having a characteristic effect on gene expression in a
 CC yeast cell comprising contacting a yeast cell with a candidate drug and
 CC monitoring expression in the yeast cell of at least 1 NORF gene whose
 CC expression is affected by the class of drugs. The NORF genes may be used
 CC to study, monitor and affect phases of the cell cycle, the differentially
 CC expressed genes may be used as markers of phases of the cell cycle. The
 CC methods may be used to identify candidate drugs which affect the cell
 CC cycle and for identification of antifungal drugs. AAF33268 to AAF44064
 CC represent SAGE tags used in the exemplification of the present invention.
 CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
 CC method, in the exemplification of the present invention
 XX
 SQ Sequence 10 BP; 4 A; 2 C; 3 G; 1 T; 0 U; 0 Other;

Query Match 33.3%; Score 9; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2221 CCAAAAGTT 2229
 DB 2 CCAAAAGTT 10
 |||||

RESULT 413
 AAF34702/C
 ID AAF34702 standard; DNA; 10 BP.

AC AAF34702;
 XX
 XX 23-MAR-2001 (first entry)

XX Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:1441.

XX Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
 KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
 KW serial analysis of gene expression; antifungal; tag; identification;
 KW linker; PCR primer; ds.

XX Saccharomyces cerevisiae.

XX WO200077214-A2.

XX 21-DEC-2000.

XX 14-JUN-2000; 2000WO-US016223.

XX 16-JUN-1999; 99US-00335032.

XX (UYJO) UNIV JOHNS HOPKINS.

XX Velulescu V, Vogelstein B, Kinzler K;

XX WPI; 2001-061874/07.

XX Yeast gene coding sequences comprising NORF genes with serial analysis of
 PT gene expression (SAGE) tags, useful for studying, monitoring and

XX WPI; 2002-383121/41.
DR
XX Novel genetic variants of G protein-coupled receptor 7 gene useful for
PT therapeutic purposes and for expressing GPR7 protein useful in
PT identifying drugs to treat psychological and neurological disorders.
XX
XX Claim 18; Page 13; 69pp; English.
XX
XX The invention relates to an isolated polynucleotide (I) comprising a
CC nucleotide sequence which is a polymorphic variant of a reference
CC sequence for G-protein coupled receptor 7 (GPR7) gene or its fragment, or
CC a polymorphic variant of a reference sequence for a GPR7 cDNA or its
CC fragment. The encoded polypeptide (II) is useful for screening for drugs
CC targeting the polypeptide. (I) is useful for identifying an association
CC between a trait such as a clinical response to a drug targeting GPR7 and
CC a haplotype or haplotype pair of GPR7 gene. Such methods have
CC applicability in developing diagnostic tests and therapeutic treatments
CC psychological and neurological disorders. (I) is useful for studying the
CC expression and function of GPR7 and expressing GPR7 protein for use in
CC screening for candidate drugs to treat diseases related to GPR7 activity.
CC The polymorphism and haplotype data are useful for validating whether
CC GPR7 is a suitable target for drugs to treat psychological and
CC neurological disorders, screening for such drugs and reducing bias in
CC clinical trials of such drugs. (I) is useful for therapeutic purposes.
CC Establishing the GPR7 haplotype or haplotype pair of an individual is
CC useful for improving the efficiency and reliability of several steps in
CC the discovery and development of drugs for treating diseases associated
CC with GPR7 activity psychological and neurological disorders. The
CC haplotyping method is useful to validate GPR7 as a candidate target for
CC treating a specific condition or disease predicted to be associated with
CC GPR7 activity. The method is also useful in screening for compounds
CC targeting GPR7 to treat a specific condition or disease predicted to be
CC associated with GPR7 activity, e.g. detecting which of the GPR7
CC haplotypes or haplotype pairs present in individual members of a
CC population with the specific disease of interest enables one to screen
CC for compounds that display the highest desired agonist or antagonist
CC activity for each of the most frequent GPR7 isoforms present in the
CC disease population. A polymorphic variant of GPR7 is useful in studying
CC the effect of the variation on the biological activity of GPR7, on the
CC binding affinity of candidate drugs targeting GPR7 for the treatment of
CC psychological and neurological disorders and in assays to measure the
CC binding affinities of one or more candidate drugs targeting the GPR7
CC protein. (I) is useful for studying expression of the GPR7 isoforms in
CC vivo, for in vivo screening and testing of drugs against GPR7 protein and
CC for testing the efficacy of therapeutic agents and compounds for
CC psychological and neurological disorders in a biological system. Antibody
CC to (II) is useful for diagnostic and prognostic formats and therapeutic
CC methods, for immunoprecipitating (II) from solution, for detecting GPR7
CC protein isoforms in biological samples, frozen tissue sections, cells
CC which have been fixed or unfixed and prepared on slides, for use in
CC immunocytochemical, immunohistochemical and immunofluorescence
CC techniques. ABX70517-ABX70558 represent human GPR7 allele-specific probes
CC and primers used in haplotyping of human GPR7 as described in the
CC invention
XX
XX Sequence 10 BP; 5 A; 1 C; 1 G; 3 T; 0 U; 0 Other;
SQ
Query Match 33.3%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2224 AAGATTACA 2232
DB 2 AAGATTACA 10
RESULT 416
ABV69773
ID ABV69773 standard; cDNA; 11 BP.
XX
AC ABV69773;
XX

DT 21-OCT-2002 (first entry)
XX Human skin EST 7559.
DE
XX Human; skin; dermatological; vulnary; antipsoriatic; antiseborrhaic;
KW immunosuppressive; antinflammatory; cytostatic; SAGE; neurodermatitis;
KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX
OS Homo sapiens.
XX
XX WO200253774-A2.
PN
XX 11-JUL-2002.
PD
XX 20-DEC-2001; 2001WO-EP015179.
PF
XX 03-JAN-2001; 2001DE-01000127.
PR
XX (HENK) HENKEL KGAA.
PA
XX Petersohn D, Conradt M, Hofmann K;
PI
XX WPI; 2002-590638/63.
DR
XX In vitro identification of skin-expressed genes, useful for determining
PT homeostasis and identifying cosmetic or pharmaceutical agents against
PT e.g. skin cancer.
XX
XX Claim 24; Page 239; 1345pp; German.
PS
XX The invention relates to in vitro identification (M1) of genes expressed
CC in the skin of humans or animals by subjecting a mixture of genetically
CC encoded factors from skin, to serial analysis of gene expression (SAGE)
CC so as to identify skin-expressed genes and quantify their expression.
CC (M1) is useful for identifying genes involved in skin homeostasis; to
CC determine skin homeostasis and to test agent (A) that maintains or
CC promotes skin homeostasis or that can be used for treating skin
CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
CC skin. The present sequence is that of a human expressed sequence tag
CC (EST) of the invention
XX
XX Sequence 11 BP; 3 A; 1 C; 5 G; 2 T; 0 U; 0 Other;
SQ
Query Match 33.3%; Score 9; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2212 AGAGGTGCA 2220
DB 3 AGAGGTGCA 11
RESULT 417
ABV66253/c
ID ABV66253 standard; cDNA; 11 BP.
XX
XX ABV66253;
AC
XX 21-OCT-2002 (first entry)
DT
XX Human skin EST 4039.
DE
XX Human; skin; dermatological; vulnary; antipsoriatic; antiseborrhaic;
KW immunosuppressive; antinflammatory; cytostatic; SAGE; neurodermatitis;
KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX
OS Homo sapiens.
XX
XX WO200253774-A2.
PN
XX 11-JUL-2002.
PD

XX PF 20-DEC-2001; 2001WO-EP015179.
 XX PR 03-JAN-2001; 2001DE-01000127.
 XX PA (HENKEL) HENKEL KGAA.
 XX PI Petersohn D, Conradt M, Hofmann K;
 XX WPI; 2002-590638/63.
 XX In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against
 PT e.g. skin cancer.
 XX Disclosure; Page 137; 1345pp; German.
 XX The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 XX SQ Sequence 11 BP; 3 A; 2 C; 2 G; 4 T; 0 U; 0 Other;
 Query Match 33.3%; Score 9; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 2.2e+02;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2221 CCAAAAGTTT 2229
 DB 11 CCAAAAGTTT 3
 RESULT 418
 ABV62352
 ID ABV62352 standard; cDNA; 11 BP.
 AC ABV62352;
 XX 21-OCT-2002 (first entry)
 DT Human skin EST 138.
 DE Human; skin; dermatological; vulvular; antipsoriatic; antiseborrheic;
 KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX Homo sapiens.
 OS WO200253774-A2.
 PN 11-JUL-2002.
 PD 20-DEC-2001; 2001WO-EP015179.
 PF 03-JAN-2001; 2001DE-01000127.
 PR (HENKEL) HENKEL KGAA.
 XX Petersohn D, Conradt M, Hofmann K;
 XX WPI; 2002-590638/63.
 XX In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against

PT e.g. skin cancer.
 XX Disclosure; Page 30; 1345pp; German.
 XX The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 XX SQ Sequence 11 BP; 3 A; 1 C; 5 G; 2 T; 0 U; 0 Other;
 Query Match 33.3%; Score 9; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 2.2e+02;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2212 AGAGTGTCGA 2220
 DB 3 AGAGTGTCGA 11
 RESULT 419
 ABL91964
 ID ABL91964 standard; cDNA; 11 BP.
 XX ABL91964;
 AC 30-MAY-2002 (first entry)
 DT Human Pan-Endothelial Marker SEQ ID NO 62.
 DE Human; mouse; rat; TEM; tumour endothelial marker; NEM; PEM; cytostatic;
 KW normal endothelial marker; pan-endothelial marker; immunostimulant;
 KW antiangiogenic; tumour; neovascularisation; vascularised tumour;
 KW polycystic kidney disease; diabetes; retinopathy; rheumatoid arthritis;
 KW psoriasis; ss.
 XX Homo sapiens.
 OS WO200210217-A2.
 PN 07-FEB-2002.
 PD 01-AUG-2001; 2001WO-US024031.
 PF 02-AUG-2000; 2000US-0222599P.
 PR 11-AUG-2000; 2000US-0224360P.
 PR 11-APR-2001; 2001US-0282850P.
 XX (UYJO) UNIV JOHNS HOPKINS.
 PA St Croix B, Kinzler KW, Vogelstein B;
 PI WPI; 2002-291856/33.
 DR An isolated molecule comprising an antibody variable region which
 PT specifically binds to an extracellular domain of a tumour endothelial
 PT marker (TEM) protein, useful for inhibiting tumor growth.
 XX Example 4; Page 325; 331pp; English.
 XX The invention relates to an isolated molecule comprising an antibody
 CC variable region which specifically binds to an extracellular domain of a
 CC tumour endothelial marker (TEM) protein selected from ABB90732, ABB90740,
 CC ABB90749, ABB90750 and ABB90769. The antibodies which bind to TEM
 CC proteins have cytostatic, immunostimulant and antiangiogenic activity.

CC They are useful for inhibiting tumour growth, neoangiogenesis in subjects
CC bearing a vascularised tumour, polycystic kidney disease, diabetic
CC retinopathy, rheumatoid arthritis and psoriasis. Human, mouse and rat TEM
CC genes and the encoded proteins (ABL92075-ABL92141 and ABB90721-ABB90789)
CC are disclosed, as are marker oligonucleotide sequences: tumour
CC endothelial markers (TEM) ABL91996-ABL92041 and ABL92143-ABL92191; normal
CC endothelial markers (NEM) ABL92042-ABL92074; and pan-endothelial markers
CC (PEM) ABL91903-ABL91995. The present sequence is that of an
CC oligonucleotide marker useful to the invention
XX
SQ Sequence 11 BP; 3 A; 1 C; 5 G; 2 T; 0 U; 0 Other;
Query Match 33.3%; Score 9; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.2e+02; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 2212 AGAGTGTGA 2220
Db 3 AGAGTGTGA 11
RESULT 420
ABX71889
ID ABX71889 standard; DNA; 11 BP.
XX AC
XX ABX71889;
XX
DT 12-MAR-2003 (first entry)
XX
DE DNA tag used to identify human gene encoding PEM 62.
XX
KW Human; endothelial cell; EC; tumour endothelial cell; TEM; NEM;
KW Tumour endothelial marker; normal endothelial marker; PEM;
KW pan-endothelial marker; polycystic kidney disease; psoriasis;
KW diabetic retinopathy; rheumatoid arthritis; tumour angiogenesis;
KW neoangiogenesis; immune response; cytostatic; antidiabetic;
KW ophthalmological; antirheumatic; antiarthritic; antipsoriatic; ds.
XX
OS Homo sapiens.
XX
XX WO200283874-A2.
XX
XX 24-OCT-2002.
XX
XX 10-APR-2002; 2002WO-US008253.
XX
XX 11-APR-2001; 2001US-0282850P.
XX
XX 06-FEB-2002; 2002US-0354262P.
XX
XX (UJVO) UNIV JOHNS HOPKINS.
XX
XX Carson-Walter E, St Croix B, Kinzler KW, Vogelstein B;
XX WPI; 2003-093016/08.
XX
XX New purified human transmembrane protein, designated as tumor endothelial
XX marker (TEM) 3, useful for detecting, diagnosing or treating tumors,
XX polycystic kidney disease, diabetic retinopathy, rheumatoid arthritis or
XX psoriasis.
XX
XX Disclosure; Page 96; 374pp; English.
XX
CC The present invention relates to a novel method for the isolation of
CC endothelial cells (ECs), and the identification of genes expressed in
CC normal and tumour ECs. Tumour endothelial marker (TEM), normal
CC endothelial marker (NEM), and pan-endothelial marker (PEM) genes are
CC identified in human ECs. The human EC marker proteins and the
CC polynucleotide sequences encoding them are useful for detecting,
CC diagnosing or treating tumours as well as polycystic kidney disease,
CC diabetic retinopathy, rheumatoid arthritis, and psoriasis. They are also
CC useful for inhibiting neoangiogenesis or tumour angiogenesis, for
CC inducing an immune response to tumour endothelial cells in a patient, or
CC for identifying candidate drugs for treating tumours. ABX71828-ABX71999

CC represent DNA tags for human PEM, TEM or NEM genes
XX
SQ Sequence 11 BP; 3 A; 1 C; 5 G; 2 T; 0 U; 0 Other;
Query Match 33.3%; Score 9; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.2e+02; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 2212 AGAGTGTGA 2220
Db 3 AGAGTGTGA 11
RESULT 421
ADQ34600/c
ID ADQ34600 standard; DNA; 11 BP.
XX AC
XX ADQ34600;
XX
DT 23-SEP-2004 (first entry)
XX
DE Human facial skin-associated DNA fragment SEQ ID NO 2690.
XX
KW facial skin; human; serial analysis of gene expression; SAGE;
KW homeostasis; biochip; cosmetic; pharmaceutical; ds.
XX
OS Homo sapiens.
XX
XX DE10260928-A1.
XX
XX 08-JUL-2004.
XX
XX 20-DEC-2002; 2002DE-01060928.
XX
XX 20-DEC-2002; 2002DE-01060928.
XX
XX (HENK) HENKEL KGAA.
XX
XX Petersohn D, Schlotmann K, Gassenmeier T, Holtkoetter O;
XX Conradt M, Hofmann K;
XX WPI; 2004-518855/50.
XX
XX In vitro identification of genes important for facial skin, useful for
XX assessing homeostasis and in screening for pharmaceutical or cosmetic
XX agents, based on differential expression analysis.
XX
XX Claim 4; SEQ ID NO 2690; 577pp; German.
XX
CC This invention describes a novel in vitro method for identifying genes
CC that are significant for facial skin in humans. The method comprises
CC recovering, from facial skin, a first mixture of genetically expressed
CC (transcribed and optionally translated) factors (i.e. proteins, mRNA or
CC their fragments), recovering a second, similar mixture from some other
CC human tissue, preferably skin from a protected area, especially from the
CC breast and subjecting the mixtures to serial analysis of gene expression
CC (SAGE) to identify those genes for which expression is markedly different
CC between facial skin and the other tissue. The invention also describes an
CC in vitro method for determining homeostasis of human facial skin; a test
CC kit which comprises a solid support (flexible or rigid) on which are
CC immobilised probes that bind specifically to the factors of interest and
CC a biochip for determining homeostasis of human facial skin. The products
CC of the invention are also used in a method which determines activity of
CC cosmetic and pharmaceutical agents for use against disorders or
CC disturbances of the homeostasis of human skin and a screening method for
CC identifying cosmetic and pharmaceutical agents. The method allows
CC identification of as many as possible of the genes important for facial
CC skin and thus of a very wide range of potential therapeutic and cosmetic
CC agents. ADQ34600-ADQ35111 represent human DNA tag fragments used to
CC identify the facial skin-associated genes described in the invention.
XX
XX Sequence 11 BP; 2 A; 2 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 33.3%; Score 9; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2221 CCAAAAGTT 2229
DB 9 CCAAAAGTT 1

RESULT 422

ADQ32402
ID ADQ32402 standard; DNA; 11 BP.

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

OY 2218 TGACCAAAA 2226
DB 1 TGACCAAAA 9

RESULT 423

ABI67341
ID ABI67341 standard; DNA; 12 BP.

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

Query Match 33.3%; Score 9; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2221 CCAAAAGTT 2229
DB 9 CCAAAAGTT 1

RESULT 422

ADQ32402
ID ADQ32402 standard; DNA; 11 BP.

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

OY 2218 TGACCAAAA 2226
DB 1 TGACCAAAA 9

RESULT 423

ABI67341
ID ABI67341 standard; DNA; 12 BP.

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

Query Match 33.3%; Score 9; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2221 CCAAAAGTT 2229
DB 9 CCAAAAGTT 1

RESULT 422

ADQ32402
ID ADQ32402 standard; DNA; 11 BP.

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

DE Oligonucleotide primer SEQ ID NO 351601 for detecting SNP TSC0047395.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 351601; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -AB099989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 4 A; 0 C; 4 G; 4 T; 0 U; 0 Other;
XX Query Match 33.3%; Score 9; DB 1; Length 12;
XX Best Local Similarity 100.0%; Pred. No. 2.4e+02;
XX Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 2212 AGAGTGTCGA 2220
DB |||||||
3 AGAGTGTCGA 11
RESULT 425
ABI19573
ID ABI19573 standard; DNA; 12 BP.
AC ABI19573;
XX 22-FEB-2002 (first entry)
DE Oligonucleotide primer SEQ ID NO 319546 for detecting SNP TSC00292930.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 319546; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -AB099989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 3 A; 0 C; 7 G; 2 T; 0 U; 0 Other;
XX Query Match 33.3%; Score 9; DB 1; Length 12;
XX Best Local Similarity 100.0%; Pred. No. 2.4e+02;
XX Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 2212 AGAGTGTCGA 2220
DB |||||||
3 AGAGTGTCGA 11
RESULT 426
ABI68656/C
ID ABI68656 standard; DNA; 12 BP.
XX ABI68656;
XX 22-FEB-2002 (first entry)
DE Oligonucleotide primer SEQ ID NO 368629 for detecting SNP TSC0057125.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX


```

PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 283700; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 5 A; 3 C; 0 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX Best Local Similarity 83.3%; Pred. NO. 2.7e+02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 2221 CCAAAAGTTTACA 2232
XX ||| ||| |||
XX 1 CCATAATTACA 12
XX
XX RESULT 432
XX AB111382/c
XX ID AB111382 standard; DNA; 12 BP.
XX AC AB111382;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 311355 for detecting SNP TSC0024444.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 311355; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 5 A; 3 C; 0 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX Best Local Similarity 83.3%; Pred. NO. 2.7e+02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 2221 CCAAAAGTTTACA 2232
XX ||| ||| |||
XX 1 CCATAATTACA 12
XX
XX RESULT 432
XX AB111382/c
XX ID AB111382 standard; DNA; 12 BP.
XX AC AB111382;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 311355 for detecting SNP TSC0024444.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 311355; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 5 A; 3 C; 0 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX Best Local Similarity 83.3%; Pred. NO. 2.7e+02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 2221 CCAAAAGTTTACA 2232
XX ||| ||| |||
XX 1 CCATAATTACA 12
XX
XX RESULT 433
XX AB143475
XX ID AB143475 standard; DNA; 12 BP.
XX AC AB143475;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 343448 for detecting SNP TSC0043074.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 343448; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
XX
XX Query Match 32.6%; Score 8.8; DB 1; Length 12;

```

Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2227 GTTACATGTTTG 2238
|||||
Db 1 GTTATATTTTG 12

RESULT 434
ABI61564
ID ABI61564 standard; DNA; 12 BP.
XX AC
XX ABI61564;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 361537 for detecting SNP TSC0052684.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 361537; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2221 CCAAAAGTTTACA 2232
|||||
Db 1 CCAAAAATACA 12

RESULT 435
ABI63012
ID ABI63012 standard; DNA; 12 BP.
XX AC
XX ABI63012;

XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 362985 for detecting SNP TSC0053575.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 362985; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 4 A; 0 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2213 GAGTGTGACCAA 2224
|||||
Db 1 GAGTGTGAGGAA 12

RESULT 436
ABI79659
ID ABI79659 standard; DNA; 12 BP.
XX AC
XX ABI79659;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 379632 for detecting SNP TSC0063394.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX

PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 XX methylation status.
 XX
 XX Claim 1; SEQ ID NO 379632; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 XX and cytosine methylation status in chemically pretreated genomic DNA. The
 XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 XX range of diseases including immune system, gastrointestinal, respiratory,
 XX central nervous system, cardiovascular and metabolic disorders. The
 XX oligomers are also used for detecting cell type differentiation. ABC00010
 XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 XX represent the oligomers described in the invention. NOTE: The sequence
 XX data for this patent did not form part of the printed specification, but
 XX was obtained in electronic format from WIPO at
 XX ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
 XX
 XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
 XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 XX Mismatches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 XX 2221 CCAGAAAGTTTACA 2232
 XX 1 CAAAAATTTTACA 12
 XX
 XX RESULT 437
 XX ABH69606/c
 XX ID ABH69606 standard; DNA; 12 BP.
 XX
 XX AC ABH69606;
 XX
 XX 22-FEB-2002 (first entry)
 XX
 XX Oligonucleotide primer SEQ ID NO 269583 for detecting SNP TSC0001812.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX Homo sapiens.
 XX
 XX WO200177384-A2.
 XX
 XX 18-OCT-2001.
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 XX
 XX 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIG-) EPIGENOMICS AG.
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine.
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 269583; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 XX and cytosine methylation status in chemically pretreated genomic DNA. The
 XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 XX range of diseases including immune system, gastrointestinal, respiratory,
 XX central nervous system, cardiovascular and metabolic disorders. The
 XX oligomers are also used for detecting cell type differentiation. ABC00010
 XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 XX represent the oligomers described in the invention. NOTE: The sequence
 XX data for this patent did not form part of the printed specification, but
 XX was obtained in electronic format from WIPO at
 XX ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 3 A; 0 C; 4 G; 5 T; 0 U; 0 Other;
 XX
 XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
 XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 XX Mismatches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 XX 2220 ACCAAAGTTTAC 2231
 XX 12 ACCAATTTTAC 1
 XX
 XX RESULT 438
 XX ABH73239/c
 XX ID ABH73239 standard; DNA; 12 BP.
 XX
 XX AC ABH73239;
 XX
 XX 22-FEB-2002 (first entry)
 XX
 XX Oligonucleotide primer SEQ ID NO 273224 for detecting SNP TSC0003096.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX Homo sapiens.
 XX
 XX WO200177384-A2.
 XX
 XX 18-OCT-2001.
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 XX
 XX 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIG-) EPIGENOMICS AG.
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 XX methylation status.
 XX
 XX Claim 1; SEQ ID NO 273224; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 XX and cytosine methylation status in chemically pretreated genomic DNA. The
 XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 XX range of diseases including immune system, gastrointestinal, respiratory,
 XX central nervous system, cardiovascular and metabolic disorders. The
 XX oligomers are also used for detecting cell type differentiation. ABC00010
 XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 5 A; 2 C; 0 G; 5 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 2225 AAGTTACATGTT 2236
|||||
Db 12 AAGTTACATGTT 1
RESULT 439
ABI01684
ID ABI01684 standard; DNA; 12 BP.
XX AC
AC ABI01684;
XX
XX 22-FEB-2002 (first entry)
DE Oligonucleotide primer SEQ ID NO 301657 for detecting SNP TSC0019597.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPT; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 301657; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 2225 AAGTTACATGTT 2236
|||||

Db 1 AAGTTTAAATGTT 12
RESULT 440
ABI06155
ID ABI06155 standard; DNA; 12 BP.
XX AC
AC ABI06155;
XX
XX 22-FEB-2002 (first entry)
DT
DE Oligonucleotide primer SEQ ID NO 306128 for detecting SNP TSC0021818.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPT; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 306128; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 4 A; 0 C; 3 G; 5 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 2226 AGTTACATGTT 2237
|||||
Db 1 AGTGAATGTT 12
RESULT 441
ABI33010/C
ID ABI33010 standard; DNA; 12 BP.
XX AC
AC ABI33010;
XX
XX 22-FEB-2002 (first entry)
DT
DE Oligonucleotide primer SEQ ID NO 332983 for detecting SNP TSC0037310.
XX

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 332983; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 6 A; 1 C; 0 G; 5 T; 0 U; 0 Other;
SQ
This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2224 AAAGTTTACATCT 2235
DB 12 AAAGTTTATTTT 1
RESULT 442
ABI12796/C
ID ABI12796 standard; DNA; 12 BP.
XX ABI12796;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 312769 for detecting SNP TSC0025278.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 34198; 29pp + Sequence Listing; German.

XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 312769; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 6 A; 2 C; 0 G; 4 T; 0 U; 0 Other;
SQ
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2227 GTTACATGTTT 2238
DB 12 GTTAAATATTT 1
RESULT 443
ABI44225/C
ID ABI44225 standard; DNA; 12 BP.
XX ABI44225;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 34198 for detecting SNP TSC0043438.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 34198; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI92073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 2 A; 0 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2220 ACCAAAAGTTAC 2231
Db 12 ACCAAAATATAC 1
|||||
|

RESULT 444
ABI49223/C
ID ABI49223 standard; DNA; 12 BP.
XX AC ABI49223;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 349196 for detecting SNP TSC0045973.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 349196; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI92073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 12 BP; 5 A; 4 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2227 GTTACATGTTTG 2238
Db 12 GTTAAAGTTTG 1
|||||
|

RESULT 445
ABI74456
ID ABI74456 standard; DNA; 12 BP.
XX AC ABI74456;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 374429 for detecting SNP TSC0060686.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 374429; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI92073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 7 A; 0 C; 2 G; 3 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2223 AAAAGTTACATG 2234
Db 1 AAAAGTAATATG 12
|||||
|

RESULT 446
ABI77494/C

DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 299919; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2222 CAAGAAGTTACAT 2233
DB 12 CAAGAATTACT 1
RESULT 449
ABI11682/c
ID ABI11682 standard; DNA; 12 BP.
AC ABI11682;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 311655 for detecting SNP TSC0024599.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
DE Oligonucleotide primer SEQ ID NO 311655 for detecting SNP TSC0024599.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 311655; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2220 ACCAAAAGTTTAC 2231
DB 12 AACAAAATTTC 1
RESULT 450
ABI40821/c
ID ABI40821 standard; DNA; 12 BP.
XX
XX AC ABI40821;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 340794 for detecting SNP TSC0006025.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 340794; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2226 AGTTACATGTTT 2237
 DB 12 AGTTTAATGTTT 1

RESULT 451
 ABH90835
 ID ABH90835 standard; DNA; 12 BP.
 AC ABH90835;
 XX
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 290828 for detecting SNP TSC0014532.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 290828; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
 Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2221 CCAAAAGTTTACA 2232
 DB 1 CCAAAATTTAA 12

RESULT 452
 ABI52092/c
 ID ABI52092 standard; DNA; 12 BP.
 AC ABI52092;
 XX
 XX
 DT 22-FEB-2002 (first entry)
 XX

QY 2222 CAAAAGTTTACAT 2233
 DB 12 CAAAATTACTT 1

RESULT 453
 ABI57321
 ID ABI57321 standard; DNA; 12 BP.
 AC ABI57321;
 XX
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 357294 for detecting SNP TSC0050547.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX

PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 357294; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 4 A; 0 C; 3 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
OY 2226 AGTTACATGTT 2237
Db 1 AGTTAAATGTT 12
XX
RESULT 454
ABI62405
ID ABI62405 standard; DNA; 12 BP.
XX
XX ABI62405;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 362378 for detecting SNP TSC0053191.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

XX
PS Claim 1; SEQ ID NO 362378; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 6 A; 0 C; 1 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
OY 2224 AAAGTTACATGTT 2235
Db 1 AAAGTTATATAT 12
XX
RESULT 455
ABH71095/c
ID ABH71095 standard; DNA; 12 BP.
XX
XX ABH71095;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 271072 for detecting SNP TSC0002388.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 271072; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 2 A; 0 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2222 CAAAAGTTACAT 2233
 Db 12 CAAAAGTTACAT 1
 ||||| |||||

RESULT 456
 AB100641
 ID AB100641 standard; DNA; 12 BP.
 XX
 AC AB100641;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 300614 for detecting SNP TSC0019116.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 PI WPI; 2001-657177/75.
 XX
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT
 XX Claim 1; SEQ ID NO 300614; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 PS Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2220 ACCAAAGTTAC 2231
 Db 1 AACAAAGTTAC 12
 ||||| |||||

RESULT 458
 AB106822
 ID AB106822 standard; DNA; 12 BP.
 XX
 AC AB106822;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 306795 for detecting SNP TSC0022172.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;


```
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 306795; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
XX
XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 2226 AGTTACATGTTT 2237
DB 1 AGTTATTGTTT 12
|||||
RESULT 459
ABI35155
ID ABI35155 standard; DNA; 12 BP.
XX
AC ABI35155;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 335128 for detecting SNP TSC0038616.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
```

```
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 335128; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 2 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 2226 AGTTACATGTTT 2237
DB 1 AGTTATTGTTT 12
|||||
RESULT 460
ABI10551
ID ABI10551 standard; DNA; 12 BP.
XX
AC ABI10551;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 310524 for detecting SNP TSC0024021.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 310524; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
```

CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2226 AGTTACATGTTT 2237
 Db 1 AGATATATGTTT 12
 |||||

RESULT 461
 ABH89652
 ID ABH89652 standard; DNA; 12 BP.
 AC ABH89652;
 XX
 DT 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 289645 for detecting SNP TSC0014029.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 FN
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 289645; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 7 A; 3 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2220 ACCAAGTCTTAC 2231
 Db 1 AACAAACTTAC 12
 |||||

RESULT 462
 ABI50659
 ID ABI50659 standard; DNA; 12 BP.
 XX
 AC ABI50659;
 XX
 DT 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 350632 for detecting SNP TSC0046788.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 FN
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 350632; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2225 AAGTACATGTTT 2236
 Db 1 AAGTATTGTTT 12
 |||||

RESULT 463
 ABI54006/C
 ID ABI54006 standard; DNA; 12 BP.
 XX

```
AC ABI54006;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 353979 for detecting SNP TSC0048830.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 353979; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 7 A; 1 C; 0 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 2226 AGTTACATGTTT 2237
Db 12 AGTTAAATTTT 1
XX
RESULT 464
ABI70902
ID ABI70902 standard; DNA; 12 BP.
XX
AC ABI70902;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 370875 for detecting SNP TSC0058443.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
```

```
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 370875; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 3 A; 1 C; 3 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 2226 AGTTACATGTTT 2237
Db 1 AGTTACGTGATT 12
XX
RESULT 465
ABI62037
ID ABI62037 standard; DNA; 12 BP.
XX
AC ABI62037;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 362010 for detecting SNP TSC0052990.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
```

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 362010; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 7 A; 0 C; 3 G; 2 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2223 AAAAGTTACATG 2234

Db 1 AAAAGTTAAGG 12

RESULT 466

ABH93579
 ID ABH93579 standard; DNA; 12 BP.

AC ABH93579;

DT 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 293572 for detecting SNP TSC0015681.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 293572; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 7 A; 1 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2222 CAAAAGTTACAT 2233

Db 1 CAAAAGTTATAT 12

RESULT 467

ABH94835/C
 ID ABH94835 standard; DNA; 12 BP.

XX AC ABH94835;

XX 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 294828 for detecting SNP TSC0016298.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 294828; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 2 A; 0 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2222 CAAAAGTTACAT 2233

```

Db          ||||| |||||
            12 CAAACATACAT 1

RESULT 468
ID  ABI01273 standard; DNA; 12 BP.
AC  ABI01273;
XX
DT  22-FEB-2002 (first entry)
XX
DE  Oligonucleotide primer SEQ ID NO 301246 for detecting SNP TSC0019422.
XX
KW  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS  Homo sapiens.
XX
PN  WO200177384-A2.
XX
PD  18-OCT-2001.
XX
PF  Oligonucleotide primer SEQ ID NO 301246 for detecting SNP TSC0019422.
XX
PR  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
PI  Olek A, Piepenbrock C, Berlin K;
XX
WI  2001-657177/75.
XX
PT  Set of oligonucleotides, useful for diagnosis and cell typing, is
PT  designed to detect single-nucleotide polymorphisms and cytosine
PT  methylation status.
XX
PS  Claim 1; SEQ ID NO 301246; 29pp + Sequence Listing; German.
XX
CC  This invention describes novel oligonucleotide primers or peptide nucleic
CC  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC  and cytosine methylation status in chemically pretreated genomic DNA. The
CC  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC  range of diseases including immune system, gastrointestinal, respiratory,
CC  central nervous system, cardiovascular and metabolic disorders. The
CC  oligomers are also used for detecting cell type differentiation. ABC00010
CC  -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC  represent the oligomers described in the invention. NOTE: The sequence
CC  data for this patent did not form part of the printed specification, but
CC  was obtained in electronic format from WIPO at
CC  ftp.wipo.int/pub/published_pct_sequences
XX
SQ  Sequence 12 BP; 6 A; 0 C; 1 G; 5 T; 0 U; 0 Other;

Query Match      32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY  2223 AAAAGTTACATG 2234
    ||||| |||||
Db  1 AAAATTATATG 12

RESULT 469
ID  ABI30087 standard; DNA; 12 BP.
XX
AC  ABI30087;
XX
DT  22-FEB-2002 (first entry)
XX
DE  Oligonucleotide primer SEQ ID NO 330060 for detecting SNP TSC0035302.

```

```

XX
KW  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS  Homo sapiens.
XX
PN  WO200177384-A2.
XX
PD  18-OCT-2001.
XX
PF  06-APR-2001; 2001WO-IB000713.
XX
PR  07-APR-2000; 2000DE-01019173.
XX  (EPIG-) EPIGENOMICS AG.
XX
PI  Olek A, Piepenbrock C, Berlin K;
XX
WI  2001-657177/75.
XX
PT  Set of oligonucleotides, useful for diagnosis and cell typing, is
PT  designed to detect single-nucleotide polymorphisms and cytosine
PT  methylation status.
XX
PS  Claim 1; SEQ ID NO 330060; 29pp + Sequence Listing; German.
XX
CC  This invention describes novel oligonucleotide primers or peptide nucleic
CC  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC  and cytosine methylation status in chemically pretreated genomic DNA. The
CC  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC  range of diseases including immune system, gastrointestinal, respiratory,
CC  central nervous system, cardiovascular and metabolic disorders. The
CC  oligomers are also used for detecting cell type differentiation. ABC00010
CC  -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC  represent the oligomers described in the invention. NOTE: The sequence
CC  data for this patent did not form part of the printed specification, but
CC  was obtained in electronic format from WIPO at
CC  ftp.wipo.int/pub/published_pct_sequences
XX
SQ  Sequence 12 BP; 6 A; 2 C; 0 G; 4 T; 0 U; 0 Other;

Query Match      32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY  2222 CAAAAGTTACAT 2233
    ||||| |||||
Db  1 CAATAATTACAT 12

RESULT 470
ID  ABH88743 standard; DNA; 12 BP.
XX
AC  ABH88743;
XX
DT  22-FEB-2002 (first entry)
XX
DE  Oligonucleotide primer SEQ ID NO 288736 for detecting SNP TSC0013650.
XX
KW  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS  Homo sapiens.
XX
PN  WO200177384-A2.
XX
PD  18-OCT-2001.
XX
PF  06-APR-2001; 2001WO-IB000713.
XX

```

```

PR 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 289736; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2226 AGTTACATGTTT 2237
DB 1 AGTTTATGTTT 12
|||||
RESULT 471
ABH90387/C
ID ABH90387 standard; DNA; 12 BP.
XX AC ABH90387;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 290380 for detecting SNP TSC0014328.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX DE Oligonucleotide primer SEQ ID NO 290380 for detecting SNP TSC0014328.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 290380; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2221 CCAAAAGCTTACA 2232
DB 12 CCTAAATTTACA 1
|||||
RESULT 472
ABI43598/C
ID ABI43598 standard; DNA; 12 BP.
XX AC ABI43598;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 343571 for detecting SNP TSC0010300.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 343571; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

```

```
XX SQ Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2221 CCAGAAAGTTTACA 2232
DB 12 CTAAAAATTACA 1

RESULT 473
ABI48638/C
ID ABI48638 standard; DNA; 12 BP.
XX AC
XX ABH70189;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 270166 for detecting SNP TSC00020256.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 270166; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 2 A; 0 C; 5 G; 5 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2227 GTTACATGTTTG 2238
DB 1 GTTACATGTTTG 12

RESULT 475
ABI33966
ID ABI33966 standard; DNA; 12 BP.
XX AC ABI33966;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 333939 for detecting SNP TSC0037852.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
```

```

OS Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 336771; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 12 BP; 1 A; 0 C; 4 G; 7 T; 0 U; 0 Other;
XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 2227 GTTACATGTTTG 2238
XX ||||| |||||
XX 1 GTTATGTTTG 12
XX
XX RESULT 476
XX ABI36798
XX ID ABI36798 standard; DNA; 12 BP.
XX AC ABI36798;
XX XX
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 336771 for detecting SNP TSC0039515.
XX XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX XX
XX OS Homo sapiens.
XX XX
XX PN WO200177384-A2.
XX XX
XX PD 18-OCT-2001.
XX XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX XX
XX PR 07-APR-2000; 2000DE-01019173.
XX XX
XX PA (EPIG-) EPIGENOMICS AG.
XX XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX XX
XX DR WPI; 2001-657177/75.
XX XX
XX XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX XX
XX PS Claim 1; SEQ ID NO 336771; 29pp + Sequence Listing; German.
XX XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX CC
XX SQ Sequence 12 BP; 1 A; 0 C; 4 G; 7 T; 0 U; 0 Other;
XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 2227 GTTACATGTTTG 2238
XX ||||| |||||
XX 1 GTTATGTTTG 12
XX
XX RESULT 477
XX ABI48139/c
XX ID ABI48139 standard; DNA; 12 BP.
XX AC ABI48139;
XX XX
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 348112 for detecting SNP TSC0045447.
XX XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX XX
XX OS Homo sapiens.
XX XX
XX PN WO200177384-A2.
XX XX
XX PD 18-OCT-2001.
XX XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX XX
XX PR 07-APR-2000; 2000DE-01019173.
XX XX
XX PA (EPIG-) EPIGENOMICS AG.
XX XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX XX
XX DR WPI; 2001-657177/75.
XX XX
XX XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX XX
XX PS Claim 1; SEQ ID NO 348112; 29pp + Sequence Listing; German.
XX XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX CC
XX SQ Sequence 12 BP; 1 A; 0 C; 4 G; 7 T; 0 U; 0 Other;
XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 2227 GTTACATGTTTG 2238
XX ||||| |||||
XX 1 GTTATGTTTG 12
XX
XX RESULT 478
XX ABI36798
XX ID ABI36798 standard; DNA; 12 BP.
XX AC ABI36798;
XX XX
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 336771 for detecting SNP TSC0039515.
XX XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX XX
XX OS Homo sapiens.
XX XX
XX PN WO200177384-A2.
XX XX
XX PD 18-OCT-2001.
XX XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX XX
XX PR 07-APR-2000; 2000DE-01019173.
XX XX
XX PA (EPIG-) EPIGENOMICS AG.
XX XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX XX

```


CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 4 A; 0 C; 1 G; 7 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2224 AAGTTACATGT 2235
 |||||
 Db 12 AAAATTACATAT 1

RESULT 478

ABI171978
 ID ABI171978 standard; DNA; 12 BP.
 XX
 AC ABI171978;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 371951 for detecting SNP TSC0059080.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.

PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX

PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 371951; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

SQ Sequence 12 BP; 6 A; 3 C; 0 G; 3 T; 0 U; 0 Other;
 Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;

Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2222 CAAAAGTTTACAT 2233
 |||||
 Db 1 CAAAATTTCCAT 12

RESULT 479

ABI73808/C
 ID ABI73808 standard; DNA; 12 BP.
 XX
 AC ABI73808;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 373781 for detecting SNP TSC0060316.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.

PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX

PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 373781; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

SQ Sequence 12 BP; 2 A; 0 C; 4 G; 6 T; 0 U; 0 Other;
 Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2220 ACCAAAAGTTTAC 2231
 |||||
 Db 12 ACCAAAATTCAC 1

RESULT 480

ABI60517
 ID ABI60517 standard; DNA; 12 BP.
 XX
 AC ABI60517;
 XX

DT 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 360490 for detecting SNP TSC0006625.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 EN
 XX 18-OCT-2001.
 PD
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT
 XX Claim 1; SEQ ID NO 360490; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 7 A; 4 C; 0 G; 1 T; 0 U; 0 Other;
 SQ
 CC Query Match 32.6%; Score 8.8; DB 1; Length 12;
 CC Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 CC Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2220 ACCAAAAGTTAC 2231
 DB 1 ACCAAAAGTTAC 12
 RESULT 481
 ABI81509
 ID ABI81509 standard; DNA; 12 BP.
 XX
 XX ABI81509;
 AC
 XX 22-FEB-2002 (first entry)
 DT
 XX Oligonucleotide primer SEQ ID NO 381482 for detecting SNP TSC0064387.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 EN
 XX 18-OCT-2001.
 PD
 XX

XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT
 XX Claim 1; SEQ ID NO 381482; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
 SQ
 CC Query Match 32.6%; Score 8.8; DB 1; Length 12;
 CC Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 CC Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2221 CCAAAAAGTTACA 2232
 DB 1 CAAAAAATTACA 12
 RESULT 482
 ABH97913
 ID ABH97913 standard; DNA; 12 BP.
 XX
 XX ABH97913;
 AC
 XX 22-FEB-2002 (first entry)
 DT
 XX Oligonucleotide primer SEQ ID NO 297906 for detecting SNP TSC0017825.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 EN
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT

methylation status.

PT
XX
PS
PP
XX

Claim 1; SEQ ID NO 297906; 29pp + Sequence Listing; German.

This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010-ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2222 CAAGTGTACAT 2233
DB 1 CAATTTCAT 12

RESULT 483
ABI23994
ID ABI23994 standard; DNA; 12 BP.
XX
XX ABI23994;
XX
XX
DT 22-FEB-2002 (first entry)
DE Oligonucleotide primer SEQ ID NO 32367 for detecting SNP TSC0031695.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX WO200177384-A2.
PN
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
PP
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIG-) EPIGENOMICS AG.
PA Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
DR WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PP 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.
XX
PS Claim 1; SEQ ID NO 323967; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010-ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2222 CAAGTGTACAT 2233
DB 1 CAATTTCAT 12

RESULT 483
ABI23994
ID ABI23994 standard; DNA; 12 BP.
XX
XX ABI23994;
XX
XX
DT 22-FEB-2002 (first entry)
DE Oligonucleotide primer SEQ ID NO 32367 for detecting SNP TSC0031695.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX WO200177384-A2.
PN
PD 18-OCT-2001.
XX
PP 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.
XX
PS Claim 1; SEQ ID NO 323967; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010-ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2222 CAAGTGTACAT 2233
DB 1 CAATTTCAT 12

RESULT 483
ABI23994
ID ABI23994 standard; DNA; 12 BP.
XX
XX ABI23994;
XX
XX
DT 22-FEB-2002 (first entry)
DE Oligonucleotide primer SEQ ID NO 32367 for detecting SNP TSC0031695.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX WO200177384-A2.
PN
PD 18-OCT-2001.
XX
PP 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.
XX
PS Claim 1; SEQ ID NO 323967; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010-ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2222 CAAGTGTACAT 2233
DB 1 CAATTTCAT 12

RESULT 483
ABI23994
ID ABI23994 standard; DNA; 12 BP.
XX
XX ABI23994;
XX
XX
DT 22-FEB-2002 (first entry)
DE Oligonucleotide primer SEQ ID NO 32367 for detecting SNP TSC0031695.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX WO200177384-A2.
PN
PD 18-OCT-2001.
XX
PP 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.
XX
PS Claim 1; SEQ ID NO 323967; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010-ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2222 CAAGTGTACAT 2233
DB 1 CAATTTCAT 12

RESULT 483
ABI23994
ID ABI23994 standard; DNA; 12 BP.
XX
XX ABI23994;
XX
XX
DT 22-FEB-2002 (first entry)
DE Oligonucleotide primer SEQ ID NO 32367 for detecting SNP TSC0031695.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX WO200177384-A2.
PN
PD 18-OCT-2001.
XX
PP 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.
XX
PS Claim 1; SEQ ID NO 323967; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010-ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels

```

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB0000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 274950; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 5 A; 4 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 2227 GTTACATGTTTG 2238
XX Db 12 GTTAGAGTTAG 1
XX
XX RESULT 486
XX ABH76558/c
XX ID ABH76558 standard; DNA; 12 BP.
XX
XX AC ABH76558;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 274950 for detecting SNP TSC0004222.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB0000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 274950; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 5 A; 4 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 2227 GTTACATGTTTG 2238
XX Db 12 GTTAGAGTTAG 1
XX
XX RESULT 486
XX ABH76558/c
XX ID ABH76558 standard; DNA; 12 BP.
XX
XX AC ABH76558;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 274951 for detecting SNP TSC0004222.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

```

```

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB0000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 276551; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 4 A; 3 C; 0 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 2225 AAGTTACATGTT 2236
XX Db 12 AAGTTAAAGTT 1
XX
XX RESULT 487
XX AB108258
XX ID AB108258 standard; DNA; 12 BP.
XX
XX AC AB108258;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 308231 for detecting SNP TSC0022918.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB0000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX

```

PA (EPIG-) EPIGENOMICS AG.
 PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 308231; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 2 A; 0 C; 4 G; 6 T; 0 U; 0 Other;
 XX
 Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 QY 2227 GTTACATGTTTG 2238
 DB 1 GTTATAGTTTG 12
 XX
 RESULT 488
 ABH8907
 ID ABH8907 standard; DNA; 12 BP.
 XX
 AC ABH8907;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 288900 for detecting SNP TSC0013725.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 288900; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
 XX
 Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 QY 2222 CAAAAGTTTACAT 2233
 DB 1 CAAAATAATACAT 12
 XX
 RESULT 489
 ABI47584
 ID ABI47584 standard; DNA; 12 BP.
 XX
 AC ABI47584;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 347557 for detecting SNP TSC0045161.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 347557; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 5 A; 2 C; 0 G; 5 T; 0 U; 0 Other;

```

Query Match          32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2218 TGACCAAAAGTT 2229
Db 1 TTACCAAAATTT 12
|||||
|

RESULT 490
ABI53872/c
ID ABI53872 standard; DNA; 12 BP.
XX AC ABI53872;
XX DE 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 353845 for detecting SNP TSC0048761.
XX DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX DE peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX DE central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 353845; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABT00010-ABT82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 5 A; 2 C; 0 G; 5 T; 0 U; 0 Other;
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABT00010-ABT82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 5 A; 2 C; 0 G; 5 T; 0 U; 0 Other;

Query Match          32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2225 AGTTACATGTT 2236
Db 12 AGTTATAGTT 1
|||||
|

RESULT 491
ABI68385
ID ABI68385 standard; DNA; 12 BP.
XX AC ABI68385;
XX DE 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 356192 for detecting SNP TSC0050005.
XX DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX DE peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX DE central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.

```

```

XX AC ABI68385;
XX DE 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 368358 for detecting SNP TSC0050955.
XX DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX DE peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX DE central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 368358; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABT00010-ABT82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 7 A; 4 C; 0 G; 1 T; 0 U; 0 Other;
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABT00010-ABT82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 7 A; 4 C; 0 G; 1 T; 0 U; 0 Other;
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABT00010-ABT82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 7 A; 4 C; 0 G; 1 T; 0 U; 0 Other;

Query Match          32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2221 CCAAAAGTTACA 2232
Db 1 CCAAAATCACA 12
|||||
|

RESULT 492
ABI56219/c
ID ABI56219 standard; DNA; 12 BP.
XX AC ABI56219;
XX DE 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 356192 for detecting SNP TSC0050005.
XX DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX DE peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX DE central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.

```

```

XX WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX DR WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX
XX PS Claim 1; SEQ ID NO 361515; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI0010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 12 BP; 2 A; 1 C; 1 G; 8 T; 0 U; 0 Other;
XX
XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 2219 GACCAAAAGTTA 2230
XX DB 12 GAACAAAATTA 1
XX
XX RESULT 493
XX ABI61542
XX ID ABI61542 standard; DNA; 12 BP.
XX
XX AC ABI61542;
XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide primer SEQ ID NO 361515 for detecting SNP TSC0052678.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX DR WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX
XX PS Claim 1; SEQ ID NO 361515; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI0010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 12 BP; 2 A; 1 C; 1 G; 8 T; 0 U; 0 Other;
XX
XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 2219 GACCAAAAGTTA 2230
XX DB 12 GAACAAAATTA 1
XX
XX RESULT 493
XX ABI61542
XX ID ABI61542 standard; DNA; 12 BP.
XX
XX AC ABI61542;
XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide primer SEQ ID NO 361515 for detecting SNP TSC0052678.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX DR WPI; 2001-657177/75.
XX
```

```

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX
XX PS Claim 1; SEQ ID NO 361515; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 12 BP; 5 A; 0 C; 1 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 2224 AAAGTTACATGT 2235
XX DB 1 AAATTTATATGT 12
XX
XX RESULT 494
XX ABI20408/C
XX ID ABI20408 standard; DNA; 12 BP.
XX
XX AC ABI20408;
XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide primer SEQ ID NO 320381 for detecting SNP TSC0029678.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX DR WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX
XX PS Claim 1; SEQ ID NO 320381; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
```

CC Oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2222 CAAGTACAT 2233
 Db 12 CAAGTACAT 1

RESULT 495
 ABH85618/C
 ID ABH85618 standard; DNA; 12 BP.
 XX
 AC ABH85618;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 285611 for detecting SNP TSC0012377.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.

XX WO200177384-A2.
 XX
 PD 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 285611; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 7 A; 1 C; 0 G; 4 T; 0 U; 0 Other;
 Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2225 AAGTACATGTT 2236
 Db 12 AAGTATATTTT 1

RESULT 496
 ABI10848/C
 ID ABI10848 standard; DNA; 12 BP.
 XX
 AC ABI10848;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 310821 for detecting SNP TSC0024131.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.

XX WO200177384-A2.
 XX
 PD 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 310821; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 5 A; 4 C; 0 G; 3 T; 0 U; 0 Other;
 Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2226 AGTACATGTTT 2237
 Db 12 AGTGAGATGTTT 1

RESULT 497
 ABH86904/C
 ID ABH86904 standard; DNA; 12 BP.
 XX
 AC ABH86904;
 XX
 DT 22-FEB-2002 (first entry)
 XX


```

DE Oligonucleotide primer SEQ ID NO 286897 for detecting SNP TSC0012870.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 286897; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 4 A; 0 C; 3 G; 5 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2222 CAAAGCTTACAT 2233
DB 12 CATACTTACAT 1
RESULT 498
ABI37828
ID ABI37828 standard; DNA; 12 BP.
XX
AC ABI37828;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 337801 for detecting SNP TSC0040080.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.

```

```

XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 337801; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 8 A; 2 C; 1 G; 1 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2219 GACCAAAAGTTA 2230
DB 1 GACCAAAATATA 12
RESULT 499
ABH91107/c
ID ABH91107 standard; DNA; 12 BP.
XX
AC ABH91107;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 291100 for detecting SNP TSC0014633.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX

```

PS Claim 1; SEQ ID NO 291100; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 1 A; 0 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2220 ACCAAAGTTAC 2231

Db 12 ACCAAAGTTAC 1

RESULT 500

ABI46624/C
 ID ABI46624 standard; DNA; 12 BP.

AC ABI46624;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 346597 for detecting SNP TSC0044666.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 346597; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 12 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2222 CAAAAGTTACAT 2233

Db 12 CAAAAGTTACAT 1

RESULT 501

ABI56299
 ID ABI56299 standard; DNA; 12 BP.

AC ABI56299;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 356272 for detecting SNP TSC0050039.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 356272; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 2 A; 0 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2227 GTTACATGTTG 2238

Db 1 GTTACATGTTG 12

RESULT 502
ABI59543
ID ABI59543 standard; DNA; 12 BP.
XX AC ABI59543;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 359516 for detecting SNP TSC0010776.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 359516; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 5 A; 3 C; 0 G; 4 T; 0 U; 0 Other;
XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 2220 ACCAAAGTTAC 2231
XX 1 ACCATAATTAC 12
XX
RESULT 503
ABI80453/C
ID ABI80453 standard; DNA; 12 BP.
XX AC ABI80453;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 380426 for detecting SNP TSC0063819.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 380426; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 5 A; 3 C; 0 G; 4 T; 0 U; 0 Other;
XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 2220 ACCAAAGTTAC 2231
XX 1 ACCATAATTAC 12
XX
RESULT 504
ABH68117
ID ABH68117 standard; DNA; 12 BP.
XX AC ABH68117;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 268094 for detecting SNP TSC0000870.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 380426; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 3 A; 1 C; 2 G; 6 T; 0 U; 0 Other;
XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 2219 GACCAAAAGTTA 2230
XX 12 GACCATTAATTA 1
XX
RESULT 504
ABH68117
ID ABH68117 standard; DNA; 12 BP.
XX AC ABH68117;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 268094 for detecting SNP TSC0000870.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 380426; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 3 A; 1 C; 2 G; 6 T; 0 U; 0 Other;
XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 2219 GACCAAAAGTTA 2230
XX 12 GACCATTAATTA 1
XX

PI Olek A, Piepenbrock C, Berlin K;
 DR WPI; 2001-657177/75.
 XX
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX
 PS Claim 1; SEQ ID NO 268094; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT99989
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 6 A; 1 C; 0 G; 5 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2222 CAAAAGTTACAT 2233
 DB 1 CAAAATTATAT 12
 ||||| |||||

RESULT 505
 ABH73023/C
 ID ABH73023 standard; DNA; 12 BP.
 XX
 AC ABH73023;
 XX
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 273008 for detecting SNP TSC0003011.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX
 PS Claim 1; SEQ ID NO 273008; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT99989
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 6 A; 2 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2225 AAGTTACATGTT 2236
 DB 12 AATTAGATGTT 1
 ||||| |||||

RESULT 506
 ABH83888/C
 ID ABH83888 standard; DNA; 12 BP.
 XX
 AC ABH83888;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 283981 for detecting SNP TSC0011547.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX
 PS Claim 1; SEQ ID NO 283981; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT99989
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 4 A; 1 C; 0 G; 7 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;

```
Best Local Similarity 83.3%; Pred. No. 2.7e+02; Indels 0; Gaps 0;
Matches 10; Conservative 0; Mismatches 2;

QY 2223 AAAAGTTACATG 2234
Db 12 AAAAATTATATG 1

RESULT 507
ABH90635/c
ID ABH90635 standard; DNA; 12 BP.
XX AC ABH90635;
XX
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 290628 for detecting SNP TSC0014446.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 290628; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
XX
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2226 AGTTACATGTTT 2237
Db 12 AGTATTATGTTT 1

RESULT 508
ABH91770/c
ID ABH91770 standard; DNA; 12 BP.
XX AC ABH91770;
XX
```

```
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 291763 for detecting SNP TSC0014924.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 291763; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 5 A; 2 C; 0 G; 5 T; 0 U; 0 Other;
XX
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2225 AAGTTACATGTT 2236
Db 12 AAGTATTATGTT 1

RESULT 509
ABI60352
ID ABI60352 standard; DNA; 12 BP.
XX AC ABI60352;
XX
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 360325 for detecting SNP TSC0006977.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
```


CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2220 ACCAAAGTTAC 2231

DB 1 ACAAATAATTAC 12

RESULT 512

ABI65524/C
ID ABI65524 standard; DNA; 12 BP.

XX AC ABI65524;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 365497 for detecting SNP TSC0055166.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX XX 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX XX WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.

XX PS Claim 1; SEQ ID NO 365497; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010

XX CC -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 7 A; 3 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2227 GTTACATGTTG 2238

|||||

DB 12 GTTAAATGTTG 1

RESULT 513

ABI65731
ID ABI65731 standard; DNA; 12 BP.

XX AC ABI65731;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 365704 for detecting SNP TSC0055288.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX XX 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX XX WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.

XX PS Claim 1; SEQ ID NO 365704; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 4 A; 0 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2224 AAAGTTACATGT 2235

DB 1 AAAGTTACATGT 12

RESULT 514

ABH77539
ID ABH77539 standard; DNA; 12 BP.

XX AC ABH77539;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 277532 for detecting SNP TSC0004498.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 8 A; 1 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 2226 AGTTACATGTTT 2237
Db 12 ATTTATGTTT 1
RESULT 517
ABI48414/C
ID ABI48414 standard; DNA; 12 BP.
XX
AC ABI48414;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 348387 for detecting SNP TSC0045573.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 348387; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

SQ Sequence 12 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 2227 GTTACATGTTTG 2238
Db 12 GTTTATGTTT 1
RESULT 518
ABI73304/C
ID ABI73304 standard; DNA; 12 BP.
XX
AC ABI73304;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 373277 for detecting SNP TSC0059941.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 373277; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 2222 CAAAAGTTACAT 2233
Db 12 CAAACATTACAT 1
RESULT 519
ABI74430

```

ID  ABI74430 standard; DNA; 12 BP.
XX  AC
XX  ABI74430;
DT  22-FEB-2002 (first entry)
XX  DE
XX  Oligonucleotide primer SEQ ID NO 374403 for detecting SNP TSC0060671.
XX  KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX  KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX  KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX  OS Homo sapiens.
XX  PN WO200177384-A2.
XX  PD 18-OCT-2001.
XX  PF 06-APR-2001; 2001WO-IB000713.
XX  PR 07-APR-2000; 2000DE-01019173.
XX  PA (EPG-) EPIGENOMICS AG.
XX  PI Olek A, Piepenbrock C, Berlin K;
XX  DR WPI; 2001-657177/75.
XX  PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX  PT designed to detect single-nucleotide polymorphisms and cytosine
XX  PT methylation status.
XX  PS Claim 1; SEQ ID NO 374403; 29pp + Sequence Listing; German.
XX  CC This invention describes novel oligonucleotide primers or peptide nucleic
XX  CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX  CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX  CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX  CC range of diseases including immune system, gastrointestinal, respiratory,
XX  CC central nervous system, cardiovascular and metabolic disorders. The
XX  CC oligomers are also used for detecting cell type differentiation. ABC00010
XX  CC -ABC99889, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX  CC represent the oligomers described in the invention. NOTE: The sequence
XX  CC data for this patent did not form part of the printed specification, but
XX  CC was obtained in electronic format from WIPO at
XX  CC ftp.wipo.int/pub/published_pct_sequences
XX  SQ Sequence 12 BP; 6 A; 0 C; 1 G; 5 T; 0 U; 0 Other;
XX  CC This invention describes novel oligonucleotide primers or peptide nucleic
XX  CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX  CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX  CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX  CC range of diseases including immune system, gastrointestinal, respiratory,
XX  CC central nervous system, cardiovascular and metabolic disorders. The
XX  CC oligomers are also used for detecting cell type differentiation. ABC00010
XX  CC -ABC99889, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX  CC represent the oligomers described in the invention. NOTE: The sequence
XX  CC data for this patent did not form part of the printed specification, but
XX  CC was obtained in electronic format from WIPO at
XX  CC ftp.wipo.int/pub/published_pct_sequences
XX  SQ Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX  Best Local Similarity 83.3%; Pred. No. 2.7e+02;
XX  Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX  OY 2224 AAAGTTACATCT 2235
XX  DB 1 AAATTTAAATCT 12
XX  RESULT 520
XX  ABH77088/c
XX  ID ABH77088 standard; DNA; 12 BP.
XX  AC ABH77088;
XX  DT 22-FEB-2002 (first entry)
XX  DE Oligonucleotide primer SEQ ID NO 277081 for detecting SNP TSC0004378.
XX  KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX  KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX  KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX  OS Homo sapiens.

```

```

XX  WO200177384-A2.
XX  PN 18-OCT-2001.
XX  PD 06-APR-2001; 2001WO-IB000713.
XX  PF 07-APR-2000; 2000DE-01019173.
XX  PR (EPG-) EPIGENOMICS AG.
XX  PA Olek A, Piepenbrock C, Berlin K;
XX  PI WPI; 2001-657177/75.
XX  DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX  DR designed to detect single-nucleotide polymorphisms and cytosine
XX  DR methylation status.
XX  PS Claim 1; SEQ ID NO 277081; 29pp + Sequence Listing; German.
XX  CC This invention describes novel oligonucleotide primers or peptide nucleic
XX  CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX  CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX  CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX  CC range of diseases including immune system, gastrointestinal, respiratory,
XX  CC central nervous system, cardiovascular and metabolic disorders. The
XX  CC oligomers are also used for detecting cell type differentiation. ABC00010
XX  CC -ABC99889, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX  CC represent the oligomers described in the invention. NOTE: The sequence
XX  CC data for this patent did not form part of the printed specification, but
XX  CC was obtained in electronic format from WIPO at
XX  CC ftp.wipo.int/pub/published_pct_sequences
XX  SQ Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
XX  CC Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX  CC Best Local Similarity 83.3%; Pred. No. 2.7e+02;
XX  CC Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX  OY 2221 CCAAAAGTTACA 2232
XX  DB 12 CTAATAACTTACA 1
XX  RESULT 521
XX  AB103021
XX  ID AB103021 standard; DNA; 12 BP.
XX  AC AB103021;
XX  DT 22-FEB-2002 (first entry)
XX  DE Oligonucleotide primer SEQ ID NO 302994 for detecting SNP TSC0020264.
XX  KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX  KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX  KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX  OS Homo sapiens.
XX  PN WO200177384-A2.
XX  PD 18-OCT-2001.
XX  PF 06-APR-2001; 2001WO-IB000713.
XX  PR 07-APR-2000; 2000DE-01019173.
XX  PA (EPG-) EPIGENOMICS AG.
XX  PI Olek A, Piepenbrock C, Berlin K;
XX  OS

```

DR WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 302994; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
XX
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
C
Qy 2225 AAGTTACATGTT 2236
Db 1 AAGTTAGTTGTT 12
|||||
RESULT 522
ABH81621/c
ID ABH81621 standard; DNA; 12 BP.
XX
AC ABH81621;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 281614 for detecting SNP TSC0009939.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 281614 for detecting SNP TSC0009939.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 281614; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 7 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
XX
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
C
Qy 2226 AGTTACATGTTT 2237
Db 12 AGTTATGTTT 1
|||||
RESULT 523
ABH82934/c
ID ABH82934 standard; DNA; 12 BP.
XX
AC ABH82934;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 282927 for detecting SNP TSC0011060.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
DT 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 282927; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
XX
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2221 CCAAAAGTTTACA 2232
 DB 12 CCAAAATTTAA 1

RESULT 524
 ABI09379/c
 ID ABI09379 standard; DNA; 12 BP.
 XX
 AC ABI09379;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 309352 for detecting SNP TSC0023494.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 FN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 309352; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 4 A; 0 C; 3 G; 5 T; 0 U; 0 Other;
 XX
 CC Query Match 32.6%; Score 8.8; DB 1; Length 12;
 CC Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 CC Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 QY 2220 ACCAAAGTTTAC 2231
 DB 12 ACCAAATTTTC 1

RESULT 525
 ABI13600/c
 ID ABI13600 standard; DNA; 12 BP.
 XX
 AC ABI13600;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 291456 for detecting SNP TSC0014801.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 FN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 309352; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 4 A; 0 C; 3 G; 5 T; 0 U; 0 Other;
 XX
 CC Query Match 32.6%; Score 8.8; DB 1; Length 12;
 CC Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 CC Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX

XX Oligonucleotide primer SEQ ID NO 313573 for detecting SNP TSC0025845.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 FN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 313573; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 5 A; 4 C; 1 G; 2 T; 0 U; 0 Other;
 XX
 CC Query Match 32.6%; Score 8.8; DB 1; Length 12;
 CC Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 CC Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 QY 2225 AGTTTACATGTT 2236
 DB 12 AGTTTACGTTT 1

RESULT 526
 ABH91463
 ID ABH91463 standard; DNA; 12 BP.
 XX
 AC ABH91463;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 291456 for detecting SNP TSC0014801.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 FN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 313573; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 5 A; 4 C; 1 G; 2 T; 0 U; 0 Other;
 XX
 CC Query Match 32.6%; Score 8.8; DB 1; Length 12;
 CC Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 CC Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX

PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 291456; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
SQ
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2221 CCAAACTTACA 2232
DB 1 CTAATAATTACA 12
RESULT 527
ABH91653/C
ID ABH91653 standard; DNA; 12 BP.
XX
AC ABH91653;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 291456 for detecting SNP TSC0014871.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX

XX Claim 1; SEQ ID NO 291646; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 0 Other;
SQ
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2227 GTTACATCTTG 2238
DB 12 GTTATTCTTG 1
RESULT 528
ABI55743/C
ID ABI55743 standard; DNA; 12 BP.
XX
AC ABI55743;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 355716 for detecting SNP TSC0049786.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 355716; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

```
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 4 A; 3 C; 0 G; 5 T; 0 U; 0 Other;

Query Match      32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2223 AAAAGTTACATG 2234
    |||||
Db 12 AAAAGTTGATG 1

RESULT 529
ABI69810/C
ID ABI69810 standard; DNA; 12 BP.
XX
XX ABI69810;
AC
XX
XX
XX 22-FEB-2002 (first entry)
DE
DE Oligonucleotide primer SEQ ID NO 369783 for detecting SNP TSC0057823.
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX WO200177384-A2.
PN
XX
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 369783; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 6 A; 5 C; 0 G; 1 T; 0 U; 0 Other;

Query Match      32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2227 GTTACATGTTTG 2238
    |||||
Db 12 GTTAGGTTTG 1

RESULT 530
ABI70259
ID ABI70259 standard; DNA; 12 BP.
XX
XX ABI70259;
AC
XX
XX 22-FEB-2002 (first entry)
DE
DE Oligonucleotide primer SEQ ID NO 370232 for detecting SNP TSC0058063.
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX WO200177384-A2.
PN
XX
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 370232; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 5 A; 4 C; 0 G; 3 T; 0 U; 0 Other;

Query Match      32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2222 CAAAAGTTACAT 2233
    |||||
Db 1 CCAAACCTACAT 12

RESULT 531
ABI74416
ID ABI74416 standard; DNA; 12 BP.
XX
XX ABI74416;
AC
XX
XX 22-FEB-2002 (first entry)
DE
DE Oligonucleotide primer SEQ ID NO 374389 for detecting SNP TSC0060667.
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
```


CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

SQ Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2227 GTTACATGTTTG 2238
 Db 12 GTTATATTTTG 1

RESULT 534
 ABH70658
 ID ABH70658 standard; DNA; 12 BP.

XX AC ABH70658;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 270635 for detecting SNP TSC0002209.

XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 270635; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

SQ Sequence 12 BP; 7 A; 0 C; 2 G; 3 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2223 AAAAGTTACATG 2234
 Db 1 AAAAGATATATG 12

RESULT 535
 ABH99406

ID ABH99406 standard; DNA; 12 BP.

XX AC ABH99406;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 299399 for detecting SNP TSC0018556.

XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 299399; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

SQ Sequence 12 BP; 5 A; 0 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2225 AAGTTACATGTT 2236
 Db 1 AAGTAATATGTT 12

RESULT 536

ABH74790/C

ID ABH74790 standard; DNA; 12 BP.

XX

AC ABH74790;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 274775 for detecting SNP TSC0003672.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PF Claim 1; SEQ ID NO 274775; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 6 A; 0 C; 1 G; 5 T; 0 U; 0 Other;
 Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e-02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2225 AAGTTACATGTT 2236
 DB 12 AAATTACATTTT 1
 RESULT 537
 ABI25180
 ID ABI25180 standard; DNA; 12 BP.
 AC ABI25180;
 XX
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 325153 for detecting SNP TSC0032421.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.

XX 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PF Claim 1; SEQ ID NO 325153; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 7 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
 Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e-02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2221 CCACAAAGTTTACA 2232
 DB 1 CCAAAATTAACA 12
 RESULT 538
 ABI03377/C
 ID ABI03377 standard; DNA; 12 BP.
 AC ABI03377;
 XX
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 303350 for detecting SNP TSC0020448.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 303350; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 0 Other;

XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2222 CAAAGTTACAT 2233

DB 12 CATAAATTACAT 1

RESULT 539

ABH78775/c

ID ABH78775 standard; DNA; 12 BP.

AC ABH78775;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 278768 for detecting SNP TSC0006367.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 278768; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 4 A; 2 C; 0 G; 6 T; 0 U; 0 Other;

XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2224 AAAGTTACATGT 2235

DB 12 AAAGTTAGATAT 1

RESULT 540

ABI29999

ID ABI29999 standard; DNA; 12 BP.

AC ABI29999;

DT 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 329972 for detecting SNP TSC0035257.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 329972; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 6 A; 3 C; 0 G; 3 T; 0 U; 0 Other;

XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2222 CAAAGTTACAT 2233

```

Db      1 CAAAAATTACT 12
|||||
RESULT 541
ABI13012/C
ID      ABI13012 standard; DNA; 12 BP.
AC      ABI13012;
XX
DT      22-FEB-2002 (first entry)
XX
DE      Oligonucleotide primer SEQ ID NO 312985 for detecting SNP TSC0025413.
XX
KW      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
PN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX
DT      22-FEB-2002 (first entry)
XX
DE      Oligonucleotide primer SEQ ID NO 312985 for detecting SNP TSC0025413.
XX
KW      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
PN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX
DT      06-APR-2001; 2001WO-IB000713.
XX
DE      Oligonucleotide primer SEQ ID NO 312985; 29pp + Sequence Listing; German.
XX
KW      (EPIC-) EPIGENOMICS AG.
XX
PI      Olek A, Piepenbrock C, Berlin K;
XX
DR      WPI; 2001-657177/75.
XX
PT      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX
PS      Claim 1; SEQ ID NO 312985; 29pp + Sequence Listing; German.
XX
XX      This invention describes novel oligonucleotide primers or peptide nucleic
XX      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX      and cytosine methylation status in chemically pretreated genomic DNA. The
XX      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX      range of diseases including immune system, gastrointestinal, respiratory,
XX      central nervous system, cardiovascular and metabolic disorders. The
XX      oligomers are also used for detecting cell type differentiation. ABC00010
XX      -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX      represent the oligomers described in the invention. NOTE: The sequence
XX      data for this patent did not form part of the printed specification, but
XX      was obtained in electronic format from WIPO at
XX      ftp.wipo.int/pub/published_pct_sequences
XX
SQ      Sequence 12 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 0 Other;
XX
Query Match      32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY      2221 CCAAAAGTTACA 2232
DB      12 CTAAAAATTACA 1
|||||
RESULT 542
ABI66523/C
ID      ABI66523 standard; DNA; 12 BP.
XX
AC      ABI66523;
XX
DT      22-FEB-2002 (first entry)
XX
DE      Oligonucleotide primer SEQ ID NO 366496 for detecting SNP TSC0006059.
XX

```

```

XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
PN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX
DT      06-APR-2001; 2001WO-IB000713.
XX
DE      Oligonucleotide primer SEQ ID NO 312985; 29pp + Sequence Listing; German.
XX
KW      (EPIC-) EPIGENOMICS AG.
XX
PI      Olek A, Piepenbrock C, Berlin K;
XX
DR      WPI; 2001-657177/75.
XX
PT      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX
PS      Claim 1; SEQ ID NO 366496; 29pp + Sequence Listing; German.
XX
XX      This invention describes novel oligonucleotide primers or peptide nucleic
XX      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX      and cytosine methylation status in chemically pretreated genomic DNA. The
XX      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX      range of diseases including immune system, gastrointestinal, respiratory,
XX      central nervous system, cardiovascular and metabolic disorders. The
XX      oligomers are also used for detecting cell type differentiation. ABC00010
XX      -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX      represent the oligomers described in the invention. NOTE: The sequence
XX      data for this patent did not form part of the printed specification, but
XX      was obtained in electronic format from WIPO at
XX      ftp.wipo.int/pub/published_pct_sequences
XX
SQ      Sequence 12 BP; 5 A; 1 C; 0 G; 6 T; 0 U; 0 Other;
XX
Query Match      32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY      2225 AAGTTACATGTT 2236
DB      12 AAATTAATGTT 1
|||||
RESULT 543
ABI81819/C
ID      ABI81819 standard; DNA; 12 BP.
XX
AC      ABI81819;
XX
DT      22-FEB-2002 (first entry)
XX
DE      Oligonucleotide primer SEQ ID NO 381792 for detecting SNP TSC0064552.
XX
KW      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
PN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX
DT      06-APR-2001; 2001WO-IB000713.
XX

```



```
XX SQ Sequence 12 BP; 4 A; 0 C; 1 G; 7 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2226 AGTACATGTTT 2237
Db 1 ATTTAAATGTTT 12

RESULT 546
ABI33492/c
ID ABI33492 standard; DNA; 12 BP.
XX AC
XX ABI33492;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 333465 for detecting SNP TSC0037558.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 333465; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 5 A; 4 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2227 GTTACATGTTT 2238
Db 12 GTTAAATGTTG 1

RESULT 547
ABI33492/c
ID ABI33492 standard; DNA; 12 BP.
XX AC
XX ABI33492;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 333465 for detecting SNP TSC0037558.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 333465; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 5 A; 4 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2227 GTTACATGTTT 2238
Db 12 GTTAAATGTTG 1

RESULT 548
ABH86758/c
ID ABH86758 standard; DNA; 12 BP.
XX AC
XX ABH86758;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 286751 for detecting SNP TSC0012809.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 308916; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 7 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2227 GTTACATGTTT 2238
Db 12 GTTACATGTTT 1

RESULT 548
ABH86758/c
ID ABH86758 standard; DNA; 12 BP.
XX AC
XX ABH86758;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 286751 for detecting SNP TSC0012809.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 308916; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 7 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2227 GTTACATGTTT 2238
Db 12 GTTACATGTTT 1
```


CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF0010-ABF99989, ABH0010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 6 A; 4 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2227 GTTACATGTTG 2238
Db 12 GGTATAGTTG 1
|||||
|
RESULT 551
ABI50778/C
ID ABI50778 standard; DNA; 12 BP.
XX
AC ABI50778;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 350751 for detecting SNP TSC0046859.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.
XX
Claim 1; SEQ ID NO 350751; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation. ABC00010
-ABC99989, ABF0010-ABF99989, ABH0010-ABH99989 and AB100010-AB182073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 8 A; 1 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2226 AGTTACATGTTT 2237
Db 12 ACTTATATTTT 1
|||||
|
RESULT 552
ABI53415
ID ABI53415 standard; DNA; 12 BP.
XX
AC ABI53415;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 353388 for detecting SNP TSC0048496.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.
XX
Claim 1; SEQ ID NO 353388; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation. ABC00010
-ABC99989, ABF0010-ABF99989, ABH0010-ABH99989 and AB100010-AB182073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 6 A; 2 C; 1 G; 3 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2223 AAAAGTTACATG 2234
Db 1 AAAATTTACACG 12
|||||
|
RESULT 553
ABH93581
ID ABH93581 standard; DNA; 12 BP.
XX
AC ABH93581;
XX

```
DT 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 293574 for detecting SNP TSC0015683.
DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS
XX WO200177384-A2.
PN
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
FF
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 293574; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 0 Other;
SQ
XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2226 AGTTACATGTTT 2237
DB ||||| |||
DB 1 AGTTATATGATT 12
RESULT 554
ABH70836
ID ABH70836 standard; DNA; 12 BP.
AC
XX ABH70836;
XX
XX 22-FEB-2002 (first entry)
DT
XX Oligonucleotide primer SEQ ID NO 270813 for detecting SNP TSC0002288.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS
XX WO200177384-A2.
PN
XX 18-OCT-2001.
PD
XX
```

```
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 270813; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 7 A; 1 C; 0 G; 4 T; 0 U; 0 Other;
SQ
XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
XX Best Local Similarity 83.3%; Pred. No. 2.7e+02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2222 CAAAGATTACAT 2233
DB ||||| |||
DB 1 CAAATTTAAAT 12
RESULT 555
AB100546
ID AB100546 standard; DNA; 12 BP.
XX
XX AB100546;
XX
XX 22-FEB-2002 (first entry)
DT
XX Oligonucleotide primer SEQ ID NO 300519 for detecting SNP TSC0019073.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS
XX WO200177384-A2.
PN
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
FF
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT
```


PT methylation status.
 XX Claim 1; SEQ ID NO 300519; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 7 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
 SQ Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2222 CAAAGTACAT 2233
 DB 1 CAAACATACAT 12
 RESULT 556
 ABH79073/C
 ID ABH79073 standard; DNA; 12 BP.
 XX
 AC ABH79073;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 DE Oligonucleotide primer SEQ ID NO 279066 for detecting SNP TSC0006840.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 FN
 XX 18-OCT-2001.
 PD
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 PA
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS
 PS Claim 1; SEQ ID NO 279066; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
 SQ Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2227 GTTACATGTTTG 2238
 DB 12 GTTAAATTTTG 1
 RESULT 557
 ABI29888
 ID ABI29888 standard; DNA; 12 BP.
 XX
 AC ABI29888;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 DE Oligonucleotide primer SEQ ID NO 329861 for detecting SNP TSC0035200.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 FN
 XX 18-OCT-2001.
 PD
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 PA
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS
 PS Claim 1; SEQ ID NO 329861; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 7 A; 4 C; 0 G; 1 T; 0 U; 0 Other;
 SQ Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2220 ACCAAAGTTAC 2231
 DB 1 ACCAAACATAC 12

```

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
AC AB133246;
XX
XX 22-FEB-2002 (first entry)
DT
DE Oligonucleotide primer SEQ ID NO 333219 for detecting SNP TSC0037423.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX WO200177384-A2.
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 333219; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
SQ
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2218 TGACCAAAAGTT 2229
Dd 12 TAACCAAAAATT 1
XX
XX RESULT 559
XX AB137243/C
XX ID AB137243 standard; DNA; 12 BP.
XX AC AB137243;
XX
XX 22-FEB-2002 (first entry)
DT
DE Oligonucleotide primer SEQ ID NO 337216 for detecting SNP TSC0039739.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX WO200177384-A2.
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 333219; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
SQ
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2218 TGACCAAAAGTT 2229
Dd 12 TAACCAAAAATT 1
XX
XX RESULT 558
XX AB133246/C
XX ID AB133246 standard; DNA; 12 BP.
XX AC AB133246;
XX
XX 22-FEB-2002 (first entry)
DT
DE Oligonucleotide primer SEQ ID NO 333219 for detecting SNP TSC0037423.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX WO200177384-A2.
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 337216; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 2 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
SQ
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2222 CAAAAGTTACAT 2233
Dd 12 CAAAAGTTACAT 1
XX
XX RESULT 560
XX AB149693
XX ID AB149693 standard; DNA; 12 BP.
XX AC AB149693;
XX
XX 22-FEB-2002 (first entry)
DT
DE Oligonucleotide primer SEQ ID NO 349666 for detecting SNP TSC0046254.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX WO200177384-A2.
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX
```

```

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 337216; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 2 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
SQ
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2222 CAAAAGTTACAT 2233
Dd 12 CAAAAGTTACAT 1
XX
XX RESULT 560
XX AB149693
XX ID AB149693 standard; DNA; 12 BP.
XX AC AB149693;
XX
XX 22-FEB-2002 (first entry)
DT
DE Oligonucleotide primer SEQ ID NO 349666 for detecting SNP TSC0046254.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX WO200177384-A2.
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX
```

PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 349666; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 6 A; 0 C; 3 G; 3 T; 0 U; 0 Other;
XX

Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX

QY 2214 AGTGTGACCAAA 2225
Db 1 AGTGTGATAAA 12
|||||

RESULT 561
ABI74720
ID ABI74720 standard; DNA; 12 BP.
XX
AC ABI74720;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 374693 for detecting SNP TSC0060844.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 374693; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 5 A; 0 C; 4 G; 3 T; 0 U; 0 Other;
XX

Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX

QY 2217 GTGACCAAAAGT 2228
Db 1 GTGAGTAAAGT 12
|||||

RESULT 562
ABI62368
ID ABI62368 standard; DNA; 12 BP.
XX
AC ABI62368;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 362341 for detecting SNP TSC0053169.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 362341; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 6 A; 0 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2223 AAAAGTTACATG 2234
 Db 1 AGAAGTTAAATG 12
 |||||

RESULT 563
 ABI76317
 ID ABI76317 standard; DNA; 12 BP.
 AC
 XX
 XX ABI76317;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX
 XX Oligonucleotide primer SEQ ID NO 376290 for detecting SNP TSC0061715.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 FN
 XX
 XX 18-OCT-2001.
 PD
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPITG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS
 XX Claim 1; SEQ ID NO 376290; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 1 A; 0 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2227 GTTACATGTTG 2238
 Db 1 GTTATTGTTG 12
 |||||

RESULT 564
 ABI65421
 ID ABI65421 standard; DNA; 12 BP.
 AC
 XX
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX
 XX Oligonucleotide primer SEQ ID NO 279745 for detecting SNP TSC0007781.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 FN
 XX
 XX 18-OCT-2001.
 PD
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPITG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS
 XX Claim 1; SEQ ID NO 376290; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 1 A; 0 C; 3 G; 8 T; 0 U; 0 Other;

XX
 AC
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX
 XX Oligonucleotide primer SEQ ID NO 365394 for detecting SNP TSC005090.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 FN
 XX
 XX 18-OCT-2001.
 PD
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPITG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS
 XX Claim 1; SEQ ID NO 365394; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 5 A; 0 C; 1 G; 6 T; 0 U; 0 Other;

Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2225 AAGTTACATGTT 2236
 Db 1 AATTTAAATGTT 12
 |||||

RESULT 565
 ABH79752
 ID ABH79752 standard; DNA; 12 BP.
 AC
 XX
 XX ABH79752;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX
 XX Oligonucleotide primer SEQ ID NO 279745 for detecting SNP TSC0007781.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX

CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 7 A; 0 C; 3 G; 2 T; 0 U; 0 Other;
 Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2223 AAAAGTTACATG 2234
 DB 1 AAAAGATAGTG 12
 RESULT 568
 ABI02621
 ID ABI02621 standard; DNA; 12 BP.
 XX
 AC ABI02621;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 302594 for detecting SNP TSC0020074.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 302594; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 6 A; 2 C; 0 G; 4 T; 0 U; 0 Other;
 Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2222 CAAAAGTTACAT 2233
 DB 1 CAAAATTTTCAT 12
 RESULT 569
 ABH81997/C
 ID ABH81997 standard; DNA; 12 BP.
 XX
 AC ABH81997;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 281990 for detecting SNP TSC0010237.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 281990; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
 Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2221 CCAAAGTTACAT 2232
 DB 12 CCAATATTACA 1
 RESULT 570
 ABI08371
 ID ABI08371 standard; DNA; 12 BP.
 XX
 AC ABI08371;
 XX
 DT 22-FEB-2002 (first entry)
 XX

DE Oligonucleotide primer SEQ ID NO 308344 for detecting SNP TSC0022964.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 308344; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABIO0010-ABI92073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 1 A; 0 C; 4 G; 7 T; 0 U; 0 Other;
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABIO0010-ABI92073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2227 GTTACATGTTTG 2238
Db 1 GTTGTATGTTTG 12
RESULT 571
ABI09674
ID ABI09674 standard; DNA; 12 BP.
XX AC ABI09674;
XX 22-FEB-2002 (first entry)
DE Oligonucleotide primer SEQ ID NO 309647 for detecting SNP TSC0023602.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 308344; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABIO0010-ABI92073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2227 GTTACATGTTTG 2238
Db 1 GTTGTATGTTTG 12
RESULT 571
ABI09674
ID ABI09674 standard; DNA; 12 BP.
XX AC ABI09674;
XX 22-FEB-2002 (first entry)
DE Oligonucleotide primer SEQ ID NO 309647 for detecting SNP TSC0023602.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 309647; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABIO0010-ABI92073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
CC Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2220 ACCAAAAGTTAC 2231
Db 1 ACTAAAATTAC 12
RESULT 572
ABH87275/c
ID ABH87275 standard; DNA; 12 BP.
XX AC ABH87275;
XX 22-FEB-2002 (first entry)
DE Oligonucleotide primer SEQ ID NO 287268 for detecting SNP TSC0013021.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX

```
PS Claim 1; SEQ ID NO 287268; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 6 A; 2 C; 0 G; 4 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2226 AGTTACATGTTT 2237
DB 12 AGTTAAGTTT 1
RESULT 573
ABI47891/C
ID ABI47891 standard; DNA; 12 BP.
XX
AC ABI47891;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 347864 for detecting SNP TSC0045309.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.
XX
Claim 1; SEQ ID NO 347864; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligomers are also used for detecting cell type differentiation. ABC00010
-ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 5 A; 2 C; 0 G; 5 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2225 AGTTACATGTTT 2236
DB 12 AAGTTTATGTT 1
RESULT 574
ABI62180/C
ID ABI62180 standard; DNA; 12 BP.
XX
AC ABI62180;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 362153 for detecting SNP TSC0053039.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.
XX
Claim 1; SEQ ID NO 362153; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligomers are also used for detecting cell type differentiation. ABC00010
-ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 5 A; 2 C; 0 G; 5 T; 0 U; 0 Other;
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2223 AAAAGTTACATG 2234
DB 12 ATAAGTTATATG 1
```


RESULT 575
AB163029/c
ID AB163029 standard; DNA; 12 BP.
XX AC AB163029;
XX AC
XX 22-FEB-2002 (first entry)
DT
XX Oligonucleotide primer SEQ ID NO 363002 for detecting SNP TSC0053586.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
DE KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
PD
XX 06-APR-2001; 2001WO-IB000713.
XX PF
XX 07-APR-2000; 2000DE-01019173.
XX PR
XX (EPIC-) EPIGENOMICS AG.
XX PA
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
PT
XX Claim 1; SEQ ID NO 363002; 29pp + Sequence Listing; German.
PS
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
SQ
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2226 AGTTACATGTTT 2237
DB 12 ATTAGATGTTT 1
RESULT 576
ABX15954/c
ID ABX15954 standard; DNA; 12 BP.
XX AC ABX15954;
XX
XX 31-MAR-2003 (first entry)
DT
XX Antisense oligonucleotide for the E. coli acpP gene #4.
DE
XX AcpP; antisense; ss; protein nucleic acid; PNA; bacterial infection;
XX genetically modified micro-organism.
KW

OS Escherichia coli.
XX
XX Key Location/Qualifiers
FT modified_base 1
FT /*tag= a
FT /mod_base= OTHER
FT /note= "T is covalently linked to a Lysine residue"
XX
XX WO200279467-A2.
PN
XX 10-OCT-2002.
PD
XX 26-MAR-2002; 2002WO-DK000208.
XX PF
XX 29-MAR-2001; 2001DK-00000523.
XX PR
XX (UYKO-) UNIV KOENHAVNS.
XX PA
XX Nielsen PE, Good L;
XX FI
XX WPI; 2003-103273/09.
XX DR
XX Selecting genetically modified cells useful for isolation and industrial
XX growth of transformed organisms comprises treating the modified cells
XX with an antisense or antigen construct directed against the essential
XX gene X of the cells.
XX
XX Claim 24; Page 52; 92pp; English.
XX
XX The invention relates to selecting genetically modified cells comprising:
XX (a) modifying cells containing a growth essential gene X, with a vector
XX containing gene Y; and (b) treating the modified cells with an antisense
XX or antigen construct directed against the essential gene X of the cells
XX to obtain preferential growth of the modified cells over other non-
XX modified cells. Also included is a product manufactured fully or
XX partially by use of the new method. The method is useful for selecting
XX genetically modified cells and manufacturing a product. It is useful for
XX research the isolation and industrial growth maintenance of transforming
XX organisms. The new method has the advantage of selecting and maintaining
XX a plasmid containing bacterial culture without the use of antibiotics.
XX This has a wide variety of applications in research, development, and
XX industrial production involving genetically modified micro-organisms. The
XX method inhibits bacterial infections in eukaryotic cell cultures. The
XX present sequence is an antisense oligonucleotide (incorporated into a
XX peptide nucleic acid (PNA) molecule) which targets the E. coli acpP gene
XX (gene X in this example)
XX
XX Sequence 12 BP; 2 A; 4 C; 1 G; 5 T; 0 U; 0 Other;
SQ
Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2212 AGAGTGTGACCA 2223
DB 12 AGAGTATGAGCA 1
RESULT 577
ABX16005/c
ID ABX16005 standard; DNA; 12 BP.
XX AC ABX16005;
XX
XX 31-MAR-2003 (first entry)
DT
XX Antisense oligonucleotide for the E. coli AcpP gene, SP146.
DE
XX AcpP; antisense; ss; protein nucleic acid; PNA; bacterial infection;
XX genetically modified micro-organism.
KW
XX Escherichia coli.
XX OS
XX

FH Key Location/Qualifiers
 FT modified_base 1
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "T is covalently linked to the peptide appearing
 FT as ABG73942 via a polyethylene glycol moiety"
 FT 12
 FT modified_base 2
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "T is amidated"
 XX
 PN W0200279467-A2.
 XX
 PD 10-OCT-2002.
 XX
 PF 26-MAR-2002; 2002WO-DK000208.
 XX
 PR 29-MAR-2001; 2001DK-00000523.
 XX
 PA (UYKO-) UNIV KOENHAVNS.
 PI Nielsen PE, Good L;
 XX
 DR WPI; 2003-103273/09.
 XX
 PT Selecting genetically modified cells useful for isolation and industrial
 PT growth of transformed organisms comprises treating the modified cells
 PT with an antisense or antigen construct directed against the essential
 PT gene X of the cells.
 PS
 PS Example 4; Page 30; 92pp; English.
 XX
 CC The invention relates to selecting genetically modified cells comprising:
 CC (a) modifying cells containing a growth essential gene X, with a vector
 CC containing gene Y; and (b) treating the modified cells with an antisense
 CC or antigen construct directed against the essential gene X of the cells
 CC to obtain preferential growth of the modified cells over other non-
 CC modified cells. Also included is a product manufactured fully or
 CC partially by use of the new method. The method is useful for selecting
 CC genetically modified cells and manufacturing a product. It is useful for
 CC research the isolation and industrial growth maintenance of transformed
 CC organisms. The new method has the advantage of selecting and maintaining
 CC a plasmid containing bacterial culture without the use of antibiotics.
 CC This has a wide variety of applications in research, development, and
 CC industrial production involving genetically modified micro-organisms. The
 CC method inhibits bacterial infections in eukaryotic cell cultures. The
 CC present sequence is an antisense oligonucleotide (incorporated into a
 CC peptide nucleic acid (PNA) molecule) which targets the E. coli acpP gene
 CC (gene X in this example)
 XX
 SQ Sequence 12 BP; 2 A; 4 C; 1 G; 5 T; 0 U; 0 Other;
 Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2.7e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2212 AGAGTGTGACCA 2223
 Db 12 AGAGTGTGACCA 1
 RESULT 578
 AAQ38703/C
 ID AAQ38703 standard; RNA; 10 BP.
 XX
 AC AAQ38703;
 XX
 DT 25-MAR-2003 (revised)
 DT 15-JUL-1993 (first entry)
 XX
 DE 2'-O-methyl oligonucleotide for calibration of ras binding.
 XX
 KW oligonucleotide binding; nucleotide binding; DNA detection; binding DNA;

KW treatment; diagnosis; testing; assay; Candida; papillomavirus;
 KW cytomegalovirus; Epstein-Barr virus; rhinovirus; hepatitis virus;
 KW liver disease; human immunodeficiency virus; herpes simplex virus; HSV;
 KW human immunodeficiency virus; HIV; AIDS; influenza virus;
 KW genetic disease; genetic abnormalities.
 XX
 OS Synthetic.
 XX
 PN W09305182-A1.
 XX
 PD 18-MAR-1993.
 XX
 PF 04-SEP-1992; 92WO-US007489.
 XX
 PR 05-SEP-1991; 91US-00755485.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Bruce TW;
 XX
 DR WPI; 1993-101001/12.
 XX
 PT Determn. of oligo:nucleotide(s) with specific activity for a bio:molecule
 PT - for use in therapeutics, diagnostics and research reagents.
 XX
 PS Example 12; Page 37; 61pp; English.
 XX
 CC This sequence was used as a calibration oligonucleotide to investigate
 CC random 2'-O-methyl oligonucleotide binding to ras RNA using continuous
 CC flow mass transport methodology to effect stringent binding selection.
 CC The oligonucleotides are added to a FPLC column together with a mixture
 CC of calibration oligonucleotides that have been incubated with ras RNA to
 CC form any possible hybridisation complexes. This is to enable an elution
 CC profile to be obtained. Following calibration, either the random
 CC oligonucleotide pool is loaded onto the column followed by the ras RNA or
 CC the pool and ras RNA are pre-incubated prior to loading on the column.
 CC Bound oligonucleotide/ras RNA complexes are dissociated using stepwise or
 CC gradient low salt and/or increased temperature and the oligonucleotides
 CC are recovered by RNase treatment to selectively degrade the ras RNA. The
 CC selected 2'-O-methyl oligonucleotides are characterised by microbore
 CC HPLC. Complete and limited fragmentation of the recovered 2'-O-methyl
 CC oligonucleotides can be accomplished by appropriate base and nuclease
 CC treatment to facilitate sequence reconstruction in comparison to pre-
 CC calibrated retention times of standard mono, di, and tri 2'-O-methyl
 CC standards. (Updated on 25-MAR-2003 to correct PN field.)
 XX
 SQ Sequence 10 BP; 2 A; 4 C; 1 G; 0 T; 3 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 2.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2215 GTGTGACCAA 2224
 Db 10 GTGTGACCAA 1
 RESULT 579
 AAT96111/C
 ID AAT96111 standard; RNA; 10 BP.
 XX
 AC AAT96111;
 XX
 DT 31-MAR-1998 (first entry)
 DE Calibration oligonucleotide.
 XX
 KW Determination; oligonucleotide; specific activity; therapy;
 KW target biomolecule; randomised oligonucleotide; diagnosis; research;
 KW calibration oligonucleotide; ss.
 XX
 OS Synthetic.

PN US5686242-A.
XX
PD 11-NOV-1997.
XX
PF 27-OCT-1994; 94US-00330000.
XX
PR 05-SEP-1991; 91US-00755485.
XX
PR 04-SEP-1992; 92WO-US007489.
XX
PA (ISIS-) ISIS PHARM INC.
XX
XX Lima WF, Bruice TW;
PI WPI; 1997-558135/51.
XX
XX Determination of oligo-nucleotide with specific activity for target bio-
PT molecule - using set of randomised oligo-nucleotide(s).
XX
XX Example 12; Col 29-30; 22pp; English.
XX
XX The present sequence was used in the development of a method of
CC determining an oligonucleotide having specific activity for a target
CC biomolecule. The method comprises assaying a set of randomised
CC oligonucleotides for activity against a target biomolecule, separating
CC active from inactive oligonucleotides and recovering, amplifying and
CC determining the nucleic acid sequence of the active oligonucleotides. The
CC oligonucleotides can be used for therapeutic, diagnostic and research
CC purposes
XX
SQ Sequence 10 BP; 2 A; 4 C; 1 G; 0 T; 3 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2215 GTGTGACCAA 2224
DB ||||| |||||
10 GTGTGACCAA 1
RESULT 580
AAZ82626/C
ID AAZ82626 standard; DNA; 10 BP.
XX
AC AAZ82626;
XX
DT 07-APR-2000 (first entry)
XX
DE Metastatic breast tumour cell upregulated transcript tag #1860.
XX
KW Human; metastatic breast tumour tissue; breast cancer; tag; primer;
KW non-metastatic breast tumour tissue; gene therapy; anticancer;
XX antimetastatic; vaccine; diagnosis; ss.
XX
OS Homo sapiens.
XX
PN WO965928-A2.
XX
PD 23-DEC-1999.
XX
PF 18-JUN-1999; 99WO-US013647.
XX
PR 19-JUN-1998; 98US-0089853P.
XX
PR 19-JUN-1998; 98US-0089997P.
XX
PR 19-JUN-1998; 98US-0090039P.
XX
PR 19-JUN-1998; 98US-0090040P.
XX
XX (GENZ) GENZYME CORP.
XX (ROBE/) ROBERTS B.L.
XX (SHAN/) SHANKARA S.
XX
PI Roberts BL, Shankara S;

XX WPI; 2000-106079/09.
XX
XX Isolated polynucleotides differentially expressed between metastatic and
PT non-metastatic breast cancer cells, useful for diagnosis, prevention and
PT treatment of cancer.
XX
XX Claim 1; Page 109; 219pp; English.
XX
XX AAZ80767 to AAZ83941 represent tags corresponding to distinct transcripts
CC that are preferentially transcribed in the metastatic breast tumour
CC tissue (i.e. are upregulated in metastatic breast tumour cells). AAZ83942
CC to AAZ86677 represent tags corresponding to distinct transcripts that are
CC preferentially transcribed in the primary or non-metastatic breast tumour
CC tissue (i.e. are downregulated in metastatic breast tumour cells). These
CC transcripts can be used for diagnosis, prognosis, monitoring and
CC treatment of breast cancer, particularly where metastatic. Diagnosis is
CC by standard immunoassays or hybridisation/amplification reactions.
CC Compounds that modulate expression of the transcripts are potentially
CC useful for treatment of (metastatic) breast cancer, while promoters from
CC the transcripts are used to direct expression in selected cell types, of
CC e.g. therapeutic genes (also ribozymes or antisense sequences),
CC particularly an antigen-encoding sequence for use in gene or cell-based
CC vaccines. Polypeptides encoded by the transcripts are also useful in
CC antibodies (Ab). Ab are used to detect the polypeptides or as therapeutic
CC agents. Host cells that produce the polypeptides can be used to expand
CC and isolate populations of educated, antigen-specific immune effector
CC cells, e.g. cytotoxic T lymphocytes, and these used for adoptive
CC immunotherapy
XX
SQ Sequence 10 BP; 2 A; 4 C; 1 G; 3 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2215 GTGTGACCAA 2224
DB ||||| |||||
10 GTGTGACCAA 1
RESULT 581
AAZ86089
ID AAZ86089 standard; DNA; 10 BP.
XX
AC AAZ86089;
XX
DT 07-APR-2000 (first entry)
XX
DE Metastatic breast tumour cell downregulated transcript tag #5323.
XX
KW Human; metastatic breast tumour tissue; breast cancer; tag; primer;
KW non-metastatic breast tumour tissue; gene therapy; anticancer;
XX antimetastatic; vaccine; diagnosis; ss.
XX
OS Homo sapiens.
XX
PN WO9965928-A2.
XX
PD 23-DEC-1999.
XX
PF 18-JUN-1999; 99WO-US013647.
XX
PR 19-JUN-1998; 98US-0089853P.
XX
PR 19-JUN-1998; 98US-0089997P.
XX
PR 19-JUN-1998; 98US-0090039P.
XX
PR 19-JUN-1998; 98US-0090040P.
XX
XX (GENZ) GENZYME CORP.
XX (ROBE/) ROBERTS B.L.
XX (SHAN/) SHANKARA S.
XX
PA

XX Roberts BL, Shankara S;
 PI WPI; 2000-106079/09.
 DR Isolated polynucleotides differentially expressed between metastatic and
 XX non-metastatic breast cancer cells, useful for diagnosis, prevention and
 XX treatment of cancer.
 XX Claim 1; Page 200; 219pp; English.
 XX AAZ80767 to AAZ83941 represent tags corresponding to distinct transcripts
 CC that are preferentially transcribed in the metastatic breast tumour
 CC tissue (i.e. are upregulated in metastatic breast tumour cells). AAZ83942
 CC to AAZ86677 represent tags corresponding to distinct transcripts that are
 CC preferentially transcribed in the primary or non-metastatic breast tumour
 CC tissue (i.e. are downregulated in metastatic breast tumour cells). These
 CC transcripts can be used for diagnosis, prognosis, monitoring and
 CC treatment of breast cancer, particularly where metastatic. Diagnosis is
 CC by standard immunoassays or hybridisation/amplification reactions.
 CC Compounds that modulate expression of the transcripts are potentially
 CC useful for treatment of (metastatic) breast cancer, while promoters from
 CC the transcripts are used to direct expression, in selected cell types, of
 CC e.g. therapeutic genes (also ribozymes or antisense sequences),
 CC particularly an antigen-encoding sequence for use in gene or cell-based
 CC vaccines. Polypeptides encoded by the transcripts are also useful in
 CC antibodies (Ab). Ab are used to detect the polypeptides or as therapeutic
 CC agents. Host cells that produce the polypeptides can be used to expand
 CC and isolate populations of educated, antigen-specific immune effector
 CC cells, e.g. cytotoxic T lymphocytes, and these used for adoptive
 CC immunotherapy
 XX
 SQ Sequence 10 BP; 4 A; 3 C; 2 G; 1 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 2.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2219 GACCAAAAGT 2228
 |||||
 Db 1 GACCAACAGT 10
 RESULT 582
 AAZ81055/c
 ID AAZ81055 standard; DNA; 10 BP.
 AC AAZ81055;
 XX
 DT 07-APR-2000 (first entry)
 XX
 DE Metastatic breast tumour cell upregulated transcript tag #289.
 XX
 DE Human; metastatic breast tumour tissue; breast cancer; tag; primer;
 KW non-metastatic breast tumour tissue; gene therapy; anticancer;
 KW antimetastatic; vaccine; diagnosis; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO9965928-A2.
 XX
 XX 23-DEC-1999.
 XX
 XX 18-JUN-1999; 99WO-US013647.
 XX
 XX 19-JUN-1998; 98US-0089853P.
 XX
 XX 19-JUN-1998; 98US-0089997P.
 XX
 XX 19-JUN-1998; 98US-0090039P.
 XX
 XX 19-JUN-1998; 98US-0090040P.
 XX
 XX 19-JUN-1998; 98US-0090041P.
 XX
 XX (GENZ) GENZYME CORP.

PA (ROBE/) ROBERTS B L.
 XX (SHAN/) SHANKARA S.
 PI Roberts BL, Shankara S;
 XX WPI; 2000-106079/09.
 DR Isolated polynucleotides differentially expressed between metastatic and
 XX non-metastatic breast cancer cells, useful for diagnosis, prevention and
 XX treatment of cancer.
 XX Claim 1; Page 55; 219pp; English.
 XX AAZ80767 to AAZ83941 represent tags corresponding to distinct transcripts
 CC that are preferentially transcribed in the metastatic breast tumour
 CC tissue (i.e. are upregulated in metastatic breast tumour cells). AAZ83942
 CC to AAZ86677 represent tags corresponding to distinct transcripts that are
 CC preferentially transcribed in the primary or non-metastatic breast tumour
 CC tissue (i.e. are downregulated in metastatic breast tumour cells). These
 CC transcripts can be used for diagnosis, prognosis, monitoring and
 CC treatment of breast cancer, particularly where metastatic. Diagnosis is
 CC by standard immunoassays or hybridisation/amplification reactions.
 CC Compounds that modulate expression of the transcripts are potentially
 CC useful for treatment of (metastatic) breast cancer, while promoters from
 CC the transcripts are used to direct expression, in selected cell types, of
 CC e.g. therapeutic genes (also ribozymes or antisense sequences),
 CC particularly an antigen-encoding sequence for use in gene or cell-based
 CC vaccines. Polypeptides encoded by the transcripts are also useful in
 CC antibodies (Ab). Ab are used to detect the polypeptides or as therapeutic
 CC agents. Host cells that produce the polypeptides can be used to expand
 CC and isolate populations of educated, antigen-specific immune effector
 CC cells, e.g. cytotoxic T lymphocytes, and these used for adoptive
 CC immunotherapy
 XX
 SQ Sequence 10 BP; 3 A; 1 C; 1 G; 5 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 2.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTTACA 2232
 |||||
 Db 10 AAAAGTTTCA 1
 RESULT 583
 AAZ88682/c
 ID AAZ88682 standard; RNA; 10 BP.
 AC AAZ88682;
 XX
 DT 11-MAY-2000 (first entry)
 XX
 DE Ras RNA binding 2'-O-methyl oligonucleotide #3.
 XX
 DE primer; detection; diagnosis; ras gene; RNA binding; 2'-O-methyl; ss.
 KW
 KW Unidentified.
 OS
 XX
 PH Key Location/Qualifiers
 FT misc_RNA 1..10
 FT /*tag= a
 FT /note= "2'-O-methyl nucleotides"
 XX
 XX US6022691-A.
 XX
 XX 08-FEB-2000.
 XX
 XX 07-NOV-1997; 97US-00965908.
 XX
 XX 05-SEP-1991; 91US-00755485.
 XX
 XX 04-SEP-1992; 92WO-US007489.


```

XX PF 21-NOV-2000; 2000WO-US031922.
XX AAH63362/c
XX ID AAH63362 standard; cDNA; 10 BP.
XX AC AAH63362;
XX DT 20-SEP-2001 (first entry)
XX DE Human melanocyte specific transcriptome sequence SEQ ID NO: 202.
XX KW Human; transcriptome; gene expression pattern; cancer; drug screening;
XX KW cancer diagnosis; cell specific gene expression; ss.
XX OS Homo sapiens.
XX PN WO200138577-A2.
XX PD 31-MAY-2001.
XX PF 21-NOV-2000; 2000WO-US031922.
XX PR 24-NOV-1999; 99US-00448480.
XX PA (UYJO ) UNIV JOHNS HOPKINS.
XX PI Velculescu VE, Vogelstein B, Kinzler KW;
XX DR WPI; 2001-367706/38.
XX The present invention describes a method of identifying the type of cell
CC in a sample, involving determining which of the sequences AAH63361-
CC AAH64724 is expressed by the cell. The transcriptomes described in the
CC invention are cell-type specific, cancer specific or ubiquitously
CC expressed in humans. They can also be used to screen for drugs, reduce
CC cancer specific gene expression, standardise expression and restore the
CC function of a diseased cell or tissue. The present sequence is one of the
CC transcriptomes described in the exemplification of the invention
XX SQ Sequence 10 BP; 2 A; 1 C; 2 G; 5 T; 0 U; 0 Other;
XX Query Match 31.1%; Score 8.4; DB 1; Length 10;
XX Best Local Similarity 90.0%; Pred. No. 2.6e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2216 TGTGACCAAA 2225
DB 10 TGTACCAAA 1
RESULT 586
AAH74044
ID AAF74044 standard; DNA; 10 BP.
XX AC AAF74044;
XX DT 30-APR-2001 (first entry)
XX DE Human SLC6A4 allele-specific oligonucleotide primer #164.
XX KW Solute carrier family 6 neurotransmitter transporter; seotonin 4; SLC6A4;
XX KW genotyping; allele specific oligonucleotide; ss.
XX OS Homo sapiens.
XX PN WO200109161-A1.
XX PD 08-FEB-2001.
XX PF 31-JUL-2000; 2000WO-US020638.
XX PR 29-JUL-1999; 99US-0146290P.
XX PA (GENA-) GENAISSANCE PHARM INC.
XX PI Denton RR, Duda A, Nandabalan K, Sanchis A, Stephens JC;
XX DR WPI; 2001-123317/13.
XX New isolated polynucleotide comprising a polymorphic variant for the
PT solute carrier family 6 neurotransmitter transporter, serotonin member 4
PT gene for identifying drugs for treating disorders related to expression
PT of the protein.
PS Disclosure; Page 23; 152pp; English.
XX
XX PF 21-NOV-2000; 2000WO-US031922.
XX AAH63362/c
XX ID AAH63362 standard; cDNA; 10 BP.
XX AC AAH63362;
XX DT 20-SEP-2001 (first entry)
XX DE Human melanocyte specific transcriptome sequence SEQ ID NO: 202.
XX KW Human; transcriptome; gene expression pattern; cancer; drug screening;
XX KW cancer diagnosis; cell specific gene expression; ss.
XX OS Homo sapiens.
XX PN WO200138577-A2.
XX PD 31-MAY-2001.
XX PF 21-NOV-2000; 2000WO-US031922.
XX PR 24-NOV-1999; 99US-00448480.
XX PA (UYJO ) UNIV JOHNS HOPKINS.
XX PI Velculescu VE, Vogelstein B, Kinzler KW;
XX DR WPI; 2001-367706/38.
XX The present invention describes a method of identifying the type of cell
CC in a sample, involving determining which of the sequences AAH63361-
CC AAH64724 is expressed by the cell. The transcriptomes described in the
CC invention are cell-type specific, cancer specific or ubiquitously
CC expressed in humans. They can also be used to screen for drugs, reduce
CC cancer specific gene expression, standardise expression and restore the
CC function of a diseased cell or tissue. The present sequence is one of the
CC transcriptomes described in the exemplification of the invention
XX SQ Sequence 10 BP; 2 A; 1 C; 2 G; 5 T; 0 U; 0 Other;
XX Query Match 31.1%; Score 8.4; DB 1; Length 10;
XX Best Local Similarity 90.0%; Pred. No. 2.6e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2216 TGTGACCAAA 2225
DB 10 TGTACCAAA 1
RESULT 587
AAH63364/c
ID AAH63364 standard; cDNA; 10 BP.
XX AC AAH63364;
XX DT 20-SEP-2001 (first entry)
XX DE Human melanocyte specific transcriptome sequence SEQ ID NO: 204.
XX KW Human; transcriptome; gene expression pattern; cancer; drug screening;
XX KW cancer diagnosis; cell specific gene expression; ss.
XX OS Homo sapiens.
XX PN WO200138577-A2.
XX PD 31-MAY-2001.

```

CC The present invention relates to a polymorphic variant of a reference
CC sequence for the solute carrier family 6 neurotransmitter transporter,
CC serotonin member 4 (SLC6A4) gene or a fragment of it or a sequence
CC complementary to the first sequence. The invention is used in producing a
CC recombinant organism that can be used to express SLC6A4 for protein
CC structure analysis and binding studies. A composition comprising a
CC genotyping oligonucleotide is used to detect a polymorphism in the SLC6A4
CC gene

XX Sequence 10 BP; 6 A; 0 C; 2 G; 2 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 10;

Best Local Similarity 90.0%; Pred. No. 2.6e-02;

Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTTACA 2232

DB 1 AAAAGTTTACA 10

RESULT 589

AAF40439/C

ID AAF40439 standard; DNA; 10 BP.

AC AAF40439;

XX 23-MAR-2001 (first entry)

DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:7178.

XX Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;

KW nor previously assigned open reading frame; nonannotated ORF; SAGE;

KW serial analysis of gene expression; antifungal; tag; identification;

KW linker; PCR primer; ds.

XX Saccharomyces cerevisiae.

OS WO200077214-A2.

XX 21-DEC-2000.

XX 14-JUN-2000; 2000WO-US016223.

XX 16-JUN-1999; 99US-00335032.

XX (UWJO) UNIV JOHNS HOPKINS.

XX Veiculescu V, Vogelstein B, Kinzler K;

XX WPI; 2001-061874/07.

XX Yeast gene coding sequences comprising NORF genes with serial analysis of
PT gene expression (SAGE) tags, useful for studying, monitoring and
PT affecting phases of the cell cycle.

XX Example; Page 256; 419pp; English.

XX The present invention describes an isolated DNA molecule comprising a
CC coding sequence of a yeast gene selected from a group of 745 NORF (not
CC previously assigned open reading frame; or nonannotated ORF) genes
CC comprising a SAGE (serial analysis of gene expression) tag. Also
CC described are: (1) a method (M1) of using NORF genes to affect the cell
CC cycle comprising administering a NORF gene whose expression varies by at
CC least 10% between any two phases of the cell cycle selected from log
CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
CC antifungal drugs comprising: (a) contacting a test substance with a yeast
CC cell; and (b) monitoring expression of a NORF gene whose expression
CC varies as in M1, where a test substance which modifies the expression of
CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
CC identifying human genes which are involved in cell cycle progression
CC comprising contacting human DNA with a probe which comprises at least 10
CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
CC and (4) a method (M4) for identifying a candidate drug as a member of a

CC class of drugs having a characteristic effect on gene expression in a
CC yeast cell comprising contacting a yeast cell with a candidate drug and
CC monitoring expression in the yeast cell of at least 1 NORF gene whose
CC expression is affected by the class of drugs. The NORF genes may be used
CC to study, monitor and affect phases of the cell cycle, the differentially
CC expressed genes may be used as markers of phases of the cell cycle. The
CC methods may be used to identify candidate drugs which affect the cell
CC cycle and for identification of antifungal drugs. AAF33268 to AAF44064
CC represent SAGE tags used in the exemplification of the present invention.
CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
CC method, in the exemplification of the present invention

XX Sequence 10 BP; 5 A; 2 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 10;

Best Local Similarity 90.0%; Pred. No. 2.6e-02;

Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2229 TACATGTTTG 2238

DB 10 TAAATGTTTG 1

RESULT 590

AAF41011

ID AAF41011 standard; DNA; 10 BP.

AC AAF41011;

XX 23-MAR-2001 (first entry)

DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:7750.

XX Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;

KW nor previously assigned open reading frame; nonannotated ORF; SAGE;

KW serial analysis of gene expression; antifungal; tag; identification;

KW linker; PCR primer; ds.

XX Saccharomyces cerevisiae.

OS WO200077214-A2.

XX 21-DEC-2000.

XX 14-JUN-2000; 2000WO-US016223.

XX 16-JUN-1999; 99US-00335032.

XX (UWJO) UNIV JOHNS HOPKINS.

XX Veiculescu V, Vogelstein B, Kinzler K;

XX WPI; 2001-061874/07.

XX Yeast gene coding sequences comprising NORF genes with serial analysis of
PT gene expression (SAGE) tags, useful for studying, monitoring and
PT affecting phases of the cell cycle.

XX Example; Page 276; 419pp; English.

XX The present invention describes an isolated DNA molecule comprising a
CC coding sequence of a yeast gene selected from a group of 745 NORF (not
CC previously assigned open reading frame; or nonannotated ORF) genes
CC comprising a SAGE (serial analysis of gene expression) tag. Also
CC described are: (1) a method (M1) of using NORF genes to affect the cell
CC cycle comprising administering a NORF gene whose expression varies by at
CC least 10% between any two phases of the cell cycle selected from log
CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
CC antifungal drugs comprising: (a) contacting a test substance with a yeast
CC cell; and (b) monitoring expression of a NORF gene whose expression
CC varies as in M1, where a test substance which modifies the expression of
CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
CC identifying human genes which are involved in cell cycle progression

phase, S phase and G2/M; (2) a method (M2) for screening candidate antifungal drugs comprising: (a) contacting a test substance with a yeast cell; and (b) monitoring expression of a NORF gene whose expression varies as in M1, where a test substance which modifies the expression of the yeast gene is a candidate antifungal drug; (3) a method (M3) for identifying human genes which are involved in cell cycle progression comprising contacting human DNA with a probe which comprises at least 10 contiguous nucleotides of a NORF gene whose expression varies as in M1; and (4) a method (M4) for identifying a candidate drug as a member of a class of drugs having a characteristic effect on gene expression in a yeast cell comprising contacting a yeast cell with a candidate drug and monitoring expression in the yeast cell of at least 1 NORF gene whose expression is affected by the class of drugs. The NORF genes may be used to study, monitor and affect phases of the cell cycle, the differentially expressed genes may be used as markers of phases of the cell cycle. The methods may be used to identify candidate drugs which affect the cell cycle and for identification of antifungal drugs. AAF33268 to AAF44064 represent SAGE tags used in the exemplification of the present invention. AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE method, in the exemplification of the present invention.

Sequence 10 BP; 2 A; 1 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTTACA 2232
D 10 AAAAGTTTACA 1

RESULT 593
AAF40798
ID AAF40798 standard; DNA; 10 BP.
AC AAF40798;
DT 23-MAR-2001 (first entry)
DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:7537.
KW Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
KW serial analysis of gene expression; antifungal; tag; identification;
KW linker; PCR primer; ds.
XX Saccharomyces cerevisiae.
OS WO200077214-A2.
PN WO200077214-A2.
PD 21-DEC-2000.
PF 14-JUN-2000; 2000WO-US016223.
PR 16-JUN-1999; 99US-00335032.
XX (UYJO) UNIV JOHNS HOPKINS.
PA Velulescu V, Vogelstein B, Kinzler K;
PI WPI; 2001-061874/07.
DR Yeast gene coding sequences comprising NORF genes with serial analysis of
PT gene expression (SAGE) tags, useful for studying, monitoring and
PT affecting phases of the cell cycle.
XX Example; Page 269; 419pp; English.

The present invention describes an isolated DNA molecule comprising a coding sequence of a yeast gene selected from a group of 745 NORF (not previously assigned open reading frame; or nonannotated ORF) genes comprising a SAGE (serial analysis of gene expression) tag. Also

described are: (1) a method (M1) of using NORF genes to affect the cell cycle comprising administering a NORF gene whose expression varies by at least 10% between any two phases of the cell cycle selected from log phase, S phase and G2/M; (2) a method (M2) for screening candidate antifungal drugs comprising: (a) contacting a test substance with a yeast cell; and (b) monitoring expression of a NORF gene whose expression varies as in M1, where a test substance which modifies the expression of the yeast gene is a candidate antifungal drug; (3) a method (M3) for identifying human genes which are involved in cell cycle progression comprising contacting human DNA with a probe which comprises at least 10 contiguous nucleotides of a NORF gene whose expression varies as in M1; and (4) a method (M4) for identifying a candidate drug as a member of a class of drugs having a characteristic effect on gene expression in a yeast cell comprising contacting a yeast cell with a candidate drug and monitoring expression in the yeast cell of at least 1 NORF gene whose expression is affected by the class of drugs. The NORF genes may be used to study, monitor and affect phases of the cell cycle, the differentially expressed genes may be used as markers of phases of the cell cycle. The methods may be used to identify candidate drugs which affect the cell cycle and for identification of antifungal drugs. AAF33268 to AAF44064 represent SAGE tags used in the exemplification of the present invention. AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE method, in the exemplification of the present invention.

Sequence 10 BP; 4 A; 2 C; 2 G; 2 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2221 CCAAGTTTA 2230
D 1 CCAAGTTTA 10

RESULT 594
AAF38269
ID AAF38269 standard; DNA; 10 BP.
AC AAF38269;
DT 23-MAR-2001 (first entry)
DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:5008.
KW Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
KW serial analysis of gene expression; antifungal; tag; identification;
KW linker; PCR primer; ds.
XX Saccharomyces cerevisiae.
OS WO200077214-A2.
PN WO200077214-A2.
PD 21-DEC-2000.
PF 14-JUN-2000; 2000WO-US016223.
PR 16-JUN-1999; 99US-00335032.
XX (UYJO) UNIV JOHNS HOPKINS.
PA Velulescu V, Vogelstein B, Kinzler K;
PI WPI; 2001-061874/07.
DR Yeast gene coding sequences comprising NORF genes with serial analysis of
PT gene expression (SAGE) tags, useful for studying, monitoring and
PT affecting phases of the cell cycle.
XX Example; Page 178; 419pp; English.
PS The present invention describes an isolated DNA molecule comprising a
XX

CC coding sequence of a yeast gene selected from a group of 745 NORF (not
CC previously assigned open reading frame; or nonannotated ORF) genes
CC comprising a SAGE (serial analysis of gene expression) tag. Also
CC described are: (1) a method (M1) of using NORF genes to affect the cell
CC cycle comprising administering a NORF gene whose expression varies by at
CC least 10% between any two phases of the cell cycle selected from log
CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
CC antifungal drugs comprising: (a) contacting a test substance with a yeast
CC cell; and (b) monitoring expression of a NORF gene whose expression
CC varies as in M1, where a test substance which modifies the expression of
CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
CC identifying human genes which are involved in cell cycle progression
CC comprising contacting human DNA with a probe which comprises at least 10
CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
CC and (4) a method (M4) for identifying a candidate drug as a member of a
CC class of drugs having a characteristic effect on gene expression in a
CC yeast cell comprising contacting a yeast cell with a candidate drug and
CC monitoring expression in the yeast cell of at least 1 NORF gene whose
CC expression is affected by the class of drugs. The NORF genes may be used
CC to study, monitor and affect phases of the cell cycle, the differentially
CC expressed genes may be used as markers of phases of the cell cycle. The
CC methods may be used to identify candidate drugs which affect the cell
CC cycle and for identification of antifungal drugs. AAF33268 to AAF44064
CC represent SAGE tags used in the exemplification of the present invention.
CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
CC method, in the exemplification of the present invention
XX
SQ Sequence 10 BP; 3 A; 0 C; 1 G; 6 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTT 2237
DB 1 TTAAATGTTT 10

RESULT 595
AAF35345/C
ID AAF35345 standard; DNA; 10 BP.
XX AAF35345;
AC AAF35345;
XX
DT 23-MAR-2001 (first entry)
XX
DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:2084.
XX
KW Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
KW serial analysis of gene expression; antifungal; tag; identification;
KW linker; PCR primer; ds.
XX
OS Saccharomyces cerevisiae.
XX
PN WO200077214-A2.
XX
XX 21-DEC-2000.
XX
XX 14-JUN-2000; 2000WO-US016223.
XX
XX 16-JUN-1999; 99US-00335032.
XX
XX (UYJO) UNIV JOHNS HOPKINS.
XX
XX Velculescu V, Vogelstein B, Kinzler K;
XX WPI; 2001-061874/07.
XX
XX Yeast gene coding sequences comprising NORF genes with serial analysis of
PT gene expression (SAGE) tags; useful for studying, monitoring and
PT affecting phases of the cell cycle.
XX

PS Example; Page 74; 419pp; English.
XX
CC The present invention describes an isolated DNA molecule comprising a
CC coding sequence of a yeast gene selected from a group of 745 NORF (not
CC previously assigned open reading frame; or nonannotated ORF) genes
CC comprising a SAGE (serial analysis of gene expression) tag. Also
CC described are: (1) a method (M1) of using NORF genes to affect the cell
CC cycle comprising administering a NORF gene whose expression varies by at
CC least 10% between any two phases of the cell cycle selected from log
CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
CC antifungal drugs comprising: (a) contacting a test substance with a yeast
CC cell; and (b) monitoring expression of a NORF gene whose expression
CC varies as in M1, where a test substance which modifies the expression of
CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
CC identifying human genes which are involved in cell cycle progression
CC comprising contacting human DNA with a probe which comprises at least 10
CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
CC and (4) a method (M4) for identifying a candidate drug as a member of a
CC class of drugs having a characteristic effect on gene expression in a
CC yeast cell comprising contacting a yeast cell with a candidate drug and
CC monitoring expression in the yeast cell of at least 1 NORF gene whose
CC expression is affected by the class of drugs. The NORF genes may be used
CC to study, monitor and affect phases of the cell cycle, the differentially
CC expressed genes may be used as markers of phases of the cell cycle. The
CC methods may be used to identify candidate drugs which affect the cell
CC cycle and for identification of antifungal drugs. AAF33268 to AAF44064
CC represent SAGE tags used in the exemplification of the present invention.
CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
CC method, in the exemplification of the present invention
XX
SQ Sequence 10 BP; 2 A; 0 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2222 CAAAAGTTAC 2231
DB 10 CAAAAGTTAC 1

RESULT 596
AAF43860/C
ID AAF43860 standard; DNA; 10 BP.
XX AAF43860;
AC AAF43860;
XX
DT 23-MAR-2001 (first entry)
XX
DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:11999.
XX
KW Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
KW serial analysis of gene expression; antifungal; tag; identification;
KW linker; PCR primer; ds.
XX
OS Saccharomyces cerevisiae.
XX
PN WO200077214-A2.
XX
XX 21-DEC-2000.
XX
XX 14-JUN-2000; 2000WO-US016223.
XX
XX 16-JUN-1999; 99US-00335032.
XX
XX (UYJO) UNIV JOHNS HOPKINS.
XX
XX Velculescu V, Vogelstein B, Kinzler K;
XX WPI; 2001-061874/07.
XX
XX Yeast gene coding sequences comprising NORF genes with serial analysis of
PT

PT gene expression (SAGE) tags, useful for studying, monitoring and
PT affecting phases of the cell cycle.
PS Example; Page 378; 419pp; English.
XX
CC The present invention describes an isolated DNA molecule comprising a
CC coding sequence of a yeast gene selected from a group of 745 NORF (not
CC previously assigned open reading frame; or nonannotated ORF) genes
CC comprising a SAGE (serial analysis of gene expression) tag. Also
CC described are: (1) a method (M1) of using NORF genes to affect the cell
CC cycle comprising administering a NORF gene whose expression varies by at
CC least 10% between any two phases of the cell cycle selected from log
CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
CC antifungal drugs comprising: (a) contacting a test substance with a yeast
CC cell; and (b) monitoring expression of a NORF gene whose expression
CC varies as in M1, where a test substance which modifies the expression of
CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
CC identifying human genes which are involved in cell cycle progression
CC comprising contacting human DNA with a probe which comprises at least 10
CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
CC and (4) a method (M4) for identifying a candidate drug as a member of a
CC class of drugs having a characteristic effect on gene expression in a
CC yeast cell comprising contacting a yeast cell with a candidate drug and
CC monitoring expression in the yeast cell of at least 1 NORF gene whose
CC expression is affected by the class of drugs. The NORF genes may be used
CC to study, monitor and affect phases of the cell cycle, the differentially
CC expressed genes may be used as markers of phases of the cell cycle. The
CC methods may be used to identify candidate drugs which affect the cell
CC cycle and for identification of antifungal drugs. AAF33268 to AAF4064
CC represent SAGE tags used in the exemplification of the present invention.
CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
CC method, in the exemplification of the present invention
XX
SQ Sequence 10 BP; 2 A; 1 C; 0 G; 7 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 2223 AAAAGTTTACA 2232
DB 10 AAAAGTTTAAA 1
RESULT 597
AAF38462
ID AAF38462 standard; DNA; 10 BP.
XX AAF38462;
XX 23-MAR-2001 (first entry)
XX Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:5201.
XX Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
KW serial analysis of gene expression; antifungal; tag; identification;
KW linker; PCR primer; ds.
XX Saccharomyces cerevisiae.
OS WC200077214-A2.
XX WC200077214-A2.
PN 21-DEC-2000.
XX 14-JUN-2000; 2000WO-US016223.
PF 16-JUN-1999; 99US-00335032.
XX (UYJO) UNIV JOHNS HOPKINS.
XX Velculescu V, Vogelstein B, Kinzler K;
PI

DR WPI; 2001-061874/07.
XX Yeast gene coding sequences comprising NORF genes with serial analysis of
PT gene expression (SAGE) tags, useful for studying, monitoring and
PT affecting phases of the cell cycle.
XX Example; Page 185; 419pp; English.
XX The present invention describes an isolated DNA molecule comprising a
CC coding sequence of a yeast gene selected from a group of 745 NORF (not
CC previously assigned open reading frame; or nonannotated ORF) genes
CC comprising a SAGE (serial analysis of gene expression) tag. Also
CC described are: (1) a method (M1) of using NORF genes to affect the cell
CC cycle comprising administering a NORF gene whose expression varies by at
CC least 10% between any two phases of the cell cycle selected from log
CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
CC antifungal drugs comprising: (a) contacting a test substance with a yeast
CC cell; and (b) monitoring expression of a NORF gene whose expression
CC varies as in M1, where a test substance which modifies the expression of
CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
CC identifying human genes which are involved in cell cycle progression
CC comprising contacting human DNA with a probe which comprises at least 10
CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
CC and (4) a method (M4) for identifying a candidate drug as a member of a
CC class of drugs having a characteristic effect on gene expression in a
CC yeast cell comprising contacting a yeast cell with a candidate drug and
CC monitoring expression in the yeast cell of at least 1 NORF gene whose
CC expression is affected by the class of drugs. The NORF genes may be used
CC to study, monitor and affect phases of the cell cycle, the differentially
CC expressed genes may be used as markers of phases of the cell cycle. The
CC methods may be used to identify candidate drugs which affect the cell
CC cycle and for identification of antifungal drugs. AAF33268 to AAF4064
CC represent SAGE tags used in the exemplification of the present invention.
CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
CC method, in the exemplification of the present invention
XX
SQ Sequence 10 BP; 6 A; 2 C; 1 G; 1 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 2223 AAAAGTTTACA 2232
DB 1 AAAAGTCACA 10
RESULT 598
AAF38459
ID AAF38459 standard; DNA; 10 BP.
XX AAF38459;
XX 23-MAR-2001 (first entry)
XX Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:5198.
DE Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
KW serial analysis of gene expression; antifungal; tag; identification;
KW linker; PCR primer; ds.
XX Saccharomyces cerevisiae.
OS WC200077214-A2.
XX WC200077214-A2.
PN 21-DEC-2000.
XX 14-JUN-2000; 2000WO-US016223.
PF 16-JUN-1999; 99US-00335032.
XX (UYJO) UNIV JOHNS HOPKINS.
XX Velculescu V, Vogelstein B, Kinzler K;
PI

```

XX  Velulescu V, Vogelstein B, Kinzler K;
PI  WPI; 2001-061874/07.
XX
XX  Yeast gene coding sequences comprising NORF genes with serial analysis of
PT  gene expression (SAGE) tags, useful for studying, monitoring and
PT  affecting phases of the cell cycle.
XX  Example; Page 185; 419pp; English.
XX
XX  The present invention describes an isolated DNA molecule comprising a
CC  coding sequence of a yeast gene selected from a group of 745 NORF (not
CC  previously assigned open reading frame; or nonannotated ORF) genes
CC  comprising a SAGE (serial analysis of gene expression) tag. Also
CC  described are: (1) a method (M1) of using NORF genes to affect the cell
CC  cycle comprising administering a NORF gene whose expression varies by at
CC  least 10% between any two phases of the cell cycle selected from log
CC  phase, S phase and G2/M; (2) a method (M2) for screening candidate
CC  antifungal drugs comprising: (a) contacting a test substance with a yeast
CC  cell; and (b) monitoring expression of a NORF gene whose expression
CC  varies as in M1, where a test substance which modifies the expression of
CC  the yeast gene is a candidate antifungal drug; (3) a method (M3) for
CC  identifying human genes which are involved in cell cycle progression
CC  comprising contacting human DNA with a probe which comprises at least 10
CC  contiguous nucleotides of a NORF gene whose expression varies as in M1;
CC  and (4) a method (M4) for identifying a candidate drug as a member of a
CC  class of drugs having a characteristic effect on gene expression in a
CC  yeast cell comprising contacting a yeast cell with a candidate drug and
CC  monitoring expression in the yeast cell of at least 1 NORF gene whose
CC  expression is affected by the class of drugs. The NORF genes may be used
CC  to study, monitor and affect phases of the cell cycle, the differentially
CC  expressed genes may be used as markers of phases of the cell cycle. The
CC  methods may be used to identify candidate drugs which affect the cell
CC  cycle and for identification of antifungal drugs. AAF33268 to AAF4064
CC  represent SAGE tags used in the exemplification of the present invention.
CC  AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
CC  method, in the exemplification of the present invention.
XX
XX  Sequence 10 BP; 6 A; 1 C; 2 G; 1 T; 0 U; 0 Other;
SQ
Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2223 AAAAGTTACA 2232
DB 1 AAAAGTTACA 10
RESULT 599
AAF36865/C
ID AAF36865 standard; DNA; 10 BP.
AC AAF36865;
XX
XX 23-MAR-2001 (first entry)
XX
XX Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:3604.
XX
XX Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
KW serial analysis of gene expression; antifungal; tag; identification;
KW linker; PCR primer; ds.
XX
XX Saccharomyces cerevisiae.
XX
XX WO200077214-A2.
XX
XX 21-DEC-2000.
XX
XX 14-JUN-2000; 2000WO-US016223.
XX
XX
XX 16-JUN-1999; 99US-00335032.
XX (UYJO ) UNIV JOHNS HOPKINS.
XX
XX Velulescu V, Vogelstein B, Kinzler K;
PI WPI; 2001-061874/07.
XX
XX Yeast gene coding sequences comprising NORF genes with serial analysis of
PT gene expression (SAGE) tags, useful for studying, monitoring and
PT affecting phases of the cell cycle.
XX Example; Page 128; 419pp; English.
XX
XX The present invention describes an isolated DNA molecule comprising a
CC coding sequence of a yeast gene selected from a group of 745 NORF (not
CC previously assigned open reading frame; or nonannotated ORF) genes
CC comprising a SAGE (serial analysis of gene expression) tag. Also
CC described are: (1) a method (M1) of using NORF genes to affect the cell
CC cycle comprising administering a NORF gene whose expression varies by at
CC least 10% between any two phases of the cell cycle selected from log
CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
CC antifungal drugs comprising: (a) contacting a test substance with a yeast
CC cell; and (b) monitoring expression of a NORF gene whose expression
CC varies as in M1, where a test substance which modifies the expression of
CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
CC identifying human genes which are involved in cell cycle progression
CC comprising contacting human DNA with a probe which comprises at least 10
CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
CC and (4) a method (M4) for identifying a candidate drug as a member of a
CC class of drugs having a characteristic effect on gene expression in a
CC yeast cell comprising contacting a yeast cell with a candidate drug and
CC monitoring expression in the yeast cell of at least 1 NORF gene whose
CC expression is affected by the class of drugs. The NORF genes may be used
CC to study, monitor and affect phases of the cell cycle, the differentially
CC expressed genes may be used as markers of phases of the cell cycle. The
CC methods may be used to identify candidate drugs which affect the cell
CC cycle and for identification of antifungal drugs. AAF33268 to AAF4064
CC represent SAGE tags used in the exemplification of the present invention.
CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
CC method, in the exemplification of the present invention.
XX
XX Sequence 10 BP; 3 A; 1 C; 2 G; 4 T; 0 U; 0 Other;
SQ
Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2216 TGTGACCAAA 2225
DB 10 TGTGACCAAA 1
RESULT 600
AAF38454
ID AAF38454 standard; DNA; 10 BP.
AC AAF38454;
XX
XX 23-MAR-2001 (first entry)
XX
XX Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:5193.
XX
XX Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
KW serial analysis of gene expression; antifungal; tag; identification;
KW linker; PCR primer; ds.
XX
XX Saccharomyces cerevisiae.
XX
XX WO200077214-A2.
XX
XX 21-DEC-2000.
XX
XX 14-JUN-2000; 2000WO-US016223.
XX
XX

```

```
XX 14-JUN-2000; 2000WO-US016223.
XX 16-JUN-1999; 99US-00335032.
XX (UYJO ) UNIV JOHNS HOPKINS.
XX Velculescu V, Vogelstein B, Kinzler K;
XX WPI; 2001-061874/07.
XX Yeast gene coding sequences comprising NORF genes with serial analysis of
PT gene expression (SAGE) tags, useful for studying, monitoring and
PT affecting phases of the cell cycle.
XX Example; Page 185; 419pp; English.
XX The present invention describes an isolated DNA molecule comprising a
CC coding sequence of a yeast gene selected from a group of 745 NORF (not
CC previously assigned open reading frame; or nonannotated ORF) genes
CC comprising a SAGE (serial analysis of gene expression) tag. Also
CC described are: (1) a method (M1) of using NORF genes to affect the cell
CC cycle comprising administering a NORF gene whose expression varies by at
CC least 10% between any two phases of the cell cycle selected from log
CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
CC antifungal drugs comprising: (a) contacting a test substance with a yeast
CC cell; and (b) monitoring expression of a NORF gene whose expression
CC varies as in M1, where a test substance which modifies the expression of
CC identifying human genes which are involved in cell cycle progression
CC comprising contacting human DNA with a probe which comprises at least 10
CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
CC and (4) a method (M4) for identifying a candidate drug as a member of a
CC class of drugs having a characteristic effect on gene expression in a
CC yeast cell comprising contacting a yeast cell with a candidate drug and
CC monitoring expression in the yeast cell of at least 1 NORF gene whose
CC expression is affected by the class of drugs. The NORF genes may be used
CC to study, monitor and affect phases of the cell cycle. The differentially
CC expressed genes may be used as markers of phases of the cell cycle. The
CC methods may be used to identify candidate drugs which affect the cell
CC cycle and for identification of antifungal drugs. AAF33268 to AAF44064
CC represent SAGE tags used in the exemplification of the present invention.
CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
CC method, in the exemplification of the present invention.
XX Sequence 10 BP; 6 A; 2 C; 1 G; 1 T; 0 U; 0 Other;
SQ Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2223 AAAAGTTACA 2232
DB 1 AAAAGCTACA 10
|||||
RESULT 601
AAF37124/C
ID AAF37124 standard; DNA; 10 BP.
XX AAF37124;
XX 23-MAR-2001 (first entry)
XX Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:3863.
XX Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
KW serial analysis of gene expression; antifungal; tag; identification;
KW linker; PCR primer; ds.
XX Saccharomyces cerevisiae.
XX
```

```
PN W0200077214-A2.
PD 21-DEC-2000.
XX 14-JUN-2000; 2000WO-US016223.
XX 16-JUN-1999; 99US-00335032.
XX (UYJO ) UNIV JOHNS HOPKINS.
XX Velculescu V, Vogelstein B, Kinzler K;
XX WPI; 2001-061874/07.
XX Yeast gene coding sequences comprising NORF genes with serial analysis of
PT gene expression (SAGE) tags, useful for studying, monitoring and
PT affecting phases of the cell cycle.
XX Example; Page 138; 419pp; English.
XX The present invention describes an isolated DNA molecule comprising a
CC coding sequence of a yeast gene selected from a group of 745 NORF (not
CC previously assigned open reading frame; or nonannotated ORF) genes
CC comprising a SAGE (serial analysis of gene expression) tag. Also
CC described are: (1) a method (M1) of using NORF genes to affect the cell
CC cycle comprising administering a NORF gene whose expression varies by at
CC least 10% between any two phases of the cell cycle selected from log
CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
CC antifungal drugs comprising: (a) contacting a test substance with a yeast
CC cell; and (b) monitoring expression of a NORF gene whose expression
CC varies as in M1, where a test substance which modifies the expression of
CC identifying human genes which are involved in cell cycle progression
CC comprising contacting human DNA with a probe which comprises at least 10
CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
CC and (4) a method (M4) for identifying a candidate drug as a member of a
CC class of drugs having a characteristic effect on gene expression in a
CC yeast cell comprising contacting a yeast cell with a candidate drug and
CC monitoring expression in the yeast cell of at least 1 NORF gene whose
CC expression is affected by the class of drugs. The NORF genes may be used
CC to study, monitor and affect phases of the cell cycle. The differentially
CC expressed genes may be used as markers of phases of the cell cycle. The
CC methods may be used to identify candidate drugs which affect the cell
CC cycle and for identification of antifungal drugs. AAF33268 to AAF44064
CC represent SAGE tags used in the exemplification of the present invention.
CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
CC method, in the exemplification of the present invention.
XX Sequence 10 BP; 1 A; 3 C; 2 G; 4 T; 0 U; 0 Other;
SQ Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2219 GACCAGAAAGT 2228
DB 10 GACCAGAAAGT 1
|||||
RESULT 602
AAF39808
ID AAF39808 standard; DNA; 10 BP.
XX AAF39808;
XX 23-MAR-2001 (first entry)
XX Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:6547.
XX Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
KW serial analysis of gene expression; antifungal; tag; identification;
KW linker; PCR primer; ds.
XX
```

XX nor previously assigned open reading frame; nonannotated ORF; SAGE;
 OS serial analysis of gene expression; antifungal; tag; identification;
 PN linker; PCR primer; ds.
 PD Saccharomyces cerevisiae.
 PP WO200077214-A2.
 XX 21-DEC-2000.
 PF 14-JUN-2000; 2000WO-US016223.
 XX 16-JUN-1999; 99US-00335032.
 PR (UYJO) UNIV JOHNS HOPKINS.
 PA Velulescu V, Vogelstein B, Kinzler K;
 XX WPI; 2001-061874/07.
 XX Yeast gene coding sequences comprising NORF genes with serial analysis of
 DR gene expression (SAGE) tags, useful for studying, monitoring and
 PT affecting phases of the cell cycle.
 XX Example; Page 233; 419pp; English.
 PS The present invention describes an isolated DNA molecule comprising a
 CC coding sequence of a yeast gene selected from a group of 745 NORF (not
 CC previously assigned open reading frame; or nonannotated ORF) genes
 CC comprising a SAGE (serial analysis of gene expression) tag. Also
 CC described are: (1) a method (M1) of using NORF genes to affect the cell
 CC cycle comprising administering a NORF gene whose expression varies by at
 CC least 10% between any two phases of the cell cycle selected from log
 CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
 CC antifungal drugs comprising: (a) contacting a test substance with a yeast
 CC cell; and (b) monitoring expression of a NORF gene whose expression
 CC varies as in M1, where a test substance which modifies the expression of
 CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
 CC identifying human genes which are involved in cell cycle progression
 CC comprising contacting human DNA with a probe which comprises at least 10
 CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
 CC and (4) a method (M4) for identifying a candidate drug as a member of a
 CC class of drugs having a characteristic effect on gene expression in a
 CC yeast cell comprising contacting a yeast cell with a candidate drug and
 CC monitoring expression in the yeast cell of at least 1 NORF gene whose
 CC expression is affected by the class of drugs. The NORF genes may be used
 CC to study, monitor and affect phases of the cell cycle, the differentially
 CC expressed genes may be used as markers of phases of the cell cycle. The
 CC methods may be used to identify candidate drugs which affect the cell
 CC cycle and for identification of antifungal drugs. AAF33268 to AAF4064
 CC represent SAGE tags used in the exemplification of the present invention.
 CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
 CC method, in the exemplification of the present invention
 XX
 SQ Sequence 10 BP; 4 A; 2 C; 3 G; 1 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 2.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2214 AGTGACCA 2223
 |||||
 Db 1 AGTGACCA 10
 RESULT 603
 AAF43316/C
 ID AAF43316 standard; DNA; 10 BP.
 XX AAF43316;
 AC AAF43316;
 XX 23-MAR-2001 (first entry)
 DT Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:11455.
 DE Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
 XX

KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
 KW serial analysis of gene expression; antifungal; tag; identification;
 XX linker; PCR primer; ds.
 OS Saccharomyces cerevisiae.
 PN WO200077214-A2.
 XX 21-DEC-2000.
 PD 14-JUN-2000; 2000WO-US016223.
 PF 16-JUN-1999; 99US-00335032.
 PR (UYJO) UNIV JOHNS HOPKINS.
 PA Velulescu V, Vogelstein B, Kinzler K;
 XX WPI; 2001-061874/07.
 XX Yeast gene coding sequences comprising NORF genes with serial analysis of
 DR gene expression (SAGE) tags, useful for studying, monitoring and
 PT affecting phases of the cell cycle.
 XX Example; Page 359; 419pp; English.
 PS The present invention describes an isolated DNA molecule comprising a
 CC coding sequence of a yeast gene selected from a group of 745 NORF (not
 CC previously assigned open reading frame; or nonannotated ORF) genes
 CC comprising a SAGE (serial analysis of gene expression) tag. Also
 CC described are: (1) a method (M1) of using NORF genes to affect the cell
 CC cycle comprising administering a NORF gene whose expression varies by at
 CC least 10% between any two phases of the cell cycle selected from log
 CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
 CC antifungal drugs comprising: (a) contacting a test substance with a yeast
 CC cell; and (b) monitoring expression of a NORF gene whose expression
 CC varies as in M1, where a test substance which modifies the expression of
 CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
 CC identifying human genes which are involved in cell cycle progression
 CC comprising contacting human DNA with a probe which comprises at least 10
 CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
 CC and (4) a method (M4) for identifying a candidate drug as a member of a
 CC class of drugs having a characteristic effect on gene expression in a
 CC yeast cell comprising contacting a yeast cell with a candidate drug and
 CC monitoring expression in the yeast cell of at least 1 NORF gene whose
 CC expression is affected by the class of drugs. The NORF genes may be used
 CC to study, monitor and affect phases of the cell cycle, the differentially
 CC expressed genes may be used as markers of phases of the cell cycle. The
 CC methods may be used to identify candidate drugs which affect the cell
 CC cycle and for identification of antifungal drugs. AAF33268 to AAF4064
 CC represent SAGE tags used in the exemplification of the present invention.
 CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
 CC method, in the exemplification of the present invention
 XX
 SQ Sequence 10 BP; 2 A; 2 C; 1 G; 5 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 2.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTTACA 2232
 |||||
 Db 10 AAAAGTTTACA 1
 RESULT 604
 ABV84769
 ID ABV84769 standard; cDNA; 10 BP.
 XX ABV84769;
 AC ABV84769;
 XX 12-DEC-2002 (first entry)
 DT
 XX

DE Chronic hepatitis C/HCC differentially expressed gene SAGE tag #579.
 XX SAGE tag; serial analysis of gene expression; human; chronic hepatitis C;
 KW CH; liver tissue; hepatocellular carcinoma; cancer; tumour; HCC;
 KW expression pattern; differential expression; ss.
 XX Homo sapiens.
 OS
 XX JP2002209591-A.
 PN 30-JUL-2002.
 XX 19-JAN-2001; 2001JP-00012328.
 XX 19-JAN-2001; 2001JP-00012328.
 PF (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.
 XX WPI; 2002-631294/68.
 XX Human chronic hepatitis C tissue expression exasperating gene group
 PT comprises 100 high-ranking genes.
 XX Claim 46; Page 26; 139pp; Japanese.
 PS The invention relates to SAGE (serial analysis of gene expression) tags
 XX representing groups of genes which are differentially expressed in human
 CC chronic hepatitis C (CH) liver tissue or hepatitis C-induced
 CC hepatocellular carcinoma (HCC) compared with normal human liver tissue.
 CC The SAGE tags of this invention consist of a sequence of 10 nucleotides
 CC located downstream of the 5'-CATG-3' sequence motif lying nearest to the
 CC polyA region of cDNAs derived from a variety of genes. These tags serve
 CC to uniquely identify each transcript and can thus be used to analyse the
 CC pattern of gene expression in particular cell types. The invention also
 CC relates to proteins encoded by the genes expressed in chronic hepatitis C
 CC liver tissue or HCC, antibodies against these proteins, and inhibitors of
 CC the expression of groups of genes that are overexpressed in chronic
 CC hepatitis C liver tissue or HCC. Groups of genes differentially expressed
 CC in chronic hepatitis C tissue or HCC may be used for the diagnosis and
 CC treatment of these diseases. Such genes, inhibitors of their expression
 CC or activity, and antibodies against the gene products may be used in the
 CC development of drugs to treat chronic hepatitis C and/or HCC. Sequences
 CC ABV84691-ABV84790 are SAGE tags representing the 100 least highly
 CC expressed genes out of those genes which are underexpressed in
 CC hepatocellular carcinoma compared with chronic hepatitis C liver tissue
 XX
 SQ Sequence 10 BP; 4 A; 2 C; 3 G; 1 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 2.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2218 TGACCAAAAG 2227
 DB 1 TGACCAAG 10
 RESULT 605
 ABV84230
 ID ABV84230 standard; cDNA; 10 BP.
 XX
 AC ABV84230;
 XX
 XX 12-DEC-2002 (first entry)
 DT Human chronic hepatitis C tissue overexpressed gene SAGE tag #40.
 DE SAGE tag; serial analysis of gene expression; human; chronic hepatitis C;
 KW CH; liver tissue; hepatocellular carcinoma; cancer; tumour; HCC;
 KW expression pattern; differential expression; ss.
 XX Homo sapiens.
 OS

PN JP2002209591-A.
 XX 30-JUL-2002.
 XX 19-JAN-2001; 2001JP-00012328.
 XX 19-JAN-2001; 2001JP-00012328.
 PF (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.
 XX WPI; 2002-631294/68.
 XX Human chronic hepatitis C tissue expression exasperating gene group
 PT comprises 100 high-ranking genes.
 XX Claim 1; Page 10; 139pp; Japanese.
 PS The invention relates to SAGE (serial analysis of gene expression) tags
 XX representing groups of genes which are differentially expressed in human
 CC chronic hepatitis C (CH) liver tissue or hepatitis C-induced
 CC hepatocellular carcinoma (HCC) compared with normal human liver tissue.
 CC The SAGE tags of this invention consist of a sequence of 10 nucleotides
 CC located downstream of the 5'-CATG-3' sequence motif lying nearest to the
 CC polyA region of cDNAs derived from a variety of genes. These tags serve
 CC to uniquely identify each transcript and can thus be used to analyse the
 CC pattern of gene expression in particular cell types. The invention also
 CC relates to proteins encoded by the genes expressed in chronic hepatitis C
 CC liver tissue or HCC, antibodies against these proteins, and inhibitors of
 CC the expression of groups of genes that are overexpressed in chronic
 CC hepatitis C liver tissue or HCC. Groups of genes differentially expressed
 CC in chronic hepatitis C tissue or HCC may be used for the diagnosis and
 CC treatment of these diseases. Such genes, inhibitors of their expression
 CC or activity, and antibodies against the gene products may be used in the
 CC development of drugs to treat chronic hepatitis C and/or HCC. Sequences
 CC ABV84191-ABV84290 are SAGE tags representing the 100 most highly
 CC expressed genes out of those genes which are overexpressed in chronic
 CC hepatitis C liver tissue compared with normal liver tissue
 XX
 SQ Sequence 10 BP; 4 A; 2 C; 3 G; 1 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 2.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2218 TGACCAAAAG 2227
 DB 1 TGACCAAG 10
 RESULT 606
 ABK70750
 ID ABK70750 standard; DNA; 10 BP.
 XX
 AC ABK70750;
 XX
 XX 15-JUL-2002 (first entry)
 DT Primer-extension oligonucleotide #7 to detect human SCYA8 polymorphisms.
 DE Human; single nucleotide polymorphism; SNP; monocyte chemotactic protein;
 KW small inducible cytokine subfamily A member 8; SCYA8; anti-HIV;
 KW haplotyping; genotyping; inflammatory disease; HIV infection;
 KW human immunodeficiency virus; primer; ss.
 XX Homo sapiens.
 OS
 XX WO200222888-A1.
 PN 21-MAR-2002.
 XX 17-SEP-2001; 2001WO-US029332.
 PF 15-SEP-2000; 2000US-0232755P.
 PR

CC sequences given in the exemplification of the present invention
 XX
 SQ Sequence 10 BP; 3 A; 2 C; 4 G; 1 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 2.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2213 GAGTGTGACC 2222
 Db 1 GAGTGTGACC 10

RESULT 609
 ADE73174
 ID ADE73174 standard; DNA; 10 BP.

XX ADE73174;

XX 29-JAN-2004 (first entry)

XX Oligon #11 used to illustrate nucleic acid characterisation method.

XX Mutation detection; identification; ss.

XX Synthetic.

XX WO2003091408-A2.

XX 06-NOV-2003.

XX 25-APR-2003; 2003WO-US012962.

XX 26-APR-2002; 2002US-0375640P.

XX (UTAH) UNIV UTAH.

XX Wittwer CT, Dummer CW;

XX WPI; 2003-845591/78.

XX Characterizing single stranded nucleic acid, by combining nucleic acid
 PT with specific dye to form detectable complex, varying temperature to
 PT determine melting temperature for each secondary structures in complex.

XX Example 2; Fig 8; 94pp; English.

XX The present invention relates to a method (M1) for characterizing single
 CC stranded nucleic acid (SNA). The method involves combining SNA with
 CC double stranded nucleic acid-specific dye to form detectable complex
 CC between dye and one or more double strand secondary structures within
 CC SNA, and varying temperature of SNA to determine melting temperature (Tm)
 CC for each of the secondary structures in detectable complex, where Tm(s)
 CC define a Tm profile characterizing SNA. (M1) is useful for detecting a
 CC difference between the sequence of a first and a second single stranded
 CC nucleic acid which involves determining the Tm profile of a first single
 CC stranded nucleic acid using a double stranded nucleic acid-specific dye,
 CC and comparing the Tm profile of the first single stranded nucleic acid
 CC with the Tm profile of the second single stranded nucleic acid, where a
 CC difference in Tm profile between the first and the second single stranded
 CC nucleic acid indicates a difference in sequence between the first and
 CC second nucleic acids. The determining is by combining the first single
 CC stranded nucleic acid with a double stranded nucleic acid-specific dye to
 CC form a detectable complex between the dye and one or more double strand
 CC secondary structures within the first single stranded nucleic acid and
 CC measuring the fluorescence emission of the double strand nucleic acid-
 CC specific dye while varying the temperature of the combination. A change
 CC in fluorescence indicates a change in secondary structure of the single
 CC stranded nucleic acid. (M1) is useful for detecting a change (mutation)
 CC in the sequence of a sample nucleic acid as compared with a nucleic acid
 CC having a known sequence which involves determining the Tm profile of a
 CC single stranded nucleic acid sample using a double strands nucleic acid-
 CC specific dye, where a difference between the Tm profile of the nucleic

CC acid sample and the Tm profile of the nucleic acid having a known
 CC sequence indicates an alteration in the sequence of the sample nucleic
 CC acid as compared to the known sequence. (M1) is useful for identifying
 CC the species type of a cell (bacterial or plant cell) which involves
 CC determining the Tm profile of a sample rRNA or its fragment from a cell
 CC using a double stranded nucleic acid-specific dye, where a match between
 CC the determined Tm profile and the Tm profile of a corresponding rRNA or
 CC its fragment of a cell from a known species type indicates that the
 CC sample rRNA is from the known rRNA cell type. The sample rRNA or its
 CC fragment is an amplified rRNA gene or its fragment. The determining is by
 CC combining the rRNA gene or its fragment with a double stranded nucleic
 CC acid-specific dye to form a detectable complex between the dye and one or
 CC more double strand secondary structures within the amplified rRNA gene or
 CC its fragment and measuring the fluorescence emission of the double strand
 CC nucleic acid-specific dye while varying the temperature of the
 CC combination. In an example from the invention, a model oligonucleotide
 CC system was designed to (1) demonstrate secondary structure melting curves
 CC by monitoring fluorescence intensity of ds DNA specific nucleic acid dye
 CC SYBR Green 1, (2) empirically determine secondary structure melting
 CC temperature ranges, (3) demonstrate multiple domain melting using SYBR
 CC Green I fluorescence and (4) demonstrate sequence specific melting of
 CC secondary structures using SYBR Green I. The present sequence is an
 CC oligonucleotide used in the model system.

SQ Sequence 10 BP; 5 A; 2 C; 2 G; 1 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 10;

Best Local Similarity 90.0%; Pred. No. 2.6e+02;

Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2220 ACCAAAAGTT 2229

Db 1 ACCAAAAGTT 10

RESULT 610

AAL56066/c

ID AAL56066 standard; DNA; 10 BP.

XX AAL56066;

XX 11-MAR-2004 (first entry)

XX Human BAGE 5 intron/exon junction #5.

XX BAGE; tumour antigen; melanoma; cancer; cytostatic; gene therapy; gene;
 XX ds.

XX Homo sapiens.

XX WO2003084990-A1.

XX 16-OCT-2003.

XX 05-APR-2002; 2002WO-EP003811.

XX 05-APR-2002; 2002WO-EP003811.

XX (CNRS) CENT NAT RECH SCI.

XX De Sario A, Ruault M;

XX WPI; 2003-804293/75.

XX New BAGE proteins useful for manufacturing a medicament for diagnosing
 PT and treating cancer, particularly melanoma.

XX Disclosure; Page 13; Opp; English.

XX The present invention provides the protein and coding sequences of a
 CC number of members of the BAGE family of proteins from humans. The
 CC proteins or their antibodies are useful for manufacturing a medicament
 CC for the treatment of pathologies (e.g. tumours such as melanomas) linked

CC to the expression, at the surface of the cells of the organism, of
CC complexes between the peptide fragments and HLA molecules. The methods
CC may also be used for treating a subject with a tumour, such as melanoma.
CC The nucleotide sequences, host cells, cytolytic cells or antibodies are
CC also useful for in vitro diagnosis of the disorders cited above. The
CC present sequence is a coding sequence/fragment of the invention
XX
XX
SQ Sequence 10 BP; 6 A; 0 C; 2 G; 2 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTT 2237
DB 10 TTACATCTTT 1

RESULT 611
AAL56049/C
ID AAL56049 standard; DNA; 10 BP.
XX
AC AAL56049;
XX
DT 11-MAR-2004 (first entry)
XX
DE Human BAGE 2 intron/exon junction #5.
XX
KW BAGE; tumour antigen; melanoma; cancer; cytostatic; gene therapy; gene;
KW ds.
XX
OS Homo sapiens.
XX
PN WO2003084990-A1.
XX
PD 16-OCT-2003.
XX
PF 05-APR-2002; 2002WO-EP003811.
XX
PR 05-APR-2002; 2002WO-EP003811.
XX
PS (CNRS) CENT NAT RECH SCI.
XX
PI De Sario A, Ruault M;
XX
PP WPI; 2003-804293/75.
XX
PT New BAGE proteins useful for manufacturing a medicament for diagnosing
PT and treating cancer, particularly melanoma.
XX
PS Disclosure; Page 13; Opp; English.
XX
CC The present invention provides the protein and coding sequences of a
CC number of members of the BAGE family of proteins from humans. The
CC proteins or their antibodies are useful for manufacturing a medicament
CC for the treatment of pathologies (e.g. tumours such as melanomas) linked
CC to the expression, at the surface of the cells of the organism, of
CC complexes between the peptide fragments and HLA molecules. The methods
CC may also be used for treating a subject with a tumour, such as melanoma.
CC The nucleotide sequences, host cells, cytolytic cells or antibodies are
CC also useful for in vitro diagnosis of the disorders cited above. The
CC present sequence is a coding sequence/fragment of the invention
XX
XX
SQ Sequence 10 BP; 6 A; 0 C; 2 G; 2 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTT 2237
DB 10 TTACATCTTT 1

RESULT 612
ADL96132/C
ID ADL96132 standard; DNA; 10 BP.
XX
AC ADL96132;
XX
DT 20-MAY-2004 (first entry)
XX
DE CD15+ myeloid cell associated probe seqid 30.
XX
KW cytostatic; gene therapy; microarray; gene expression characteristic;
KW haematopoietic cell; haematopoiesis; myeloid leukaemia; probe;
XX
KW CD15+ myeloid cell; ss.
XX
OS Homo sapiens.
XX
PN US2003165949-A1.
XX
PD 04-SEP-2003.
XX
PF 23-DEC-2002; 2002US-00329465.
XX
PR 27-DEC-2001; 2001US-0343826P.
XX
PA (WANG/) WANG S M.
PA (LEES/) LEE S.
PA (CHEN/) CHEN J.
PA (ZHOU/) ZHOU G.
PA (ROWL/) ROWLEY J D.
XX
PI Wang SM, Lee S, Chen J, Zhou G, Rowley JD;
XX
PP WPI; 2003-863699/80.
XX
PT New microarray for measuring gene expression characteristics of
PT hematopoietic cells, useful for preparing a composition for diagnosing or
PT treating myeloid leukemia.
XX
PS Claim 1; SEQ ID NO 30; 32pp; English.
XX
CC The invention describes a microarray for measuring gene expression
CC characteristics of haematopoietic cells comprising at least 5
CC polynucleotides having distinct sequences. Also described are: a method
CC of diagnosing or treating an abnormality associated with haematopoiesis;
CC and diagnosing myeloid leukaemia in a patient. The microarray is useful
CC for preparing a composition for diagnosing or treating myeloid leukaemia.
CC This sequence represents a polynucleotide probe comprising a portion of
CC an expressed gene isolated from a population of CD15+ myeloid cells and
CC suitable for use in the microarray of the invention.
XX
SQ Sequence 10 BP; 2 A; 2 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2214 AGTGTGACCA 2223
DB 10 AGTATGACCA 1

RESULT 613
ADH14478
ID ADH14478 standard; DNA; 10 BP.
XX
AC ADH14478;
XX
DT 11-MAR-2004 (first entry)
XX
DE Human retinoblastoma 1 (RB1CC1) genomic DNA 3' border of exon 14.
XX
KW cell nucleus; transcription; gene expression; retinoblastoma-1; RB1CC1;

diagnosis; cancer; primer; ss.
 Homo sapiens.
 WO2003102028-A1.
 11-DEC-2003.
 30-JAN-2003; 2003WO-JF000882.
 03-JUN-2002; 2002JP-00161400.
 24-JUL-2002; 2002JP-00214978.
 (OKAB/) OKABE H.
 (IKEG/) IKEGAWA S.
 (CHAN/) CHANO T.
 Chano T;
 MPI; 2004-081932/08.
 Protein in the nuclei of human and animal cells associated with
 expression of retinoblastoma-1 gene for diagnosis of cancer.
 Disclosure; Page 11; 113pp; Japanese.
 The invention relates to a protein or polypeptide found in the nuclei of
 human and animal cells that are associated with transcription and/or
 induction of expression of retinoblastoma-1 gene (RB1CC1). The detection
 of RB1CC1 gene and its protein is useful for the diagnosis of cancer. The
 human RB1CC1 cDNA is 6.6 kb containing a 4782 bp ORF, encoding a 180 kD
 1594 amino acid protein. This sequence corresponds to the sequence at the
 junction between an intron and an exon in the human RB1CC1 genomic
 sequence.
 Sequence 10 BP; 6 A; 1 C; 2 G; 1 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 2.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2218 TGACCAAAAG 2227
 ||| |||||
 DB 1 TGAACAAAAG 10
 RESULT 614
 ADK13337
 ID ADK13337 standard; DNA; 10 BP.
 AC ADK13337;
 XX 20-MAY-2004 (first entry)
 DE Human glioma endothelial marker (GEM) SAGE tag oligonucleotide.
 XX glioma; brain tissue; neoplastic; glioma endothelial marker; GEM;
 KW anticancer; antiglioma; immune response; cytostatic;
 KW multi-drug sensitive glioma; human; SAGE tag; ss.
 OS Homo sapiens.
 OS Synthetic.
 XX WO2004016758-A2.
 XX 26-FEB-2004.
 XX 15-AUG-2003; 2003WO-US025614.
 PF 15-AUG-2002; 2002US-0403390P.
 PR 01-APR-2003; 2003US-0458978P.
 XX (GENZ) GENZYME CORP.

PA (UYJO) UNIV JOHNS HOPKINS.
 XX Madden SI, Wang CJ, Cook BP, Lattexa J, Walter K;
 XX MPI; 2004-247973/23.
 XX Diagnosing glioma by detecting expression product of any one of 255
 PT genes, glioma endothelial markers, in brain tissue sample suspected of
 PT being neoplastic, and comparing the expression with expression in normal
 PT brain tissue sample.
 XX Example 10; Page 64; 114pp; English.
 XX The present invention describes a method (M1) for aiding in the diagnosis
 CC of glioma. (M1) involves detecting an expression product of at least one
 CC gene (I) in a first brain tissue sample (T) suspected of being
 CC neoplastic, where (I) is chosen from any one of 255 genes (glioma
 CC endothelial markers (GEMs)) as given in specification, and comparing the
 CC expression of (I) in (T) with expression of (I) in a second normal brain
 CC tissue sample (R), where increased expression of (I) in (T) relative to
 CC (R), identifies (T) as likely to be neoplastic. Also described: (1)
 CC treating (M2) glioma involves contacting cells of the glioma with an
 CC antibody that specifically binds to a extracellular epitope; (2)
 CC identifying (M3) a test compound as potential anticancer or antiglioma
 CC drug involves contacting a test compound with the cell which expresses
 CC (1), monitoring an expression product of the at least one gene and
 CC identifying test compound as a potential anticancer drug if it decreases
 CC the expression of at least one gene; (3) identifying (M4) a test compound
 CC as potential anticancer or antiglioma drug involves contacting a test
 CC compound with the cell which expresses mRNA of at least one gene
 CC identified by a tag as described above, monitoring mRNA of the gene, and
 CC identifying the test compound as a potential anticancer drug if it
 CC decreases the expression of at least one gene; and (4) inducing (M5) an
 CC immune response to glioma involves administering to a mammal, a protein
 CC or (I). (I) have cytostatic activities, and can be used to trigger immune
 CC destruction of glioma cells, and as immune response inducers. (M1) is
 CC useful for aiding in diagnosing glioma. (M2) is useful for inducing an immune
 CC -drug sensitive glioma in a human. (M5) is useful for inducing an immune
 CC response to a glioma in a mammal having glioma or in a mammal who has had
 CC a glioma surgically removed. The present sequence represents a human GEM
 CC SAGE tag oligonucleotide, which is used in the exemplification of the
 CC present invention.
 XX Sequence 10 BP; 3 A; 2 C; 4 G; 1 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 2.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2213 GAGTGTGACC 2222
 ||||| |||||
 DB 1 GAGTGAGACC 10
 RESULT 615
 ADK12886
 ID ADK12886 standard; DNA; 10 BP.
 XX AC ADK12886;
 XX 20-MAY-2004 (first entry)
 DE Human glioma endothelial marker (GEM) standard tag SEQ ID NO:64.
 XX glioma; brain tissue; neoplastic; glioma endothelial marker; GEM;
 KW anticancer; antiglioma; immune response; cytostatic;
 KW multi-drug sensitive glioma; human; standard tag; ss.
 OS Homo sapiens.
 OS Synthetic.
 XX WO2004016758-A2.


```

XX AC AAV82624;
XX DT 11-FEB-1999 (first entry)
XX DE Target binding site for the polyamides of the invention.
XX KW Binding site; polyamide; hairpin turn; gamma-aminobutyric acid; GABA;
XX KW minor groove; (R)-2,4-diaminobutyric acid; R-DAB; gene expression;
XX KW inhibition; detection; ds.
XX OS Synthetic.
XX PN WO9845284-A1.
XX PD 15-OCT-1998.
XX PF 29-JAN-1998; 98WO-US003829.
XX PR 20-FEB-1997; 97WO-US003332.
XX PR 08-APR-1997; 97US-0043444P.
XX PR 16-APR-1997; 97US-0042022P.
XX PR 21-APR-1997; 97US-00837524.
XX PR 08-MAY-1997; 97US-00853522.
XX PR 21-JUL-1997; 97WO-US012722.
XX PA (CALY ) CALIFORNIA INST OF TECHNOLOGY.
XX PI Baird EE, Dervan PB;
XX WPI; 1998-594477/50.
XX New hairpin polyamides including R-2,4-diaminobutyric acid residue in the
XX hairpin - bind more tightly to complementary bases in the minor groove of
XX DNA, particularly of regulatory regions for therapeutic or diagnostic
XX inhibition of gene expression.
XX Example 9; Page 43; 79pp; English.
XX The present sequence represents a target binding site for the polyamides
XX of the invention. These polyamides have a hairpin turn derived from gamma
XX -aminobutyric acid (GABA) and bind specifically to base pairs in the
XX minor groove of DNA. The GABA in the hairpin of the polyamides is
XX replaced by the residue of (R)-2,4-diaminobutyric acid (R-DAB). The
XX polyamides are used to inhibit gene expression by sequence-specific
XX binding to the double-stranded regulatory region of the gene. They can be
XX used therapeutically or diagnostically, e.g. for detection or isolation
XX of target DNA
XX Sequence 11 BP; 2 A; 0 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2227 GTTACATGTT 2236
Db 2 GTTATATGTT 11

RESULT 618
AAH55107/c
ID AAH55107 standard; DNA; 11 BP.
XX AAH55107;
XX 03-SEP-2001 (first entry)
XX Genomic DNA methylation parallel detection associated DNA fragment #9.
XX DNA methylation; parallel detection; 5-unmethylated cytosine; CpG; CpNpG;
XX amplification; transcription regulation; genetic imprinting;
XX tumorigenesis; primer; ss.

XX AC AAV82624;
XX DT 11-FEB-1999 (first entry)
XX DE Target binding site for the polyamides of the invention.
XX KW Binding site; polyamide; hairpin turn; gamma-aminobutyric acid; GABA;
XX KW minor groove; (R)-2,4-diaminobutyric acid; R-DAB; gene expression;
XX KW inhibition; detection; ds.
XX OS Synthetic.
XX PN WO9845284-A1.
XX PD 15-OCT-1998.
XX PF 29-JAN-1998; 98WO-US003829.
XX PR 20-FEB-1997; 97WO-US003332.
XX PR 08-APR-1997; 97US-0043444P.
XX PR 16-APR-1997; 97US-0042022P.
XX PR 21-APR-1997; 97US-00837524.
XX PR 08-MAY-1997; 97US-00853522.
XX PR 21-JUL-1997; 97WO-US012722.
XX PA (CALY ) CALIFORNIA INST OF TECHNOLOGY.
XX PI Baird EE, Dervan PB;
XX WPI; 1998-594477/50.
XX New hairpin polyamides including R-2,4-diaminobutyric acid residue in the
XX hairpin - bind more tightly to complementary bases in the minor groove of
XX DNA, particularly of regulatory regions for therapeutic or diagnostic
XX inhibition of gene expression.
XX Example 9; Page 43; 79pp; English.
XX The present sequence represents a target binding site for the polyamides
XX of the invention. These polyamides have a hairpin turn derived from gamma
XX -aminobutyric acid (GABA) and bind specifically to base pairs in the
XX minor groove of DNA. The GABA in the hairpin of the polyamides is
XX replaced by the residue of (R)-2,4-diaminobutyric acid (R-DAB). The
XX polyamides are used to inhibit gene expression by sequence-specific
XX binding to the double-stranded regulatory region of the gene. They can be
XX used therapeutically or diagnostically, e.g. for detection or isolation
XX of target DNA
XX Sequence 11 BP; 2 A; 0 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2227 GTTACATGTT 2236
Db 2 GTTATATGTT 11

RESULT 618
AAH55107/c
ID AAH55107 standard; DNA; 11 BP.
XX AAH55107;
XX 03-SEP-2001 (first entry)
XX Genomic DNA methylation parallel detection associated DNA fragment #9.
XX DNA methylation; parallel detection; 5-unmethylated cytosine; CpG; CpNpG;
XX amplification; transcription regulation; genetic imprinting;
XX tumorigenesis; primer; ss.

```

```

XX OS Unidentified.
XX PN WO200142493-A2.
XX PD 14-JUN-2001.
XX PF 06-DEC-2000; 2000WO-DE004381.
XX PR 06-DEC-1999; 99DE-01059691.
XX PA (EPIC-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C;
XX WPI; 2001-381705/40.
XX Parallel detection of the methylation pattern of many genomic DNA
XX regions, useful for detecting aberrant methylation, includes multiple
XX amplification of chemically modified DNA.
XX Claim 18; Page 19; 63pp; German.
XX This invention describes a novel method for the parallel detection of the
XX methylation status of genomic DNA (I) which involves a (I) sample being
XX treated chemically to convert 5-unmethylated cytosine to uracil,
XX thymidine or some other base having hybridization behavior different from
XX that of C, then amplifying simultaneously at least 10 different fragments
XX (of fewer than 2 kb) using synthetic oligonucleotide (ON) primers. These
XX primers are based on regulatory, transcribed and/or translated segments
XX present in the sample after chemical treatment. The sequence context of
XX all, or some, of the CpG and CpNpG motifs in the amplified products is
XX then determined. The method is used to detect aberrant methylation of
XX patterns in the genome, these are implicated in regulation of
XX transcription, genetic imprinting and tumorigenesis. Many target regions
XX in the genome can be analyzed simultaneously and it is not essential to
XX know the sequence context of all targeted regions. Primers may be
XX designed for preferential amplification of particular segments of
XX interest (e.g. promoters and exons)
XX Sequence 11 BP; 2 A; 0 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2223 AAAAGTTACA 2232
Db 11 AAAAATTACA 2

RESULT 619
AAH55108
ID AAH55108 standard; DNA; 11 BP.
XX AAH55108;
XX 03-SEP-2001 (first entry)
XX Genomic DNA methylation parallel detection associated DNA fragment #10.
XX DNA methylation; parallel detection; 5-unmethylated cytosine; CpG; CpNpG;
XX amplification; transcription regulation; genetic imprinting;
XX tumorigenesis; primer; ss.
XX Unidentified.
XX OS
XX PN WO200142493-A2.
XX PD 14-JUN-2001.
XX PF 06-DEC-2000; 2000WO-DE004381.
XX

```

PR 06-DEC-1999; 99DE-01059691.
 PA (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C;
 XX WPI; 2001-381705/40.
 XX
 PT Parallel detection of the methylation pattern of many genomic DNA
 PT regions, useful for detecting aberrant methylation, includes multiple
 PT amplification of chemically modified DNA.
 XX
 PS Claim 18; Page 19; 63pp; German.
 XX
 CC This invention describes a novel method for the parallel detection of the
 CC methylation status of genomic DNA (I) which involves a (I) sample being
 CC treated chemically to convert 5-unmethylated cytosine to uracil,
 CC thymidine or some other base having hybridization behavior different from
 CC that of C, then amplifying simultaneously at least 10 different fragments
 CC (of fewer than 2 kb) using synthetic oligonucleotide (ON) primers. These
 CC primers are based on regulatory, transcribed and/or translated segments
 CC present in the sample after chemical treatment. The sequence context of
 CC all, or some, of the CpG and CpNpG motifs in the amplified products is
 CC then determined. The method is used to detect aberrant methylation of
 CC patterns in the genome, these are implicated in regulation of
 CC transcription, genetic imprinting and tumorigenesis. Many target regions
 CC in the genome can be analyzed simultaneously and it is not essential to
 CC know the sequence context of all targeted regions. Primers may be
 CC designed for preferential amplification of particular segments of
 CC interest (e.g. promoters and exons)
 XX
 SQ Sequence 11 BP; 7 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 11;
 Best Local Similarity 90.0%; Pred. No. 3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTACA 2232
 DB 1 AAAAATTACA 10
 RESULT 620
 ABQ86506/C
 ID ABQ86506 standard; cDNA; 11 BP.
 XX
 AC ABQ86506;
 XX
 DT 10-SEP-2002 (first entry)
 DE Human skin stress/ageing related EST SEQ ID NO 261.
 XX
 KW Human; skin ageing; skin stress; EST; expressed sequence tag; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200253773-A2.
 XX
 PD 11-JUL-2002.
 XX
 PF 20-DEC-2001; 2001WO-EP015178.
 XX
 PR 03-JAN-2001; 2001DE-01000121.
 XX
 PA (HENK) HENKEL KGAA.
 XX
 PI Petersohn D, Conradt M, Hofmann K;
 XX
 DR WPI; 2002-528865/56.
 XX
 PT Identifying genes involved in skin stress and aging, useful e.g. in
 PT screening for cosmetic or therapeutic agents, based on differential gene
 PT expression.

XX Claim 8; Page 47; 325pp; German.
 PS
 CC The invention relates to identifying (M1) genes in vitro that, in humans
 CC or animals, are important for skin ageing and/or skin stress by serial
 CC analysis of gene expression between mixtures of transcribed and
 CC optionally translated, genetically encoded factors (A) obtained from
 CC young and aged skin, to identify that genes that show strong differential
 CC expression. (A) comprises protein or mRNAs or their fragments. (M1) is
 CC useful for: identifying markers of skin ageing and/or stress; determining
 CC skin ageing and/or stress; and identifying or determining the effects of
 CC pharmaceutical or cosmetic agents for control of skin ageing. The present
 CC sequence is one of a group of human skin ageing/stress related expressed
 CC sequence tags (ABQ86246-ABQ87680) of the invention
 XX
 SQ Sequence 11 BP; 1 A; 1 C; 2 G; 7 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 11;
 Best Local Similarity 90.0%; Pred. No. 3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTACA 2232
 DB 11 AAAAGATACA 2
 RESULT 621
 ABQ87043/C
 ID ABQ87043 standard; cDNA; 11 BP.
 XX
 AC ABQ87043;
 XX
 DT 10-SEP-2002 (first entry)
 DE Human skin stress/ageing related EST SEQ ID NO 798.
 XX
 KW Human; skin ageing; skin stress; EST; expressed sequence tag; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200253773-A2.
 XX
 PD 11-JUL-2002.
 XX
 PF 20-DEC-2001; 2001WO-EP015178.
 XX
 PR 03-JAN-2001; 2001DE-01000121.
 XX
 PA (HENK) HENKEL KGAA.
 XX
 PI Petersohn D, Conradt M, Hofmann K;
 XX
 DR WPI; 2002-528865/56.
 XX
 PT Identifying genes involved in skin stress and aging, useful e.g. in
 PT screening for cosmetic or therapeutic agents, based on differential gene
 PT expression.
 XX
 PS Claim 8; Page 70; 325pp; German.
 XX
 CC The invention relates to identifying (M1) genes in vitro that, in humans
 CC or animals, are important for skin ageing and/or skin stress by serial
 CC analysis of gene expression between mixtures of transcribed and
 CC optionally translated, genetically encoded factors (A) obtained from
 CC young and aged skin, to identify that genes that show strong differential
 CC expression. (A) comprises protein or mRNAs or their fragments. (M1) is
 CC useful for: identifying markers of skin ageing and/or stress; determining
 CC skin ageing and/or stress; and identifying or determining the effects of
 CC pharmaceutical or cosmetic agents for control of skin ageing. The present
 CC sequence is one of a group of human skin ageing/stress related expressed
 CC sequence tags (ABQ86246-ABQ87680) of the invention
 XX
 SQ Sequence 11 BP; 6 A; 2 C; 1 G; 2 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACAGTTT 2237
Db 11 TTACAGTTT 2

RESULT 622
ABQ87534/c
ID ABQ87534 standard; cDNA; 11 BP.
XX AC
XX ABQ87534;
DT 10-SEP-2002 (first entry)
XX DE Human skin stress/ageing related EST SEQ ID NO 1289.
XX DE Human; skin ageing; skin stress; EST; expressed sequence tag; ss.
XX OS Homo sapiens.
XX PN WO200253773-A2.
XX PD 11-JUL-2002.
XX PF 20-DEC-2001; 2001WO-EP015178.
XX PR 03-JAN-2001; 2001DE-01000121.
XX PA (HENK) HENKEL KGAA.
XX PI Petersohn D, Conradt M, Hofmann K;
XX DR WPI; 2002-528865/56.
XX PT Identifying genes involved in skin stress and aging, useful e.g. in
XX PT screening for cosmetic or therapeutic agents, based on differential gene
XX PT expression.
XX PS Claim 8; Page 90; 325pp; German.
XX CC The invention relates to identifying (M1) genes in vitro that, in humans
XX CC or animals, are important for skin ageing and/or skin stress by serial
XX CC analysis of gene expression between mixtures of transcribed and
XX CC optionally translated, genetically encoded factors (A) obtained from
XX CC young and aged skin, to identify that genes that show strong differential
XX CC expression. (A) comprises protein or mRNAs or their fragments. (M1) is
XX CC useful for: identifying markers of skin ageing and/or stress; determining
XX CC skin ageing and/or stress; and identifying or determining the effects of
XX CC pharmaceutical or cosmetic agents for control of skin ageing. The present
XX CC sequence is one of a group of human skin ageing/stress related expressed
XX CC sequence tags (ABQ86246-ABQ87680) of the invention
XX SQ Sequence 11 BP; 3 A; 2 C; 1 G; 5 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTTACA 2232
Db 10 AAAAGTTTCA 1

RESULT 623
ABQ87282/c
ID ABQ87282 standard; cDNA; 11 BP.
XX AC
XX ABQ87282;

10-SEP-2002 (first entry)
XX DE Human skin stress/ageing related EST SEQ ID NO 1037.
XX DE Human; skin ageing; skin stress; EST; expressed sequence tag; ss.
XX OS Homo sapiens.
XX PN WO200253773-A2.
XX PD 11-JUL-2002.
XX PF 20-DEC-2001; 2001WO-EP015178.
XX PR 03-JAN-2001; 2001DE-01000121.
XX PA (HENK) HENKEL KGAA.
XX PI Petersohn D, Conradt M, Hofmann K;
XX DR WPI; 2002-528865/56.
XX PT Identifying genes involved in skin stress and aging, useful e.g. in
XX PT screening for cosmetic or therapeutic agents, based on differential gene
XX PT expression.
XX PS Claim 8; Page 80; 325pp; German.
XX CC The invention relates to identifying (M1) genes in vitro that, in humans
XX CC or animals, are important for skin ageing and/or skin stress by serial
XX CC analysis of gene expression between mixtures of transcribed and
XX CC optionally translated, genetically encoded factors (A) obtained from
XX CC young and aged skin, to identify that genes that show strong differential
XX CC expression. (A) comprises protein or mRNAs or their fragments. (M1) is
XX CC useful for: identifying markers of skin ageing and/or stress; determining
XX CC skin ageing and/or stress; and identifying or determining the effects of
XX CC pharmaceutical or cosmetic agents for control of skin ageing. The present
XX CC sequence is one of a group of human skin ageing/stress related expressed
XX CC sequence tags (ABQ86246-ABQ87680) of the invention
XX SQ Sequence 11 BP; 1 A; 3 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2219 GACCAAAAGT 2228
Db 11 GCCCAAAAGT 2

RESULT 624
ABV64034
ID ABV64034 standard; cDNA; 11 BP.
XX AC
XX ABV64034;
XX DT 21-OCT-2002 (first entry)
XX DE Human skin EST 1820.
XX DE Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhoeic;
XX KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
XX KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX OS Homo sapiens.
XX PN WO200253774-A2.
XX PD 11-JUL-2002.
XX PF 20-DEC-2001; 2001WO-EP015179.
XX SQ

PR 03-JAN-2001; 2001DE-01000127.
 XX (HENK) HENKEL KGAA.
 PA Petersohn D, Conradt M, Hofmann K;
 PI WPI; 2002-590638/63.
 XX In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against
 PT e.g. skin cancer.
 PT Disclosure; Page 75; 1345pp; German.
 PS
 XX The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 XX Sequence 11 BP; 6 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 31.1%; Score 8.4; DB 1; Length 11;
 Best Local Similarity 90.0%; Pred. No. 3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTACA 2232
 DB 2 AAAAGTTACA 11
 RESULT 625
 ABV69946
 ID ABV69946 standard; cDNA; 11 BP.
 XX
 AC ABV69946;
 XX
 DT 21-OCT-2002 (first entry)
 XX Human skin EST 7732.
 DE
 XX Human; skin; dermatological; vulvular; antipsoriatic; antiseborrhaic;
 KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200253774-A2.
 XX
 PD 11-JUL-2002.
 XX
 PF 20-DEC-2001; 2001WO-EP015179.
 XX
 PR 03-JAN-2001; 2001DE-01000127.
 XX (HENK) HENKEL KGAA.
 PA Petersohn D, Conradt M, Hofmann K;
 PI WPI; 2002-590638/63.
 XX In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against
 PT e.g. skin cancer.
 PT Claim 24; Page 246; 1345pp; German.
 PS

XX The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 XX Sequence 11 BP; 7 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
 SQ
 Query Match 31.1%; Score 8.4; DB 1; Length 11;
 Best Local Similarity 90.0%; Pred. No. 3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2221 CCAAAAGTTA 2230
 DB 1 CCAAAAGTTA 10
 RESULT 626
 ABV67422/c
 ID ABV67422 standard; cDNA; 11 BP.
 XX
 AC ABV67422;
 XX
 DT 21-OCT-2002 (first entry)
 XX Human skin EST 5208.
 DE
 XX Human; skin; dermatological; vulvular; antipsoriatic; antiseborrhaic;
 KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200253774-A2.
 XX
 PD 11-JUL-2002.
 XX
 PF 20-DEC-2001; 2001WO-EP015179.
 XX
 PR 03-JAN-2001; 2001DE-01000127.
 XX (HENK) HENKEL KGAA.
 PA Petersohn D, Conradt M, Hofmann K;
 PI WPI; 2002-590638/63.
 XX In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against
 PT e.g. skin cancer.
 PT Disclosure; Page 169; 1345pp; German.
 PS
 XX The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 XX Sequence 11 BP; 7 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
 SQ


```
XX SQ Sequence 11 BP; 1 A; 1 C; 2 G; 7 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACA 2232
DB 11 AAAAGATACA 2

RESULT 627
ABV69109/c
ID ABV69109 standard; cDNA; 11 BP.
XX AC ABV69109;
XX DT 21-OCT-2002 (first entry)
XX DE Human skin EST 6895.
XX KW Human; skin; dermatological; vulnary; antipsoriatic; antiseborrhaeic;
XX KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
XX KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX OS Homo sapiens.
XX PN WO200253774-A2.
XX PD 11-JUL-2002.
XX PF 20-DEC-2001; 2001WO-EP015179.
XX PR 03-JAN-2001; 2001DE-01000127.
XX PA (HENK ) HENKEL KGAA.
XX PI Petersohn D, Conradt M, Hofmann K;
XX PT WPI; 2002-590638/63.
XX PT In vitro identification of skin-expressed genes, useful for determining
XX PT homeostasis and identifying cosmetic or pharmaceutical agents against
XX PT e.g. skin cancer.
XX PS Disclosure; Page 141; 1345pp; German.
XX CC The invention relates to in vitro identification (M1) of genes expressed
XX CC in the skin of humans or animals by subjecting a mixture of genetically
XX CC encoded factors from skin, to serial analysis of gene expression (SAGE)
XX CC so as to identify skin-expressed genes and quantify their expression.
XX CC (M1) is useful for identifying genes involved in skin homeostasis; to
XX CC determine skin homeostasis and to test agent (A) that maintains or
XX CC promotes skin homeostasis or that can be used for treating skin
XX CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
XX CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
XX CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
XX CC skin. The present sequence is that of a human expressed sequence tag
XX CC (EST) of the invention
XX SQ Sequence 11 BP; 1 A; 3 C; 3 G; 4 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2219 GACCAAAAGT 2228
DB 11 GCCCAAAAGT 2

RESULT 628
ABV71455
ID ABV71455 standard; cDNA; 11 BP.
XX AC ABV71455;
XX DT 21-OCT-2002 (first entry)
XX DE Human skin EST 9241.
XX KW Human; skin; dermatological; vulnary; antipsoriatic; antiseborrhaeic;
XX KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
XX KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX XX
```

```
ABV66433
ID ABV66433 standard; cDNA; 11 BP.
XX AC ABV66433;
XX DT 21-OCT-2002 (first entry)
XX DE Human skin EST 4219.
XX KW Human; skin; dermatological; vulnary; antipsoriatic; antiseborrhaeic;
XX KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
XX KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX OS Homo sapiens.
XX PN WO200253774-A2.
XX PD 11-JUL-2002.
XX PF 20-DEC-2001; 2001WO-EP015179.
XX PR 03-JAN-2001; 2001DE-01000127.
XX PA (HENK ) HENKEL KGAA.
XX PI Petersohn D, Conradt M, Hofmann K;
XX PT WPI; 2002-590638/63.
XX PT In vitro identification of skin-expressed genes, useful for determining
XX PT homeostasis and identifying cosmetic or pharmaceutical agents against
XX PT e.g. skin cancer.
XX PS Disclosure; Page 141; 1345pp; German.
XX CC The invention relates to in vitro identification (M1) of genes expressed
XX CC in the skin of humans or animals by subjecting a mixture of genetically
XX CC encoded factors from skin, to serial analysis of gene expression (SAGE)
XX CC so as to identify skin-expressed genes and quantify their expression.
XX CC (M1) is useful for identifying genes involved in skin homeostasis; to
XX CC determine skin homeostasis and to test agent (A) that maintains or
XX CC promotes skin homeostasis or that can be used for treating skin
XX CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
XX CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
XX CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
XX CC skin. The present sequence is that of a human expressed sequence tag
XX CC (EST) of the invention
XX SQ Sequence 11 BP; 7 A; 2 C; 1 G; 1 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2217 GTGACCAAAA 2226
DB 1 GTACCAAAA 10

RESULT 629
ABV71455
ID ABV71455 standard; cDNA; 11 BP.
XX AC ABV71455;
XX DT 21-OCT-2002 (first entry)
XX DE Human skin EST 9241.
XX KW Human; skin; dermatological; vulnary; antipsoriatic; antiseborrhaeic;
XX KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
XX KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX XX
```


CC (M1) is useful for identifying genes involved in skin homeostasis; to
CC determine skin homeostasis and to test agent (A) that maintains or
CC promotes skin homeostasis or that can be used for treating skin
CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
CC skin. The present sequence is that of a human expressed sequence tag
CC (EST) of the invention
XX
SQ Sequence 11 BP; 1 A; 3 C; 1 G; 6 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACA 2232
DB 10 AAAAGGTACA 1
|||||
RESULT 632
ABV66821
ID ABV66821 standard; cDNA; 11 BP.
XX
AC ABV66821;
XX
DT 21-OCT-2002 (first entry)
XX
DE Human skin EST 4607.
XX
KW Human; skin; dermatological; vulnary; antipsoriatic; antiseborrhaeic;
KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX
OS Homo sapiens.
XX
PN WO200253774-A2.
XX
PD 11-JUL-2002.
XX
PF 20-DEC-2001; 2001WO-EP015179.
XX
PR 03-JAN-2001; 2001DE-01000127.
XX
PA (HENK) HENKEL KGAA.
XX
PI Petersohn D, Conradt M, Hofmann K;
XX
DR WO200253774-A2.
XX
PD 11-JUL-2002.
XX
PF 20-DEC-2001; 2001WO-EP015179.
XX
PR 03-JAN-2001; 2001DE-01000127.
XX
PA (HENK) HENKEL KGAA.
XX
PI Petersohn D, Conradt M, Hofmann K;
XX
DR WO2002-590638/63.
XX
PT In vitro identification of skin-expressed genes, useful for determining
PT homeostasis and identifying cosmetic or pharmaceutical agents against
PT e.g. skin cancer.
XX
PS Disclosure; Page 152; 1345pp; German.
XX
CC The invention relates to in vitro identification (M1) of genes expressed
CC in the skin of humans or animals by subjecting a mixture of genetically
CC encoded factors from skin, to serial analysis of gene expression (SAGE)
CC so as to identify skin-expressed genes and quantify their expression.
CC (M1) is useful for identifying genes involved in skin homeostasis; to
CC determine skin homeostasis and to test agent (A) that maintains or
CC promotes skin homeostasis or that can be used for treating skin
CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
CC skin. The present sequence is that of a human expressed sequence tag
CC (EST) of the invention
XX
SQ Sequence 11 BP; 6 A; 2 C; 2 G; 1 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2219 GACCAAAAGT 2228
DB 1 GACCAAAAGT 10
|||||
RESULT 633
ABV65066/c
ID ABV65066 standard; cDNA; 11 BP.
XX
AC ABV65066;
XX
DT 21-OCT-2002 (first entry)
XX
DE Human skin EST 2852.
XX
KW Human; skin; dermatological; vulnary; antipsoriatic; antiseborrhaeic;
KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX
OS Homo sapiens.
XX
PN WO200253774-A2.
XX
PD 11-JUL-2002.
XX
PF 20-DEC-2001; 2001WO-EP015179.
XX
PR 03-JAN-2001; 2001DE-01000127.
XX
PA (HENK) HENKEL KGAA.
XX
PI Petersohn D, Conradt M, Hofmann K;
XX
DR WO2002-590638/63.
XX
PT In vitro identification of skin-expressed genes, useful for determining
PT homeostasis and identifying cosmetic or pharmaceutical agents against
PT e.g. skin cancer.
XX
PS Disclosure; Page 104; 1345pp; German.
XX
CC The invention relates to in vitro identification (M1) of genes expressed
CC in the skin of humans or animals by subjecting a mixture of genetically
CC encoded factors from skin, to serial analysis of gene expression (SAGE)
CC so as to identify skin-expressed genes and quantify their expression.
CC (M1) is useful for identifying genes involved in skin homeostasis; to
CC determine skin homeostasis and to test agent (A) that maintains or
CC promotes skin homeostasis or that can be used for treating skin
CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
CC skin. The present sequence is that of a human expressed sequence tag
CC (EST) of the invention
XX
SQ Sequence 11 BP; 2 A; 2 C; 1 G; 6 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2217 GTGACCAAAA 2226
DB 10 GTGATCAAAA 1
|||||
RESULT 634
ABV71994/c
ID ABV71994 standard; cDNA; 11 BP.
XX
AC ABV71994;
XX

PT e.g. skin cancer.
 PS Disclosure; Page 126; 1345pp; German.
 XX
 CC The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 XX
 SQ Sequence 11 BP; 2 A; 3 C; 2 G; 4 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 11;
 Best Local Similarity 90.0%; Pred. No. 3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2217 GTGACCAAAA 2226
 Db 11 GTGGCCAAA 2
 RESULT 637
 ABV66721/c
 ID ABV66721 standard; cDNA; 11 BP.
 AC ABV66721;
 XX
 DT 21-OCT-2002 (first entry)
 DE Human skin EST 4507.
 XX
 KW Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhaic;
 KW immunosuppressive; antiinflammatory; cyostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200253774-A2.
 XX
 PD 11-JUL-2002.
 XX
 PF 20-DEC-2001; 2001WO-EP015179.
 XX
 PR 03-JAN-2001; 2001DE-01000127.
 XX
 PA (HENK) HENKEL KGAA.
 XX
 PI Petersohn D, Conradt M, Hofmann K;
 XX
 DR WPI; 2002-590638/63.
 XX
 PT In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against
 PT e.g. skin cancer.
 XX
 PS Disclosure; Page 149; 1345pp; German.
 XX
 CC The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;

CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 XX
 SQ Sequence 11 BP; 6 A; 2 C; 1 G; 2 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 11;
 Best Local Similarity 90.0%; Pred. No. 3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2228 TTACAGTTTT 2237
 Db 11 TTACAGTTTT 2
 RESULT 638
 ABV67158
 ID ABV67158 standard; cDNA; 11 BP.
 XX
 AC ABV67158;
 XX
 DT 21-OCT-2002 (first entry)
 DE Human skin EST 4944.
 XX
 KW Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhaic;
 KW immunosuppressive; antiinflammatory; cyostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200253774-A2.
 XX
 PD 11-JUL-2002.
 XX
 PF 20-DEC-2001; 2001WO-EP015179.
 XX
 PR 03-JAN-2001; 2001DE-01000127.
 XX
 PA (HENK) HENKEL KGAA.
 XX
 PI Petersohn D, Conradt M, Hofmann K;
 XX
 DR WPI; 2002-590638/63.
 XX
 PT In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against
 PT e.g. skin cancer.
 XX
 PS Disclosure; Page 161; 1345pp; German.
 XX
 CC The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 XX
 SQ Sequence 11 BP; 3 A; 3 C; 4 G; 1 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 11;
 Best Local Similarity 90.0%; Pred. No. 3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2213 GAGTGTGACC 2222
 Db 1 GAGTGTGACC 10

RESULT 639
 ID ABV66189 standard; cDNA; 11 BP.
 AC ABV66189;
 XX
 XX 21-OCT-2002 (first entry)
 XX
 XX Human skin EST 3975.
 XX
 XX Human; skin; dermatological; vulvular; antipsoriatic; antiseborrheic;
 KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO200253774-A2.
 PN
 XX 11-JUL-2002.
 XX
 XX 20-DEC-2001; 2001WO-EP045179.
 XX
 XX 03-JAN-2001; 2001DE-01000127.
 XX
 XX (HENK) HENKEL KGAA.
 PA
 XX Petersohn D, Conradt M, Hofmann K;
 PI
 XX WPI; 2002-590638/63.
 DR
 XX
 XX In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against
 PT e.g. skin cancer.
 PT
 XX Disclosure; Page 135; 1345pp; German.
 PS
 XX The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 XX
 SQ Sequence 11 BP; 3 A; 2 C; 1 G; 5 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 11;
 Best Local Similarity 30.0%; Pred. No. 3e+02; Mismatches 0; Gaps 0;
 Matches 9; Conservative 0; Indels 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTTACA 2232
 Db 10 AAAAGTTTCA 1
 RESULT 640
 ID ABL92008 standard; cDNA; 11 BP.
 AC ABL92008;
 XX
 XX 30-MAY-2002 (first entry)
 XX
 XX Short human Tumour Endothelial Marker SEQ ID NO 106.
 DE
 XX Human; mouse; rat; TEM; tumour endothelial marker; NEM; PEM; cytostatic;
 KW

KW normal endothelial marker; pan-endothelial marker; immunostimulant;
 KW antiangiogenic; tumour; neoangiogenesis; vascularised tumour;
 KW polycystic kidney disease; diabetes; retinopathy; rheumatoid arthritis;
 KW psoriasis; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO200210217-A2.
 PN
 XX 07-FEB-2002.
 XX
 XX 01-AUG-2001; 2001WO-US024031.
 XX
 XX 02-AUG-2000; 2000US-0222599P.
 PR
 XX 11-AUG-2000; 2000US-0224360P.
 PR
 XX 11-APR-2001; 2001US-0282850P.
 PR
 XX (UYJO) UNIV JOHNS HOPKINS.
 PA
 XX St Croix B, Kinzler KW, Vogelstein B;
 PI
 XX WPI; 2002-291856/33.
 DR
 XX An isolated molecule comprising an antibody variable region which
 PT specifically binds to an extracellular domain of a tumor endothelial
 PT marker (TEM) protein, useful for inhibiting tumor growth.
 PT
 XX Example 5; Page 20; 331pp; English.
 PS
 XX The invention relates to an isolated molecule comprising an antibody
 CC variable region which specifically binds to an extracellular domain of a
 CC tumour endothelial marker (TEM) protein selected from ABB90732, ABB90740,
 CC ABB90749, ABB90750 and ABB90769. The antibodies which bind to TEM
 CC proteins have cytostatic, immunostimulant and antiangiogenic activity.
 CC They are useful for inhibiting tumour growth, neoangiogenesis in subjects
 CC bearing a vascularised tumour, polycystic kidney disease, diabetic
 CC retinopathy, rheumatoid arthritis and psoriasis. Human, mouse and rat TEM
 CC genes and the encoded proteins (ABL92075-ABL92141 and ABB90721-ABB90789)
 CC are disclosed, as are marker oligonucleotide sequences: tumour
 CC endothelial markers (TEM) ABL91996-ABL92041 and ABL92143-ABL92191; normal
 CC endothelial markers (NEM) ABL92042-ABL92074; and pan-endothelial markers
 CC (PEM) ABL91903-ABL91995. The present sequence is that of an
 CC oligonucleotide marker useful to the invention
 XX
 SQ Sequence 11 BP; 3 A; 3 C; 4 G; 1 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 11;
 Best Local Similarity 30.0%; Pred. No. 3e+02; Mismatches 0; Gaps 0;
 Matches 9; Conservative 0; Indels 1; Indels 0; Gaps 0;
 QY 2213 GAGTGTGACC 2222
 Db 1 GAGTGTGACC 10
 RESULT 641
 ID ACA61503 standard; DNA; 11 BP.
 XX
 XX ACA61503;
 XX
 XX 23-JUL-2003 (first entry)
 XX
 XX Modified promoter associated DNA #3.
 DE
 XX Promoter; Bacillus genus microbe; protein production; ds.
 KW
 XX Synthetic.
 OS
 XX JP2002272466-A.
 PN
 XX 24-SEP-2002.
 PD
 XX

PF 15-MAR-2001; 2001JP-00074780.
XX
PR 15-MAR-2001; 2001JP-00074780.
XX
PA (SHOS) SHOWA SANGYO CO.
XX
XX WPI; 2003-345599/33.
XX
XX A modified promoter, an expression cassette, an expression vector, a
PT recombinant microbe, preparation of a protein.
XX
XX Example 5; Page 8; 15pp; Japanese.
XX
XX The invention describes a promoter which can function in a Bacillus genus
CC microbe in which the ratio of adenine to cytosine in the sequence near
CC the 3'-end of said promoter is 0.5 to 2 and the activity of the promoter
CC is higher than that of a natural promoter. The promoter is useful in the
CC preparation of a protein. This sequence represents a modified promoter
CC associated DNA
XX
SQ Sequence 11 BP; 2 A; 4 C; 2 G; 3 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 2213 GAGTGTGACC 2222
DB 11 GAGTGTGACC 2
RESULT 642
ABX71933
ID ABX71933 standard; DNA; 11 BP.
XX
AC ABX71933;
XX
XX 12-MAR-2003 (first entry)
DT
DE DNA tag used to identify human gene encoding TEM 13.
XX
XX Human; endothelial cell; EC; tumour endothelial cell; TEM; NEM;
KW Tumour endothelial marker; normal endothelial marker; PEM;
KW pan-endothelial marker; polycystic kidney disease; psoriasis;
KW diabetic retinopathy; rheumatoid arthritis; tumour angiogenesis;
KW neocangiogenesis; immune response; cytostatic; antidiabetic;
KW ophthalmological; antirheumatic; antiarthritic; antipsoriatic; ds.
XX
OS Homo sapiens.
XX
XX WO200283874-A2.
XX
XX 24-OCT-2002.
XX
XX 10-APR-2002; 2002WO-US008253.
XX
XX 11-APR-2001; 2001US-0282850P.
PR
XX 06-FEB-2002; 2002US-0354262P.
XX
XX (UYJO) UNIV JOHNS HOPKINS.
XX
XX Carson-Walter E, St Croix B, Kinzler KW, Vogelstein B;
PI
XX WPI; 2003-093016/08.
XX
XX New purified human transmembrane protein, designated as tumour endothelial
PT marker (TEM) 3, useful for detecting, diagnosing or treating tumors,
PT polycystic kidney disease, diabetic retinopathy, rheumatoid arthritis or
PT psoriasis.
XX
XX Disclosure; Page 102; 374pp; English.
PS
XX The present invention relates to a novel method for the isolation of

CC endothelial cells (ECs), and the identification of genes expressed in
CC normal and tumour ECs. Tumour endothelial marker (TEM), normal
CC endothelial marker (NEM), and pan-endothelial marker (PEM) genes are
CC identified in human ECs. The human EC marker proteins and the
CC polynucleotide sequences encoding them are useful for detecting,
CC diagnosing or treating tumours as well as polycystic kidney disease,
CC diabetic retinopathy, rheumatoid arthritis, and psoriasis. They are also
CC useful for inhibiting neocangiogenesis or tumour angiogenesis, for
CC inducing an immune response to tumour endothelial cells in a patient, or
CC for identifying candidate drugs for treating tumours. ABX71828-ABX71999
CC represent DNA tags for human PEM, TEM or NEM genes
XX
SQ Sequence 11 BP; 3 A; 3 C; 4 G; 1 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 2213 GAGTGTGACC 2222
DB 1 GAGTGTGACC 10
RESULT 643
ADQ29874
ID ADQ29874 standard; DNA; 11 BP.
XX
AC ADQ29874;
XX
XX 09-SEP-2004 (first entry)
DT
DE Human VRI exon la transcription factor binding fragment #1.
XX
XX ds; VRI receptor; vanilloid receptor type 1; modulator;
KW pain transmission; primary sensory neuron; transcription factor;
KW detection; MZF1; NFKappaB; NFAT; GATA1; sensitivity disorder; analgesia;
KW hypalgesia; hyperalgesia; neuralgia; myalgia; human.
XX
OS Homo sapiens.
XX
XX WO2004053120-A2.
XX
XX 24-JUN-2004.
XX
XX 01-DEC-2003; 2003WO-EP013522.
PF
XX 09-DEC-2002; 2002DE-01057421.
PR
XX (CHEF) GRUENTHAL GMBH.
XX
XX Weihe E, Bieller A, Schaefer MKH;
PI
XX WPI; 2004-468865/44.
XX
XX New nucleic acid that modulates expression of the vanilloid receptor-1,
PT useful for control of pain or sensitivity disorders, comprises sequences
PT from control regions of the receptor gene.
XX
XX Disclosure; Page 44; 68pp; German.
XX
XX This invention describes a novel nucleic acid containing a specific
CC segment having at least one region that modulates expression of the VRI
CC (vanilloid receptor type 1) receptor, or a functional derivative, allele
CC or fragment of this region, or a sequence that hybridises to it under
CC standard conditions. The VRI modulator is derived from one or more of
CC positions 22191-22344 of GenBank A570399, 31673-36359 of AL63116, or
CC 44731-44231 or 36616-33151 of AF168787 and is involved in transmission of
CC pain, particularly in primary sensory neurons. The invention also
CC describes a vector that contains the VRI modulator, host cells containing
CC this vector (other than human germ or embryonal stem cells) and a method
CC for modulating expression of the VRI receptor by introducing the
CC modulator or the vector into a cell that contains the VRI gene. The
CC products of the invention are used for detecting a transcription factor

mcgarry191-19.rng

Thu Nov 18 12:41:57 2004

CC from its binding to a regulatory sequence (or a double-stranded
CC oligonucleotide fragment of it), e.g. by Western blotting or enzyme-
CC linked immunosorbent assay, particularly for diagnosis of diseases
CC associated with overexpression or underexpression of the transcription
CC factor. The region that modulates VRL receptor expression includes a
CC binding site for a transcription factor, e.g. MZF1, NFKAPPAB, NFAT or
CC GATA1. The nucleic acids of the invention, or vectors containing them,
CC are used for prevention or treatment of pain, also for treating
CC sensitivity disorders, e.g. analgesia, hyperalgesia or hyperalgesia, also
CC neuralgia and myalgia, that are associated with activity of the VRL
CC receptor. This sequence represents a fragment of human VRL exon 1a DNA
CC which is capable of binding to a transcription factor.

XX
SQ Sequence 11 BP; 5 A; 2 C; 3 G; 1 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2217 GTGACCAAAA 2226
DQ 2 GTGACCAGAA 11
|||||

RESULT 644
ADQ29856
ID ADQ29856 standard; DNA; 11 BP.
XX
AC ADQ29856;
XX
DT 09-SEP-2004 (first entry)
XX
DE Murine VRL exon 1a transcription factor binding fragment #52.
XX
KW ds; VRL receptor; vanilloid receptor type 1; modulator;
KW pain transmission; primary sensory neuron; transcription factor;
KW detection; MZF1; NFKAPPAB; NFAT; GATA1; sensitivity disorder; analgesia;
KW hyperalgesia; hyperalgesia; neuralgia; myalgia; murine.
XX
OS Mus sp.
XX
PN WO2004053120-A2.
XX
PD 24-JUN-2004.
XX
PF 01-DEC-2003; 2003WO-EP013522.
XX
PR 09-DEC-2002; 2002DE-01057421.
XX
PA (CHEF) GRUENENTHAL GMBH.
XX
PI Weihe E, Bieller A, Schaefer MKH;
XX
PI WPI; 2004-468868/44.
XX
PT New nucleic acid that modulates expression of the vanilloid receptor-1,
PT useful for control of pain or sensitivity disorders, comprises sequences
PT from control regions of the receptor gene.
XX
PS Disclosure; Page 43; 68pp; German.
XX
CC This invention describes a novel nucleic acid containing a specific
CC segment having at least one region that modulates expression of the VRL
CC (vanilloid receptor type 1) receptor, or a functional derivative, allele
CC or fragment of this region, or a sequence that hybridizes to it under
CC standard conditions. The VRL modulator is derived from one or more of
CC positions 22191-223344 of GenBank AL670399, 31673-36359 of AL663116, or
CC 44731-43231 or 36116-33131 of AF168787 and is involved in transmission of
CC pain, particularly in primary sensory neurons. The invention also
CC describes a vector that contains the VRL modulator, host cells containing
CC this vector (other than human germ or embryonal stem cells) and a method
CC for modulating expression of the VRL receptor by introducing the
CC modulator or the vector into a cell that contains the VRL gene. The

CC products of the invention are used for detecting a transcription factor
CC from its binding to a regulatory sequence (or a double-stranded
CC oligonucleotide fragment of it), e.g. by Western blotting or enzyme-
CC linked immunosorbent assay, particularly for diagnosis of diseases
CC associated with overexpression or underexpression of the transcription
CC factor. The region that modulates VRL receptor expression includes a
CC binding site for a transcription factor, e.g. MZF1, NFKAPPAB, NFAT or
CC GATA1. The nucleic acids of the invention, or vectors containing them,
CC are used for prevention or treatment of pain, also for treating
CC sensitivity disorders, e.g. analgesia, hyperalgesia or hyperalgesia, also
CC neuralgia and myalgia, that are associated with activity of the VRL
CC receptor. This sequence represents a fragment of murine VRL exon 1a DNA
CC which is capable of binding to a transcription factor.

XX
SQ Sequence 11 BP; 5 A; 2 C; 2 G; 2 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2218 TGACCAAAAG 2227
DQ 1 TGACCAATAG 10
|||||

RESULT 645
ADQ35599/c
ID ADQ35599 standard; DNA; 11 BP.
XX
AC ADQ35599;
XX
DT 23-SEP-2004 (first entry)
XX
DE Human hair-bearing skin-associated DNA fragment SEQ ID NO 416.
XX
KW hair-bearing skin; human; serial analysis of gene expression; SAGE;
KW homeostasis; cosmetic; pharmaceutical; biochip; ds.
XX
OS Homo sapiens.
XX
PN DE10260931-A1.
XX
PD 08-JUL-2004.
XX
PF 20-DEC-2002; 2002DE-01060931.
XX
PR 20-DEC-2002; 2002DE-01060931.
XX
PA (HENK) HENKEL KGAA.
XX
PI Petersohn D, Schlotmann K, Gassenmeier T, Holtkoetter O;
PI Conrad M, Hofmann K;
XX
PI WPI; 2004-518857/50.
XX
PT In vitro identification of genes important for hair-bearing skin, useful
PT for assessing homeostasis and in screening for pharmaceutical or cosmetic
PT agents, based on differential expression analysis.
XX
PS Claim 5; SEQ ID NO 416; 350pp; German.
XX
CC This invention describes a novel in vitro method for identifying genes
CC that are significant for hair-bearing skin in humans. The method
CC comprises recovering, from hair-bearing skin, a first mixture of
CC genetically expressed (transcribed and optionally translated) factors
CC (i.e. proteins, mRNA or their fragments), recovering a second, similar
CC mixture from skin on which hair does not grow and subjecting both
CC mixtures to serial analysis of gene expression (SAGE) to identify those
CC genes for which expression is markedly different between the two types of
CC skin. The invention also describes in vitro methods for determining
CC homeostasis of human hair-bearing skin and for determining disorders or
CC cosmetic and pharmaceutical agents for use against disorders or
CC disturbances of the homeostasis of human hair-bearing skin. A biochip and

CC a test kit comprising a solid support (flexible or rigid) with
CC immobilised probes are also described for determining homeostasis. The
CC hair-bearing skin is from the scalp and the other skin is from the face.
CC The method allows identification of as many as possible of the genes
CC important for hair-bearing skin, and therefore, of a very wide range of
CC potential therapeutic and cosmetic agents. ADQ35184-ADQ36518 represent
CC human DNA tag fragments used to identify genes associated with hair-
CC bearing skin.
SQ Sequence 11 BP; 1 A; 1 C; 2 G; 7 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2223 AAAAGTTTACA 2232
DB 11 AAAGATACA 2
RESULT 646
ADQ35819
ID ADQ35819 standard; DNA; 11 BP.
XX AC ADQ35819;
XX DT 23-SEP-2004 (first entry)
XX DE Human hair-bearing skin-associated DNA fragment SEQ ID NO 636.
XX KW hair-bearing skin; human; serial analysis of gene expression; SAGE;
XX KW homeostasis; cosmetic; pharmaceutical; biochip; ds.
XX OS Homo sapiens.
XX PN DE10260931-A1.
XX PD 08-JUL-2004.
XX PF 20-DEC-2002; 2002DE-01060931.
XX PR 20-DEC-2002; 2002DE-01060931.
XX PA (HENK) HENKEL KGAA.
XX PI Petersohn D, Schlotmann K, Gassenmeier T, Holtkoetter O;
XX PI Conradt M, Hofmann K;
XX DR WPI; 2004-518857/50.
XX PS Claim 5; SEQ ID NO 636; 250pp; German.
XX CC This invention describes a novel in vitro method for identifying genes
XX CC that are significant for hair-bearing skin in humans. The method
XX CC comprises recovering, from hair-bearing skin, a first mixture of
XX CC genetically expressed (transcribed and optionally translated) factors
XX CC (i.e. proteins, mRNA or their fragments), recovering a second, similar
XX CC mixture from skin on which hair does not grow and subjecting both
XX CC mixtures to serial analysis of gene expression (SAGE) to identify those
XX CC genes for which expression is markedly different between the two types of
XX CC skin. The invention also describes in vitro methods for determining
XX CC homeostasis of human hair-bearing skin and for determining activity of
XX CC cosmetic and pharmaceutical agents for use against disorders or
XX CC disturbances of the homeostasis of human hair-bearing skin. A biochip and
XX CC a test kit comprising a solid support (flexible or rigid) with
XX CC immobilised probes are also described for determining homeostasis. The
XX CC hair-bearing skin is from the scalp and the other skin is from the face.
XX CC The method allows identification of as many as possible of the genes
XX CC important for hair-bearing skin, and therefore, of a very wide range of

CC potential therapeutic and cosmetic agents. ADQ35184-ADQ36518 represent
CC human DNA tag fragments used to identify genes associated with hair-
CC bearing skin.
SQ Sequence 11 BP; 4 A; 3 C; 3 G; 1 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2219 GACCAAAAGT 2228
DB 1 GACCAACAGT 10
RESULT 647
ADQ36261/c
ID ADQ36261 standard; DNA; 11 BP.
XX AC ADQ36261;
XX DT 23-SEP-2004 (first entry)
XX DE Human hair-bearing skin-associated DNA fragment SEQ ID NO 1078.
XX KW hair-bearing skin; human; serial analysis of gene expression; SAGE;
XX KW homeostasis; cosmetic; pharmaceutical; biochip; ds.
XX OS Homo sapiens.
XX PN DE10260931-A1.
XX PD 08-JUL-2004.
XX PF 20-DEC-2002; 2002DE-01060931.
XX PR 20-DEC-2002; 2002DE-01060931.
XX PA (HENK) HENKEL KGAA.
XX PI Petersohn D, Schlotmann K, Gassenmeier T, Holtkoetter O;
XX PI Conradt M, Hofmann K;
XX DR WPI; 2004-518857/50.
XX PS Claim 4; SEQ ID NO 1078; 250pp; German.
XX CC This invention describes a novel in vitro method for identifying genes
XX CC that are significant for hair-bearing skin in humans. The method
XX CC comprises recovering, from hair-bearing skin, a first mixture of
XX CC genetically expressed (transcribed and optionally translated) factors
XX CC (i.e. proteins, mRNA or their fragments), recovering a second, similar
XX CC mixture from skin on which hair does not grow and subjecting both
XX CC mixtures to serial analysis of gene expression (SAGE) to identify those
XX CC genes for which expression is markedly different between the two types of
XX CC skin. The invention also describes in vitro methods for determining
XX CC homeostasis of human hair-bearing skin and for determining activity of
XX CC cosmetic and pharmaceutical agents for use against disorders or
XX CC disturbances of the homeostasis of human hair-bearing skin. A biochip and
XX CC a test kit comprising a solid support (flexible or rigid) with
XX CC immobilised probes are also described for determining homeostasis. The
XX CC hair-bearing skin is from the scalp and the other skin is from the face.
XX CC The method allows identification of as many as possible of the genes
XX CC important for hair-bearing skin, and therefore, of a very wide range of
XX CC potential therapeutic and cosmetic agents. ADQ35184-ADQ36518 represent
XX CC human DNA tag fragments used to identify genes associated with hair-
XX CC bearing skin.
SQ Sequence 11 BP; 4 A; 2 C; 2 G; 3 T; 0 U; 0 Other;

QY 2215 GTGTGACCAA 2224 31.1%; Score 8.4; DB 1; Length 11;
 ADQ36457 90.0%; Pred. No. 3e+02;
 ID ADQ36457 standard; DNA; 11 BP.
 XX
 AC ADQ36457;
 DT 23-SEP-2004 (first entry)
 DE Human hair-bearing skin-associated DNA fragment SEQ ID NO 1274.
 KW hair-bearing skin; human; serial analysis of gene expression; SAGE;
 KW homeostasis; cosmetic; pharmaceutical; biochip; ds.
 XX Homo sapiens.
 OS
 PN DE10260931-A1.
 XX
 PD 08-JUL-2004.
 XX
 PF 20-DEC-2002; 2002DE-01060931.
 XX
 PR 20-DEC-2002; 2002DE-01060931.
 XX
 PA (HENK) HENKEL KGAA.
 XX
 PI Petersohn D, Schlotmann K, Gassenmeier T, Holtkoetter O;
 PI Conradt M, Hofmann K;
 XX
 DR WPI; 2004-518857/50.
 XX
 PT In vitro identification of genes important for hair-bearing skin, useful
 PT for assessing homeostasis and in screening for pharmaceutical or cosmetic
 PT agents, based on differential expression analysis.
 XX
 PS Claim 4; SEQ ID NO 1274; 250pp; German.
 XX
 CC This invention describes a novel in vitro method for identifying genes
 CC that are significant for hair-bearing skin in humans. The method
 CC comprises recovering, from hair-bearing skin, a first mixture of
 CC genetically expressed (transcribed and optionally translated) factors
 CC (i.e. proteins, mRNA or their fragments), recovering a second, similar
 CC mixture from skin on which hair does not grow and subjecting both
 CC mixtures to serial analysis of gene expression (SAGE) to identify those
 CC genes for which expression is markedly different between the two types of
 CC skin. The invention also describes in vitro methods for determining
 CC homeostasis of human hair-bearing skin and for determining activity of
 CC cosmetic and pharmaceutical agents for use against disorders or
 CC disturbances of the homeostasis of human hair-bearing skin. A biochip and
 CC a test kit comprising a solid support (flexible or rigid) with
 CC immobilised probes are also described for determining homeostasis. The
 CC hair-bearing skin is from the scalp and the other skin is from the face.
 CC The method allows identification of as many as possible of the genes
 CC important for hair-bearing skin, and therefore, of a very wide range of
 CC potential therapeutic and cosmetic agents. ADQ35184-ADQ36518 represent
 CC human DNA tag fragments used to identify genes associated with hair-
 CC bearing skin.
 XX
 SQ Sequence 11 BP; 6 A; 2 C; 2 G; 1 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 11;
 Best Local Similarity 90.0%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2219 GACCAAACT 2228
 DB 1 GACCAAACT 10
 RESULT 649
 ID ADQ35882/c
 XX ADQ35882;
 DT 23-SEP-2004 (first entry)
 DE Human hair-bearing skin-associated DNA fragment SEQ ID NO 699.
 KW hair-bearing skin; human; serial analysis of gene expression; SAGE;
 KW homeostasis; cosmetic; pharmaceutical; biochip; ds.
 XX Homo sapiens.
 OS
 PN DE10260931-A1.
 XX
 PD 08-JUL-2004.
 XX
 PF 20-DEC-2002; 2002DE-01060931.
 XX
 PR 20-DEC-2002; 2002DE-01060931.
 XX
 PA (HENK) HENKEL KGAA.
 XX
 PI Petersohn D, Schlotmann K, Gassenmeier T, Holtkoetter O;
 PI Conradt M, Hofmann K;
 XX
 DR WPI; 2004-518857/50.
 XX
 PT In vitro identification of genes important for hair-bearing skin, useful
 PT for assessing homeostasis and in screening for pharmaceutical or cosmetic
 PT agents, based on differential expression analysis.
 XX
 PS Claim 5; SEQ ID NO 699; 250pp; German.
 XX
 CC This invention describes a novel in vitro method for identifying genes
 CC that are significant for hair-bearing skin in humans. The method
 CC comprises recovering, from hair-bearing skin, a first mixture of
 CC genetically expressed (transcribed and optionally translated) factors
 CC (i.e. proteins, mRNA or their fragments), recovering a second, similar
 CC mixture from skin on which hair does not grow and subjecting both
 CC mixtures to serial analysis of gene expression (SAGE) to identify those
 CC genes for which expression is markedly different between the two types of
 CC skin. The invention also describes in vitro methods for determining
 CC homeostasis of human hair-bearing skin and for determining activity of
 CC cosmetic and pharmaceutical agents for use against disorders or
 CC disturbances of the homeostasis of human hair-bearing skin. A biochip and
 CC a test kit comprising a solid support (flexible or rigid) with
 CC immobilised probes are also described for determining homeostasis. The
 CC hair-bearing skin is from the scalp and the other skin is from the face.
 CC The method allows identification of as many as possible of the genes
 CC important for hair-bearing skin, and therefore, of a very wide range of
 CC potential therapeutic and cosmetic agents. ADQ35184-ADQ36518 represent
 CC human DNA tag fragments used to identify genes associated with hair-
 CC bearing skin.
 XX
 SQ Sequence 11 BP; 2 A; 2 C; 1 G; 6 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 11;
 Best Local Similarity 90.0%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2217 GTGACCAAAA 2226
 DB 10 GTGACCAAAA 1

```

RESULT 650
ADQ34842/c
ID ADQ34842 standard; DNA; 11 BP.
XX
AC ADQ34842;
XX
DT 23-SEP-2004 (first entry)
XX
DE Human facial skin-associated DNA fragment SEQ ID NO 2932.
XX
KW facial skin; human; serial analysis of gene expression; SAGE;
KW homeostasis; biochip; cosmetic; pharmaceutical; ds.
XX
OS Homo sapiens.
XX
PN DE10260928-A1.
XX
PD 08-JUL-2004.
XX
PF 20-DEC-2002; 2002DE-01060928.
XX
PR 20-DEC-2002; 2002DE-01060928.
XX
PA (HENK ) HENKEL KGAA.
XX
PI Petersohn D, Schlotmann K, Gassenmeier T, Holtkoetter O;
PI Conradt M, Hofmann K;
XX
WPI; 2004-518855/50.
XX
In vitro identification of genes important for facial skin, useful for
assessing homeostasis and in screening for pharmaceutical or cosmetic
agents, based on differential expression analysis.
XX
Claim 4; SEQ ID NO 2932; 577bp; German.
XX
This invention describes a novel in vitro method for identifying genes
that are significant for facial skin in humans. The method comprises
recovering, from facial skin, a first mixture of genetically expressed
(transcribed and optionally translated) factors (i.e. proteins, mRNA or
their fragments), recovering a second, similar mixture from some other
human tissue, preferably skin from a protected area, especially from the
breast and subjecting the mixtures to serial analysis of gene expression
(SAGE) to identify those genes for which expression is markedly different
between facial skin and the other tissue. The invention also describes an
in vitro method for determining homeostasis of human facial skin; a test
kit which comprises a solid support (flexible or rigid) on which are
immobilised probes that bind specifically to the factors of interest and
a biochip for determining homeostasis of human facial skin. The products
of the invention are also used in a method which determines activity of
cosmetic and pharmaceutical agents for use against disorders or
disturbances of the homeostasis of human skin and a screening method for
identifying cosmetic and pharmaceutical agents. The method allows
identification of as many as possible of the genes important for facial
skin and thus of a very wide range of potential therapeutic and cosmetic
agents. ADQ31911-ADQ35111 represent human DNA tag fragments used to
identify the facial skin-associated genes described in the invention.
XX
Sequence 11 BP; 6 A; 2 C; 1 G; 2 T; 0 U; 0 Other;
XX
Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 2228 TTACATGTTT 2237
DB 11 TTACAGGTTT 2
XX
RESULT 651
ADQ32411/c
ID ADQ32411 standard; DNA; 11 BP.
XX
AC ADQ32411;
XX
DT 23-SEP-2004 (first entry)
XX
DE Human facial skin-associated DNA fragment SEQ ID NO 501.
XX
KW facial skin; human; serial analysis of gene expression; SAGE;
KW homeostasis; biochip; cosmetic; pharmaceutical; ds.
XX
OS Homo sapiens.
XX
PN DE10260928-A1.
XX
PD 08-JUL-2004.
XX
PF 20-DEC-2002; 2002DE-01060928.
XX
PR 20-DEC-2002; 2002DE-01060928.
XX
PA (HENK ) HENKEL KGAA.
XX
PI Petersohn D, Schlotmann K, Gassenmeier T, Holtkoetter O;
PI Conradt M, Hofmann K;
XX
WPI; 2004-518855/50.
XX
In vitro identification of genes important for facial skin, useful for
assessing homeostasis and in screening for pharmaceutical or cosmetic
agents, based on differential expression analysis.
XX
Claim 6; SEQ ID NO 501; 577bp; German.
XX
This invention describes a novel in vitro method for identifying genes
that are significant for facial skin in humans. The method comprises
recovering, from facial skin, a first mixture of genetically expressed
(transcribed and optionally translated) factors (i.e. proteins, mRNA or
their fragments), recovering a second, similar mixture from some other
human tissue, preferably skin from a protected area, especially from the
breast and subjecting the mixtures to serial analysis of gene expression
(SAGE) to identify those genes for which expression is markedly different
between facial skin and the other tissue. The invention also describes an
in vitro method for determining homeostasis of human facial skin; a test
kit which comprises a solid support (flexible or rigid) on which are
immobilised probes that bind specifically to the factors of interest and
a biochip for determining homeostasis of human facial skin. The products
of the invention are also used in a method which determines activity of
cosmetic and pharmaceutical agents for use against disorders or
disturbances of the homeostasis of human skin and a screening method for
identifying cosmetic and pharmaceutical agents. The method allows
identification of as many as possible of the genes important for facial
skin and thus of a very wide range of potential therapeutic and cosmetic
agents. ADQ31911-ADQ35111 represent human DNA tag fragments used to
identify the facial skin-associated genes described in the invention.
XX
Sequence 11 BP; 1 A; 3 C; 2 G; 5 T; 0 U; 0 Other;
XX
Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 2219 GACCAAAAGT 2228
DB 11 GGCCAAAAGT 2
XX
RESULT 652
ADQ32947/c
ID ADQ32947 standard; DNA; 11 BP.
XX
AC ADQ32947;
XX
DT 23-SEP-2004 (first entry)
XX
```

DE Human facial skin-associated DNA fragment SEQ ID NO 1037.
 XX facial skin; human; serial analysis of gene expression; SAGE;
 KW homeostasis; biochip; cosmetic; pharmaceutical; ds.
 XX Homo sapiens.
 XX DE10260928-A1.
 XX 08-JUL-2004.
 XX 20-DEC-2002; 2002DE-01060928.
 XX 20-DEC-2002; 2002DE-01060928.
 XX (HENK) HENKEL KGAA.
 XX Petersohn D, Schlotmann K, Gassenmeier T, Holtkoetter O;
 PI Conradt M, Hofmann K;
 XX WPI; 2004-518855/50.
 XX In vitro identification of genes important for facial skin, useful for
 PT assessing homeostasis and in screening for pharmaceutical or cosmetic
 PT agents, based on differential expression analysis.
 XX Claim 5; SEQ ID NO 1037; 577pp; German.
 XX This invention describes a novel in vitro method for identifying genes
 CC that are significant for facial skin in humans. The method comprises
 CC recovering from facial skin, a first mixture of genetically expressed
 CC (transcribed and optionally translated) factors (i.e. proteins, mRNA or
 CC their fragments), recovering a second, similar mixture from some other
 CC human tissue, preferably skin from a protected area, especially from the
 CC breast and subjecting the mixtures to serial analysis of gene expression
 CC (SAGE) to identify those genes for which expression is markedly different
 CC between facial skin and the other tissue. The invention also describes an
 CC in vitro method for determining homeostasis of human facial skin; a test
 CC kit which comprises a solid support (flexible or rigid) on which are
 CC immobilised probes that bind specifically to the factors of interest and
 CC a biochip for determining homeostasis of human facial skin. The products
 CC of the invention are also used in a method which determines activity of
 CC cosmetic and pharmaceutical agents for use against disorders or
 CC disturbances of the homeostasis of human skin and a screening method for
 CC identifying cosmetic and pharmaceutical agents. The method allows
 CC identification of as many as possible of the genes important for facial
 CC skin and thus of a very wide range of potential therapeutic and cosmetic
 CC agents. ADQ31911-ADQ35111 represent human DNA tag fragments used to
 CC identify the facial skin-associated genes described in the invention.
 XX Sequence 11 BP; 6 A; 1 C; 2 G; 2 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 11;
 Best Local Similarity 30.0%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTT 2237
 DB 11 TTACCTGTTT 2
 RESULT 653
 ADQ33099/c
 ID ADQ33099 standard; DNA; 11 BP.
 XX ADQ33099;
 XX 23-SEP-2004 (first entry)
 XX Human facial skin-associated DNA fragment SEQ ID NO 1189.
 XX facial skin; human; serial analysis of gene expression; SAGE;
 KW homeostasis; biochip; cosmetic; pharmaceutical; ds.

XX Homo sapiens.
 OS DE10260928-A1.
 PN 08-JUL-2004.
 XX 20-DEC-2002; 2002DE-01060928.
 XX 20-DEC-2002; 2002DE-01060928.
 XX (HENK) HENKEL KGAA.
 XX Petersohn D, Schlotmann K, Gassenmeier T, Holtkoetter O;
 PI Conradt M, Hofmann K;
 XX WPI; 2004-518855/50.
 XX In vitro identification of genes important for facial skin, useful for
 PT assessing homeostasis and in screening for pharmaceutical or cosmetic
 PT agents, based on differential expression analysis.
 XX Claim 5; SEQ ID NO 1189; 577pp; German.
 XX This invention describes a novel in vitro method for identifying genes
 CC that are significant for facial skin in humans. The method comprises
 CC recovering from facial skin, a first mixture of genetically expressed
 CC (transcribed and optionally translated) factors (i.e. proteins, mRNA or
 CC their fragments), recovering a second, similar mixture from some other
 CC human tissue, preferably skin from a protected area, especially from the
 CC breast and subjecting the mixtures to serial analysis of gene expression
 CC (SAGE) to identify those genes for which expression is markedly different
 CC between facial skin and the other tissue. The invention also describes an
 CC in vitro method for determining homeostasis of human facial skin; a test
 CC kit which comprises a solid support (flexible or rigid) on which are
 CC immobilised probes that bind specifically to the factors of interest and
 CC a biochip for determining homeostasis of human facial skin. The products
 CC of the invention are also used in a method which determines activity of
 CC cosmetic and pharmaceutical agents for use against disorders or
 CC disturbances of the homeostasis of human skin and a screening method for
 CC identifying cosmetic and pharmaceutical agents. The method allows
 CC identification of as many as possible of the genes important for facial
 CC skin and thus of a very wide range of potential therapeutic and cosmetic
 CC agents. ADQ31911-ADQ35111 represent human DNA tag fragments used to
 CC identify the facial skin-associated genes described in the invention.
 XX Sequence 11 BP; 1 A; 2 C; 1 G; 7 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 11;
 Best Local Similarity 30.0%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACA 2232
 DB 11 AAAAGTTACA 2
 RESULT 654
 ADQ33003
 ID ADQ33003 standard; DNA; 11 BP.
 XX ADQ33003;
 XX 23-SEP-2004 (first entry)
 XX Human facial skin-associated DNA fragment SEQ ID NO 1093.
 XX facial skin; human; serial analysis of gene expression; SAGE;
 KW homeostasis; biochip; cosmetic; pharmaceutical; ds.
 XX Homo sapiens.
 PN DE10260928-A1.

```
XX PD 08-JUL-2004.
XX PF 20-DEC-2002; 2002DE-01060928.
XX PR 20-DEC-2002; 2002DE-01060928.
XX PA (HENK ) HENKEL KGAA.
XX PI Petersohn D, Schlotmann K, Gassenmeier T, Holtkoetter O;
XX PI Conradt M, Hofmann K;
XX DR WPI; 2004-518855/50.
XX PT In vitro identification of genes important for facial skin, useful for
XX PT assessing homeostasis and in screening for pharmaceutical or cosmetic
XX PT agents, based on differential expression analysis.
XX PS Claim 5; SEQ ID NO 1093; 577pp; German.
XX CC This invention describes a novel in vitro method for identifying genes
XX CC that are significant for facial skin in humans. The method comprises
XX CC recovering, from facial skin, a first mixture of genetically expressed
XX CC (transcribed and optionally translated) factors (i.e. proteins, mRNA or
XX CC human tissue), recovering a second, similar mixture from some other
XX CC human tissue, preferably skin from a protected area, especially from the
XX CC breast and subjecting the mixtures to serial analysis of gene expression
XX CC (SAGE) to identify those genes for which expression is markedly different
XX CC between facial skin and the other tissue. The invention also describes an
XX CC in vitro method for determining homeostasis of human facial skin; a test
XX CC kit which comprises a solid support (flexible or rigid) on which are
XX CC immobilised probes that bind specifically to the factors of interest and
XX CC a biochip for determining homeostasis of human facial skin. The products
XX CC of the invention are also used in a method which determines activity of
XX CC cosmetic and pharmaceutical agents for use against disorders or
XX CC disturbances of the homeostasis of human skin and a screening method for
XX CC identifying cosmetic and pharmaceutical agents. The method allows
XX CC identification of as many as possible of the genes important for facial
XX CC skin and thus of a very wide range of potential therapeutic and cosmetic
XX CC agents. ADQ31911-ADQ35111 represent human DNA Tag fragments used to
XX CC identify the facial skin-associated genes described in the invention.
XX SQ Sequence 11 BP; 7 A; 2 C; 1 G; 1 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 2221 CCAAAAGTTA 2230
DB 1 CCAAAAAGTAA 10
RESULT 655
ADQ32752
ID ADQ32752 standard; DNA; 11 BP.
XX AC ADQ32752;
XX DT 23-SEP-2004 (first entry)
XX DE Human facial skin-associated DNA fragment SEQ ID NO 842.
XX KW facial skin; human; serial analysis of gene expression; SAGE;
XX KW homeostasis; biochip; cosmetic; pharmaceutical; ds.
XX OS Homo sapiens.
XX PN DE10260928-A1.
XX PD 08-JUL-2004.
XX PF 20-DEC-2002; 2002DE-01060928.
```

```
XX PR 20-DEC-2002; 2002DE-01060928.
XX PA (HENK ) HENKEL KGAA.
XX PI Petersohn D, Schlotmann K, Gassenmeier T, Holtkoetter O;
XX PI Conradt M, Hofmann K;
XX DR WPI; 2004-518855/50.
XX PT In vitro identification of genes important for facial skin, useful for
XX PT assessing homeostasis and in screening for pharmaceutical or cosmetic
XX PT agents, based on differential expression analysis.
XX PS Claim 5; SEQ ID NO 842; 577pp; German.
XX CC This invention describes a novel in vitro method for identifying genes
XX CC that are significant for facial skin in humans. The method comprises
XX CC recovering, from facial skin, a first mixture of genetically expressed
XX CC (transcribed and optionally translated) factors (i.e. proteins, mRNA or
XX CC human tissue), recovering a second, similar mixture from some other
XX CC human tissue, preferably skin from a protected area, especially from the
XX CC breast and subjecting the mixtures to serial analysis of gene expression
XX CC (SAGE) to identify those genes for which expression is markedly different
XX CC between facial skin and the other tissue. The invention also describes an
XX CC in vitro method for determining homeostasis of human facial skin; a test
XX CC kit which comprises a solid support (flexible or rigid) on which are
XX CC immobilised probes that bind specifically to the factors of interest and
XX CC a biochip for determining homeostasis of human facial skin. The products
XX CC of the invention are also used in a method which determines activity of
XX CC cosmetic and pharmaceutical agents for use against disorders or
XX CC disturbances of the homeostasis of human skin and a screening method for
XX CC identifying cosmetic and pharmaceutical agents. The method allows
XX CC identification of as many as possible of the genes important for facial
XX CC skin and thus of a very wide range of potential therapeutic and cosmetic
XX CC agents. ADQ31911-ADQ35111 represent human DNA Tag fragments used to
XX CC identify the facial skin-associated genes described in the invention.
XX SQ Sequence 11 BP; 3 A; 2 C; 2 G; 4 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 2216 TGTGACCAAA 2225
DB 2 TGTGTCCAAA 11
RESULT 656
AAC93147
ID AAC93147 standard; DNA; 12 BP.
XX AC AAC93147;
XX DT 21-MAR-2001 (first entry)
XX DE Newcastle disease virus virulent strain F protein cDNA 3' end.
XX KW Newcastle disease virus; NDV; RT; reverse transcriptase; virucide;
XX KW vaccine; F protein; ss.
XX OS Newcastle disease virus.
XX PN WO2000077218-A1.
XX PD 21-DEC-2000.
XX PF 05-JUN-2000; 2000WC-IB000748.
XX PR 10-JUN-1999; 99ZA-00003896.
XX PA (AGRI-) AGRIC RES COUNCIL.
```

XX Cohen AS, Viljoen GJ;
 PI WPI; 2001-071275/08.
 DR Novel vaccine comprising recombinant DNA molecule coding for F protein of
 PT virulent strain of Newcastle disease virus or its portion, or
 PT bioprecursor, useful for treating diseases caused by Newcastle disease
 PT virus.
 XX Claim 10; Page 12; 21pp; English.
 XX The present sequence is claimed in a specification relating to a gene
 CC coding for the F protein of a virulent strain of Newcastle disease virus
 CC (NDV). The F protein is useful for treating diseases caused by virulent
 CC NDV. Serotype specific probes are useful for diagnosing or
 CC detecting virulent NDV in animals. A vaccine including a recombinant
 CC plasmid nucleic acid coding for the F protein of a virulent NDV strain is
 CC capable of raising satisfactory levels of antibody against the F protein
 XX Sequence 12 BP; 5 A; 2 C; 4 G; 1 T; 0 U; 0 Other;
 SQ

Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2218 TGACCAAAAG 2227
 DB 3 TGACCAAAAG 12

RESULT 657
 ABH94949/C
 ID ABH94949 standard; DNA; 12 BP.
 XX
 AC ABH94949;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 294942 for detecting SNP TSC0016361.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 XX 18-OCT-2001.
 XX
 PD 06-APR-2001; 2001WO-IB000713.
 XX
 PF 07-APR-2000; 2000DE-01019173.
 XX
 PR (EPIG-) EPIGENOMICS AG.
 XX
 PA Olek A, Piepenbrock C, Berlin K;
 XX
 PI WPI; 2001-657177/75.
 XX
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 XX methylation status.
 XX
 PT Claim 1; SEQ ID NO 294942; 29pp + Sequence Listing; German.
 XX
 PS This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABH00010-ABH99989, ABH00010-ABH99989 and ABH00010-ABH99989
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABH00010-ABH99989, ABH00010-ABH99989 and ABH00010-ABH99989
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 4 A; 1 C; 0 G; 7 T; 0 U; 0 Other;
 SQ

Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACA 2232
 DB 10 AAAAGTTAAA 1

RESULT 658
 ABI20692
 ID ABI20692 standard; DNA; 12 BP.
 XX
 AC ABI20692;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 320665 for detecting SNP TSC0029837.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 XX 18-OCT-2001.
 XX
 PD 06-APR-2001; 2001WO-IB000713.
 XX
 PF 07-APR-2000; 2000DE-01019173.
 XX
 PR (EPIG-) EPIGENOMICS AG.
 XX
 PA Olek A, Piepenbrock C, Berlin K;
 XX
 PI WPI; 2001-657177/75.
 XX
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 XX methylation status.
 XX
 PT Claim 1; SEQ ID NO 320665; 29pp + Sequence Listing; German.
 XX
 PS This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABH00010-ABH99989, ABH00010-ABH99989 and ABH00010-ABH99989
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 4 A; 0 C; 1 G; 7 T; 0 U; 0 Other;
 SQ

Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

QY      2228 TTACATGTTT 2237
DB      3 TTAATGTTT 12
      ||| |||||
RESULT 659
ABH70818
ID ABH70818 standard; DNA; 12 BP.
XX
XX ABH70818;
XX
XX
XX 22-FEB-2002 (first entry)
XX
DE      Oligonucleotide primer SEQ ID NO 270795 for detecting SNP TSC0002280.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX
XX 22-FEB-2002 (first entry)
XX
DE      Oligonucleotide primer SEQ ID NO 270795 for detecting SNP TSC0002280.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 270795; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI0010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 2 A; 0 C; 4 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY      2227 GTTACATGTTT 2236
DB      2 GTTATGTTT 11
      ||| |||||
RESULT 660
ABI21917
ID ABI21917 standard; DNA; 12 BP.
XX
XX ABI21917;
XX
XX 22-FEB-2002 (first entry)
XX

```

```

DE      Oligonucleotide primer SEQ ID NO 321890 for detecting SNP TSC0030548.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 321890; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI0010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 3 A; 2 C; 0 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY      2228 TTACATGTTT 2237
DB      1 TTACATTTT 10
      ||| |||||
RESULT 661
ABH74210
ID ABH74210 standard; DNA; 12 BP.
XX
XX ABH74210;
XX
XX 22-FEB-2002 (first entry)
XX
DE      Oligonucleotide primer SEQ ID NO 274195 for detecting SNP TSC0003472.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX

```

XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 274195; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2220 ACCAAAGTT 2229
 Db 3 ACCAAAGTT 12
 |||||
 |||||
 RESULT 662
 ABI32127
 ID ABI32127 standard; DNA; 12 BP.
 AC ABI32127;
 XX
 XX 22-FEB-2002 (first entry)
 DE
 DE Oligonucleotide primer SEQ ID NO 332100 for detecting SNP TSC0036705.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 XX
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX

PS Claim 1; SEQ ID NO 332100; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 5 A; 0 C; 3 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2224 AAGTTACAT 2233
 Db 3 AAGTTACAT 12
 |||||
 |||||
 RESULT 663
 ABI34257/C
 ID ABI34257 standard; DNA; 12 BP.
 AC ABI34257;
 XX
 XX 22-FEB-2002 (first entry)
 DE
 DE Oligonucleotide primer SEQ ID NO 334230 for detecting SNP TSC0038022.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 XX
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 334230; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 9 A; 1 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTT 2237
DB 11 TTATATGTTT 2

RESULT 664
ABH84898
ID ABH84898 standard; DNA; 12 BP.
AC ABH84898;
XX
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 284891 for detecting SNP TSC0012044.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 284891; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 5 A; 4 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2222 CAAAAGTTAC 2231
DB 1 CAAAATTAC 10

RESULT 665
ABI10267/C
ID ABI10267 standard; DNA; 12 BP.
XX
AC ABI10267;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 310240 for detecting SNP TSC003881.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 310240; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 8 A; 1 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTT 2237
DB 12 TTATATGTTT 3

RESULT 666
ABI15800
ID ABI15800 standard; DNA; 12 BP.
XX
AC ABI15800;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 315773 for detecting SNP TSC0027088.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177/75.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC9989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 3 A; 0 C; 1 G; 8 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTT 2237
 Db 1 TTATATGTTT 10

RESULT 667
 ABI43356/C
 ID ABI43356 standard; DNA; 12 BP.
 XX AC ABI43356;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 143329 for detecting SNP TSC0043002.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX CC Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.
 XX PS Claim 1; SEQ ID NO 343329; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC9989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 4 A; 2 C; 0 G; 6 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2224 AAAGTTACAT 2233
 Db 10 AAAGTTAAAT 1

RESULT 668
 ABI51324
 ID ABI51324 standard; DNA; 12 BP.
 XX AC ABI51324;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 351297 for detecting SNP TSC0047213.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177/75.
 XX CC Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.
 XX PS Claim 1; SEQ ID NO 351297; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC9989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 2 A; 0 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2229 TACATGTTTG 2238
DB 1 TAGATGTTTG 10

RESULT 669
ABI73035/c
ID ABI73035 standard; DNA; 12 BP.
XX
AC ABI73035;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 373008 for detecting SNP TSC0059784.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
FN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 373008; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 5 A; 2 C; 0 G; 5 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2229 TACATGTTTG 2238
DB 1 TAGATGTTTG 10

RESULT 670
ABI60884
ID ABI60884 standard; DNA; 12 BP.
XX
AC ABI60884;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 360857 for detecting SNP TSC0052325.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
FN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 360857; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 6 A; 3 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2220 ACCAAAAGTT 2229
DB 2 ACCAAAAGTT 11

RESULT 671
ABI61879/c
ID ABI61879 standard; DNA; 12 BP.
XX
AC ABI61879;

Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2229 TACATGTTTG 2238
DB 11 TAAATGTTTG 2

RESULT 670
ABI60884
ID ABI60884 standard; DNA; 12 BP.
XX
AC ABI60884;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 360857 for detecting SNP TSC0052325.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
FN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 360857; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 6 A; 3 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2220 ACCAAAAGTT 2229
DB 2 ACCAAAAGTT 11

RESULT 671
ABI61879/c
ID ABI61879 standard; DNA; 12 BP.
XX
AC ABI61879;

XX 22-FEB-2002 (first entry)
 DI Oligonucleotide primer SEQ ID NO 361852 for detecting SNP TSC0052890.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPiG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 361852; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 3 A; 0 C; 1 G; 5 T; 0 U; 0 Other;
 PS Query Match 31.1%; Score 8.4; DB 1; Length 12;
 CC Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 CC Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTACA 2232
 DB |||||
 10 AAAAATTACA 1
 RESULT 672
 AB180290
 ID ABI80290 standard; DNA; 12 BP.
 AC ABI80290;
 XX 22-FEB-2002 (first entry)
 DI Oligonucleotide primer SEQ ID NO 380263 for detecting SNP TSC0063727.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 22-FEB-2002 (first entry)
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPiG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 380263; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 3 A; 0 C; 1 G; 5 T; 0 U; 0 Other;
 PS Query Match 31.1%; Score 8.4; DB 1; Length 12;
 CC Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 CC Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTACA 2232
 DB |||||
 10 AAAAATTACA 1
 RESULT 672
 AB180290
 ID ABI80290 standard; DNA; 12 BP.
 AC ABI80290;
 XX 22-FEB-2002 (first entry)
 DI Oligonucleotide primer SEQ ID NO 269504 for detecting SNP TSC0001784.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPiG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 380263; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 6 A; 1 C; 0 G; 3 T; 0 U; 2 Other;
 PS Query Match 31.1%; Score 8.4; DB 1; Length 12;
 CC Best Local Similarity 75.0%; Pred. No. 3.3e+02;
 CC Matches 9; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 2222 CAAAAGTTACAT 2233
 DB 1 CAAAANTTATAT 12
 RESULT 673
 ABH69527
 ID ABH69527 standard; DNA; 12 BP.
 XX ABH69527;
 XX 22-FEB-2002 (first entry)
 DI Oligonucleotide primer SEQ ID NO 269504 for detecting SNP TSC0001784.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPiG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PD 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPiG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 380263; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 6 A; 1 C; 0 G; 3 T; 0 U; 2 Other;
 PS Query Match 31.1%; Score 8.4; DB 1; Length 12;
 CC Best Local Similarity 75.0%; Pred. No. 3.3e+02;
 CC Matches 9; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 2222 CAAAAGTTACAT 2233
 DB 1 CAAAANTTATAT 12
 RESULT 673
 ABH69527
 ID ABH69527 standard; DNA; 12 BP.
 XX ABH69527;
 XX 22-FEB-2002 (first entry)
 DI Oligonucleotide primer SEQ ID NO 269504 for detecting SNP TSC0001784.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPiG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 269504; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 4 A; 0 C; 1 G; 7 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Oy 2228 TTACATGTTT 2237
Db 1 TTAATGTTT 10
RESULT 674
ABI19758
ID ABI19758 standard; DNA; 12 BP.
XX
AC ABI19758;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 319731 for detecting SNP TSC0029382.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
FN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 319731; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Oy 2229 TACATGTTT 2238
Db 1 TAAATGTTT 10
RESULT 675
ABI23870/C
ID ABI23870 standard; DNA; 12 BP.
XX
AC ABI23870;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 323843 for detecting SNP TSC0031638.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
FN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 323843; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 5 A; 3 C; 0 G; 4 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Oy 2227 GTTACATGTT 2236
Db 1 TTAATGTTT 10

XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 282359; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 8 A; 0 C; 1 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2228 TTACATGTTT 2237
XX DB 12 TTACATTTT 3
XX
XX RESULT 679
XX ABH83243
XX ID ABH83243 standard; DNA; 12 BP.
XX AC ABH83243;
XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide primer SEQ ID NO 283236 for detecting SNP TSC0011220.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 282356; 29pp + Sequence Listing; German.
XX

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 7 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2223 AAAAGTTTACA 2232
XX DB 2 AAAACTTACA 11
XX
XX RESULT 680
XX AB139437/C
XX ID AB139437 standard; DNA; 12 BP.
XX AC AB139437;
XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide primer SEQ ID NO 339410 for detecting SNP TSC0040990.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 339410; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX

XX WO200177384-A2.
 PN
 PD 18-OCT-2001.
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIC-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 345811; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
 SQ Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX
 XX 2228 TTACATGTTT 2237
 Db |||||
 |||
 11 TTATATGTTT 2
 XX
 RESULT 684
 ABI55931/C
 ID ABI55931 standard; DNA; 12 BP.
 XX
 XX AC ABI55931;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX
 DE Oligonucleotide primer SEQ ID NO 355904 for detecting SNP TSC0049863.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX Homo sapiens.
 OS
 XX
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIC-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 345811; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
 SQ Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX
 XX 2228 TTACATGTTT 2237
 Db |||||
 |||
 11 TTATATGTTT 2
 XX
 RESULT 684
 ABI55931/C
 ID ABI55931 standard; DNA; 12 BP.
 XX
 XX AC ABI55931;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX
 DE Oligonucleotide primer SEQ ID NO 355904 for detecting SNP TSC0050219.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX Homo sapiens.
 OS
 XX
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIC-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 356607; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
 SQ Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX
 XX 2222 CAAAAGTTAC 2231
 Db |||||
 |||
 11 CAAAATATAC 2
 XX
 RESULT 685
 ABI56634/C
 ID ABI56634 standard; DNA; 12 BP.
 XX
 XX AC ABI56634;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX
 DE Oligonucleotide primer SEQ ID NO 356607 for detecting SNP TSC0050219.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX Homo sapiens.
 OS
 XX
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIC-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 356607; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
 SQ Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX
 XX 2222 CAAAAGTTAC 2231
 Db |||||
 |||
 11 CAAAATATAC 2
 XX

DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 355904; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
 SQ Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX
 XX 2222 CAAAAGTTAC 2231
 Db |||||
 |||
 11 CAAAATATAC 2
 XX
 RESULT 685
 ABI56634/C
 ID ABI56634 standard; DNA; 12 BP.
 XX
 XX AC ABI56634;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX
 DE Oligonucleotide primer SEQ ID NO 356607 for detecting SNP TSC0050219.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX Homo sapiens.
 OS
 XX
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIC-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 356607; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
 SQ Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX
 XX 2222 CAAAAGTTAC 2231
 Db |||||
 |||
 11 CAAAATATAC 2
 XX

XX Oligonucleotide primer SEQ ID NO 375058 for detecting SNP TSC0061049.
 DE
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIG-) EPIGENOMICS AG.
 PA
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 375058; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: the sequence
 CC data for this patent did not form part of the invention. NOTE: the sequence
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 3 A; 0 C; 1 G; 8 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e-02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTTACA 2332
 DB 11 AAAAATTACA 2
 RESULT 689
 ABI78626/c
 ID ABI78626 standard; DNA; 12 BP.
 AC
 XX ABI78626;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 378599 for detecting SNP TSC0062862.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX

PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 378599; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the invention. NOTE: The sequence
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e-02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2224 AAAAGTTTACAT 2233
 DB 11 AAAAATTACAT 2
 RESULT 690
 ABH68239
 ID ABH68239 standard; DNA; 12 BP.
 AC
 XX ABH68239;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 268216 for detecting SNP TSC0000987.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 DE Oligonucleotide primer SEQ ID NO 378599 for detecting SNP TSC0062862.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 DE Oligonucleotide primer SEQ ID NO 378599 for detecting SNP TSC0062862.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX

XX PS Claim 1; SEQ ID NO 268216; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 8 A; 1 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACA 2232
Db 2 AAAAATTACA 11

RESULT 691

AB103629
ID AB103629 standard; DNA; 12 BP.

XX AC AB103629;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 303602 for detecting SNP TSC0020547.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS; peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss; central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX FN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.

XX Claim 1; SEQ ID NO 303602; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

CC was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 5 A; 0 C; 1 G; 6 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2224 AAAATTACAT 2233
Db 2 AAAATTATAT 11

RESULT 692

ABH79574/C
ID ABH79574 standard; DNA; 12 BP.

XX AC ABH79574;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 279567 for detecting SNP TSC0007512.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS; peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss; central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX FN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.

XX Claim 1; SEQ ID NO 279567; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 7 A; 1 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTT 2237
Db 12 TTATATGTTT 3

```

RESULT 693
ABI07513
ID ABI07513 standard; DNA; 12 BP.
XX AC
XX ABI07513;
XX DT
XX 22-FEB-2002 (first entry)
XX DE
XX Oligonucleotide primer SEQ ID NO 307486 for detecting SNP TSC0022521.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS
XX Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF
XX 06-APR-2001; 2001WO-IB000713.
XX PR
XX 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX PS
XX Claim 1; SEQ ID NO 307486; 29pp + Sequence Listing; German.
XX CC
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX SQ
XX Sequence 12 BP; 6 A; 3 C; 0 G; 3 T; 0 U; 0 Other;
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Mismatches 0; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2220 ACCAAAGTT 2229
XX DB 2 ACCAAAGTT 11
XX
XX RESULT 694
ABI07790
ID ABI07790 standard; DNA; 12 BP.
XX AC
XX ABI07790;
XX DT
XX 22-FEB-2002 (first entry)
XX DE
XX Oligonucleotide primer SEQ ID NO 307763 for detecting SNP TSC0022574.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS
XX Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF
XX 06-APR-2001; 2001WO-IB000713.
XX PR
XX 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX PS
XX Claim 1; SEQ ID NO 307486; 29pp + Sequence Listing; German.
XX CC
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX SQ
XX Sequence 12 BP; 6 A; 3 C; 0 G; 3 T; 0 U; 0 Other;
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Mismatches 0; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2220 ACCAAAGTT 2229
XX DB 2 ACCAAAGTT 11
XX
XX RESULT 695
ABI48543/c
ID ABI48543 standard; DNA; 12 BP.
XX AC
XX ABI48543;
XX DT
XX 22-FEB-2002 (first entry)
XX DE
XX Oligonucleotide primer SEQ ID NO 348516 for detecting SNP TSC0045629.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS
XX Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF
XX 06-APR-2001; 2001WO-IB000713.
XX PR
XX 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.

```

```

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF
XX 06-APR-2001; 2001WO-IB000713.
XX PR
XX 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX PS
XX Claim 1; SEQ ID NO 307763; 29pp + Sequence Listing; German.
XX CC
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX SQ
XX Sequence 12 BP; 7 A; 1 C; 0 G; 4 T; 0 U; 0 Other;
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Mismatches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2223 AAAAGTTTACA 2232
XX DB 3 AAAAGTTTACA 12
XX
XX RESULT 695
ABI48543/c
ID ABI48543 standard; DNA; 12 BP.
XX AC
XX ABI48543;
XX DT
XX 22-FEB-2002 (first entry)
XX DE
XX Oligonucleotide primer SEQ ID NO 348516 for detecting SNP TSC0045629.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS
XX Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF
XX 06-APR-2001; 2001WO-IB000713.
XX PR
XX 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.

```

XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 348516; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 6 A; 0 C; 1 G; 5 T; 0 U; 0 Other;
 SQ

Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2224 AAGATTACAT 2233
 DB 11 AAGATTACAT 2

RESULT 696
 ABI53698/c
 ID ABI53698 standard; DNA; 12 BP.
 AC ABI53698;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 353671 for detecting SNP TSC0048648.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 353671; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 6 A; 2 C; 0 G; 4 T; 0 U; 0 Other;
 SQ

Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2229 TACATGTTTG 2238
 DB 10 TAAATGTTTG 1

RESULT 697
 ABI70210
 ID ABI70210 standard; DNA; 12 BP.
 XX ABI70210;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 370183 for detecting SNP TSC0058045.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 370183; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 5 A; 3 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e-02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2224 AAAGTTACAT 2233
DB 1 AAATTTACAT 10
|||||

RESULT 698
ABI60008
ID ABI60008 standard; DNA; 12 BP.
XX
AC ABI60008;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 359981 for detecting SNP TSC0051873.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 359981; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABR00010-ABR82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 4 A; 0 C; 1 G; 7 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e-02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTT 2237
DB 2 TTAAATGTTT 11
|||||

RESULT 699
ABI74866
ID ABI74866 standard; DNA; 12 BP.
XX

ABI74866;
22-FEB-2002 (first entry)
Oligonucleotide primer SEQ ID NO 374839 for detecting SNP TSC0060923.
SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
central nervous system; gastrointestinal; respiratory; immune; metabolic.
Homo sapiens.
WO200177384-A2.
18-OCT-2001.
06-APR-2001; 2001WO-IB000713.
07-APR-2000; 2000DE-01019173.
(EPIG-) EPIGENOMICS AG.
Olek A, Piepenbrock C, Berlin K;
WPI; 2001-657177/75.
Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.
Claim 1; SEQ ID NO 374839; 29pp + Sequence Listing; German.
This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligomers are also used for detecting cell type differentiation. ABC00010
-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABR00010-ABR82073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences
Sequence 12 BP; 8 A; 1 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e-02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTTACA 2232
DB 2 AAAATTTTACA 11
|||||

RESULT 700
ABH67627/C
ID ABH67627 standard; DNA; 12 BP.
XX
AC ABH67627;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 267604 for detecting SNP TSC0000375.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.

XX 18-OCT-2001.
PD 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPiG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 267604; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 3 A; 0 C; 4 G; 5 T; 0 U; 0 Other;
SQ
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2220 ACCAAAGTT 2229
Db 12 ACCAAAGTT 3
RESULT 701
ABH70324/c
ID ABH70324 standard; DNA; 12 BP.
XX AC ABH70324;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 270301 for detecting SNP TSC0002082.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPiG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 270301; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 7 A; 0 C; 2 G; 3 T; 0 U; 0 Other;
SQ
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2228 TTACATGTTT 2237
Db 10 TTACATGTTT 1
RESULT 702
ABH82215
ID ABH82215 standard; DNA; 12 BP.
XX AC ABH82215;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 282208 for detecting SNP TSC0010580.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPiG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 282208; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 7 A; 0 C; 2 G; 3 T; 0 U; 0 Other;
SQ

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2223 AAAAGTTACA 2232
Db 1 AAAAATTACA 10

RESULT 703
ABH86310/c
ID ABH86310 standard; DNA; 12 BP.
XX
AC ABH86310;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 286303 for detecting SNP TSC0012663.
XX
XX SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 286303; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 8 A; 2 C; 1 G; 1 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2228 TTACATGTTT 2237

Db 10 TTACGTTT 1

RESULT 704
ABI12868/c
ID ABI12868 standard; DNA; 12 BP.
XX
AC ABI12868;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 312841 for detecting SNP TSC0025330.
XX
XX SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 312841; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 6 A; 4 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2229 TACATGTTTG 2238
Db 11 TATATGTTTG 2

RESULT 705
ABI41815
ID ABI41815 standard; DNA; 12 BP.
XX
AC ABI41815;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 341788 for detecting SNP TSC0042229.

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 341789; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
 SQ Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2224 AAAGTTACAT 2233
 DB ||| |||||
 1 AAAATTACAT 10
 RESULT 706
 ABI49149/C
 ID ABI49149 standard; DNA; 12 BP.
 XX AC
 XX ABI49149;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 349122 for detecting SNP TSC0045928.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX Claim 1; SEQ ID NO 349122; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
 SQ Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2224 AAAGTTACAT 2233
 DB ||| |||||
 1 AAAATTACAT 10
 RESULT 705
 ABI49149/C
 ID ABI49149 standard; DNA; 12 BP.
 XX AC
 XX ABI49149;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 349122 for detecting SNP TSC0057460.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX Claim 1; SEQ ID NO 349127; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
 SQ Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2228 TTACATGTTT 2237
 DB ||| |||||
 12 TTACATGTTT 3
 RESULT 707
 ABI69154
 ID ABI69154 standard; DNA; 12 BP.
 XX AC
 XX ABI69154;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 369127 for detecting SNP TSC0057460.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 369127; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
 SQ Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2228 TTACATGTTT 2237
 DB ||| |||||
 12 TTACATGTTT 3

PR 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 349122; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
 SQ Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2228 TTACATGTTT 2237
 DB ||| |||||
 12 TTACATGTTT 3
 RESULT 707
 ABI69154
 ID ABI69154 standard; DNA; 12 BP.
 XX AC
 XX ABI69154;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 369127 for detecting SNP TSC0057460.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 369127; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
 SQ Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2228 TTACATGTTT 2237
 DB ||| |||||
 12 TTACATGTTT 3
 RESULT 707
 ABI69154
 ID ABI69154 standard; DNA; 12 BP.
 XX AC
 XX ABI69154;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 369127 for detecting SNP TSC0057460.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 369127; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
 SQ Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2228 TTACATGTTT 2237
 DB ||| |||||
 12 TTACATGTTT 3

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 2 A; 1 C; 2 G; 7 T; 0 U; 0 Other;
SQ Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2228 TTACATGTTT 2237
DB 1 TTACATGTTT 10
|||||

RESULT 708
ABI74582/C
ID ABI74582 standard; DNA; 12 BP.
XX AC ABI74582;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 374555 for detecting SNP TSC0007192.
XX SNF; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX PN 18-OCT-2001.
XX PD 06-APR-2001; 2001WO-IB000713.
XX PF 07-APR-2000; 2000DE-01019173.
XX PR (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 374555; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 1 A; 1 C; 2 G; 8 T; 0 U; 0 Other;
SQ Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2217 GTGACCAAAA 2226
DB 12 GTAACCAAAA 3
|||||

RESULT 709
ABH69592
ID ABH69592 standard; DNA; 12 BP.
XX AC ABH69592;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 269569 for detecting SNP TSC0001808.
XX SNF; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX PN 18-OCT-2001.
XX PD 06-APR-2001; 2001WO-IB000713.
XX PF 07-APR-2000; 2000DE-01019173.
XX PR (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 269569; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
SQ Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2228 TTACATGTTT 2237
DB 1 TTACATGTTT 10
|||||

RESULT 710

ABH74068
ID ABH74068 standard; DNA; 12 BP.
XX AC ABH74068;
XX
DT 22-FEB-2002 (first entry)
XX
XX
DE Oligonucleotide primer SEQ ID NO 274053 for detecting SNP TSC0003410.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX WO200177384-A2.
FN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PT
XX Claim 1; SEQ ID NO 274053; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -AB09989, AB00010-ABF9989, ABH0010-ABH9989 and AB100010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Claim 1; SEQ ID NO 274053; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -AB09989, AB00010-ABF9989, ABH0010-ABH9989 and AB100010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 7 A; 0 C; 1 G; 4 T; 0 U; 0 Other;
SQ
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 223 AAAAGTTTACA 2232
DB 3 AAAAGTTTAAA 12
RESULT 711
ABH74532/c
ID ABH74532 standard; DNA; 12 BP.
XX AC ABH74532;
XX
XX 22-FEB-2002 (first entry)
DT
XX Oligonucleotide primer SEQ ID NO 274517 for detecting SNP TSC0003579.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX

OS Homo sapiens.
XX WO200177384-A2.
FN
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PT
XX Claim 1; SEQ ID NO 274517; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -AB09989, AB00010-ABF9989, ABH0010-ABH9989 and AB100010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 3 A; 0 C; 1 G; 8 T; 0 U; 0 Other;
SQ
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 223 AAAAGTTTACA 2232
DB 12 AAAAATTACA 3
RESULT 712
ABH99676/c
ID ABH99676 standard; DNA; 12 BP.
XX AC ABH99676;
XX
XX 22-FEB-2002 (first entry)
DT
XX Oligonucleotide primer SEQ ID NO 299669 for detecting SNP TSC0018671.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX WO200177384-A2.
FN
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI

XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 299669; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 2 A; 0 C; 1 G; 9 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTACAT 2232
 Db 10 AAAATTACAT 1
 RESULT 713
 ABH75004
 ID ABH75004 standard; DNA; 12 BP.
 AC ABH75004;
 XX
 DT 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 274991 for detecting SNP TSC0003754.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 274991; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 6 A; 2 C; 0 G; 4 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2224 AAAAGTTACAT 2233
 Db 3 AAAATTACAT 12
 RESULT 714
 ABI25982
 ID ABI25982 standard; DNA; 12 BP.
 AC ABI25982;
 XX
 DT 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 325955 for detecting SNP TSC0032823.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 325955; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 5 A; 2 C; 0 G; 5 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;

Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2222 CAAAAGTTAC 2231
 |||||
 Db 3 CAAAATTTAC 12

RESULT 715
 ABI26700/c
 ID ABI26700 standard; DNA; 12 BP.
 XX
 AC ABI26700;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 326673 for detecting SNP TSC0033216.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 FN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 DT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 326673; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 2 A; 3 C; 0 G; 7 T; 0 U; 0 Other;
 XX
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2223 AAAAGTTACA 2232
 |||||
 Db 12 AAAAGTTAGA 3

RESULT 716
 ABI44041/c
 ID ABI44041 standard; DNA; 12 BP.
 XX
 AC ABI44041;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 354133 for detecting SNP TSC0001249.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 FN WO200177384-A2.
 XX
 PD 18-OCT-2001.

DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 344014 for detecting SNP TSC0043333.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 FN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 DT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 344014; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 2 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
 XX
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2220 ACCAAAAGTT 2229
 |||||
 Db 10 ACCAAAAGTT 1

RESULT 717
 ABI54160
 ID ABI54160 standard; DNA; 12 BP.
 XX
 AC ABI54160;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 354133 for detecting SNP TSC0001249.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 FN WO200177384-A2.
 XX
 PD 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 354133; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACA 2232
 DB 2 AAAAATTACA 11
 ||||| |||||

RESULT 718

ABI55384
 ID ABI55384 standard; DNA; 12 BP.
 AC ABI55384;
 DT 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 355357 for detecting SNP TSC0006294.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PT methylation status.
 XX Claim 1; SEQ ID NO 355357; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2221 CCAAAAGTTA 2230
 DB 1 CCAAAAGTTA 10
 ||||| |||||

RESULT 719

ABI70168/C
 ID ABI70168 standard; DNA; 12 BP.
 AC ABI70168;
 DT 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 370141 for detecting SNP TSC0058018.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 370141; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
 . Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2228 TTACATGTTT 2237
 ||| |||||
 Db 11 TTACATGTTT 2

RESULT 720
 ABI59356/C
 ID ABI59356 standard; DNA; 12 BP.

XX AC ABI59356;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 359329 for detecting SNP TSC0051569.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 359329; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 4 A; 2 C; 0 G; 6 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2225 AAGTTACATG 2234
 ||| |||||
 Db 11 AAGTTAAATG 2

RESULT 721

ABI73271
 ID ABI73271 standard; DNA; 12 BP.

XX AC ABI73271;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 373244 for detecting SNP TSC0059921.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 373244; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 8 A; 0 C; 2 G; 2 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2223 AAAAGTTTACA 2232
 ||| |||||
 Db 1 AAAAGTTTACA 10

RESULT 722

ABI22008
 ID ABI22008 standard; DNA; 12 BP.

XX AC ABI22008;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 321981 for detecting SNP TSC0030585.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 321981; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 4 A; 0 C; 3 G; 5 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2226 AGTTACATGT 2235
 DB 1 AGTTACATGT 10
 RESULT 723
 ABI07647
 ID ABI07647 standard; DNA; 12 BP.
 AC ABI07647;
 XX 22-FEB-2002 (first entry)
 DT Oligonucleotide primer SEQ ID NO 307620 for detecting SNP TSC0022594.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 286369; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic

PA (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 307620; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTTACA 2232
 DB 3 AAAAGTTTACA 12
 RESULT 724
 ABH86376/c
 ID ABH86376 standard; DNA; 12 BP.
 AC ABH86376;
 XX 22-FEB-2002 (first entry)
 DT Oligonucleotide primer SEQ ID NO 286369 for detecting SNP TSC0012695.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 286369; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 5 A; 4 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2229 TACATGTTTG 2238
Db 11 TAGATGTTTG 2

RESULT 725
ABI44219
ID ABI44219 standard; DNA; 12 BP.
AC ABI44219;
XX
XX
XX 22-FEB-2002 (first entry)
DE Oligonucleotide primer SEQ ID NO 344192 for detecting SNP TSC0043435.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 344192; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 2229 TACATGTTTG 2238
Db 1 TATATGTTTG 10
RESULT 726
ABI45183
ID ABI45183 standard; DNA; 12 BP.
XX
XX ABI45183;
XX
XX 22-FEB-2002 (first entry)
DE Oligonucleotide primer SEQ ID NO 345156 for detecting SNP TSC0043898.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 345156; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 380462; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 6 A; 4 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2227 GTTACATGTT 2236
DB 10 GTTAGATGTT 1

RESULT 730
ABI25674
ID ABI25674 standard; DNA; 12 BP.
XX
AC ABI25674;
XX
XX 22-FEB-2002 (first entry)
DE Oligonucleotide primer SEQ ID NO 325647 for detecting SNP TSC0032642.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 325647; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 2 A; 0 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2229 TACATGTTTG 2238
DB 2 TATATGTTTG 11

RESULT 731
ABI27809
ID ABI27809 standard; DNA; 12 BP.
XX
AC ABI27809;
XX
XX 22-FEB-2002 (first entry)
DE Oligonucleotide primer SEQ ID NO 327782 for detecting SNP TSC0033890.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 327782; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 4 A; 0 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

QY      2226 AGTACATGT 2235
Db      2 AGTATATGT 11
||||| |||||
RESULT 732
ABH78190/C
ID      ABH78190 standard; DNA; 12 BP.
XX      AC
XX      ABH78190;
XX
DT      22-FEB-2002 (first entry)
XX
DE      Oligonucleotide primer SEQ ID NO 278183 for detecting SNP TSC0005767.
XX
KW      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
PN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX
DT      22-FEB-2002 (first entry)
XX
DE      Oligonucleotide primer SEQ ID NO 278183 for detecting SNP TSC0005767.
XX
KW      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
PN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX
PF      06-APR-2001; 2001WO-IB000713.
XX
PR      07-APR-2000; 2000DE-01019173.
XX
PA      (EPiG-) EPIGENOMICS AG.
XX
PI      Olek A, Piepenbrock C, Berlin K;
XX
PI      WPI; 2001-657177/75.
XX
DR      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX
PS      Claim 1; SEQ ID NO 278183; 29pp + Sequence Listing; German.
XX
CC      This invention describes novel oligonucleotide primers or peptide nucleic
CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX
XX      Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
XX
CC      This invention describes novel oligonucleotide primers or peptide nucleic
CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX
XX      Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
XX
Query Match      31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2223 AAAAGTTACA 2232
Db      11 AAAACTTACA 2
||||| |||||
RESULT 733
ABI30496/C
ID      ABI30496 standard; DNA; 12 BP.
XX
XX      AC
XX      ABI30496;
XX
DT      22-FEB-2002 (first entry)
XX
DE      Oligonucleotide primer SEQ ID NO 307745 for detecting SNP TSC0022660.
XX
KW      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
PN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX
PF      06-APR-2001; 2001WO-IB000713.

```

```

DE      Oligonucleotide primer SEQ ID NO 330469 for detecting SNP TSC0035544.
XX
KW      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
PN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX
DT      06-APR-2001; 2001WO-IB000713.
XX
PR      07-APR-2000; 2000DE-01019173.
XX
PA      (EPiG-) EPIGENOMICS AG.
XX
PI      Olek A, Piepenbrock C, Berlin K;
XX
PI      WPI; 2001-657177/75.
XX
DR      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX
PS      Claim 1; SEQ ID NO 330469; 29pp + Sequence Listing; German.
XX
CC      This invention describes novel oligonucleotide primers or peptide nucleic
CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX
XX      Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
XX
Query Match      31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2223 AAAAGTTACA 2232
Db      12 AAAACTTACA 3
||||| |||||
RESULT 734
ABI07772
ID      ABI07772 standard; DNA; 12 BP.
XX
XX      AC
XX      ABI07772;
XX
DT      22-FEB-2002 (first entry)
XX
DE      Oligonucleotide primer SEQ ID NO 307745 for detecting SNP TSC0022660.
XX
KW      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
PN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX
PF      06-APR-2001; 2001WO-IB000713.

```



```
CC ftp.wipo.int/pub/published_pct_sequences
SQ Sequence 12 BP; 6 A; 0 C; 1 G; 5 T; 0 U; 0 Other;

Query Match      31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2224 AAAAGTTACAT 2233
Db 1 AAAAGTTATAT 10

RESULT 737
ABI69035
ID ABI69035 standard; DNA; 12 BP.
XX AC
AC ABI69035;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 369008 for detecting SNP TSC0057399.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX OS
XX WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 369008; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;

Query Match      31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2227 GTTACATGTT 2236
Db 3 GTTAATGTT 12

RESULT 738
ABI80435
ID ABI80435 standard; DNA; 12 BP.
XX AC
AC ABI80435;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 380408 for detecting SNP TSC0007102.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX OS
XX WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 380408; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 7 A; 0 C; 2 G; 3 T; 0 U; 0 Other;

Query Match      31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTTACA 2232
Db 2 AAAAGTTTATA 11

RESULT 739
ABH94461/c
ID ABH94461 standard; DNA; 12 BP.
XX AC
AC ABH94461;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 294454 for detecting SNP TSC0016128.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
```

OS Homo sapiens.
 XX WO200177384-A2.
 PN 18-OCT-2001.
 PD
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 294454; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP).
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 2 A; 1 C; 3 G; 6 T; 0 U; 0 Other;
 SQ
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Oy 2217 GTGACCAAAA 2236
 Db 11 GTACCAAAA 2
 |||||
 RESULT 740
 AB119759
 ID AB119759 standard; DNA; 12 BP.
 XX
 XX AB119759;
 AC
 XX 22-FEB-2002 (first entry)
 DT
 XX Oligonucleotide primer SEQ ID NO 319732 for detecting SNP TSC0029382.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 302095; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP).
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 2 A; 1 C; 3 G; 6 T; 0 U; 0 Other;
 SQ

PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 319732; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP).
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 3 A; 1 C; 3 G; 5 T; 0 U; 0 Other;
 SQ
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Oy 2229 TACATGTTTG 2238
 Db 1 TAAATGTTTG 10
 |||||
 RESULT 741
 AB102122/c
 ID AB102122 standard; DNA; 12 BP.
 XX
 XX AB102122;
 AC
 XX 22-FEB-2002 (first entry)
 DT
 XX Oligonucleotide primer SEQ ID NO 302095 for detecting SNP TSC0019789.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 302095; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP).
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

Sequence 12 BP; 5 A; 0 C; 1 G; 6 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2224 AAAAGTTACAT 2233
DB 12 AAAATTACAT 3
|||||

RESULT 742
ABI03729
ID ABI03729 standard; DNA; 12 BP.
XX
AC ABI03729;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 303702 for detecting SNP TSC0020611.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO2001:77384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.
XX
PS Claim 1; SEQ ID NO 303702; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

Sequence 12 BP; 9 A; 1 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;

Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACA 2232
DB 1 AAAAATTACA 10
|||||

RESULT 743
ABI31308
ID ABI31308 standard; DNA; 12 BP.
XX
AC ABI31308;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 331281 for detecting SNP TSC0036096.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO2001:77384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.
XX
PS Claim 1; SEQ ID NO 331281; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

Sequence 12 BP; 7 A; 1 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACA 2232
DB 3 AAAAATTACA 12
|||||

RESULT 744
ABI43477
ID ABI43477 standard; DNA; 12 BP.
XX
AC ABI43477;

PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 345939; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 9 A; 0 C; 1 G; 2 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 |||||
 QY 2228 TTACATGTTT 2237
 Db 10 TTACATGTTT 1
 |||||
 RESULT 747
 ABI70868
 ID ABI70868 standard; DNA; 12 BP.
 AC ABI70868;
 XX
 DT 22-FEB-2002 (first entry)
 DE
 DE Oligonucleotide primer SEQ ID NO 370841 for detecting SNP TSC0058426.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 370841; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 9 A; 0 C; 1 G; 2 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 |||||
 QY 2228 TTACATGTTT 2237
 Db 10 TTACATGTTT 1
 |||||

CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 |||||
 QY 2229 TACATGTTTG 2238
 Db 1 TACATGTTTG 10
 |||||
 RESULT 748
 ABI57581
 ID ABI57581 standard; DNA; 12 BP.
 AC ABI57581;
 XX
 DT 22-FEB-2002 (first entry)
 DE
 DE Oligonucleotide primer SEQ ID NO 357554 for detecting SNP TSC0007336.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 357554; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 |||||
 QY 2228 TTACATGTTT 2237
 |||||

Db 2 TTACATGTTT 11

RESULT 749
ABI74058
ID ABI74058 standard; DNA; 12 BP.
XX
AC ABI74058;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 374031 for detecting SNP TSC0010878.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 374031; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 4 A; 0 C; 3 G; 5 T; 0 U; 0 Other;
XX
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2225 AAGTTACATG 2234
DB 3 AAGTTACATG 12
RESULT 750
ABI76381
ID ABI76381 standard; DNA; 12 BP.
XX
AC ABI76381;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 376354 for detecting SNP TSC0061749.
XX

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 376354; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 4 A; 0 C; 3 G; 5 T; 0 U; 0 Other;
XX
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2229 TACATGTTTG 2238
DB 1 TAAATGTTTG 10
RESULT 751
ABI63441
ID ABI63441 standard; DNA; 12 BP.
XX
AC ABI63441;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 363414 for detecting SNP TSC0053832.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX

XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 363414; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI0010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 6 A; 1 C; 2 G; 3 T; 0 U; 0 Other;
SQ
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2221 CCAAAAGTTA 2230
DB 1 CGAAAAGTTA 10
RESULT 752
ABI80040/C
ID ABI80040 standard; DNA; 12 BP.
XX AC ABI80040;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 380013 for detecting SNP TSC0063595.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX W0200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 380013; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI0010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 3 A; 1 C; 2 G; 6 T; 0 U; 0 Other;
SQ
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 2224 AAAGTTACAT 2233
DB 10 AAAATTACAT 1
RESULT 753
ABI80160
ID ABI80160 standard; DNA; 12 BP.
XX AC ABI80160;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 380133 for detecting SNP TSC0063654.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX W0200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 380133; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI0010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.
XX PS Claim 1; SEQ ID NO 283882; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 4 A; 0 C; 3 G; 5 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2227 GTTACATGTT 2236
Db 1 GTTACATGTT 10
|||||
|||||

RESULT 758
ABI39196
ID ABI39196 standard; DNA; 12 BP.
XX AC ABI39196;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 339169 for detecting SNP TSC0040877.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.
XX PS Claim 1; SEQ ID NO 339169; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.
XX PS Claim 1; SEQ ID NO 300043; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 3 A; 0 C; 0 G; 5 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2225 AAGTTACATG 2234
Db 12 AAGTTACATG 3
|||||
|||||

RESULT 757
ABH83889
ID ABH83889 standard; DNA; 12 BP.
XX AC ABH83889;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 283882 for detecting SNP TSC0011547.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.
XX PS Claim 1; SEQ ID NO 283882; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTT 2237
DB 2 TTACATGTTT 11

RESULT 759
ABI40471
ID ABI40471 standard; DNA; 12 BP.

AC ABI40471;
XX
XX 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 340444 for detecting SNP TSC0041532.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

XX Claim 1; SEQ ID NO 340444; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 5 A; 3 C; 0 G; 4 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTT 2237
DB 2 TTACATGTTT 11

RESULT 759
ABI40471
ID ABI40471 standard; DNA; 12 BP.

AC ABI40471;
XX
XX 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 292086 for detecting SNP TSC0015079.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

QY 2222 CAAAAGTTAC 2231
DB 3 CAAAAGTTAC 12

RESULT 760
ABH92093/C
ID ABH92093 standard; DNA; 12 BP.

XX ABH92093;
XX 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 292086 for detecting SNP TSC0015079.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

XX Claim 1; SEQ ID NO 292086; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 3 A; 3 C; 0 G; 6 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTTACA 2232
DB 12 AAAAGTTTACA 3

RESULT 761
ABI49451
ID ABI49451 standard; DNA; 12 BP.

AC ABI49451;
XX
XX 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 292086 for detecting SNP TSC0015079.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.


```

XX DE Oligonucleotide primer SEQ ID NO 349424 for detecting SNP TSC0046132.
XX DE
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX WO200177384-A2.
XX XX
XX PD 18-OCT-2001.
XX XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX XX
XX PR 07-APR-2000; 2000DE-01019173.
XX XX
XX PA (EPIG-) EPIGENOMICS AG.
XX XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX XX
XX DR WPI; 2001-657177/75.
XX XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX XX
XX PS Claim 1; SEQ ID NO 349424; 29pp + Sequence Listing; German.
XX XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX XX
XX SQ Sequence 12 BP; 7 A; 0 C; 2 G; 3 T; 0 U; 0 Other;
XX XX
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2223 AAAAGTTACA 2232
Db 3 AAAAGTTATA 12

RESULT 762
ABI68097/C
ID ABI68097 standard; DNA; 12 BP.
XX AC
XX AC ABI68097;
XX DT
XX DT 22-FEB-2002 (first entry)
XX XX
XX DE Oligonucleotide primer SEQ ID NO 368070 for detecting SNP TSC0056733.
XX XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX WO200177384-A2.
XX XX
XX PD 18-OCT-2001.
XX XX

```

```

PF 06-APR-2001; 2001WO-IB000713.
XX XX
XX 07-APR-2000; 2000DE-01019173.
XX XX
XX PA (EPIG-) EPIGENOMICS AG.
XX XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX XX
XX DR WPI; 2001-657177/75.
XX XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX XX
XX PS Claim 1; SEQ ID NO 368070; 29pp + Sequence Listing; German.
XX XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX XX
XX SQ Sequence 12 BP; 2 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
XX XX
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2220 ACCAAAAGTT 2229
Db 10 ACCAAAAGTT 1

RESULT 763
ABI68747/C
ID ABI68747 standard; DNA; 12 BP.
XX AC
XX AC ABI68747;
XX DT
XX DT 22-FEB-2002 (first entry)
XX XX
XX DE Oligonucleotide primer SEQ ID NO 368720 for detecting SNP TSC0057183.
XX XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX WO200177384-A2.
XX XX
XX PD 18-OCT-2001.
XX XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX XX
XX PR 07-APR-2000; 2000DE-01019173.
XX XX
XX PA (EPIG-) EPIGENOMICS AG.
XX XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX XX
XX DR WPI; 2001-657177/75.
XX XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.

```

XX PS Claim 1; SEQ ID NO 368720; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP).

XX CC and cytosine methylation status in chemically pretreated genomic DNA. The

XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

XX CC range of diseases including immune system, gastrointestinal, respiratory,

XX CC central nervous system, cardiovascular and metabolic disorders. The

XX CC oligomers are also used for detecting cell type differentiation. ABC00010

XX CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073

XX CC represent the oligomers described in the invention. NOTE: The sequence

XX CC data for this patent did not form part of the printed specification, but

XX CC was obtained in electronic format from WIPO at

XX CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 1 A; 1 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;

Best Local Similarity 90.0%; Pred. No. 3.3e+02;

Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2217 GTGACCAAAA 2226

DB 10 GTACCAAAA 1

RESULT 764

ABI56919/c

ID ABI56919 standard; DNA; 12 BP.

XX AC ABI56919;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 356892 for detecting SNP TSC0050363.

XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is

XX designed to detect single-nucleotide polymorphisms and cytosine

XX methylation status.

XX Claim 1; SEQ ID NO 356892; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;

Best Local Similarity 90.0%; Pred. No. 3.3e+02;

Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2224 AAAGTTACAT 2233

DB 12 AAAGTTACAT 3

RESULT 765

ABI62778/c

ID ABI62778 standard; DNA; 12 BP.

XX AC ABI62778;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 362751 for detecting SNP TSC0053419.

XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is

XX designed to detect single-nucleotide polymorphisms and cytosine

XX methylation status.

XX Claim 1; SEQ ID NO 362751; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but

XX was obtained in electronic format from WIPO at

XX ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 3 A; 0 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;

Best Local Similarity 90.0%; Pred. No. 3.3e+02;

Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2221 CCAAAAGTTA 2230

DB 10 CCAAAAGTTA 1

RESULT 766
ABI77268
ID ABI77268 standard; DNA; 12 BP.
XX AC ABI77268;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 377241 for detecting SNP TSC0010490.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX WO200177384-A2.
XX XX 18-OCT-2001.
XX XX 06-APR-2001; 2001WO-IB000713.
XX XX 07-APR-2000; 2000DE-01019173.
XX XX (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX XX WPI; 2001-657177/75.
XX XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX XX Claim 1; SEQ ID NO 377241; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 3 A; 2 C; 1 G; 6 T; 0 U; 0 Other;
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2228 TTACAGTTT 2237
DB 1 TTACAGTTT 10
RESULT 767
ABI65580/c
ID ABI65580 standard; DNA; 12 BP.
XX AC ABI65580;
XX XX 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 365553 for detecting SNP TSC0055201.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX Claim 1; SEQ ID NO 365553; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 4 A; 0 C; 3 G; 5 T; 0 U; 0 Other;
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2221 CCAAAAGTTA 2230
DB 11 CCAAAAGTTA 2
RESULT 768
ABI66101/c
ID ABI66101 standard; DNA; 12 BP.
XX AC ABI66101;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 366074 for detecting SNP TSC0055521.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX WO200177384-A2.
XX XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;
 XX WI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 366074; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC range of diseases including immune system, cardiovascular, respiratory,
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 5 A; 1 C; 0 G; 6 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2224 AAGTTTACAT 2233
 Db 10 AAGTTTAAAT 1
 RESULT 769
 ABI80039/C
 ID ABI80039 standard; DNA; 12 BP.
 AC ABI80039;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 380012 for detecting SNP TSC0063595.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 380012; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2224 AAGTTTACAT 2233
 Db 10 AAGTTTACAT 1
 RESULT 770
 ABH71218/C
 ID ABH71218 standard; DNA; 12 BP.
 AC ABH71218;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 271195 for detecting SNP TSC0002423.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 271195; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;

```
Query Match      31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2229 TACATGTTTG 2238
DB 12 TATATGTTTG 3

RESULT 771
ABI26809/c
ID ABI26809 standard; DNA; 12 BP.
XX AC
XX AC ABI26809;
XX DT
XX DE 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 326782 for detecting SNP TSC0033276.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO2001.77384-A2.
XX PD 18-OCT-2001.
XX DT
XX DE 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 326782 for detecting SNP TSC0033276.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO2001.77384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 326782; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;

Query Match      31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2221 CCAAAAGTTA 2230
DB 11 CCAAAATTTA 2

RESULT 772
ABI02095/c
ID ABI02095 standard; DNA; 12 BP.
XX AC
XX AC ABI02095;
XX DT
XX DE 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 302264 for detecting SNP TSC0019895.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO2001.77384-A2.
```

XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 302264; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
 SQ Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 2223 AAAAGTTACA 2232
 Db 3 AAAACTTACA 12
 RESULT 774
 AB103272/c
 ID AB103272 standard; DNA; 12 BP.
 AC AB103272;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 303245 for detecting SNP TSC0020406.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
 SQ Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 303245; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 2 A; 0 C; 4 G; 6 T; 0 U; 0 Other;
 SQ Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 2221 CCAAAAGTTA 2230
 Db 11 CCAAAACTTA 2
 RESULT 775
 ABH78244/c
 ID ABH78244 standard; DNA; 12 BP.
 AC ABH78244;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 278237 for detecting SNP TSC0005824.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 278237; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 2222 CAAGAATTAC 2231
Db 11 CAATAATAC 2
RESULT 776
ABI0491
ID ABI0491 standard; DNA; 12 BP.
XX
AC ABI0491;
DT 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 330464 for detecting SNP TSC0035540.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WC200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 330464; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 2224 AAAGTTACAT 2233

Db 3 AAAATTACAT 12
RESULT 777
ABH0892
ID ABH0892 standard; DNA; 12 BP.
XX
AC ABH0892;
DT 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 280885 for detecting SNP TSC0009196.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 280885; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 9 A; 1 C; 0 G; 2 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 2223 AAAAGTTAC 2232
Db 3 AAAAATTACA 12
RESULT 778
ABI08067/c
ID ABI08067 standard; DNA; 12 BP.
XX
AC ABI08067;
DT 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 308040 for detecting SNP TSC0022851.


```

XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 8 A; 1 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2228 TTACATGTTT 2237
XX Db 11 TTAATGTTT 2
XX
XX RESULT 781
XX ABI14259
XX ID ABI14259 standard; DNA; 12 BP.
XX AC ABI14259;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 314232 for detecting SNP TSC0026218.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 314232; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 8 A; 1 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2228 TTACATGTTT 2237
XX Db 11 TTAATGTTT 2
XX
XX RESULT 781
XX ABI14259
XX ID ABI14259 standard; DNA; 12 BP.
XX AC ABI14259;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 314232 for detecting SNP TSC0026218.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 314232; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

```

```

XX SQ Sequence 12 BP; 7 A; 1 C; 0 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2224 AAAGTTACAT 2233
XX Db 2 AAAATTACAT 11
XX
XX RESULT 782
XX ABH90009/C
XX ID ABH90009 standard; DNA; 12 BP.
XX AC ABH90009;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 290002 for detecting SNP TSC0014182.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 290002; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 4 A; 0 C; 1 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2224 AAAGTTACAT 2233
XX Db 10 AAAATTACAT 1
XX
XX RESULT 783

```

ABI49736/c
ID ABI49736 standard; DNA; 12 BP.
XX AC ABI49736;
XX AC ABI49736;
XX AC ABI49736;
DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 349709 for detecting SNP TSC0046267.
XX DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX OS WO200177384-A2.
XX PN 18-OCT-2001.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 349709; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 6 A; 3 C; 0 G; 3 T; 0 U; 0 Other;
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2227 GTTACATGTT 2236
DB 10 GTTAAATGTT 1
RESULT 784
ABI74883/c
ID ABI74883 standard; DNA; 12 BP.
XX AC ABI74883;
XX AC ABI74883;
DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 374856 for detecting SNP TSC0060939.
XX DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX OS WO200177384-A2.
XX PN 18-OCT-2001.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;

OS Homo sapiens.
XX WO200177384-A2.
XX PN 18-OCT-2001.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 374856; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2228 TTACATGTT 2237
DB 10 TTAATGTT 1
RESULT 785
ABI18050/c
ID ABI18050 standard; DNA; 12 BP.
XX AC ABI18050;
XX AC ABI18050;
DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 318023 for detecting SNP TSC0028398.
XX DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX OS WO200177384-A2.
XX PN 18-OCT-2001.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;

```
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 318023; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 4 A; 4 C; 0 G; 4 T; 0 U; 0 Other;
SQ
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2226 AGTTACATGT 2235
DB 11 AGTTAAATGT 2
RESULT 786
ABH93224/c
ID ABH93224 standard; DNA; 12 BP.
XX
XX ABH93224;
AC
XX
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide primer SEQ ID NO 293217 for detecting SNP TSC0015548.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIG-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 293217; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
```

```
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 0 Other;
SQ
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2221 CCAAAAGTTA 2230
DB 10 CCAAAATTA 1
RESULT 787
ABH68672
ID ABH68672 standard; DNA; 12 BP.
XX
XX ABH68672;
AC
XX
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide primer SEQ ID NO 268649 for detecting SNP TSC0001276.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIG-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 268649; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 3 A; 0 C; 1 G; 8 T; 0 U; 0 Other;
SQ
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
```

Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTT 2237
||| |||||
Db 1 TTAAATGTTT 10

RESULT 788
ABH74218/C
ID ABH74218 standard; DNA; 12 BP.
XX
AC ABH74218;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 274203 for detecting SNP TSC0003475.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 274203; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP).
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB12073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2227 GTTACATGTTT 2236
||| |||||
Db 10 GTTAAATGTTT 1

RESULT 789
ABH99975/C
ID ABH99975 standard; DNA; 12 BP.
XX
AC ABH99975;
XX
XX

DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 299968 for detecting SNP TSC0018823.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 299968; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP).
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB12073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 5 A; 4 C; 1 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2227 GTTACATGTTT 2236
||| |||||
Db 12 GTTACATGTTT 3

RESULT 790
ABH75361
ID ABH75361 standard; DNA; 12 BP.
XX
AC ABH75361;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 275352 for detecting SNP TSC0003869.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX

CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2223 AAAAGTTTACA 2232

DB 1 AAAAATTACA 10

RESULT 793

AB107539
 ID AB107539 standard; DNA; 12 BP.

XX AC AB107539;

DT 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 307512 for detecting SNP TSC0022534.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX FN WO200177384-A2.

XX PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 307512; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 9 A; 0 C; 1 G; 2 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2223 AAAAGTTTACA 2232

DB 2 AAAAGTTTAA 11

RESULT 794

ABH86141
 ID ABH86141 standard; DNA; 12 BP.

XX AC ABH86141;

DT 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 286134 for detecting SNP TSC0012595.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX FN WO200177384-A2.

XX PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 286134; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2220 ACCAAAGTTT 2229

DB 3 ACCAAAGTTT 12

RESULT 795

AB117314
 ID AB117314 standard; DNA; 12 BP.

XX AC AB117314;

DT 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 317287 for detecting SNP TSC0027908.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 3 A; 0 C; 1 G; 8 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2228 TTACATGTTT 2237
 Db 2 TTAAATGTTT 11
 |||||
 |||||

RESULT 798
 ABI54181/c
 ID ABI54181 standard; DNA; 12 BP.
 XX
 AC ABI54181;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 354154 for detecting SNP TSC0048938.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 DT 06-APR-2001; 2001WO-IB000713.
 XX
 DE 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 354154; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2221 CCAAAAGTTA 2230
 Db 11 CCAAAAGTTA 2
 |||||
 |||||

RESULT 799
 ABI54184
 ID ABI54184 standard; DNA; 12 BP.
 XX
 AC ABI54184;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 354157 for detecting SNP TSC0048942.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 DT 06-APR-2001; 2001WO-IB000713.
 XX
 DE 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 354157; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 4 A; 1 C; 0 G; 7 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2228 TTACATGTTT 2237
 Db 1 TTACATATT 10
 |||||
 |||||

RESULT 800
 ABI68709
 ID ABI68709 standard; DNA; 12 BP.


```
XX AC AB168709;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 368682 for detecting SNP TSC0057150.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX PI WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 368682; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -AB09989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 6 A; 0 C; 3 G; 3 T; 0 U; 0 Other;
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX QY 2223 AAAAGTTACA 2232
XX Db |||||
XX 2 AAAAGTTATA 11
XX RESULT 801
XX AB168786/C
XX ID AB168786 standard; DNA; 12 BP.
XX AC AB168786;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 368759 for detecting SNP TSC0057206.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
```

```
PN WO200177384-A2.
XX 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX PI WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 368759; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -AB09989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX QY 2220 ACCAAAAGTT 2229
XX Db |||||
XX 10 ACCAAAAGTT 1
XX RESULT 802
XX AB156803/C
XX ID AB156803 standard; DNA; 12 BP.
XX AC AB156803;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 356776 for detecting SNP TSC0007348.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX PI WPI; 2001-657177/75.
```


QY 2227 GTTACATGTT 2236
|||||
Db 3 GTTATAGTT 12

RESULT 805
AB167192/c
ID AB167192 standard; DNA; 12 BP.
AC
AC AB167192;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 367165 for detecting SNP TSC0056206.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 367165 for detecting SNP TSC0056206.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 367165; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 0 Other;
XX
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2221 CCAAAAGTTA 2230
|||||
Db 12 CCAAAATTA 3

RESULT 806
ABH67895/c
ID ABH67895 standard; DNA; 12 BP.
XX
AC ABH67895;
XX
DT 22-FEB-2002 (first entry)
XX

DE Oligonucleotide primer SEQ ID NO 267872 for detecting SNP TSC0000618.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 267872; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 9 A; 1 C; 0 G; 2 T; 0 U; 0 Other;
XX
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTT 2237
|||||
Db 12 TTATAGTTT 3

RESULT 807
ABH77338
ID ABH77338 standard; DNA; 12 BP.
XX
AC ABH77338;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 277331 for detecting SNP TSC0004440.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 277331; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
 SQ Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTACA 2232
 DB 2 AAAAATTACA 11
 RESULT 808
 ABI34133/C
 ID ABI34133 standard; DNA; 12 BP.
 AC ABI34133;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 334106 for detecting SNP TSC0037943.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 334106; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
 SQ Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTACA 2232
 DB 2 AAAAATTACA 11
 RESULT 808
 ABI34133/C
 ID ABI34133 standard; DNA; 12 BP.
 AC ABI34133;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 334106 for detecting SNP TSC0037943.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 334106; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

PS Claim 1; SEQ ID NO 334106; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 4 A; 0 C; 3 G; 5 T; 0 U; 0 Other;
 SQ Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2224 AAAAGTTACAT 2233
 DB 10 AAACCTTACAT 1
 RESULT 809
 ABI36475/C
 ID ABI36475 standard; DNA; 12 BP.
 AC ABI36475;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 336448 for detecting SNP TSC0039364.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 336448; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

RESULT 811										
ABI44537										
ID	ABI44537	standard; DNA; 12 BP.								
XX	AC	AC								
XX	ABI44537;									
XX										
DT	22-FEB-2002	(first entry)								
XX										
DE	oligonucleotide primer	SEQ ID NO 344510 for detecting SNP TSC0043590.								
XX										
XX	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;									
KW	peptide nucleic acid; cytosine methylation; human; cardiovascular; primer; ss;									
KW	central nervous system; gastrointestinal; respiratory; immune; metabolic.									
XX										
OS	Homo sapiens.									
XX										
PN	WO200177384-A2.									
XX										
PD	18-OCT-2001.									
XX										
PF	06-APR-2001; 2001WO-IB000713.									
XX										
PR	07-APR-2000; 2000DE-01019173.									
XX	(EPIG-) EPIGENOMICS AG.									
PA										
PI	Olek A, Piepenbrock C, Berlin K;									
XX										
DR	WPI; 2001-657177/75.									
XX										
PT	Set of oligonucleotides, useful for diagnosis and cell typing, is									
PT	designed to detect single-nucleotide polymorphisms and cytosine									
PT	methylation status.									
XX										
PS	Claim 1; SEQ ID NO 344510; 29pp + Sequence Listing; German.									
XX										
CC	This invention describes novel oligonucleotide primers or peptide nucleic									
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)									
CC	and cytosine methylation status in chemically pretreated genomic DNA. The									
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a									
CC	range of diseases including immune system, gastrointestinal, respiratory,									
CC	central nervous system, cardiovascular and metabolic disorders. The									
CC	oligomers are also used for detecting cell type differentiation. ABC00010									
CC	-ABC99989, ABF00010-ABF99989, ABH0010-ABH99989 and ABI00010-ABI82073									
CC	represent the oligomers described in the invention. NOTE: The sequence									
CC	data for this patent did not form part of the printed specification, but									
CC	was obtained in electronic format from WIPO at									
CC	ftp.wipo.int/pub/published_pct_sequences									
XX										
SQ	Sequence 12 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 0 Other;									
	Query Match	31.1%; Score 8.4; DB 1; Length 12;								
	Best Local Similarity	90.0%; Pred. No. 3.3e+02;								
	Matches	9; Conservative 0; Mismatches 1; Indels 0; Gaps 0								
QY	2228	TTACATGTTT 2237								
DB	1	TTAAATGTTT 10								
RESULT 812										
ABI45007/c										
ID	ABI45007	standard; DNA; 12 BP.								
XX	AC	AC								
XX	ABI45007;									
XX										
DT	22-FEB-2002	(first entry)								
XX										
DE	oligonucleotide primer	SEQ ID NO 344980 for detecting SNP TSC0043808.								
XX										
XX	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;									
KW	peptide nucleic acid; cytosine methylation; human; cardiovascular; primer; ss;									
KW	central nervous system; gastrointestinal; respiratory; immune; metabolic.									
KW										

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABH00010-ABH82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 5 A; 0 C; 1 G; 6 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTT 2237
 DB 1 TTAATGTTT 10

RESULT 815
 ABI76427/C
 ID ABI76427 standard; DNA; 12 BP.
 XX AC
 AC ABI76427;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 376400 for detecting SNP TSC0061795.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX
 PS Claim 1; SEQ ID NO 376400; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABH00010-ABH82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX
 SQ Sequence 12 BP; 6 A; 3 C; 0 G; 3 T; 0 U; 0 Other;
 XX
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2227 GTTACATGTT 2236
 DB 11 GTTAGATGTT 2

RESULT 816
 ABI78268/C
 ID ABI78268 standard; DNA; 12 BP.
 XX AC
 AC ABI78268;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 378241 for detecting SNP TSC0062685.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX
 PS Claim 1; SEQ ID NO 378241; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABH00010-ABH82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX
 SQ Sequence 12 BP; 3 A; 0 C; 1 G; 8 T; 0 U; 0 Other;
 XX
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTTACA 2232
 DB 12 AAAATTATACA 3

RESULT 817
 ABI79156/C
 ID ABI79156 standard; DNA; 12 BP.
 XX AC
 AC ABI79156;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 379129 for detecting SNP TSC0003097.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is

XX PT designed to detect single-nucleotide polymorphisms and cytosine

XX PT methylation status.

XX PS Claim 1; SEQ ID NO 379129; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic

XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

XX CC and cytosine methylation status in chemically pretreated genomic DNA. The

XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

XX CC range of diseases including immune system, gastrointestinal, respiratory,

XX CC central nervous system, cardiovascular and metabolic disorders. The

XX CC oligomers are also used for detecting cell type differentiation. ABC00010

XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

XX CC represent the oligomers described in the invention. NOTE: The sequence

XX CC data for this patent did not form part of the printed specification, but

XX CC was obtained in electronic format from WIPO at

XX CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 4 A; 0 C; 1 G; 7 T; 0 U; 0 Other;

XX Query Match 31.1%; Score 8.4; DB 1; Length 12;

XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;

XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTTACA 2232

DB |||||

10 AAAATTTACA 1

RESULT 818

ABI79510/c.

ID ABI79510 standard; DNA; 12 BP.

XX AC ABI79510;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 379483 for detecting SNP TSC0000821.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is

XX PT designed to detect single-nucleotide polymorphisms and cytosine

XX PT methylation status.

XX PS Claim 1; SEQ ID NO 379129; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic

XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

XX CC and cytosine methylation status in chemically pretreated genomic DNA. The

XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

XX CC range of diseases including immune system, gastrointestinal, respiratory,

XX CC central nervous system, cardiovascular and metabolic disorders. The

XX CC oligomers are also used for detecting cell type differentiation. ABC00010

XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

XX CC represent the oligomers described in the invention. NOTE: The sequence

XX CC data for this patent did not form part of the printed specification, but

XX CC was obtained in electronic format from WIPO at

XX CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 4 A; 0 C; 1 G; 7 T; 0 U; 0 Other;

XX Query Match 31.1%; Score 8.4; DB 1; Length 12;

XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;

XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTTACA 2232

DB |||||

10 AAAATTTACA 1

RESULT 818

ABI79510/c.

ID ABI79510 standard; DNA; 12 BP.

XX AC ABI79510;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 379483 for detecting SNP TSC0005297.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is

PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is

XX PT designed to detect single-nucleotide polymorphisms and cytosine

XX PT methylation status.

XX PS Claim 1; SEQ ID NO 379483; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic

XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

XX CC and cytosine methylation status in chemically pretreated genomic DNA. The

XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

XX CC range of diseases including immune system, gastrointestinal, respiratory,

XX CC central nervous system, cardiovascular and metabolic disorders. The

XX CC oligomers are also used for detecting cell type differentiation. ABC00010

XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

XX CC represent the oligomers described in the invention. NOTE: The sequence

XX CC data for this patent did not form part of the printed specification, but

XX CC was obtained in electronic format from WIPO at

XX CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;

XX Query Match 31.1%; Score 8.4; DB 1; Length 12;

XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;

XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2224 AAAGTTTACAT 2233

DB |||||

12 AAAGTTTACAT 3

RESULT 819

ABI65753

ID ABI65753 standard; DNA; 12 BP.

XX AC ABI65753;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 365726 for detecting SNP TSC0005297.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
PS Claim 1; SEQ ID NO 365726; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX
SQ Sequence 12 BP; 9 A; 1 C; 0 G; 2 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 2223 AAAAGTTACA 2232
Db 2 AAAAATTACA 11
|||||
RESULT 820
ABH73741/C
ID ABH73741 standard; DNA; 12 BP.
XX
XX
AC ABH73741;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 273726 for detecting SNP TSC0003286.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 273726; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX
SQ Sequence 12 BP; 9 A; 1 C; 0 G; 2 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 2223 AAAAGTTACA 2232
Db 2 AAAAATTACA 11
|||||
RESULT 821
ABI02843/C
ID ABI02843 standard; DNA; 12 BP.
XX
XX
AC ABI02843;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 302816 for detecting SNP TSC0020175.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 302816; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX
SQ Sequence 12 BP; 1 A; 1 C; 5 G; 5 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 2219 GACCAAACT 2228
|||||

Db 10 GACCAAACT 1
 RESULT 822
 ABH78716
 ID ABH78716 standard; DNA; 12 BP.
 XX AC ABH78716;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 278709 for detecting SNP TSC0006283.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 XX 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 278709; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2228 TTACATGTTT 2237
 Db 3 TTACATGTTT 12
 RESULT 823
 ABH78834
 ID ABH78834 standard; DNA; 12 BP.
 XX AC ABH78834;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 278827 for detecting SNP TSC0006455.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 XX 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 278709; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2228 TTACATGTTT 2237
 Db 3 TTACATGTTT 12

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 XX 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 278827; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 8 A; 1 C; 0 G; 3 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTTACA 2232
 Db 1 AAAAATTACA 10
 RESULT 824
 ABH82209
 ID ABH82209 standard; DNA; 12 BP.
 XX AC ABH82209;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 282202 for detecting SNP TSC0010577.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 XX 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.

XX WO200177384-A2.
 PN XX
 PD 18-OCT-2001.
 XX PF
 XX 06-APR-2001; 2001WO-IB000713.
 XX PR
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPiG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 370877; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
 XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
 XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2220 ACCAAAAGTT 2229
 Db 12 ACCAAAATT 3
 RESULT 830
 ABI62344
 ID ABI62344 standard; DNA; 12 BP.
 AC ABI62344;
 XX DT 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 362317 for detecting SNP TSC0053155.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 FN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 XX PF
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPiG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 362317; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
 XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
 XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

DR WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 362317; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 6 A; 0 C; 2 G; 4 T; 0 U; 0 Other;
 XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
 XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2224 AAAAGTTACAT 2233
 Db 3 AAAAGTTATAT 12
 RESULT 831
 ABI65740
 ID ABI65740 standard; DNA; 12 BP.
 AC ABI65740;
 XX DT 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 365713 for detecting SNP TSC0055295.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 FN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 XX PF
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPiG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 365713; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 4 A; 1 C; 0 G; 7 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2228 TTACATGTTT 2237
 DB 2 TTACATATTT 11
 RESULT 832
 ABH67811/C
 ID ABH67811 standard; DNA; 12 BP.
 XX
 AC ABH67811;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 267788 for detecting SNP TSC0000529.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 267788; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 6 A; 0 C; 1 G; 5 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2228 TTACATGTTT 2237
 DB 2 TTACATATTT 11
 RESULT 832
 ABH67811/C
 ID ABH67811 standard; DNA; 12 BP.
 XX
 AC ABH67811;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 267788 for detecting SNP TSC0000529.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 267788; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 6 A; 0 C; 1 G; 5 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTT 2237
 DB 11 TTACATATTT 2
 RESULT 833
 ABI19419/C
 ID ABI19419 standard; DNA; 12 BP.
 XX
 AC ABI19419;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 319392 for detecting SNP TSC0029191.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 319392; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2220 ACCAAAAGTT 2229
 DB 10 ACCAAAATT 1
 RESULT 834
 ABH74722
 ID ABH74722 standard; DNA; 12 BP.
 XX
 AC ABH74722;
 XX
 DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 274707 for detecting SNP TSC0003650.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX FN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX XX
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177/75.
 XX XX
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX PT designed to detect single-nucleotide polymorphisms and cytosine
 XX PT methylation status.
 XX XX
 XX PS Claim 1; SEQ ID NO 274707; 29pp + Sequence Listing; German.
 XX XX
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
 XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 XX CC range of diseases including immune system, gastrointestinal, respiratory,
 XX CC central nervous system, cardiovascular and metabolic disorders. The
 XX CC oligomers are also used for detecting cell type differentiation. ABC00010
 XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 XX CC represent the oligomers described in the invention. NOTE: The sequence
 XX CC data for this patent did not form part of the printed specification, but
 XX CC was obtained in electronic format from WIPO at
 XX CC ftp.wipo.int/pub/published_pct_sequences
 XX XX
 XX SQ Sequence 12 BP; 3 A; 1 C; 4 G; 4 T; 0 U; 0 Other;
 XX
 XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
 XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX
 XX QY 2212 AGAGTGTGAC 2221
 XX Db ||||| |||||
 XX 2 AGAGTTTGAC 11
 XX
 XX RESULT 835
 XX ABH99973/C
 XX ID ABH99973 standard; DNA; 12 BP.
 XX AC
 XX ABH99973;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 299966 for detecting SNP TSC0018823.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX FN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX XX
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX PT designed to detect single-nucleotide polymorphisms and cytosine
 XX PT methylation status.

PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 DR
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 299966; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
 XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 XX CC range of diseases including immune system, gastrointestinal, respiratory,
 XX CC central nervous system, cardiovascular and metabolic disorders. The
 XX CC oligomers are also used for detecting cell type differentiation. ABC00010
 XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 XX CC represent the oligomers described in the invention. NOTE: The sequence
 XX CC data for this patent did not form part of the printed specification, but
 XX CC was obtained in electronic format from WIPO at
 XX CC ftp.wipo.int/pub/published_pct_sequences
 XX XX
 XX SQ Sequence 12 BP; 6 A; 4 C; 0 G; 2 T; 0 U; 0 Other;
 XX
 XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
 XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX
 XX QY 2227 GTTACATGTT 2236
 XX Db ||||| |||||
 XX 12 GTTACATGTT 3
 XX
 XX RESULT 836
 XX ABI26971
 XX ID ABI26971 standard; DNA; 12 BP.
 XX AC
 XX ABI26971;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 326944 for detecting SNP TSC0033363.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX FN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177/75.
 XX
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX PT designed to detect single-nucleotide polymorphisms and cytosine
 XX PT methylation status.

RESULT 839
ABH83255/c
ID ABH83255 standard; DNA; 12 BP.
XX
AC ABH83255;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 283248 for detecting SNP TSC0011233.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
Claim 1; SEQ ID NO 283248; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -AB09989, ABF0010-ABF99989, ABH0010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 5 A; 1 C; 0 G; 6 T; 0 U; 0 Other;
XX
This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -AB09989, ABF0010-ABF99989, ABH0010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 5 A; 1 C; 0 G; 6 T; 0 U; 0 Other;
XX
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2224 AAGTTTACAT 2233
DB 11 AAGTTTATAT 2
RESULT 840
ABI33514
ID ABI33514 standard; DNA; 12 BP.
XX
AC ABI33514;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 333487 for detecting SNP TSC0037567.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
Claim 1; SEQ ID NO 333487; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -AB09989, ABF0010-ABF99989, ABH0010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 5 A; 4 C; 1 G; 2 T; 0 U; 0 Other;
XX
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2220 ACCAAAGTT 2229
DB 1 ACCAAACGTT 10
RESULT 841
ABI42680/c
ID ABI42680 standard; DNA; 12 BP.
XX
AC ABI42680;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 342653 for detecting SNP TSC0010690.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 342653; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 9 A; 1 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2228 TTACATGTTT 2237
XX ||| |||||
XX 10 TTATATGTTT 1
XX
XX RESULT 842
XX ABI44148
XX ID ABI44148 standard; DNA; 12 BP.
XX AC ABI44148;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 344121 for detecting SNP TSC0043393.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 344121; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 2 A; 1 C; 3 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2229 TACATGTTTG 2238
XX ||| |||||
XX 3 TATATGTTTG 12
XX
XX RESULT 843
XX ABI55912
XX ID ABI55912 standard; DNA; 12 BP.
XX AC ABI55912;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 355885 for detecting SNP TSC0049846.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 355885; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;

```

Query Match      31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACA 2232
DB 1 AAAACTTACA 10

RESULT 846
ABI56477/C
ID ABI56477 standard; DNA; 12 BP.
XX
AC ABI56477;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 356450 for detecting SNP TSC0050119.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 356450; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;

Query Match      31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2221 CCAAAAGTTA 2230
DB 11 CCAAAATTA 2

RESULT 845
ABI71747/C
ID ABI71747 standard; DNA; 12 BP.
XX

```

```

AC ABI71747;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 371720 for detecting SNP TSC0058938.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 371720; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 6 A; 1 C; 0 G; 5 T; 0 U; 0 Other;

Query Match      31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTT 2237
DB 11 TTAATGTTT 2

RESULT 846
ABI72421/C
ID ABI72421 standard; DNA; 12 BP.
XX
AC ABI72421;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 372394 for detecting SNP TSC0059365.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX

```

```

XX PD 18-OCT-2001.
XX PF
XX XX
XX PR 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPiG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 372394; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred.No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2222 CAAAAGTTTAC 2231
XX DB 11 CAAAATTTAC 2
XX
XX RESULT 847
XX AB161602/c
XX ID AB161602 standard; DNA; 12 BP.
XX AC
XX AC AB161602;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 361575 for detecting SNP TSC0052702.
XX XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX
XX WO200177384-A2.
XX PN
XX PD 18-OCT-2001.
XX PF
XX PR 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPiG-) EPIGENOMICS AG.
XX XX
XX Olek A, Piepenbrock C, Berlin K;
XX PI
XX DR WPI; 2001-657177/75.
XX XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 375940; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 2 A; 2 C; 0 G; 8 T; 0 U; 0 Other;
XX
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred.No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2223 AAAAGTTTACA 2232
XX DB 10 AAAAGTTTAAA 1
XX
XX RESULT 848
XX AB175967/c
XX ID AB175967 standard; DNA; 12 BP.
XX AC
XX AC AB175967;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 375940 for detecting SNP TSC0061535.
XX XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX
XX WO200177384-A2.
XX PN
XX PD 18-OCT-2001.
XX PF
XX PR 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPiG-) EPIGENOMICS AG.
XX XX
XX Olek A, Piepenbrock C, Berlin K;
XX PI
XX DR WPI; 2001-657177/75.
XX XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 375940; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences

```

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 3 A; 0 C; 1 G; 8 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2224 AAAAGTTACAT 2233
 ||| |||||
 12 AAAAGTTACAT 3

Db ABI62699/C
 ID ABI62699 standard; DNA; 12 BP.
 AC AC
 XX ABI62699;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 362672 for detecting SNP TSC0053365.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 XX methylation status.

XX Claim 1; SEQ ID NO 362672; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 2 A; 1 C; 2 G; 7 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACA 2232
 ||| |||||
 3 AAAAGTTACA 12

Db ABH68673
 ID ABH68673 standard; DNA; 12 BP.
 AC ABH68673;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 268650 for detecting SNP TSC0001276.

Db 10 AAACGTTACA 1
 ||| |||||
 RESULT 850
 ABI65459
 ID ABI65459 standard; DNA; 12 BP.
 AC AC
 XX ABI65459;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 365432 for detecting SNP TSC0055122.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 XX methylation status.

XX Claim 1; SEQ ID NO 365432; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 7 A; 0 C; 2 G; 3 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACA 2232
 ||| |||||
 3 AAAAGTTACA 12

Db ABH68673
 ID ABH68673 standard; DNA; 12 BP.
 AC ABH68673;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 268650 for detecting SNP TSC0001276.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 286650; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 3 A; 1 C; 1 G; 7 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e-02;
 Mismatches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2228 TTACATGTTT 2237
 Db 1 TTAATGTTT 10
 RESULT 852
 ABH77024/C
 ID ABH77024 standard; DNA; 12 BP.
 XX ABH77024;
 AC ABH77024;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 277017 for detecting SNP TSC0004360.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 DE peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 DE central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 304961; 29pp + Sequence Listing; German.

PR 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 277017; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 4 A; 0 C; 2 G; 5 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e-02;
 Mismatches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2220 ACCAAAGTTT 2229
 Db 11 ACCAAAGTTT 2
 RESULT 853
 AB104988/C
 ID AB104988 standard; DNA; 12 BP.
 XX AB104988;
 AC AB104988;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 304961 for detecting SNP TSC0021190.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 DE peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 DE central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 304961; 29pp + Sequence Listing; German.

```
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2223 AAAAGTTTACA 2232
XX Db 12 AAAATTTTACA 3
XX
XX RESULT 854
XX ABI05944/C
XX ID ABI05944 standard; DNA; 12 BP.
XX AC ABI05944;
XX XX
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 305917 for detecting SNP TSC0021700.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 305917; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
```

```
XX
XX Sequence 12 BP; 7 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2227 GTTACATGTT 2236
XX Db 10 GTTATATGTT 1
XX
XX RESULT 855
XX ABI07069
XX ID ABI07069 standard; DNA; 12 BP.
XX AC ABI07069;
XX XX
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 307042 for detecting SNP TSC0022311.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 307042; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 6 A; 3 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2223 AAAAGTTTACA 2232
XX Db 1 AAAATTTTACA 10
XX
XX RESULT 856
```

ABH82172
 ID ABH82172 standard; DNA; 12 BP.
 AC ABH82172;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 282165 for detecting SNP TSC0010514.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 PN
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 282165; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 6 A; 0 C; 1 G; 5 T; 0 U; 0 Other;
 SQ
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2224 AAAAGTTACAT 2233
 Db 3 AAAAGTTATAT 12
 RESULT 857
 ABH84146/c
 ID ABH84146 standard; DNA; 12 BP.
 AC ABH84146;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 284139 for detecting SNP TSC0011685.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX

OS Homo sapiens.
 XX
 XX WO200177384-A2.
 PN
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 284139; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 3 A; 0 C; 1 G; 8 T; 0 U; 0 Other;
 SQ
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTACA 2232
 Db 10 AAAAATTACA 1
 RESULT 858
 ABH87939/c
 ID ABH87939 standard; DNA; 12 BP.
 AC ABH87939;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 287932 for detecting SNP TSC0013313.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 PN
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 287932; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 0 Other;
SQ

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2224 AAGTTACAT 2233
DB 11 AAATTACAT 2

RESULT 859
ABH89692/C
ID ABH89692 standard; DNA; 12 BP.
XX AC ABH89692;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 289685 for detecting SNP TSC0014043.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 289685; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 2 A; 0 C; 1 G; 9 T; 0 U; 0 Other;
SQ

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2223 AAAAGTTACA 2232
DB 12 AAAAATTACA 3

RESULT 860
ABI44215/C
ID ABI44215 standard; DNA; 12 BP.
XX AC ABI44215;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 344188 for detecting SNP TSC0043433.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 344188; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 4 A; 2 C; 0 G; 6 T; 0 U; 0 Other;
SQ

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;

Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2224 AAAGTTACAT 2233
 |||||
 10 AAAGTTAAAT 1

DB

RESULT 861
 ABI67950/c
 ID ABI67950 standard; DNA; 12 BP.
 AC
 AC ABI67950;
 XX
 XX
 XX
 DT 22-FEB-2002 (first entry)
 XX
 XX Oligonucleotide primer SEQ ID NO 367923 for detecting SNP TSC0056652.
 DE
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 PN
 XX
 XX 18-OCT-2001.
 PD
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT
 XX Claim 1; SEQ ID NO 367923; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 XX Sequence 12 BP; 3 A; 1 C; 2 G; 6 T; 0 U; 0 Other;
 SQ
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2224 AAAGTTACAT 2233
 |||||
 12 AACGTTACAT 3

DB

RESULT 862
 ABI70580
 ID ABI70580 standard; DNA; 12 BP.
 AC
 AC ABI70580;
 XX
 XX

DT 22-FEB-2002 (first entry)
 XX
 XX Oligonucleotide primer SEQ ID NO 370553 for detecting SNP TSC0006739.
 DE
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 PN
 XX
 XX 18-OCT-2001.
 PD
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT
 XX Claim 1; SEQ ID NO 370553; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 XX Sequence 12 BP; 2 A; 0 C; 4 G; 6 T; 0 U; 0 Other;
 SQ
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2227 GTTACATGTT 2236
 |||||
 2 GTTACATGTT 11

DB

RESULT 863
 ABI75010/c
 ID ABI75010 standard; DNA; 12 BP.
 AC
 AC ABI75010;
 XX
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX Oligonucleotide primer SEQ ID NO 374983 for detecting SNP TSC0061022.
 DE
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 PN
 XX
 XX 18-OCT-2001.
 PD

XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 374983; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 6 A; 3 C; 0 G; 3 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2229 TACATGTTTG 2238
 Db 12 TAATGTTTG 3
 RESULT 864
 ABI67100/c
 ID ABI67100 standard; DNA; 12 BP.
 XX AC ABI67100;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 367073 for detecting SNP TSC0056139.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.
 XX Claim 1; SEQ ID NO 367073; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 6 A; 2 C; 0 G; 4 T; 0 U; 0 Other;
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2226 AGTTACATGT 2235
 Db 10 AGTTAAATGT 1
 RESULT 865
 ABH92370/c
 ID ABH92370 standard; DNA; 12 BP.
 XX AC ABH92370;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 292363 for detecting SNP TSC0015185.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 292363; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 297535; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 2 A; 0 C; 1 G; 9 T; 0 U; 0 Other;
 XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
 XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2228 TTATATGTTT 2237
 DB 2 TTATATGTTT 11
 RESULT 869
 ABH74170
 ID ABH74170 standard; DNA; 12 BP.
 AC ABH74170;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 274155 for detecting SNP TSC0003451.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX This invention describes novel oligonucleotide primers or peptide nucleic

PA (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 274155; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
 XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
 XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2223 AAAAGTTTACA 2232
 DB 1 AAAAGTTTACA 10
 RESULT 870
 ABH74595/c
 ID ABH74595 standard; DNA; 12 BP.
 XX ABH74595;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 274580 for detecting SNP TSC0003600.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 274580; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 1 A; 1 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2217 GTGACCAAAA 2226
 DB 12 GTGACCAAAA 3

RESULT 871
 ABI33653/c
 ID ABI33653 standard; DNA; 12 BP.
 XX
 AC ABI33653;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 333626 for detecting SNP TSC0037648.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 333626; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTT 2237
 DB 10 TTACATGTTT 1

RESULT 872
 ABI09881
 ID ABI09881 standard; DNA; 12 BP.
 XX
 AC ABI09881;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 309854 for detecting SNP TSC0023708.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 309854; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 5 A; 4 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2221 CCAAAAGTTA 2230
 DB 3 CCAAAAGTTA 12

RESULT 873
 ABH84928/c
 ID ABH84928 standard; DNA; 12 BP.

```
XX ABH84928;
XX AC
XX DT 22-FEB-2002 (first entry)
XX DE
XX DE Oligonucleotide primer SEQ ID NO 284921 for detecting SNP TSC0012055.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PN
XX PD 18-OCT-2001.
XX PF
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIC-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX PI WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 284921; 29pp + Sequence Listing; German.
XX XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 1 A; 1 C; 3 G; 7 T; 0 U; 0 Other;
XX XX
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX QY 2219 GACCAAAAGT 2228
XX Db 12 GACCAAAAGT 3
XX RESULT 874
XX ABI36547
XX ID ABI36547 standard; DNA; 12 BP.
XX AC
XX AC ABI36547;
XX DT 22-FEB-2002 (first entry)
XX DE
XX DE Oligonucleotide primer SEQ ID NO 336520 for detecting SNP TSC0039398.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS
XX OS Homo sapiens.
```

```
PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIC-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX PI WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 336520; 29pp + Sequence Listing; German.
XX XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 0 Other;
XX XX
XX Query Match 31.1%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 3.3e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX QY 2229 TACATGTTTG 2238
XX Db 3 TATATGTTTG 12
XX RESULT 875
XX ABI14909/c
XX ID ABI14909 standard; DNA; 12 BP.
XX AC
XX AC ABI14909;
XX DT 22-FEB-2002 (first entry)
XX DE
XX DE Oligonucleotide primer SEQ ID NO 314882 for detecting SNP TSC0026600.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIC-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX PI WPI; 2001-657177/75.
XX DR
```

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 314882; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 5 A; 4 C; 0 G; 3 T; 0 U; 0 Other;
SQ Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2229 TACATGTTTG 2238
DB 12 TACATGTTTG 3
RESULT 876
ABI40947/C
ID ABI40947 standard; DNA; 12 BP.
XX ABI40947;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 340920 for detecting SNP TSC0007216.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 340920; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 3 A; 1 C; 1 G; 7 T; 0 U; 0 Other;
SQ Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTTACA 2232
DB 10 AAAAATTACA 1
RESULT 877
ABI16868/C
ID ABI16868 standard; DNA; 12 BP.
XX ABI16868;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 316841 for detecting SNP TSC0027631.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 316841; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 6 A; 2 C; 0 G; 4 T; 0 U; 0 Other;
SQ Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 376028; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
 SQ
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2221 CCAAAAGTTA 2230
 Db 12 CCAAAAGTTA 3
 RESULT 881
 ABI64981
 ID ABI64981 standard; DNA; 12 BP.
 AC ABI64981;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 364954 for detecting SNP TSC0054825.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 FN 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 364954; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 4 A; 0 C; 1 G; 7 T; 0 U; 0 Other;
 SQ
 Query Match 31.1%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2228 TTACATGTTT 2237
 Db 1 TTAATGTTT 10
 RESULT 882
 ABI66823/C
 ID ABI66823 standard; DNA; 12 BP.
 XX
 AC ABI66823;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 366796 for detecting SNP TSC0055977.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 FN 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 366796; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at

```
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 2 A; 2 C; 0 G; 8 T; 0 U; 0 Other;

Query Match      31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTTACA 2232
Db 11 AAAAGTTTAGA 2

RESULT 883
AB180759/c
ID AB180759 standard; DNA; 12 BP.
XX AC AB180759;
XX
XX 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 380732 for detecting SNP TSC0063954.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 380732; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 2 A; 0 C; 3 G; 7 T; 0 U; 0 Other;

Query Match      31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTTACA 2232
Db 12 AAAAGTTTACA 3

RESULT 884
AB234313/c
ID AB234313 standard; DNA; 12 BP.
XX AC AB234313;
XX
XX 31-JAN-2003 (first entry)
XX DE HIV-1 reverse transcriptase mutation detection probe SEQ ID NO:555.
XX
XX Human immunodeficiency virus; HIV; reverse transcriptase; RT; enzyme;
XX detection; mutation; anti-HIV drug resistance; polymorphism; resistance;
XX probe; ss.
XX
XX Human immunodeficiency virus 1.
XX Synthetic.
XX
XX WO200255741-A2.
XX
XX 18-JUL-2002.
XX
XX 09-JAN-2002; 2002WO-EP000153.
XX
XX 11-JAN-2001; 2001EP-00870005.
XX
XX 20-APR-2001; 2001EP-00870085.
XX
XX 24-APR-2001; 2001US-0286102P.
XX
XX (INNO-) INNOGENETICS NV.
XX
XX De Smet K, Stuyver L;
XX
XX WPI; 2002-590680/63.
XX
XX Detecting mutations associated with anti-HIV drug resistance comprises
XX detecting at least one of the mutations in the HIV reverse transcriptase
XX gene by using probes optimized to function together in a reverse-
XX hybridization assay.
XX
XX Claim 2; Page 32; 117pp; English.
XX
XX The present invention describes a method for detecting mutations
XX associated with anti-HIV drug resistance in a patient by detecting at
XX least one of the mutations K103N/R, V106A/I/L, Y181C/I, M184V/I, Y188L,
XX G190A/S/R, T215Y/F/D/S/A and/or Q151M/L in the reverse transcriptase (RT)
XX of HIV strains in a biological sample using a specific set of probes
XX optimised to function together in a reverse-hybridisation assay. The
XX method and the nucleic acid sequences used in the method are useful for
XX determining viral mutations and/or polymorphisms in the HIV RT gene
XX associated with resistance. The probes are useful for the genetic
XX detection, preferably in vitro detection of the mutations K103N/R,
XX V106A/I/L, Y181C/I, Q151M/L, M184V/I, Y188L, G190A/S/R and/or
XX T215Y/F/D/S/A in the RT of HIV strains in a biological sample, where the
XX mutation is associated with anti-HIV drug resistance. The method provides
XX a rapid, reliable and precise assay or determination and monitoring of
XX antiviral drug resistance or mutations associated with drug resistance of
XX viruses containing RT genes. AB233759 to AB234642 represent HIV RT
XX sequences and probes which are used in the exemplification of the present
XX invention
XX
XX Sequence 12 BP; 3 A; 3 C; 4 G; 2 T; 0 U; 0 Other;

Query Match      31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2215 GTGTGACCAA 2224
Db 12 GTGTGTCCTCA 3

RESULT 885
ADF78584
ID ADF78584 standard; DNA; 12 BP.
```

XX AC ADF78584;
XX AC
XX DT 26-FEB-2004 (first entry)
XX DE Chromosomal abnormality detection-related PCR primer 165.
XX DE
XX KW chromosomal abnormality; maternal locus; genetic disorder; foetus;
KW mutation; translocation; transversion; monosomy; trisomy 21;
KW chromosome 21; Down's Syndrome; aneuploidies; chromosome deletion;
KW chromosome addition; chromosome amplification; chromosome translocation;
KW chromosome rearrangement; single nucleotide polymorphism detection;
KW SNP detection; pregnant female; PCR; primer; ss.
XX OS
XX OS Homo sapiens.
XX PN WO2003074723-A2.
XX PD 12-SEP-2003.
XX PF 28-FEB-2003; 2003WO-US006198.
XX PR 01-MAR-2002; 2002US-0360232P.
XX PR 11-MAR-2002; 2002US-00093618.
XX PR 08-MAY-2002; 2002US-0378354P.
XX PA (DHALLAN R.
XX PI Dhallan R;
XX DR WPI; 2003-845073/78.
XX DR
XX PT Detection of chromosomal abnormalities e.g. Down's Syndrome, non-
PT invasively in a fetus, comprises forming a ratio of amounts of alleles at
PT a locus of interest and a different heterozygous locus.
XX PS
XX PS Example 11; Page 227; 164pp; English.
XX CC This invention relates to a novel method of detecting chromosomal
CC abnormalities by determining the sequence of alleles of a locus of
CC interest from template DNA, determining which alleles are present and
CC comparing to amounts of alleles at a different, selected heterozygous
CC locus (for example on another chromosome or a maternal locus); relative
CC amounts are expressed as a ratio indicating presence or absence of the
CC abnormality. The method is useful for the detection of genetic disorders,
CC especially in a fetus, including chromosomal abnormalities and
CC mutations, for example translocations, transversions, monosomies,
CC trisomies (for example trisomy 21 in which an additional copy of
CC chromosome 21 results in Down's Syndrome) and other aneuploidies,
CC deletions, additions, amplifications, translocations and rearrangements.
CC It can be used to detect any alterations in a gene sequence, especially
CC single nucleotide polymorphisms (SNPs), and may be used to detect
CC numerous abnormalities simultaneously, for example if several SNPs are
CC associated with a particular disease. The method provides a rapid, non-
CC invasive method for determining the sequence of DNA from a fetus using a
CC sample from a pregnant female, for example to detect genetic disorders as
CC above or to determine if a fetus is a carrier of a disease or
CC predisposed to a disease.
XX SQ Sequence 12 BP; 4 A; 2 C; 1 G; 5 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 2229 TACATGTTG 2238
|||||
Db 1 TACATCTTG 10
RESULT 886
ADF78619
ID ADF78619 standard; DNA; 12 BP.

XX AC ADF78619;
XX AC
XX DT 26-FEB-2004 (first entry)
XX DE Chromosomal abnormality detection-related PCR primer 200.
XX DE
XX KW chromosomal abnormality; maternal locus; genetic disorder; foetus;
KW mutation; translocation; transversion; monosomy; trisomy 21;
KW chromosome 21; Down's Syndrome; aneuploidies; chromosome deletion;
KW chromosome addition; chromosome amplification; chromosome translocation;
KW chromosome rearrangement; single nucleotide polymorphism detection;
KW SNP detection; pregnant female; PCR; primer; ss.
XX OS
XX OS Homo sapiens.
XX PN WO2003074723-A2.
XX PD 12-SEP-2003.
XX PF 28-FEB-2003; 2003WO-US006198.
XX PR 01-MAR-2002; 2002US-0360232P.
XX PR 11-MAR-2002; 2002US-00093618.
XX PR 08-MAY-2002; 2002US-0378354P.
XX PA (DHALLAN R.
XX PI Dhallan R;
XX DR WPI; 2003-845073/78.
XX DR
XX PT Detection of chromosomal abnormalities e.g. Down's Syndrome, non-
PT invasively in a fetus, comprises forming a ratio of amounts of alleles at
PT a locus of interest and a different heterozygous locus.
XX PS
XX PS Example 11; Page 232; 164pp; English.
XX CC This invention relates to a novel method of detecting chromosomal
CC abnormalities by determining the sequence of alleles of a locus of
CC interest from template DNA, determining which alleles are present and
CC comparing to amounts of alleles at a different, selected heterozygous
CC locus (for example on another chromosome or a maternal locus); relative
CC amounts are expressed as a ratio indicating presence or absence of the
CC abnormality. The method is useful for the detection of genetic disorders,
CC especially in a fetus, including chromosomal abnormalities and
CC mutations, for example translocations, transversions, monosomies,
CC trisomies (for example trisomy 21 in which an additional copy of
CC chromosome 21 results in Down's Syndrome) and other aneuploidies,
CC deletions, additions, amplifications, translocations and rearrangements.
CC It can be used to detect any alterations in a gene sequence, especially
CC single nucleotide polymorphisms (SNPs), and may be used to detect
CC numerous abnormalities simultaneously, for example if several SNPs are
CC associated with a particular disease. The method provides a rapid, non-
CC invasive method for determining the sequence of DNA from a fetus using a
CC sample from a pregnant female, for example to detect genetic disorders as
CC above or to determine if a fetus is a carrier of a disease or
CC predisposed to a disease.
XX SQ Sequence 12 BP; 5 A; 0 C; 1 G; 6 T; 0 U; 0 Other;
Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.3e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 2228 TTACATGTTT 2237
|||||
Db 1 TTAAATGTTT 10
Search completed: November 18, 2004, 08:16:21
Job time : 4 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 18, 2004, 08:17:36 ; Search time 0.001 Seconds
(without alignments)
19.278 Million cell updates/sec

Title: US-10-006-191-19
Perfect score: 27
Sequence: 1 agagtgtgacaaaagtacattgttg 27

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 35 seqs, 357 residues

Total number of hits satisfying chosen parameters: 70

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 35 summaries

Database : rni19.seq.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
C 1	11.4	42.2	15	1	US-09-081-646-31
C 2	9.4	34.8	12	1	US-09-512-563C-55
C 3	9.4	34.8	13	1	US-08-990-735C-4
C 4	8.4	31.1	10	1	US-08-330-000-5
C 5	8.4	31.1	10	1	US-08-965-908-5
C 6	8.4	31.1	10	1	US-09-322-484-2
C 7	8.4	31.1	12	1	US-08-068-945A-33
C 8	8.4	31.1	12	1	US-08-442-806-33
C 9	8	29.6	8	1	US-08-859-954-20
C 10	8	29.6	10	1	US-08-623-428B-34
C 11	8	29.6	10	1	US-09-508-753B-219
C 12	8	29.6	11	1	US-09-249-155A-122
C 13	7.8	28.9	11	1	US-09-157-257-42
C 14	7.8	28.9	11	1	US-09-404-912-12
C 15	7.4	27.4	9	1	US-08-360-051A-45
C 16	7.4	27.4	9	1	US-08-360-051A-48
C 17	7.4	27.4	9	1	US-08-375-151-5
C 18	7.4	27.4	9	1	US-09-425-072-5
C 19	7.4	27.4	9	1	US-09-194-842A-21
C 20	7.4	27.4	9	1	US-10-096-596-12
C 21	7.4	27.4	9	1	US-09-982-658A-4
C 22	7.4	27.4	9	1	PCT-US94-08023-39
C 23	7.4	27.4	10	1	US-08-631-751A-15
C 24	7.4	27.4	10	1	US-08-388-353-115
C 25	7.4	27.4	10	1	US-08-388-353-116
C 26	7.4	27.4	10	1	US-08-488-551B-115
C 27	7.4	27.4	10	1	US-08-488-551B-116
C 28	7.4	27.4	10	1	US-09-180-903-14
C 29	7.4	27.4	10	1	US-09-171-759-20
C 30	7.4	27.4	10	1	US-09-083-235A-40
C 31	7.4	27.4	10	1	US-09-083-235A-41
C 32	7.4	27.4	10	1	US-09-083-235A-42
C 33	7.4	27.4	10	1	US-09-693-467A-13

Sequence 16, Appl
Sequence 17, Appl

10 1 US-09-693-467A-16
10 1 US-09-822-250A-17

ALIGNMENTS

RESULT 1
US-09-081-646-31/c
; Sequence 31, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
; FILE REFERENCE: 01107.74664
; CURRENT APPLICATION NUMBER: US/09/081,646
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 31
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-31

Query Match 42.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 1.2;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2222 CAAAAGTTACATG 2234
|||||
DB 13 CAAAATTACATG 1

RESULT 2
US-09-512-563C-55/c
; Sequence 55, Application US/09512563C
; Patent No. 6579969
; GENERAL INFORMATION:
; APPLICANT: Saus, Juan
; TITLE OF INVENTION: Goodpasture Binding Protein
; FILE REFERENCE: 98-723-A
; CURRENT APPLICATION NUMBER: US/09/512,563C
; CURRENT FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: 60/121,483
; PRIOR FILING DATE: 1999-02-24
; NUMBER OF SEQ ID NOS: 63
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 55
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-512-563C-55

Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 5;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2216 TGTGACCAAAA 2226
|||||
DB 11 TGTGACTAAA 1

RESULT 3
US-08-890-735C-4
; Sequence 4, Application US/08890735C
; Patent No. 6518014

```

; GENERAL INFORMATION:
; APPLICANT: Bristol-Myers Squibb Company
; TITLE OF INVENTION: HEPADNAVIRUS CORES
; FILE REFERENCE: DC44A
; CURRENT APPLICATION NUMBER: US/08/890,735C
; CURRENT FILING DATE: 1997-07-11
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Hepatitis B Virus
US-08-890-735C-4

Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 4.6;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2223 AAAAGTTACAT 2233
| | | | | | | |
Db 3 AAAAGTTGCAT 13

RESULT 4
US-08-330-000-5/c
; Sequence 5, Application US/08330000
; Patent No. 5686242
; GENERAL INFORMATION:
; APPLICANT: Bruce, Thomas W.
; APPLICANT: Lima, Walter F.
; TITLE OF INVENTION: DETERMINATION OF OLIGONUCLEOTIDES
; TITLE OF INVENTION: FOR THERAPEUTICS, DIAGNOSTICS AND RESEARCH REAGENTS
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and
; ADDRESSEE: No. 5686242ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/330,000
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/330,000
; FILING DATE:
; APPLICATION NUMBER: 755,485
; FILING DATE: September 5, 1991
; APPLICATION NUMBER: PCT/US92/07489
; FILING DATE: September 4, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Ralph, Rebecca Lynne
; REGISTRATION NUMBER: 35,152
; REFERENCE/DOCKET NUMBER: ISIS-1723
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: RNA
US-08-330-000-5

Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 10;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2215 GTGTGACCAA 2224
| | | | | | | |
Db 10 GTGTGACCAA 1

RESULT 6
US-09-322-484-2/c
; Sequence 2, Application US/09322484
; Patent No. 6417330
; GENERAL INFORMATION:
; APPLICANT: Bruce, Thomas W.
; APPLICANT: Lima, Walter F.
; TITLE OF INVENTION: DETERMINATION OF OLIGONUCLEOTIDES
; TITLE OF INVENTION: FOR THERAPEUTICS, DIAGNOSTICS AND RESEARCH REAGENTS
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and
; ADDRESSEE: No. 6022691ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/965,908
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/330,000
; FILING DATE:
; APPLICATION NUMBER: 755,485
; FILING DATE: September 5, 1991
; APPLICATION NUMBER: PCT/US92/07489
; FILING DATE: September 4, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Ralph, Rebecca Lynne
; REGISTRATION NUMBER: 35,152
; REFERENCE/DOCKET NUMBER: ISIS-1723
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: RNA
US-08-965-908-5

Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 10;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2215 GTGTGACCAA 2224
| | | | | | | |
Db 10 GTGTGACCAA 1
```

; APPLICANT: Desmond MASARENHAS
; APPLICANT: David PASSMORE
; APPLICANT: Stephen DANKO
; TITLE OF INVENTION: INSULIN-LIKE GROWTH FACTOR BINDING
; TITLE OF INVENTION: PROTEIN VARIANTS
; FILE REFERENCE: 22095209100
; CURRENT APPLICATION NUMBER: US/09/322.484
; CURRENT FILING DATE: 1999-05-27
; PRIOR APPLICATION NUMBER: 60/087.559
; PRIOR FILING DATE: 1998-06-01
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Saccharomyces cerevisiae
US-09-322-484-2

Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 10;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2226 AGTTACATGT 2235
Db 10 AATTACATGT 1

RESULT 7
US-08-068-945A-33
; Sequence 33, Application US/08068945A
; Patent No. 5616483

; GENERAL INFORMATION:
; APPLICANT: Bjursell, Gunnar
; APPLICANT: Carlsson, Peter
; APPLICANT: Enerback, Sven
; APPLICANT: Hansson, Lennart
; APPLICANT: Lidberg, Ulf
; APPLICANT: Nilsson, Jeanette
; APPLICANT: Tornell, Jan
; TITLE OF INVENTION: New DNA Sequences
; NUMBER OF SEQUENCES: 58
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: White & Case
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: United States
; ZIP: 10036-2787
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/068.945A
; FILING DATE: 27-MAY-1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: SE 9201809-2
; FILING DATE: 11-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: SE 9201826-6
; FILING DATE: 12-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: SE 9202088-2
; FILING DATE: 03-JUL-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: SE 9300902-5
; FILING DATE: 19-MAR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Sterner, Richard J.
; REGISTRATION NUMBER: 35,372
; REFERENCE/DOCKET NUMBER: 1103326-052

; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)819-8783
; TELEFAX: (212)354-8113
; INFORMATION FOR SEQ ID NO: 33:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-068-945A-33

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 8.7;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2227 GTTACATGTT 2236
Db 1 GGTACATGTT 10

RESULT 8
US-08-442-806-33
; Sequence 33, Application US/08442806
; Patent No. 5716817
; GENERAL INFORMATION:
; APPLICANT: Bjursell, Gunnar
; APPLICANT: Carlsson, Peter
; APPLICANT: Enerback, Sven
; APPLICANT: Hansson, Lennart
; APPLICANT: Lidberg, Ulf
; APPLICANT: Nilsson, Jeanette
; APPLICANT: Tornell, Jan
; TITLE OF INVENTION: Genomic DNA Sequences
; TITLE OF INVENTION: Encoding Human BSSL/CEL
; NUMBER OF SEQUENCES: 58
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: White & Case
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: United States
; ZIP: 10036-2787
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/442.806
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/068.945
; FILING DATE: 27-MAY-1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: SE 9201809-2
; FILING DATE: 11-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: SE 9201826-6
; FILING DATE: 12-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: SE 9202088-2
; FILING DATE: 03-JUL-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: SE 9300902-5
; FILING DATE: 19-MAR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Sterner, Richard J.
; REGISTRATION NUMBER: 35,372
; REFERENCE/DOCKET NUMBER: 1103326-052
; TELECOMMUNICATION INFORMATION:

mcgarry191-19.rni

Thu Nov 18 12:41:58 2004

TELEPHONE: (212)819-8783
TELEFAX: (212)354-8113
INFORMATION FOR SEQ ID NO: 33:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-442-806-33

Query Match 31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 8.7;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2227 GTTACATGTT 2236
Db 1 GGTACATGTT 10

RESULT 9
US-08-859-954-20/c
Sequence 20, Application US/08859954
Patent No. 6083695
GENERAL INFORMATION:
APPLICANT: Hardin, Susan H.
APPLICANT: Komayouni, Ramin
TITLE OF INVENTION: Design and Optimized Primer Library for
TITLE OF INVENTION: Design and Optimized Primer Library for
NUMBER OF SEQUENCES: 566
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fulbright & Jaworski L.L.P.
STREET: 1301 McKinney, Suite 5100
CITY: Houston
STATE: Texas
COUNTRY: U.S.A.
ZIP: 77010-3095
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/859,954
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/632,782
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Paul, Thomas D.
REGISTRATION NUMBER: 32,714
REFERENCE/DOCKET NUMBER: D-5900
TELECOMMUNICATION INFORMATION:
TELEPHONE: 713/651-5325
TELEFAX: 713/651-5246
INFORMATION FOR SEQ ID NO: 20:
SEQUENCE CHARACTERISTICS:
LENGTH: 8 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "oligonucleotide"
HYPOTHETICAL: YES
ANTI-SENSE: YES
US-08-859-954-20

Query Match 29.6%; Score 8; DB 1; Length 8;
Best Local Similarity 100.0%; Pred. No. 69;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2214 AGTGAC 2221
Db 8 AGTGAC 1
RESULT 10
US-08-623-428D-34/c
Sequence 34, Application US/08623428D
Patent No. 6312890
GENERAL INFORMATION:
APPLICANT: W. LERMAN, FARIDA LATIF AND BERTON ZBAR
TITLE OF INVENTION: PARTIAL INTRON SEQUENCE
OF VHL DISEASE GENE AND ITS USE IN DIAGNOSIS
OF DISEASE CARRIERS
NUMBER OF SEQUENCES: 63
CORRESPONDENCE ADDRESS:
ADDRESSEE: MORGAN & FINNEGAN, L.L.P.
STREET: 345 PARK AVENUE
CITY: NEW YORK
STATE: NEW YORK
COUNTRY: USA
ZIP: 10154
COMPUTER READABLE FORM:
MEDIUM TYPE: FLOPPY DISK
COMPUTER: IBM PC COMPATIBLE
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: MICROSOFT WORD 97
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/623,428D
FILING DATE: 05-Sep-2000
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/623,428
FILING DATE: MARCH 28, 1996
APPLICATION NUMBER: 08/061,889
FILING DATE: May 14, 1993
ATTORNEY/AGENT INFORMATION:
NAME: Kathryn M. Brown
REGISTRATION NUMBER: 34,556
REFERENCE/DOCKET NUMBER: 2026-4078US3
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 758-4800
TELEFAX: (212) 751-6849
TELEX: 421792
INFORMATION FOR SEQ ID NO: 34:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
SEQUENCE DESCRIPTION: SEQ ID NO: 34:
US-08-623-428D-34

Query Match 29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2217 GTGACCA 2224
Db 10 GTGACCA 3

RESULT 11
US-09-508-753B-219/c
Sequence 219, Application US/09508753B
Patent No. 6544736
GENERAL INFORMATION:
APPLICANT: Akira SHIMAMOTO
APPLICANT: Yasuhiro FURUICHI
APPLICANT: Yuko SHIBATA
APPLICANT: Hiroko FUNAKI

; APPLICANT: Eiji OHARA
 ; APPLICANT: Masanori WATAHIKI
 ; TITLE OF INVENTION: Method for Synthesizing cDNA from mRNA sample
 ; FILE REFERENCE: 00162/HG
 ; CURRENT APPLICATION NUMBER: US/09/508,753B
 ; CURRENT FILING DATE: 2000-06-16
 ; PRIOR APPLICATION NUMBER: JP 9/270324
 ; PRIOR FILING DATE: 1997-09-18
 ; NUMBER OF SEQ ID NOS: 472
 ; SEQ ID NO 219
 ; LENGTH: 10
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: Primer
 US-09-508-753B-219

Query Match 29.6%; Score 8; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 13;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2221 CCRAAAGT 2228
 |||||
 Db 8 CCRAAAGT 1

RESULT 12
 US-09-249-155A-122
 ; Sequence 122, Application US/09249155A
 ; Patent No. 6538173
 ; GENERAL INFORMATION:
 ; APPLICANT: Heber-Katz, Ellen
 ; TITLE OF INVENTION: Compositions and Methods for Wound
 ; TITLE OF INVENTION: Healing
 ; FILE REFERENCE: 00486.78503
 ; CURRENT APPLICATION NUMBER: US/09/249,155A
 ; CURRENT FILING DATE: 1999-02-12
 ; PRIOR APPLICATION NUMBER: US 60/074,737
 ; PRIOR FILING DATE: 1998-02-13
 ; PRIOR APPLICATION NUMBER: US 60/097,937
 ; PRIOR FILING DATE: 1998-08-26
 ; PRIOR APPLICATION NUMBER: US 60/102,051
 ; PRIOR FILING DATE: 1998-09-28
 ; NUMBER OF SEQ ID NOS: 346
 ; SOFTWARE: FastSeq for Windows Version 4.0
 ; SEQ ID NO 122
 ; LENGTH: 11
 ; TYPE: DNA
 ; ORGANISM: Mus musculus
 US-09-249-155A-122

Query Match 29.6%; Score 8; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 12;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2216 TGTGACCA 2223
 |||||
 Db 3 TGTGACCA 10

RESULT 13
 US-09-157-257-42/c
 ; Sequence 42, Application US/09157257
 ; Patent No. 6375954
 ; GENERAL INFORMATION:
 ; APPLICANT: DUTTA, Sukanta K.
 ; APPLICANT: BISWAS, Biswajit
 ; APPLICANT: VENULAPALLI, Ramesh
 ; TITLE OF INVENTION: A SIZE-VARIABLE STRAIN-SPECIFIC PROTECTIVE ANTIGEN FOR
 ; TITLE OF INVENTION: POTOMAC HORSE FEVER
 ; FILE REFERENCE: 8172-9016
 ; CURRENT APPLICATION NUMBER: US/09/157,257
 ; CURRENT FILING DATE: 1998-09-18

; EARLIER APPLICATION NUMBER: 60/059,252
 ; EARLIER FILING DATE: 1997-09-18
 ; NUMBER OF SEQ ID NOS: 48
 ; SOFTWARE: PatentIn Ver. 2.0
 ; SEQ ID NO 42
 ; LENGTH: 11
 ; TYPE: DNA
 ; ORGANISM: Ehrlichia risticii
 US-09-157-257-42

Query Match 28.9%; Score 7.8; DB 1; Length 11;
 Best Local Similarity 81.8%; Pred. No. 13;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2225 AAGTTACATGT 2235
 |||||
 Db 11 AAGTTACCGT 1

RESULT 14
 US-09-404-912-12
 ; Sequence 12, Application US/09404912
 ; Patent No. 6703228
 ; GENERAL INFORMATION:
 ; APPLICANT: John Landers
 ; APPLICANT: David Houseman
 ; APPLICANT: Barbara Jordan
 ; APPLICANT: Alain Charest
 ; TITLE OF INVENTION: Methods and Products Related to
 ; TITLE OF INVENTION: Genotyping and DNA Analysis
 ; FILE REFERENCE: M0856/7045 (HCL/NAT)
 ; CURRENT APPLICATION NUMBER: US/09/404,912
 ; CURRENT FILING DATE: 1999-09-24
 ; PRIOR APPLICATION NUMBER: US 60/101,757
 ; PRIOR FILING DATE: 1998-09-25
 ; PRIOR APPLICATION NUMBER: PCT/US99/22283
 ; PRIOR FILING DATE: 1999-09-24
 ; NUMBER OF SEQ ID NOS: 691
 ; SOFTWARE: FastSeq for Windows Version 3.0
 ; SEQ ID NO 12
 ; LENGTH: 11
 ; TYPE: DNA
 ; ORGANISM: Homo Sapiens
 US-09-404-912-12

Query Match 28.9%; Score 7.8; DB 1; Length 11;
 Best Local Similarity 81.8%; Pred. No. 13;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2225 AAGTTACATGT 2235
 |||||
 Db 1 AAATTAATGT 11

RESULT 15
 US-08-360-051A-45/c
 ; Sequence 45, Application US/08360051A
 ; Patent No. 5891881
 ; GENERAL INFORMATION:
 ; APPLICANT: Mallet, Francois
 ; APPLICANT: Guillou-Bonnici, Francoise
 ; APPLICANT: Cleuziat, Philippe
 ; APPLICANT: Levasseur, Pierre
 ; TITLE OF INVENTION: MODIFIED PROMOTER FOR RNA POLYMERASE,
 ; TITLE OF INVENTION: ITS PREPARATION AND ITS APPLICATIONS
 ; NUMBER OF SEQUENCES: 65
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: OLIFF & BERRIDGE
 ; STREET: 700 South Washington Street, Suite 300
 ; CITY: Alexandria
 ; STATE: VA
 ; COUNTRY: USA
 ; ZIP: 22314

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/360,051A
FILING DATE: 20-DEC-1994
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Berridge, William P.
REGISTRATION NUMBER: 30,024
REFERENCE/DOCKET NUMBER: WPB 36049
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-836-6400
TELEFAX: 703-836-2787
INFORMATION FOR SEQ ID NO: 45:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "DNA"
US-08-360-051A-45

Query Match 27.4%; Score 7.4; DB 1; Length 9;
Best Local Similarity 88.9%; Pred. No. 62;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2214 AGTGTGACC 2222
|||||
DB 9 AGTGTGACC 1

RESULT 16
US-08-360-051A-48/c
Sequence 48, Application US/08360051A
Patent No. 5891681
GENERAL INFORMATION:
APPLICANT: Mallet, Francois
APPLICANT: Guillon-Bonnici, Francoise
APPLICANT: Cleuziat, Philippe
APPLICANT: Levassuer, Pierre
TITLE OF INVENTION: MODIFIED PROMOTER FOR RNA POLYMERASE,
TITLE OF INVENTION: ITS PREPARATION AND ITS APPLICATIONS
NUMBER OF SEQUENCES: 65
CORRESPONDENCE ADDRESS:
ADDRESSEE: OLIFF & BERRIDGE
STREET: 700 South Washington Street, Suite 300
CITY: Alexandria
STATE: VA
COUNTRY: USA
ZIP: 22314
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/360,051A
FILING DATE: 20-DEC-1994
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Berridge, William P.
REGISTRATION NUMBER: 30,024
REFERENCE/DOCKET NUMBER: WPB 36049
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-836-6400
TELEFAX: 703-836-2787
INFORMATION FOR SEQ ID NO: 48:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 base pairs

TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "DNA"
US-08-360-051A-48

Query Match 27.4%; Score 7.4; DB 1; Length 9;
Best Local Similarity 88.9%; Pred. No. 62;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2214 AGTGTGACC 2222
|||||
DB 9 AGTGTGACC 1

RESULT 17
US-08-375-151-5/c
Sequence 5, Application US/08375151
Patent No. 6060237
GENERAL INFORMATION:
APPLICANT: Hakan Nygren and Manne
APPLICANT: Stenberg
TITLE OF INVENTION: Devices and Methods for
TITLE OF INVENTION: Optical Detection of Nucleic
TITLE OF INVENTION: Acid Hybridization
NUMBER OF SEQUENCES: 5
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: USA
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44Mb storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM MS-DOS (Version 5.0)
SOFTWARE: Wordperfect (Version 5.1)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/375,151
FILING DATE: January 17, 1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 07/965,661
FILING DATE: September 17, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 210/215
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 9
TYPE: nucleic
STRANDEDNESS: single
TOPOLOGY: linear
US-08-375-151-5

Query Match 27.4%; Score 7.4; DB 1; Length 9;
Best Local Similarity 88.9%; Pred. No. 62;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2229 TACATGTTT 2237
|||||
DB 9 TACATGTTT 1

RESULT 18
US-09-425-072-5/c
; Sequence 5, Application US/09425072
; Patent No. 6355429
; GENERAL INFORMATION:
; APPLICANT: Hakan Nygren and Manne
; APPLICANT: Stenberg
; TITLE OF INVENTION: Devices and Methods for
; TITLE OF INVENTION: Optical Detection of Nucleic
; TITLE OF INVENTION: Acid Hybridization
; NUMBER OF SEQUENCES: 5
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: USA
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44Mb storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM MS-DOS (Version 5.0)
; SOFTWARE: WordPerfect (Version 5.1)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/425,072
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/375,151
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 210/215
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 9
; TYPE: nucleic
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-425-072-5

Query Match 27.4%; Score 7.4; DB 1; Length 9;
Best Local Similarity 88.9%; Pred. No. 62;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2229 TACATGTTT 2237
Db 9 TACATCTTT 1

RESULT 19
US-09-194-842A-21/c
; Sequence 21, Application US/09194842A
; Patent No. 6416948
; GENERAL INFORMATION:
; APPLICANT: Pilarski, Linda M.
; APPLICANT: Belch, Andrew R.
; APPLICANT: Szczepek, Agnieszka J.
; TITLE OF INVENTION: METHODS FOR DETECTION OF REARRANGED DNA
; FILE REFERENCE: SPI-008USCPA
; CURRENT APPLICATION NUMBER: US/09/194,842A
; CURRENT FILING DATE: 1999-01-04
; PRIOR APPLICATION NUMBER: US 60/019,106
; PRIOR FILING DATE: 1996-06-03
; PRIOR APPLICATION NUMBER: PCT/US97/09534
; PRIOR FILING DATE: 1997-06-03
; NUMBER OF SEQ ID NOS: 76
; SOFTWARE: Patentin Ver. 2.0

; SEQ ID NO 21
; LENGTH: 9
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-194-842A-21

Query Match 27.4%; Score 7.4; DB 1; Length 9;
Best Local Similarity 88.9%; Pred. No. 62;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2215 GTGTGACCA 2223
Db 9 GTGTGACCA 1

RESULT 20
US-10-096-596-12
; Sequence 12, Application US/10096596
; Patent No. 6746845
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth W
; APPLICANT: Vogelstein, Bert
; APPLICANT: Velculescu, Victor
; APPLICANT: Zhang, Lin
; TITLE OF INVENTION: METHOD FOR SERIAL ANALYSIS OF GENE EXPRESSION
; FILE REFERENCE: 001107.00242
; CURRENT APPLICATION NUMBER: US/10/096,596
; CURRENT FILING DATE: 2002-03-14
; PRIOR APPLICATION NUMBER: US 08/527,154
; PRIOR FILING DATE: 1995-09-12
; PRIOR APPLICATION NUMBER: US 08/544,861
; PRIOR FILING DATE: 1995-10-18
; PRIOR APPLICATION NUMBER: US 09/107,228
; PRIOR FILING DATE: 1998-06-30
; NUMBER OF SEQ ID NOS: 41
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 12
; LENGTH: 9
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-096-596-12

Query Match 27.4%; Score 7.4; DB 1; Length 9;
Best Local Similarity 88.9%; Pred. No. 62;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2215 GTGTGACCA 2223
Db 1 GCGTGACCA 9

RESULT 21
US-09-982-658A-4/c
; Sequence 4, Application US/09982658A
; Patent No. 6783938
; GENERAL INFORMATION:
; APPLICANT: HAKAN, NYGREN
; APPLICANT: MANNE, STENBERG
; TITLE OF INVENTION: DEVICES AND METHODS FOR OPTICAL DETECTION OF NUCLEIC ACID
; TITLE OF INVENTION: HYBRIDIZATION
; FILE REFERENCE: 074022/2305
; CURRENT APPLICATION NUMBER: US/09/982,658A
; CURRENT FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/425,072
; PRIOR FILING DATE: 1999-10-21
; PRIOR APPLICATION NUMBER: 08/375,151
; PRIOR FILING DATE: 1995-01-17
; PRIOR APPLICATION NUMBER: 07/965,661
; PRIOR FILING DATE: 1992-09-17
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: Patentin version 2.1
; SEQ ID NO 4
; LENGTH: 9

```
; TYPE: DNA
; ORGANISM: Bacteriophage M13mp18
; FEATURE:
; OTHER INFORMATION: 9-mer
US-09-982-658A-4

Query Match      27.4%; Score 7.4; DB 1; Length 9;
Best Local Similarity 88.9%; Pred. No. 62;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2229 TACATGTTT 2237
Db      9 TACATCTTT 1

RESULT 22
PCT-US94-08023-39/c
; Sequence 39, Application PC/TUS9408023
; GENERAL INFORMATION:
; APPLICANT: de Kloet, Siwo R.
; TITLE OF INVENTION: Sex-Specific DNA Probe For Parrots,
; TITLE OF INVENTION: Methods And Kits
; NUMBER OF SEQUENCES: 44
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Ruden, Barnett, McClosky, Smith, Schuster &
; ADDRESSEE: Russell, P.A.
; STREET: 200 East Broadway Boulevard
; CITY: Fort Lauderdale
; STATE: FL
; COUNTRY: USA
; ZIP: 33301
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/08023
; FILING DATE: 15-JUL-1994
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/093,198
; FILING DATE: 15-JUL-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Manso, Peter J.
; REGISTRATION NUMBER: 32,264
; REFERENCE/DOCKET NUMBER: FL20979-34
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 305-527-2498
; TELEFAX: 305-764-4986
; INFORMATION FOR SEQ ID NO: 39:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 9 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
PCT-US94-08023-39

Query Match      27.4%; Score 7.4; DB 1; Length 9;
Best Local Similarity 88.9%; Pred. No. 62;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2220 ACCAAAGCT 2228
Db      9 ACCAAAAAT 1

RESULT 23
US-08-631-751A-15/c
; Sequence 15, Application US/08631751A
; Patent No. 5843767
; GENERAL INFORMATION:
; APPLICANT: Beattie, Kenneth L.
; TITLE OF INVENTION: Microfabricated, Flowthrough Porous
; TITLE OF INVENTION: Apparatus for Discrete Detection of Binding Reactions
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Vinson & Elkins
; STREET: 1455 Pennsylvania Avenue, N.W.
; CITY: Washington
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20004-1008
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/631,751A
; FILING DATE: 11-April-1996
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Sanzo, Michael A.
; REGISTRATION NUMBER: 36,912
; REFERENCE/DOCKET NUMBER: HARC0001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)639-6500
; TELEFAX: (202)639-6604
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: both
; TOPOLOGY: linear
US-08-631-751A-15

Query Match      27.4%; Score 7.4; DB 1; Length 10;
Best Local Similarity 88.9%; Pred. No. 18;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2230 ACATGTTTG 2238
Db      10 ACAAGTTTG 2

RESULT 24
US-08-388-353-115/C
; Sequence 115, Application US/08388353
; Patent No. 6010895
; GENERAL INFORMATION:
; APPLICANT: Deacon, Nicholas J.
; APPLICANT: Learmont, Jennifer C.
; APPLICANT: McPhee, Dale A.
; APPLICANT: Crowe, Suzanne
; APPLICANT: Cooper, David
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 800
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: United States
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/388,353
; FILING DATE: 14-FEB-1995
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
```

NAME: DiGiglio, Frank S.
REGISTRATION NUMBER: 31,346
REFERENCE/DOCKET NUMBER: 9606
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
TELEX: 230 901 SANS UR
INFORMATION FOR SEQ ID NO: 115:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-388-353-115

Query Match 27.4%; Score 7.4; DB 1; Length 10;
Best Local Similarity 88.9%; Pred. No. 18;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2229 TACATGTTT 2237
DB 10 TCCATGTTT 2

RESULT 25
US-08-388-353-116/c
Sequence 116, Application US/08388353
Patent No. 601895
GENERAL INFORMATION:
APPLICANT: Deacon, Nicholas J.
APPLICANT: Leamont, Jennifer C.
APPLICANT: McPhee, Dale A.
APPLICANT: Crowe, Suzanne
APPLICANT: Cooper, David
TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
NUMBER OF SEQUENCES: 80
CORRESPONDENCE ADDRESS:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: United States
ZIP: 11530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/388,353
FILING DATE: 14-FEB-1995
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: DiGiglio, Frank S.
REGISTRATION NUMBER: 31,346
REFERENCE/DOCKET NUMBER: 9606
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
TELEX: 230 901 SANS UR
INFORMATION FOR SEQ ID NO: 116:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-388-353-116

Query Match 27.4%; Score 7.4; DB 1; Length 10;
Best Local Similarity 88.9%; Pred. No. 18;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2229 TACATGTTT 2237
DB 9 TCCATGTTT 1

RESULT 26
US-08-488-551B-115/c
Sequence 115, Application US/08488551B
Patent No. 6015661
GENERAL INFORMATION:
APPLICANT: Nicholas J. Deacon
APPLICANT: Dale A. McPhee
APPLICANT: David Cooper
TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
NUMBER OF SEQUENCES: 841
CORRESPONDENCE ADDRESS:
ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
STREET: 400 GARDEN CITY PLAZA
CITY: GARDEN CITY
STATE: NEW YORK
COUNTRY: U.S.A.
ZIP: 11530-0299
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/488,551B
FILING DATE: 07-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PM3864 (AU)
FILING DATE: 14-FEB-1994
APPLICATION NUMBER: PM4002 (AU)
FILING DATE: 21-FEB-1994
APPLICATION NUMBER: PM0284 (AU)
FILING DATE: 23-DEC-1994
APPLICATION NUMBER: US 08/388,353
FILING DATE: 14-FEB-1995
APPLICATION NUMBER: PM3021/95
FILING DATE: 17-MAY-1995
ATTORNEY/AGENT INFORMATION:
NAME: FRANK S. DIGIGLIO
REFERENCE/DOCKET NUMBER: 96062
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
INFORMATION FOR SEQ ID NO: 115:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-488-551B-115

Query Match 27.4%; Score 7.4; DB 1; Length 10;
Best Local Similarity 88.9%; Pred. No. 18;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2229 TACATGTTT 2237
DB 10 TCCATGTTT 2

RESULT 27
US-08-488-551B-116/c
Sequence 116, Application US/08488551B
Patent No. 6015661
GENERAL INFORMATION:
APPLICANT: Nicholas J. Deacon
APPLICANT: Dale A. McPhee

APPLICANT: David Cooper
TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
NUMBER OF SEQUENCES: 841
CORRESPONDENCE ADDRESS:
ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
STREET: 400 GARDEN CITY PLAZA
CITY: GARDEN CITY
STATE: NEW YORK
COUNTRY: U.S.A.
ZIP: 11530-0299
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/488,551B
FILING DATE: 07-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PM3864 (AU)
FILING DATE: 14-FEB-1994
APPLICATION NUMBER: PM4002 (AU)
FILING DATE: 21-FEB-1994
APPLICATION NUMBER: PM0284 (AU)
FILING DATE: 23-DEC-1994
APPLICATION NUMBER: US 08/388,353
FILING DATE: 14-FEB-1995
APPLICATION NUMBER: PN3021/95
FILING DATE: 17-MAY-1995
ATTORNEY/AGENT INFORMATION:
NAME: FRANK S. DIGIGLIO
REFERENCE/DOCKET NUMBER: 9606Z
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
INFORMATION FOR SEQ ID NO: 116:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-488-551B-116

Query Match 27.4%; Score 7.4; DB 1; Length 10;
Best Local Similarity 88.9%; Pred. No. 18;
Matches 8; Conservative 0; Mismatches 1; Indels 1; Gaps 0;

QY 2229 TACATGTTT 2237
DB 9 TCCATGTTT 1

RESULT 28
US-09-180-903-14
Sequence 14, Application US/09180903
Patent No. 6316190
GENERAL INFORMATION:
APPLICANT: Rein, Alan
Casas-Finet, Jose
Fisher, Robert
Fivash, Matthew
Henderson, Louis E.
TITLE OF INVENTION: Oligonucleotides Which Specifically Bind
Retroviral Nucleocapsid Proteins
NUMBER OF SEQUENCES: 15
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/180,903
FILING DATE: 12-JUL-1999
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/017,128
FILING DATE: 20-MAY-1996
APPLICATION NUMBER: WO PCT/US97/08936
FILING DATE: 19-MAY-1997
ATTORNEY/AGENT INFORMATION:
NAME: Choi, Kathleen L.
REGISTRATION NUMBER: 43,433
REFERENCE/DOCKET NUMBER: 015280-279100US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
SEQUENCE DESCRIPTION: SEQ ID NO: 14:
US-09-180-903-14

Query Match 27.4%; Score 7.4; DB 1; Length 10;
Best Local Similarity 88.9%; Pred. No. 18;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2219 GACCAAAAG 2227
DB 1 GACTAAAG 9

RESULT 29
US-09-171-759-20
Sequence 20, Application US/09171759
Patent No. 6346415
GENERAL INFORMATION:
APPLICANT: Feldhaus, Andrew
TITLE OF INVENTION: TRANSCRIPTIONALLY-ACTIVATED
AAV INVERTED TERMINAL REPEATS (ITRs) FOR USE WITH RECOMBINant
AAV VECTORS
NUMBER OF SEQUENCES: 21
CORRESPONDENCE ADDRESS:
ADDRESSEE: MORRISON & FOERSTER
STREET: 755 PAGE MILL ROAD
CITY: PALO ALTO
STATE: CA
COUNTRY: USA
ZIP: 94304-1018
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/171,759
FILING DATE: 20-Oct-1998
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: <Unknown>
FILING DATE: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: Dylan, Tyler M
REGISTRATION NUMBER: 37,612
REFERENCE/DOCKET NUMBER: 22627-20038.01

```
;
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-813-5600
; TELEFAX: 650-494-0792
; TELEX: 706141
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 20:
US-09-171-759-20

Query Match      27.4%; Score 7.4; DB 1; Length 10;
Best Local Similarity 88.9%; Pred. No. 18;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      2221 CCAAAAGTT 2229
Db      1 CCGAAGTT 9

RESULT 30
US-09-083-235A-40/c
; Sequence 40, Application US/09083235A
; Patent No. 6632919
; GENERAL INFORMATION:
; APPLICANT: Nielsen, Peter E
; APPLICANT: Haaima, Gerald
; APPLICANT: Eldrup, Anne B
; TITLE OF INVENTION: Peptide Nucleic Acid Monomers and Oligomers
; FILE REFERENCE: ISIS3044
; CURRENT APPLICATION NUMBER: US/09/083,235A
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 08/862,629
; NUMBER OF SEQ ID NOS: 87
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 40
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6632919el Sequence
US-09-083-235A-40

Query Match      27.4%; Score 7.4; DB 1; Length 10;
Best Local Similarity 88.9%; Pred. No. 18;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      2212 AGAGTGTGA 2220
Db      10 AGAGTTTGA 2

RESULT 31
US-09-083-235A-41/c
; Sequence 41, Application US/09083235A
; Patent No. 6632919
; GENERAL INFORMATION:
; APPLICANT: Nielsen, Peter E
; APPLICANT: Haaima, Gerald
; APPLICANT: Eldrup, Anne B
; TITLE OF INVENTION: Peptide Nucleic Acid Monomers and Oligomers
; FILE REFERENCE: ISIS3044
; CURRENT APPLICATION NUMBER: US/09/083,235A
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 08/862,629
; NUMBER OF SEQ ID NOS: 87
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 41
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6632919el Sequence
US-09-083-235A-41

Query Match      27.4%; Score 7.4; DB 1; Length 10;
Best Local Similarity 88.9%; Pred. No. 18;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      2212 AGAGTGTGA 2220
Db      10 AGAGTTTGA 2

RESULT 32
US-09-083-235A-42
; Sequence 42, Application US/09083235A
; Patent No. 6632919
; GENERAL INFORMATION:
; APPLICANT: Nielsen, Peter E
; APPLICANT: Haaima, Gerald
; APPLICANT: Eldrup, Anne B
; TITLE OF INVENTION: Peptide Nucleic Acid Monomers and Oligomers
; FILE REFERENCE: ISIS3044
; CURRENT APPLICATION NUMBER: US/09/083,235A
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 08/862,629
; NUMBER OF SEQ ID NOS: 87
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 42
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6632919el Sequence
US-09-083-235A-42

Query Match      27.4%; Score 7.4; DB 1; Length 10;
Best Local Similarity 88.9%; Pred. No. 18;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      2212 AGAGTGTGA 2220
Db      10 AGAGTTTGA 2

RESULT 33
US-09-693-467A-13/c
; Sequence 13, Application US/09693467A
; Patent No. 6686513
; GENERAL INFORMATION:
; APPLICANT: Albert, Henrik H.
; APPLICANT: Wei, Hairong
; TITLE OF INVENTION: PLANT PROMOTER SEQUENCES AND METHODS OF USE THEREOF
; FILE REFERENCE: UH-04331
; CURRENT APPLICATION NUMBER: US/09/693,467A
; CURRENT FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: 09/270,976
; PRIOR FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 13
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Saacharum Hybrid Cultivar H32-8560
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (9)
; OTHER INFORMATION: The "n" at position 9 is any nucleotide.
US-09-693-467A-13
```

mcgarry191-19.rni

Thu Nov 18 12:41:58 2004

Search completed: November 18, 2004, 08:17:36
Job time : 0.001 secs

Query Match 27.4%; Score 7.4; DB 1; Length 10;
Best Local Similarity 80.0%; Pred. No. 18;
Matches 8; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2220 ACCAARAGTT 2229
| | | | | | | | | |
Db 10 ANCAAAACTT 1

RESULT 34
US-09-693-467A-16/c
; Sequence 16, Application US/09693467A
; Patent No. 6686513
; GENERAL INFORMATION:
; APPLICANT: Albert, Henrik H.
; APPLICANT: Wei, Haihong
; TITLE OF INVENTION: PLANT PROMOTER SEQUENCES AND METHODS OF USE THEREOF
; FILE REFERENCE: UH-04331
; CURRENT APPLICATION NUMBER: US/09/693,467A
; CURRENT FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: 09/270,976
; PRIOR FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 16
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Saccharum Hybrid Cultivar H32-8560
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (9)
; OTHER INFORMATION: The "n" at position 9 is any nucleotide.
US-09-693-467A-16

Query Match 27.4%; Score 7.4; DB 1; Length 10;
Best Local Similarity 80.0%; Pred. No. 18;
Matches 8; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2220 ACCAARAGTT 2229
| | | | | | | | | |
Db 10 ANCAAAACTT 1

RESULT 35
US-09-822-250A-17/c
; Sequence 17, Application US/09822250A
; Patent No. 6706477
; GENERAL INFORMATION:
; APPLICANT: Zauderer, Maurice
; TITLE OF INVENTION: Methods for Producing Polynucleotide Libraries in Vaccinia Virus
; FILE REFERENCE: 1821.0010001
; CURRENT APPLICATION NUMBER: US/09/822,250A
; CURRENT FILING DATE: 2001-04-02
; PRIOR APPLICATION NUMBER: US 08/935,377
; PRIOR FILING DATE: 1997-09-22
; NUMBER OF SEQ ID NOS: 38
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: MP_9 primer
US-09-822-250A-17

Query Match 27.4%; Score 7.4; DB 1; Length 10;
Best Local Similarity 88.9%; Pred. No. 18;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2216 TGTGACCA 2224
| | | | | | | | | |
Db 9 TGTGACCGA 1

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 18, 2004, 08:18:59 ; Search time 0.001 Seconds
(without alignments)
19.494 Million cell updates/sec

Title: US-10-006-191-19

Perfect score: 27

Sequence: 1 agsgtgcacaaagtacatgttg 27

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 31 seqs, 361 residues

Total number of hits satisfying chosen parameters: 62

Minimum DB seq length: 8

Maximum DB seq length: 50

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 31 summaries

Database : rnpb19.seq*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
C 1	20	74.1	20	1	US-10-006-191-47
C 2	20	74.1	20	1	US-10-006-191-48
C 3	20	74.1	20	1	US-10-006-191-63
C 4	20	74.1	20	1	US-10-006-191-64
C 5	16	59.3	20	1	US-10-006-191-46
C 6	10	37.0	10	1	US-10-293-222-313
C 7	9	33.3	10	1	US-10-033-145-571
C 8	9	33.3	11	1	US-09-918-715-62
C 9	8.4	31.1	10	1	US-09-986-944-2
C 10	8.4	31.1	10	1	US-10-329-465-30
C 11	8.4	31.1	10	1	US-10-423-765-213
C 12	8.4	31.1	10	1	US-10-330-627-88
C 13	8.4	31.1	10	1	US-10-330-627-150
C 14	8.4	31.1	10	1	US-10-330-627-202
C 15	8.4	31.1	10	1	US-10-330-627-204
C 16	8.4	31.1	10	1	US-10-423-621-11
C 17	8	29.6	10	1	US-09-989-789-1315
C 18	8	29.6	10	1	US-09-989-789-1323
C 19	8	29.6	10	1	US-09-989-789-1324
C 20	8	29.6	10	1	US-09-989-186-1315
C 21	8	29.6	10	1	US-09-990-186-1323
C 22	8	29.6	10	1	US-09-990-186-1324
C 23	8	29.6	10	1	US-09-989-994-1315
C 24	8	29.6	10	1	US-09-989-994-1323
C 25	8	29.6	10	1	US-09-989-994-1324
C 26	8	29.6	10	1	US-10-033-145-639
C 27	8	29.6	10	1	US-10-033-145-697
C 28	8	29.6	10	1	US-10-033-145-1053
C 29	8	29.6	10	1	US-10-330-627-1311
C 30	8	29.6	10	1	US-10-091-281-239
C 31	8	29.6	10	1	US-10-160-401-28

ALIGNMENTS

RESULT 1

US-10-006-191-47/c
; Sequence 47, Application US/10006191
; Publication No. US20030144223A1

; GENERAL INFORMATION:

; APPLICANT: William Gaarde

; APPLICANT: Andrew T. Watt

; TITLE OF INVENTION: ANTISENSE MODULATION OF CONNECTIVE TISSUE GROWTH FACTOR EXPRESSION

; FILE REFERENCE: RTS-0274

; CURRENT APPLICATION NUMBER: US/10/006,191

; CURRENT FILING DATE: 2001-12-10

; NUMBER OF SEQ ID NOS: 153

; SEQ ID NO 47

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-006-191-47

Query Match 74.1%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 0.32;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2213 GAGTGTGACCAAAAGTTTACA 2232

DB 20 GAGTGTGACCAAAAGTTTACA 1

RESULT 2

US-10-006-191-48/c

; Sequence 48, Application US/10006191

; Publication No. US20030144223A1

; GENERAL INFORMATION:

; APPLICANT: William Gaarde

; APPLICANT: Andrew T. Watt

; TITLE OF INVENTION: ANTISENSE MODULATION OF CONNECTIVE TISSUE GROWTH FACTOR EXPRESSION

; FILE REFERENCE: RTS-0274

; CURRENT APPLICATION NUMBER: US/10/006,191

; CURRENT FILING DATE: 2001-12-10

; NUMBER OF SEQ ID NOS: 153

; SEQ ID NO 48

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-006-191-48

Query Match 74.1%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 0.32;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2218 TGACCAAAAGTTTACATGTTT 2237

DB 20 TGACCAAAAGTTTACATGTTT 1

RESULT 3

US-10-006-191-63/c

; Sequence 63, Application US/10006191

; Publication No. US20030144223A1

; GENERAL INFORMATION:

; APPLICANT: William Gaarde

; APPLICANT: Andrew T. Watt

; TITLE OF INVENTION: ANTISENSE MODULATION OF CONNECTIVE TISSUE GROWTH FACTOR EXPRESSION

; FILE REFERENCE: RTS-0274

; CURRENT APPLICATION NUMBER: US/10/006,191

; CURRENT FILING DATE: 2001-12-10

; NUMBER OF SEQ ID NOS: 153

; SEQ ID NO 63
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-006-191-63

Query Match 74.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.32;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2212 AGAGTGTGACCAAAAGTTAC 2231
|||||
DB 20 AGAGTGTGACCAAAAGTTAC 1

RESULT 4
US-10-006-191-64/c

; Sequence 64, Application US/10006191
; Publication No. US20030144223A1
; GENERAL INFORMATION:
; APPLICANT: William Gaarde
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF CONNECTIVE TISSUE GROWTH FACTOR EXPRESSION

; FILE REFERENCE: RTS-0274
; CURRENT APPLICATION NUMBER: US/10/006,191
; CURRENT FILING DATE: 2001-12-10
; NUMBER OF SEQ ID NOS: 153
; SEQ ID NO 64
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-006-191-64

Query Match 74.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.32;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2219 GACCAAAAGTTACATGTTTG 2238
|||||
DB 20 GACCAAAAGTTACATGTTTG 1

RESULT 5
US-10-006-191-46/c

; Sequence 46, Application US/10006191
; Publication No. US20030144223A1
; GENERAL INFORMATION:
; APPLICANT: William Gaarde
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF CONNECTIVE TISSUE GROWTH FACTOR EXPRESSION

; FILE REFERENCE: RTS-0274
; CURRENT APPLICATION NUMBER: US/10/006,191
; CURRENT FILING DATE: 2001-12-10
; NUMBER OF SEQ ID NOS: 153
; SEQ ID NO 46
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-006-191-46

Query Match 59.3%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2212 AGAGTGTGACCAAAAG 2227
|||||
DB 16 AGAGTGTGACCAAAAG 1

RESULT 6

US-10-293-222-313/c
; Sequence 313, Application US/10293222
; Publication No. US2004003932A1
; GENERAL INFORMATION:
; APPLICANT: Versteeg, Rogier
; APPLICANT: Caron, Hubertus N.
; TITLE OF INVENTION: MYC targets
; FILE REFERENCE: 2183-5580US
; CURRENT APPLICATION NUMBER: US/10/293,222
; CURRENT FILING DATE: 2002-11-12
; PRIOR APPLICATION NUMBER: PCT/NL01/00361
; PRIOR FILING DATE: 2001-05-11
; PRIOR APPLICATION NUMBER: EP 00201698.8
; PRIOR FILING DATE: 2000-05-11
; PRIOR APPLICATION NUMBER: EP 00202284.6
; PRIOR FILING DATE: 2000-06-29
; NUMBER OF SEQ ID NOS: 455
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 313
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-293-222-313

Query Match 37.0%; Score 10; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2221 CCAAAAAGTTA 2230
|||||
DB 10 CCAAAAAGTTA 1

RESULT 7

US-10-033-145-571/c
; Sequence 571, Application US/10033145
; Publication No. US2002015151A1
; GENERAL INFORMATION:
; APPLICANT: GENZYME CORPORATION
; APPLICANT: ROBERTS, BRUCE
; APPLICANT: SHANKARA, SRINIVAS
; TITLE OF INVENTION: PREPARATION AND USE OF SUPERIOR VACCINES
; FILE REFERENCE: GA0201C
; CURRENT APPLICATION NUMBER: US/10/033,145
; CURRENT FILING DATE: 2001-11-05
; PRIOR APPLICATION NUMBER: PCT/US99/13800
; PRIOR FILING DATE: 1999-06-18
; NUMBER OF SEQ ID NOS: 2137
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 571
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-033-145-571

Query Match 33.3%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 16;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2214 AGTGTGACC 2222
|||||
DB 9 AGTGTGACC 1

RESULT 8

US-09-918-715-62
; Sequence 62, Application US/09918715
; Publication No. US20030017157A1
; GENERAL INFORMATION:
; APPLICANT: Brad St. Croix

; APPLICANT: Bert Vogelstein
; APPLICANT: Kenneth Kinzler
; TITLE OF INVENTION: ENDOTHELIAL CELL EXPRESSION PATTERNS
; FILE REFERENCE: 1107.00134
; CURRENT APPLICATION NUMBER: US/09/918,715
; CURRENT FILING DATE: 2001-08-01
; PRIOR APPLICATION NUMBER: 60/222,599
; PRIOR FILING DATE: 2000-08-02
; PRIOR APPLICATION NUMBER: 60/224,360
; PRIOR FILING DATE: 2000-08-11
; PRIOR APPLICATION NUMBER: 60/282,850
; PRIOR FILING DATE: 2000-04-11
; NUMBER OF SEQ ID NOS: 358
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 62
; LENGTH: 11
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-918-715-62

Query Match 33.1%; Score 9; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2212 AGAGTGTGA 2220
Db 3 AGAGTGTGA 11

RESULT 9
US-09-986-944-2/c
; Sequence 2, Application US/09985944
; Patent No. US20020072589A1
; GENERAL INFORMATION:
; APPLICANT: Desmond MASCARENHAS
; APPLICANT: David PASSMORE
; APPLICANT: Stephen DANKO
; TITLE OF INVENTION: INSULIN-LIKE GROWTH FACTOR BINDING
; TITLE OF INVENTION: PROTEIN VARIANTS
; FILE REFERENCE: 22095209100
; CURRENT APPLICATION NUMBER: US/09/986,944
; CURRENT FILING DATE: 2001-11-13
; PRIOR APPLICATION NUMBER: US 09/322,484
; PRIOR FILING DATE: 1999-05-27
; PRIOR APPLICATION NUMBER: 60/087,559
; PRIOR FILING DATE: 1998-06-01
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Saccharomyces cerevisiae
US-09-986-944-2

Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 19;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2226 AGTTACATGT 2235
Db 10 AATTACATGT 1

RESULT 10
US-10-329-465-30/c
; Sequence 30, Application US/10329465
; Publication No. US20030165949A1
; GENERAL INFORMATION:
; APPLICANT: Wang et al.
; TITLE OF INVENTION: GENES ABNORMALLY EXPRESSED IN MYELOID LEUKEMIA CELLS WITH AN MLL-
; TITLE OF INVENTION: FUSION
; FILE REFERENCE: 27373/37928A
; CURRENT APPLICATION NUMBER: US/10/329,465

; CURRENT FILING DATE: 2002-12-23
; PRIOR APPLICATION NUMBER: US 60/343,826
; PRIOR FILING DATE: 2001-12-27
; NUMBER OF SEQ ID NOS: 315
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 30
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide
US-10-329-465-30

Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 19;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2214 AGTGTGACCA 2223
Db 10 AGTATGACCA 1

RESULT 11
US-10-223-765-213
; Sequence 213, Application US/10223765
; Publication No. US20030165997A1
; GENERAL INFORMATION:
; APPLICANT: Kim, Jin-Soo
; APPLICANT: Bae, Kwang-Hee
; APPLICANT: Park, Kyung-Soon
; APPLICANT: Kwon, Young Do
; APPLICANT: Ryu, Eun-Hyun
; APPLICANT: Hwang, Moon-Sun
; TITLE OF INVENTION: ZINC FINGER DOMAIN LIBRARIES
; FILE REFERENCE: 12279-005001
; CURRENT APPLICATION NUMBER: US/10/223,765
; CURRENT FILING DATE: 2002-08-19
; PRIOR APPLICATION NUMBER: 60/374,355
; PRIOR FILING DATE: 2002-04-22
; PRIOR APPLICATION NUMBER: 60/313,402
; PRIOR FILING DATE: 2001-08-17
; NUMBER OF SEQ ID NOS: 305
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 213
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetically generated oligonucleotide
US-10-223-765-213

Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 19;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2213 GAGTGTGACC 2222
Db 1 GAGTGAGACC 10

RESULT 12
US-10-330-627-88
; Sequence 88, Application US/10330627
; Publication No. US20030175771A1
; GENERAL INFORMATION:
; APPLICANT: Velculescu, Victor E.
; APPLICANT: Kinzler, Kenneth W
; APPLICANT: Vogelstein, Bert
; TITLE OF INVENTION: Human Transcriptomes
; FILE REFERENCE: 001107.00319
; CURRENT APPLICATION NUMBER: US/10/330,627
; CURRENT FILING DATE: 2002-12-30
; PRIOR APPLICATION NUMBER: US 09/448,480

; PRIOR FILING DATE: 1999-11-24
; NUMBER OF SEQ ID NOS: 1564
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 88
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-330-627-88

Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 19;
Matches 9; Conservative 0; Mismatches 1; Indels 1; Gaps 0;

QY 2221 CCAAAAGTTA 2230
||| |||||
Db 1 CAAAAGTTA 10

RESULT 13
US-10-330-627-150
; Sequence 150, Application US/10330627
; Publication No. US2003017577A1
; GENERAL INFORMATION:
; APPLICANT: Velculescu, Victor E.
; APPLICANT: Kinzler, Kenneth W.
; APPLICANT: Vogelstein, Bert
; TITLE OF INVENTION: Human Transcriptomes
; FILE REFERENCE: 001107.00319
; CURRENT APPLICATION NUMBER: US/10/330,627
; CURRENT FILING DATE: 2002-12-30
; PRIOR APPLICATION NUMBER: US 09/448,480
; PRIOR FILING DATE: 1999-11-24
; NUMBER OF SEQ ID NOS: 1564
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 150
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-330-627-150

Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 19;
Matches 9; Conservative 0; Mismatches 1; Indels 1; Gaps 0;

QY 2218 TGACCAAAAG 2227
||| |||||
Db 1 TGACCAATAG 10

RESULT 14
US-10-330-627-202/c
; Sequence 202, Application US/10330627
; Publication No. US2003017577A1
; GENERAL INFORMATION:
; APPLICANT: Velculescu, Victor E.
; APPLICANT: Kinzler, Kenneth W.
; APPLICANT: Vogelstein, Bert
; TITLE OF INVENTION: Human Transcriptomes
; FILE REFERENCE: 001107.00319
; CURRENT APPLICATION NUMBER: US/10/330,627
; CURRENT FILING DATE: 2002-12-30
; PRIOR APPLICATION NUMBER: US 09/448,480
; PRIOR FILING DATE: 1999-11-24
; NUMBER OF SEQ ID NOS: 1564
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 202
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-330-627-202

Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 19;

Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2216 TGTGACCAAA 2225
||| |||||
Db 10 TGTAAACCAAA 1

RESULT 15
US-10-330-627-204/c
; Sequence 204, Application US/10330627
; Publication No. US2003017577A1
; GENERAL INFORMATION:
; APPLICANT: Velculescu, Victor E.
; APPLICANT: Kinzler, Kenneth W.
; APPLICANT: Vogelstein, Bert
; TITLE OF INVENTION: Human Transcriptomes
; FILE REFERENCE: 001107.00319
; CURRENT APPLICATION NUMBER: US/10/330,627
; CURRENT FILING DATE: 2002-12-30
; PRIOR APPLICATION NUMBER: US 09/448,480
; PRIOR FILING DATE: 1999-11-24
; NUMBER OF SEQ ID NOS: 1564
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 204
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-330-627-204

Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 19;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2216 TGTGACCAAA 2225
||| |||||
Db 10 TGTAAACCAAA 1

RESULT 16
US-10-423-621-11
; Sequence 11, Application US/10423621
; Publication No. US20040033518A1
; GENERAL INFORMATION:
; APPLICANT: The University of Utah
; TITLE OF INVENTION: Characterization of Single Stranded Nucleic Acids By Melting
; TITLE OF INVENTION: Analysis of Secondary Structure Using Double Strand-Specific
; FILE REFERENCE: A-70575-1
; CURRENT APPLICATION NUMBER: US/10/423,621
; CURRENT FILING DATE: 2003-04-25
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-423-621-11

Query Match 31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 19;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2220 ACCAAAAGTT 2229
||| |||||
Db 1 ACCAAAAGT 10

RESULT 17
US-09-989-789-1315
; Sequence 1315, Application US/09989789
; Patent No. US20020063379A1
; GENERAL INFORMATION:
; APPLICANT: LIU, Qiang

;
; TITLE OF INVENTION: POSITION DEPENDENT RECOGNITION OF GNN NUCLEOTIDE
; TITLE OF INVENTION: TRIPLETS BY ZINC FINGERS
; FILE REFERENCE: 8325-0011.20 / S11-US2
; CURRENT APPLICATION NUMBER: US/09/989,789
; CURRENT FILING DATE: 2002-03-25
; NUMBER OF SEQ ID NOS: 4085
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 1315
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
;
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: example target
; OTHER INFORMATION: DNA
US-09-989-789-1315

Query Match 29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 21;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2213 GAGTGTGA 2220
Db 1 GAGTGTGA 8
|||||

RESULT 18
US-09-989-789-1323
; Sequence 1323, Application US/09989789
; Publication No. US20020063379A1
; GENERAL INFORMATION:
; APPLICANT: LIU, Qiang
; TITLE OF INVENTION: POSITION DEPENDENT RECOGNITION OF GNN NUCLEOTIDE
; TITLE OF INVENTION: TRIPLETS BY ZINC FINGERS
; FILE REFERENCE: 8325-0011.20 / S11-US2
; CURRENT APPLICATION NUMBER: US/09/989,789
; CURRENT FILING DATE: 2002-03-25
; NUMBER OF SEQ ID NOS: 4085
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 1323
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
;
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: example target
; OTHER INFORMATION: DNA
US-09-989-789-1323

Query Match 29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 21;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2213 GAGTGTGA 2220
Db 1 GAGTGTGA 8
|||||

RESULT 19
US-09-989-789-1324
; Sequence 1324, Application US/09989789
; Patent No. US20020063379A1
; GENERAL INFORMATION:
; APPLICANT: LIU, Qiang
; TITLE OF INVENTION: POSITION DEPENDENT RECOGNITION OF GNN NUCLEOTIDE
; TITLE OF INVENTION: TRIPLETS BY ZINC FINGERS
; FILE REFERENCE: 8325-0011.20 / S11-US2
; CURRENT APPLICATION NUMBER: US/09/989,789
; CURRENT FILING DATE: 2002-03-25
; NUMBER OF SEQ ID NOS: 4085
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 1324
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence

;
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: example target
; OTHER INFORMATION: DNA
US-09-989-789-1324

Query Match 29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 21;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2213 GAGTGTGA 2220
Db 1 GAGTGTGA 8
|||||

RESULT 20
US-09-990-186-1315
; Sequence 1315, Application US/09990186
; Publication No. US2003006675A1
; GENERAL INFORMATION:
; APPLICANT: LIU, Qiang
; TITLE OF INVENTION: POSITION DEPENDENT RECOGNITION OF GNN NUCLEOTIDE
; TITLE OF INVENTION: TRIPLETS BY ZINC FINGERS
; FILE REFERENCE: 8325-0011.21 / S11-US3
; CURRENT APPLICATION NUMBER: US/09/990,186
; CURRENT FILING DATE: 2001-11-20
; NUMBER OF SEQ ID NOS: 4085
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 1315
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
;
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: example target
; OTHER INFORMATION: DNA
US-09-990-186-1315

Query Match 29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 21;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2213 GAGTGTGA 2220
Db 1 GAGTGTGA 8
|||||

RESULT 21
US-09-990-186-1323
; Sequence 1323, Application US/09990186
; Publication No. US2003006675A1
; GENERAL INFORMATION:
; APPLICANT: LIU, Qiang
; TITLE OF INVENTION: POSITION DEPENDENT RECOGNITION OF GNN NUCLEOTIDE
; TITLE OF INVENTION: TRIPLETS BY ZINC FINGERS
; FILE REFERENCE: 8325-0011.21 / S11-US3
; CURRENT APPLICATION NUMBER: US/09/990,186
; CURRENT FILING DATE: 2001-11-20
; NUMBER OF SEQ ID NOS: 4085
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 1323
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
;
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: example target
; OTHER INFORMATION: DNA
US-09-990-186-1323

Query Match 29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 21;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2213 GAGTGTGA 2220
Db 1 GAGTGTGA 8
|||||


```
; ORGANISM: Homo sapiens
US-10-033-145-639

Query Match      29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 21;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2224 AAAGTTAC 2231
Db 3 AAAGTTAC 10

RESULT 27
US-10-033-145-697/c
; Sequence 697, Application US/10033145
; Publication No. US2002015151A1
; GENERAL INFORMATION:
; APPLICANT: GENZYME CORPORATION
; APPLICANT: ROBERTS, BRUCE
; APPLICANT: SHANKARA, SRINIVAS
; TITLE OF INVENTION: PREPARATION AND USE OF SUPERIOR VACCINES
; FILE REFERENCE: GA0201C
; CURRENT APPLICATION NUMBER: US/10/033,145
; CURRENT FILING DATE: 2001-11-05
; PRIOR APPLICATION NUMBER: PCT/US99/13800
; PRIOR FILING DATE: 1999-06-18
; NUMBER OF SEQ ID NOS: 2137
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 697
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-033-145-697

Query Match      29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 21;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2221 CCAAAAGT 2228
Db 9 CCAAAAGT 2

RESULT 28
US-10-033-145-1053/c
; Sequence 1053, Application US/10033145
; Publication No. US2002015151A1
; GENERAL INFORMATION:
; APPLICANT: GENZYME CORPORATION
; APPLICANT: ROBERTS, BRUCE
; APPLICANT: SHANKARA, SRINIVAS
; TITLE OF INVENTION: PREPARATION AND USE OF SUPERIOR VACCINES
; FILE REFERENCE: GA0201C
; CURRENT APPLICATION NUMBER: US/10/033,145
; CURRENT FILING DATE: 2001-11-05
; PRIOR APPLICATION NUMBER: PCT/US99/13800
; PRIOR FILING DATE: 1999-06-18
; NUMBER OF SEQ ID NOS: 2137
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1053
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-033-145-1053

Query Match      29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 21;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2226 AGTTACAT 2233
Db 10 AGTTACAT 3
```

```
RESULT 29
US-10-330-627-1311/c
; Sequence 1311, Application US/10330627
; Publication No. US2003017571A1
; GENERAL INFORMATION:
; APPLICANT: Velculescu, Victor E.
; APPLICANT: Kinzler, Kenneth W.
; APPLICANT: Vogelstein, Bert
; TITLE OF INVENTION: Human Transcriptomes
; FILE REFERENCE: 001107.00319
; CURRENT APPLICATION NUMBER: US/10/330,627
; CURRENT FILING DATE: 2002-12-30
; PRIOR APPLICATION NUMBER: US 09/448,480
; PRIOR FILING DATE: 1999-11-24
; NUMBER OF SEQ ID NOS: 1564
; SOFTWARE: FastSeq For Windows Version 4.0
; SEQ ID NO 1311
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-330-627-1311

Query Match      29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 21;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2221 CCAAAAGT 2228
Db 9 CCAAAAGT 2

RESULT 30
US-10-091-281-239
; Sequence 239, Application US/10091281
; Publication No. US20030190617A1
; GENERAL INFORMATION:
; APPLICANT: RAYMOND, VINCENT
; APPLICANT: SI, ERWIN
; APPLICANT: MORISSETTE, JEAN
; TITLE OF INVENTION: OPTINEURIN NUCLEIC ACID MOLECULES AND USES THEREOF
; FILE REFERENCE: 13587.338
; CURRENT APPLICATION NUMBER: US/10/091,281
; CURRENT FILING DATE: 2002-03-06
; NUMBER OF SEQ ID NOS: 463
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 239
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Putative VBPF/VBP.01 motif
US-10-091-281-239

Query Match      29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 21;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2228 TTACATGT 2235
Db 2 TTACATGT 9

RESULT 31
US-10-160-401-28
; Sequence 28, Application US/10160401
; Publication No. US20030207281A1
; GENERAL INFORMATION:
; APPLICANT: Genalsance Pharmaceuticals, Inc.
; APPLICANT: Bentivegna, Steven C.
; APPLICANT: Biesiecki, Karyn M.
; APPLICANT: Koshy, Beena
; APPLICANT: Monroe, Glen
```

```

; APPLICANT: Rounds, Eileen
; TITLE OF INVENTION: HAPLOTYPES OF THE CXCR4 GENE
; FILE REFERENCE: MHH-0121US
; CURRENT APPLICATION NUMBER: US/10/160,401
; CURRENT FILING DATE: 2002-05-03
; PRIOR APPLICATION NUMBER: PCT/US01/12268
; PRIOR FILING DATE: 2001-04-13
; PRIOR APPLICATION NUMBER: US 60/197,025
; PRIOR FILING DATE: 2000-04-13
; NUMBER OF SEQ ID NOS: 31
; SOFTWARE: Patent version 3.1
; SEQ ID NO 28
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-160-401-28

```

```

Query Match      29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred.No. 21;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 2223 AAAAGTTA 2230
    |||||
Db 3 AAAAGTTA 10

```

Search completed: November 18, 2004, 08:18:59
Job time : 0.001 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 18, 2004, 08:20:33 ; Search time 0.001 Seconds
(without alignments)
9.828 Million cell updates/sec

Title: US-10-006-191-19

Perfect score: 27
Sequence: 1 agagtgtaccacaaagtacatgtttg 27

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 17 seqs, 182 residues

Total number of hits satisfying chosen parameters: 34

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 18 summaries

Database : rst19.seq *

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query %	Match	Length	DB ID	Description
C 1	12.8	47.4	17	1	AJ592065	ACCESSION:AJ592065
C 2	9.4	34.8	12	1	AJ587276	ACCESSION:AJ587276
C 3	9.4	34.8	13	1	CAB51722	ACCESSION:CAB51722
C 4	8.8	32.6	12	1	AJ587214	ACCESSION:AJ587214
C 5	8.4	31.1	10	1	AJ587288	ACCESSION:AJ587288
C 6	8.4	31.1	10	1	CL437117	ACCESSION:CL437117
C 7	8.4	31.1	10	1	CL437320	ACCESSION:CL437320
C 8	8	29.6	10	1	CL438191	ACCESSION:CL438191
C 9	7.4	27.4	10	1	AJ587436	ACCESSION:AJ587436
C 10	7.4	27.4	10	1	AJ587438	ACCESSION:AJ587438
C 11	7.4	27.4	10	1	CL435950	ACCESSION:CL435950
C 12	7.4	27.4	10	1	CL439224	ACCESSION:CL439224
C 13	7	25.9	10	1	CL436271	ACCESSION:CL436271
C 14	7	25.9	10	1	CL437495	ACCESSION:CL437495
C 15	7	25.9	10	1	CL437824	ACCESSION:CL437824
C 16	7	25.9	12	1	AJ587214	ACCESSION:AJ587214
C 17	6.4	23.7	9	1	CF300175	ACCESSION:CF300175
C 18	6.4	23.7	9	1	CF301840	ACCESSION:CF301840

ALIGNMENTS

RESULT 1
AJ592065/c
LOCUS
DEFINITION Arabidopsis thaliana T-DNA flanking sequence, right border, clone
602E03, genomic survey sequence.
ACCESSION AJ592065
VERSION AJ592065.1 GI:37941689
KEYWORDS GSS; right border; T-DNA flanking sequence.
SOURCE Arabidopsis thaliana (thale cress)
ORGANISM Arabidopsis thaliana

REFERENCE AUTHORS

TITLE

JOURNAL MEDLINE

REFERENCE PUBMED

REFERENCE AUTHORS

TITLE

JOURNAL

COMMENT

FEATURES source

1. .17
Location/Qualifiers
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassiljewskija"
/db_xref="taxon:3702"
/clone="602E03"
misc_feature
1. .17
/note="T-DNA flanking sequence
right border"

Query Match 47.4%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 0.18;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2223 AAAAGTACATCTTTG 2238

Db 17 AAAAGTACATCTTTG 2

RESULT 2 AJ587276/c

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE AUTHORS

TITLE

JOURNAL MEDLINE

REFERENCE PUBMED

REFERENCE AUTHORS

Bukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

1

Brunaud, V., Balzergue, S., Dubreucq, B., Aubourg, S., Samson, F.,
Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G.,
Lepiniec, L., Caboche, M. and Lecharny, A.

T-DNA integration into the Arabidopsis genome depends on sequences
of pre-insertion sites

EMBO Rep. 3 (12), 1152-1157 (2002)

22363535

12446565

2 (bases 1 to 17)

Balzergue, S.

Direct Submission

Submitted (23-OCT-2003) Balzergue S., UMRGV, INRA/CNRS, 2 rue

Gaston Cremieux, 91057 Evry cedex, FRANCE

PCR was performed on DNA from transformants of Arabidopsis thaliana
plants from INRA (Versailles). The DNA fragment(s) resulting from

the PCR were directly sequenced from the left or the right border
to determine the genomic sequence flanking the insertion. T-DNA

derived sequences were removed. Information to order the
corresponding mutant line and a link to a database providing a

graphical display of the insertion site are available at
<http://dbgap.versailles.inra.fr/publiclines/>. This sequence has

been generated in the framework of the French plant genomics
program 'Genoplante' (<http://www.genoplante.com> and
<http://genoplante-info.inbio.gen.fr>).

/clone_lib="Arabidopsis thaliana T-DNA insertion lines"

12 bp DNA linear GSS 15-JAN-2004

Arabidopsis thaliana T-DNA flanking sequence, left border, clone

257E01, genomic survey sequence.

AJ587276

AJ587276.1 GI:37936865

GSS; left border; T-DNA flanking sequence.

Arabidopsis thaliana (thale cress)

Arabidopsis thaliana

Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;

Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;

rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

1

Brunaud, V., Balzergue, S., Dubreucq, B., Aubourg, S., Samson, F.,
Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G.,
Lepiniec, L., Caboche, M. and Lecharny, A.

T-DNA integration into the Arabidopsis genome depends on sequences
of pre-insertion sites

EMBO Rep. 3 (12), 1152-1157 (2002)

22363535

12446565

2 (bases 1 to 12)

Balzergue, S.

TITLE
JOURNAL

COMMENT
Direct Submission
Submitted (23-OCT-2003) Balzergue S., UMRGV, INRA/CNRS, 2 rue Gaston Cremieux, 91057 Evry cedex, FRANCE
PCR was performed on DNA from transformants of Arabidopsis thaliana plants from INRA (Versailles). The DNA fragment(s) resulting from the PCR were directly sequenced from the left or the right border to determine the genomic sequence flanking the insertion. T-DNA derived sequences were removed. Information to order the corresponding mutant line and a link to a database providing a graphical display of the insertion site are available at <http://dbsgap.versailles.inra.fr/publiclines/>. This sequence has been generated in the framework of the French plant genomics program 'Genoplante' (<http://www.genoplante.com> and <http://genoplante-info.infobiogen.fr>).
Location/Qualifiers
1. .12
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassiljewskija"
/db_xref="taxon:3702"
/clone="257501"
/clone_lib="Arabidopsis thaliana T-DNA insertion lines"
misc_feature
1. .12
/note="T-DNA flanking sequence
left border"

Query Match 34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2.3;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACAT 2233
|||||
Db 11 AAAATTACAT 1

RESULT 3
LOCUS CA851722
DEFINITION D16G12_N24.14.abi cDNA Peking library 2, 4 day SCN3 Glycine max
cDNA clone D16G12.5', mRNA sequence.
ACCESSION CA851722
VERSION CA851722.1 GI:33388515
KEYWORDS EST.
SOURCE Glycine max (soybean)
ORGANISM Glycine max
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids; eurosids I; Fabales; Fabaceae; Papilionoideae; Phaseoleae; Glycine.

REFERENCE
1 (bases 1 to 13)
AUTHORS Alkharouf, N.W., Khan, R. and Matthews, B.F.
TITLE Analysis of expressed sequence tags from roots of resistant soybean infected by the soybean cyst nematode
JOURNAL Unpublished (2002)
COMMENT Contact: Alkharouf, N.W.
Soybean Genomics and Improvement Laboratory (SGIL)
US Department of Agriculture (USDA), ARS, PSI
Bldg.006, Rm 118, 10300 Baltimore Ave., Beltsville, MD 20705-2350, USA
Tel: 301 504 5750
Fax: 301 504 5728
Email: alkharouf@ba.ars.usda.gov.
Location/Qualifiers
1. .13
/organism="Glycine max"
/mol_type="mRNA"
/cultivar="Peking"
/db_xref="taxon:3847"
/clone="D16G12"
/tissue_type="Roots"
/dev_stage="Seedlings"
/clone_lib="cDNA Peking library 2, 4 day SCN3"
/note="Vector: pBluescript SK-; cDNA clones from mRNA

extracted from Peking roots 2 and 4 days past invasion."

Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 76.9%; Pred. No. 2.1;
Matches 10; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2223 AAAAGTTACATGT 2235
|||||
Db 1 AAAAATACATNT 13

RESULT 4
LOCUS AJ587214
DEFINITION Arabidopsis thaliana T-DNA flanking sequence, left border, clone 243A02, genomic survey sequence.
ACCESSION AJ587214
VERSION AJ587214.1 GI:37936803
KEYWORDS GSS; left border; T-DNA flanking sequence.
SOURCE Arabidopsis thaliana (thale cress)
ORGANISM Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsi.

REFERENCE
1
AUTHORS Brunaud, V., Balzergue, S., Dubreucq, B., Aubourg, S., Samson, F., Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G., Lepiniec, L., Caboche, M. and Lecharny, A.
TITLE T-DNA integration into the Arabidopsis genome depends on sequences of pre-insertion sites
JOURNAL EMBO Rep. 3 (12), 1152-1157 (2002)
MEDLINE 22363535
PUBMED 12446565
REFERENCE 2 (bases 1 to 12)
AUTHORS Balzergue, S.
TITLE Direct Submission
JOURNAL Submitted (23-OCT-2003) Balzergue S., UMRGV, INRA/CNRS, 2 rue Gaston Cremieux, 91057 Evry cedex, FRANCE
COMMENT PCR was performed on DNA from transformants of Arabidopsis thaliana plants from INRA (Versailles). The DNA fragment(s) resulting from the PCR were directly sequenced from the left or the right border to determine the genomic sequence flanking the insertion. T-DNA derived sequences were removed. Information to order the corresponding mutant line and a link to a database providing a graphical display of the insertion site are available at <http://dbsgap.versailles.inra.fr/publiclines/>. This sequence has been generated in the framework of the French plant genomics program 'Genoplante' (<http://www.genoplante.com> and <http://genoplante-info.infobiogen.fr>).
Location/Qualifiers
1. .12
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassiljewskija"
/db_xref="taxon:3702"
/clone="243A02"
/clone_lib="Arabidopsis thaliana T-DNA insertion lines"
misc_feature
1. .12
/note="T-DNA flanking sequence
left border"

Query Match 32.6%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 3.3;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2226 AGTTACATGTTT 2237
|||||
Db 1 AATAACATGTTT 12

RESULT 5
LOCUS AJ587288/c
DEFINITION Arabidopsis thaliana T-DNA flanking sequence, left border, clone 243A02, genomic survey sequence.
ACCESSION AJ587288
VERSION AJ587288.1 GI:37936804
KEYWORDS GSS; left border; T-DNA flanking sequence.
SOURCE Arabidopsis thaliana (thale cress)
ORGANISM Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsi.

```

DEFINITION Arabidopsis thaliana T-DNA flanking sequence, left border, clone
259D10, genomic survey sequence.
ACCESSION AJ587288.1 GI:37936877
VERSION GSS; left border; T-DNA flanking sequence.
KEYWORDS Arabidopsis thaliana (thale cress)
SOURCE Arabidopsis thaliana
ORGANISM Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids I; Brassicales; Brassicaceae; Arabidopsids.
REFERENCE 1
AUTHORS Brunaud,V., Balzergue,S., Dubreucq,B., Aubourg,S., Samson,F.,
Chauvin,S., Bechtold,N., Cruaud,C., DeRose,R., Pelletier,G.,
Leplincic,L., Caboche,M. and Leclarmy,A.
TITLE T-DNA integration into the Arabidopsis genome depends on sequences
of pre-insertion sites
JOURNAL EMBO Rep. 3 (12), 1152-1157 (2002)
MEDLINE 22363535
PUBMED 12446565
REFERENCE 2 (bases 1 to 10)
AUTHORS Balzergue,S.
TITLE Direct Submission
JOURNAL Submitted (23-OCT-2003) Balzergue S., UMRGV, INRA/CNRS, 2 rue
Gaston Cremieux, 91057 Evry cedex, FRANCE
COMMENT PCR was performed on DNA from transformants of Arabidopsis thaliana
plants from INRA (Versailles). The DNA fragment(s) resulting from
the PCR were directly sequenced from the left or the right border
to determine the genomic sequence flanking the insertion. T-DNA
derived sequences were removed. Information to order the
corresponding mutant line and a link to a database providing a
graphical display of the insertion site are available at
http://dbsgap.versailles.inra.fr/publiclines/. This sequence has
been generated in the framework of the French plant genomics
program 'Genoplante' (http://www.genoplante.com and
http://genoplante-info.infobiogen.fr).

FEATURES
    source
        Location/Qualifiers
            1..10
                /organism="Arabidopsis thaliana"
                /mol_type="genomic DNA"
                /cultivar="Wassilewskij"
                /db_xref="taxon:3702"
                /clone="259D10"
                /clone_lib="Arabidopsis thaliana T-DNA insertion lines"
            1..10
                /notes="T-DNA flanking sequence
                left border"

    misc_feature
        31.1%; Score 8.4; DB 1; Length 10;
        Best Local Similarity 90.0%; Pred. No. 5;
        Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Query Match
Best Local Similarity 90.0%; Pred. No. 5;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Cy 2224 AAGTTACAT 2233
Db 10 AAGTTGCAT 1

RESULT 6
CL437117/c
LOCUS CL437117
DEFINITION PST4537-NL.Seq MICB1 Mus musculus genomic clone PST4537-NL.Seq,
genomic survey sequence.
ACCESSION CL437117
VERSION CL437117.1 GI:45572568
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
REFERENCE 1 (bases 1 to 10)
AUTHORS Hicks G.G.
TITLE www.Escells.ca
JOURNAL Unpublished (2002)
COMMENT Contact: Hicks GG

Mammalian Functional Genomics Centre
Manitoba Institute of Cell Biology, University of Manitoba
CN5029, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada
Tel: 204 787 2133
Fax: 204 787 2190
Email: hicks@cc.umanitoba.ca
U3NeosV1 gene trap. Tag generated by plasmid rescue. Additional
sequence information and target gene cloning can be generated. ES
cell line harboring insertion mutation of target gene is available.
Sequence analysis available from
http://140.193.242.7/esdb/public_search_frame.php?PST=PST4537-NL.Se
q
Class: Gene Trap.
Location/Qualifiers
    1..10
        /organism="Mus musculus"
        /mol_type="genomic DNA"
        /strain="129 sv"
        /db_xref="taxon:10090"
        /clone="PST4537-NL.Seq"
        /sex="Male"
        /cell_type="Embryonic stem cell"
        /cell_lines="D3H (J1 subclone)"
        /clone_lib="MICB1"
        /note="Vector: U3NeosV1"

Query Match
Best Local Similarity 90.0%; Pred. No. 5;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Cy 2225 AAGTTACATG 2234
Db 10 AAGTCACATG 1

RESULT 7
CL437320/c
LOCUS CL437320
DEFINITION PST5052-NL.Seq MICB1 Mus musculus genomic clone PST5052-NL.Seq,
genomic survey sequence.
ACCESSION CL437320
VERSION CL437320.1 GI:45572935
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
REFERENCE 1 (bases 1 to 10)
AUTHORS Hicks G.G.
TITLE www.Escells.ca
JOURNAL Unpublished (2002)
COMMENT Contact: Hicks GG

Mammalian Functional Genomics Centre
Manitoba Institute of Cell Biology, University of Manitoba
CN5029, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada
Tel: 204 787 2133
Fax: 204 787 2190
Email: hicks@cc.umanitoba.ca
U3NeosV1 gene trap. Tag generated by plasmid rescue. Additional
sequence information and target gene cloning can be generated. ES
cell line harboring insertion mutation of target gene is available.
Sequence analysis available from
http://140.193.242.7/esdb/public_search_frame.php?PST=PST5052-NL.Se
q
Class: Gene Trap.
Location/Qualifiers
    1..10
        /organism="Mus musculus"
        /mol_type="genomic DNA"
        /strain="129 sv"
        /db_xref="taxon:10090"
        /clone="PST5052-NL.Seq"
        /sex="Male"

```

```

Mammalian Functional Genomics Centre
Manitoba Institute of Cell Biology, University of Manitoba
CN5029, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada
Tel: 204 787 2133
Fax: 204 787 2190
Email: hicks@cc.umanitoba.ca
U3NeosV1 gene trap. Tag generated by plasmid rescue. Additional
sequence information and target gene cloning can be generated. ES
cell line harboring insertion mutation of target gene is available.
Sequence analysis available from
http://140.193.242.7/esdb/public_search_frame.php?PST=PST4537-NL.Se
q
Class: Gene Trap.
Location/Qualifiers
    1..10
        /organism="Mus musculus"
        /mol_type="genomic DNA"
        /strain="129 sv"
        /db_xref="taxon:10090"
        /clone="PST4537-NL.Seq"
        /sex="Male"

Query Match
Best Local Similarity 90.0%; Pred. No. 5;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Cy 2225 AAGTTACATG 2234
Db 10 AAGTCACATG 1

RESULT 7
CL437320/c
LOCUS CL437320
DEFINITION PST5052-NL.Seq MICB1 Mus musculus genomic clone PST5052-NL.Seq,
genomic survey sequence.
ACCESSION CL437320
VERSION CL437320.1 GI:45572935
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
REFERENCE 1 (bases 1 to 10)
AUTHORS Hicks G.G.
TITLE www.Escells.ca
JOURNAL Unpublished (2002)
COMMENT Contact: Hicks GG

Mammalian Functional Genomics Centre
Manitoba Institute of Cell Biology, University of Manitoba
CN5029, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada
Tel: 204 787 2133
Fax: 204 787 2190
Email: hicks@cc.umanitoba.ca
U3NeosV1 gene trap. Tag generated by plasmid rescue. Additional
sequence information and target gene cloning can be generated. ES
cell line harboring insertion mutation of target gene is available.
Sequence analysis available from
http://140.193.242.7/esdb/public_search_frame.php?PST=PST5052-NL.Se
q
Class: Gene Trap.
Location/Qualifiers
    1..10
        /organism="Mus musculus"
        /mol_type="genomic DNA"
        /strain="129 sv"
        /db_xref="taxon:10090"
        /clone="PST5052-NL.Seq"
        /sex="Male"

```

```

/cell_type="Embryonic stem cell"
/cell_line="D3H (J1 subclone)"
/clone_lib="MICB1"
/notes="Vector: U3NeoSV1"

Query Match      31.1%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 5;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2225 AAGTTACATG 2234
Db 10 AGTTACATG 1

RESULT 8
CL438191
LOCUS
DEFINITION PST6982-NL.Seq MICB1 Mus musculus genomic clone PST6982-NL.Seq
similar to Gf2a1, genomic survey sequence.
ACCESSION CL438191
VERSION CL438191.1 GI:45574499
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
Hicks,G.G.
1 (bases 1 to 10)
www.Escellis.ca
Unpublished (2002)
Contact: Hicks GG
Mammalian Functional Genomics Centre
Manitoba Institute of Cell Biology, University of Manitoba
ONS029, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada
Tel: 204 787 2133
Fax: 204 787 2190
Email: hicksgg@cc.umanitoba.ca
U3NeoSV1 gene trap. Tag generated by plasmid rescue. Additional
sequence information and target gene cloning can be generated. ES
cell line harboring insertion mutation of target gene is available.
Sequence analysis available from
http://140.193.242.7/esdb/public_search_frame.php?PST=PST6982-NL.Se
q
Class: Gene Trap.
Location/Qualifiers
source
1..10
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="129 sv"
/db_xref="taxon:10090"
/clone="PST6982-NL.Seq"
/sex="Male"
/cell_type="Embryonic stem cell"
/cell_line="D3H (J1 subclone)"
/clone_lib="MICB1"
/notes="Vector: U3NeoSV1"

Query Match      29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 6.4;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2231 CATGTTTG 2238
Db 1 CATGTTTG 8

RESULT 9
AJ587436
LOCUS
DEFINITION Arabidopsis thaliana T-DNA flanking sequence, left border, clone
277E10, genomic survey sequence.
ACCESSION AJ587436
VERSION AJ587436.1 GI:37937060

/cell_type="Embryonic stem cell"
/cell_line="D3H (J1 subclone)"
/clone_lib="MICB1"
/notes="Vector: U3NeoSV1"

Query Match      29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 6.4;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2231 CATGTTTG 2238
Db 1 CATGTTTG 8

RESULT 9
AJ587436
LOCUS
DEFINITION Arabidopsis thaliana T-DNA flanking sequence, left border, clone
277E10, genomic survey sequence.
ACCESSION AJ587436
VERSION AJ587436.1 GI:37937060

```

```

GSS, left border; T-DNA flanking sequence.
Arabidopsis thaliana (thale cress)
Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
1
Brunaud,V., Balzergue,S., Dubreucq,B., Aubourg,S., Samson,F.,
Chauvin,S., Bechtold,N., Cruaud,C., Derose,R., Pelletier,G.,
Lepiniec,L., Caboche,M. and Lecharny,A.
T-DNA integration into the Arabidopsis genome depends on sequences
of pre-insertion sites
EMBO Rep. 3 (12), 1152-1157 (2002)
JOURNAL
MEDLINE 22363535
PUBMED 12446585
REFERENCE
2 (bases 1 to 10)
Balzergue,S.
Direct Submission
Submitted (23-OCT-2003) Balzergue S., UMRGV, INRA/CNRS, 2 rue
Gaston Cremieux, 91057 Evry cedex, FRANCE
PCR was performed on DNA from transformants of Arabidopsis thaliana
plants from INRA (Versailles). The DNA fragment(s) resulting from
the PCR were directly sequenced from the left or the right border
to determine the genomic sequence flanking the insertion. T-DNA
derived sequences were removed. Information to order the
corresponding mutant line and a link to a database providing a
graphical display of the insertion site are available at
http://dbgap.versailles.inra.fr/publiclines/. This sequence has
been generated in the framework of the French plant genomics
program 'Genoplante' (http://www.genoplante.com and
http://genoplante-info.infobiogen.fr/).
Location/Qualifiers
source
1..10
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassilewskija"
/db_xref="taxon:3702"
/clone="277E10"
/clone_lib="Arabidopsis thaliana T-DNA insertion lines"
/misc_feature 1..10
/notes="T-DNA flanking sequence
left border"

Query Match      27.4%; Score 7.4; DB 1; Length 10;
Best Local Similarity 88.9%; Pred. No. 9;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2229 TACATGTTT 2237
Db 1 TTCAATGTTT 9

RESULT 10
AJ587438
LOCUS
DEFINITION Arabidopsis thaliana T-DNA flanking sequence, left border, clone
277H05, genomic survey sequence.
ACCESSION AJ587438
VERSION AJ587438.1 GI:37937062
KEYWORDS GSS; left border; T-DNA flanking sequence.
SOURCE Arabidopsis thaliana (thale cress)
ORGANISM Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
1
Brunaud,V., Balzergue,S., Dubreucq,B., Aubourg,S., Samson,F.,
Chauvin,S., Bechtold,N., Cruaud,C., Derose,R., Pelletier,G.,
Lepiniec,L., Caboche,M. and Lecharny,A.
T-DNA integration into the Arabidopsis genome depends on sequences
of pre-insertion sites
EMBO Rep. 3 (12), 1152-1157 (2002)
JOURNAL
MEDLINE 22363535

```

```

PUBMED
REFERENCE 12446565
AUTHORS Balzergue,S.
TITLE Direct Submission
JOURNAL Submitted (23-OCT-2003) Balzergue S., UMRGV, INRA/CNRS, 2 rue
COMMENT PCR was performed on DNA from transformants of Arabidopsis thaliana
Gaston Cremieux, 91057 Evry cedex, FRANCE
plants from INRA (Versailles). The DNA fragment(s) resulting from
the PCR were directly sequenced from the left or the right border
to determine the genomic sequence flanking the insertion. T-DNA
derived sequences were removed. Information to order the
corresponding mutant line and a link to a database providing a
graphical display of the insertion site are available at
http://dbgap.versailles.inra.fr/publiclines/. This sequence has
been generated in the framework of the French plant genomics
program "Genoplante" (http://www.genoplante.com and
http://genoplante-info.inbio.gen.fr).

FEATURES
source
1..10
Location/Qualifiers
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Waslillewskija"
/db_xref="taxon:3702"
/clone="277H05"
/clone_lib="Arabidopsis thaliana T-DNA insertion lines"
misc_feature 1..10
/note="T-DNA flanking sequence
left border"

Query Match 27.4%; Score 7.4; DB 1; Length 10;
Best Local Similarity 88.9%; Pred. No. 9;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2229 TACATGTTT 2237
Db 1 TTCAATTT 9

RESULT 11
CL435950/c
LOCUS 10 bp DNA linear GSS 18-MAR-2004
DEFINITION PST2011-NL.Seq MICB1 Mus musculus genomic clone PST2011-NL.Seq
similar to 2310003G12Rik, genomic survey sequence.
ACCESSION CL435950
VERSION CL435950.1 GI:45570151
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
Hicks,G.G.
www.EScells.ca
Unpublished (2002)
Contact: Hicks GG
Mammalian Functional Genomics Centre
Manitoba Institute of Cell Biology, University of Manitoba
ON5029, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada
Tel: 204 787 2133
Fax: 204 787 2190
Email: hicksgg@cc.umanitoba.ca
U3NeosV1 gene trap. Tag generated by plasmid rescue. Additional
sequence information and target gene cloning can be generated. ES
cell line harboring insertion mutation of target gene is available.
Sequence analysis available from
http://140.193.242.7/esdb/public_search_frame.php?PST=PST2011-NL.Se
q
Class: Gene Trap.
Location/Qualifiers
1..10
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="129 sv"
/db_xref="taxon:10090"
/clone="PST8889-NL.Seq"
/sex="Male"
/cell_type="Embryonic stem cell"
/cell_line="D3H (J1 subclone)"
/clone_lib="MICB1"
/clone_vector="U3NeosV1"

FEATURES
source
1..10
Location/Qualifiers
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="129 sv"
/db_xref="taxon:10090"
/clone="PST8889-NL.Seq"
/sex="Male"
/cell_type="Embryonic stem cell"
/cell_line="D3H (J1 subclone)"
/clone_lib="MICB1"
/clone_vector="U3NeosV1"

Query Match 27.4%; Score 7.4; DB 1; Length 10;
Best Local Similarity 88.9%; Pred. No. 9;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2226 AGTTACATG 2234
Db 9 AGATACATG 1

RESULT 12
CL439224/c
LOCUS 10 bp DNA linear GSS 18-MAR-2004
DEFINITION PST8889-NL.Seq MICB1 Mus musculus genomic clone PST8889-NL.Seq,
genomic survey sequence.
ACCESSION CL439224
VERSION CL439224.1 GI:45576538
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
Hicks,G.G.
www.EScells.ca
Unpublished (2002)
Contact: Hicks GG
Mammalian Functional Genomics Centre
Manitoba Institute of Cell Biology, University of Manitoba
ON5029, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada
Tel: 204 787 2133
Fax: 204 787 2190
Email: hicksgg@cc.umanitoba.ca
U3NeosV1 gene trap. Tag generated by plasmid rescue. Additional
sequence information and target gene cloning can be generated. ES
cell line harboring insertion mutation of target gene is available.
Sequence analysis available from
http://140.193.242.7/esdb/public_search_frame.php?PST=PST8889-NL.Se
q
Class: Gene Trap.
Location/Qualifiers
1..10
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="129 sv"
/db_xref="taxon:10090"
/clone="PST8889-NL.Seq"
/sex="Male"
/cell_type="Embryonic stem cell"
/cell_line="D3H (J1 subclone)"
/clone_lib="MICB1"
/clone_vector="U3NeosV1"

FEATURES
source
1..10
Location/Qualifiers
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="129 sv"
/db_xref="taxon:10090"
/clone="PST8889-NL.Seq"
/sex="Male"
/cell_type="Embryonic stem cell"
/cell_line="D3H (J1 subclone)"
/clone_lib="MICB1"
/clone_vector="U3NeosV1"

Query Match 27.4%; Score 7.4; DB 1; Length 10;
Best Local Similarity 88.9%; Pred. No. 9;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2226 AGTTACATG 2234
Db 9 AGATACATG 1

RESULT 13
CL436271/c
LOCUS 10 bp DNA linear GSS 18-MAR-2004
DEFINITION PST2633-NR.Seq MICB1 Mus musculus genomic clone PST2633-NR.Seq

```

similar to Zfp162, genomic survey sequence.

ACCESSION CL436271
 VERSION CL436271.1 GI:45570909
 KEYWORDS GSS.
 SOURCE Mus musculus (house mouse)
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 10)
 HICKS.G.G.
 www.EScells.ca
 Unpublished (2002)
 CONTACT: Hicks GG
 Mammalian Functional Genomics Centre
 Manitoba Institute of Cell Biology, University of Manitoba
 ON5029, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada
 Tel: 204 787 2133
 Fax: 204 787 2190
 Email: hicksgg@cc.umanitoba.ca
 U3NeoSV1 gene trap. Tag generated by plasmid rescue. Additional sequence information and target gene cloning can be generated. ES cell line harboring insertion mutation of target gene is available. Sequence analysis available from
 http://140.193.242.7/esdb/public_search_frame.php?PST=PST2633-NR.Se

q
 Class: Gene Trap.

FEATURES
 source
 Location/Qualifiers
 1..10
 /organism="Mus musculus"
 /mol_type="genomic DNA"
 /strain="129 sv"
 /db_xref="taxon:10090"
 /clone="PST2633-NR.Seq"
 /sex="Male"
 /cell_type="Embryonic stem cell"
 /cell_line="D3H (J1 subclone)"
 /clone_lib="MICB1"
 /note="Vector: U3NeoSV1"

Query Match 25.9%; Score 7; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 11;
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2218 TGACCAA 2224
 |||||
 Db 7 TGACCAA 1

RESULT 14
 CL437495
 LOCUS 10 bp DNA linear GSS 18-MAR-2004
 DEFINITION PST5634-NL.Seq MICB1 Mus musculus genomic clone PST5634-NL.Seq, genomic survey sequence.
 ACCESSION CL437495
 VERSION CL437495.1 GI:45573235
 KEYWORDS GSS.
 SOURCE Mus musculus (house mouse)
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 10)
 HICKS.G.G.
 www.EScells.ca
 Unpublished (2002)
 CONTACT: Hicks GG
 Mammalian Functional Genomics Centre
 Manitoba Institute of Cell Biology, University of Manitoba
 ON5029, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada
 Tel: 204 787 2133
 Fax: 204 787 2190
 Email: hicksgg@cc.umanitoba.ca
 U3NeoSV1 gene trap. Tag generated by plasmid rescue. Additional sequence information and target gene cloning can be generated. ES

cell line harboring insertion mutation of target gene is available. Sequence analysis available from
 http://140.193.242.7/esdb/public_search_frame.php?PST=PST5634-NL.Se

q

Class: Gene Trap.
 Location/Qualifiers
 1..10
 /organism="Mus musculus"
 /mol_type="genomic DNA"
 /strain="129 sv"
 /db_xref="taxon:10090"
 /clone="PST5634-NL.Seq"
 /sex="Male"
 /cell_type="Embryonic stem cell"
 /cell_line="D3H (J1 subclone)"
 /clone_lib="MICB1"
 /note="Vector: U3NeoSV1"

Query Match 25.9%; Score 7; DB 1; Length 10;
 Best Local Similarity 87.5%; Pred. No. 11;
 Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2231 CATGTTTG 2238
 |||||
 Db 1 CATGTTG 8

RESULT 15
 CL437824/c
 LOCUS 10 bp DNA linear GSS 18-MAR-2004
 DEFINITION PST6362-NR.Seq MICB1 Mus musculus genomic clone PST6362-NR.Seq, genomic survey sequence.
 ACCESSION CL437824
 VERSION CL437824.1 GI:45573802
 KEYWORDS GSS.
 SOURCE Mus musculus (house mouse)
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 10)
 HICKS.G.G.
 www.EScells.ca
 Unpublished (2002)
 CONTACT: Hicks GG
 Mammalian Functional Genomics Centre
 Manitoba Institute of Cell Biology, University of Manitoba
 ON5029, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada
 Tel: 204 787 2133
 Fax: 204 787 2190
 Email: hicksgg@cc.umanitoba.ca
 U3NeoSV1 gene trap. Tag generated by plasmid rescue. Additional sequence information and target gene cloning can be generated. ES cell line harboring insertion mutation of target gene is available. Sequence analysis available from
 http://140.193.242.7/esdb/public_search_frame.php?PST=PST6362-NR.Se

q

Class: Gene Trap.
 Location/Qualifiers
 1..10
 /organism="Mus musculus"
 /mol_type="genomic DNA"
 /strain="129 sv"
 /db_xref="taxon:10090"
 /clone="PST6362-NR.Seq"
 /sex="Male"
 /cell_type="Embryonic stem cell"
 /cell_line="D3H (J1 subclone)"
 /clone_lib="MICB1"
 /note="Vector: U3NeoSV1"

Query Match 25.9%; Score 7; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 11;
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY      2221  CCAAAG 2227
SOURCE  |||||
ORGANISM

RESULT 16
AJ587214/c
LOCUS   AJ587214.1 12 bp DNA linear GSS 15-JAN-2004
DEFINITION Arabidopsis thaliana T-DNA flanking sequence, left border, clone 243A02, genomic survey sequence.
ACCESSION AJ587214.1 GI:37936803
VERSION   AJ587214.1
KEYWORDS  GSS; left border; T-DNA flanking sequence.
SOURCE    Arabidopsis thaliana (thale cress)
ORGANISM  Arabidopsis thaliana
          Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
          Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
          rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsi.

REFERENCE
AUTHORS  Brunaud,V., Balzerque,S., Dubreucq,B., Aubourg,S., Samson,F.,
          Chauvin,S., Bechtold,M., Cruaud,C., Dekose,R., Pelletier,G.,
          Lepiniec,L., Caboche,M. and Lecharny,A.
TITLE     T-DNA integration into the Arabidopsis genome depends on sequences
          of pre-insertion sites
JOURNAL   EMBO Rep. 3 (12), 1152-1157 (2002)
MEDLINE   22363535
PUBMED   12446565
REFERENCE 2 (bases 1 to 12)
AUTHORS   Balzerque,S.
TITLE     Direct Submission
JOURNAL   Submitted (23-OCT-2003) Balzerque S., UMRGV, INRA/CNRS, 2 rue
          Gaston Cremieux, 91057 Evry cedex, FRANCE
COMMENT   PCR was performed on DNA from transformants of Arabidopsis thaliana
          plants from INRA (Versailles). The DNA fragment(s) resulting from
          the PCR were directly sequenced from the left or the right border
          to determine the genomic sequence flanking the insertion. T-DNA
          derived sequences were removed. Information to order the
          corresponding mutant line and a link to a database providing a
          graphical display of the insertion site are available at
          http://dbsgap.versailles.inra.fr/publiclines/. This sequence has
          been generated in the framework of the French plant genomics
          program 'Genoplante' (http://www.genoplante.com and
          http://genoplante-info.infobiogen.fr).

FEATURES             source
   source
   1..12
   /organism="Arabidopsis thaliana"
   /mol_type="genomic DNA"
   /cultivar="Massillewskija"
   /db_xref="taxon:3702"
   /clone="243A02"
   /note="T-DNA insertion lines"

misc_feature         1..12
   /note="T-DNA flanking sequence
   left border"

Query Match      25.98; Score 7; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 9.3;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2230  ACATGTT 2236
SOURCE  |||||
ORGANISM

RESULT 17
CF300175
LOCUS   CF300175.1 9 bp mRNA linear EST 15-AUG-2003
DEFINITION 7LEAF--04-H16.g1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
          sativa (japonica cultivar-group) cDNA clone 7LEAF--04-H16, mRNA
          sequence.
ACCESSION CF300175
VERSION   CF300175.1 GI:33671936

```

```

KEYWORDS  Oryza sativa (japonica cultivar-group)
SOURCE     Oryza sativa (japonica cultivar-group)
ORGANISM   Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
          Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
          Ehrhartoideae; Oryzae; Oryza.

REFERENCE 1 (bases 1 to 9)
AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
          Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
TITLE     Large-scale Sequencing Analysis of Rice ESTs
JOURNAL   Unpublished (2003)
COMMENT   Contact: Nahm B.H.
          Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
          of Bioscience and Bioinformatics, Myongji University
          Yongin, Kyeonggi, Korea
          Tel: 82 31 330 6193
          Fax: 82 31 321 6355
          Email: bhnaah@gbio.com, bhnaah@bio.myongji.ac.kr.
          Location/Qualifiers
            1..9
            /organism="Oryza sativa (japonica cultivar-group)"
            /mol_type="mRNA"
            /cultivar="Nackdong"
            /db_xref="taxon:39947"
            /clone="7LEAF--04-H16"
            /tissue_type="leaf"
            /dev_stage="7 days after germination"
            /lab_host="E.coli DH10B"
            /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
            /note="Vector: PCR4-TOPO; Site 1: EcoRI; mRNA was capped
            with oligoribonucleotides and then used as templates for
            RT-PCR."

Query Match      23.7%; Score 6.4; DB 1; Length 9;
Best Local Similarity 87.5%; Pred. No. 36;
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2223  AAAAGTTA 2230
SOURCE  |||||
ORGANISM   2 AAAAATTA 9

RESULT 18
CF301840
LOCUS   CF301840.1 9 bp mRNA linear EST 15-AUG-2003
DEFINITION 7LEAF--06-N14.g1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
          sativa (japonica cultivar-group) cDNA clone 7LEAF--06-N14, mRNA
          sequence.
ACCESSION CF301840
VERSION   CF301840.1 GI:33673601
KEYWORDS  EST.
SOURCE     Oryza sativa (japonica cultivar-group)
ORGANISM   Oryza sativa (japonica cultivar-group)
          Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
          Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
          Ehrhartoideae; Oryzae; Oryza.

REFERENCE 1 (bases 1 to 9)
AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
          Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
TITLE     Large-scale Sequencing Analysis of Rice ESTs
JOURNAL   Unpublished (2003)
COMMENT   Contact: Nahm B.H.
          Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
          of Bioscience and Bioinformatics, Myongji University
          Yongin, Kyeonggi, Korea
          Tel: 82 31 330 6193
          Fax: 82 31 321 6355
          Email: bhnaah@gbio.com, bhnaah@bio.myongji.ac.kr.
          Location/Qualifiers
            1..9
            /organism="Oryza sativa (japonica cultivar-group)"
            /mol_type="mRNA"
            /cultivar="Nackdong"

```

```

/db_xref="taxon:39947"
/clone="7LEAF-06-N14"
/tissue_type="leaf"
/dev_stages="7 days after germination"
/lab_host="E.coli DH10B"
/clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
/note="Vector: PCR4-TOPO; Site 1: EcoRI; mRNA was capped
with oligoribonucleotides and then used as templates for
RT-PCR."

```

```

Query Match      23.7%; Score 6.4; DB 1; Length 9;
Best Local Similarity 87.5%; Pred.No.36;
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

Oy 2223 AAAAGTTA 2230
    |||||
Db 1 AAAATTGA 8

```

```

Search completed: November 18, 2004, 08:20:33
Job time : 0.001 secs

```


GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 18, 2004, 08:14:46 ; Search time 1 Seconds

(without alignments)

0.106 Million cell updates/sec

Title: US-10-006-191-19

Perfect score: 27

Sequence: 1 agagtgtgacaaaagtacatgttgg 27

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 0.5

Searched: 178 seqs, 1971 residues

Total number of hits satisfying chosen parameters: 356

Minimum DB seq length: 8

Maximum DB seq length: 50

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 179 summaries

Database : rge19.seq*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
C 1	14.4	53.3	20	1	AX201565
C 2	12.2	45.2	17	1	AX306622
C 3	12.2	45.2	17	1	AX735739
C 4	11.4	42.2	15	1	AX179963
C 5	10.8	40.0	15	1	AC00722
C 6	10	37.0	10	1	AX301599
C 7	9.4	34.8	11	1	AX190492
C 8	9.4	34.8	11	1	AX190703
C 9	9.4	34.8	11	1	AX231888
C 10	9.4	34.8	11	1	AX24319
C 11	9.4	34.8	11	1	AX628728
C 12	9.4	34.8	11	1	AX630609
C 13	9.4	34.8	11	1	AX631740
C 14	9.4	34.8	12	1	AR343744
C 15	9.4	34.8	13	1	AR79729
C 16	9.4	34.8	13	1	ATH530046
C 17	9.4	34.8	13	1	ATH530079
C 18	9	33.3	10	1	BD239153
C 19	9	33.3	11	1	CQ835434
C 20	9	33.3	11	1	CQ837632
C 21	9	33.3	11	1	AX393132
C 22	9	33.3	11	1	AX523097
C 23	9	33.3	11	1	AX626998
C 24	9	33.3	11	1	AX630518
C 25	8.8	32.6	12	1	AX573600
C 26	8.4	31.1	10	1	I73191
C 27	8.4	31.1	10	1	AR217931
C 28	8.4	31.1	10	1	AX152173
C 29	8.4	31.1	10	1	AX152235
C 30	8.4	31.1	10	1	AX152287
C 31	8.4	31.1	10	1	AX152289
C 32	8.4	31.1	10	1	BD166495
C 33	8.4	31.1	10	1	BD167034

C 34	8.4	31.1	11	1	BD174614
C 35	8.4	31.1	11	1	CQ828431
C 36	8.4	31.1	11	1	CQ828449
C 37	8.4	31.1	11	1	CQ833045
C 38	8.4	31.1	11	1	CQ833265
C 39	8.4	31.1	11	1	CQ833328
C 40	8.4	31.1	11	1	CQ833707
C 41	8.4	31.1	11	1	CQ833903
C 42	8.4	31.1	11	1	CQ835443
C 43	8.4	31.1	11	1	CQ835784
C 44	8.4	31.1	11	1	CQ835979
C 45	8.4	31.1	11	1	CQ836035
C 46	8.4	31.1	11	1	CQ836131
C 47	8.4	31.1	11	1	CQ837874
C 48	8.4	31.1	11	1	AX175020
C 49	8.4	31.1	11	1	AX175021
C 50	8.4	31.1	11	1	AX393176
C 51	8.4	31.1	11	1	AX470684
C 52	8.4	31.1	11	1	AX471221
C 53	8.4	31.1	11	1	AX471460
C 54	8.4	31.1	11	1	AX471712
C 55	8.4	31.1	11	1	AX623270
C 56	8.4	31.1	11	1	AX624779
C 57	8.4	31.1	11	1	AX625318
C 58	8.4	31.1	11	1	AX625811
C 59	8.4	31.1	11	1	AX625811
C 60	8.4	31.1	11	1	AX625934
C 61	8.4	31.1	11	1	AX627178
C 62	8.4	31.1	11	1	AX627466
C 63	8.4	31.1	11	1	AX627566
C 64	8.4	31.1	11	1	AX627903
C 65	8.4	31.1	11	1	AX628167
C 66	8.4	31.1	11	1	AX629648
C 67	8.4	31.1	11	1	AX629854
C 68	8.4	31.1	11	1	AX630691
C 69	8.4	31.1	11	1	AX632200
C 70	8.4	31.1	11	1	AX632739
C 71	8.4	31.1	12	1	CQ766537
C 72	8.4	31.1	12	1	CQ766563
C 73	8.4	31.1	12	1	I38923
C 74	8.4	31.1	12	1	I87954
C 75	8.4	31.1	12	1	AX572515
C 76	8	29.6	8	1	E02036
C 77	8	29.6	8	1	AR176517
C 78	8	29.6	10	1	BD239221
C 79	8	29.6	10	1	BD239279
C 80	8	29.6	10	1	BD239635
C 81	8	29.6	10	1	CQ828615
C 82	8	29.6	10	1	AR303494
C 83	8	29.6	10	1	AR351773
C 84	8	29.6	10	1	AR351781
C 85	8	29.6	10	1	AR351782
C 86	8	29.6	10	1	AX153396
C 87	8	29.6	10	1	AX667866
C 88	8	29.6	10	1	AX667874
C 89	8	29.6	10	1	AX667875
C 90	8	29.6	10	1	AX955930
C 91	8	29.6	10	1	BD007825
C 92	8	29.6	10	1	BD166573
C 93	8	29.6	11	1	CQ833105
C 94	8	29.6	11	1	CQ833109
C 95	8	29.6	11	1	CQ836060
C 96	8	29.6	11	1	CQ836293
C 97	8	29.6	11	1	AR301541
C 98	8	29.6	11	1	AX470578
C 99	8	29.6	11	1	AX472174
C 100	8	29.6	11	1	AX625287
C 101	8	29.6	11	1	AX625400
C 102	8	29.6	11	1	AX625627
C 103	8	29.6	11	1	AX626945
C 104	8	29.6	11	1	AX627307
C 105	8	29.6	11	1	AX627680
C 106	8	29.6	11	1	AX628092

ACCESSION:BD174614
ACCESSION:CQ828431
ACCESSION:CQ828449
ACCESSION:CQ833045
ACCESSION:CQ833265
ACCESSION:CQ833328
ACCESSION:CQ833707
ACCESSION:CQ833903
ACCESSION:CQ835443
ACCESSION:CQ835784
ACCESSION:CQ835979
ACCESSION:CQ836035
ACCESSION:CQ836131
ACCESSION:CQ837874
ACCESSION:AX175020
ACCESSION:AX175021
ACCESSION:AX393176
ACCESSION:AX470684
ACCESSION:AX471221
ACCESSION:AX471460
ACCESSION:AX471712
ACCESSION:AX623270
ACCESSION:AX624779
ACCESSION:AX625318
ACCESSION:AX625811
ACCESSION:AX625811
ACCESSION:AX625934
ACCESSION:AX627178
ACCESSION:AX627466
ACCESSION:AX627566
ACCESSION:AX627903
ACCESSION:AX628167
ACCESSION:AX629648
ACCESSION:AX629854
ACCESSION:AX630691
ACCESSION:AX632200
ACCESSION:AX632739
ACCESSION:CQ766537
ACCESSION:CQ766563
ACCESSION:I38923
ACCESSION:I87954
ACCESSION:AX572515
ACCESSION:E02036
ACCESSION:AR176517
ACCESSION:BD239221
ACCESSION:BD239279
ACCESSION:BD239635
ACCESSION:CQ828615
ACCESSION:AR303494
ACCESSION:AR351773
ACCESSION:AR351781
ACCESSION:AR351782
ACCESSION:AX153396
ACCESSION:AX667866
ACCESSION:AX667874
ACCESSION:AX667875
ACCESSION:AX955930
ACCESSION:BD007825
ACCESSION:BD166573
ACCESSION:CQ833105
ACCESSION:CQ833109
ACCESSION:CQ836060
ACCESSION:CQ836293
ACCESSION:AR301541
ACCESSION:AX470578
ACCESSION:AX472174
ACCESSION:AX625287
ACCESSION:AX625400
ACCESSION:AX625627
ACCESSION:AX626945
ACCESSION:AX627307
ACCESSION:AX627680
ACCESSION:AX628092

[illegible][illegible]

```

Db      11 AAAAATTACAT 1

RESULT 8
LOCUS   AX190703
DEFINITION Sequence 54 from Patent WO0142493.
ACCESSION AX190703
VERSION   AX190703.1 GI:15143987
KEYWORDS
SOURCE   synthetic construct
ORGANISM synthetic construct
          artificial sequences.
REFERENCE
AUTHORS Olek,A. and Piepenbrock,C.
TITLE    Method for the parallel detection of the degree of methylation of
JOURNAL  genomic dna
          Patent: WO 0142493-A 54 14-JUN-2001;
          Epigenomics AG (DE)
FEATURES
          Location/Qualifiers
            source
              1..11
                /organism="synthetic construct"
                /mol_type="unassigned DNA"
                /db_xref="taxon:32630"
                /note="chemisch vorbehandelte Genom-DNA"

Query Match      34.8%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 37;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2220 ACCAAAGTTA 2230
Db      11 ACCAAAGTAA 1

RESULT 11
LOCUS   AX628728/c
DEFINITION Sequence 5769 from Patent WO02053774.
ACCESSION AX628728
VERSION   AX628728.1 GI:28456766
KEYWORDS
SOURCE   Homo sapiens (human)
ORGANISM Homo sapiens
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE    Method for determining homeostasis of the skin
JOURNAL  Patent: WO 02053774-A 5769 11-JUL-2002;
          Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
          Location/Qualifiers
            source
              1..11
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      34.8%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 37;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2222 CAAAAGTTACA 2232
Db      11 CAAAAGTTACA 1

RESULT 12
LOCUS   AX630609/c
DEFINITION Sequence 7650 from Patent WO02053774.
ACCESSION AX630609
VERSION   AX630609.1 GI:28458647
KEYWORDS
SOURCE   Homo sapiens (human)
ORGANISM Homo sapiens
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE    Method for determining homeostasis of the skin
JOURNAL  Patent: WO 02053774-A 7650 11-JUL-2002;
          Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
          Location/Qualifiers
            source
              1..11

Db      11 AAAAATTACAT 1

RESULT 9
LOCUS   AX623188/c
DEFINITION Sequence 229 from Patent WO02053774.
ACCESSION AX623188
VERSION   AX623188.1 GI:28451129
KEYWORDS
SOURCE   Homo sapiens (human)
ORGANISM Homo sapiens
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE    Method for determining homeostasis of the skin
JOURNAL  Patent: WO 02053774-A 229 11-JUL-2002;
          Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
          Location/Qualifiers
            source
              1..11
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      34.8%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 37;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2223 AAAAGTTACAT 2233
Db      11 AAAAGTACAT 1

RESULT 10
LOCUS   AX624319/c
DEFINITION Sequence 1360 from Patent WO02053774.
ACCESSION AX624319
VERSION   AX624319.1 GI:28452260
KEYWORDS
SOURCE   Homo sapiens (human)
ORGANISM Homo sapiens
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE    Method for determining homeostasis of the skin
JOURNAL  Patent: WO 02053774-A 1360 11-JUL-2002;
          Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
          Location/Qualifiers
            source
              1..11

```

```

/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      34.8%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 37;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACAT 2233
Db 11 AAAAGTCACAT 1

RESULT 13
AX6311740/c
LOCUS AX6311740 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 8782 from Patent WO02053774.
ACCESSION AX631740
VERSION AX631740.1 GI:28459847
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 8782 11-JUL-2002;
FEATURES Location/Qualifiers
source 1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      34.8%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 37;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2220 ACCAAAAGTAA 2230
Db 11 ACCAAAAGTAA 1

RESULT 14
AR343744/c
LOCUS AR343744 12 bp DNA linear PAT 17-AUG-2003
DEFINITION Sequence 55 from patent US 6579969.
ACCESSION AR343744
VERSION AR343744.1 GI:33739603
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 12)
AUTHORS Saus,J.
TITLE Goodpasture antigen binding protein
JOURNAL Patent: US 6579969-A 55 17-JUN-2003;
FEATURES Location/Qualifiers
source 1..12
/organism="unknown"
/mol_type="genomic DNA"

Query Match      34.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 40;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2216 TGTGACCAAAA 2226
Db 11 TGTGACCAAAA 1

RESULT 15

```

```

AR279729
LOCUS AR279729 13 bp DNA linear PAT 10-APR-2003
DEFINITION Sequence 4 from patent US 6518014.
ACCESSION AR279729
VERSION AR279729.1 GI:29714872
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 13)
AUTHORS Seifer,M., Hamatake,R. and Standing,D.N.
TITLE Hepadnavirus cores
JOURNAL Patent: US 6518014-A 4 11-FEB-2003;
FEATURES Location/Qualifiers
source 1..13
/organism="unknown"
/mol_type="genomic DNA"

Query Match      34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 43;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACAT 2233
Db 3 AAAAGTTCCAT 13

RESULT 16
ATH530046/c
LOCUS ATH530046 13 bp DNA linear PLN 29-MAR-2003
DEFINITION Arabidopsis thaliana T-DNA flanking sequence, left border, clone 201D06.
ACCESSION AJ530046
VERSION AJ530046.1 GI:26798306
KEYWORDS left border; T-DNA flanking sequence.
SOURCE Arabidopsis thaliana (thale cress)
ORGANISM Arabidopsis thaliana
Eukaryota: Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsi.
REFERENCE 1
AUTHORS Brunaud,V., Balzerque,S., Dubreucq,B., Aubourg,S., Samson,F.,
Chauvin,S., Bechtold,N., Cruaud,C., DeRose,R., Pelletier,G.,
Lepiniec,L., Caboche,M. and Lecharny,A.
TITLE T-DNA integration into the Arabidopsis genome depends on sequences
of pre-insertion sites
JOURNAL EMO Rep. 3 (12), 1152-1157 (2002)
MEDLINE 22363535
PUBMED 12446565
REFERENCE 2 (bases 1 to 13)
AUTHORS Balzerque,S.
TITLE Direct Submission
JOURNAL Submitted (21-NOV-2002) Balzerque S., UMRGV, INRA/CNRS, 2 rue
Gaston Cremieux, 91057 Evry cedex, FRANCE
COMMENT PCR was performed on DNA from transformants of Arabidopsis thaliana
plants from INRA (Versailles). The DNA fragment(s) resulting from
the PCR were directly sequenced from the left or the right border
to determine the genomic sequence flanking the insertion. T-DNA
derived sequences were removed. Information to order the
corresponding mutant line and a link to a database providing a
graphical display of the insertion site are available at
http://dbsgap.versailles.inra.fr/publiclines/. This sequence has
been generated in the framework of the French plant genomics
program 'Genoplante' (http://www.genoplante.com and
http://genoplante-info.infobiogen.fr).
FEATURES Location/Qualifiers
source 1..13
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassiliewskija"
/db_xref="taxon:3702"
/clone="201D06"
/clone_lib="Arabidopsis thaliana T-DNA insertion lines"

```

```

misc_feature 1..13
/notes="T-DNA flanking sequence
left border"

Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 43;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2223 AAAAGTTACAT 2233
||| |||||
Db 12 AACGTTACAT 2

RESULT 17
ATHS30079/c
LOCUS Arabidopsis thaliana T-DNA flanking sequence, left border, clone
201H01.
ACCESSION AJ530079.1 GI:26798339
VERSION left border; T-DNA flanking sequence.
KEYWORDS Arabidopsis thaliana (thale cress)
SOURCE Arabidopsis thaliana
ORGANISM Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsids.
REFERENCE 1
AUTHORS Brunaud, V., Balzerque, S., Dubreucq, B., Aubourg, S., Saneon, F.,
Chauvin, S., Bechtold, N., Cruaud, C., Denose, R., Pelletier, G.,
Lepiniec, L., Caboche, M., and Lecharny, A.
TITLE T-DNA integration into the Arabidopsis genome depends on sequences
of pre-insertion sites
JOURNAL EMBO Rep. 3 (12), 1152-1157 (2002)
MEDLINE 22363515
PubMed 12446565
REFERENCE 2 (bases 1 to 13)
AUTHORS Balzerque, S.
TITLE Direct Submission
JOURNAL Submitted (21-NOV-2002) Balzerque S., UMRGV, INRA/CNRS, 2 rue
Gaston Cremieux, 91057 Evry cedex, FRANCE
COMMENT PCR was performed on DNA from transformants of Arabidopsis thaliana
plants from INRA (Versailles). The DNA fragment(s) resulting from
the PCR were directly sequenced from the left or the right border
to determine the genomic sequence flanking the insertion. T-DNA
derived sequences were removed. Information to order the
corresponding mutant line and a link to a database providing a
graphical display of the insertion site are available at
http://dbsgap-versailles.inra.fr/publiclines/. This sequence has
been generated in the framework of the French plant genomics
program 'Genoplante' (http://www.genoplante.com and
http://genoplante-info.inbio.gen.fr).
FEATURES
source
1..13
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassiljewskaja"
/db_xref="taxon:3702"
/clone="201H01"
/clone_lib="Arabidopsis thaliana T-DNA insertion lines"
misc_feature 1..13
/notes="T-DNA flanking sequence
left border"

Query Match 34.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 43;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2223 AAAAGTTACAT 2233
||| |||||
Db 12 AACGTTACAT 2

RESULT 18

```

```

BD239153/c
LOCUS Preparation and use of superior vaccines.
DEFINITION BD239153
ACCESSION BD239153
VERSION BD239153.1 GI:33048923
KEYWORDS JP 2002534056-A/571.
SOURCE Homo sapiens (human)
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 10)
AUTHORS Roberts, B.L. and Shankara, S.
TITLE Preparation and use of superior vaccines
JOURNAL Patent: JP 2002534056-A 571 15-OCT-2002;
GENZYME CORP
COMMENT OS Homo sapiens (human)
PN JP 2002534056-A/571
PD 15-OCT-2002
PF 18-JUN-1999 JP 2000554749
PR 19-JUN-1998 US 60/090039, 19-JUN-1998 US 60/090040 PR
19-JUN-1998 US 60/090041, 19-JUN-1998 US 60/089853 PR
19-JUN-1998 US 60/089957, 19-JUN-1998 US 60/090079 PR
19-JUN-1998 US 60/090035, 19-JUN-1998 US 60/089993 PR
19-JUN-1998 US 60/089982, 19-JUN-1998 US 60/090072 PR
19-JUN-1998 US 60/089878, 19-JUN-1998 US 60/089991 PR
19-JUN-1998 US 60/090000, 19-JUN-1998 US 60/090043 PR
19-JUN-1998 US 60/089999, 19-JUN-1998 US 60/090048 PR
19-JUN-1998 US 60/090042, 19-JUN-1998 US 60/090036 PR
19-JUN-1998 US 60/090044, 19-JUN-1998 US 60/089844 PR
19-JUN-1998 US 60/090080, 19-JUN-1998 US 60/089833 PR
19-JUN-1998 US 60/089994, 19-JUN-1998 US 60/090077 PR
19-JUN-1998 US 60/090078, 19-JUN-1998 US 60/090047 PR
19-JUN-1998 US 60/090076, 19-JUN-1998 US 60/090045 PR
08-DEC-1998 US 60/111715
PI BRUCE L ROBERTS, SRINIVAS SHANKARA
PC C12N15/09, C12N15/09, A61P35/00, A61P37/04, C12N1/15, PC
C12N1/19, C12N5/10, G01N33/15, G01N33/50, G01N33/53, G01N33/566, PC
G01N33/00,
PC C12N15/00, C12N5/00, C12N15/00
CC Preparation and use of superior vaccines
FH Key Location/Qualifiers
FT source 1..10
FT /organism="Homo sapiens (human)"
FEATURES
source
1..10
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
Query Match 33.3%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 41;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2214 AGTGTGACC 2222
|||||
Db 9 AGTGTGACC 1

RESULT 19
CQ835434
LOCUS Sequence 492 from Patent WO2004059001.
DEFINITION CQ835434
ACCESSION CQ835434
VERSION CQ835434.1 GI:50834968
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Petersohn, D., Schlormann, K., Gassenmeier, T., Holtkoetter, O.,
Conrad, M. and Hofmann, K.

```

TITLE Method for determining markers of human facial skin
JOURNAL Patent: WO 2004059001-A 432 15-JUL-2004;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES Location/Qualifiers
source
1. .11

Query Match 33.3%; Score 9; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2218 TGACCAAAA 2226
Db 1 TGACCAAAA 9

RESULT 20
LOCUS CQ837632 11 bp DNA linear PAT 29-JUL-2004
DEFINITION Sequence 2690 from Patent WO2004059001.
ACCESSION CQ837632
VERSION CQ837632.1 GI:50837166
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE 1
AUTHORS Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
Conradt,M. and Hofmann,K.
TITLE Method for determining markers of human facial skin
JOURNAL Patent: WO 2004059001-A 2690 15-JUL-2004;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES Location/Qualifiers
source
1. .11

/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 33.3%; Score 9; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2221 CCAAAAGTT 2229
Db 9 CCAAAAGTT 1

RESULT 21
LOCUS AX393132 11 bp DNA linear PAT 23-MAR-2002
DEFINITION Sequence 62 from Patent WO0210217.
ACCESSION AX393132
VERSION AX393132.1 GI:19701182
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE 1
AUTHORS St Croix,B., Kinzler,K.W. and Vogelstein,B.
TITLE Endothelial cell expression patterns
JOURNAL Patent: WO 0210217-A 62 07-FEB-2002;
The Johns Hopkins University (US)
FEATURES Location/Qualifiers
source
1. .11

/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 33.3%; Score 9; DB 1; Length 11;

Best Local Similarity 100.0%; Pred. No. 45;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2212 AGAGTGTGA 2220
Db 3 AGAGTGTGA 11

RESULT 22
LOCUS AX623097 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 138 from Patent WO02053774.
ACCESSION AX623097
VERSION AX623097.1 GI:28451038
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE 1
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 138 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES Location/Qualifiers
source
1. .11

/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 33.3%; Score 9; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2212 AGAGTGTGA 2220
Db 3 AGAGTGTGA 11

RESULT 23
LOCUS AX626998/c 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 4039 from Patent WO02053774.
ACCESSION AX626998
VERSION AX626998.1 GI:28455036
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE 1
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 4039 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES Location/Qualifiers
source
1. .11

/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 33.3%; Score 9; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2221 CCAAAAGTT 2229
Db 11 CCAAAAGTT 3

RESULT 24
LOCUS AX630518 11 bp DNA linear PAT 21-FEB-2003

DEFINITION Sequence 7559 from Patent WO02053774.
 ACCESSION AX630518
 VERSION AX630518.1 GI:28458556
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
 TITLE Method for determining homeostasis of the skin
 JOURNAL Patent: WO 02053774-A 7559 11-JUL-2002;
 Henkel Kommanditgesellschaft auf Aktien (DE)
 FEATURES
 source Location/Qualifiers
 1..11
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"
 Query Match 33.3%; Score 9; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 45;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2212 AGAGTGTGA 2220
 Db 3 AGAGTGTGA 11
 RESULT 25
 AX573600/c
 LOCUS AX573600 12 bp DNA linear PAT 07-JAN-2003
 DEFINITION Sequence 10 from Patent WO02079467.
 ACCESSION AX573600
 VERSION AX573600.1 GI:27551270
 KEYWORDS synthetic construct
 SOURCE synthetic construct
 ORGANISM artificial sequences.
 REFERENCE 1
 AUTHORS Nielsen,P.E. and Good,L.
 TITLE Antibiotic-free bacterial strain selection with antisense molecules
 JOURNAL Patent: WO 02079467-A 10 10-OCT-2002;
 Koebenhavns Universitet (DK)
 FEATURES
 source Location/Qualifiers
 1..12
 /organism="synthetic construct"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32630"
 /note="synthetic antisense oligonucleotide"
 Query Match 32.6%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 54;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2212 AGAGTGTGACCA 2223
 Db 12 AGAGTGTGACCA 1
 RESULT 26
 I73191/c
 LOCUS I73191 10 bp DNA linear PAT 03-APR-1998
 DEFINITION Sequence 5 from patent US 5686242.
 ACCESSION I73191
 VERSION I73191.1 GI:3009330
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 10)
 AUTHORS Bruce,T.W. and Lima,W.F.
 TITLE Determination of oligonucleotides for therapeutics, diagnostics and research reagents

JOURNAL Patent: US 5686242-A 5 11-NOV-1997;
 FEATURES Location/Qualifiers
 source 1..10
 /organism="unknown"
 /mol_type="unassigned DNA"
 Query Match 31.1%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 55;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2215 GTGTGACCAA 2224
 Db 10 GTGTGACCAA 1
 RESULT 27
 AR217931/c
 LOCUS AR217931 10 bp DNA linear PAT 25-SEP-2002
 DEFINITION Sequence 2 from patent US 6417330.
 ACCESSION AR217931
 VERSION AR217931.1 GI:23318234
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 10)
 AUTHORS Mascarenhas,D., Passmore,D. and Danko,S.
 TITLE Insulin-like growth factor binding protein variants
 JOURNAL Patent: US 6417330-A 2 09-JUL-2002;
 FEATURES
 source Location/Qualifiers
 1..10
 /organism="unknown"
 /mol_type="genomic DNA"
 Query Match 31.1%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 55;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2226 AGTTACATGT 2235
 Db 10 AATTACATGT 1
 RESULT 28
 AX152173
 LOCUS AX152173 10 bp DNA linear PAT 22-JUN-2001
 DEFINITION Sequence 88 from Patent WO0138577.
 ACCESSION AX152173
 VERSION AX152173.1 GI:14533824
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Velculescu,V.E., Vogelstein,B. and Kinzler,K.W.
 TITLE Human transcriptomes
 JOURNAL Patent: WO 0138577-A 88 31-MAY-2001;
 The Johns Hopkins University (US)
 FEATURES
 source Location/Qualifiers
 1..10
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"
 Query Match 31.1%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 55;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2221 CCAAAAGTTA 2230
 Db 1 CAAAGTTA 10


```

RESULT 29
LOCUS       AX152235                10 bp    DNA          linear    PAT 22-JUN-2001
DEFINITION   Sequence 150 from Patent WO0138577.
ACCESSION   AX152235
VERSION      AX152235.1  GI:14533886
KEYWORDS     Homo sapiens (human)
SOURCE       Homo sapiens
ORGANISM     Homo sapiens
REFERENCE    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS      Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE        Velculescu,V.E., Vogelstein,B. and Kinzler,K.W.
JOURNAL      Human transcriptsomes
PATENT: WO 0138577-A 150 31-MAY-2001;
The Johns Hopkins University (US)
FEATURES     Location/Qualifiers
             source
             1..10
             |||||
             /organism="Homo sapiens"
             /mol_type="unassigned DNA"
             /db_xref="taxon:9606"
             31.1%; Score 8.4; DB 1; Length 10;
             Best Local Similarity 90.0%; Pred.No.55;
             Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Query Match
Best Local Similarity 90.0%; Pred.No.55;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2218 TGACCAAAAG 2227
|||
Db 1 TGACCAATAG 10

RESULT 30
LOCUS       AX152287/c             10 bp    DNA          linear    PAT 22-JUN-2001
DEFINITION   Sequence 202 from Patent WO0138577.
ACCESSION   AX152287
VERSION      AX152287.1  GI:14533938
KEYWORDS     Homo sapiens (human)
SOURCE       Homo sapiens
ORGANISM     Homo sapiens
REFERENCE    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS      Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE        Velculescu,V.E., Vogelstein,B. and Kinzler,K.W.
JOURNAL      Human transcriptsomes
PATENT: WO 0138577-A 202 31-MAY-2001;
The Johns Hopkins University (US)
FEATURES     Location/Qualifiers
             source
             1..10
             |||||
             /organism="Homo sapiens"
             /mol_type="unassigned DNA"
             /db_xref="taxon:9606"
             31.1%; Score 8.4; DB 1; Length 10;
             Best Local Similarity 90.0%; Pred.No.55;
             Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Query Match
Best Local Similarity 90.0%; Pred.No.55;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2216 TGTGACCAAA 2225
|||
Db 10 TGTACCAAAA 1

RESULT 31
LOCUS       AX152289/c             10 bp    DNA          linear    PAT 22-JUN-2001
DEFINITION   Sequence 204 from Patent WO0138577.
ACCESSION   AX152289
VERSION      AX152289.1  GI:14533940
KEYWORDS     Homo sapiens (human)
SOURCE       Homo sapiens
ORGANISM     Homo sapiens
REFERENCE    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

```

```

Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1
AUTHORS      Velculescu,V.E., Vogelstein,B. and Kinzler,K.W.
TITLE        Human transcriptsomes
JOURNAL      Patent: WO 0138577-A 204 31-MAY-2001;
The Johns Hopkins University (US)
FEATURES     Location/Qualifiers
             source
             1..10
             |||||
             /organism="Homo sapiens"
             /mol_type="unassigned DNA"
             /db_xref="taxon:9606"
             31.1%; Score 8.4; DB 1; Length 10;
             Best Local Similarity 90.0%; Pred.No.55;
             Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Query Match
Best Local Similarity 90.0%; Pred.No.55;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2216 TGTGACCAAA 2225
|||
Db 10 TGTACCAAAA 1

RESULT 32
LOCUS       BD166495              10 bp    DNA          linear    PAT 17-JAN-2003
DEFINITION   Human liver disease-expressing genes.
ACCESSION   BD166495
VERSION      BD166495.1  GI:27872307
KEYWORDS     JP 2002209591-A/40.
SOURCE       unidentified
ORGANISM     unidentified.
REFERENCE    1 (bases 1 to 10)
AUTHORS      Matsushima,K., Hashimoto,S., Kaneko,S. and Yamashita,T.
TITLE        Human liver disease-expressing genes
JOURNAL      Patent: JP 2002209591-A 40 30-JUL-2002;
JAPAN SCIENCE AND TECHNOLOGY CORP
COMMENT      OS Homo sapiens (human)
            PN JP 2002209591-A/40
            PF 30-JUL-2002
            PP 19-JAN-2001
            PI KOJI MATSUSHIMA,SHINICHI HASHIMOTO,SHUICHI KANEKO,TARO PI
            PC C12N15/09,C07K14/47,C07K16/18,G0IN33/50//C12P21/02,
            PC C12P21/08,
            PC C12N15/00
            CC Human liver disease-expressing genes
            FH Key
            FT source
            1..10
            /organism="Homo sapiens (human)".
            Location/Qualifiers
            source
            1..10
            |||||
            /organism="unidentified"
            /mol_type="genomic DNA"
            /db_xref="taxon:32644"
            31.1%; Score 8.4; DB 1; Length 10;
            Best Local Similarity 90.0%; Pred.No.55;
            Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Query Match
Best Local Similarity 90.0%; Pred.No.55;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2218 TGACCAAAAG 2227
|||
Db 1 TGACCAAGAG 10

RESULT 33
LOCUS       BD167034              10 bp    DNA          linear    PAT 17-JAN-2003
DEFINITION   Human liver disease-expressing genes.
ACCESSION   BD167034
VERSION      BD167034.1  GI:27872846
KEYWORDS     JP 2002209591-A/579.
SOURCE       unidentified
ORGANISM     unidentified

```



```

KEYWORDS      Homo sapiens (human)
SOURCE         Homo sapiens
ORGANISM       Mammalia; Eutheria; Chordata; Craniata; Vertebrata; Euteleostomi;
REFERENCE      1
AUTHORS        Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
                Conradt,M. and Hofmann,K.
TITLE          Method for determining the homeostasis of hairy skin
JOURNAL        Patent: WO 2004059002-A 416 15-JUL-2004;
                Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES       1. .11
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match    31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTACA 2232
Db 11 AAAAGATACA 2

RESULT 38
LOCUS          CQ833265 11 bp DNA linear PAT 29-JUL-2004
DEFINITION     Sequence 636 from Patent WO2004059002.
ACCESSION      CQ833265
VERSION        CQ833265.1 GI:50832872
KEYWORDS       Homo sapiens (human)
SOURCE         Homo sapiens
ORGANISM       Mammalia; Eutheria; Chordata; Craniata; Vertebrata; Euteleostomi;
REFERENCE      1
AUTHORS        Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
                Conradt,M. and Hofmann,K.
TITLE          Method for determining the homeostasis of hairy skin
JOURNAL        Patent: WO 2004059002-A 636 15-JUL-2004;
                Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES       1. .11
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match    31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2219 GACCAAAAGT 2228
Db 1 GACCAACAGT 10

RESULT 39
LOCUS          CQ833328/c 11 bp DNA linear PAT 29-JUL-2004
DEFINITION     Sequence 699 from Patent WO2004059002.
ACCESSION      CQ833328
VERSION        CQ833328.1 GI:50832935
KEYWORDS       Homo sapiens (human)
SOURCE         Homo sapiens
ORGANISM       Mammalia; Eutheria; Chordata; Craniata; Vertebrata; Euteleostomi;
REFERENCE      1
AUTHORS        Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
                Conradt,M. and Hofmann,K.
TITLE          Method for determining the homeostasis of hairy skin
JOURNAL        Patent: WO 2004059002-A 699 15-JUL-2004;
                Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES       1. .11
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match    31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2215 GTGTGACCAA 2224
Db 10 GTTTGACCAA 1

RESULT 41
LOCUS          CQ833303 11 bp DNA linear PAT 29-JUL-2004
DEFINITION     Sequence 1274 from Patent WO2004059002.
ACCESSION      CQ833303
VERSION        CQ833303.1 GI:50833510
KEYWORDS       Homo sapiens (human)
SOURCE         Homo sapiens
ORGANISM       Mammalia; Eutheria; Chordata; Craniata; Vertebrata; Euteleostomi;
REFERENCE      1
AUTHORS        Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
                Conradt,M. and Hofmann,K.
TITLE          Method for determining the homeostasis of hairy skin
JOURNAL        Patent: WO 2004059002-A 1274 15-JUL-2004;
                Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES       1. .11
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match    31.1%; Score 8.4; DB 1; Length 11;

```

```

JOURNAL        Patent: WO 2004059002-A 699 15-JUL-2004;
                Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES       1. .11
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match    31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2217 GTGACCAAAA 2226
Db 10 GTGATCAAAA 1

RESULT 40
LOCUS          CQ8333707/c 11 bp DNA linear PAT 29-JUL-2004
DEFINITION     Sequence 1078 from Patent WO2004059002.
ACCESSION      CQ8333707
VERSION        CQ8333707.1 GI:50833314
KEYWORDS       Homo sapiens (human)
SOURCE         Homo sapiens
ORGANISM       Mammalia; Eutheria; Chordata; Craniata; Vertebrata; Euteleostomi;
REFERENCE      1
AUTHORS        Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
                Conradt,M. and Hofmann,K.
TITLE          Method for determining the homeostasis of hairy skin
JOURNAL        Patent: WO 2004059002-A 1078 15-JUL-2004;
                Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES       1. .11
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match    31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2215 GTGTGACCAA 2224
Db 10 GTTTGACCAA 1

RESULT 41
LOCUS          CQ833303 11 bp DNA linear PAT 29-JUL-2004
DEFINITION     Sequence 1274 from Patent WO2004059002.
ACCESSION      CQ833303
VERSION        CQ833303.1 GI:50833510
KEYWORDS       Homo sapiens (human)
SOURCE         Homo sapiens
ORGANISM       Mammalia; Eutheria; Chordata; Craniata; Vertebrata; Euteleostomi;
REFERENCE      1
AUTHORS        Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
                Conradt,M. and Hofmann,K.
TITLE          Method for determining the homeostasis of hairy skin
JOURNAL        Patent: WO 2004059002-A 1274 15-JUL-2004;
                Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES       1. .11
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match    31.1%; Score 8.4; DB 1; Length 11;

```



```

REFERENCE
AUTHORS      Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
Conradt,M. and Hofmann,K.
TITLE        Method for determining markers of human facial skin
JOURNAL      Patent: WO 2004059001-A 1189 15-JUL-2004;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES     Location/Qualifiers
source
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      2223 AAAAGTTACA 2232
Db      11 AAAAGTTACA 2

RESULT 47
CQ837874/c
LOCUS      CQ837874      11 bp      DNA      linear      PAT 29-JUL-2004
DEFINITION Sequence 2932 from Patent WO2004059001.
ACCESSION  CQ837874
VERSION     CQ837874.1 GI:50837408
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
AUTHORS      Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
Conradt,M. and Hofmann,K.
TITLE        Method for determining markers of human facial skin
JOURNAL      Patent: WO 2004059001-A 2932 15-JUL-2004;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES     Location/Qualifiers
source
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      2228 TTACAGTTT 2237
Db      11 TTACAGTTT 2

RESULT 48
AX175020/c
LOCUS      AX175020      11 bp      DNA      linear      PAT 08-AUG-2001
DEFINITION Sequence 9 from Patent WO0142493.
ACCESSION  AX175020
VERSION     AX175020.2 GI:15142039
KEYWORDS
SOURCE      synthetic construct
ORGANISM    synthetic construct
artificial sequences.

REFERENCE
1
Olek,A. and Piepenbrock,C.
TITLE        Method for the parallel detection of the degree of methylation of
genomic dna
JOURNAL      Patent: WO 0142493-A 9 14-JUN-2001;
Epigenomics AG (DE)
COMMENT      On Aug 9, 2001 this sequence version replaced gi:14598480.
FEATURES     Location/Qualifiers
source
1..11

Query Match      31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      2223 AAAAGTTTAC 2232
Db      1 AAAAGTTTAC 10

RESULT 50
AX393176
LOCUS      AX393176      11 bp      DNA      linear      PAT 23-MAR-2002
DEFINITION Sequence 106 from Patent WO0210217.
ACCESSION  AX393176
VERSION     AX393176.1 GI:19701226
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
1
St Croix,B., Kinzler,K.W. and Vogelstein,B.
AUTHORS
TITLE        Endothelial cell expression patterns
JOURNAL      Patent: WO 0210217-A 106 07-FEB-2002;
The Johns Hopkins University (US)
FEATURES     Location/Qualifiers
source
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="chemisch vorbehandelte Genom-DNA"

Query Match      31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      2223 AAAAGTTACA 2232
Db      11 AAAAGTTACA 2

RESULT 49
AX175021
LOCUS      AX175021      11 bp      DNA      linear      PAT 08-AUG-2001
DEFINITION Sequence 10 from Patent WO0142493.
ACCESSION  AX175021
VERSION     AX175021.2 GI:15142040
KEYWORDS
SOURCE      synthetic construct
ORGANISM    synthetic construct
artificial sequences.

REFERENCE
1
Olek,A. and Piepenbrock,C.
TITLE        Method for the parallel detection of the degree of methylation of
genomic dna
JOURNAL      Patent: WO 0142493-A 10 14-JUN-2001;
Epigenomics AG (DE)
COMMENT      On Aug 9, 2001 this sequence version replaced gi:14598481.
FEATURES     Location/Qualifiers
source
1..11
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="chemisch vorbehandelte Genom-DNA"

Query Match      31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      2223 AAAAGTTTACA 2232
Db      1 AAAAGTTTACA 10

RESULT 50
AX393176
LOCUS      AX393176      11 bp      DNA      linear      PAT 23-MAR-2002
DEFINITION Sequence 106 from Patent WO0210217.
ACCESSION  AX393176
VERSION     AX393176.1 GI:19701226
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
1
St Croix,B., Kinzler,K.W. and Vogelstein,B.
AUTHORS
TITLE        Endothelial cell expression patterns
JOURNAL      Patent: WO 0210217-A 106 07-FEB-2002;
The Johns Hopkins University (US)
FEATURES     Location/Qualifiers
source
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

Qy 2213 GAGTGTGACC 2222
Db 1 GAGTGAGACC 10

RESULT 51
AX470684/c
LOCUS 11 bp DNA linear PAT 09-AUG-2002
DEFINITION Sequence 261 from Patent WO02053773.
ACCESSION AX470684
VERSION AX470684.1 GI:22205809
KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Hofmann,K., Conradt,M. and Petersohn,D.
TITLE Method for determining skin stress or skin ageing in vitro
JOURNAL Patent: WO 02053773-A 261 11-JUL-2002;
HENKEL KGAA (DE)

FEATURES
source
1..11
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2223 AACAGTTTACA 2232
Db 11 AACAGTTTACA 2

RESULT 52
AX471221/c
LOCUS 11 bp DNA linear PAT 09-AUG-2002
DEFINITION Sequence 798 from Patent WO02053773.
ACCESSION AX471221
VERSION AX471221.1 GI:22206346
KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Hofmann,K., Conradt,M. and Petersohn,D.
TITLE Method for determining skin stress or skin ageing in vitro
JOURNAL Patent: WO 02053773-A 798 11-JUL-2002;
HENKEL KGAA (DE)

FEATURES
source
1..11
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2228 TTACATGTTT 2237
Db 11 TTACAGTTT 2

RESULT 53
AX471460/c
LOCUS 11 bp DNA linear PAT 09-AUG-2002
DEFINITION Sequence 1037 from Patent WO02053773.
ACCESSION AX471460
VERSION AX471460.1 GI:22206585

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2229 GACCAAAAGT 2228
Db 11 GCCCAAAAGT 2

RESULT 54
AX471712/c
LOCUS 11 bp DNA linear PAT 09-AUG-2002
DEFINITION Sequence 1289 from Patent WO02053773.
ACCESSION AX471712
VERSION AX471712.1 GI:22206837
KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Hofmann,K., Conradt,M. and Petersohn,D.
TITLE Method for determining skin stress or skin ageing in vitro
JOURNAL Patent: WO 02053773-A 1289 11-JUL-2002;
HENKEL KGAA (DE)

FEATURES
source
1..11
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2233 AAAAGTTTACA 2232
Db 10 AAAAGTTTACA 1

RESULT 55
AX623270
LOCUS 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 311 from Patent WO02053774.
ACCESSION AX623270
VERSION AX623270.1 GI:28451211
KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 311 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)

FEATURES
Location/Qualifiers

```

source
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 31.1%; Score 8.4; DB 1; Length 11;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2221 CCAAAATTGA 2230
Db 1 CCAAAAATTA 10
|||||

RESULT 56
AX624779
LOCUS
DEFINITION Sequence 1820 from Patent WO02053774.
ACCESSION AX624779
VERSION AX624779.1 GI:28452720
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Petersohn,D., Conradt,M. and Hofmann,K.
AUTHORS Method for determining homeostasis of the skin
TITLE Patent: WO 02053774-A 1820 11-JUL-2002;
JOURNAL Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
Location/Qualifiers
source
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 31.1%; Score 8.4; DB 1; Length 11;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2223 AAAAGTTACA 2232
Db 2 AAAACTTACA 11
|||||

RESULT 57
AX625318/c
LOCUS
DEFINITION Sequence 2359 from Patent WO02053774.
ACCESSION AX625318
VERSION AX625318.1 GI:28453259
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Petersohn,D., Conradt,M. and Hofmann,K.
AUTHORS Method for determining homeostasis of the skin
TITLE Patent: WO 02053774-A 2359 11-JUL-2002;
JOURNAL Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
Location/Qualifiers
source
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 31.1%; Score 8.4; DB 1; Length 11;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2223 AAAAGTTACA 2232
Db 1 CCAAAAATTA 10
|||||

RESULT 58
AX625811/c
LOCUS
DEFINITION Sequence 2852 from Patent WO02053774.
ACCESSION AX625811
VERSION AX625811.1 GI:28453752
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Petersohn,D., Conradt,M. and Hofmann,K.
AUTHORS Method for determining homeostasis of the skin
TITLE Patent: WO 02053774-A 2852 11-JUL-2002;
JOURNAL Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
Location/Qualifiers
source
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 31.1%; Score 8.4; DB 1; Length 11;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2217 GTGACCAAAA 2226
Db 10 GTGATCAAAA 1
|||||

RESULT 59
AX626606/c
LOCUS
DEFINITION Sequence 3647 from Patent WO02053774.
ACCESSION AX626606
VERSION AX626606.1 GI:28454644
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Petersohn,D., Conradt,M. and Hofmann,K.
AUTHORS Method for determining homeostasis of the skin
TITLE Patent: WO 02053774-A 3647 11-JUL-2002;
JOURNAL Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
Location/Qualifiers
source
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 31.1%; Score 8.4; DB 1; Length 11;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2217 GTGACCAAAA 2226
Db 11 GTGGCCAAAA 2
|||||

RESULT 60
AX626934/c
LOCUS
DEFINITION Sequence 3975 from Patent WO02053774.
ACCESSION AX626934
VERSION AX626934.1 GI:28454972
KEYWORDS
SOURCE Homo sapiens (human)

```

```

Db 10 AAAAGGTACA 1

RESULT 58
AX625811/c
LOCUS
DEFINITION Sequence 2852 from Patent WO02053774.
ACCESSION AX625811
VERSION AX625811.1 GI:28453752
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Petersohn,D., Conradt,M. and Hofmann,K.
AUTHORS Method for determining homeostasis of the skin
TITLE Patent: WO 02053774-A 2852 11-JUL-2002;
JOURNAL Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
Location/Qualifiers
source
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 31.1%; Score 8.4; DB 1; Length 11;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2217 GTGACCAAAA 2226
Db 10 GTGATCAAAA 1
|||||

RESULT 59
AX626606/c
LOCUS
DEFINITION Sequence 3647 from Patent WO02053774.
ACCESSION AX626606
VERSION AX626606.1 GI:28454644
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Petersohn,D., Conradt,M. and Hofmann,K.
AUTHORS Method for determining homeostasis of the skin
TITLE Patent: WO 02053774-A 3647 11-JUL-2002;
JOURNAL Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
Location/Qualifiers
source
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 31.1%; Score 8.4; DB 1; Length 11;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2217 GTGACCAAAA 2226
Db 11 GTGGCCAAAA 2
|||||

RESULT 60
AX626934/c
LOCUS
DEFINITION Sequence 3975 from Patent WO02053774.
ACCESSION AX626934
VERSION AX626934.1 GI:28454972
KEYWORDS
SOURCE Homo sapiens (human)

```

```

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Petersohn,D., Conrad,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 3975 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
Location/Qualifiers
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTTACA 2232
|||||
Db 10 AAAAGTTTCA 1

RESULT 61
AX627178 11 bp DNA linear PAT 21-FEB-2003
LOCUS AX627178
DEFINITION Sequence 4219 from Patent WO02053774.
ACCESSION AX627178
VERSION AX627178.1 GI:28455216
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Petersohn,D., Conrad,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 4219 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
Location/Qualifiers
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2217 GTGACCAAAA 2226
|||||
Db 1 GTACCAAAA 10

RESULT 62
AX627466/c 11 bp DNA linear PAT 21-FEB-2003
LOCUS AX627466/c
DEFINITION Sequence 4507 from Patent WO02053774.
ACCESSION AX627466
VERSION AX627466.1 GI:28455504
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Petersohn,D., Conrad,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 4507 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
Location/Qualifiers
1..11
/organism="Homo sapiens"

```

```

/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTT 2237
|||||
Db 11 TTACAGTTT 2

RESULT 63
AX627566 11 bp DNA linear PAT 21-FEB-2003
LOCUS AX627566
DEFINITION Sequence 4607 from Patent WO02053774.
ACCESSION AX627566
VERSION AX627566.1 GI:28455604
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Petersohn,D., Conrad,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 4607 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
Location/Qualifiers
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2219 GACCAAAAGT 2228
|||||
Db 1 GACAAAGT 10

RESULT 64
AX627903 11 bp DNA linear PAT 21-FEB-2003
LOCUS AX627903
DEFINITION Sequence 4944 from Patent WO02053774.
ACCESSION AX627903
VERSION AX627903.1 GI:28455941
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Petersohn,D., Conrad,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 4944 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
Location/Qualifiers
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2213 GAGTGTGACC 2222
|||||
Db 1 GAGTGAGACC 10

```



```

RESULT 65
AX628167/c
LOCUS AX628167 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 5208 from Patent WO02053774.
ACCESSION AX628167
VERSION AX628167.1 GI:28456205
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 5208 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
Location/Qualifiers
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 2223 AAAAGTTACA 2232
Db 11 AAAAGATACA 2
RESULT 66
AX629648/c
LOCUS AX629648 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 6689 from Patent WO02053774.
ACCESSION AX629648
VERSION AX629648.1 GI:28457686
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 6689 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
Location/Qualifiers
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 2229 TACATGTTTG 2238
Db 11 TACACGTTTG 2
RESULT 67
AX629854/c
LOCUS AX629854 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 6895 from Patent WO02053774.
ACCESSION AX629854
VERSION AX629854.1 GI:28457892
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

```

```

Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 6895 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
Location/Qualifiers
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 2219 GACCAAAAGT 2228
Db 11 GCCCAAAAGT 2
RESULT 68
AX630691
LOCUS AX630691 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 7732 from Patent WO02053774.
ACCESSION AX630691
VERSION AX630691.1 GI:28458729
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 7732 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
Location/Qualifiers
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 2221 CCAAAAGTTA 2230
Db 1 CCAAAAGTTA 10
RESULT 69
AX632200
LOCUS AX632200 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 9242 from Patent WO02053774.
ACCESSION AX632200
VERSION AX632200.1 GI:28467815
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 9242 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
Location/Qualifiers
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

```

```

Query Match      31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTTACA 2232
| | | | | | | | | |
Db 2 AAAACTTACA 11

RESULT 70
LOCUS AX632739/c 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 9781 from Patent WO20053774.
ACCESSION AX632739
VERSION AX632739.1 GI:28468354
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 9781 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DB)
FEATURES
source
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      31.1%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 61;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2223 AAAAGTTTACA 2232
| | | | | | | | | |
Db 10 AAAAGGTACA 1

RESULT 71
LOCUS CQ766537 12 bp DNA linear PAT 03-MAR-2004
DEFINITION Sequence 498 from Patent WO2004005547.
ACCESSION CQ766537
VERSION CQ766537.1 GI:44908797
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Weinzierl,R.
TITLE Method
JOURNAL Patent: WO 2004005547-A 498 15-JAN-2004;
IMPERIAL COLLEGE INNOVATIONS LIMITED (GB)
FEATURES
source
1..12
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="HS motif"

Query Match      31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 66;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTT 2237
| | | | | | | | | |
Db 1 TTTCATGTTT 10

RESULT 72
LOCUS CQ766563 12 bp DNA linear PAT 03-MAR-2004
DEFINITION Sequence 524 from Patent WO2004005547.
ACCESSION CQ766563
VERSION CQ766563.1 GI:44908823
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Weinzierl,R.
TITLE Method
JOURNAL Patent: WO 2004005547-A 524 15-JAN-2004;
IMPERIAL COLLEGE INNOVATIONS LIMITED (GB)
FEATURES
source
1..12
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="HS motif"

Query Match      31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 66;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 TTACATGTTT 2237
| | | | | | | | | |
Db 1 TTTCATGTTT 10

RESULT 73
LOCUS I38923 12 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 33 from patent US 5616483.
ACCESSION I38923
VERSION I38923.1 GI:2083401
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 12)
AUTHORS Bjursell,K.G., Carlsson,P.N.I., Enerback,C.S.M., Hansson,S.L.,
Lidberg,U.P.P., Nilsson,J.A. and Tornell,J.B.F.
TITLE Genomic DNA sequences encoding human BSSL/CEL
JOURNAL Patent: US 5616483-A 33 01-APR-1997;
LOCATION/Qualifiers
FEATURES
source
1..12
/organism="unknown"
/mol_type="unassigned DNA"

Query Match      31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 66;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2227 GTTACATGTT 2236
| | | | | | | | | |
Db 1 GGTACATGTT 10

RESULT 74
LOCUS I87954 12 bp DNA linear PAT 10-AUG-1998
DEFINITION Sequence 33 from patent US 5716817.
ACCESSION I87954
VERSION I87954.1 GI:3407894
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 12)
AUTHORS Tornell,J Birger,Fredrik.
TITLE Transgenic non-human mammals that express human BSSL/CEL
JOURNAL Patent: US 5716817-A 33 10-FEB-1998;

```

```

FEATURES             Location/Qualifiers
     source             1..12
                        /organism="unknown"
                        /mol_type="unassigned DNA"

Query Match          31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 66;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2227 GTTACATGTT 2236
Db 1 GGTCATGTT 10

RESULT 75
AX572515/c          12 bp DNA linear PAT 29-NOV-2002
LOCUS               AX572515
DEFINITION          Sequence 555 from Patent WO02055741.
ACCESSION           AX572515
VERSION             AX572515.1 GI:26004605
KEYWORDS            Human immunodeficiency virus
SOURCE              Human immunodeficiency virus
ORGANISM             Viruses; Retroviridae; Lentivirus; Primate
                    lentivirus group.
REFERENCE            1
AUTHORS              de Smet K. and Stuyver L.
TITLE               Method for detection of drug-induced mutations in the hiv reverse
                    transcriptase gene
JOURNAL              Patent: WO 02055741-A 555 18-JUL-2002;
                    INNOGENETICS N.V. (BE)
FEATURES             Location/Qualifiers
     source             1..12
                        /organism="Human immunodeficiency virus"
                        /mol_type="unassigned DNA"
                        /db_xref="taxon:12721"

Query Match          31.1%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 66;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2215 GTGTGACCAA 2224
Db 12 GTGTGTCCAA 3

RESULT 76
E02036/c           E02036          8 bp DNA linear PAT 29-SEP-1997
LOCUS              E02036
DEFINITION          DNA sequence before initiation codon containing initiation codon.
ACCESSION           E02036
VERSION             E02036.1 GI:22026667
KEYWORDS            JP 1989196296-A/3.
SOURCE              synthetic construct
ORGANISM             artificial sequences.
REFERENCE            1 (bases 1 to 8)
AUTHORS              Sakurai, T., Naruto, M. and Ozawa, H.
TITLE               MANIFESTATION VECTOR FOR ANIMAL CELL
JOURNAL              Patent: JP 1989196296-A 3 08-AUG-1989;
                    TORAY IND INC
COMMENT             OS Artificial gene
                    OC Artificial sequence; Genes.
                    PN JP 1989196296-A/3
                    PD 08-AUG-1989
                    PF 29-JAN-1988 JP 1988020174
                    PI SAKURAI TORU, NARUTO MASANOBU, OZAWA HITOSHI
                    PC C12N15/00.
                    CC strandedness: Single;
                    CC topology: Linear;
                    CC hypothetical: No;
                    CC anti-sense: No;
                    PH Key Location/Qualifiers

FEATURES             Location/Qualifiers
     source             1..12
                        /organism="unknown"
                        /mol_type="unassigned DNA"

Query Match          29.6%; Score 8; DB 1; Length 8;
Best Local Similarity 100.0%; Pred. No. 4.9e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2231 CATGTTTG 2238
Db 8 CATGTTTG 1

RESULT 77
AR176517/c         AR176517        10 bp DNA linear PAT 17-DEC-2001
LOCUS              AR176517
DEFINITION          Sequence 34 from patent US 6312890.
ACCESSION           AR176517
VERSION             AR176517.1 GI:17918872
KEYWORDS            Unknown.
SOURCE              Unknown.
ORGANISM             Unclassified.
REFERENCE            1 (bases 1 to 10)
AUTHORS              Linehan, W. Marston., Lerman, M. I., Latif, F. and Zbar, B.
TITLE               Partial intron sequence of von hippel-lindau (VHL) disease gene and
                    its use in diagnosis of disease
JOURNAL              Patent: US 6312890-A 34 06-NOV-2001;
FEATURES             Location/Qualifiers
     source             1..10
                        /organism="unknown"
                        /mol_type="unassigned DNA"

Query Match          29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2217 GTGACCAA 2224
Db 10 GTGACCAA 3

RESULT 78
BD239221           BD239221        10 bp DNA linear PAT 17-JUL-2003
LOCUS              BD239221
DEFINITION          Preparation and use of superior vaccines.
ACCESSION           BD239221
VERSION             BD239221.1 GI:33048991
KEYWORDS            JP 2002534056-A/639.
SOURCE              Homo sapiens (human)
ORGANISM             Homo sapiens
                    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE            1 (bases 1 to 10)
AUTHORS              Roberts, B. L. and Shankara, S.
TITLE               Preparation and use of superior vaccines
JOURNAL              Patent: JP 2002534056-A 639 15-OCT-2002;
                    GENZYME CORP
COMMENT             CS Homo sapiens (human)
                    PN JP 2002534056-A/639
                    PD 15-OCT-2002
                    PF 18-JUN-1999 JP 2000554749
                    PR 19-JUN-1998 US 60/090039; 19-JUN-1998 US 60/090040 PR
                    19-JUN-1998 US 60/090041; 19-JUN-1998 US 60/089853 PR
                    19-JUN-1998 US 60/089997; 19-JUN-1998 US 60/090079 PR
                    19-JUN-1998 US 60/090035; 19-JUN-1998 US 60/089993 PR
                    19-JUN-1998 US 60/089992; 19-JUN-1998 US 60/090072 PR
                    19-JUN-1998 US 60/089878; 19-JUN-1998 US 60/089991 PR

```

```

19-JUN-1998 US 60/090000,19-JUN-1998 US 60/090048 PR
19-JUN-1998 US 60/089999,19-JUN-1998 US 60/090043 PR
19-JUN-1998 US 60/090042,19-JUN-1998 US 60/090036 PR
19-JUN-1998 US 60/090044,19-JUN-1998 US 60/089844 PR
19-JUN-1998 US 60/090080,19-JUN-1998 US 60/089833 PR
19-JUN-1998 US 60/089994,19-JUN-1998 US 60/090077 PR
19-JUN-1998 US 60/090078,19-JUN-1998 US 60/090047 PR
19-JUN-1998 US 60/090076,19-JUN-1998 US 60/090045 PR
08-DEC-1998 US 60/111715
PI BRUCE L ROBERTS, SRINIVAS SHANKARA
PC C12N15/09, C12N15/09, A61K39/00, A61P35/00, A61P37/04, C12N1/15, PC
C12N1/19, C12N5/10, G01N33/15, G01N33/50, G01N33/53, G01N33/566, PC
G01N37/00,
CC Preparation and use of superior vaccines
FH Key Location/Qualifiers
FT source 1..10
/organism='Homo sapiens (human)'.
FEATURES
source
1..10
Location/Qualifiers
/organism='Homo sapiens'
/mol_type='genomic DNA'
/db_xref='taxon:9606'

Query Match 29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2224 AAAGTTAC 2231
DB 3 AAAGTTAC 10

RESULT 79
BD239279/c
LOCUS 10 bp DNA linear PAT 17-JUL-2003
DEFINITION Preparation and use of superior vaccines.
ACCESSION BD239279.1 GI:33049049
VERSION JP 2002534056-A/697.
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 10)
Robert, B.L. and Shankara, S.
AUTHORS
TITLE Preparation and use of superior vaccines
JOURNAL Patent: JP 2002534056-A 697 15-OCT-2002;
GENZYME CORP
COMMENT OS Homo sapiens (human)
PN JP 2002534056-A/697
PD 15-OCT-2002
PF 18-JUN-1998 JP 2000554749
PR 19-JUN-1998 US 60/090039,19-JUN-1998 US 60/090040 PR
19-JUN-1998 US 60/090041,19-JUN-1998 US 60/089853 PR
19-JUN-1998 US 60/089997,19-JUN-1998 US 60/090079 PR
19-JUN-1998 US 60/090035,19-JUN-1998 US 60/089993 PR
19-JUN-1998 US 60/089992,19-JUN-1998 US 60/090072 PR
19-JUN-1998 US 60/089878,19-JUN-1998 US 60/089991 PR
19-JUN-1998 US 60/090000,19-JUN-1998 US 60/090048 PR
19-JUN-1998 US 60/089999,19-JUN-1998 US 60/090043 PR
19-JUN-1998 US 60/090042,19-JUN-1998 US 60/090036 PR
19-JUN-1998 US 60/090044,19-JUN-1998 US 60/089844 PR
19-JUN-1998 US 60/090080,19-JUN-1998 US 60/089833 PR
19-JUN-1998 US 60/089994,19-JUN-1998 US 60/090077 PR
19-JUN-1998 US 60/090078,19-JUN-1998 US 60/090047 PR
19-JUN-1998 US 60/090076,19-JUN-1998 US 60/090045 PR
08-DEC-1998 US 60/111715
PI BRUCE L ROBERTS, SRINIVAS SHANKARA
PC C12N15/09, C12N15/09, A61K39/00, A61P35/00, A61P37/04, C12N1/15, PC
C12N1/19, C12N5/10, G01N33/15, G01N33/50, G01N33/53, G01N33/566, PC
G01N37/00,
CC Preparation and use of superior vaccines
FH Key Location/Qualifiers
FT source 1..10
/organism='Homo sapiens (human)'.
FEATURES
source
1..10
Location/Qualifiers
/organism='Homo sapiens'
/mol_type='genomic DNA'
/db_xref='taxon:9606'

Query Match 29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2221 CCAAAAGT 2228
DB 9 CCAAAAGT 2

RESULT 80
BD239635/c
LOCUS 10 bp DNA linear PAT 17-JUL-2003
DEFINITION Preparation and use of superior vaccines.
ACCESSION BD239635
VERSION BD239635.1 GI:33049405
KEYWORDS JP 2002534056-A/1053.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 10)
Robert, B.L. and Shankara, S.
AUTHORS
TITLE Preparation and use of superior vaccines
JOURNAL Patent: JP 2002534056-A 1053 15-OCT-2002;
GENZYME CORP
COMMENT OS Homo sapiens (human)
PN JP 2002534056-A/1053
PD 15-OCT-2002
PF 18-JUN-1998 JP 2000554749
PR 19-JUN-1998 US 60/090039,19-JUN-1998 US 60/090040 PR
19-JUN-1998 US 60/090041,19-JUN-1998 US 60/089853 PR
19-JUN-1998 US 60/089997,19-JUN-1998 US 60/090079 PR
19-JUN-1998 US 60/090035,19-JUN-1998 US 60/089993 PR
19-JUN-1998 US 60/089992,19-JUN-1998 US 60/090072 PR
19-JUN-1998 US 60/089878,19-JUN-1998 US 60/089991 PR
19-JUN-1998 US 60/090000,19-JUN-1998 US 60/090048 PR
19-JUN-1998 US 60/089999,19-JUN-1998 US 60/090043 PR
19-JUN-1998 US 60/090042,19-JUN-1998 US 60/090036 PR
19-JUN-1998 US 60/090044,19-JUN-1998 US 60/089844 PR
19-JUN-1998 US 60/090080,19-JUN-1998 US 60/089833 PR
19-JUN-1998 US 60/089994,19-JUN-1998 US 60/090077 PR
19-JUN-1998 US 60/090078,19-JUN-1998 US 60/090047 PR
19-JUN-1998 US 60/090076,19-JUN-1998 US 60/090045 PR
08-DEC-1998 US 60/111715
PI BRUCE L ROBERTS, SRINIVAS SHANKARA
PC C12N15/09, C12N15/09, A61K39/00, A61P35/00, A61P37/04, C12N1/15, PC
C12N1/19, C12N5/10, G01N33/15, G01N33/50, G01N33/53, G01N33/566, PC
G01N37/00,
CC Preparation and use of superior vaccines
FH Key Location/Qualifiers
FT source 1..10
/organism='Homo sapiens (human)'.
FEATURES
source
1..10
Location/Qualifiers
/organism='Homo sapiens'
/mol_type='genomic DNA'
/db_xref='taxon:9606'

Query Match 29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2221 CCAAAAGT 2228
DB 9 CCAAAAGT 2

RESULT 80
BD239635/c
LOCUS 10 bp DNA linear PAT 17-JUL-2003
DEFINITION Preparation and use of superior vaccines.
ACCESSION BD239635
VERSION BD239635.1 GI:33049405
KEYWORDS JP 2002534056-A/1053.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 10)
Robert, B.L. and Shankara, S.
AUTHORS
TITLE Preparation and use of superior vaccines
JOURNAL Patent: JP 2002534056-A 1053 15-OCT-2002;
GENZYME CORP
COMMENT OS Homo sapiens (human)
PN JP 2002534056-A/1053
PD 15-OCT-2002
PF 18-JUN-1998 JP 2000554749
PR 19-JUN-1998 US 60/090039,19-JUN-1998 US 60/090040 PR
19-JUN-1998 US 60/090041,19-JUN-1998 US 60/089853 PR
19-JUN-1998 US 60/089997,19-JUN-1998 US 60/090079 PR
19-JUN-1998 US 60/090035,19-JUN-1998 US 60/089993 PR
19-JUN-1998 US 60/089992,19-JUN-1998 US 60/090072 PR
19-JUN-1998 US 60/089878,19-JUN-1998 US 60/089991 PR
19-JUN-1998 US 60/090000,19-JUN-1998 US 60/090048 PR
19-JUN-1998 US 60/089999,19-JUN-1998 US 60/090043 PR
19-JUN-1998 US 60/090042,19-JUN-1998 US 60/090036 PR
19-JUN-1998 US 60/090044,19-JUN-1998 US 60/089844 PR
19-JUN-1998 US 60/090080,19-JUN-1998 US 60/089833 PR
19-JUN-1998 US 60/089994,19-JUN-1998 US 60/090077 PR
19-JUN-1998 US 60/090078,19-JUN-1998 US 60/090047 PR
19-JUN-1998 US 60/090076,19-JUN-1998 US 60/090045 PR
08-DEC-1998 US 60/111715
PI BRUCE L ROBERTS, SRINIVAS SHANKARA
PC C12N15/09, C12N15/09, A61K39/00, A61P35/00, A61P37/04, C12N1/15, PC
C12N1/19, C12N5/10, G01N33/15, G01N33/50, G01N33/53, G01N33/566, PC
G01N37/00,
CC Preparation and use of superior vaccines
FH Key Location/Qualifiers
FT source 1..10
/organism='Homo sapiens (human)'.
FEATURES
source
1..10
Location/Qualifiers
/organism='Homo sapiens'
/mol_type='genomic DNA'
/db_xref='taxon:9606'

Query Match 29.6%; Score 8; DB 1; Length 10;

```

Best Local Similarity 100.0%; Pred. No. 68;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2226 AGTTACAT 2233
Db 10 AGTTACAT 3

RESULT 81
LOCUS C0828615 10 bp DNA linear PAT 05-JUL-2004
DEFINITION Sequence 333 from Patent WO2004053120.
ACCESSION C0828615
VERSION C0828615.1 GI:49732098
KEYWORDS
SOURCE Rattus norvegicus (Norway rat)
ORGANISM Rattus norvegicus
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
Rattus.

REFERENCE 1
AUTHORS Weihe, E., Bieller, A. and Schaefer, M.K.
TITLE Regulatory elements in the 5' region of the vr1 gene
JOURNAL Patent: WO 2004053120-A 333 24-JUN-2004;
Gruenthal GmbH (DE)
FEATURES
source Location/Qualifiers
1..10
/organism="Rattus norvegicus"
/mol_type="unassigned DNA"
/db_xref="taxon:10116"
/note="V\$VBP 01"

Query Match 29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2227 GTTACATG 2234
Db 1 GTTACATG 8

RESULT 82
LOCUS AR303494/c 10 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 219 from patent US 6544736.
ACCESSION AR303494
VERSION AR303494.1 GI:31692270
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 10)
AUTHORS Shimamoto, A., Furuichi, Y., Shibata, Y., Funaki, H., Ohara, E. and Watahiki, M.
TITLE Method for synthesizing cDNA from mRNA sample
JOURNAL Patent: US 6544736-A 219 08-APR-2003;
FEATURES
source Location/Qualifiers
1..10
/organism="unknown"
/mol_type="genomic DNA"

Query Match 29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2221 CCAAAAGT 2228
Db 8 CCAAAAGT 1

RESULT 83
LOCUS AR351773 10 bp DNA linear PAT 17-AUG-2003

DEFINITION Sequence 1315 from patent US 6588746.
ACCESSION AR351773
VERSION AR351773.1 GI:33753569
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 10)
AUTHORS Dobrindt, D. and Fischer, U.
TITLE Device for generating an offset of transported flexible sheet material
JOURNAL Patent: US 6588746-A 1315 08-JUL-2003;
FEATURES
source Location/Qualifiers
1..10
/organism="unknown"
/mol_type="genomic DNA"

Query Match 29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2213 GAGTGTGA 2220
Db 1 GAGTGTGA 8

RESULT 84
LOCUS AR351781 10 bp DNA linear PAT 17-AUG-2003
DEFINITION Sequence 1323 from patent US 6588746.
ACCESSION AR351781
VERSION AR351781.1 GI:33753577
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 10)
AUTHORS Dobrindt, D. and Fischer, U.
TITLE Device for generating an offset of transported flexible sheet material
JOURNAL Patent: US 6588746-A 1323 08-JUL-2003;
FEATURES
source Location/Qualifiers
1..10
/organism="unknown"
/mol_type="genomic DNA"

Query Match 29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2213 GAGTGTGA 2220
Db 1 GAGTGTGA 8

RESULT 85
LOCUS AR351782 10 bp DNA linear PAT 17-AUG-2003
DEFINITION Sequence 1324 from patent US 6588746.
ACCESSION AR351782
VERSION AR351782.1 GI:33753578
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 10)
AUTHORS Dobrindt, D. and Fischer, U.
TITLE Device for generating an offset of transported flexible sheet material
JOURNAL Patent: US 6588746-A 1324 08-JUL-2003;
FEATURES
source Location/Qualifiers
1..10
/organism="unknown"

```

/mol_type="genomic DNA"

Query Match      29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2213 GAGTGTGA 2220
    |||||
Db 1 GAGTGTGA 8

RESULT 86
AX153396/c
LOCUS AX153396 10 bp DNA linear PAT 22-JUN-2001
DEFINITION Sequence 1311 from Patent WO0138577.
ACCESSION AX153396
VERSION AX153396.1 GI:14535047
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Velculescu,V.E., Vogelstein,B. and Kinzler,K.W.
TITLE Human transcriptomes
JOURNAL Patent: WO 0138577-A 1311 31-MAY-2001;
The Johns Hopkins University (US)
FEATURES
source
1..10
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2221 CCAAAAGT 2228
    |||||
Db 9 CCAAAAGT 2

RESULT 87
AX667866
LOCUS AX667866 10 bp DNA linear PAT 26-MAR-2003
DEFINITION Sequence 1315 from Patent WO0242459.
ACCESSION AX667866
VERSION AX667866.1 GI:29291403
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Liu,Q.
TITLE Position dependent recognition of gnn nucleotide triplets by zinc
fingers
JOURNAL Patent: WO 0242459-A 1315 30-MAY-2002;
Sangamo Biosciences Inc. (US)
FEATURES
source
1..10
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="example target DNA"

Query Match      29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2213 GAGTGTGA 2220
    |||||
Db 1 GAGTGTGA 8

RESULT 88
AX667874
LOCUS AX667874 10 bp DNA linear PAT 26-MAR-2003
DEFINITION Sequence 1323 from Patent WO0242459.
ACCESSION AX667874
VERSION AX667874.1 GI:29291411
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Liu,Q.
TITLE Position dependent recognition of gnn nucleotide triplets by zinc
fingers
JOURNAL Patent: WO 0242459-A 1323 30-MAY-2002;
Sangamo Biosciences Inc. (US)
FEATURES
source
1..10
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="example target DNA"

Query Match      29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2213 GAGTGTGA 2220
    |||||
Db 1 GAGTGTGA 8

RESULT 89
AX667875
LOCUS AX667875 10 bp DNA linear PAT 26-MAR-2003
DEFINITION Sequence 1324 from Patent WO0242459.
ACCESSION AX667875
VERSION AX667875.1 GI:29291412
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Liu,Q.
TITLE Position dependent recognition of gnn nucleotide triplets by zinc
fingers
JOURNAL Patent: WO 0242459-A 1324 30-MAY-2002;
Sangamo Biosciences Inc. (US)
FEATURES
source
1..10
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="example target DNA"

Query Match      29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2213 GAGTGTGA 2220
    |||||
Db 1 GAGTGTGA 8

RESULT 90
AX955930/c
LOCUS AX955930 10 bp DNA linear PAT 08-JAN-2004
DEFINITION Sequence 12 from Patent WO03095653.
ACCESSION AX955930
VERSION AX955930.1 GI:40784552
KEYWORDS Pichia angusta
SOURCE Pichia angusta

```

```

ORGANISM Pichia angusta
Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
Saccharomycetales; Saccharomycetaceae; Pichia.
REFERENCE
AUTHORS Suckow,M.
TITLE Promoters having a modified transcription efficiency and derived
        from methylotropic yeast
JOURNAL Patent: WO 03095653-A 12 20-NOV-2003;
        RHEIN BIOTECH GESELLSCHAFT FUER NEUE BIOTECHNOLOGISCHE PRO; ZESSE
        UND PRODUKTE MBH (DE)
FEATURES
source 1..10
        /organism="Pichia angusta"
        /mol_type="unassigned DNA"
        /db_xref="taxon:4905"
        /note="Beschreibung der Sequenz: MOX-Promotorabschnitt"
Query Match 29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 2218 TGACCAAA 2225
Db 9 TGACCAAA 2
RESULT 91
BD007825 10 bp DNA linear PAT 31-JAN-2002
LOCUS BD007825
DEFINITION LPS activated human monocyte expressing genes.
ACCESSION BD007825
VERSION BD007825.1 GI:18636198
KEYWORDS JP 2001069993-A/101.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 10)
Matsushima,K., Hashimoto,S. and Suzuki,T.
LPS activated human monocyte expressing genes
Patent: JP 2001069993-A 101 21-MAR-2001;
JAPAN SCIENCE AND TECHNOLOGY CORP
COMMENT OS Homo sapiens (human)
PN JP 2001069993-A/101
PD 21-MAR-2001
PR 28-APR-2000 JP 2000131079
PI KOJI MATSUSHIMA,SHINICHI HASHIMOTO,TAKUJI SUZUKI PC
C12N15/09,C07K14/47,C07K16/18,G01N33/50,G01N33/53//A61K45/00, PC
A61P29/00.
PC A61P31/00,C12P21/08,C12N15/00
CC
FH Key Location/Qualifiers
FT source 1..10
        /organism="Homo sapiens (human)"
        /mol_type="genomic DNA"
        /db_xref="taxon:9606"
Query Match 29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 2215 GTGTGACC 2222
Db 2 GTGTGACC 9
RESULT 92
BD166573/c 10 bp DNA linear PAT 17-JAN-2003
LOCUS BD166573

```

```

DEFINITION Human liver disease-expressing genes.
ACCESSION BD166573
VERSION BD166573.1 GI:27872385
KEYWORDS JP 2002209591-A/118.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 10)
AUTHORS Matsushima,K., Hashimoto,S., Kaneko,S. and Yamashita,T.
TITLE Human liver disease-expressing genes
JOURNAL Patent: JP 2002209591-A 118 30-JUL-2002;
        JAPAN SCIENCE AND TECHNOLOGY CORP
COMMENT OS Homo sapiens (human)
PN JP 2002209591-A/118
PD 30-JUL-2002
PR 19-JAN-2001 JP 2001012328
PI KOJI MATSUSHIMA,SHINICHI HASHIMOTO,SHUICHI KANEKO,TARO PI
YAMASHITA
PC C12N15/09,C07K14/47,C07K16/18,G01N33/15,G01N33/50//C12P21/02,
PC C12P21/08,
PC C12N15/00
CC Human liver disease-expressing genes
FH Key Location/Qualifiers
FT source 1..10
        /organism="Homo sapiens (human)"
        /mol_type="genomic DNA"
        /db_xref="taxon:32644"
Query Match 29.6%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 2225 AAGTTACA 2232
Db 8 AAGTTACA 1
RESULT 93
CQ833105/c
LOCUS CQ833105
DEFINITION Sequence 476 from Patent WO2004059002.
ACCESSION CQ833105
VERSION CQ833105.1 GI:50832712
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
Conrad,M. and Hofmann,K.
Method for determining the homeostasis of hairy skin
Patent: WO 2004059002-A 476 15-JUL-2004;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source 1..11
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"
Query Match 29.6%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 74;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 2226 AGTTACAT 2233
Db 8 AGTTACAT 1
RESULT 94

```

```

CQ833109/c
LOCUS      CQ833109      11 bp      DNA      linear      PAT 29-JUL-2004
DEFINITION Sequence 480 from Patent WO2004059002.
ACCESSION  CQ833109
VERSION    CQ833109.1  GI:50832716
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
REFERENCE  1
AUTHORS   Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
          Conradt,M. and Hofmann,K.
TITLE     Method for determining the homeostasis of hairy skin
JOURNAL   Patent: WO 2004059002-A 480 15-JUL-2004;
          Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES   Location/Qualifiers
            1..11
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
Query Match      29.6%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 74;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      2223 AAAAGTTA 2230
Db      11 AAAAGTTA 4
RESULT 95
LOCUS      CQ836060      11 bp      DNA      linear      PAT 29-JUL-2004
DEFINITION Sequence 1118 from Patent WO2004059001.
ACCESSION  CQ836060
VERSION    CQ836060.1  GI:50835594
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
REFERENCE  1
AUTHORS   Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
          Conradt,M. and Hofmann,K.
TITLE     Method for determining markers of human facial skin
JOURNAL   Patent: WO 2004059001-A 1118 15-JUL-2004;
          Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES   Location/Qualifiers
            1..11
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
Query Match      29.6%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 74;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      2220 ACCAAAG 2227
Db      3 ACCAAAG 10
RESULT 96
LOCUS      CQ836293      11 bp      DNA      linear      PAT 29-JUL-2004
DEFINITION Sequence 1351 from Patent WO2004059001.
ACCESSION  CQ836293
VERSION    CQ836293.1  GI:50835827
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
REFERENCE  1
AUTHORS   Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
          Conradt,M. and Hofmann,K.
TITLE     Method for determining skin stress or skin ageing in vitro
JOURNAL   Patent: WO 02053773-A 155 11-JUL-2002;
          HENKEL KGAA (DE)
FEATURES   Location/Qualifiers
            1..11
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
Query Match      29.6%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 74;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      2226 TGTGACCA 2232
Db      3 TGTGACCA 10
RESULT 97
LOCUS      AR301541      11 bp      DNA      linear      PAT 12-JUN-2003
DEFINITION Sequence 122 from patent US 6538173.
ACCESSION  AR301541
VERSION    AR301541.1  GI:31689343
KEYWORDS   Unknown.
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 11)
AUTHORS   Heber-Katz,E.
TITLE     Compositions and methods for wound healing
JOURNAL   Patent: US 6538173-A 122 25-MAR-2003;
          Location/Qualifiers
            1..11
            /organism="unknown"
            /mol_type="genomic DNA"
Query Match      29.6%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 74;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      2216 TGTGACCA 2223
Db      3 TGTGACCA 10
RESULT 98
LOCUS      AX470578/c      11 bp      DNA      linear      PAT 09-AUG-2002
DEFINITION Sequence 155 from Patent WO02053773.
ACCESSION  AX470578
VERSION    AX470578.1  GI:22205703
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
REFERENCE  1
AUTHORS   Hofmann,K., Conradt,M. and Petersohn,D.
TITLE     Method for determining skin stress or skin ageing in vitro
JOURNAL   Patent: WO 02053773-A 155 11-JUL-2002;
          HENKEL KGAA (DE)
FEATURES   Location/Qualifiers
            1..11
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
Query Match      29.6%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 74;
Matches      8; Conservative 0; Mismatches 0; Indels 1;
QY      2225 AAGTTACA 2232
Db      8 AAGTTACA 1

```

```

Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE  1
AUTHORS   Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
          Conradt,M. and Hofmann,K.
TITLE     Method for determining markers of human facial skin
JOURNAL   Patent: WO 2004059001-A 1351 15-JUL-2004;
          Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES   Location/Qualifiers
            1..11
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
Query Match      29.6%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 74;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      2225 AAGTTACA 2232
Db      8 AAGTTACA 1
RESULT 97
LOCUS      AR301541      11 bp      DNA      linear      PAT 12-JUN-2003
DEFINITION Sequence 122 from patent US 6538173.
ACCESSION  AR301541
VERSION    AR301541.1  GI:31689343
KEYWORDS   Unknown.
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 11)
AUTHORS   Heber-Katz,E.
TITLE     Compositions and methods for wound healing
JOURNAL   Patent: US 6538173-A 122 25-MAR-2003;
          Location/Qualifiers
            1..11
            /organism="unknown"
            /mol_type="genomic DNA"
Query Match      29.6%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 74;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      2216 TGTGACCA 2223
Db      3 TGTGACCA 10
RESULT 98
LOCUS      AX470578/c      11 bp      DNA      linear      PAT 09-AUG-2002
DEFINITION Sequence 155 from Patent WO02053773.
ACCESSION  AX470578
VERSION    AX470578.1  GI:22205703
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
REFERENCE  1
AUTHORS   Hofmann,K., Conradt,M. and Petersohn,D.
TITLE     Method for determining skin stress or skin ageing in vitro
JOURNAL   Patent: WO 02053773-A 155 11-JUL-2002;
          HENKEL KGAA (DE)
FEATURES   Location/Qualifiers
            1..11
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
Query Match      29.6%; Score 8; DB 1; Length 11;

```



```

Best Local Similarity 100.0%; Pred. No. 74;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2221 CCAAAAGT 2228
Db 11 CCAAAAGT 4

RESULT 99
AX472174/c
LOCUS AX472174 11 bp DNA linear PAT 09-AUG-2002
DEFINITION Sequence 165 from Patent WO02053775.
ACCESSION AX472174
VERSION AX472174.1 GI:22207211
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS Hustert,E., Haberl,M. and Wojnowski,L.
TITLE Identification of the genetic determinants of the polymorphic
JOURNAL cyp3a5 expression
Patent: WO 02053775-A-165 11-JUL-2002;
EPIDAUROS BIOTECHNOLOGIE AG (DE)
FEATURES
source
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 29.6%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 74;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2214 AGTGTGAC 2221
Db 10 AGTGTGAC 3

RESULT 100
AX625287/c
LOCUS AX625287 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 2328 from Patent WO02053774.
ACCESSION AX625287
VERSION AX625287.1 GI:28453228
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A-2328 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 29.6%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 74;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2220 ACCAAAG 2227
Db 10 ACCAAAG 3

RESULT 101
AX625400/c
LOCUS AX625400 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 2441 from Patent WO02053774.
ACCESSION AX625400
VERSION AX625400.1 GI:28453341
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A-2441 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 29.6%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 74;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2213 GAGTGTGA 2220
Db 10 GAGTGTGA 3

RESULT 102
AX625627/c
LOCUS AX625627 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 2668 from Patent WO02053774.
ACCESSION AX625627
VERSION AX625627.1 GI:28453568
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A-2668 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 29.6%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 74;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2221 CCAAAAGT 2228
Db 11 CCAAAAGT 4

RESULT 103
AX626945/c
LOCUS AX626945 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 3986 from Patent WO02053774.
ACCESSION AX626945
VERSION AX626945.1 GI:28454983
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.

```

```

TITLE      Method for determining homeostasis of the skin
JOURNAL    Patent: WO 02053774-A 3986 11-JUL-2002;
           Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
  source
    1. .11
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match      29.6%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 74;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2223 AAAAGTTA 2230
DB      8 AAAAGTTA 1

RESULT 104
AX627307/c
LOCUS      AX627307
DEFINITION Sequence 4348 from Patent WO02053774.
ACCESSION  AX627307
VERSION     AX627307.1 GI:28455345
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1
  Petersohn,D., Conradt,M. and Hofmann,K.
  Method for determining homeostasis of the skin
  Patent: WO 02053774-A 5133 11-JUL-2002;
  Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
  source
    1. .11
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match      29.6%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 74;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2216 TGTGACCA 2223
DB      4 TGTGACCA 11

RESULT 107
AX632708/c
LOCUS      AX632708
DEFINITION Sequence 9750 from Patent WO02053774.
ACCESSION  AX632708
VERSION     AX632708.1 GI:28468323
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1
  Petersohn,D., Conradt,M. and Hofmann,K.
  Method for determining homeostasis of the skin
  Patent: WO 02053774-A 9750 11-JUL-2002;
  Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
  source
    1. .11
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match      29.6%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 74;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2220 ACCAAAAG 2227
DB      10 ACCAAAAG 3

RESULT 108
BD124291
LOCUS      BD124291
DEFINITION Compositions and method for healing wound.

Query Match      29.6%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 74;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2222 CAAAAGTT 2229
DB      10 CAAAAGTT 3

RESULT 106
AX628092
LOCUS      AX628092
DEFINITION Sequence 5133 from Patent WO02053774.
ACCESSION  AX628092
VERSION     AX628092.1 GI:28456130
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1
  Petersohn,D., Conradt,M. and Hofmann,K.
  Method for determining homeostasis of the skin
  Patent: WO 02053774-A 5133 11-JUL-2002;
  Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
  source
    1. .11
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match      29.6%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 74;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2223 AAAAGTTA 2230
DB      8 AAAAGTTA 1

RESULT 104
AX627307/c
LOCUS      AX627307
DEFINITION Sequence 4348 from Patent WO02053774.
ACCESSION  AX627307
VERSION     AX627307.1 GI:28455345
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1
  Petersohn,D., Conradt,M. and Hofmann,K.
  Method for determining homeostasis of the skin
  Patent: WO 02053774-A 4348 11-JUL-2002;
  Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
  source
    1. .11
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match      29.6%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 74;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2223 AAAAGTTA 2230
DB      9 AAAAGTTA 2

RESULT 105
AX627680/c
LOCUS      AX627680
DEFINITION Sequence 4721 from Patent WO02053774.
ACCESSION  AX627680
VERSION     AX627680.1 GI:28455718
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1
  Petersohn,D., Conradt,M. and Hofmann,K.
  Method for determining homeostasis of the skin
  Patent: WO 02053774-A 4721 11-JUL-2002;
  Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
  source
    1. .11
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match      29.6%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 74;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2222 CAAAAGTT 2229
DB      10 CAAAAGTT 3

RESULT 106
AX628092
LOCUS      AX628092
DEFINITION Sequence 5133 from Patent WO02053774.
ACCESSION  AX628092
VERSION     AX628092.1 GI:28456130
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1
  Petersohn,D., Conradt,M. and Hofmann,K.
  Method for determining homeostasis of the skin
  Patent: WO 02053774-A 5133 11-JUL-2002;
  Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
  source
    1. .11
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match      29.6%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 74;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2220 ACCAAAAG 2227
DB      10 ACCAAAAG 3

RESULT 108
BD124291
LOCUS      BD124291
DEFINITION Compositions and method for healing wound.

Query Match      29.6%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 74;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2222 CAAAAGTT 2229
DB      10 CAAAAGTT 3

RESULT 106
AX628092
LOCUS      AX628092
DEFINITION Sequence 5133 from Patent WO02053774.
ACCESSION  AX628092
VERSION     AX628092.1 GI:28456130
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1
  Petersohn,D., Conradt,M. and Hofmann,K.
  Method for determining homeostasis of the skin
  Patent: WO 02053774-A 5133 11-JUL-2002;
  Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
  source
    1. .11
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match      29.6%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 74;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2220 ACCAAAAG 2227
DB      10 ACCAAAAG 3

RESULT 108
BD124291
LOCUS      BD124291
DEFINITION Compositions and method for healing wound.

```

```

ACCESSION      BD124291
VERSION        BD124291.1  GI:23219236
KEYWORDS       JP 2002503460-A/122.
SOURCE         Mus musculus (house mouse)
ORGANISM       Mus musculus
               Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE      Katz,B.H.
AUTHORS        Compositions and method for healing wound
TITLE          THE WISTAR INSTITUTE
JOURNAL        OS  Mus musculus (mouse)
COMMENT        PN  JP 2002503460-A/122
               PD  05-FEB-2002
               PF  12-FEB-1999  JP 2000531545
               PR  13-FEB-1998  US  60/074737,26-AUG-1998  US  60/097937  PR
               28-SEP-1998  US  60/102051
               PI  ELLEN HEBER KATZ
               PC  C12N15/09,A01K67/027,C12N5/10,C12Q1/68,G01N33/50,C12N15/00, PC
               C12N5/00
               CC  Compositions and method for healing wound
               FH  Key
               FT  Location/Qualifiers
                   1..11
                   /organism="Mus musculus (mouse)".
FEATURES       source
               1..11
               /organism="Mus musculus"
               /mol_type="genomic DNA"
               /db_xref="taxon:10090"
Query Match    29.6%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 74;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2216 TGTGACCA 2223
Db 3 TGTGACCA 10
RESULT 109
BD241065
LOCUS          BD241065
DEFINITION     Methods and products related to genotyping and DNA analysis.
ACCESSION      BD241065
VERSION        BD241065.1  GI:33050835
KEYWORDS       JP 2002525127-A/12.
SOURCE         Homo sapiens (human)
ORGANISM       Homo sapiens
               Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
               Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE      Landers,J.E., Jordan,B., Housman,D.E. and Charest,A.
AUTHORS        Methods and products related to genotyping and DNA analysis
TITLE          Patent: JP 2002525127-A 12 13-AUG-2002;
JOURNAL        MASSACHUSETTS INSTITUTE OF TECHNOLOGY
COMMENT        OS  Homo sapiens (human)
               PN  JP 2002525127-A/12
               PD  13-AUG-2002
               PF  24-SEP-1999  JP 2000572407
               PR  25-SEP-1998  US  60/101757
               PI  JOHN E LANDERS, BARBARA JORDAN, DAVID E HOUSMAN, ALAIN CHAREST PC
               C12N15/09,C12Q1/68,G01N33/53,G01N33/566,G01N33/58,G01N37/00, PC
               G01N37/00,
               CC  C12N15/00
               PC  Methods and products related to genotyping and DNA analysis FH
               Key
               FT  Location/Qualifiers
                   1..11
                   /organism="Homo sapiens (human)".
FEATURES       source
               1..11
               /organism="Homo sapiens"
               /mol_type="genomic DNA"

```

```

/db_xref="taxon:9606"
Query Match    28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2225 AAGTTACATGT 2235
Db 1 AAATTAATGT 11
RESULT 110
CQ828430
LOCUS          CQ828430
DEFINITION     Sequence 148 from Patent WO2004053120.
ACCESSION      CQ828430
VERSION        CQ828430.1  GI:49731913
KEYWORDS       Mus musculus (house mouse)
SOURCE         Mus musculus
ORGANISM       Mus musculus
               Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
               Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE      Weihe,B., Bieller,A. and Schaefer,M.K.
AUTHORS        Regulatory elements in the 5' region of the vrl gene
TITLE          Patent: WO 2004053120-A 148 24-JUN-2004;
JOURNAL        Gruenenthal GmbH (DE)
FEATURES       Location/Qualifiers
               1..11
               /organism="Mus musculus"
               /mol_type="unassigned DNA"
               /db_xref="taxon:10090"
               /note="V$APIFJ Q2"
Query Match    28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2216 TGTGACCAAAA 2226
Db 1 TCTGACCAATA 11
RESULT 111
CQ832651
LOCUS          CQ832651/c
DEFINITION     Sequence 22 from Patent WO2004059002.
ACCESSION      CQ832651
VERSION        CQ832651.1  GI:50832258
KEYWORDS       Homo sapiens (human)
SOURCE         Homo sapiens
ORGANISM       Homo sapiens
               Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
               Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE      Petersohn,D., Schlottmann,K., Gassenmeier,T., Holtkoetter,O.,
AUTHORS        Conrad,M. and Hofmann,K.
TITLE          Method for determining the homeostasis of hairy skin
JOURNAL        Patent: WO 2004059002-A 22 15-JUL-2004;
               Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES       Location/Qualifiers
               1..11
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"
Query Match    28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2216 TGTGACCAAAA 2226
Db 11 TGTGAGTAAAA 1

```

```

RESULT 112
CQ833007
LOCUS      CQ833007      11 bp      DNA      linear      PAT 29-JUL-2004
DEFINITION Sequence 378 from Patent WO2004059002.
ACCESSION CQ833007
VERSION   CQ833007.1 GI:50832614
KEYWORDS  Homo sapiens (human)
SOURCE    Homo sapiens
ORGANISM  Homo sapiens
REFERENCE 1
AUTHORS   Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
          Conradt,M. and Hofmann,K.
TITLE     Method for determining the homeostasis of hairy skin
JOURNAL   Patent: WO 2004059002-A 378 15-JUL-2004; (DE)
          Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES  Location/Qualifiers
           source
             1..11
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"
Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2216 TGTGACCAAAA 2226
Db 1 TATGAACAAA 11

RESULT 113
CQ833297/c
LOCUS      CQ833297      11 bp      DNA      linear      PAT 29-JUL-2004
DEFINITION Sequence 668 from Patent WO2004059002.
ACCESSION CQ833297
VERSION   CQ833297.1 GI:50832904
KEYWORDS  Homo sapiens (human)
SOURCE    Homo sapiens
ORGANISM  Homo sapiens
REFERENCE 1
AUTHORS   Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
          Conradt,M. and Hofmann,K.
TITLE     Method for determining the homeostasis of hairy skin
JOURNAL   Patent: WO 2004059002-A 668 15-JUL-2004;
          Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES  Location/Qualifiers
           source
             1..11
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"
Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2224 AAAGTTACATG 2234
Db 11 AAACCTAAATG 11

RESULT 114
CQ833314/c
LOCUS      CQ833314      11 bp      DNA      linear      PAT 29-JUL-2004
DEFINITION Sequence 685 from Patent WO2004059002.
ACCESSION CQ833314
VERSION   CQ833314.1 GI:50832921
KEYWORDS  Homo sapiens (human)
SOURCE    Homo sapiens
ORGANISM  Homo sapiens
REFERENCE 1
AUTHORS   Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
          Conradt,M. and Hofmann,K.
TITLE     Method for determining the homeostasis of hairy skin
JOURNAL   Patent: WO 2004059002-A 685 15-JUL-2004;
          Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES  Location/Qualifiers
           source
             1..11
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"
Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2216 TGTGACCAAAA 2226
Db 1 TGTGACCAAGA 11

RESULT 115
CQ833337
LOCUS      CQ833337      11 bp      DNA      linear      PAT 29-JUL-2004
DEFINITION Sequence 708 from Patent WO2004059002.
ACCESSION CQ833337
VERSION   CQ833337.1 GI:50832944
KEYWORDS  Homo sapiens (human)
SOURCE    Homo sapiens
ORGANISM  Homo sapiens
REFERENCE 1
AUTHORS   Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
          Conradt,M. and Hofmann,K.
TITLE     Method for determining the homeostasis of hairy skin
JOURNAL   Patent: WO 2004059002-A 708 15-JUL-2004;
          Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES  Location/Qualifiers
           source
             1..11
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"
Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2216 TGTGACCAAAA 2226
Db 11 TGTGACTAATA 11

RESULT 116
CQ833857/c
LOCUS      CQ833857      11 bp      DNA      linear      PAT 29-JUL-2004
DEFINITION Sequence 1228 from Patent WO2004059002.
ACCESSION CQ833857
VERSION   CQ833857.1 GI:50833464
KEYWORDS  Homo sapiens (human)
SOURCE    Homo sapiens
ORGANISM  Homo sapiens
REFERENCE 1
AUTHORS   Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
          Conradt,M. and Hofmann,K.
TITLE     Method for determining the homeostasis of hairy skin
JOURNAL   Patent: WO 2004059002-A 1228 15-JUL-2004;
          Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES  Location/Qualifiers
           source
             1..11
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"
Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2216 TGTGACCAAAA 2226
Db 1 TGTGACCAAGA 11

RESULT 117
CQ833857/c
LOCUS      CQ833857      11 bp      DNA      linear      PAT 29-JUL-2004
DEFINITION Sequence 1228 from Patent WO2004059002.
ACCESSION CQ833857
VERSION   CQ833857.1 GI:50833464
KEYWORDS  Homo sapiens (human)
SOURCE    Homo sapiens
ORGANISM  Homo sapiens
REFERENCE 1
AUTHORS   Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
          Conradt,M. and Hofmann,K.
TITLE     Method for determining the homeostasis of hairy skin
JOURNAL   Patent: WO 2004059002-A 1228 15-JUL-2004;
          Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES  Location/Qualifiers
           source
             1..11
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"
Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2216 TGTGACCAAAA 2226
Db 1 TGTGACCAAGA 11

```

```

FEATURES
  source
    Henkel Kommanditgesellschaft auf Aktien (DE)
    Location/Qualifiers
    1..11
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match
  28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2217 GTGACCAAAAG 2227
Db 11 GTGCAAAAAG 1

RESULT 117
CQ835548
LOCUS
  CQ835548 11 bp DNA linear PAT 29-JUL-2004
DEFINITION
  Sequence 606 from Patent WO2004059001.
ACCESSION
  CQ835548
VERSION
  CQ835548.1 GI:50835082
KEYWORDS
  Homo sapiens (human)
SOURCE
  Homo sapiens
  ORGANISM
    Homo sapiens
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1
  Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
  Conradt,M. and Hofmann,K.
  Method for determining markers of human facial skin
  Patent: WO 2004059001-A 606 15-JUL-2004;
  Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
  source
    1..11
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match
  28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2223 AAAAGTTACAT 2233
Db 1 AAGAGTTACGT 11

RESULT 118
CQ835699/c
LOCUS
  CQ835699 11 bp DNA linear PAT 29-JUL-2004
DEFINITION
  Sequence 757 from Patent WO2004059001.
ACCESSION
  CQ835699
VERSION
  CQ835699.1 GI:50835233
KEYWORDS
  Homo sapiens (human)
SOURCE
  Homo sapiens
  ORGANISM
    Homo sapiens
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1
  Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
  Conradt,M. and Hofmann,K.
  Method for determining markers of human facial skin
  Patent: WO 2004059001-A 757 15-JUL-2004;
  Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
  source
    1..11
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match
  28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;

FEATURES
  source
    Henkel Kommanditgesellschaft auf Aktien (DE)
    Location/Qualifiers
    1..11
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match
  28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2221 CCAAAAGTTAC 2231
Db 11 CAAAAAGTTGC 1

RESULT 119
CQ835746
LOCUS
  CQ835746 11 bp DNA linear PAT 29-JUL-2004
DEFINITION
  Sequence 804 from Patent WO2004059001.
ACCESSION
  CQ835746
VERSION
  CQ835746.1 GI:50835280
KEYWORDS
  Homo sapiens (human)
SOURCE
  Homo sapiens
  ORGANISM
    Homo sapiens
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1
  Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
  Conradt,M. and Hofmann,K.
  Method for determining markers of human facial skin
  Patent: WO 2004059001-A 804 15-JUL-2004;
  Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
  source
    1..11
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match
  28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2219 GACCAAAAGTT 2229
Db 1 GACCAAGGGT 11

RESULT 120
CQ836423
LOCUS
  CQ836423 11 bp DNA linear PAT 29-JUL-2004
DEFINITION
  Sequence 1481 from Patent WO2004059001.
ACCESSION
  CQ836423
VERSION
  CQ836423.1 GI:50835957
KEYWORDS
  Homo sapiens (human)
SOURCE
  Homo sapiens
  ORGANISM
    Homo sapiens
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1
  Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
  Conradt,M. and Hofmann,K.
  Method for determining markers of human facial skin
  Patent: WO 2004059001-A 1481 15-JUL-2004;
  Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
  source
    1..11
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match
  28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2216 TGTGACCAAAA 2226
Db 1 TATGACCAAA 11

RESULT 121
CQ836724/c

```

```

REFERENCE
AUTHORS      Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
              Conrad,M. and Hofmann,K.
TITLE        Method for determining markers of human facial skin
JOURNAL      Patent: WO 2004059001-A 2193 15-JUL-2004;
              Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES     Location/Qualifiers
              1..11
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2212 AGAGTGTGACC 2222
Db      1 ACAGGGTGACC 11

RESULT 124
LOCUS      CQ837140              11 bp      DNA
DEFINITION Sequence 2198 from Patent WO2004059001.
ACCESSION  CQ837140
VERSION     CQ837140.1 GI:50836674
KEYWORDS    Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
AUTHORS      Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
              Conrad,M. and Hofmann,K.
TITLE        Method for determining markers of human facial skin
JOURNAL      Patent: WO 2004059001-A 2198 15-JUL-2004;
              Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES     Location/Qualifiers
              1..11
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2221 CCAAAAGTTAC 2231
Db      11 CTAAAAGTCC 1

RESULT 125
LOCUS      CQ837309              11 bp      DNA
DEFINITION Sequence 2367 from Patent WO2004059001.
ACCESSION  CQ837309
VERSION     CQ837309.1 GI:50836843
KEYWORDS    Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
AUTHORS      Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
              Conrad,M. and Hofmann,K.
TITLE        Method for determining markers of human facial skin
JOURNAL      Patent: WO 2004059001-A 2367 15-JUL-2004;
              Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES     Location/Qualifiers
              1..11
              /organism="Homo sapiens"

```

```

/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2227 GTTACATGTTT 2237
Db 11 GATACATCTTT 1

RESULT 126
LOCUS      CQ837817
DEFINITION Sequence 2875 from Patent WO2004059001.
ACCESSION  CQ837817
VERSION     CQ837817.1 GI:50837351
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
            Conradt,M. and Hofmann,K.
TITLE       Method for determining markers of human facial skin
JOURNAL     Patent: WO 2004059001-A 2875 15-JUL-2004;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES    Location/Qualifiers
            source
              1..11
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2216 TGTGACCAAAA 2226
Db 1 TGTGATCACAA 11

RESULT 127
LOCUS      AR367561/c
DEFINITION Sequence 42 from patent US 6375954.
ACCESSION  AR367561
VERSION     AR367561.1 GI:34600872
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 11)
AUTHORS     Dutta,S., Biswas,B. and Vemulapalli,R.
TITLE       Size-variable strain-specific protective antigen for potomac horse
            fever
JOURNAL     Patent: US 6375954-A 42 23-APR-2002;
            Location/Qualifiers
            source
              1..11
                /organism="unknown"
                /mol_type="genomic DNA"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2225 AAGTTACATGT 2235
Db 11 AAGTTACCGT 1

RESULT 128
LOCUS      AR482566
DEFINITION Sequence 12 from patent US 6703228.
ACCESSION  AR482566
VERSION     AR482566.1 GI:47245089
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 11)
AUTHORS     Landers,J., Jordan,B., Housman,D.E. and Charest,A.
TITLE       Methods and products related to genotyping and DNA analysis
JOURNAL     Patent: US 6703228-A 12 09-MAR-2004;
            Location/Qualifiers
            source
              1..11
                /organism="unknown"
                /mol_type="genomic DNA"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2225 AAGTTACATGT 2235
Db 1 AAATTAAATGT 11

RESULT 129
LOCUS      AX190714/c
DEFINITION Sequence 65 from Patent WO0142493.
ACCESSION  AX190714
VERSION     AX190714.1 GI:15143998
KEYWORDS
SOURCE      synthetic construct
            synthetic construct
            artificial sequences.
REFERENCE   1
AUTHORS     Olek,A. and Piepenbrock,C.
TITLE       Method for the parallel detection of the degree of methylation of
            genomic dna
JOURNAL     Patent: WO 0142493-A 65 14-JUN-2001;
            Epigenomics AG (DE)
FEATURES    Location/Qualifiers
            source
              1..11
                /organism="synthetic construct"
                /mol_type="unassigned DNA"
                /db_xref="taxon:32630"
                /note="chemisch vorbehandelte Genom-DNA"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2223 AAAAGTTACAT 2233
Db 11 AAATATTACAT 1

RESULT 130
LOCUS      AX190725
DEFINITION Sequence 76 from Patent WO0142493.
ACCESSION  AX190725
VERSION     AX190725.1 GI:15144009
KEYWORDS
SOURCE      synthetic construct
            synthetic construct
            artificial sequences.
REFERENCE   1
AUTHORS     Olek,A. and Piepenbrock,C.
TITLE       Method for the parallel detection of the degree of methylation of

```

```

genomic dna
Patent: WO 0142493-A 76 14-JUN-2001;
Epigenomics AG (DE)
FEATURES
    source
        1..11
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"
            /note="chemisch vorbehandelte Genom-DNA"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2223 AAAAGTTACAT 2233
Db      1 AAATATTACAT 11

RESULT 131
AX190727/c
LOCUS      AX190727      11 bp      DNA      linear      PAT 08-AUG-2001
DEFINITION Sequence 78 from Patent WO0142493.
ACCESSION  AX190727
VERSION     AX190727.1 GI:15144011
KEYWORDS    .
SOURCE      synthetic construct
            synthetic construct
            artificial sequences.
ORGANISM
REFERENCE
AUTHORS     Olek A. and Piepenbrock C.
TITLE       Method for the parallel detection of the degree of methylation of
            genomic dna
JOURNAL     Patent: WO 0142493-A 78 14-JUN-2001;
            Epigenomics AG (DE)
FEATURES
    source
        1..11
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"
            /note="chemisch vorbehandelte Genom-DNA"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2226 AGTTACATGTT 2236
Db      11 ATTACATATT 11

RESULT 132
AX190728
LOCUS      AX190728      11 bp      DNA      linear      PAT 08-AUG-2001
DEFINITION Sequence 79 from Patent WO0142493.
ACCESSION  AX190728
VERSION     AX190728.1 GI:15144012
KEYWORDS    .
SOURCE      synthetic construct
            synthetic construct
            artificial sequences.
ORGANISM
REFERENCE
AUTHORS     Olek A. and Piepenbrock C.
TITLE       Method for the parallel detection of the degree of methylation of
            genomic dna
JOURNAL     Patent: WO 0142493-A 79 14-JUN-2001;
            Epigenomics AG (DE)
FEATURES
    source
        1..11
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"
            /note="chemisch vorbehandelte Genom-DNA"

genomic dna
Patent: WO 0142493-A 76 14-JUN-2001;
Epigenomics AG (DE)
FEATURES
    source
        1..11
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"
            /note="chemisch vorbehandelte Genom-DNA"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2226 AGTTACATGTT 2236
Db      11 ATTACATATT 11

RESULT 133
AX252926/c
LOCUS      AX252926      11 bp      DNA      linear      PAT 05-OCT-2001
DEFINITION Sequence 396 from Patent WO0168910.
ACCESSION  AX252926
VERSION     AX252926.1 GI:15986197
KEYWORDS    .
SOURCE      synthetic construct
            synthetic construct
            artificial sequences.
ORGANISM
REFERENCE
AUTHORS     Berlin K.
TITLE       Oligonucleotides or pna oligomers and a method for detecting the
            methylation state of genomic dna in a parallel manner
            Patent: WO 0168910-A 396 20-SEP-2001;
            Epigenomics AG (DE)
FEATURES
    source
        1..11
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"
            /note="Beschreibung der kunstlichen
            Sequenz:Oligonukleotid"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2228 TTACATGTTTG 2238
Db      11 TGAATGTTTG 11

RESULT 134
AX470847
LOCUS      AX470847      11 bp      DNA      linear      PAT 09-AUG-2002
DEFINITION Sequence 424 from Patent WO02053773.
ACCESSION  AX470847
VERSION     AX470847.1 GI:22205972
KEYWORDS    .
SOURCE      Homo sapiens (human)
            Homo sapiens
            Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
ORGANISM
REFERENCE
AUTHORS     Hofmann, K., Conradt, M. and Petersohn, D.
TITLE       Method for determining skin stress or skin ageing in vitro
            Patent: WO 02053773-A 424 11-JUL-2002;
            HENKEL KGAA (DE)
FEATURES
    source
        1..11
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2227 GTTACATGTTT 2237
Db      1 GTTACCAGTTT 11

```



```

RESULT 135
AX470905          AX470905          11 bp      DNA          linear      PAT 09-AUG-2002
LOCUS
DEFINITION      Sequence 482 from Patent WO02053773.
ACCESSION      AX470905
VERSION        AX470905.1  GI:22206030
KEYWORDS
SOURCE
ORGANISM      Homo sapiens (human)
               Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS      Hofmann,K., Conradt,M. and Petersohn,D.
TITLE        Method for determining skin stress or skin ageing in vitro
JOURNAL
JOURNAL
HENSEL KGAA (DE)
FEATURES
Location/Qualifiers
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2214 AGTGTGACCAA 2224
||| |||||
Db 1 AGTATGACCTA 11

RESULT 136
AX471379/c
AX471379          AX471379          11 bp      DNA          linear      PAT 09-AUG-2002
LOCUS
DEFINITION      Sequence 956 from Patent WO02053773.
ACCESSION      AX471379
VERSION        AX471379.1  GI:22206504
KEYWORDS
SOURCE
ORGANISM      Homo sapiens (human)
               Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS      Hofmann,K., Conradt,M. and Petersohn,D.
TITLE        Method for determining skin stress or skin ageing in vitro
JOURNAL
JOURNAL
HENSEL KGAA (DE)
FEATURES
Location/Qualifiers
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2214 AGTGTGACCAA 2224
||| |||||
Db 1 AGTATGACCTA 11

RESULT 137
AX471509/c
AX471509          AX471509          11 bp      DNA          linear      PAT 09-AUG-2002
LOCUS
DEFINITION      Sequence 1086 from Patent WO02053773.
ACCESSION      AX471509
VERSION        AX471509.1  GI:22206634
KEYWORDS
SOURCE
ORGANISM      Homo sapiens (human)
               Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS      Petersohn,D., Conradt,M. and Hofmann,K.
TITLE        Method for determining homeostasis of the skin
JOURNAL
JOURNAL
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
Location/Qualifiers
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"

```

```

REFERENCE
AUTHORS      Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE        Hofmann,K., Conradt,M. and Petersohn,D.
JOURNAL      Method for determining skin stress or skin ageing in vitro
JOURNAL      Patent: WO 02053773-A 1086 11-JUL-2002;
HENSEL KGAA (DE)
FEATURES
Location/Qualifiers
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2213 GAGTGTGACCA 2223
||| |||||
Db 11 GAGAGGGACCA 1

RESULT 138
AX472091/c
AX472091          AX472091          11 bp      DNA          linear      PAT 09-AUG-2002
LOCUS
DEFINITION      Sequence 82 from Patent WO02053775.
ACCESSION      AX472091
VERSION        AX472091.1  GI:22207132
KEYWORDS
SOURCE
ORGANISM      Homo sapiens (human)
               Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS      Huster,E., Habert,M. and Wojnowski,L.
TITLE        Identification of the genetic determinants of the polymorphic
JOURNAL      cy3a5 expression
JOURNAL      Patent: WO 02053775-A 82 11-JUL-2002;
JOURNAL      EPIDAUROS BIOTECHNOLOGIE AG (DE)
FEATURES
Location/Qualifiers
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2224 AAAGTTACATG 2234
||| |||||
Db 11 AAAGTCCCATG 1

RESULT 139
AX623259
AX623259          AX623259          11 bp      DNA          linear      PAT 21-FEB-2003
LOCUS
DEFINITION      Sequence 300 from Patent WO02053774.
ACCESSION      AX623259
VERSION        AX623259.1  GI:28451200
KEYWORDS
SOURCE
ORGANISM      Homo sapiens (human)
               Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS      Petersohn,D., Conradt,M. and Hofmann,K.
TITLE        Method for determining homeostasis of the skin
JOURNAL
JOURNAL      Patent: WO 02053774-A 300 11-JUL-2002;
JOURNAL      Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
Location/Qualifiers
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"

```

/db_xref="taxon:9606"

Query Match 28.9%; Score 7.8; DB 1; Length 11;
 Best Local Similarity 81.8%; Pred. No. 81;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2220 ACCAAAAGTTA 2230

Db 1 ATCAAGGTTA 11

RESULT 140

AX623274

LOCUS

DEFINITION Sequence 315 from Patent WO02053774. PAT 21-FEB-2003

ACCESSION AX623274

VERSION AX623274.1 GI:28451215

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

AUTHORS

TITLE Petersohn, D., Conradt, M. and Hofmann, K.

JOURNAL Method for determining homeostasis of the skin

FEATURES Patent: WO 02053774-A 315 11-JUL-2002;

Henkel Kommanditgesellschaft auf Aktien (DE)

LOCATION/Qualifiers

1. .11

/organism="Homo sapiens"

/mol_type="unassigned DNA"

/db_xref="taxon:9606"

Query Match

Best Local Similarity 28.9%; Score 7.8; DB 1; Length 11;

Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2224 AAAGTTACATG 2234

Db 1 AAAGTGAAATG 11

RESULT 141

AX623312/c

LOCUS

DEFINITION Sequence 353 from Patent WO02053774. PAT 21-FEB-2003

ACCESSION AX623312

VERSION AX623312.1 GI:28451253

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

AUTHORS

TITLE Petersohn, D., Conradt, M. and Hofmann, K.

JOURNAL Method for determining homeostasis of the skin

FEATURES Patent: WO 02053774-A 353 11-JUL-2002;

Henkel Kommanditgesellschaft auf Aktien (DE)

LOCATION/Qualifiers

1. .11

/organism="Homo sapiens"

/mol_type="unassigned DNA"

/db_xref="taxon:9606"

Query Match

Best Local Similarity 28.9%; Score 7.8; DB 1; Length 11;

Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2217 GTGACCAAAAG 2227

Db 11 GTGGCAAAAG 1

RESULT 142

AX623252/c

LOCUS

DEFINITION Sequence 566 from Patent WO02053774. PAT 21-FEB-2003

ACCESSION AX623252

VERSION AX623252.1 GI:28451466

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

AUTHORS

TITLE Petersohn, D., Conradt, M. and Hofmann, K.

JOURNAL Method for determining homeostasis of the skin

FEATURES Patent: WO 02053774-A 566 11-JUL-2002;

Henkel Kommanditgesellschaft auf Aktien (DE)

LOCATION/Qualifiers

1. .11

/organism="Homo sapiens"

/mol_type="unassigned DNA"

/db_xref="taxon:9606"

Query Match

Best Local Similarity 28.9%; Score 7.8; DB 1; Length 11;

Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2222 CAAAAGTTTACA 2232

Db 11 CAAAAGTTTACA 1

RESULT 143

AX624334

LOCUS

DEFINITION Sequence 1375 from Patent WO02053774. PAT 21-FEB-2003

ACCESSION AX624334

VERSION AX624334.1 GI:28452275

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

AUTHORS

TITLE Petersohn, D., Conradt, M. and Hofmann, K.

JOURNAL Method for determining homeostasis of the skin

FEATURES Patent: WO 02053774-A 1375 11-JUL-2002;

Henkel Kommanditgesellschaft auf Aktien (DE)

LOCATION/Qualifiers

1. .11

/organism="Homo sapiens"

/mol_type="unassigned DNA"

/db_xref="taxon:9606"

Query Match

Best Local Similarity 28.9%; Score 7.8; DB 1; Length 11;

Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2214 AGTGTGACCAA 2224

Db 1 AGTATGACCTA 11

RESULT 144

AX624403/c

LOCUS

DEFINITION Sequence 1444 from Patent WO02053774. PAT 21-FEB-2003

ACCESSION AX624403

VERSION AX624403.1 GI:28452344

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

```

REFERENCE
1
Petersohn,D., Conradt,M. and Hofmann,K.
TITLE      Method for determining homeostasis of the skin
JOURNAL    Patent: WO 02053774-A 1444 11-JUL-2002;
           Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2227 GTTACATGTTT 2237
Db 11 GATACATCTTT 1

RESULT 145
AX624408/c
LOCUS      AX624408      11 bp      DNA      linear      PAT 21-FEB-2003
DEFINITION Sequence 1449 from Patent WO02053774.
ACCESSION  AX624408
VERSION     AX624408.1 GI:28452349
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
           Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
Petersohn,D., Conradt,M. and Hofmann,K.
AUTHORS
TITLE      Method for determining homeostasis of the skin
JOURNAL    Patent: WO 02053774-A 1449 11-JUL-2002;
           Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2216 TGTGACCAAA 2226
Db 11 TCTGACCAAA 1

RESULT 146
AX624854/c
LOCUS      AX624854      11 bp      DNA      linear      PAT 21-FEB-2003
DEFINITION Sequence 1895 from Patent WO02053774.
ACCESSION  AX624854
VERSION     AX624854.1 GI:28452795
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
           Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
Petersohn,D., Conradt,M. and Hofmann,K.
AUTHORS
TITLE      Method for determining homeostasis of the skin
JOURNAL    Patent: WO 02053774-A 1895 11-JUL-2002;
           Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2214 ACTGTGACCAA 2224
Db 11 AGTCTGGCAA 1

RESULT 147
AX625019
LOCUS      AX625019      11 bp      DNA      linear      PAT 21-FEB-2003
DEFINITION Sequence 2060 from Patent WO02053774.
ACCESSION  AX625019
VERSION     AX625019.1 GI:28452960
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
           Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
Petersohn,D., Conradt,M. and Hofmann,K.
AUTHORS
TITLE      Method for determining homeostasis of the skin
JOURNAL    Patent: WO 02053774-A 2060 11-JUL-2002;
           Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2225 AAGTTACATGT 2235
Db 11 AAGTTGCATCT 11

RESULT 148
AX625472/c
LOCUS      AX625472      11 bp      DNA      linear      PAT 21-FEB-2003
DEFINITION Sequence 2513 from Patent WO02053774.
ACCESSION  AX625472
VERSION     AX625472.1 GI:28453413
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
           Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
Petersohn,D., Conradt,M. and Hofmann,K.
AUTHORS
TITLE      Method for determining homeostasis of the skin
JOURNAL    Patent: WO 02053774-A 2513 11-JUL-2002;
           Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2228 TTACATGTTTG 2238
Db 11 TTAAGGTTTG 1

RESULT 149
AX625510

```

Thu Nov 18 12:41:57 2004

```

LOCUS      AX625510                      11 bp      DNA          PAT 21-FEB-2003
DEFINITION Sequence 2551 from Patent WO02053774.
ACCESSION  AX625510
VERSION     AX625510.1  GI:28453451
KEYWORDS   . Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Petersohn,D., Conradt,M. and Hofmann,K.
TITLE       Method for determining homeostasis of the skin
JOURNAL     Patent: WO 02053774-A 2551 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES   source
            1..11
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2227 GTTACATGTTT 2237
Db 1 GTTACCATGTTT 11

RESULT 150
LOCUS      AX625578                      11 bp      DNA          PAT 21-FEB-2003
DEFINITION Sequence 2619 from Patent WO02053774.
ACCESSION  AX625578
VERSION     AX625578.1  GI:28453519
KEYWORDS   . Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Petersohn,D., Conradt,M. and Hofmann,K.
TITLE       Method for determining homeostasis of the skin
JOURNAL     Patent: WO 02053774-A 2619 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES   source
            1..11
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2228 TTACATGTTTG 2238
Db 11 TTGAATGTTTG 1

RESULT 151
LOCUS      AX626006                      11 bp      DNA          PAT 21-FEB-2003
DEFINITION Sequence 3047 from Patent WO02053774.
ACCESSION  AX626006
VERSION     AX626006.1  GI:28454044
KEYWORDS   . Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Petersohn,D., Conradt,M. and Hofmann,K.

```

```

TITLE       Method for determining homeostasis of the skin
JOURNAL     Patent: WO 02053774-A 3047 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES   source
            1..11
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2219 GACCAAAAGTT 2229
Db 1 GATCAAAATTT 11

RESULT 152
LOCUS      AX626175                      11 bp      DNA          PAT 21-FEB-2003
DEFINITION Sequence 3216 from Patent WO02053774.
ACCESSION  AX626175
VERSION     AX626175.1  GI:28454213
KEYWORDS   . Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Petersohn,D., Conradt,M. and Hofmann,K.
TITLE       Method for determining homeostasis of the skin
JOURNAL     Patent: WO 02053774-A 3216 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES   source
            1..11
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2219 GACCAAAAGTT 2229
Db 1 GACCAAAATGTT 11

RESULT 153
LOCUS      AX626353                      11 bp      DNA          PAT 21-FEB-2003
DEFINITION Sequence 3394 from Patent WO02053774.
ACCESSION  AX626353
VERSION     AX626353.1  GI:28454391
KEYWORDS   . Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Petersohn,D., Conradt,M. and Hofmann,K.
TITLE       Method for determining homeostasis of the skin
JOURNAL     Patent: WO 02053774-A 3394 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES   source
            1..11
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2219 GACCAAAAGTT 2229
Db 1 GACCAAAATGTT 11

```

```

Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2223 AAAAGTTACAT 2233
Db 1 AAATGTAACAT 11

RESULT 154
AX626353/c
LOCUS
DEFINITION Sequence 3394 from Patent WO02053774.
ACCESSION AX626353
VERSION AX626353.1 GI:28454391
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Petersohn,D., Conradt,M. and Hofmann,K.
AUTHORS Method for determining homeostasis of the skin
TITLE Patent: WO 02053774-A 3394 11-JUL-2002;
JOURNAL Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
Location/Qualifiers
source
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2225 AAGTTACATCT 2235
Db 11 ATGTTACATTT 1

RESULT 155
AX626437/c
LOCUS
DEFINITION Sequence 3478 from Patent WO02053774.
ACCESSION AX626437
VERSION AX626437.1 GI:28454475
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Petersohn,D., Conradt,M. and Hofmann,K.
AUTHORS Method for determining homeostasis of the skin
TITLE Patent: WO 02053774-A 3478 11-JUL-2002;
JOURNAL Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
Location/Qualifiers
source
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2227 GTTACATGTTT 2237
Db 11 GTTACATTTT 1

RESULT 156
AX626538
LOCUS
DEFINITION Sequence 3579 from Patent WO02053774.

```

```

ACCESSION AX626538
VERSION AX626538.1 GI:28454576
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Petersohn,D., Conradt,M. and Hofmann,K.
AUTHORS Method for determining homeostasis of the skin
TITLE Patent: WO 02053774-A 3579 11-JUL-2002;
JOURNAL Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
Location/Qualifiers
source
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2217 GTGACCAAAAG 2227
Db 1 GCGACAAAAG 11

RESULT 157
AX626611/c
LOCUS
DEFINITION Sequence 3652 from Patent WO02053774.
ACCESSION AX626611
VERSION AX626611.1 GI:28454649
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Petersohn,D., Conradt,M. and Hofmann,K.
AUTHORS Method for determining homeostasis of the skin
TITLE Patent: WO 02053774-A 3652 11-JUL-2002;
JOURNAL Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
Location/Qualifiers
source
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2217 GTGACCAAAAG 2227
Db 11 GCGACCAACAG 1

RESULT 158
AX626972/c
LOCUS
DEFINITION Sequence 4013 from Patent WO02053774.
ACCESSION AX626972
VERSION AX626972.1 GI:28455010
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Petersohn,D., Conradt,M. and Hofmann,K.
AUTHORS Method for determining homeostasis of the skin
TITLE Patent: WO 02053774-A 4013 11-JUL-2002;
JOURNAL

```

Henkel Kommanditgesellschaft auf Aktien (DE)

FEATURES

source
1. .11
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 28.9%; Score 7.8; DB 1; Length 11;

Best Local Similarity 81.8%; Pred. No. 81;

Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2215 GTGTGACCAA 2225

Db 11 GTGTGACCAA 1

RESULT 159

AX627073 AX627073 11 bp DNA linear PAT 21-FEB-2003

LOCUS Sequence 4114 from Patent WO02053774.

DEFINITION AX627073

ACCESSION AX627073

VERSION AX627073.1 GI:28455111

KEYWORDS Homo sapiens (human)

SOURCE Homo sapiens

ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE

1 Petersohn,D., Conradt,M. and Hofmann,K.

AUTHORS Method for determining homeostasis of the skin

TITLE Patent: WO 02053774-A 4114 11-JUL-2002;

JOURNAL Henkel Kommanditgesellschaft auf Aktien (DE)

FEATURES

source
1. .11
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 28.9%; Score 7.8; DB 1; Length 11;

Best Local Similarity 81.8%; Pred. No. 81;

Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2215 GTGTGACCAA 2225

Db 1 GTGTGACCTAA 11

RESULT 160

AX627090/c AX627090 11 bp DNA linear PAT 21-FEB-2003

LOCUS Sequence 4131 from Patent WO02053774.

DEFINITION AX627090

ACCESSION AX627090

VERSION AX627090.1 GI:28455128

KEYWORDS Homo sapiens (human)

SOURCE Homo sapiens

ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE

1 Petersohn,D., Conradt,M. and Hofmann,K.

AUTHORS Method for determining homeostasis of the skin

TITLE Patent: WO 02053774-A 4131 11-JUL-2002;

JOURNAL Henkel Kommanditgesellschaft auf Aktien (DE)

FEATURES

source
1. .11
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 28.9%; Score 7.8; DB 1; Length 11;

Best Local Similarity 81.8%; Pred. No. 81;

Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2224 AAAGTTACATG 2234

Db 11 AAAATTACAGG 1

RESULT 161

AX627203/c AX627203 11 bp DNA linear PAT 21-FEB-2003

LOCUS Sequence 4244 from Patent WO02053774.

DEFINITION AX627203

ACCESSION AX627203

VERSION AX627203.1 GI:28455241

KEYWORDS Homo sapiens (human)

SOURCE Homo sapiens

ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE

1 Petersohn,D., Conradt,M. and Hofmann,K.

AUTHORS Method for determining homeostasis of the skin

TITLE Patent: WO 02053774-A 4244 11-JUL-2002;

JOURNAL Henkel Kommanditgesellschaft auf Aktien (DE)

FEATURES

source
1. .11
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 28.9%; Score 7.8; DB 1; Length 11;

Best Local Similarity 81.8%; Pred. No. 81;

Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2214 AGTGTGACCAA 2224

Db 11 AGTGTGACCAA 1

RESULT 162

AX627736/c AX627736 11 bp DNA linear PAT 21-FEB-2003

LOCUS Sequence 4777 from Patent WO02053774.

DEFINITION AX627736

ACCESSION AX627736

VERSION AX627736.1 GI:28455774

KEYWORDS Homo sapiens (human)

SOURCE Homo sapiens

ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE

1 Petersohn,D., Conradt,M. and Hofmann,K.

AUTHORS Method for determining homeostasis of the skin

TITLE Patent: WO 02053774-A 4777 11-JUL-2002;

JOURNAL Henkel Kommanditgesellschaft auf Aktien (DE)

FEATURES

source
1. .11
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 28.9%; Score 7.8; DB 1; Length 11;

Best Local Similarity 81.8%; Pred. No. 81;

Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2221 CCAAAAGTTAC 2231

Db 11 CAAAAAGTTGC 1

RESULT 163

AX628352/c AX628352 11 bp DNA linear PAT 21-FEB-2003

LOCUS Sequence 5393 from Patent WO02053774.

DEFINITION AX628352

ACCESSION AX628352

VERSION AX628352.1 GI:28456390

```

KEYWORDS      Homo sapiens (human)
SOURCE         Homo sapiens
ORGANISM       Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
               Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE      1
AUTHORS        Petersohn,D., Conradt,M. and Hofmann,K.
TITLE          Method for determining homeostasis of the skin
JOURNAL        Patent: WO 02053774-A 5393 11-JUL-2002;
               Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES       Location/Qualifiers
               source
               1..11
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"

Query Match    28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2217 GTGACCAAAAG 2227
Db 11 GGGACCATAG 1

RESULT 164
AX628372/c
LOCUS          AX628372
DEFINITION     Sequence 5413 from Patent WO02053774.
ACCESSION      AX628372
VERSION        AX628372.1 GI:28456410
KEYWORDS       Homo sapiens (human)
SOURCE         Homo sapiens
ORGANISM       Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
               Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE      1
AUTHORS        Petersohn,D., Conradt,M. and Hofmann,K.
TITLE          Method for determining homeostasis of the skin
JOURNAL        Patent: WO 02053774-A 5413 11-JUL-2002;
               Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES       Location/Qualifiers
               source
               1..11
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"

Query Match    28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2213 GAGGTGACCA 2223
Db 11 GAGAGGGACCA 1

RESULT 165
AX629084/c
LOCUS          AX629084
DEFINITION     Sequence 6125 from Patent WO02053774.
ACCESSION      AX629084
VERSION        AX629084.1 GI:28457122
KEYWORDS       Homo sapiens (human)
SOURCE         Homo sapiens
ORGANISM       Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
               Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE      1
AUTHORS        Petersohn,D., Conradt,M. and Hofmann,K.
TITLE          Method for determining homeostasis of the skin
JOURNAL        Patent: WO 02053774-A 6125 11-JUL-2002;
               Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES       Location/Qualifiers
               source
               1..11
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"

Query Match    28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2216 TGTGACCAAAA 2226
Db 11 TGTGAGTAAAA 1

RESULT 166
AX629205
LOCUS          AX629205
DEFINITION     Sequence 6246 from Patent WO02053774.
ACCESSION      AX629205
VERSION        AX629205.1 GI:28457243
KEYWORDS       Homo sapiens (human)
SOURCE         Homo sapiens
ORGANISM       Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
               Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE      1
AUTHORS        Petersohn,D., Conradt,M. and Hofmann,K.
TITLE          Method for determining homeostasis of the skin
JOURNAL        Patent: WO 02053774-A 6246 11-JUL-2002;
               Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES       Location/Qualifiers
               source
               1..11
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"

Query Match    28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2212 AGAGTGTGACC 2222
Db 1 ACAGGGTGACC 11

RESULT 167
AX629421
LOCUS          AX629421
DEFINITION     Sequence 6462 from Patent WO02053774.
ACCESSION      AX629421
VERSION        AX629421.1 GI:28457459
KEYWORDS       Homo sapiens (human)
SOURCE         Homo sapiens
ORGANISM       Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
               Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE      1
AUTHORS        Petersohn,D., Conradt,M. and Hofmann,K.
TITLE          Method for determining homeostasis of the skin
JOURNAL        Patent: WO 02053774-A 6462 11-JUL-2002;
               Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES       Location/Qualifiers
               source
               1..11
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"

Query Match    28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2215 GAGGTGACCA 2225
Db 11 GAGAGGGACCA 11

RESULT 168
AX629084/c
LOCUS          AX629084
DEFINITION     Sequence 6125 from Patent WO02053774.
ACCESSION      AX629084
VERSION        AX629084.1 GI:28457122
KEYWORDS       Homo sapiens (human)
SOURCE         Homo sapiens
ORGANISM       Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
               Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE      1
AUTHORS        Petersohn,D., Conradt,M. and Hofmann,K.
TITLE          Method for determining homeostasis of the skin
JOURNAL        Patent: WO 02053774-A 6125 11-JUL-2002;
               Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES       Location/Qualifiers
               source
               1..11
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"

Query Match    28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2216 TGTGACCAAAA 2226
Db 11 TGTGAGTAAAA 1

```

Db 1 TGTGATCACAA 11

RESULT 168
AX629615
LOCUS AX629615 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 6656 from Patent WO02053774.
ACCESSION AX629615
VERSION AX629615.1 GI:28457653
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 6656 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source 1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2214 AGTGTGACCAC 2224
Db 1 ATTGTGAACAA 11

RESULT 169
AX629663/c
LOCUS AX629663 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 6704 from Patent WO02053774.
ACCESSION AX629663
VERSION AX629663.1 GI:28457701
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 6704 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source 1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2221 CCAAAAGTTAC 2231
Db 11 CTAAAAGTTCC 1

RESULT 170
AX630680
LOCUS AX630680 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 7721 from Patent WO02053774.
ACCESSION AX630680
VERSION AX630680.1 GI:28458718
KEYWORDS
SOURCE Homo sapiens (human)

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 7721 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source 1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2220 ACCAAAGTTA 2230
Db 1 ATCAAAGTTA 11

RESULT 171
AX630695
LOCUS AX630695 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 7736 from Patent WO02053774.
ACCESSION AX630695
VERSION AX630695.1 GI:28458733
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 7736 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source 1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2224 AAAGTTACATG 2234
Db 1 AAAGTGAATG 11

RESULT 172
AX630733/c
LOCUS AX630733 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 7774 from Patent WO02053774.
ACCESSION AX630733
VERSION AX630733.1 GI:28458771
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 7774 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source 1. .11
/organism="Homo sapiens"


```

/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2217 GTGACCAAAAG 2227
DB 11 GTGGCAAAAAG 1

RESULT 173
AX630946/c
LOCUS      AX630946      11 bp      DNA      linear      PAT 21-FEB-2003
DEFINITION Sequence 7987 from Patent WO02053774.
ACCESSION  AX630946
VERSION     AX630946.1 GI:28458988
KEYWORDS   .
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS    Petersohn,D., Conradt,M. and Hofmann,K.
TITLE      Method for determining homeostasis of the skin
JOURNAL    Patent: WO 02053774-A 7987 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES   Location/Qualifiers
            source
            1..11
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2222 CAAAGTTTACA 2232
DB 11 CAAAGTTTACA 1

RESULT 174
AX631755/c
LOCUS      AX631755      11 bp      DNA      linear      PAT 21-FEB-2003
DEFINITION Sequence 8797 from Patent WO02053774.
ACCESSION  AX631755
VERSION     AX631755.1 GI:28459862
KEYWORDS   .
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS    Petersohn,D., Conradt,M. and Hofmann,K.
TITLE      Method for determining homeostasis of the skin
JOURNAL    Patent: WO 02053774-A 8797 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES   Location/Qualifiers
            source
            1..11
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2214 AGTGTACCA 2224
DB 1 AGTATGACCTA 11

RESULT 177
AX632275/c
LOCUS      AX632275      11 bp      DNA      linear      PAT 21-FEB-2003
DEFINITION Sequence 9317 from Patent WO02053774.
ACCESSION  AX632275
VERSION     AX632275.1 GI:28467890
KEYWORDS   .
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

```

```

/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2227 GTTACATGTTT 2237
DB 11 GATACATCTTT 1

RESULT 176
AX631829/c
LOCUS      AX631829      11 bp      DNA      linear      PAT 21-FEB-2003
DEFINITION Sequence 8871 from Patent WO02053774.
ACCESSION  AX631829
VERSION     AX631829.1 GI:28459936
KEYWORDS   .
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS    Petersohn,D., Conradt,M. and Hofmann,K.
TITLE      Method for determining homeostasis of the skin
JOURNAL    Patent: WO 02053774-A 8871 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES   Location/Qualifiers
            source
            1..11
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      28.9%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 81;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2216 TGTGACCAAAA 2226
DB 11 TCTGAGCAAAA 1

RESULT 177
AX632275/c
LOCUS      AX632275      11 bp      DNA      linear      PAT 21-FEB-2003
DEFINITION Sequence 9317 from Patent WO02053774.
ACCESSION  AX632275
VERSION     AX632275.1 GI:28467890
KEYWORDS   .
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

```

REFERENCE 1 Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

AUTHORS Petersohn, D., Conradt, M. and Hofmann, K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 9317 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)

FEATURES Location/Qualifiers

source 1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 28.9%; Score 7.8; DB 1; Length 11;

Best Local Similarity 81.8%; Pred. No. 81;

Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2214 AGTGTGACCAA 2224

Db 11 AGTCTGGCCAA 1

RESULT 178

AX632440

LOCUS AX632440 11 bp DNA linear PAT 21-FEB-2003

DEFINITION Sequence 9482 from Patent WO02053774.

ACCESSION AX632440

VERSION AX632440.1 GI:28469055

KEYWORDS Homo sapiens (human)

SOURCE Homo sapiens

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE 1

AUTHORS Petersohn, D., Conradt, M. and Hofmann, K.

TITLE Method for determining homeostasis of the skin

JOURNAL Patent: WO 02053774-A 9482 11-JUL-2002;

Henkel Kommanditgesellschaft auf Aktien (DE)

FEATURES Location/Qualifiers

source 1..11

/organism="Homo sapiens"

/mol_type="unassigned DNA"

/db_xref="taxon:9606"

Query Match 28.9%; Score 7.8; DB 1; Length 11;

Best Local Similarity 81.8%; Pred. No. 81;

Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2225 AAGTTACATGT 2235

Db 1 AAGTTGCACT 11

RESULT 179

AX772275

LOCUS AX772275 11 bp DNA linear PAT 02-JUL-2003

DEFINITION Sequence 65 from Patent WO03042407.

ACCESSION AX772275

VERSION AX772275.1 GI:32438848

KEYWORDS Drosophila melanogaster (fruit fly)

SOURCE Drosophila melanogaster

ORGANISM Drosophila melanogaster

Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;

Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;

Ephydroidea; Drosophilidae; Drosophila.

REFERENCE 1

AUTHORS Dickson, B., Berger, J., Suzuki, T. and Knoblich, J.

TITLE Method for identifying therapeutic targets by use of genetic

JOURNAL screens in Drosophila melanogaster

Patent: WO 03042407-A 65 22-MAY-2003;

BOEHRINGER INGELHEIM INTERNATIONAL GMBH; CD Patents (DE)

FEATURES Location/Qualifiers

source 1..11

/organism="Drosophila melanogaster"

/mol_type="unassigned DNA"
/db_xref="taxon:7227"

Query Match 28.9%; Score 7.8; DB 1; Length 11;

Best Local Similarity 81.8%; Pred. No. 81;

Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2227 GTTACATGTTT 2237

Db 1 GGTATATGTTT 11

Search completed: November 18, 2004, 08:14:47

Job time: 1 secs